Clustering O 0 7.079073111526668e-05
of O 0 4.8285974116879515e-06
missense O 0 3.670249134302139e-05
mutations O 0 2.7377054721000604e-06
in O 0 5.711500534744118e-07
the O 0 1.987490577448625e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 2.4529928850824945e-05
in O 0 2.1583959153304022e-07
a O 0 6.650727186752192e-07
sporadic B-Disease 0 0.015529747121036053
T I-Disease 1 0.999998927116394
- I-Disease 1 0.9979427456855774
cell I-Disease 1 0.5538302063941956
leukaemia I-Disease 0 0.25935110449790955
. O 0 2.8506547096185386e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999867677688599
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.7343983194659813e-07
is O 0 1.475664479499983e-08
a O 0 3.376908352947794e-08
recessive B-Disease 0 3.245936341045308e-06
multi I-Disease 0 0.0006729903980158269
- I-Disease 0 0.00028448732336983085
system I-Disease 0 9.200432396028191e-05
disorder I-Disease 0 0.028443949297070503
caused O 0 5.706900196855713e-07
by O 0 3.414134752688369e-08
mutations O 0 3.892027677920851e-08
in O 0 1.8165875914633034e-08
the O 0 7.340590002513636e-08
ATM O 0 3.4091028737748275e-06
gene O 0 1.552694897100082e-07
at O 0 1.1216801567570656e-06
11q22 O 0 1.2777685697074048e-05
- O 0 9.342905286757741e-06
q23 O 0 3.6856989027000964e-05
( O 0 7.297328465938335e-07
ref O 0 1.3920824130764231e-05
. O 0 1.6432728955351195e-07
3 O 0 3.975450908910716e-06
) O 0 1.6148027270901366e-06
. O 0 1.1204378097318113e-05

The O 0 4.219403308525216e-06
risk O 0 4.070893282914767e-06
of O 0 5.20409503224073e-06
cancer B-Disease 0 0.0001669373014010489
, O 0 5.855767426510283e-07
especially O 0 3.072352910749032e-06
lymphoid B-Disease 1 0.998477041721344
neoplasias I-Disease 1 0.9581764936447144
, O 0 3.4092906275873247e-07
is O 0 2.9206207230458858e-08
substantially O 0 2.104326739527096e-07
elevated O 0 4.068665475642774e-06
in O 0 1.003879503969074e-07
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 6.476652174569608e-07
and O 0 6.121068452102918e-08
has O 0 2.4588274527559406e-08
long O 0 1.9453709754202464e-08
been O 0 2.0633731168118175e-08
associated O 0 5.598814567520094e-08
with O 0 3.2136179584085767e-07
chromosomal O 1 0.999993085861206
instability O 1 0.9999984502792358
. O 0 0.00016499149205628783

By O 0 9.621173376217484e-06
analysing O 0 6.523237971123308e-05
tumour B-Disease 1 0.999968409538269
DNA O 0 2.2163731046020985e-06
from O 0 1.0366848357534764e-07
patients O 0 5.183402862485309e-08
with O 0 7.195151141559109e-08
sporadic B-Disease 0 7.647429447388276e-05
T I-Disease 1 0.9995787739753723
- I-Disease 0 0.012820350006222725
cell I-Disease 0 0.0019542528316378593
prolymphocytic I-Disease 0 0.0011941737029701471
leukaemia I-Disease 0 0.2184155285358429
( O 0 1.247940076609666e-06
T B-Disease 0 0.006833345629274845
- I-Disease 0 3.460137304500677e-05
PLL I-Disease 0 0.06280160695314407
) O 0 1.047655331376518e-07
, O 0 4.8883027403689994e-08
a O 0 8.722722100173996e-08
rare O 0 5.210931135479768e-07
clonal B-Disease 0 2.3023363610263914e-05
malignancy I-Disease 0 6.790205588913523e-06
with O 0 3.239968293655693e-08
similarities O 0 1.3440080692816991e-07
to O 0 5.182295836902995e-08
a O 0 3.5158933542334125e-07
mature B-Disease 0 4.209246617392637e-05
T I-Disease 0 0.03130263835191727
- I-Disease 0 2.9774759241263382e-05
cell I-Disease 0 1.2790364962711465e-05
leukaemia I-Disease 0 1.962096939678304e-05
seen O 0 1.385604662118567e-07
in O 0 3.797484637857451e-08
A B-Disease 1 0.8045026659965515
- I-Disease 0 0.003443655092269182
T I-Disease 1 0.999956488609314
, O 0 4.994060986973636e-08
we O 0 1.9763415792795058e-08
demonstrate O 0 2.9312575478002145e-08
a O 0 1.4104273304837989e-08
high O 0 6.538589047977439e-08
frequency O 0 1.1233079533212731e-07
of O 0 5.2834995045714095e-08
ATM O 0 2.629819391586352e-06
mutations O 0 4.4489786432677647e-07
in O 0 3.855425916299282e-07
T B-Disease 0 0.0014966133749112487
- I-Disease 0 0.0002513899526093155
PLL I-Disease 0 0.016804585233330727
. O 0 1.9363425963092595e-05

In O 0 2.522917839087313e-06
marked O 0 3.0675048492412316e-06
contrast O 0 5.729427243750251e-07
to O 0 6.880317471313901e-08
the O 0 1.7389076845120144e-07
ATM O 0 6.353094249789137e-06
mutation O 0 2.4310048729603295e-07
pattern O 0 5.215156875237881e-07
in O 0 1.0389711491143316e-07
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999926090240479
T I-Disease 1 1.0
, O 0 1.6579579664721678e-07
the O 0 2.4778097795774556e-08
most O 0 4.841127054788785e-09
frequent O 0 6.663365859083115e-09
nucleotide O 0 1.4961464955831616e-08
changes O 0 1.4705114459445667e-08
in O 0 9.449495408375697e-09
this O 0 2.570384083355748e-08
leukaemia B-Disease 0 7.722532245679758e-06
were O 0 6.304600788098469e-07
missense O 0 3.625858516898006e-05
mutations O 0 2.0412178855622187e-05
. O 0 2.9486682251445018e-05

These O 0 1.649588057262008e-06
clustered O 0 3.205722123311716e-06
in O 0 8.119467764799992e-08
the O 0 9.960292857158493e-08
region O 0 1.2286845674225333e-07
corresponding O 0 6.76454519066283e-08
to O 0 1.4918578372657976e-08
the O 0 6.668568630630034e-08
kinase O 0 7.820979135431116e-07
domain O 0 9.785469501366606e-08
, O 0 1.474153865643757e-08
which O 0 1.0017865648137558e-08
is O 0 9.320595850681457e-09
highly O 0 3.179853891310813e-08
conserved O 0 1.1379123776578126e-07
in O 0 3.678697169107181e-08
ATM O 0 9.591803063813131e-06
- O 0 5.248015781944559e-07
related O 0 4.204594716838983e-08
proteins O 0 2.0999721073167166e-08
in O 0 2.8964112885887516e-08
mouse O 0 3.0866033284837613e-07
, O 0 6.307475075573166e-08
yeast O 0 2.4158791802619817e-06
and O 0 8.672900548845064e-07
Drosophila O 0 1.3847126865584869e-05
. O 0 8.267526027339045e-06

The O 0 6.7617725107993465e-06
resulting O 0 9.027940905070864e-06
amino O 0 6.8419349190662615e-06
- O 0 1.6944497929216595e-06
acid O 0 3.840025044610229e-07
substitutions O 0 4.11871241112749e-07
are O 0 2.472409121878627e-08
predicted O 0 3.416789979837631e-07
to O 0 3.105606438680297e-08
interfere O 0 1.9612090795817494e-07
with O 0 1.5985504830950958e-07
ATP O 0 0.00020355386368464679
binding O 0 3.1199985528473917e-07
or O 0 1.069374491180497e-07
substrate O 0 8.660965704621049e-07
recognition O 0 1.0811202173499623e-06
. O 0 6.409928573702928e-06

Two O 0 4.635600362234982e-06
of O 0 4.019028892798815e-06
seventeen O 0 2.707227031351067e-05
mutated O 0 1.631769737286959e-05
T B-Disease 0 0.0007987623102962971
- I-Disease 0 2.8413049221853726e-05
PLL I-Disease 0 0.0002492667408660054
samples O 0 2.0777689258011378e-07
had O 0 1.286388595644894e-07
a O 0 2.1856384080365387e-07
previously O 0 1.3825216456098133e-06
reported O 0 2.7856060569320107e-06
A B-Disease 1 0.9999840259552002
- I-Disease 1 0.9999186992645264
T I-Disease 1 0.9999998807907104
allele O 0 0.0009641689830459654
. O 0 2.7115525881526992e-05

In O 0 1.482237848904333e-06
contrast O 0 1.7232489426532993e-06
, O 0 2.1087002721742465e-07
no O 0 9.892946195577679e-08
mutations O 0 1.1852418424496136e-07
were O 0 4.13748253436097e-08
detected O 0 1.0368984248998458e-07
in O 0 1.1998600335516585e-08
the O 0 4.296462563502246e-08
p53 O 0 6.764661719671494e-08
gene O 0 4.720451229900391e-08
, O 0 1.7072652624960938e-08
suggesting O 0 6.980273070666954e-08
that O 0 8.154477093569312e-09
this O 0 3.510799828632116e-08
tumour B-Disease 1 0.9999998807907104
suppressor O 0 3.5891644074581563e-05
is O 0 2.0221095908823372e-08
not O 0 1.2389965498016409e-08
frequently O 0 5.884352205498544e-08
altered O 0 5.252792334431433e-07
in O 0 1.6323845386523317e-07
this O 0 1.0380941830590018e-06
leukaemia B-Disease 0 0.0028532531578093767
. O 0 1.902269468700979e-05

Occasional O 0 3.052472311537713e-05
missense O 0 4.557849752018228e-05
mutations O 0 2.752470209088642e-06
in O 0 3.284437752881786e-07
ATM O 0 0.0001211795533890836
were O 0 1.090873297471262e-06
also O 0 1.9487509916871204e-07
found O 0 1.6443421202438913e-07
in O 0 2.267860992333226e-07
tumour B-Disease 1 0.9999997615814209
DNA O 0 1.788596591723035e-06
from O 0 4.440522261006663e-08
patients O 0 3.946184179426382e-08
with O 0 6.557660725547976e-08
B B-Disease 0 0.00404356187209487
- I-Disease 0 0.00015115835412871093
cell I-Disease 0 3.486293644527905e-05
non I-Disease 0 5.934307773713954e-05
- I-Disease 0 0.004013795405626297
Hodgkins I-Disease 1 0.9999977350234985
lymphomas I-Disease 0 0.004765390884131193
( O 0 3.867740758778382e-07
B B-Disease 0 6.09017797614797e-06
- I-Disease 0 7.055203354866535e-07
NHL I-Disease 0 1.065723699866794e-05
) O 0 3.125042624674279e-08
and O 0 2.152668088228893e-08
a O 0 7.470651297580844e-08
B B-Disease 0 9.782017514226027e-06
- I-Disease 0 1.707117576188466e-06
NHL I-Disease 0 9.504469198873267e-05
cell O 0 1.6904494259506464e-05
line O 0 1.0874998224608134e-05
. O 0 1.1237262697250117e-05

The O 0 1.0353703601140296e-06
evidence O 0 7.187290975707583e-07
of O 0 1.537292035891369e-07
a O 0 5.512422873721334e-08
significant O 0 4.985923496292344e-08
proportion O 0 8.087365443998351e-08
of O 0 1.4467919129401707e-07
loss O 0 3.776044422920677e-06
- O 0 1.2838312386520556e-06
of O 0 3.1796966482033895e-07
- O 0 4.200250600661093e-07
function O 0 2.9332486661814983e-08
mutations O 0 1.59772994834384e-08
and O 0 3.7215757142661232e-09
a O 0 7.719929584482088e-09
complete O 0 3.70802304416884e-08
absence O 0 8.938368267763508e-08
of O 0 4.372378725747694e-08
the O 0 3.9633821558027194e-08
normal O 0 4.750175364165443e-08
copy O 0 4.483106863517605e-08
of O 0 3.609003584870152e-08
ATM O 0 1.1493185638755676e-06
in O 0 1.8215283503764113e-08
the O 0 3.59953027384563e-08
majority O 0 8.231709358597072e-08
of O 0 8.09849325378309e-07
mutated O 0 1.7828637282946147e-05
tumours B-Disease 1 0.9999991655349731
establishes O 0 2.5100662242039107e-06
somatic O 0 2.476018153174664e-06
inactivation O 0 1.8562595869298093e-06
of O 0 6.059213575326794e-08
this O 0 7.167903603999548e-09
gene O 0 2.7769640809083285e-08
in O 0 1.55230779341764e-08
the O 0 9.507041909273539e-08
pathogenesis O 0 0.00012821047857869416
of O 0 1.3516397530111135e-06
sporadic B-Disease 0 0.038770075887441635
T I-Disease 1 0.9999878406524658
- I-Disease 0 0.12950564920902252
PLL I-Disease 0 0.11773424595594406
and O 0 4.460691727103949e-08
suggests O 0 4.205773862508977e-08
that O 0 5.780075085226599e-09
ATM O 0 1.1350211934768595e-06
acts O 0 1.8035602522559202e-07
as O 0 2.441755668769474e-07
a O 0 1.7377235508320155e-06
tumour B-Disease 1 0.9999984502792358
suppressor O 0 0.0012355007929727435
. O 0 3.291357643320225e-05

As O 0 2.2667309167445637e-06
constitutional O 0 4.129774424654897e-06
DNA O 0 1.3937648191131302e-06
was O 0 4.080791313754162e-07
not O 0 2.637101914615414e-08
available O 0 9.735316552905715e-08
, O 0 9.942070988699925e-08
a O 0 3.2634875424264465e-07
putative O 0 8.943072316469625e-06
hereditary O 0 0.020705824717879295
predisposition O 0 6.92222238285467e-05
to O 0 4.135512881475734e-06
T B-Disease 1 0.9999936819076538
- I-Disease 1 0.9844512939453125
PLL I-Disease 1 0.683974027633667
will O 0 1.0539667272269071e-07
require O 0 8.781482563335885e-08
further O 0 1.9024575692583312e-07
investigation O 0 8.466727763334347e-07
. O 0 4.904670163341507e-07
. O 0 6.491328349511605e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00030831160256639123
kinase O 0 1.0980818842654116e-05
is O 0 1.983819331030645e-08
involved O 0 1.5043131185166203e-08
in O 0 4.446223389464876e-09
the O 0 1.2824340700490211e-08
modulation O 0 4.388545846722991e-07
of O 0 4.2742467343259705e-08
the O 0 1.2075425104285387e-07
Ca2 O 0 1.4521749562845798e-06
+ O 0 3.40901192430465e-06
homeostasis O 0 2.4428731194348074e-05
in O 0 9.798222890822217e-07
skeletal O 0 0.029333658516407013
muscle O 0 0.0014733970165252686
cells O 0 0.00011447770521044731
. O 0 2.61674722423777e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999809265136719
DM B-Disease 1 1.0
) O 0 3.892535914928885e-06
, O 0 1.0054393584368881e-07
the O 0 8.736075329807136e-08
most O 0 7.656102241071494e-08
prevalent O 0 0.05627644807100296
muscular B-Disease 1 1.0
disorder I-Disease 1 0.9999942779541016
in O 0 5.879174409528787e-07
adults O 0 1.0058888619823847e-06
, O 0 6.876355485019303e-08
is O 0 2.4439822610133888e-08
caused O 0 3.073057541769231e-07
by O 0 9.482991458753531e-08
( O 0 3.3516718644932553e-07
CTG O 0 4.5687120291404426e-05
) O 0 1.0138779771295958e-07
n O 0 2.8777060379070463e-07
- O 0 9.884610108201741e-08
repeat O 0 7.622589492939369e-08
expansion O 0 8.095467762814224e-08
in O 0 1.0505123881898726e-08
a O 0 3.569563844507684e-08
gene O 0 5.2214666368399776e-08
encoding O 0 2.4505831675014633e-07
a O 0 1.6351673082226625e-07
protein O 0 9.055758596332453e-07
kinase O 0 4.5045794649922755e-06
( O 0 5.609144295704027e-07
DM B-Disease 1 0.9999669790267944
protein O 0 1.2793553878509556e-06
kinase O 0 6.524151103803888e-07
; O 0 4.5267217529953996e-08
DMPK O 0 2.2269849068834446e-05
) O 0 4.473949744010497e-08
and O 0 4.873584202869097e-08
involves O 0 1.506883933188874e-07
changes O 0 1.794133623889138e-07
in O 0 1.2576325048030412e-07
cytoarchitecture O 0 1.0562006536929403e-05
and O 0 1.1880997590196785e-06
ion O 0 0.000363079336239025
homeostasis O 0 0.0021545402705669403
. O 0 2.726851926126983e-05

To O 0 5.257092539068253e-07
obtain O 0 7.394339718302945e-07
clues O 0 1.7536390259920154e-06
to O 0 5.6424465100235466e-08
the O 0 7.135469104468939e-08
normal O 0 1.2787245395884383e-07
biological O 0 2.2509379959956277e-07
role O 0 1.3838814538758015e-07
of O 0 4.2821415036087274e-07
DMPK O 0 0.0017560599371790886
in O 0 3.21283039284026e-07
cellular O 0 4.945810815115692e-06
ion O 0 2.1938127247267403e-05
homeostasis O 0 2.2384296244126745e-05
, O 0 4.473437797969382e-08
we O 0 2.1210492917589363e-08
have O 0 6.877926228554543e-09
compared O 0 4.58858053775657e-08
the O 0 3.975943485556854e-08
resting O 0 1.1020219972124323e-06
[ O 0 2.816555877416249e-07
Ca2 O 0 1.9319747934787301e-07
+ O 0 1.5055738344926795e-07
] O 0 1.578499109200493e-07
i O 0 7.971616611257559e-08
, O 0 2.0881333995248497e-08
the O 0 2.7349646103402847e-08
amplitude O 0 5.22174048001034e-07
and O 0 4.184362012438214e-08
shape O 0 7.970390356604184e-07
of O 0 4.5869879272686376e-07
depolarization O 0 4.04914908358478e-06
- O 0 6.364212481457798e-07
induced O 0 4.0340256646231865e-07
Ca2 O 0 3.458378330378764e-07
+ O 0 4.5624128119925444e-07
transients O 0 5.126773316987965e-07
, O 0 1.552923833969544e-08
and O 0 1.2658939674281555e-08
the O 0 1.0908296488310043e-08
content O 0 2.9047763305811714e-08
of O 0 8.043231503052084e-08
ATP O 0 1.3131565538060386e-05
- O 0 3.504337939830293e-07
driven O 0 5.381728556130838e-07
ion O 0 6.089858288760297e-06
pumps O 0 2.028717517532641e-06
in O 0 2.404968313385325e-07
cultured O 0 1.5640400306438096e-05
skeletal O 0 2.8781430955859832e-05
muscle O 0 9.441118891118094e-07
cells O 0 1.9347072566233692e-07
of O 0 8.450837185591809e-08
wild O 0 1.186096625360733e-07
- O 0 1.1602084271089552e-07
type O 0 1.0871018218949757e-07
and O 0 1.0636462377533462e-07
DMPK O 0 0.004119934514164925
[ O 0 3.111374553554924e-06
- O 0 4.297747636883287e-06
/ O 0 1.595983121660538e-05
- O 0 2.387758286204189e-05
] O 0 2.8133688829257153e-05
knockout O 1 0.9997497200965881
mice O 0 9.421775030205026e-05
. O 0 1.0094713616126683e-05

In O 0 1.898302616609726e-05
vitro O 0 6.10877395956777e-05
- O 0 2.4852162823663093e-05
differentiated O 0 1.935349609993864e-05
DMPK O 0 0.0011162247974425554
[ O 0 2.0381834474392235e-05
- O 0 2.6218856874038465e-05
/ O 0 6.568244134541601e-05
- O 0 2.7253674488747492e-05
] O 0 6.4220134845527355e-06
myotubes O 0 1.9798029825324193e-05
exhibit O 0 3.510107546844665e-07
a O 0 1.8358747411184595e-07
higher O 0 6.742942559867515e-07
resting O 0 3.499215608826489e-06
[ O 0 6.535609031743661e-07
Ca2 O 0 5.017075181967812e-07
+ O 0 3.2251253401227586e-07
] O 0 1.7652945416557486e-07
i O 0 9.293296443502186e-08
than O 0 2.3553944572540786e-08
do O 0 4.167953093769938e-08
wild O 0 1.6948881409462047e-07
- O 0 2.9264597856126784e-07
type O 0 6.877049827380688e-07
myotubes O 0 7.83564246376045e-06
because O 0 4.183867119422757e-08
of O 0 3.511583201998292e-08
an O 0 1.0686646234603359e-08
altered O 0 5.097749422589004e-08
open O 0 4.499829486803719e-08
probability O 0 2.6695412103094895e-08
of O 0 4.109240592242713e-08
voltage O 0 3.351836085130344e-06
- O 0 5.344556370801001e-07
dependent O 0 1.3943443377684162e-07
l O 0 6.47380488771887e-07
- O 0 8.818542340804925e-08
type O 0 1.2416656147706817e-07
Ca2 O 0 2.24474902665861e-07
+ O 0 1.9663029604544136e-07
and O 0 7.915541999636844e-08
Na O 0 3.4363390568614705e-06
+ O 0 1.2531385209513246e-06
channels O 0 2.115608367603272e-06
. O 0 3.926861154468497e-06

The O 0 1.3403246157395188e-05
mutant O 0 5.822760067530908e-05
myotubes O 0 5.8877307310467586e-05
exhibit O 0 1.40577378715534e-06
smaller O 0 5.721788056689547e-07
and O 0 2.649396435572271e-07
slower O 0 1.338277343165828e-06
Ca2 O 0 8.400357955906657e-07
+ O 0 2.6603314040585246e-07
responses O 0 3.963246442140189e-08
upon O 0 9.376552867479404e-08
triggering O 0 8.901854471332626e-07
by O 0 5.553993887019715e-08
acetylcholine O 0 6.504668021989346e-07
or O 0 8.81195205693075e-08
high O 0 1.1151919352414552e-06
external O 0 4.6216910050134175e-06
K O 0 8.260291906481143e-06
+ O 0 7.55805831431644e-06
. O 0 4.2615088204911444e-06

In O 0 1.048872491082875e-06
addition O 0 4.012328531644016e-07
, O 0 1.0219000756706009e-07
we O 0 3.929225300680628e-08
observed O 0 3.7601498803496725e-08
that O 0 3.585864938315808e-09
these O 0 1.6212878151122823e-08
Ca2 O 0 5.895529398003418e-07
+ O 0 9.304752097705205e-07
transients O 0 1.5059515590110095e-06
partially O 0 1.2435629059837083e-07
result O 0 2.4181550983826128e-08
from O 0 9.928329269826008e-09
an O 0 7.572678484280004e-09
influx O 0 4.719037960398964e-08
of O 0 1.4400275460957346e-07
extracellular O 0 3.6299391581451346e-07
Ca2 O 0 1.5921300189347676e-07
+ O 0 6.73483242508155e-08
through O 0 8.230826686883574e-09
the O 0 2.9563896219997332e-08
l O 0 5.13385259637289e-07
- O 0 9.097882269770707e-08
type O 0 1.3125637110533717e-07
Ca2 O 0 5.826917117701669e-07
+ O 0 9.61958335210511e-07
channel O 0 3.4063859857269563e-06
. O 0 2.992454028571956e-06

Neither O 0 7.612811714352574e-06
the O 0 6.940736625438149e-07
content O 0 5.318188982528227e-07
nor O 0 3.7256404539220966e-07
the O 0 5.304097783209727e-08
activity O 0 1.0717881337996005e-07
of O 0 2.2602996807563613e-07
Na O 0 5.337065886124037e-06
+ O 0 9.222794119523314e-07
/ O 0 1.3233874369689147e-06
K O 0 2.6770603653858416e-06
+ O 0 2.493946112736012e-06
ATPase O 0 7.377655947493622e-06
and O 0 3.900198919382092e-07
sarcoplasmic O 0 7.826403816579841e-06
reticulum O 0 2.9968264243507292e-06
Ca2 O 0 2.2139015527500305e-06
+ O 0 1.5940655657686875e-06
- O 0 8.245480671575933e-07
ATPase O 0 2.437496277707396e-06
are O 0 2.2697971502338987e-08
affected O 0 1.4344244902986247e-07
by O 0 2.235669285255426e-07
DMPK O 0 0.0011413590982556343
absence O 0 0.00010423480125609785
. O 0 4.121565871173516e-05

In O 0 1.0997091521858238e-06
conclusion O 0 1.7748062646205653e-06
, O 0 8.746579283069877e-08
our O 0 3.884018795474731e-08
data O 0 4.610161141727076e-08
suggest O 0 5.8117386458889086e-08
that O 0 2.0223447805278738e-08
DMPK O 0 0.00032419778290204704
is O 0 6.07517165462923e-08
involved O 0 9.950513657486226e-08
in O 0 3.27069038519312e-08
modulating O 0 1.7091277868530597e-06
the O 0 4.095312888807712e-08
initial O 0 9.354330643418507e-08
events O 0 6.800405571993906e-08
of O 0 2.788997903735435e-07
excitation O 0 0.0002888966118916869
- O 0 0.00010150663001695648
contraction O 0 1.0787992323457729e-05
coupling O 0 2.4752960598561913e-05
in O 0 2.3324525955104036e-06
skeletal O 1 0.9859080910682678
muscle O 0 0.0005594349349848926
. O 0 1.0961858606606256e-05
. O 0 2.0345480152172968e-05

Constitutional O 0 0.0017283321358263493
RB1 O 1 0.9563434720039368
- O 0 0.00013572278840001673
gene O 0 1.1776538713093032e-06
mutations O 0 7.969805437824107e-07
in O 0 1.1457964177452595e-07
patients O 0 2.303546153825664e-07
with O 0 2.557715674811334e-07
isolated O 0 1.2314206287555862e-05
unilateral B-Disease 0 0.0006695740157738328
retinoblastoma I-Disease 1 0.999998927116394
. O 0 0.0028332178480923176

In O 0 1.2627031082956819e-06
most O 0 1.7898202031574328e-07
patients O 0 9.354099006486649e-08
with O 0 3.542934123856867e-08
isolated O 0 4.917245064461895e-07
unilateral B-Disease 0 1.1604707651713397e-05
retinoblastoma I-Disease 1 0.9999778270721436
, O 0 1.4841489246464334e-06
tumor B-Disease 0 9.199960913974792e-06
development O 0 2.7196199425816303e-07
is O 0 2.5234340839119795e-08
initiated O 0 1.3556129374592274e-07
by O 0 1.1678789491043062e-08
somatic O 0 2.1911775149874302e-07
inactivation O 0 7.01393844337872e-07
of O 0 5.561255278507815e-08
both O 0 4.7556866888953664e-08
alleles O 0 3.3076673844334437e-07
of O 0 3.949618303522584e-07
the O 0 1.2070777302142233e-06
RB1 O 0 0.002118119038641453
gene O 0 1.12979405457736e-05
. O 0 2.0961835616617464e-05

However O 0 5.882858658878831e-06
, O 0 3.1803639899408154e-07
some O 0 4.574616241370677e-08
of O 0 8.135807405551532e-08
these O 0 3.165095918689076e-08
patients O 0 5.5290918510308984e-08
can O 0 1.0242027315143787e-07
transmit O 0 5.631025032926118e-06
retinoblastoma B-Disease 0 0.0001917442277772352
predisposition O 0 3.5985187878395664e-06
to O 0 2.3162525053521676e-07
their O 0 6.018199201207608e-07
offspring O 0 9.891179615806323e-06
. O 0 1.721130684018135e-05

To O 0 5.928196173954348e-07
determine O 0 3.337840439598949e-07
the O 0 8.969381326551229e-08
frequency O 0 9.9108285667171e-07
and O 0 4.030175659863744e-08
nature O 0 9.278525681111205e-08
of O 0 2.971740116208821e-07
constitutional O 0 2.760720599326305e-05
RB1 O 0 0.37507739663124084
- O 0 3.740974989341339e-06
gene O 0 8.895848679912888e-08
mutations O 0 6.669026220151864e-08
in O 0 1.4316523078150567e-08
patients O 0 3.323400221688644e-08
with O 0 1.9967224318406807e-08
isolated O 0 4.94913763304794e-07
unilateral B-Disease 0 6.902925633767154e-06
retinoblastoma I-Disease 1 0.9229065775871277
, O 0 3.9068365254024684e-07
we O 0 1.2412559158292424e-07
analyzed O 0 8.311381094472381e-08
DNA O 0 1.3559814249219926e-07
from O 0 3.5255759200936154e-08
peripheral O 0 1.8957480278913863e-05
blood O 0 7.625518492204719e-07
and O 0 9.349600418318005e-07
from O 0 2.811933882185258e-06
tumor B-Disease 0 0.15148359537124634
tissue O 0 0.001335698994807899
. O 0 0.00010384520282968879

The O 0 2.7388571197661804e-06
analysis O 0 1.186159352073446e-06
of O 0 1.932403620230616e-06
tumors B-Disease 1 0.9999948740005493
from O 0 3.2270051519844856e-07
54 O 0 2.973487880808534e-06
( O 0 1.3921837194175168e-07
71 O 0 3.006382200965163e-07
% O 0 2.9305644133614805e-08
) O 0 3.298178796740103e-08
of O 0 2.51830442721257e-07
76 O 0 4.65278480987763e-06
informative O 0 1.1977390386164188e-06
patients O 0 8.89788438485084e-08
showed O 0 4.316043771268596e-07
loss O 0 2.703782229218632e-06
of O 0 2.770954097286449e-06
constitutional O 0 0.0018280246295034885
heterozygosity O 1 0.9998581409454346
( O 0 0.0002453133638482541
LOH O 1 0.9999922513961792
) O 0 3.2630937312205788e-06
at O 0 1.7400423530489206e-05
intragenic O 0 0.000441567855887115
loci O 0 0.00016589032020419836
. O 0 5.3732790547655895e-05

Three O 0 4.607094069797313e-06
of O 0 3.3682133562251693e-06
13 O 0 3.2347190426662564e-05
uninformative O 0 0.08921830356121063
patients O 0 5.164828507986385e-06
had O 0 4.246935986884637e-06
constitutional O 0 6.817270332248881e-05
deletions O 0 0.0001572104956721887
. O 0 8.268034434877336e-05

For O 0 7.000358891673386e-06
39 O 0 1.2445227184798568e-05
randomly O 0 2.3009124561212957e-06
selected O 0 6.429128006857354e-06
tumors B-Disease 1 0.9999843835830688
, O 0 3.690275661938358e-06
SSCP O 1 0.984918475151062
, O 0 5.6444446272507776e-06
hetero O 0 0.0007336494163610041
- O 0 3.985765033576172e-06
duplex O 0 4.400206307764165e-06
analysis O 0 8.676592955225715e-08
, O 0 2.255718811738916e-08
sequencing O 0 1.1970044511144806e-07
, O 0 2.402308751925375e-08
and O 0 3.157654759888828e-08
Southern O 0 4.544725129562721e-07
blot O 0 6.679171633550141e-07
analysis O 0 5.92566422596974e-08
were O 0 2.2949413036599253e-08
used O 0 2.892574180179963e-08
to O 0 8.392400729917426e-08
identify O 0 2.6792363314598333e-06
mutations O 0 3.9128710341174155e-05
. O 0 4.411933696246706e-05

Mutations O 0 1.0287336408509873e-05
were O 0 7.087418225637521e-07
detected O 0 6.443655138355098e-07
in O 0 8.793852401822733e-08
21 O 0 1.30254227315163e-06
( O 0 1.5468451408651163e-07
91 O 0 3.0139122486616543e-07
% O 0 3.630198008863772e-08
) O 0 5.815730830249777e-08
of O 0 1.118405180022819e-06
23 O 0 0.0012348536401987076
tumors B-Disease 1 1.0
with O 0 0.0018777195364236832
LOH O 1 0.9999998807907104
. O 0 0.00013165637210477144

In O 0 1.7713060742607922e-06
6 O 0 1.1331154382787645e-05
( O 0 3.009176055002172e-07
38 O 0 5.407673597801477e-07
% O 0 5.159306226687477e-08
) O 0 4.148885679455816e-08
of O 0 2.7684711767506087e-07
16 O 0 0.00010032483260147274
tumors B-Disease 1 1.0
without O 0 0.0010328794596716762
LOH O 1 0.9999972581863403
, O 0 1.0891855595218658e-07
one O 0 2.1420234475044708e-08
mutation O 0 3.759905808919939e-08
was O 0 7.13466619117753e-08
detected O 0 4.3689190931672783e-08
, O 0 1.4695945793619103e-08
and O 0 1.837685559280544e-08
in O 0 2.152528466581316e-08
9 O 0 9.748832781042438e-07
( O 0 4.428933664257784e-08
56 O 0 8.989556476990401e-08
% O 0 1.0780655479436518e-08
) O 0 1.5434920896950644e-08
of O 0 6.477454661535376e-08
the O 0 6.923522164470342e-07
tumors B-Disease 1 1.0
without O 0 0.0003535884025041014
LOH O 1 0.9999974966049194
, O 0 1.0028193031530463e-07
both O 0 7.136939217389227e-08
mutations O 0 4.3343374045434757e-07
were O 0 5.046188107371563e-07
found O 0 1.9965832507296e-06
. O 0 1.3114569810568355e-05

Thus O 0 6.364282398862997e-06
, O 0 3.324684882954898e-07
a O 0 1.0467984878914649e-07
total O 0 3.0563271025130234e-08
of O 0 6.01154468427012e-08
45 O 0 1.4567909545348812e-07
mutations O 0 2.1983923659263382e-07
were O 0 1.1605205685327746e-07
identified O 0 4.365787162896595e-07
in O 0 3.146898848171986e-07
tumors B-Disease 1 1.0
of O 0 0.007668116595596075
36 O 0 0.21114690601825714
patients O 0 5.0343864131718874e-05
. O 0 6.909006333444268e-05

Thirty O 0 3.871570879709907e-05
- O 0 3.8621342355327215e-06
nine O 0 3.4316715868953906e-07
of O 0 6.948764763592408e-08
the O 0 7.578562133403466e-08
mutations O 0 2.805511201131594e-07
- O 0 3.4027064543806773e-07
including O 0 7.556089087756845e-08
34 O 0 5.798672191303922e-07
small O 0 6.168829003172505e-08
mutations O 0 2.0900546360280714e-07
, O 0 7.092848619549841e-08
2 O 0 6.504345719804405e-07
large O 0 1.2491420875448966e-07
structural O 0 7.01205181030673e-06
alterations O 0 3.390043048057123e-06
, O 0 6.858959977762424e-08
and O 0 7.292974402162145e-08
hypermethylation O 0 1.0593459592200816e-05
in O 0 4.579295520557025e-08
3 O 0 3.115525487373816e-06
tumors O 1 0.99998939037323
- O 0 3.1671945066591434e-07
were O 0 1.1836982949375852e-08
not O 0 3.870394671423583e-09
detected O 0 2.6284697085543485e-08
in O 0 1.3576035406970277e-08
the O 0 7.062393336809691e-08
corresponding O 0 9.676149375081877e-07
peripheral O 0 5.603476893156767e-05
blood O 0 4.007069037470501e-06
DNA O 0 8.973863259598147e-06
. O 0 8.091907147900201e-06

In O 0 1.3756117596130935e-06
6 O 0 7.666968485864345e-06
( O 0 2.786026129797392e-07
17 O 0 4.195262590656057e-07
% O 0 2.0719941318247947e-08
) O 0 1.4952735938322803e-08
of O 0 2.4945205012727456e-08
the O 0 3.856976960037173e-08
36 O 0 2.0639642173136963e-07
patients O 0 1.8705845761246565e-08
, O 0 1.1581762215939762e-08
a O 0 3.154717020947828e-08
mutation O 0 9.804825396031447e-08
was O 0 1.3647357377521985e-07
detected O 0 6.765461080249224e-08
in O 0 2.0652944243693128e-08
constitutional O 0 3.1381776466332667e-07
DNA O 0 1.3956680788851372e-07
, O 0 9.221851726692876e-09
and O 0 1.0268546901670561e-08
1 O 0 7.62794201136785e-08
of O 0 1.0054850285712291e-08
these O 0 2.9372109189296225e-09
mutations O 0 9.596088368368783e-09
is O 0 2.0627504149217657e-09
known O 0 6.211627212593385e-09
to O 0 5.765188326734005e-09
be O 0 3.411706472888909e-08
associated O 0 1.2250411884906498e-07
with O 0 2.0926634647366882e-07
reduced O 0 3.1551277061225846e-05
expressivity O 0 0.0024103845935314894
. O 0 2.424480226181913e-05

The O 0 1.0960435474771657e-06
presence O 0 2.9771578624604444e-07
of O 0 1.953052475300865e-07
a O 0 9.618594987159668e-08
constitutional O 0 7.89523767252831e-07
mutation O 0 1.3435878543077706e-07
was O 0 1.0059111588134328e-07
not O 0 7.720430517110799e-09
associated O 0 1.9333601386506416e-08
with O 0 9.19485643180451e-09
an O 0 1.4820900950951454e-08
early O 0 1.3964616982775624e-06
age O 0 1.3749199752055574e-05
at O 0 1.642591269046534e-05
treatment O 0 2.630212293297518e-05
. O 0 1.9505559976096265e-05

In O 0 1.6799458535388112e-06
1 O 0 4.570483270072145e-06
patient O 0 9.543483656671015e-07
, O 0 3.251126940995164e-07
somatic O 0 6.0072619817219675e-05
mosaicism O 0 0.0006069366936571896
was O 0 2.0135864815529203e-06
demonstrated O 0 7.074722248034959e-07
by O 0 5.321527396517922e-08
molecular O 0 3.219351185634878e-07
analysis O 0 6.414873610083305e-08
of O 0 1.2500348134381056e-07
DNA O 0 4.849910055781947e-07
and O 0 1.2369604007744783e-07
RNA O 0 1.409992364642676e-06
from O 0 3.123547287486872e-07
peripheral O 0 0.0006281317328102887
blood O 0 3.0889652407495305e-05
. O 0 4.8721918574301526e-05

In O 0 3.648764959507389e-06
2 O 0 9.5389486887143e-06
patients O 0 2.948096096133668e-07
without O 0 1.7081437420074508e-07
a O 0 1.6467053853830294e-07
detectable O 0 1.9376298041606788e-06
mutation O 0 2.5518559709780675e-07
in O 0 5.048382334393864e-08
peripheral O 0 1.1889786037500016e-05
blood O 0 5.553972073357727e-07
, O 0 3.3187512826771126e-07
mosaicism O 0 0.0005084203439764678
was O 0 4.508050892582105e-07
suggested O 0 5.5508486695998727e-08
because O 0 9.813970969219099e-09
1 O 0 1.4398847270058468e-07
of O 0 5.8339733044476816e-08
the O 0 1.2219653910960915e-07
patients O 0 6.420798968065355e-07
showed O 0 4.360834645922296e-05
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 2.034498947978136e-06
the O 0 3.270697277457657e-07
other O 0 4.494785343922558e-08
later O 0 6.571339099536999e-07
developed O 0 2.6788147806655616e-06
bilateral B-Disease 0 4.4619417167268693e-05
retinoblastoma I-Disease 0 0.05575430393218994
. O 0 2.8581511287484318e-05

In O 0 9.91996444099641e-07
conclusion O 0 2.0944394236721564e-06
, O 0 1.7979429856040952e-07
our O 0 1.569884915397779e-07
results O 0 2.282217650417806e-07
emphasize O 0 1.4417892657547782e-07
that O 0 1.2962400930405238e-08
the O 0 6.43450519532962e-08
manifestation O 0 3.1624576877220534e-06
and O 0 1.8468607265731407e-07
transmissibility O 0 1.7553275029058568e-05
of O 0 3.4725766795418167e-07
retinoblastoma B-Disease 0 1.1618350981734693e-05
depend O 0 6.129410223820742e-08
on O 0 3.67433514725235e-08
the O 0 1.377636582589048e-08
nature O 0 1.6103285815916024e-08
of O 0 1.5611025361295106e-08
the O 0 8.13037459579391e-09
first O 0 1.4469209830281216e-08
mutation O 0 1.4222733213387073e-08
, O 0 3.854342622844342e-09
its O 0 3.3656217812705336e-09
time O 0 8.904502024620342e-09
in O 0 4.150783716738715e-09
development O 0 4.3530071991426667e-08
, O 0 5.717684103956344e-09
and O 0 3.862135500298791e-09
the O 0 4.6254844399129524e-09
number O 0 3.579441187895327e-09
and O 0 4.223537519720821e-09
types O 0 1.0945019113250964e-08
of O 0 2.088762940388733e-08
cells O 0 2.316737912622102e-08
that O 0 3.1282849644043154e-09
are O 0 1.1570633340340919e-08
affected O 0 1.3826546307882381e-07
. O 0 4.461002447442297e-07
. O 0 8.673994670971297e-06

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999947547912598
of I-Disease 0 0.00023769283143337816
the I-Disease 0 1.3166262760933023e-05
fifth I-Disease 0 2.0402621885295957e-05
component I-Disease 0 1.704350438558322e-06
of I-Disease 0 9.130753824138083e-07
complement I-Disease 0 3.1478462005907204e-06
in O 0 5.286150894789898e-07
man O 0 5.3852265409659594e-05
. O 0 2.2202142645255663e-05

I O 0 0.006801981944590807
. O 0 0.00043959019239991903

Clinical O 0 0.0006636352627538145
, O 0 6.277144620980835e-06
immunochemical O 0 0.005698697175830603
, O 0 2.09339486900717e-06
and O 0 1.2678580105784931e-06
family O 0 8.629404533166962e-07
studies O 0 3.36192965733062e-06
. O 0 1.5172856365097687e-05

The O 0 3.0538967621396296e-06
first O 0 1.2944336731379735e-06
recognized O 0 6.194190973474178e-07
human O 0 9.970420933314017e-07
kindred O 0 0.00011456900392659009
with O 0 1.4454652955464553e-05
hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
of I-Disease 1 0.5003728866577148
the I-Disease 0 2.059851794911083e-05
fifth I-Disease 0 7.773887773510069e-06
component I-Disease 0 4.876950470134034e-07
of I-Disease 0 2.4965561351564247e-07
complement I-Disease 0 2.177359419874847e-06
( O 0 1.0692251635191496e-06
C5 O 1 0.9999513626098633
) O 0 2.9688447966691456e-07
is O 0 1.1991284054602147e-07
described O 0 2.028369181061862e-06
. O 0 6.656338428001618e-06

The O 0 1.216032342199469e-05
proband O 0 0.00015472265658900142
, O 0 5.221735932536831e-07
a O 0 2.1782264525427308e-07
20 O 0 6.382178980857134e-07
- O 0 4.1510395476507256e-07
year O 0 8.313093502465563e-08
- O 0 1.223810841111117e-06
old O 0 2.4603814381407574e-06
black O 0 3.805340838880511e-06
female O 0 1.0599724191706628e-05
with O 0 0.00015084963524714112
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.016877448186278343
age O 0 1.7606485926080495e-05
11 O 0 2.550413682911312e-06
, O 0 1.2839447549595207e-07
lacked O 0 6.315363407338737e-06
serum O 0 3.5610612485470483e-06
hemolytic O 0 7.110004662536085e-05
complement O 0 4.804949753633991e-07
activity O 0 2.975247639369627e-07
, O 0 8.047374677744301e-08
even O 0 2.403260452865652e-07
during O 0 2.2967446966504212e-06
remission O 0 2.2451467884820886e-05
. O 0 1.0066776667372324e-05

C5 O 1 0.9997962117195129
was O 0 6.95968556101434e-05
undetectable O 0 4.7900954086799175e-05
in O 0 1.756175009859362e-07
her O 0 7.243386335176183e-08
serum O 0 5.660814395014313e-07
by O 0 6.464101431902236e-08
both O 0 4.811479357158532e-07
immunodiffusion O 0 0.0007566809072159231
and O 0 1.8025466488325037e-05
hemolytic O 1 0.9999996423721313
assays O 0 0.0020662301685661077
. O 0 6.961252802284434e-05

Other O 0 6.183083769428777e-07
complement O 0 1.1390571899028146e-06
components O 0 1.12484246983513e-06
were O 0 1.8215617103578552e-07
normal O 0 1.2807785765289736e-07
during O 0 1.1041853298365822e-07
remission O 0 4.655344980619702e-07
of O 0 2.5497956812614575e-07
lupus O 0 0.017072143033146858
, O 0 2.341250393556038e-07
but O 0 4.510058886353363e-07
C1 O 1 0.9998875856399536
, O 0 1.999678033826058e-06
C4 O 1 0.9999303817749023
, O 0 5.667070013259945e-07
C2 O 0 0.0319230854511261
, O 0 2.590161614079989e-07
and O 0 6.823831313340634e-07
C3 O 1 0.9978935122489929
levels O 0 6.005521754559595e-06
fell O 0 4.2393625335535035e-05
during O 0 6.7948762989544775e-06
exacerbations O 0 0.0006362221320159733
. O 0 3.819270932581276e-05

A O 0 3.539653334883042e-05
younger O 0 1.606303521839436e-05
half O 0 2.8126257802796317e-06
- O 0 9.75466628005961e-06
sister O 0 1.396686911903089e-06
, O 0 1.6285967774365417e-07
who O 0 9.873398454374183e-08
had O 0 4.250710219366738e-07
no O 0 2.246075609946274e-06
underlying O 1 0.999972939491272
disease O 1 0.9996339082717896
, O 0 2.1608871065836865e-06
was O 0 5.267759661364835e-06
also O 0 4.3261234594638154e-08
found O 0 2.811681554248935e-08
to O 0 4.218853533188849e-08
lack O 0 7.215253845060943e-06
immunochemically O 0 0.02256152406334877
detectable O 0 0.044435273855924606
C5 O 1 0.9998459815979004
. O 0 4.050447387271561e-05

By O 0 1.784442429197952e-05
hemolytic O 1 0.9999089241027832
assay O 0 0.00014643701433669776
, O 0 6.865804493827454e-07
she O 0 1.0619393719935033e-07
exhibited O 0 3.5744466231335537e-07
1 O 0 4.224369547500828e-07
- O 0 1.0073800638110697e-07
2 O 0 5.465958707873142e-08
% O 0 3.265353099024537e-09
of O 0 1.2173146046734473e-08
the O 0 2.3346766298004695e-08
normal O 0 2.3785709402091015e-07
serum O 0 7.466846341230848e-07
C5 O 0 7.321134035009891e-05
level O 0 4.4933028675586684e-07
and O 0 1.673751981456917e-08
normal O 0 2.1885288248313373e-08
concentrations O 0 2.8910299931794725e-08
of O 0 2.0102078224226716e-08
other O 0 2.5554792060233922e-08
complement O 0 6.794181786062836e-07
components O 0 7.330856533371843e-06
. O 0 8.741108104004525e-06

C5 O 0 0.010165847837924957
levels O 0 2.6641246222425252e-06
of O 0 4.583271504543518e-07
other O 0 2.5294770722439353e-08
family O 0 1.2969226581560633e-08
members O 0 9.092067543292615e-09
were O 0 1.9770880044234218e-08
either O 0 5.010547710071478e-08
normal O 0 2.1403555194865476e-07
or O 0 6.927643880771939e-08
approximately O 0 1.1845354919159945e-07
half O 0 8.03262238946445e-08
- O 0 8.02207296146662e-08
normal O 0 4.890830140880098e-08
, O 0 2.3651004710245616e-08
consistent O 0 2.7819825731967285e-07
with O 0 8.518352956343733e-08
autosomal O 0 6.635234058194328e-06
codominant O 0 6.397952347469982e-06
inheritance O 0 2.195394159798525e-07
of O 0 1.3758385364326386e-07
the O 0 4.3149447037649225e-07
gene O 0 3.0610638077632757e-06
determining O 0 0.0004688468761742115
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0009350485634058714

Normal O 0 0.0003216824261471629
hemolytic O 1 0.9998214840888977
titers O 0 0.0006357732345350087
were O 0 1.7484688896729494e-06
restored O 0 2.3761547254252946e-06
to O 0 5.438203487528881e-08
both O 0 3.1477154038839217e-07
homozygous O 0 9.776173101272434e-05
C5 B-Disease 1 1.0
- I-Disease 1 0.9999972581863403
deficient I-Disease 1 1.0
( O 0 0.0004259594716131687
C5D B-Disease 1 1.0
) O 0 8.650853260405711e-07
sera O 0 5.376576609705808e-06
by O 0 2.9276145951939725e-08
addition O 0 6.774344996074433e-08
of O 0 2.843480046976765e-07
highly O 0 6.140916866570478e-06
purified O 0 1.8583372366265394e-05
human O 0 9.589259207132272e-06
C5 O 1 0.9995675683021545
. O 0 3.3547905331943184e-05

In O 0 4.5602691898238845e-06
specific O 0 4.070260729349684e-06
C5 O 1 0.9997187256813049
titrations O 0 0.00027210195548832417
, O 0 3.4059206655001617e-07
however O 0 1.9873685630500404e-07
, O 0 4.0421696212433744e-08
it O 0 9.901116371224816e-09
was O 0 5.3818940415339966e-08
noted O 0 1.0425459606722143e-08
that O 0 1.977143782028179e-09
when O 0 1.2955380768175928e-08
limited O 0 2.2062112137177792e-08
amounts O 0 2.986222114031989e-08
of O 0 2.26005823833475e-07
C5 O 0 0.1440967172384262
were O 0 1.1361395024778176e-07
assayed O 0 8.43225507196621e-07
in O 0 9.607058260030499e-09
the O 0 9.626997865552767e-09
presence O 0 3.042600482672242e-08
of O 0 5.848434625477239e-08
low O 0 6.43121097709809e-07
dilutions O 0 2.1483718228409998e-05
of O 0 7.769854164507706e-07
either O 0 7.873252798162866e-06
C5D B-Disease 1 1.0
serum O 0 2.0152647266513668e-05
, O 0 2.9751086572105123e-07
curving O 0 1.2327872127571027e-06
rather O 0 7.531240697744579e-08
than O 0 3.62727732294843e-08
linear O 0 2.464213366693002e-07
dose O 0 4.872580348092015e-07
- O 0 4.706992129399623e-08
response O 0 1.4850187746162646e-08
plots O 0 5.1392998301480475e-08
were O 0 2.166049561935779e-08
consistently O 0 8.634922465944328e-08
obtained O 0 6.155089948833847e-08
, O 0 2.7670557400938378e-08
suggesting O 0 1.0540813377701852e-07
some O 0 6.107050865011843e-08
inhibitory O 0 3.380506086614332e-06
effect O 0 6.202653366926825e-06
. O 0 9.499367479293142e-06

Further O 0 6.219623628567206e-06
studies O 0 5.955168376203801e-07
suggested O 0 3.0198680178727955e-07
that O 0 3.491393840704404e-08
low O 0 9.915158898365917e-07
dilutions O 0 0.0001066442346200347
of O 0 1.4048159755475353e-05
C5D B-Disease 1 1.0
serum O 0 1.5391534589070943e-06
contain O 0 5.775096667548496e-08
a O 0 2.2151544598614237e-08
factor O 0 5.0573454757341096e-08
( O 0 1.7044701650092975e-08
or O 0 2.0057420613284194e-08
factors O 0 8.303838683332287e-08
) O 0 3.77158464459626e-08
interfering O 0 1.262082918174201e-07
at O 0 1.5005396392098191e-07
some O 0 2.1780763859169383e-08
step O 0 2.4479575699842826e-07
in O 0 3.6841107942109375e-08
the O 0 1.8344675822845602e-07
hemolytic O 0 0.01672765053808689
assay O 0 4.250039637554437e-06
of O 0 2.94179835691466e-06
C5 O 1 0.9999957084655762
, O 0 7.592220185870246e-08
rather O 0 3.493805422749574e-08
than O 0 2.273605659297573e-08
a O 0 1.0171902431466151e-07
true O 0 2.565423073974671e-06
C5 O 1 0.9965447783470154
inhibitor O 0 9.145544754574075e-05
or O 0 2.527522383388714e-06
inactivator O 0 0.00012676024925895035
. O 0 1.595654248376377e-05

Of O 0 7.175386599556077e-06
clinical O 0 1.5083767721080221e-05
interest O 0 4.422071810950001e-07
are O 0 4.489336191682014e-08
( O 0 5.4638217505953435e-08
a O 0 4.5489656486097374e-08
) O 0 1.0140942308112244e-08
the O 0 1.657227066687028e-08
documentation O 0 2.07800084695009e-07
of O 0 1.1491277973618708e-06
membranous O 1 0.9999949932098389
glomerulonephritis B-Disease 1 1.0
, O 1 0.9998573064804077
vasculitis B-Disease 1 1.0
, O 1 0.6814438700675964
and O 1 0.8944176435470581
arthritis B-Disease 1 1.0
in O 0 3.6215126897332084e-07
an O 0 2.946459609631802e-08
individual O 0 3.65275028002543e-08
lacking O 0 5.2827399485977367e-05
C5 O 1 0.9999903440475464
( O 0 6.441332089934804e-08
and O 0 1.1852413273061302e-08
its O 0 1.1253554532686394e-08
biologic O 0 2.8079523417545715e-07
functions O 0 2.936652165885789e-08
) O 0 4.81125672635585e-09
, O 0 5.770029343210581e-09
and O 0 1.629214274601054e-08
( O 0 2.3455227093904796e-08
b O 0 1.8109905397523107e-07
) O 0 1.4737826958821643e-08
a O 0 2.5450697549445067e-08
remarkable O 0 3.274723212598474e-07
propensity O 0 1.3789348258796963e-06
to O 0 5.218709020482493e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 0.9999951124191284
in O 0 5.298768712691526e-08
the O 0 7.844840155257771e-08
proband O 0 5.175764727027854e-06
, O 0 1.3044695101882553e-08
even O 0 5.8320899221087075e-09
during O 0 1.9362312642101642e-08
periods O 0 4.8460634616276366e-08
of O 0 2.6939087405253304e-08
low O 0 2.8499849236141017e-07
- O 0 9.165007242017964e-08
dose O 0 1.5712883794094523e-07
or O 0 3.326178088514098e-08
alternate O 0 4.338874362019851e-07
- O 0 1.1454166042312863e-06
day O 0 5.434438890006277e-07
corticosteroid O 0 0.00035439798375591636
therapy O 0 7.686889148317277e-05
. O 0 1.3489687262335792e-05

Other O 0 5.448792990137008e-07
observations O 0 4.739071357562352e-07
indicate O 0 1.0907531589054997e-07
that O 0 3.921274327467472e-08
the O 0 3.852029806239443e-07
C5D B-Disease 1 0.9999996423721313
state O 0 4.818523180460943e-08
is O 0 1.528719728582928e-08
compatible O 0 2.760590973593935e-07
with O 0 1.3872371695811125e-08
normal O 0 6.097902627288931e-08
coagulation O 0 1.0668320982176738e-07
function O 0 1.900201240800925e-08
and O 0 6.08955463832217e-09
the O 0 1.7116505546255212e-08
capacity O 0 1.0820006224321332e-07
to O 0 2.2287670375931157e-08
mount O 0 6.225332526810234e-06
a O 0 3.846483195957262e-06
neutrophilic O 1 0.954626202583313
leukocytosis O 0 0.3336767852306366
during O 0 0.00013816499267704785
pyogenic B-Disease 0 0.12268293648958206
infection I-Disease 0 0.00010317430133000016
. O 0 3.4320485156058567e-06
. O 0 1.9044638975174166e-05

Susceptibility O 0 0.03730297461152077
to O 0 0.0014810184948146343
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 5.647271973430179e-05
twins O 0 6.766383012291044e-05
: O 0 6.710405386911589e-08
the O 0 1.1543299649474648e-08
role O 0 2.5651189616837655e-08
of O 0 2.5156777994084223e-08
genes O 0 2.3294724371680786e-08
, O 0 1.3105349694342294e-07
HLA O 0 5.409706136560999e-05
, O 0 2.565442684954178e-07
and O 0 4.3999236254421703e-07
the O 0 1.8591154002933763e-06
environment O 0 2.4891249267966487e-05
. O 0 2.08531509997556e-05

OBJECTIVE O 0 2.322775799257215e-05
To O 0 1.6595002705344086e-07
determine O 0 1.4303563489193039e-07
the O 0 3.752225907760476e-08
relative O 0 2.8579322020050313e-07
effects O 0 1.9156802864017664e-06
of O 0 4.4077688698962447e-07
genetic O 0 4.713932639788254e-07
and O 0 3.938574266726391e-08
environmental O 0 5.349084375438906e-08
factors O 0 4.622558691380618e-08
in O 0 2.3125128478795887e-08
susceptibility O 0 6.354996912705246e-06
to O 0 3.9884253055788577e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9173022508621216
AS B-Disease 1 0.9999995231628418
) O 0 1.1657556342470343e-06
. O 0 3.480796522126184e-06

METHODS O 0 0.00010670883784769103
Twins O 0 8.100439299596474e-05
with O 0 2.500361233614967e-07
AS B-Disease 1 0.7987334132194519
were O 0 2.1285595153130998e-07
identified O 0 7.531455992193514e-08
from O 0 1.2248047909224624e-08
the O 0 7.914425026456229e-08
Royal O 0 0.00010670069605112076
National O 0 0.007221904583275318
Hospital O 0 0.4291297495365143
for O 0 6.524047057610005e-05
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 0.9999997615814209
database O 0 8.467519364785403e-05
. O 0 8.509944018442184e-05

Clinical O 0 0.0001928053388837725
and O 0 1.9748774775507627e-06
radiographic O 0 0.00013359569129534066
examinations O 0 1.1390352483431343e-05
were O 0 2.812765842463705e-07
performed O 0 1.232231880976542e-07
to O 0 3.723771513364227e-08
establish O 0 7.156431252042239e-07
diagnoses O 0 0.009072874672710896
, O 0 5.2141895139357075e-06
and O 0 0.00027315804618410766
disease O 1 0.9992297887802124
severity O 0 0.43301233649253845
was O 0 1.3940273674961645e-05
assessed O 0 3.6357667454467446e-07
using O 0 4.2202700001325866e-08
a O 0 4.484398630211217e-08
combination O 0 3.5487477134665824e-07
of O 0 4.932367687615624e-07
validated O 0 4.783543317898875e-06
scoring O 0 5.41277449883637e-06
systems O 0 2.9183180231484585e-05
. O 0 9.909554137266241e-06

HLA O 0 0.001802466344088316
typing O 0 3.1573130399920046e-05
for O 0 1.419689738213492e-06
HLA O 0 7.466637180186808e-05
- O 0 6.386017048498616e-06
B27 O 0 1.7571597709320486e-05
, O 0 6.038210926817555e-07
HLA O 0 1.7759404727257788e-05
- O 0 1.4641243524238234e-06
B60 O 0 3.7245713429001626e-06
, O 0 1.0750455459174191e-07
and O 0 6.090313036111183e-07
HLA O 0 0.005477586295455694
- O 0 3.7355395761551335e-05
DR1 O 1 0.754406750202179
was O 0 5.491444881045027e-07
performed O 0 1.0765166535975368e-07
by O 0 4.200194325676421e-08
polymerase O 0 1.0064636626339052e-06
chain O 0 1.1189349891083111e-07
reaction O 0 8.84868498474134e-08
with O 0 3.12825676473949e-08
sequence O 0 8.84439970150197e-08
- O 0 4.574319589778497e-08
specific O 0 1.0135025263480202e-08
primers O 0 3.6342447629067465e-07
, O 0 3.720356644976164e-08
and O 0 1.4043598639545962e-07
zygosity O 0 3.0174202038324438e-05
was O 0 1.8161772459279746e-06
assessed O 0 2.6632608296495164e-06
using O 0 1.6604517441010103e-06
microsatellite O 0 7.029133121250197e-05
markers O 0 2.391205634921789e-05
. O 0 4.906134563498199e-05

Genetic O 0 1.4624282812292222e-05
and O 0 3.034058977391396e-07
environmental O 0 1.9712710752628482e-07
variance O 0 1.1169944258426767e-07
components O 0 2.8824084097323066e-07
were O 0 6.535995566991915e-08
assessed O 0 1.5316913959395606e-07
with O 0 5.87452531064514e-09
the O 0 1.4228511702185642e-08
program O 0 2.143915800445484e-08
Mx O 0 1.3910425877838861e-06
, O 0 4.296878408638349e-09
using O 0 4.200729097902922e-09
data O 0 4.986101309611968e-09
from O 0 2.147241939809419e-09
this O 0 3.115298685685275e-09
and O 0 8.916636318190285e-09
previous O 0 4.187723590121095e-08
studies O 0 3.912234802783132e-08
of O 0 7.645391519872646e-08
twins O 0 2.8451829621189972e-06
with O 0 4.449568962172634e-07
AS B-Disease 1 0.9999791383743286
. O 0 4.609322058968246e-05

RESULTS O 0 7.50318868085742e-05
Six O 0 6.596199000341585e-06
of O 0 3.243958872189978e-06
8 O 0 0.00012003078882116824
monozygotic O 1 0.8190446496009827
( O 0 2.8552361982292496e-05
MZ O 1 0.9999953508377075
) O 0 2.1505502445506863e-06
twin O 0 9.457203123020008e-05
pairs O 0 1.8970237078974606e-06
were O 0 6.687510449410183e-06
disease O 0 0.001222167513333261
concordant O 0 8.980146230896935e-05
, O 0 1.4758465738395898e-07
compared O 0 6.106829886221021e-08
with O 0 8.330342637918875e-09
4 O 0 2.27696318688686e-07
of O 0 8.818980745672889e-08
15 O 0 2.93173940235647e-07
B27 O 0 2.4445871531497687e-06
- O 0 3.0722046062692243e-07
positive O 0 3.888281128183735e-07
dizygotic O 0 0.0005105328164063394
( O 0 2.899244236687082e-06
DZ O 0 0.18055613338947296
) O 0 7.103258781171462e-07
twin O 0 9.266193956136703e-06
pairs O 0 1.887497802499638e-07
( O 0 1.3125787745593698e-07
27 O 0 4.640828024093935e-07
% O 0 1.40235583145909e-08
) O 0 9.852889171213519e-09
and O 0 1.9515104199285815e-08
4 O 0 2.9222820785435033e-07
of O 0 1.5561802513275325e-07
32 O 0 8.075455298239831e-06
DZ O 0 0.054014161229133606
twin O 0 3.5685745842783945e-06
pairs O 0 1.2109514102576213e-07
overall O 0 5.179766162655142e-07
( O 0 7.57091953573763e-08
12 O 0 1.4784740187678835e-07
. O 0 2.9065830631225253e-08
5 O 0 2.511215200229344e-07
% O 0 1.75233395793839e-07
) O 0 5.323918230715208e-07
. O 0 6.551630576723255e-06

Nonsignificant O 0 0.0007089663413353264
increases O 0 1.900272195598518e-06
in O 0 1.0263264016430185e-07
similarity O 0 1.6539830482997786e-07
with O 0 2.1090716728622283e-08
regard O 0 1.1460903692750435e-07
to O 0 1.8367568799249057e-08
age O 0 5.1170163715141825e-06
at O 0 3.913479304173961e-05
disease O 0 1.7229252989636734e-05
onset O 0 0.00039482698775827885
and O 0 7.444677407875133e-08
all O 0 3.044486973635685e-08
of O 0 1.1273753131035846e-07
the O 0 2.109410246475818e-07
disease O 0 1.4776240959690767e-06
severity O 0 1.8728962913883151e-06
scores O 0 6.509167178592179e-07
assessed O 0 3.9672704588156193e-07
were O 0 8.159584297118272e-08
noted O 0 1.5962989152740192e-07
in O 0 3.06116987758287e-07
disease O 0 0.008156649768352509
- O 0 0.0016139376675710082
concordant O 1 0.8700663447380066
MZ O 1 0.9999990463256836
twins O 0 3.8664202293148264e-05
compared O 0 1.2775083177984925e-06
with O 0 1.2028293667754042e-06
concordant O 0 0.0559065155684948
DZ O 1 0.9998912811279297
twins O 0 0.0017715718131512403
. O 0 5.399923611548729e-05

HLA O 0 0.022405698895454407
- O 0 0.0001226735330419615
B27 O 0 5.433064143289812e-05
and O 0 4.419091226282035e-07
B60 O 0 1.076099943020381e-05
were O 0 1.4743315546184022e-07
associated O 0 1.440596264501437e-07
with O 0 4.138697917710488e-08
the O 0 5.062552190793213e-07
disease O 0 1.0481372555659618e-05
in O 0 8.659530692511908e-08
probands O 0 0.001142132910899818
, O 0 4.0945320023411114e-08
and O 0 1.9367668357972434e-08
the O 0 2.8309731447961894e-08
rate O 0 9.578025128575973e-08
of O 0 1.195568017919868e-07
disease O 0 8.367296686628833e-07
concordance O 0 1.3169036492399755e-06
was O 0 2.012195494671687e-07
significantly O 0 1.1442392633398413e-07
increased O 0 2.3541757343537029e-07
among O 0 8.873908541318087e-07
DZ O 1 0.5704160332679749
twin O 0 9.411504834133666e-06
pairs O 0 6.860242507400471e-08
in O 0 2.4102901008404842e-08
which O 0 2.455687209135249e-08
the O 0 1.1170115499226085e-07
co O 0 4.133005404582946e-06
- O 0 1.223375534209481e-06
twin O 0 1.926932554852101e-06
was O 0 2.1100883884628274e-07
positive O 0 3.346043442320479e-08
for O 0 4.189648805663637e-08
both O 0 2.618939447529556e-07
B27 O 0 3.1192983442451805e-05
and O 0 5.864626018592389e-06
DR1 O 0 0.18212318420410156
. O 0 2.9916987841716036e-05

Additive O 0 1.9173774489900097e-05
genetic O 0 2.2271665329753887e-06
effects O 0 1.64892730936117e-06
were O 0 1.7646651429004123e-07
estimated O 0 5.4247873748636266e-08
to O 0 7.61732543708149e-09
contribute O 0 6.418447640044178e-08
97 O 0 1.9793770889009465e-07
% O 0 1.586294473554517e-08
of O 0 3.759260636115869e-08
the O 0 5.187487772673194e-08
population O 0 1.3766016770944134e-08
variance O 0 5.9468254676176e-07
. O 0 4.423017799126683e-06

CONCLUSION O 0 4.335292396717705e-05
Susceptibility O 0 3.04810018860735e-05
to O 0 3.7447514955601946e-07
AS B-Disease 1 0.821728527545929
is O 0 8.200039047778773e-08
largely O 0 1.0284427531814799e-07
genetically O 0 5.698590399560999e-08
determined O 0 6.815845665641973e-08
, O 0 2.2239344588115273e-08
and O 0 2.8543469809960698e-08
the O 0 5.605107844530721e-08
environmental O 0 1.7385247019774397e-07
trigger O 0 6.842273023721646e-07
for O 0 1.43118185746971e-07
the O 0 1.3434050742944237e-06
disease O 0 3.518756420817226e-05
is O 0 1.0625574020650674e-07
probably O 0 2.314339099029894e-06
ubiquitous O 0 1.721135777188465e-05
. O 0 1.2745810636261012e-05

HLA O 0 0.004781562834978104
- O 0 4.293090387363918e-05
B27 O 0 1.8142929548048414e-05
accounts O 0 8.792108019406442e-08
for O 0 3.979820561994529e-08
a O 0 4.437423584136013e-08
minority O 0 4.774555151243476e-08
of O 0 8.510914994985797e-08
the O 0 8.320136402062417e-08
overall O 0 8.891817060430185e-07
genetic O 0 6.30130045919941e-07
susceptibility O 0 3.0091096050455235e-06
to O 0 9.62107833402115e-07
AS B-Disease 1 0.9999959468841553
. O 0 0.00024837948149070144

Cell O 0 0.00012947678624186665
cycle O 0 1.537019488750957e-05
- O 0 3.125894181721378e-06
dependent O 0 6.016420002197265e-07
colocalization O 0 7.454220394720323e-06
of O 0 1.5943696780595928e-06
BARD1 O 1 0.7743248343467712
and O 0 1.0482924608368194e-06
BRCA1 O 0 1.8914182646767586e-06
proteins O 0 6.710674682608442e-08
in O 0 5.224076815579792e-08
discrete O 0 1.291263629354944e-06
nuclear O 0 7.223667125799693e-06
domains O 0 7.5380189628049266e-06
. O 0 8.840418558975216e-06

Germ O 1 0.5764824151992798
- O 0 0.00024123485491145402
line O 0 9.69940720096929e-06
mutations O 0 7.27444103176822e-07
of O 0 4.1593375499360263e-07
the O 0 3.7675408748327754e-07
BRCA1 O 0 3.3923554383363808e-06
gene O 0 2.5561354277670034e-07
predispose O 0 1.5322393664973788e-06
women O 0 1.2506225743891264e-07
to O 0 4.1791775373667406e-08
early O 0 9.911302186083049e-05
- O 1 0.9928032755851746
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 5.008932475902839e-06
compromising O 0 1.54970221046824e-05
the O 0 1.6992724738429388e-07
genes O 0 7.431228254972666e-08
presumptive O 0 1.509121602794039e-06
function O 0 4.5140043880564917e-07
as O 0 2.691246550057258e-07
a O 0 2.2578551579499617e-06
tumor B-Disease 0 0.00012926866475027055
suppressor O 0 0.002044219523668289
. O 0 7.460878987330943e-05

Although O 0 3.241834065192961e-06
the O 0 6.640492529186304e-07
biochemical O 0 4.670420821639709e-06
properties O 0 1.4563745480700163e-06
of O 0 1.337506660092913e-06
BRCA1 O 0 5.76244383410085e-06
polypeptides O 0 5.275584840092051e-07
are O 0 7.1830816850138035e-09
not O 0 1.040739938673596e-08
understood O 0 8.330044920512591e-08
, O 0 9.83857884051531e-09
their O 0 1.183630615742004e-08
expression O 0 1.3575095181295183e-07
pattern O 0 4.621730056442175e-07
and O 0 1.7090481208015262e-07
subcellular O 0 1.1731403901649173e-05
localization O 0 7.552352144557517e-06
suggest O 0 2.302753330241103e-07
a O 0 9.25420664543708e-08
role O 0 3.13749836777788e-07
in O 0 2.4016819111238874e-07
cell O 0 1.9694494767463766e-05
- O 0 7.587241725559579e-06
cycle O 0 6.3635357037128415e-06
regulation O 0 1.9055012671742588e-05
. O 0 1.1957454262301326e-05

When O 0 1.6045933080022223e-05
resting O 0 5.4282587370835245e-05
cells O 0 8.924584449232498e-07
are O 0 6.006616359854888e-08
induced O 0 4.966859705746174e-07
to O 0 3.130644543603012e-08
proliferate O 0 4.6059426495048683e-07
, O 0 3.98763155828874e-08
the O 0 2.9343116381141954e-08
steady O 0 3.212371098015865e-07
- O 0 5.3680743405948306e-08
state O 0 2.516895580839673e-09
levels O 0 2.9956922276141995e-08
of O 0 2.8789131079065555e-08
BRCA1 O 0 9.52957179833902e-08
increase O 0 7.958745662506317e-09
in O 0 9.77733183304963e-09
late O 0 4.498992893786635e-07
G1 O 0 5.9019025684392545e-06
and O 0 1.3254036979049033e-08
reach O 0 4.8342190694938836e-08
a O 0 3.448263896643766e-08
maximum O 0 6.220545287760615e-07
during O 0 7.777986752444122e-07
S O 0 1.8422570065013133e-05
phase O 0 9.124045755015686e-05
. O 0 1.4151940376905259e-05

Moreover O 0 1.9703251382452436e-05
, O 0 1.0739660183389788e-06
in O 0 3.671628121537651e-07
S O 0 1.2131851690355688e-05
phase O 0 8.241994510171935e-05
cells O 0 9.074068429981708e-07
, O 0 1.0009656392639954e-07
BRCA1 O 0 1.1593971294132643e-06
polypeptides O 0 4.257063324075716e-07
are O 0 4.348882498561579e-08
hyperphosphorylated O 0 2.5512724732834613e-06
and O 0 1.0141680917286067e-07
accumulate O 0 1.7655925432791264e-07
into O 0 9.690263169659374e-08
discrete O 0 2.5343506422359496e-06
subnuclear O 0 1.9247274394729175e-05
foci O 0 3.022719465661794e-05
termed O 0 7.5614184424921405e-06
" O 0 5.450422122521559e-06
BRCA1 O 0 5.7279881730210036e-05
nuclear O 0 0.0001690771896392107
dots O 0 0.0001817522570490837
. O 0 7.636527152499184e-05

" O 0 4.33298664574977e-05
BRCA1 O 0 8.222540782298893e-05
associates O 0 1.6185374988708645e-05
in O 0 9.580041933077155e-07
vivo O 0 7.5887828643317334e-06
with O 0 2.775371115149028e-07
a O 0 2.030846872003167e-06
structurally O 0 3.180822386639193e-05
related O 0 1.080063248082297e-05
protein O 0 4.561158493743278e-05
termed O 0 0.0001265819591935724
BARD1 O 1 0.9852446913719177
. O 0 5.727944153477438e-05

Here O 0 1.9440933556325035e-06
we O 0 1.4616603039030451e-07
show O 0 5.470902308957193e-08
that O 0 5.814906778311979e-09
the O 0 2.4963387801335557e-08
steady O 0 4.664237565066287e-07
- O 0 9.023312941280892e-08
state O 0 6.6220366967684186e-09
levels O 0 4.879080961472937e-08
of O 0 1.121336339338086e-07
BARD1 O 0 0.005134966224431992
, O 0 2.898190665234779e-08
unlike O 0 2.477965921343639e-08
those O 0 7.980665017726096e-09
of O 0 6.739805513689134e-08
BRCA1 O 0 3.3782652053560014e-07
, O 0 1.631515367250813e-08
remain O 0 5.297252769764782e-08
relatively O 0 4.4739159932305483e-08
constant O 0 3.2416036788163183e-07
during O 0 1.2055661500198767e-06
cell O 0 1.7067550288629718e-05
cycle O 0 6.82965310261352e-06
progression O 0 2.407035935902968e-05
. O 0 7.628568255313439e-06

However O 0 3.371496859472245e-05
, O 0 7.863317478040699e-06
immunostaining O 0 0.00027655891608446836
revealed O 0 1.4298629139375407e-05
that O 0 9.514104704066995e-07
BARD1 O 0 0.0013616137439385056
resides O 0 3.460602783889044e-06
within O 0 1.2371921229714644e-06
BRCA1 O 0 8.302067726617679e-06
nuclear O 0 8.445344064966775e-06
dots O 0 1.4923807611921802e-06
during O 0 3.6872256714559626e-07
S O 0 1.9074329884460894e-06
phase O 0 1.7587170759725268e-06
of O 0 5.5486363947920836e-08
the O 0 2.0102078224226716e-08
cell O 0 7.93555727796047e-08
cycle O 0 2.9382881905348768e-08
, O 0 3.1278732937067844e-09
but O 0 5.440721650984415e-09
not O 0 1.7875681379564412e-08
during O 0 3.078384054333583e-07
the O 0 1.0722793604145409e-06
G1 O 0 0.0005941638955846429
phase O 0 0.00017863269022200257
. O 0 2.7470645363791846e-05

Nevertheless O 0 0.00017477133951615542
, O 0 1.0239941730105784e-05
BARD1 O 0 0.0020789324771612883
polypeptides O 0 6.074353677831823e-06
are O 0 5.249827239595106e-08
found O 0 5.1385352861643696e-08
exclusively O 0 9.863685335176342e-08
in O 0 1.1723671811125769e-08
the O 0 2.79619332133052e-08
nuclear O 0 4.248388165706274e-07
fractions O 0 4.789619083567231e-07
of O 0 8.069584112035955e-08
both O 0 1.6972317951058358e-07
G1 O 0 5.8052839449374005e-05
- O 0 5.486409122568148e-07
and O 0 1.4854074947834306e-07
S O 0 1.4154948985378724e-05
- O 0 8.083315151452553e-06
phase O 0 0.00011043297126889229
cells O 0 8.378121492569335e-06
. O 0 4.318598257668782e-06

Therefore O 0 6.249340458452934e-06
, O 0 4.3841453134518815e-07
progression O 0 1.2727110743071535e-06
to O 0 5.38549826956114e-08
S O 0 4.102915227122139e-06
phase O 0 1.3453367500915192e-05
is O 0 1.9612944157643142e-08
accompanied O 0 4.071449311027209e-08
by O 0 9.437841619330811e-09
the O 0 1.204689414890936e-08
aggregation O 0 1.0266592198604485e-07
of O 0 7.767477683273682e-08
nuclear O 0 5.7609877330833115e-06
BARD1 O 0 0.0009394438820891082
polypeptides O 0 4.426570740179159e-06
into O 0 1.1132801773783285e-06
BRCA1 O 0 2.426642822683789e-05
nuclear O 0 6.675553595414385e-05
dots O 0 8.406968117924407e-05
. O 0 2.5475512302364223e-05

This O 0 2.9919947337475605e-06
cell O 0 1.0592267244646791e-05
cycle O 0 2.119708142345189e-06
- O 0 7.650831435057626e-07
dependent O 0 1.4425236827264598e-07
colocalization O 0 2.1975340587232495e-06
of O 0 3.09205375970123e-07
BARD1 O 0 0.1909884512424469
and O 0 3.1027408908812504e-07
BRCA1 O 0 1.4350896435644245e-06
indicates O 0 9.692998759192051e-08
a O 0 4.766957317769993e-08
role O 0 1.594962810713696e-07
for O 0 1.8679376978525397e-07
BARD1 O 0 0.0005910990294069052
in O 0 6.666812737421424e-07
BRCA1 O 0 4.8070727643789724e-05
- O 0 3.742499393410981e-05
mediated O 0 0.00024019037664402276
tumor B-Disease 0 0.00010791796375997365
suppression O 0 0.0006779535324312747
. O 0 0.00011782356159528717

Ethnic O 0 8.222463293350302e-06
differences O 0 9.271877388528083e-06
in O 0 8.105918709588877e-07
the O 0 2.8434117211872945e-06
HFE O 0 0.012154227122664452
codon O 0 0.0001651343918638304
282 O 0 0.00010092213051393628
( O 0 2.3340868210652843e-05
Cys O 1 0.9998177886009216
/ O 0 0.21396124362945557
Tyr O 0 0.4609137773513794
) O 0 1.3389703781285789e-05
polymorphism O 0 8.374489698326215e-05
. O 0 3.622415897552855e-05

Recent O 0 1.9674764644150855e-06
studies O 0 6.404879400179198e-07
have O 0 6.19354025843677e-08
shown O 0 3.1590769822287257e-07
that O 0 2.5361932785017416e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9999953508377075
HH B-Disease 1 1.0
) O 0 2.258241806885053e-07
is O 0 9.274541135084746e-09
likely O 0 1.6270281122388042e-08
to O 0 7.943533830712113e-09
be O 0 5.024443794354738e-08
caused O 0 2.663250882051216e-07
by O 0 8.378518145946146e-08
homozygosity O 0 4.562701178656425e-06
for O 0 1.1255726661829613e-07
a O 0 3.206090468665934e-07
Cys282Tyr O 0 1.2410454473865684e-05
mutation O 0 3.18845422953018e-07
in O 0 5.208486442143112e-08
the O 0 2.5517539370412123e-07
HFE O 0 0.00013522776134777814
gene O 0 1.4495087725663325e-06
located O 0 1.6550716281926725e-06
4 O 0 1.5963087207637727e-05
. O 0 2.844758637365885e-05

5 O 0 0.00017667689826339483
Mb O 0 0.00448707677423954
telomeric O 0 0.0003794071963056922
to O 0 7.661647941858973e-06
HLA O 0 0.006846539210528135
- O 0 5.2799045079154894e-05
A O 0 3.4447915822966024e-05
. O 0 2.8827796995756216e-05

Population O 0 6.954856530683173e-07
studies O 0 3.560134018698591e-07
of O 0 1.191536256328618e-07
this O 0 4.426797062251353e-08
polymorphism O 0 4.7005951842038485e-07
are O 0 1.071943156460975e-08
facilitated O 0 9.814291956899979e-08
by O 0 7.3822321589034345e-09
the O 0 9.055343141994854e-09
fact O 0 1.1797584242856374e-08
that O 0 6.144261543994389e-09
the O 0 1.1628259954932219e-07
Cys282Tyr O 0 6.474082329077646e-05
mutation O 0 1.8491249420549138e-06
creates O 0 1.4632797729063896e-06
a O 0 8.28014549369982e-07
Rsal O 0 7.163196278270334e-05
restriction O 0 4.176594757154817e-06
site O 0 8.578469532949384e-06
. O 0 1.324473305430729e-05

We O 0 2.7854623567691306e-06
have O 0 1.835123697446761e-07
studied O 0 8.774732691563258e-07
the O 0 2.63814399659168e-07
codon O 0 6.668506102869287e-06
282 O 0 1.1642418030533008e-05
( O 0 4.438330506673083e-06
Cys O 1 0.9998471736907959
/ O 0 0.01653391309082508
Tyr O 0 0.09649685025215149
) O 0 2.3919852765175165e-07
polymorphism O 0 2.230624005505888e-07
in O 0 8.489121405830247e-09
different O 0 2.2042552672019156e-08
ethnic O 0 1.295372982212939e-07
groups O 0 4.7554061666232883e-07
. O 0 8.671141586091835e-06

In O 0 1.597073946868477e-06
agreement O 0 1.2144770380473346e-06
with O 0 9.00036596362952e-08
previous O 0 2.885879553105042e-07
observations O 0 3.164679469591647e-07
the O 0 1.7335362656467623e-07
Tyr O 0 4.037201142637059e-05
allele O 0 1.2323994269536342e-06
appeared O 0 1.2157825324266014e-07
to O 0 1.1482867101619831e-08
be O 0 2.4105613505298606e-08
rare O 0 9.429693648144166e-08
or O 0 9.974931458600622e-08
absent O 0 8.974238880909979e-07
in O 0 1.350318825643626e-07
Asiatic O 0 5.902668362978147e-06
( O 0 1.8694650805173296e-07
Indian O 0 2.907596012846625e-07
, O 0 1.3729574277476786e-07
Chinese O 0 3.897042120115657e-07
) O 0 3.643524166818679e-07
populations O 0 1.8039180531559396e-06
. O 0 1.164894911198644e-05

The O 0 4.175909452897031e-06
highest O 0 3.0159958441799972e-06
allele O 0 1.7092645521188388e-06
frequency O 0 1.9008775780093856e-06
( O 0 6.72727082928759e-08
7 O 0 1.4777803869492345e-07
. O 0 1.2295937601436435e-08
5 O 0 1.0129154759397352e-07
% O 0 2.3956969741334433e-08
) O 0 3.514812974003689e-08
was O 0 2.4205090198847756e-07
found O 0 1.2313238073602406e-07
in O 0 2.309593298832624e-07
Swedes O 0 0.0001748191425576806
. O 0 3.807575558312237e-05

Saamis O 0 0.0011371694272384048
( O 0 1.918472207762534e-06
2 O 0 2.166247668355936e-06
% O 0 9.381149368437036e-08
) O 0 4.059600655637041e-08
and O 0 7.569374815830088e-08
Mordvinians O 0 2.5855197236523964e-05
( O 0 3.8721392314755576e-08
1 O 0 8.037035570396256e-08
. O 0 4.478130755103393e-09
8 O 0 5.882489162445381e-08
% O 0 6.952314723918107e-09
) O 0 9.110573628845486e-09
had O 0 2.8247434613604128e-08
significantly O 0 8.636833825903523e-08
lower O 0 3.7548181808233494e-07
frequencies O 0 1.748418867464352e-06
of O 0 2.1297046259860508e-07
the O 0 1.7595911003809306e-06
Tyr O 0 0.0003163068904541433
allele O 0 4.569827069644816e-05
. O 0 1.6210507965297438e-05

Comparisons O 0 7.554203875770327e-06
with O 0 5.85694067467557e-07
allele O 0 5.207510639593238e-06
frequencies O 0 2.623829686854151e-06
based O 0 1.2117658343413495e-07
on O 0 1.399708082772122e-07
prevalence O 0 3.410721376440051e-07
estimates O 0 6.722729750663348e-08
of O 0 2.9471152629412245e-07
HH B-Disease 1 0.6709315180778503
showed O 0 5.123542337059916e-07
some O 0 4.136488129802274e-08
disagreements O 0 7.90843273534847e-07
with O 0 3.615797083966754e-08
the O 0 2.0463814109916711e-07
RFLP O 0 1.669981429586187e-05
data O 0 1.861274654402223e-07
, O 0 7.373355970230477e-08
particularly O 0 2.9258961831146735e-07
in O 0 7.396603791676171e-07
Finns O 0 0.00012855717795901
. O 0 3.95450260839425e-05

The O 0 1.4102752174949273e-05
newly O 0 4.777823050972074e-05
described O 0 1.797792901925277e-05
HFE O 0 0.06894564628601074
marker O 0 1.0987837413267698e-05
provides O 0 3.784993225508515e-07
a O 0 8.807112550357488e-08
new O 0 5.6862674568947114e-08
approach O 0 5.085677656779808e-08
to O 0 6.168744626222633e-09
the O 0 8.622411229453064e-09
screening O 0 3.1141478729068695e-08
of O 0 7.952132818900282e-08
HH B-Disease 0 0.04075052961707115
as O 0 3.940798620760688e-08
well O 0 1.2596077958448859e-08
as O 0 1.1537026445296306e-08
studies O 0 1.3945964383310638e-08
of O 0 1.966940033071296e-08
the O 0 2.870671877985842e-08
relationship O 0 6.998817525527556e-08
between O 0 2.1858009802144807e-07
the O 0 5.818970407744928e-07
HFE O 0 0.4013197124004364
Tyr O 0 0.0011259193997830153
allele O 0 7.585280854982557e-06
and O 0 6.118629016782506e-07
different O 0 7.467113391612656e-06
disorders O 1 0.9999969005584717
including O 0 0.0017632077215239406
cancer B-Disease 1 0.9999809265136719

Autosomal B-Disease 1 0.9999864101409912
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9997552037239075
associated O 0 3.350963424963993e-06
with O 0 3.167792499425559e-07
a O 0 7.215668915705464e-07
missense O 0 1.071906717697857e-05
mutation O 0 2.183466676797252e-06
encoding O 0 8.541586794308387e-06
Gly23 O 0 0.0003449169744271785
- O 0 5.841452002641745e-05
- O 0 4.510279541136697e-05
> O 0 8.305063238367438e-05
Val O 0 7.101926894392818e-05
in O 0 7.418312293339113e-07
neurophysin O 0 0.00023715135466773063
II O 1 0.999910831451416
. O 0 3.9408449083566666e-05

Autosomal B-Disease 1 0.9999603033065796
dominant I-Disease 1 0.9999997615814209
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999998807907104
( O 0 0.0031114108860492706
ADNDI B-Disease 1 0.9999997615814209
) O 0 2.338608737773029e-06
is O 0 3.943945898754464e-07
an O 0 1.945150415849639e-06
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9690539836883545
by O 0 2.3193868400994688e-05
progressive O 1 0.9999990463256836
degeneration O 1 0.9999998807907104
of O 0 3.891269807354547e-05
the O 0 5.250265985523583e-06
magnocellular O 0 0.00144747004378587
neurons O 0 2.599466142783058e-06
of O 0 2.992080680996878e-07
the O 0 5.13920213052188e-07
hypothalamus O 0 2.7775074613600736e-06
leading O 0 8.590205879954738e-07
to O 0 3.23132809398885e-08
decreased O 0 1.993594906934959e-07
ability O 0 2.9885129038120795e-08
to O 0 3.0770507919442025e-08
produce O 0 2.498361482139444e-07
the O 0 4.862586138187908e-07
hormone O 0 1.5693140085204504e-05
arginine O 0 2.2554004317498766e-05
vasopressin O 0 2.0747738744830713e-05
( O 0 1.4815510667176568e-06
AVP O 0 0.0002769161364994943
) O 0 3.494090151434648e-06
. O 0 1.876153146440629e-05

Affected O 0 8.090240953606553e-06
individuals O 0 1.5106580519841373e-07
are O 0 4.036576584098839e-08
not O 0 6.077072356447388e-08
symptomatic O 0 1.470913048251532e-05
at O 0 1.3742231885771616e-06
birth O 0 3.388254299352411e-07
, O 0 1.235220423723149e-07
but O 0 1.9067496737079637e-07
usually O 0 2.0264744762243936e-06
develop O 0 0.007608155254274607
diabetes B-Disease 1 0.9922531247138977
insipidus I-Disease 0 0.00025734014343470335
at O 0 1.6723531643947354e-06
1 O 0 2.273286099807592e-06
- O 0 1.5712913636889425e-06
6 O 0 2.8192318950459594e-06
yr O 0 0.00011151337093906477
of O 0 1.224930656462675e-06
age O 0 1.7433127140975557e-05
. O 0 1.7928090528585017e-05

The O 0 4.871864803135395e-06
genetic O 0 2.4928713173721917e-06
locus O 0 3.7391239402495557e-06
of O 0 1.708495460661652e-06
the O 0 4.140959390497301e-06
disease O 0 0.00021118888980709016
is O 0 2.9876557050556585e-07
the O 0 3.0912628972146194e-06
AVP O 1 0.6518612504005432
- O 0 0.00015424523735418916
neurophysin O 0 0.0017215014668181539
II O 1 0.9999998807907104
( O 0 5.128194061398972e-06
NPII O 0 0.20221570134162903
) O 0 4.9297440796181036e-08
gene O 0 3.758672662002027e-08
, O 0 1.4750369814464648e-08
and O 0 2.166570212125407e-08
mutations O 0 7.818326253072883e-08
that O 0 1.1868225513467223e-08
cause O 0 8.525763064426428e-07
ADNDI B-Disease 1 0.9036598801612854
have O 0 4.104384032643793e-08
been O 0 1.9816258856053537e-08
found O 0 5.8973150807162256e-09
in O 0 2.8590860789989847e-09
both O 0 1.0502158254155347e-08
the O 0 2.6092834559676703e-08
signal O 0 3.504565029288642e-07
peptide O 0 1.3314243574313878e-07
of O 0 5.084931231635892e-08
the O 0 1.980727262207438e-07
prepro O 0 3.991268022218719e-05
- O 0 1.9311182768433355e-05
AVP O 0 0.0003485009365249425
- O 0 6.813993422838394e-06
NPII O 0 0.00024370291794184595
precursor O 0 4.132662525080377e-06
and O 0 3.8319438999678823e-07
within O 0 1.9138342395308428e-06
NPII O 0 0.0012843937147408724
itself O 0 1.0132589522982016e-05
. O 0 1.5504738257732242e-05

An O 0 4.819286459678551e-06
affected O 0 3.6745184388564667e-06
girl O 0 2.6176187475357438e-06
who O 0 1.729081589019188e-07
presented O 0 9.023481766234909e-07
at O 0 7.945475317683304e-07
9 O 0 6.087624342399067e-07
months O 0 6.629836946103751e-08
of O 0 5.2318743115620236e-08
age O 0 1.37503960218055e-07
and O 0 3.113168034474256e-08
her O 0 1.765950408127992e-08
similarly O 0 1.5862057978210942e-07
affected O 0 1.669397420300811e-07
younger O 0 1.560649138809822e-06
brother O 0 1.7286937463723007e-06
and O 0 1.5046494183934556e-07
father O 0 2.1218792767285777e-07
were O 0 6.533689145271637e-08
all O 0 1.4341092757774732e-08
found O 0 8.095851100620166e-09
to O 0 8.38559621740842e-09
have O 0 2.2717546954709178e-08
a O 0 1.4530046144045627e-07
novel O 0 4.276375307199487e-07
missense O 0 4.801134309673216e-06
mutation O 0 9.448522746424715e-07
( O 0 5.111818950354063e-07
G1758 O 0 1.679299930401612e-05
- O 0 9.864061212283559e-06
- O 0 5.005255388823571e-06
> O 0 6.809004389651818e-06
T O 0 5.413063718151534e-06
) O 0 4.319576518696522e-08
encoding O 0 2.641638445766148e-07
the O 0 7.455846429138546e-08
amino O 0 2.125674853914461e-07
acid O 0 1.608858752888409e-07
substitution O 0 1.025633196150011e-06
Gly23 O 0 5.044314457336441e-05
- O 0 1.383568269375246e-05
- O 0 1.3262264474178664e-05
> O 0 2.1252533770166337e-05
Val O 0 6.0113823565188795e-05
within O 0 5.199639872444095e-06
NPII O 0 0.002904146211221814
. O 0 4.695798270404339e-05

The O 0 8.56682800076669e-06
mutation O 0 8.759484444453847e-06
was O 0 3.0700273327965988e-06
confirmed O 0 1.1695773309838842e-06
by O 0 2.7302198191136995e-07
restriction O 0 1.5855736137382337e-06
endonuclease O 0 2.445250538585242e-05
analysis O 0 1.1158675079059321e-05
. O 0 2.477329326211475e-05

A O 0 0.0005925074219703674
T1 O 1 0.8874011039733887
- O 0 5.987541953800246e-05
weighted O 0 4.820389676751802e-06
magnetic O 0 1.1970119885518216e-05
resonance O 0 1.887707730929833e-05
imaging O 0 2.8309379558777437e-05
of O 0 2.2733815967512783e-06
the O 0 7.699853085796349e-06
fathers O 0 0.00019485603843349963
pituitary O 0 0.0017911649774760008
gland O 0 0.00013414383283816278
demonstrates O 0 1.0055578968604095e-05
an O 0 2.2453493784269085e-06
attenuated O 0 0.0015698142815381289
posterior O 0 0.40759551525115967
pituitary O 1 0.9989758729934692
bright O 1 0.9999358654022217
spot O 1 0.9845553040504456
. O 0 0.00048099271953105927

This O 0 7.209409886854701e-07
mutation O 0 1.9467593119770754e-06
may O 0 2.1147117479358712e-07
be O 0 6.111513783935152e-08
valuable O 0 3.6967213645766606e-07
for O 0 2.9371898691010756e-08
developing O 0 1.2419675954333798e-07
models O 0 3.7035565014775784e-07
of O 0 5.022977802582318e-07
dominantly B-Disease 0 0.3688119053840637
inherited I-Disease 1 0.86089026927948
neurodegeneration I-Disease 1 1.0
, O 0 2.196944137722312e-07
as O 0 2.3804334503552127e-08
the O 0 7.425402070992959e-09
early O 0 3.790450620044794e-08
age O 0 3.8119402745451225e-08
of O 0 5.785305745575897e-08
onset O 0 0.003178688930347562
of O 0 3.420497705519665e-06
symptoms O 0 4.332767639425583e-05
suggests O 0 1.4967865524795343e-07
that O 0 4.263195574338852e-09
this O 0 4.819274757039693e-09
mutation O 0 3.1211943252174024e-08
may O 0 3.135341231086386e-08
be O 0 5.71621505685016e-08
particularly O 0 1.8457900807788974e-07
deleterious O 0 3.95806773667573e-06
to O 0 1.5027751487650676e-07
the O 0 2.0078548459423473e-06
magnocellular O 0 0.000417085102526471
neuron O 0 4.284219176042825e-05
. O 0 1.6953032400124357e-06
. O 0 1.573802910570521e-05

Frequent O 0 2.0620040231733583e-05
inactivation O 0 0.000257712381426245
of O 0 5.553100709221326e-05
PTEN O 1 0.9999891519546509
/ O 1 0.9998114705085754
MMAC1 O 1 0.9999898672103882
in O 0 4.745271144201979e-05
primary O 1 0.9999969005584717
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.002423213329166174

Sporadic B-Disease 1 0.999995231628418
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.1816819096566178e-05
the O 0 8.17793591068039e-07
most O 0 1.331797676584756e-07
common O 0 8.546945764464908e-07
male B-Disease 0 1.5414377685374347e-06
cancer I-Disease 0 5.575018349190941e-07
in O 0 1.4005915538461977e-08
the O 0 6.864626556080111e-08
Western O 0 1.6709693682059878e-06
world O 0 5.136884055900737e-07
, O 0 1.296123830485385e-08
yet O 0 6.305824751251521e-09
many O 0 2.3641024693432655e-09
of O 0 9.544539381067807e-09
the O 0 1.8832501780252642e-08
major O 0 1.2105553537367086e-07
genetic O 0 8.203340229329115e-08
events O 0 3.2373925762385625e-08
involved O 0 4.0640628640176146e-08
in O 0 1.357919465760915e-08
the O 0 2.8673557750380496e-08
progression O 0 2.0908171336486703e-06
of O 0 1.208451436696123e-07
this O 0 5.544415415670301e-08
often O 0 8.53892856866878e-07
fatal O 0 0.11278372257947922
cancer B-Disease 0 1.4193976312526502e-05
remain O 0 1.0124805385203217e-06
to O 0 3.9453979638892633e-07
be O 0 2.173425855289679e-06
elucidated O 0 0.0005597784765996039
. O 0 3.256620766478591e-05

Numerous O 0 4.3310574255883694e-05
cytogenetic O 0 0.0008919085958041251
and O 0 3.4426041111146333e-06
allelotype O 0 0.00010754258983070031
studies O 0 6.028653842804488e-07
have O 0 8.172418120011571e-08
reported O 0 3.095904332894861e-07
frequent O 0 1.9520339833434264e-07
loss O 0 4.085712134838104e-06
of O 0 1.2295851774979383e-05
heterozygosity O 1 0.9897686243057251
on O 0 2.1187188394833356e-05
chromosomal O 0 0.00037660577800124884
arm O 0 0.00034913106355816126
10q O 0 0.0016699113184586167
in O 0 1.1822037777164951e-05
sporadic B-Disease 1 0.999998927116394
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0019303766312077641

Deletion O 0 0.0002033908967860043
mapping O 0 9.105153367272578e-06
studies O 0 6.962083602957136e-07
have O 0 2.4666206854817574e-07
unambiguously O 0 1.8333586240260047e-06
identified O 0 5.420386059995508e-07
a O 0 3.125963985439739e-07
region O 0 4.85327404931013e-07
of O 0 1.0983183074131375e-06
chromosome O 0 1.4242136785469484e-06
10q23 O 0 1.4260008356359322e-06
to O 0 1.573055463666151e-08
be O 0 2.0696875324688335e-08
the O 0 3.87000547164007e-08
minimal O 0 8.279087069240632e-07
area O 0 2.940254262284725e-07
of O 0 1.0862888757401379e-06
loss O 0 0.00012550182873383164
. O 0 3.6732424632646143e-05

A O 0 1.1689256098179612e-05
new O 0 1.7141373973572627e-06
tumor B-Disease 0 4.502543561102357e-06
suppressor O 0 7.844817446311936e-06
gene O 0 6.093414981478418e-07
, O 0 4.97506562169292e-07
PTEN O 1 0.8743237257003784
/ O 0 0.4426628053188324
MMAC1 O 1 0.9999880790710449
, O 0 1.1450682677605073e-06
was O 0 2.0230681911925785e-06
isolated O 0 1.7020832387970586e-07
recently O 0 2.1392862947777758e-07
at O 0 3.1734623462398304e-07
this O 0 1.5096910388479046e-08
region O 0 1.2212383637688617e-07
of O 0 3.114142259619257e-07
chromosome O 0 1.1960052006543265e-06
10q23 O 0 1.1382883258193033e-06
and O 0 1.4168283435367357e-08
found O 0 4.559335131659736e-09
to O 0 2.7089839260696635e-09
be O 0 8.05606337195286e-09
inactivated O 0 3.486533444174711e-07
by O 0 1.7565009002851184e-08
mutation O 0 2.2081061956669146e-07
in O 0 2.5925365321199934e-07
three O 0 0.00022435090795625
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.38302579522132874
lines O 0 5.554022573051043e-05
. O 0 2.5448343876632862e-05

We O 0 2.7818688977276906e-05
screened O 0 4.513394378591329e-05
80 O 0 4.25185717176646e-05
prostate B-Disease 1 0.9987367987632751
tumors I-Disease 1 0.999998927116394
by O 0 1.2616811773114023e-06
microsatellite O 0 1.7274714991799556e-05
analysis O 0 6.420767704184982e-07
and O 0 4.2803654309864214e-07
found O 0 3.27490454310464e-07
chromosome O 0 1.1779661690525245e-06
10q23 O 0 2.5848487439361634e-06
to O 0 4.789367480384499e-08
be O 0 1.1059347571062972e-07
deleted O 0 6.559649250448274e-07
in O 0 1.4634959200066078e-07
23 O 0 3.238512363168411e-06
cases O 0 2.434306907161954e-06
. O 0 1.1624567378021311e-05

We O 0 1.663334614931955e-06
then O 0 3.51654364294518e-07
proceeded O 0 5.615883083009976e-07
with O 0 1.6984566642008758e-08
sequence O 0 2.1583995035712178e-08
analysis O 0 2.1988805443129422e-08
of O 0 4.779803575161168e-08
the O 0 8.15549228150303e-08
entire O 0 2.8246624879102455e-06
PTEN O 0 0.0120708541944623
/ O 0 0.0003408394695725292
MMAC1 O 0 0.03329720348119736
coding O 0 8.627112947579008e-06
region O 0 3.1387344279210083e-07
and O 0 7.997232387424447e-08
tested O 0 2.232733038454171e-07
for O 0 4.6363510364244576e-08
homozygous O 0 4.820251433557132e-07
deletion O 0 1.500013127042621e-07
with O 0 1.899744717093199e-08
new O 0 1.0738159517131862e-07
intragenic O 0 6.707195097988006e-06
markers O 0 1.4988076202371303e-07
in O 0 1.604787946973829e-08
these O 0 2.7430724358623593e-08
23 O 0 4.861728370997298e-07
cases O 0 6.261804941232185e-08
with O 0 1.397057047825001e-07
10q23 O 0 3.11209041683469e-05
loss O 0 1.5885638276813552e-05
of O 0 2.3031558157526888e-05
heterozygosity O 1 0.7942035794258118
. O 0 0.00013565550034400076

The O 0 7.851155032767565e-07
identification O 0 3.494106124435348e-07
of O 0 3.4135558735215454e-07
the O 0 3.015723564203654e-07
second O 0 1.1626401601461112e-06
mutational O 0 1.023424010782037e-05
event O 0 7.850466090530972e-07
in O 0 7.755042474855145e-08
10 O 0 2.130127256805281e-07
( O 0 8.403485196595284e-08
43 O 0 5.249902983450738e-07
% O 0 2.0298580238886643e-07
) O 0 9.490633487985178e-07
tumors B-Disease 1 0.9999995231628418
establishes O 0 0.00010738006676547229
PTEN O 1 0.9621667861938477
/ O 0 0.0003637471527326852
MMAC1 O 0 0.000818634987808764
as O 0 1.6569937599797413e-07
a O 0 7.261576939754377e-08
main O 0 1.4446135310208774e-07
inactivation O 0 1.326383198829717e-06
target O 0 1.7470360091920156e-07
of O 0 3.258458605159831e-07
10q O 0 2.1553469196078368e-05
loss O 0 1.1759091648855247e-05
in O 0 1.6912241562749841e-06
sporadic B-Disease 1 0.999985933303833
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.210100840078667e-05
. O 0 5.1351049478398636e-05

Risk O 0 9.286177373724058e-05
reversals O 0 6.642457447014749e-05
in O 0 1.0030295243268483e-06
predictive O 0 3.681241287267767e-05
testing O 0 6.0690224927384406e-05
for O 0 0.0004371638933662325
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0011060955002903938

The O 0 5.0057806220138445e-06
first O 0 1.4406459740712307e-06
predictive O 0 6.4048144849948585e-06
testing O 0 4.016404545836849e-06
for O 0 9.528846931061707e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.225375505484408e-06
HD B-Disease 1 0.9999629259109497
) O 0 7.186318384810875e-08
was O 0 1.1240236830190042e-07
based O 0 1.4614157883841017e-08
on O 0 3.090691436113957e-08
analysis O 0 6.03378325081394e-08
of O 0 1.5134598640997865e-07
linked O 0 1.9673507267725654e-06
polymorphic O 0 2.147156692444696e-06
DNA O 0 4.888125886282069e-07
markers O 0 6.884346959168397e-08
to O 0 1.4581441831751363e-08
estimate O 0 7.94538621562424e-08
the O 0 4.155126021032629e-08
likelihood O 0 3.400662649255537e-07
of O 0 2.815081643348094e-07
inheriting O 0 1.1963405768256052e-06
the O 0 1.6792704116141977e-07
mutation O 0 4.134864184379694e-07
for O 0 8.037202405830612e-07
HD B-Disease 1 0.6999421715736389
. O 0 2.394060356891714e-05

Limits O 0 2.432914243399864e-06
to O 0 1.9741908374726336e-07
accuracy O 0 1.2896257430838887e-06
included O 0 3.0835317943456175e-07
recombination O 0 3.5103116147183755e-07
between O 0 7.347566821636065e-08
the O 0 5.360175947544121e-08
DNA O 0 1.7641434624238173e-07
markers O 0 9.885005169962824e-08
and O 0 2.957088973687405e-08
the O 0 6.284874132234108e-08
mutation O 0 2.2521896880789427e-07
, O 0 4.792236651951498e-08
pedigree O 0 5.083050496068608e-07
structure O 0 2.8948816179763526e-06
, O 0 4.2627018359553404e-08
and O 0 1.650690606425087e-08
whether O 0 2.2729164328438856e-08
DNA O 0 4.9374978772220857e-08
samples O 0 8.781193550078115e-09
were O 0 1.821712380944973e-08
available O 0 5.960622928569137e-08
from O 0 5.076074316434642e-08
family O 0 1.0971714203833471e-07
members O 0 1.1630083918134915e-06
. O 0 1.5462475857930258e-05

With O 0 6.743180165358353e-07
direct O 0 4.717602450909908e-07
tests O 0 2.1147035056401364e-07
for O 0 3.402679737973813e-08
the O 0 5.360636023965526e-08
HD B-Disease 0 8.036188228288665e-05
mutation O 0 6.3092322477587e-08
, O 0 5.739438257990059e-09
we O 0 4.959997745856981e-09
have O 0 2.408262478326151e-09
assessed O 0 3.7662868379584324e-08
the O 0 5.915667067313279e-09
accuracy O 0 7.643379262844974e-08
of O 0 3.0764287117790445e-08
results O 0 1.0250743542883356e-07
obtained O 0 7.055204065409271e-08
by O 0 2.1835337093989438e-08
linkage O 0 1.9726212485693395e-07
approaches O 0 1.7470608781877672e-07
when O 0 1.7516629924330118e-08
requested O 0 2.3946961746901252e-08
to O 0 6.925540585456247e-09
do O 0 1.0486505885864972e-08
so O 0 1.1177143655061172e-08
by O 0 1.3784514862891228e-08
the O 0 6.194899526690278e-08
test O 0 1.260453245777171e-06
individuals O 0 8.093567203104612e-07
. O 0 1.1719975191226695e-05

For O 0 1.3089178310110583e-06
six O 0 3.3274730526500207e-07
such O 0 2.2701565072225094e-08
individuals O 0 1.2670993143615306e-08
, O 0 2.591092318482424e-08
there O 0 2.3520410508126588e-08
was O 0 2.0954053070454393e-07
significant O 0 2.208152523053286e-07
disparity O 0 2.5737451778695686e-06
between O 0 7.090966960277001e-07
the O 0 1.3017672699788818e-06
tests O 0 6.695717274851631e-06
. O 0 1.1970485502388328e-05

Three O 0 4.6589925659645814e-06
went O 0 1.8277111166753457e-06
from O 0 7.123053791247003e-08
a O 0 8.435892340230566e-08
decreased O 0 1.8616847796693037e-07
risk O 0 2.9522537303705576e-08
to O 0 4.62170124393424e-09
an O 0 1.8803671952838386e-09
increased O 0 1.758773748861131e-08
risk O 0 5.115876433592348e-08
, O 0 1.0771900704753534e-08
while O 0 8.142106544539729e-09
in O 0 2.2889379280854882e-09
another O 0 9.898623254400718e-09
three O 0 7.104625332488013e-09
the O 0 1.7597233892274744e-08
risk O 0 2.024182492732507e-07
was O 0 1.7069904743038933e-06
decreased O 0 8.652084034110885e-06
. O 0 5.950994363956852e-06

Knowledge O 0 7.520082363043912e-06
of O 0 5.576475246016344e-07
the O 0 7.126465106921387e-08
potential O 0 8.391760530912507e-08
reasons O 0 5.3117108933520285e-08
for O 0 7.933919299318859e-09
these O 0 1.7853182265881173e-09
changes O 0 1.531541826693683e-08
in O 0 4.687172427964015e-09
results O 0 3.1594019844760624e-08
and O 0 8.386892069722762e-09
impact O 0 4.483380777742241e-08
of O 0 1.5310190448758476e-08
these O 0 4.294280930849936e-09
risk O 0 2.4489052563581026e-08
reversals O 0 2.1697717045299214e-07
on O 0 5.0779721760818575e-08
both O 0 2.1303014463569525e-08
patients O 0 1.1579685654794503e-08
and O 0 1.3402114085181438e-08
the O 0 2.997538217641704e-08
counseling O 0 7.038121196956126e-08
team O 0 3.5913696905254255e-08
can O 0 3.659484937301727e-09
assist O 0 5.463435570618458e-08
in O 0 5.683141512946577e-09
the O 0 1.4731335262752054e-08
development O 0 3.045741792107037e-08
of O 0 2.655038677801258e-08
strategies O 0 7.802803025924732e-08
for O 0 7.907345001001431e-09
the O 0 2.7492323084743475e-08
prevention O 0 1.5190732938208384e-07
and O 0 1.0728369304047192e-08
, O 0 1.2423425843621771e-08
where O 0 9.814963064513904e-09
necessary O 0 1.24104047927176e-07
, O 0 3.5158457478701166e-08
management O 0 1.6375939537738304e-07
of O 0 3.946763627027394e-08
a O 0 4.344530069033681e-08
risk O 0 6.997549206744225e-08
reversal O 0 2.1973380626150174e-07
in O 0 1.3442665647289687e-08
any O 0 2.680776667318696e-08
predictive O 0 6.513905077554227e-07
testing O 0 4.01806460104126e-07
program O 0 4.013492116428097e-07
. O 0 8.545364380552201e-07
. O 0 8.697395060153212e-06

A O 0 3.4995373425772414e-05
novel O 0 5.696520474884892e-06
common O 0 1.7491511243861169e-06
missense O 0 2.6298359443899244e-05
mutation O 0 2.2320484731608303e-06
G301C O 0 7.96545919001801e-06
in O 0 8.836407516810141e-08
the O 0 3.192190547451901e-07
N O 0 6.649283477599965e-06
- O 0 2.765083081612829e-06
acetylgalactosamine O 0 2.296936872880906e-05
- O 0 3.5712164390133694e-06
6 O 0 1.6888139725779183e-05
- O 0 6.396671324182535e-06
sulfate O 0 1.7671824025455862e-05
sulfatase O 0 0.00017676402057986706
gene O 0 9.047859634847555e-07
in O 0 7.786551350363879e-07
mucopolysaccharidosis B-Disease 0 0.0004169183084741235
IVA I-Disease 1 0.9021044373512268
. O 0 8.269878890132532e-05

Mucopolysaccharidosis B-Disease 1 0.6751499772071838
IVA I-Disease 1 0.9999948740005493
( O 0 0.0002536395622882992
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 1.6380718079744838e-06
is O 0 1.1711305347716916e-07
an O 0 3.835318409528554e-07
autosomal B-Disease 1 0.9725331664085388
recessive I-Disease 1 0.9999992847442627
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9981776475906372
by O 0 1.0449174624227453e-05
a O 0 0.0004974142066203058
genetic B-Disease 1 0.9999978542327881
defect I-Disease 1 0.9984816908836365
in O 0 1.1125267747047474e-06
N O 0 6.396269600372761e-05
- O 0 2.0787372704944573e-05
acetylgalactosamine O 0 3.734741767402738e-05
- O 0 3.973638740717433e-06
6 O 0 1.1196463674423285e-05
- O 0 9.466079973208252e-06
sulfate O 0 9.513118857285008e-05
sulfatase O 0 0.4065958559513092
( O 0 2.010111757044797e-06
GALNS O 0 0.0031776539981365204
) O 0 2.1261644178593997e-06
. O 0 6.823722287663259e-06

In O 0 1.1305919542792253e-06
previous O 0 6.11686743923201e-07
studies O 0 1.9427129416271782e-07
, O 0 5.188843488213024e-08
we O 0 2.9648827393202737e-08
have O 0 1.7668735807774283e-08
found O 0 2.6614221937393268e-08
two O 0 2.5851388585351742e-08
common O 0 8.734409817634514e-08
mutations O 0 2.401970391474606e-07
in O 0 7.646966082575091e-08
Caucasians O 0 4.63816968476749e-06
and O 0 3.1531232025372447e-07
Japanese O 0 1.3529834177461453e-05
, O 0 2.0303316432546126e-06
respectively O 0 1.169884762930451e-05
. O 0 1.3218033018347342e-05

To O 0 1.7016186575347092e-06
characterize O 0 3.979877874371596e-06
the O 0 5.612210998151568e-07
mutational O 0 2.526801108615473e-05
spectrum O 0 4.092723884241423e-06
in O 0 2.5553475779815926e-08
various O 0 1.0359886282174102e-08
ethnic O 0 8.414130725498126e-09
groups O 0 4.751586235585137e-09
, O 0 1.0286071550069664e-08
mutations O 0 1.8619061847857665e-08
in O 0 7.856502115544117e-09
the O 0 5.823267557047984e-08
GALNS O 0 1.7034426491591148e-05
gene O 0 1.1422363854762807e-07
in O 0 8.40513649791319e-08
Colombian O 0 5.6820990721462294e-06
MPS B-Disease 1 0.9999986886978149
IVA I-Disease 1 1.0
patients O 0 1.5316053350034053e-06
were O 0 5.889656904400908e-07
investigated O 0 7.430848199874163e-06
, O 0 1.2960354922597617e-07
and O 0 1.0840829389735518e-07
genetic O 0 3.766276677197311e-07
backgrounds O 0 5.548339458982809e-07
were O 0 2.1675772643448e-07
extensively O 0 5.517019729950334e-08
analyzed O 0 4.767184691445436e-08
to O 0 1.0767668534583663e-08
identify O 0 7.982251304383681e-08
racial O 0 3.5073736626145546e-07
origin O 0 1.98734014134061e-07
, O 0 1.432658081057525e-07
based O 0 1.9414015639540594e-07
on O 0 5.530198450287571e-07
mitochondrial O 0 1.3905029163652216e-06
DNA O 0 1.0004663408835768e-06
( O 0 2.8692741693703283e-07
mtDNA O 0 1.292880369874183e-06
) O 0 1.2186759477117448e-06
lineages O 0 2.2032789274817333e-05
. O 0 3.9151891542132944e-05

Three O 0 1.0203006240772083e-05
novel O 0 3.761699645110639e-06
missense O 0 4.301310400478542e-05
mutations O 0 3.265715122324764e-06
never O 0 1.171640519714856e-06
identified O 0 6.457920562752406e-07
previously O 0 2.543837922530656e-07
in O 0 2.4356152650284457e-08
other O 0 7.0713941369149325e-09
populations O 0 7.0017791564680465e-09
and O 0 1.4521631008790337e-08
found O 0 1.723154774424529e-08
in O 0 1.6982363959527902e-08
16 O 0 2.0199186678837577e-07
out O 0 1.480894784577913e-08
of O 0 6.982391198562254e-08
19 O 0 2.0663408122345572e-06
Colombian O 0 6.081414085201686e-06
MPS B-Disease 1 0.9981315732002258
IVA I-Disease 1 0.9999918937683105
unrelated O 0 3.96303857996827e-06
alleles O 0 8.825279564916855e-07
account O 0 2.1216405343693623e-07
for O 0 6.299408141785534e-07
84 O 0 1.716154656605795e-05
. O 0 2.5204042685800232e-05

2 O 0 1.2074337064404972e-05
% O 0 2.9462665906976326e-07
of O 0 3.0934162964513234e-07
the O 0 1.9809785101188027e-07
alleles O 0 5.396108235800057e-07
in O 0 7.748108288296862e-08
this O 0 8.032132114976775e-08
study O 0 8.503449180352618e-07
. O 0 8.276251719507854e-06

The O 0 2.2242234990699217e-05
G301C O 0 0.00011813258606707677
and O 0 2.1970877241983544e-06
S162F O 0 3.234157702536322e-05
mutations O 0 1.0725626680141431e-06
account O 0 4.695160953360755e-07
for O 0 1.2871498711319873e-06
68 O 0 3.062631003558636e-05
. O 0 3.986034425906837e-05

4 O 0 2.4179018510039896e-05
% O 0 1.4160050341160968e-06
and O 0 1.4371412362379488e-06
10 O 0 9.202110959449783e-06
. O 0 1.2639799024327658e-05

5 O 0 6.569793185917661e-06
% O 0 3.195449380655191e-07
of O 0 5.698067866433121e-07
mutations O 0 1.0485883876754087e-06
, O 0 2.708012232233159e-07
respectively O 0 8.905913659873477e-07
, O 0 1.0064524502695349e-07
whereas O 0 1.8438213089666533e-07
the O 0 6.521351281207899e-08
remaining O 0 8.607607355770597e-07
F69V O 0 0.0001319558941759169
is O 0 1.2421719652877528e-08
limited O 0 2.3249803859926033e-08
to O 0 1.2148676731271735e-08
a O 0 7.753548914024577e-08
single O 0 3.135635040507623e-07
allele O 0 1.2684346074820496e-05
. O 0 8.922004781197757e-06

The O 0 9.131927981798071e-06
skewed O 0 8.633276593172923e-06
prevalence O 0 3.156136926918407e-06
of O 0 8.334350241057109e-07
G301C O 0 8.97097106644651e-06
in O 0 6.63139232415233e-08
only O 0 9.184413585217044e-08
Colombian O 0 5.485143219630118e-07
patients O 0 5.152953264087046e-08
and O 0 7.591626882685887e-08
haplotype O 0 1.8329408248973778e-06
analysis O 0 1.6175016526176478e-07
by O 0 2.8431646370563612e-08
restriction O 0 1.0026242591720802e-07
fragment O 0 4.1503429315525864e-07
length O 0 1.4371794065937138e-07
polymorphisms O 0 1.014233887985938e-07
in O 0 1.359827095370747e-08
the O 0 7.542726621068141e-08
GALNS O 0 1.4541924429067876e-05
gene O 0 5.4143676209150726e-08
suggest O 0 3.5193544078993e-08
that O 0 2.326311054900998e-08
G301C O 0 2.661869302755804e-06
originated O 0 2.6166750899392355e-07
from O 0 8.64362306174371e-08
a O 0 3.80583088599451e-07
common O 0 2.518446535759722e-06
ancestor O 0 4.1825016523944214e-05
. O 0 4.092005474376492e-05

Investigation O 0 1.7564092559041455e-05
of O 0 7.48571267195075e-07
the O 0 1.8595146400457452e-07
genetic O 0 1.6006008252134052e-07
background O 0 9.917204124576529e-08
by O 0 2.658738118554993e-08
means O 0 1.686413639845341e-07
of O 0 1.424068045707827e-07
mtDNA O 0 1.3061367098998744e-07
lineages O 0 3.069061804694684e-08
indicate O 0 1.3298528500627071e-08
that O 0 6.955471754110931e-09
all O 0 1.903186586105221e-08
our O 0 4.029007527606154e-08
patients O 0 1.7332974167061366e-08
are O 0 9.661561328755397e-09
probably O 0 3.503098184864939e-07
of O 0 8.051640065787069e-07
native O 0 2.1248145003482932e-06
American O 0 1.818210876081139e-05
descent O 0 0.0008143833838403225

Low O 0 2.006975410040468e-05
frequency O 0 7.2544785325590055e-06
of O 0 1.6511745570824132e-06
BRCA1 O 0 9.949088962457608e-06
germline O 0 2.187559766753111e-05
mutations O 0 5.706660317628121e-07
in O 0 1.581901898362048e-07
45 O 0 4.310669282858726e-06
German O 1 1.0
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.9916213204851374e-05
. O 0 7.7343218435999e-05

In O 0 6.937944476703706e-07
this O 0 4.630748051681621e-08
study O 0 5.1848264348564044e-08
we O 0 7.41186312325226e-08
investigated O 0 8.542431260138983e-07
45 O 0 1.3816661521559581e-06
German O 1 0.9999997615814209
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.475687079429918e-08
for O 0 2.1275610606608097e-07
germline O 0 1.9504257579683326e-05
mutations O 0 1.8659737577308988e-07
in O 0 6.41497166498084e-08
the O 0 6.311638571787626e-07
BRCA1 O 0 2.8161792215541936e-05
gene O 0 1.032754789775936e-05
. O 0 2.191774001403246e-05

We O 0 3.7483962387341307e-06
identified O 0 1.719668375699257e-06
four O 0 1.1331425184835098e-06
germline O 0 0.00013052586291451007
mutations O 0 3.298555384390056e-06
in O 0 5.892893000236654e-07
three O 0 1.2012087609036826e-05
breast B-Disease 0 0.48156189918518066
cancer I-Disease 0 0.0038874479942023754
families O 0 1.0783786308365961e-07
and O 0 1.3068261068838183e-06
in O 0 3.8010100524843438e-06
one O 1 0.9301736950874329
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.2361742847133428e-06
. O 0 5.853032192248975e-08
among O 0 1.7385852757456632e-08
these O 0 8.652196292757708e-09
were O 0 6.797488083520875e-08
one O 0 7.545316549339987e-08
frameshift O 0 6.0733927966794e-06
mutation O 0 3.205146015261562e-07
, O 0 6.944312502810135e-08
one O 0 8.309922350235865e-08
nonsense O 0 2.4047901661106152e-06
mutation O 0 5.034708578932623e-07
, O 0 7.039383120854836e-08
one O 0 3.4303290874504455e-08
novel O 0 1.8576820082216727e-07
splice O 0 1.5783228946020245e-06
site O 0 2.7999567464576103e-07
mutation O 0 5.161058425073861e-07
, O 0 1.5919053453217202e-07
and O 0 3.473122944797069e-07
one O 0 1.2261367601240636e-06
missense O 0 0.00012401468120515347
mutation O 0 8.495430665789172e-05
. O 0 7.336956332437694e-05

The O 0 1.0201771146967076e-05
missense O 0 7.695345266256481e-05
mutation O 0 8.615593287686352e-06
was O 0 3.875045877066441e-06
also O 0 1.956671127345544e-07
found O 0 2.6401173158774327e-07
in O 0 3.8240983712967136e-07
2 O 0 8.760920172790065e-05
. O 0 4.3274445488350466e-05

8 O 0 6.7285805016581435e-06
% O 0 1.3124811459874763e-07
of O 0 1.5221621652017348e-07
the O 0 6.555759313187082e-08
general O 0 1.0081662082939147e-07
population O 0 4.583688539838704e-09
, O 0 1.9682573793033953e-08
suggesting O 0 5.190031160395847e-08
that O 0 9.923028621017238e-09
it O 0 3.5429206235448873e-08
is O 0 1.0683287143820053e-07
not O 0 9.463709034207568e-07
disease O 0 0.0002330040733795613
associated O 0 1.686084760876838e-05
. O 0 5.2045787015231326e-05

The O 0 3.392536655155709e-06
average O 0 9.371024702886643e-07
age O 0 1.6289428685922758e-06
of O 0 3.4861020594689762e-06
disease O 0 0.005582849960774183
onset O 0 0.19539713859558105
in O 0 8.536960649507819e-08
those O 0 3.503828693851574e-08
families O 0 4.5036674833909274e-08
harbouring O 0 5.7551565987523645e-05
causative O 0 4.894118774245726e-06
mutations O 0 1.6628983985356172e-06
was O 0 3.3907251690834528e-06
between O 0 5.577226602326846e-06
32 O 0 0.0001044222226482816
. O 0 4.674304000218399e-05

3 O 0 7.655543595319614e-05
and O 0 1.4798670235904865e-05
37 O 0 0.00011015814379788935
. O 0 7.72362036514096e-05

4 O 0 1.569838059367612e-05
years O 0 6.369804737005325e-07
, O 0 1.4604745501856087e-07
whereas O 0 2.267439498382373e-07
the O 0 1.0390108684532606e-07
family O 0 7.932515444508681e-08
harbouring O 0 1.1518046449054964e-05
the O 0 4.6499008021783084e-07
missense O 0 1.3669513464265037e-05
mutation O 0 5.661030400005984e-07
had O 0 2.026971941404554e-07
an O 0 3.608549192790633e-08
average O 0 1.3335947812720406e-07
age O 0 4.330057095103257e-07
of O 0 6.724807235514163e-07
onset O 0 0.1544993668794632
of O 0 6.190127169247717e-05
51 O 0 0.00011229416122660041
. O 0 2.1769525119452737e-05

2 O 0 0.00019889332179445773
years O 0 3.43720821547322e-05
. O 0 5.110785423312336e-05

These O 0 1.5119796898943605e-06
findings O 0 1.509317257841758e-06
show O 0 3.305422069388442e-07
that O 0 9.477006557290224e-08
BRCA1 O 0 5.293215508572757e-06
is O 0 2.1927996840531705e-07
implicated O 0 3.5989858133689268e-06
in O 0 5.941429392919417e-08
a O 0 9.311642656939512e-08
small O 0 6.649656114632307e-08
fraction O 0 6.00176122134144e-07
of O 0 0.017570199444890022
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0917354842376881e-07
suggesting O 0 2.0759030405770318e-07
the O 0 3.326127284708491e-08
involvement O 0 1.5561118971163523e-07
of O 0 9.660146815804183e-08
another O 0 1.2924978420869593e-07
susceptibility O 0 1.584551682753954e-06
gene O 0 1.9384187908144668e-06
( O 0 3.1373208457807777e-06
s O 0 0.00018705132242757827
) O 0 7.394807471428066e-05

Paternal O 0 0.0012224435340613127
transmission O 1 0.9999986886978149
of O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999992847442627

We O 0 5.4145198191690724e-06
report O 0 7.624907425451966e-07
a O 0 3.422216536819178e-07
rare O 0 5.762321961810812e-07
case O 0 1.211149424307223e-06
of O 0 7.825336979294661e-06
paternally O 1 0.9999785423278809
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 1.0
DM B-Disease 1 1.0
) O 0 0.00013129071157891303
. O 0 3.754639328690246e-05

The O 0 9.975537977879867e-06
proband O 0 0.00013366933853831142
is O 0 1.8830783687917574e-07
a O 0 1.661912421013767e-07
23 O 0 8.001181299732707e-07
year O 0 1.734498766836623e-07
old O 0 1.354664345853962e-05
, O 0 0.00012980611063539982
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 1 0.9498050808906555
who O 0 0.06496219336986542
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9999980926513672

He O 0 3.138816828140989e-05
presented O 0 4.952266681357287e-05
with O 0 2.8430289603420533e-05
respiratory O 1 0.9999994039535522
and O 0 0.00018795253708958626
feeding O 0 0.00015890099166426808
difficulties O 0 0.030867300927639008
at O 0 0.0004219140100758523
birth O 0 1.615784458408598e-05
. O 0 2.396632407908328e-05

His O 0 3.0855291697662324e-05
two O 0 2.295246667927131e-05
sibs O 1 0.9936816692352295
suffer O 0 0.0003351615450810641
from O 0 1.1837380043289158e-05
childhood O 0 0.20012103021144867
onset O 1 1.0
DM B-Disease 1 1.0
. O 1 0.9721699953079224

Their O 0 8.017160553208669e-07
late O 0 7.4870076787192374e-06
father O 0 8.316462185575801e-07
had O 0 2.845091273684375e-07
the O 0 1.6056613105774886e-07
adult O 0 1.584743642979447e-07
type O 0 8.15596479242231e-07
of O 0 9.029826287587639e-06
DM B-Disease 1 1.0
, O 0 1.9143105873808963e-06
with O 0 3.1171464343060507e-07
onset O 0 0.09287618845701218
around O 0 3.712287366397504e-07
30 O 0 7.813367801645654e-07
years O 0 4.754371900617116e-07
. O 0 3.606548034440493e-06

Only O 0 2.166330205000122e-06
six O 0 5.470202495416743e-07
other O 0 1.6993705997947472e-08
cases O 0 1.964004781029871e-08
of O 0 5.585577866895619e-08
paternal O 0 1.1226808283026912e-06
transmission O 1 0.9991376399993896
of O 1 0.9999905824661255
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.010308343917131424
been O 0 5.181315373192774e-06
reported O 0 1.6639947943986044e-06
recently O 0 5.615997451968724e-06
. O 0 1.3945751561550424e-05

We O 0 2.274296548421262e-06
review O 0 1.1897529930138262e-06
the O 0 2.3314865416068642e-07
sex O 0 1.5347957571520965e-07
related O 0 2.6591749247018015e-07
effects O 0 5.046099886385491e-06
on O 0 5.087553745397599e-06
transmission O 1 0.9997623562812805
of O 1 0.9952049255371094
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.996273398399353

Decreased O 0 3.693034886964597e-05
fertility O 0 2.237640956082032e-06
of O 0 3.310349541152391e-07
males O 0 5.637771778310707e-07
with O 0 1.526086776948432e-07
adult O 0 9.51925539993681e-06
onset O 1 0.9999972581863403
DM B-Disease 1 1.0
and O 0 2.6311640795029234e-06
contraction O 0 1.3243821967989788e-06
of O 0 6.917397854522278e-08
the O 0 3.365886769302051e-08
repeat O 0 9.586872096178922e-08
upon O 0 5.5298826850957994e-08
male O 0 9.584476856616675e-08
transmission O 0 2.788490292005008e-07
contribute O 0 1.238507518763754e-08
to O 0 5.141895353943937e-09
the O 0 1.743875799320449e-08
almost O 0 6.893164083976444e-08
absent O 0 1.5878177350714395e-07
occurrence O 0 1.1452162596015114e-07
of O 0 8.995612432727285e-08
paternal O 0 1.7461178458688664e-06
transmission O 1 0.8450100421905518
of O 1 0.9878167510032654
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9980584979057312

Also O 0 3.641589728431427e-06
the O 0 7.538763497905165e-07
fathers O 0 1.5027466133687994e-06
of O 0 3.6443583439904614e-07
the O 0 1.0886576546909055e-06
reported O 0 9.263392712455243e-06
congenitally O 0 0.003246443346142769
affected O 0 1.3224399708633428e-06
children O 0 1.1307196956522603e-07
showed O 0 5.445727992992033e-07
, O 0 1.8709846472120262e-07
on O 0 3.559828485322214e-07
average O 0 2.869052480036771e-07
, O 0 2.9902153642069607e-07
shorter O 0 9.134323590842541e-06
CTG O 0 0.002264569979161024
repeat O 0 5.069444796390599e-06
lengths O 0 7.180911325121997e-06
and O 0 8.866982881272634e-08
hence O 0 3.197290823209187e-07
less O 0 5.195468588681251e-07
severe O 0 0.0010313036618754268
clinical O 0 0.006920455954968929
symptoms O 0 2.8306951662671054e-06
than O 0 6.71304292154673e-08
the O 0 9.010396695430245e-08
mothers O 0 5.678994341451471e-08
of O 0 1.4764519562504574e-07
children O 0 5.541745053960767e-07
with O 0 0.00013061027857474983
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9534096121788025

We O 0 3.055670958929113e-06
conclude O 0 3.659672756839427e-06
that O 0 8.236688842089279e-08
paternal O 0 2.775664370346931e-06
transmission O 1 0.9960601925849915
of O 1 0.9999884366989136
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.07329186797142029
rare O 0 2.7110843348054914e-06
and O 0 1.5562395105916949e-07
preferentially O 0 1.3537048459966172e-07
occurs O 0 3.2929243332091573e-08
with O 0 1.248118763896855e-08
onset O 0 6.4778037085488904e-06
of O 0 1.7625033024160075e-06
DM B-Disease 1 1.0
past O 0 2.026119574338736e-07
30 O 0 6.942326535863685e-08
years O 0 2.0298651648431587e-08
in O 0 6.239222472004258e-09
the O 0 2.9216346675298155e-08
father O 0 3.284437752881786e-07
. O 0 4.5278616767063795e-07
. O 0 6.180498985486338e-06

The O 0 1.6683559806551784e-05
RB1 O 0 0.0007822180050425231
gene O 0 1.5969764035617118e-06
mutation O 0 1.3046383173787035e-06
in O 0 1.8052656969302916e-07
a O 0 9.862591241471819e-07
child O 0 1.749668263073545e-05
with O 0 4.120103767490946e-05
ectopic B-Disease 1 0.9999994039535522
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.019829189404845238

The O 0 1.9669587345561013e-05
RB1 O 0 0.0008913270430639386
gene O 0 3.0964440611569444e-06
mutation O 0 2.533630549805821e-06
was O 0 1.9464828255877364e-06
investigated O 0 2.8857825782324653e-06
in O 0 7.005615287880573e-08
a O 0 4.880244546257018e-07
child O 0 3.830193691101158e-06
with O 0 4.694225935963914e-06
ectopic B-Disease 1 0.9979444146156311
intracranial I-Disease 1 0.9999110698699951
retinoblastoma I-Disease 0 0.02553245984017849
using O 0 1.412826975411008e-07
DNA O 0 1.5676168629852327e-07
obtained O 0 4.995480296088317e-08
from O 0 7.539199486927828e-09
both O 0 4.120888164038661e-08
the O 0 3.663999166292342e-07
pineal B-Disease 0 0.0008255024440586567
and I-Disease 0 2.8367028335196665e-06
retinal I-Disease 1 0.9999372959136963
tumours I-Disease 1 1.0
of O 0 0.0001622608833713457
the O 0 2.8088301405659877e-05
patient O 0 2.7285766918794252e-05
. O 0 3.194937380612828e-05

A O 0 3.907151040039025e-05
nonsense O 0 3.7435740523505956e-05
mutation O 0 3.021903921762714e-06
in O 0 3.2929216331467615e-07
exon O 0 5.35196977580199e-06
17 O 0 2.9853508749511093e-06
( O 0 2.5628995103943453e-07
codon O 0 3.442521801844123e-06
556 O 0 1.2164475720055634e-06
) O 0 4.3332253341077376e-08
of O 0 1.3030114587309072e-07
the O 0 3.134779831270862e-07
RB1 O 0 0.0010372314136475325
gene O 0 3.502042602576694e-07
was O 0 3.128143930553051e-07
found O 0 1.4341830834041502e-08
to O 0 1.0203201838976383e-08
be O 0 2.3565494444710566e-08
present O 0 1.0722767740389827e-07
homozygously O 0 1.6154763216036372e-05
in O 0 6.266966323664747e-08
both O 0 1.1540398503484539e-07
the O 0 4.104009008187859e-07
retinal B-Disease 0 0.00029355776496231556
and I-Disease 0 2.241109314127243e-06
the I-Disease 0 2.8182374080643058e-05
pineal I-Disease 1 0.9990704655647278
tumours I-Disease 1 1.0
. O 0 0.0001535377959953621

The O 0 2.1477833342942176e-06
same O 0 2.4978254486995866e-07
mutation O 0 5.186191742723167e-07
was O 0 4.44995038151319e-07
present O 0 1.193195373616618e-07
heterozygously O 0 2.6198090381512884e-06
in O 0 1.8426096204393616e-08
the O 0 2.0643572185008452e-08
DNA O 0 2.6401163921718762e-08
from O 0 2.8728175394121536e-09
the O 0 1.319231923702091e-08
constitutional O 0 2.4843268420227105e-07
cells O 0 4.290623678571137e-08
of O 0 1.8698568027275542e-08
the O 0 2.257143272288431e-08
patient O 0 3.345648025288028e-08
, O 0 1.640546010150956e-08
proving O 0 1.682076913311903e-07
it O 0 5.583934203912122e-09
to O 0 6.283900511050433e-09
be O 0 3.664152359306172e-08
of O 0 5.011274311073066e-07
germline O 0 6.804623990319669e-05
origin O 0 6.083333573769778e-06
. O 0 1.7505128198536113e-05

The O 0 1.0490865633983049e-06
initial O 0 1.0016643727794872e-06
mutation O 0 4.71951494773748e-07
was O 0 1.9881250068465306e-07
shown O 0 2.0036086567642997e-08
to O 0 9.995668293072413e-09
have O 0 2.3857060327259205e-08
occurred O 0 7.233099950099131e-07
in O 0 5.052871543398396e-08
the O 0 3.950496250126889e-07
paternally O 0 1.1345741768309381e-05
derived O 0 6.565559488080908e-06
RB1 O 0 0.0020721200853586197
allele O 0 0.0002203366457251832
. O 0 5.458729719975963e-05

The O 0 1.6759551044742693e-06
mutation O 0 8.156781063917151e-07
is O 0 4.0051787664197036e-08
in O 0 1.7875168012437825e-08
an O 0 1.1603983551822239e-08
area O 0 5.0798320216927095e-08
of O 0 4.7683574422308084e-08
the O 0 8.958831898553399e-08
gene O 0 3.856013464087482e-08
that O 0 1.533740245918125e-08
encodes O 0 6.19470981177983e-08
the O 0 3.4971922246995746e-08
protein O 0 1.0705908692898447e-07
- O 0 1.52268782471765e-07
binding O 0 6.97268873750545e-08
region O 0 6.535957908226919e-08
known O 0 4.8757502923990614e-08
as O 0 2.1278161455029476e-08
the O 0 3.809759618889075e-08
pocket O 0 3.134073267574422e-06
region O 0 1.5272195241777808e-07
and O 0 2.757503736461331e-08
has O 0 1.526557724673694e-08
been O 0 9.664251621188669e-09
detected O 0 1.8814622748664078e-08
in O 0 6.325882040414399e-09
other O 0 7.762349873985386e-09
cases O 0 4.597911029691204e-08
of O 0 5.187982310417283e-07
retinoblastoma B-Disease 0 0.0021931976079940796
. O 0 3.4668128137127496e-06
. O 0 2.0012035747640766e-05

Low O 0 1.3702821888728067e-05
levels O 0 1.0047526757261949e-06
of O 0 3.229939125048986e-07
beta O 0 3.0372659693966853e-06
hexosaminidase O 0 5.648203114105854e-06
A O 0 1.8269220447564294e-07
in O 0 1.641766900206676e-08
healthy O 0 1.0332362876397383e-07
individuals O 0 1.3495844441990812e-08
with O 0 8.979600352176931e-08
apparent O 0 0.03212790936231613
deficiency O 1 0.9995914101600647
of O 0 0.00016196903015952557
this O 0 1.459571080886235e-06
enzyme O 0 8.550176971766632e-06
. O 0 3.6035467019246425e-06

Appreciable O 0 0.00031222146935760975
beta O 0 9.873993985820562e-05
hexosaminidase O 0 0.00020775232405867428
A O 0 1.210613663715776e-05
( O 0 7.593695841023873e-07
hex O 0 1.5998415619833395e-05
A O 0 7.256148819578812e-07
) O 0 4.0803115552989766e-08
activity O 0 8.904132187126379e-08
has O 0 2.831572487593803e-08
been O 0 3.901563516706119e-08
detected O 0 3.904758045791823e-07
in O 0 4.130674540192558e-07
cultured O 0 0.04580039530992508
skin O 1 0.9997007846832275
fibroblasts O 0 0.019529903307557106
and O 0 3.0286664696177468e-05
melanoma B-Disease 1 0.999990701675415
tissue O 0 1.0313385246263351e-05
from O 0 8.233280368585838e-08
healthy O 0 7.795244982844451e-07
individuals O 0 1.8389231470905543e-08
previously O 0 2.920259589700436e-07
reported O 0 1.5064584601987008e-07
as O 0 1.903553794591062e-07
having O 0 7.027670108072925e-06
deficiency B-Disease 0 0.22112290561199188
of I-Disease 0 6.733651844115229e-06
hex I-Disease 0 6.260020018089563e-05
A I-Disease 0 3.119840812360053e-07
activity O 0 7.318418226986978e-08
indistinguishable O 0 4.4999406867418656e-08
from O 0 1.9558132891006608e-09
that O 0 2.193609516254469e-09
of O 0 8.41198399825771e-08
patients O 0 2.2349912853769638e-07
with O 0 1.5261757653206587e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 1 0.5433883666992188
TSD B-Disease 1 0.9999997615814209
) O 0 1.169065035355743e-05
. O 0 1.8370676116319373e-05

Identification O 0 6.886034498165827e-06
and O 0 1.3646243814946502e-06
quantitation O 0 0.0004077281628269702
of O 0 1.208351841341937e-05
hex O 0 0.000342299957992509
A O 0 7.888510481279809e-06
, O 0 5.377337402023841e-07
amounting O 0 1.4576514786313055e-06
to O 0 3.327476179038058e-07
3 O 0 1.0892737009271514e-05
. O 0 1.1969902516284492e-05

5 O 0 3.13259988615755e-05
% O 0 4.514517968345899e-06
- O 0 3.448459392529912e-05
6 O 0 9.112055704463273e-05
. O 0 2.7769227017415687e-05

9 O 0 5.987667918816442e-06
% O 0 1.9853833066463267e-07
of O 0 9.974436920856533e-08
total O 0 8.614656366034978e-08
beta O 0 4.068228633968829e-07
hexosaminidase O 0 1.1597765023907414e-06
activity O 0 9.065075801117928e-08
, O 0 2.1334404465278567e-08
has O 0 1.0456226995358975e-08
been O 0 2.020640721411837e-08
obtained O 0 1.4731270425727416e-07
by O 0 2.1125468663285574e-07
cellulose O 0 2.220048918388784e-05
acetate O 0 4.896457539871335e-06
gel O 0 1.3902979844715446e-05
electrophoresis O 0 7.799001650710125e-06
, O 0 8.614670150564052e-07
DEAE O 0 0.00020230741938576102
- O 0 6.458299139922019e-06
cellulose O 0 1.3337641576072201e-05
ion O 0 8.871752470440697e-06
- O 0 1.4167331983117037e-06
exchange O 0 9.027579039866396e-07
chromatography O 0 3.713758269441314e-05
, O 0 2.504403937564348e-07
radial O 0 3.94076960219536e-05
immunodiffusion O 0 6.064301487640478e-05
, O 0 6.153717322376906e-07
and O 0 1.702121835478465e-06
radioimmunoassay O 0 0.00038224286981858313
. O 0 2.6230158255202696e-05

Previous O 0 2.626480272738263e-05
family O 0 5.317042450769804e-07
studies O 0 1.7850815936526487e-07
suggested O 0 1.6110926992496388e-07
that O 0 7.764541010146786e-09
these O 0 7.492909404049897e-09
individuals O 0 7.617876995880124e-09
may O 0 4.486819449311952e-08
be O 0 4.430276945299738e-08
compound O 0 6.153065896796761e-07
heterozygotes O 0 8.302855007968901e-07
for O 0 5.057605889646766e-08
the O 0 6.41808028944979e-08
common O 0 3.727879516191024e-07
mutant O 0 6.201890300872037e-06
TSD B-Disease 0 0.0003685171250253916
gene O 0 3.498500689147477e-07
and O 0 8.663859318858158e-08
a O 0 1.6957949355855817e-07
rare O 0 5.339186941455409e-07
( O 0 4.888340185971174e-07
allelic O 0 4.5567459892481565e-05
) O 0 6.173850124469027e-07
mutant O 0 1.1062455087085254e-05
gene O 0 6.273774943110766e-06
. O 0 1.950563455466181e-05

Thus O 0 1.4168536836223211e-05
, O 0 9.70730752669624e-07
the O 0 3.6845435147370154e-07
postulated O 0 2.6853676899918355e-06
rate O 0 2.4038882884269697e-07
mutant O 0 4.0142955981536943e-07
gene O 0 4.592459035279717e-08
appears O 0 2.4254211083984956e-08
to O 0 8.704767573419758e-09
code O 0 1.3251786334933513e-08
for O 0 5.504760647312423e-09
the O 0 1.162667029319664e-08
expression O 0 1.3023861100691647e-08
of O 0 2.932275222633507e-08
low O 0 2.8174665089863993e-07
amounts O 0 1.1798262988804709e-07
of O 0 8.17203442693426e-07
hex O 0 7.610704778926447e-05
A O 0 1.3454047802952118e-05
. O 0 1.5452274965355173e-05

Heterozygotes O 0 0.0004927156260237098
for O 0 1.3608995459435391e-06
the O 0 4.577195511501486e-07
rare O 0 4.884817030870181e-07
mutant O 0 9.39069764172018e-07
may O 0 6.224034621027386e-08
be O 0 3.111090407514894e-08
indistinguishable O 0 1.8303853721590713e-07
from O 0 2.8561988330011445e-08
heterozygotes O 0 1.2692298696492799e-06
for O 0 1.0521168292143557e-07
the O 0 5.529033160200925e-07
common O 0 7.215756340883672e-06
TSD B-Disease 1 0.7104065418243408
mutant O 0 0.00013843124906998128
. O 0 2.674455572559964e-05

However O 0 4.156619070272427e-06
, O 0 3.589802020087518e-07
direct O 0 2.953668456484593e-07
visualization O 0 3.606606469475082e-06
and O 0 2.1048828102721018e-07
quantitation O 0 0.00011911770707229152
of O 0 2.226431661256356e-06
hex O 0 2.1201156414463185e-05
A O 0 2.0357087748834601e-07
by O 0 7.874009000374826e-09
the O 0 1.7797569640265465e-08
methods O 0 1.9732196676613967e-07
described O 0 8.707760912329832e-08
may O 0 5.56615802338456e-08
prevent O 0 2.2040245539756143e-07
false O 0 8.394031851821637e-07
- O 0 1.7710898418954457e-06
positive O 0 2.7754080633712874e-07
prenatal O 0 1.3839014627592405e-06
diagnosis O 0 1.554693767502613e-06
of O 0 1.3344845228857594e-06
TSD B-Disease 1 0.9999295473098755
in O 0 3.835505140159512e-07
fetuses O 0 1.168759013125964e-06
having O 0 2.768782678685966e-07
the O 0 2.0693013880190847e-07
incomplete O 0 5.210203198657837e-06
hex B-Disease 0 0.001576657174155116
A I-Disease 0 9.738396329339594e-05
deficiency I-Disease 0 0.0023154709488153458
of O 0 9.70673227129737e-07
the O 0 2.680445163605327e-07
type O 0 4.467368853511289e-06
described O 0 2.4403078668910894e-07
in O 0 4.291785771215473e-08
the O 0 3.0224722991079034e-07
four O 0 3.2111840937432135e-06
healthy O 0 2.2820333470008336e-05
individuals O 0 9.211014003085438e-06

The O 0 6.945729637664044e-06
tumor B-Disease 0 3.0295763281174004e-05
suppressor O 0 7.133910548873246e-05
gene O 0 4.425541192176752e-06
Smad4 O 0 0.0012129655806347728
/ O 0 0.00035568603198044
Dpc4 O 0 0.000328011839883402
is O 0 7.862636408617618e-08
required O 0 6.021895870844673e-08
for O 0 3.390254477153576e-08
gastrulation O 0 4.756630914926063e-06
and O 0 4.715969836865952e-08
later O 0 2.2706787206061563e-07
for O 0 7.59085878598853e-08
anterior O 0 1.6544784102734411e-06
development O 0 5.593269065684581e-07
of O 0 3.998660815796029e-07
the O 0 9.521947959001409e-07
mouse O 0 6.815846063545905e-06
embryo O 0 5.309043899615062e-06
. O 0 7.197112154244678e-06

Mutations O 0 3.7876208807574585e-05
in O 0 1.2060340850439388e-06
the O 0 3.238666749894037e-06
SMAD4 O 1 0.9990032315254211
/ O 0 0.17069996893405914
DPC4 O 0 0.30436795949935913
tumor B-Disease 0 9.00439772522077e-06
suppressor O 0 7.136229214665946e-06
gene O 0 1.487357934593092e-07
, O 0 5.8069851149866736e-08
a O 0 7.779635780025274e-08
key O 0 1.1286108474450884e-06
signal O 0 2.093822104143328e-06
transducer O 0 3.203711230526096e-06
in O 0 4.7753385246096514e-08
most O 0 6.428800247704203e-08
TGFbeta O 0 5.86095338803716e-05
- O 0 1.1075121619796846e-06
related O 0 1.2173627794709319e-07
pathways O 0 1.6929043056279625e-07
, O 0 1.118840575742297e-08
are O 0 2.9070914564499617e-09
involved O 0 1.6346239917197636e-08
in O 0 1.1091854545952629e-08
50 O 0 6.748706482540001e-08
% O 0 1.6088158361071692e-07
of O 0 2.4353203116334043e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999973773956299
. O 0 0.0003849260101560503

Homozygous O 0 0.0008455684292130172
Smad4 O 0 0.004877067636698484
mutant O 0 0.0002640935417730361
mice O 0 4.0837054257281125e-05
die O 0 1.3341217709239572e-05
before O 0 5.412067366705742e-06
day O 0 6.391439910657937e-06
7 O 0 3.876820846926421e-05
. O 0 3.414935417822562e-05

5 O 0 6.987676897551864e-05
of O 0 5.377539127948694e-05
embryogenesis O 0 0.0012879744172096252
. O 0 0.00011777065083151683

Mutant O 0 4.253098086337559e-05
embryos O 0 8.704188871888618e-07
have O 0 1.3176733659747697e-07
reduced O 0 4.940154099131178e-07
size O 0 1.672804756935875e-07
, O 0 6.809582231426248e-08
fail O 0 3.654214424386737e-07
to O 0 1.1083569262382298e-07
gastrulate O 0 2.2043424905859865e-05
or O 0 2.440063440189988e-07
express O 0 2.3004091076472832e-07
a O 0 2.5982294005189033e-07
mesodermal O 0 9.561080332787242e-06
marker O 0 1.9170290670444956e-06
, O 0 2.445507902848476e-07
and O 0 2.7915660893995664e-07
show O 0 1.318348722634255e-06
abnormal O 0 1.5636731404811144e-05
visceral O 0 0.0017308318056166172
endoderm O 1 0.9430334568023682
development O 0 0.00013066473184153438
. O 0 4.500595241552219e-05

Growth B-Disease 1 0.9999955892562866
retardation I-Disease 1 0.9999998807907104
of O 0 8.141470061673317e-06
the O 0 3.773110620386433e-06
Smad4 O 0 0.2925574481487274
- O 0 1.441834683646448e-05
deficient O 0 4.1637827052909415e-07
embryos O 0 2.1068725430950508e-08
results O 0 4.5210356347524794e-08
from O 0 1.038675545572687e-08
reduced O 0 2.3013724614884268e-07
cell O 0 3.52057043073728e-07
proliferation O 0 2.1213087109117623e-07
rather O 0 2.552215683238046e-08
than O 0 3.2298430596711114e-08
increased O 0 3.2014375506150827e-07
apoptosis O 0 1.2892032827949151e-05
. O 0 3.3888438792928355e-06

Aggregation O 0 3.334558641654439e-05
of O 0 5.629516181215877e-06
mutant O 0 4.1461804357822984e-05
Smad4 O 0 0.00041817277087830007
ES O 0 0.00020719683379866183
cells O 0 8.757770046941005e-07
with O 0 1.4752795607364533e-07
wild O 0 1.1506895134516526e-06
- O 0 3.9394531086145435e-06
type O 0 1.4462830222328193e-05
tetraploid O 0 0.498022198677063
morulae O 0 0.03210967034101486
rescues O 0 4.088973946636543e-05
the O 0 5.999865607009269e-06
gastrulation B-Disease 0 0.002630404895171523
defect I-Disease 0 0.00036354915937408805
. O 0 8.019392407732084e-05

These O 0 9.28724261939351e-07
results O 0 1.3022428220210713e-06
indicate O 0 2.1659883486790932e-07
that O 0 2.6470141634149513e-08
Smad4 O 0 1.2842982869187836e-05
is O 0 2.653838748756243e-08
initially O 0 7.262712387046122e-08
required O 0 1.9326964917354417e-08
for O 0 7.551085978718675e-09
the O 0 7.47693462699317e-09
differentiation O 0 7.785840239193931e-08
of O 0 2.2967979518284665e-08
the O 0 3.3704349533536515e-08
visceral O 0 3.7637628338416107e-06
endoderm O 0 2.033647797361482e-05
and O 0 5.960849591701844e-08
that O 0 1.5940466724373437e-08
the O 0 1.6360719712338323e-07
gastrulation B-Disease 0 3.431777440709993e-05
defect I-Disease 0 1.3148091966286302e-06
in O 0 6.227751470078147e-08
the O 0 3.186618187100976e-07
epiblast O 0 0.00010134860349353403
is O 0 6.253103634890067e-08
secondary O 0 1.4691905789732118e-06
and O 0 2.646681593887479e-07
non O 0 1.3629928616865072e-05
- O 0 1.69640716194408e-05
cell O 0 1.4330301382869948e-05
autonomous O 0 3.952764018322341e-06
. O 0 1.1581899343582336e-05

Rescued O 0 0.00012209215492475778
embryos O 0 5.732576482841978e-06
show O 0 4.055630142829614e-06
severe O 0 0.027252836152911186
anterior O 0 0.15306907892227173
truncations O 1 0.9999090433120728
, O 0 1.27901137148001e-06
indicating O 0 8.14652707958885e-07
a O 0 1.8063178686134052e-07
second O 0 2.0552822377339908e-07
important O 0 6.374951766474624e-08
role O 0 2.0164696934443782e-07
for O 0 1.7635647964198142e-07
Smad4 O 0 0.0001245865860255435
in O 0 7.017584948698641e-07
anterior O 0 0.0001271135697606951
patterning O 0 0.0007472638390026987
during O 0 2.1873285731999204e-05
embryogenesis O 0 0.00024699445930309594
. O 0 4.074179378221743e-05

Prevalence O 0 6.255287735257298e-05
of O 0 6.566285719600273e-06
p16 O 0 5.470120595418848e-05
and O 0 3.7523805076489225e-06
CDK4 O 0 0.26990798115730286
germline O 0 0.0002996251860167831
mutations O 0 2.1582836779998615e-06
in O 0 3.963730819123157e-07
48 O 0 5.2068218792555854e-05
melanoma B-Disease 1 0.9999997615814209
- O 0 0.47417545318603516
prone O 0 0.0018760811071842909
families O 0 3.5166578982170904e-07
in O 0 1.5989880921551958e-06
France O 0 0.024578098207712173
. O 0 0.00017043293337337673

The O 0 2.225770367658697e-05
French O 0 0.0016502386424690485
Familial B-Disease 1 0.9890443086624146
Melanoma I-Disease 1 0.9999996423721313
Study O 0 2.650580609042663e-05
Group O 0 2.3593733203597367e-05
. O 0 4.7133224143180996e-05

Germline O 0 0.002049198606982827
mutations O 0 7.433605787809938e-06
in O 0 3.8237084254433285e-07
the O 0 4.758114187097817e-07
p16 O 0 4.515792625170434e-06
and O 0 2.795618172513059e-07
CDK4 O 0 0.0013993224129080772
genes O 0 5.820480097895597e-08
have O 0 1.110032066264921e-08
been O 0 2.143098321027992e-08
reported O 0 4.6318788804455835e-08
in O 0 2.3879778154878295e-08
a O 0 9.800805145232516e-08
subset O 0 1.4438644484471297e-06
of O 0 2.460109271851252e-06
melanoma B-Disease 1 0.8345016241073608
pedigrees O 0 1.7282438875554362e-06
, O 0 9.931665800877454e-08
but O 0 2.457271186528942e-08
their O 0 2.2549315303876938e-08
prevalence O 0 4.414466161506425e-07
is O 0 1.309934738458196e-08
not O 0 2.4883240357098657e-08
well O 0 2.2420171319481597e-07
known O 0 3.3020742193912156e-06
. O 0 2.010492426052224e-05

We O 0 5.134428647579625e-06
searched O 0 3.3445430744905025e-06
for O 0 2.0490156771302281e-07
such O 0 1.6725161344766093e-07
germline O 0 3.187934635207057e-05
mutations O 0 5.582892868005729e-07
in O 0 8.151511110554566e-08
48 O 0 3.0133080599625828e-06
French O 1 0.9928231239318848
melanoma B-Disease 1 1.0
- O 0 0.06301426142454147
prone O 0 2.344391032238491e-05
families O 0 3.5306968015902385e-08
selected O 0 1.7090677317810332e-07
according O 0 1.5561973043531907e-08
to O 0 7.670248436397742e-09
two O 0 1.9762209646501105e-08
major O 0 7.696791470834796e-08
criteria O 0 5.924014345737305e-08
families O 0 6.600977098258909e-09
with O 0 9.908446507722601e-09
at O 0 1.4458650809956453e-07
least O 0 3.2496725310693364e-08
three O 0 1.1020577339593274e-08
affected O 0 1.339393573829284e-08
members O 0 1.0506145287081381e-08
( O 0 1.7796210727283324e-08
n O 0 1.7534758001147566e-07
= O 0 3.7386388385129976e-07
20 O 0 1.0676992445723954e-07
) O 0 8.914834204176714e-09
or O 0 6.200322921756651e-09
families O 0 1.664039350757207e-09
with O 0 4.338929660008262e-09
two O 0 6.7059633401811425e-09
affected O 0 1.6044850781327114e-08
members O 0 6.0982490168726144e-09
, O 0 1.1559339263556012e-08
one O 0 4.987594337535484e-09
of O 0 1.4537426373806284e-08
them O 0 6.5098784141071064e-09
affected O 0 1.8742628782320025e-08
before O 0 2.1274995987141665e-08
the O 0 9.18253650894485e-09
age O 0 2.529892029201619e-08
of O 0 2.5193321206984365e-08
50 O 0 3.726585262597837e-08
( O 0 1.0917559301049096e-08
n O 0 1.1750248773978456e-07
= O 0 2.2685208023176529e-07
28 O 0 2.0928749222548504e-07
) O 0 9.639583353759917e-09
, O 0 1.0527548610639315e-08
and O 0 1.536870541940516e-08
one O 0 1.6804053259988905e-08
additional O 0 1.2284901629300293e-07
minor O 0 3.798154466494452e-06
criterion O 0 5.605689875665121e-05
. O 0 1.2844085176766384e-05

Sixteen O 0 0.00011811567674158141
different O 0 3.068072373935138e-06
p16 O 0 3.249791916459799e-05
germline O 0 3.940566966775805e-05
mutations O 0 6.499533924397838e-07
were O 0 9.022176783446412e-08
found O 0 2.6414209486347318e-08
in O 0 3.3097176554974794e-08
21 O 0 5.161634248906921e-07
families O 0 1.105755043084855e-08
, O 0 3.815591753664194e-08
while O 0 7.529632028990818e-08
one O 0 8.984346067109072e-08
germline O 0 1.2538578630483244e-05
mutation O 0 6.531353164973552e-07
, O 0 1.6191422957945178e-07
Arg24His O 0 0.00029854592867195606
, O 0 3.2208035349867714e-07
was O 0 8.758913736528484e-07
detected O 0 2.2445520642122574e-07
in O 0 7.119304967773132e-08
the O 0 1.0668071581676486e-06
CDK4 O 0 0.03800910711288452
gene O 0 2.9897848435211927e-05
. O 0 4.016958337160759e-05

The O 0 3.4788818084052764e-06
frequency O 0 7.525922683271347e-06
of O 0 1.3214073533163173e-06
p16 O 0 2.562083636803436e-06
gene O 0 8.390799877133759e-08
mutation O 0 5.4232359048000944e-08
in O 0 1.5362552119313477e-08
our O 0 2.1184778375982205e-08
sample O 0 1.5176912171455115e-08
( O 0 2.4317298397136256e-08
44 O 0 9.604221418157977e-08
% O 0 2.1910516068146535e-08
) O 0 2.2825783929647514e-08
is O 0 6.7350485188910625e-09
among O 0 7.433833992820382e-09
the O 0 1.2830213336201268e-08
highest O 0 8.743376866959807e-08
rates O 0 3.412598204022288e-08
yet O 0 2.9978870941249625e-08
reported O 0 2.870419990586015e-08
and O 0 2.5262657743496675e-08
the O 0 9.698806024971418e-08
CDK4 O 0 8.128163608489558e-05
mutation O 0 1.0411772422003196e-07
is O 0 7.1968777604070056e-09
the O 0 1.4471253528824946e-08
second O 0 1.1679618694415694e-07
mutation O 0 5.807693881365594e-08
detected O 0 3.1835437397376154e-08
in O 0 8.042277066522274e-09
this O 0 2.7970894933559975e-08
gene O 0 3.6436770756154147e-07
worldwide O 0 2.1534954157687025e-06
. O 0 1.1706504665198736e-05

In O 0 4.1405960473639425e-06
summary O 0 3.100046524195932e-05
, O 0 3.0797056638220965e-07
our O 0 2.5734311748237815e-07
results O 0 1.885139369051103e-07
show O 0 8.458238909270221e-08
frequent O 0 5.7448847456953445e-08
involvement O 0 4.7239822720257507e-07
of O 0 1.865660692601523e-07
the O 0 2.4697655476302316e-07
p16 O 0 3.002986204592162e-06
gene O 0 1.7710800648274017e-07
in O 0 9.243515819434833e-08
familial B-Disease 0 1.5988012819434516e-05
melanoma I-Disease 1 0.72489333152771
and O 0 2.2808795563378226e-07
confirm O 0 3.053897899008007e-07
the O 0 7.010721958522481e-08
role O 0 1.137756129310219e-07
of O 0 1.9005062767973868e-07
the O 0 6.13349243394623e-07
CDK4 O 0 0.27333617210388184
gene O 0 4.369769328604889e-07
as O 0 3.114326432296366e-07
a O 0 1.6172531331903883e-06
melanoma B-Disease 1 0.9782512187957764
- O 0 3.557643503881991e-05
predisposing O 0 8.1327407315257e-06
gene O 0 1.3477126685756957e-06
. O 0 1.4161294075165642e-06
. O 0 1.4356591236719396e-05

Progression O 0 0.0001654235675232485
of O 0 1.6803542166599073e-05
somatic O 0 0.0003209527349099517
CTG O 0 0.0013736082473769784
repeat O 0 4.524275937001221e-06
length O 0 4.880212145508267e-07
heterogeneity O 0 9.76233309302188e-07
in O 0 2.75319944620378e-08
the O 0 5.893686250146857e-08
blood O 0 3.882041710312478e-07
cells O 0 1.4598436791857239e-05
of O 1 0.6162822246551514
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9459076523780823
. O 0 0.00028098412440158427

The O 0 2.940160356956767e-06
genetic O 0 2.7298917757434538e-06
basis O 0 5.817893907078542e-06
of O 1 0.9493693113327026
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999985694885254
DM B-Disease 1 1.0
) O 0 7.072273433550436e-07
is O 0 1.2527433312925496e-08
the O 0 1.1885079587159453e-08
expansion O 0 7.240458188562116e-08
of O 0 5.535813940582557e-08
an O 0 3.40025358980256e-08
unstable O 0 3.6944024941476528e-06
CTG O 0 0.00017043229308910668
repeat O 0 1.1517676057337667e-06
in O 0 5.70532208143959e-08
the O 0 8.728164146987183e-08
34 O 0 6.688248390673834e-07
UTR O 0 1.7177970221382566e-05
of O 0 5.307285846356535e-07
the O 0 1.798078415049531e-06
DM B-Disease 1 0.9999998807907104
protein O 0 2.6448749395058258e-06
kinase O 0 1.3641167697642231e-06
gene O 0 1.3093057305013645e-07
on O 0 4.480384632188361e-07
chromosome O 0 4.617422291630646e-06
19 O 0 1.4009559890837409e-05
. O 0 2.7276062610326335e-05

One O 0 1.5036152944958303e-06
of O 0 4.777206186190597e-07
the O 0 2.3475104171666317e-07
principal O 0 1.00759211818513e-06
features O 0 1.7479526093211462e-07
of O 0 2.7544714953364746e-07
the O 0 1.3299069223648985e-06
DM B-Disease 1 1.0
mutation O 0 7.167878379732429e-07
is O 0 1.9281822360994738e-08
an O 0 1.4043633811411382e-08
extraordinarily O 0 4.0826401459526096e-07
high O 0 5.843026542606822e-07
level O 0 8.719526363165642e-07
of O 0 3.9052792999427766e-07
somatic O 0 2.428119842079468e-05
mosaicism O 0 1.37929710035678e-05
, O 0 1.714758113280368e-08
due O 0 2.1245677217507364e-08
to O 0 3.6184168994424226e-09
an O 0 3.53062112878888e-09
extremely O 0 3.544766258301024e-08
high O 0 1.1156743795481816e-07
degree O 0 3.1356768204204855e-07
of O 0 6.171642041863379e-08
somatic O 0 8.23021650830924e-07
instability O 0 9.792863409074926e-08
both O 0 1.803423899104928e-08
within O 0 3.303404483290251e-08
and O 0 3.399261316872071e-08
between O 0 2.3120371395179973e-07
different O 0 4.882353437096754e-07
tissues O 0 1.1558826372493058e-05
. O 0 8.57634313433664e-06

This O 0 1.4599122550862376e-06
instability O 0 4.758091563417111e-06
appears O 0 3.1887950058262504e-07
to O 0 1.674320238009841e-08
be O 0 1.6068891994791556e-08
biased O 0 2.2637597396624187e-07
towards O 0 7.358084275210786e-08
further O 0 3.5846085211233e-08
expansion O 0 6.217675263542333e-08
and O 0 6.7381704660363084e-09
continuous O 0 3.248978330816499e-08
throughout O 0 5.93394045012019e-09
the O 0 3.940435533422715e-09
life O 0 3.081883415134712e-09
of O 0 4.316510704427401e-09
an O 0 1.5759826776928776e-09
individual O 0 2.37205655118089e-09
, O 0 5.711242589967469e-09
features O 0 1.1972928426473572e-08
that O 0 8.552924479765522e-10
could O 0 3.3213078953764352e-09
be O 0 5.749880571670474e-09
associated O 0 9.381110110950885e-09
with O 0 5.432249761128105e-09
the O 0 6.117357287394043e-08
progressive O 0 2.0208977730362676e-05
nature O 0 5.339584276953246e-07
of O 0 1.6766489352448843e-06
the O 0 7.136242857086472e-06
disease O 0 0.004292995203286409
. O 0 1.2344611604930833e-05

Although O 0 4.987686679669423e-06
increasing O 0 2.1493099211511435e-06
measured O 0 2.069950141958543e-06
allele O 0 1.236333446286153e-06
size O 0 2.2812318434262124e-07
between O 0 2.0239856723947014e-07
patients O 0 9.633061637259743e-08
clearly O 0 1.1257809973130861e-07
correlates O 0 2.025128509330898e-07
with O 0 6.994678170002544e-09
an O 0 3.915912927254794e-09
increased O 0 3.232388223750604e-08
severity O 0 2.9007844659645343e-06
of O 0 6.017441478434193e-07
symptoms O 0 3.8143004985613516e-06
and O 0 2.5063769726330065e-08
an O 0 3.841271745130825e-09
earlier O 0 2.256820330615028e-08
age O 0 1.5197944236433614e-08
of O 0 2.815620625540305e-08
onset O 0 3.239754278183682e-06
, O 0 9.861556016232953e-09
this O 0 1.7754330228214599e-09
correlation O 0 4.955005294959847e-09
is O 0 1.0624551238791469e-09
not O 0 1.8353586428432322e-09
precise O 0 1.1845558844925108e-07
and O 0 3.640536760940449e-08
measured O 0 2.1569348973571323e-07
allele O 0 2.135472527697857e-07
length O 0 2.3572193086351945e-08
cannot O 0 9.482228335855325e-09
be O 0 4.3727599319254296e-09
used O 0 4.6867971725816915e-09
as O 0 6.540395336429583e-09
an O 0 6.987624256993286e-09
accurate O 0 2.3061552667513752e-07
predictor O 0 7.263588940986665e-06
of O 0 5.449655873235315e-07
age O 0 6.856853360659443e-06
of O 0 2.075140037050005e-05
onset O 1 0.9998118281364441
. O 0 0.00010326082701794803

In O 0 2.2251961127039976e-06
order O 0 9.950853154805372e-07
to O 0 1.5284578580576635e-07
further O 0 5.327722192305373e-07
characterize O 0 2.2036936115910066e-06
the O 0 5.133113063493511e-07
dynamics O 0 1.3332097296370193e-05
of O 0 2.564978967711795e-05
DM B-Disease 1 1.0
CTG O 1 0.9974472522735596
repeat O 0 8.629383955849335e-06
somatic O 0 7.449829354300164e-06
instability O 0 1.0711316917877411e-06
, O 0 7.995858908316222e-08
we O 0 4.901700378923124e-08
have O 0 2.389659137236322e-08
studied O 0 3.2370223834732315e-07
repeat O 0 1.8962789738452557e-07
length O 0 4.592573077388806e-08
changes O 0 2.280346045324677e-08
over O 0 2.9102221077437207e-08
time O 0 5.868839281220062e-08
in O 0 1.8718020555752446e-07
111 O 0 0.0017861861269921064
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.0794606168929022e-06
with O 0 8.578812327186824e-08
varying O 0 1.3777569165540626e-06
clinical O 0 1.3960481737740338e-05
severity O 0 1.2287716344872024e-05
and O 0 1.0018268312705914e-06
CTG O 0 0.00012041816080454737
repeat O 0 5.43462533642014e-07
size O 0 7.225006726230276e-08
over O 0 2.996475245709007e-08
time O 0 2.3550621008894268e-08
intervals O 0 5.495499877383736e-08
of O 0 2.1695310437053195e-08
1 O 0 3.2817703754517424e-07
- O 0 2.678023065527668e-07
7 O 0 9.109262464335188e-07
years O 0 8.718361641513184e-07
. O 0 5.169322321307845e-06

We O 0 1.3734567119172425e-06
have O 0 9.893456365261954e-08
found O 0 4.323656810356624e-08
a O 0 3.6677672454743515e-08
direct O 0 4.4363062556840305e-08
progression O 0 7.694815735703742e-07
of O 0 1.0675261563619642e-07
the O 0 5.719879325738475e-08
size O 0 8.2793256694913e-08
heterogeneity O 0 4.6356788629964285e-07
over O 0 6.019989484684629e-08
time O 0 6.43081179418914e-08
related O 0 3.456877450958018e-08
to O 0 1.6428632676479538e-08
initial O 0 4.4875986304759863e-07
CTG O 0 4.037043254356831e-05
repeat O 0 4.784765792464896e-07
size O 0 4.9590543227395756e-08
and O 0 1.397904103583869e-08
the O 0 1.5280345877499713e-08
time O 0 3.415183513766351e-08
interval O 0 2.0621264695819264e-07
and O 0 2.2395310494971454e-08
always O 0 1.1174292069426883e-07
biased O 0 8.311046713060932e-07
towards O 0 5.154304858479009e-07
further O 0 1.2573990488817799e-06
expansion O 0 1.1688565791700967e-05
. O 0 1.3262858374218922e-05

Attempts O 0 8.219170922529884e-06
to O 0 3.535660937359353e-07
mathematically O 0 4.159473974141292e-06
model O 0 5.849259991919098e-07
the O 0 7.988100492184458e-08
dynamics O 0 2.4086048142635264e-06
have O 0 3.2912414127395095e-08
proved O 0 1.723193122415978e-06
only O 0 5.849048179129568e-08
partially O 0 2.1072889921924798e-07
successful O 0 1.058035365986143e-07
suggesting O 0 4.121548258240182e-08
that O 0 4.728495817118983e-09
individual O 0 4.574657541667193e-09
specific O 0 7.751697062019502e-09
genetic O 0 3.368410617099471e-08
and O 0 3.3522912445960173e-08
/ O 0 9.351650078315288e-06
or O 0 4.5622432054415185e-08
environmental O 0 4.3255457882196424e-08
factors O 0 2.845546553942313e-08
also O 0 1.2239266489189049e-08
play O 0 7.076686614482242e-08
a O 0 4.4563545742448696e-08
role O 0 2.3953731442816206e-07
in O 0 1.6314726281052572e-07
somatic O 0 4.3664440454449505e-05
mosaicism O 0 0.00027688767295330763
. O 0 5.419505214376841e-06
. O 0 2.1068897694931366e-05

Aspartylglucosaminuria B-Disease 1 0.9985871315002441
among O 0 2.4546849090256728e-05
Palestinian O 0 0.00014952782657928765
Arabs O 0 0.0003379789413884282
. O 0 7.111807644832879e-05

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9884434342384338
AGU B-Disease 1 1.0
) O 0 3.0827309274172876e-06
is O 0 1.3579381175077287e-07
a O 0 2.2253821896356385e-07
rare O 0 1.3772531929134857e-05
disorder B-Disease 1 0.999915599822998
of I-Disease 0 0.4539199471473694
glycoprotein I-Disease 1 0.9999659061431885
metabolism I-Disease 0 0.05925861373543739
caused O 0 2.287544020873611e-06
by O 0 1.510806413307364e-07
the O 0 1.5182145034486894e-06
deficiency B-Disease 0 0.29690003395080566
of I-Disease 0 1.4709873539686669e-05
the I-Disease 0 1.0203026249655522e-05
lysosomal I-Disease 0 0.11161588132381439
enzyme I-Disease 0 1.1010136404365767e-05
aspartylglucosaminidase I-Disease 0 0.00022247359447646886
( O 0 2.2385906959243584e-06
AGA O 0 0.0004898477927781641
) O 0 2.9427635581669165e-06
. O 0 1.1095388799731154e-05

AGU B-Disease 1 1.0
is O 0 1.4765824744245037e-05
inherited O 0 0.0003720828681252897
as O 0 3.887646471412154e-06
an O 0 2.327331003471045e-06
autosomal O 1 0.7278175354003906
recessive O 1 0.9807662963867188
trait O 0 0.00021209959231782705
and O 0 1.2195851013530046e-06
occurs O 0 2.617373979774129e-07
with O 0 1.908450109056048e-08
a O 0 4.295339905979745e-08
high O 0 6.824963634244341e-07
frequency O 0 9.88637907539669e-07
in O 0 1.040150543474283e-08
Finland O 0 1.2190554343760596e-07
because O 0 1.0436581376893628e-08
of O 0 5.917204859429148e-08
a O 0 2.0455189542190055e-07
founder O 0 5.600188160315156e-06
effect O 0 6.092176136007765e-06
. O 0 1.0127903806278482e-05

While O 0 6.690655027341563e-06
very O 0 9.69262600847287e-07
few O 0 3.8787226230851957e-07
patients O 0 2.1345380218917853e-07
with O 0 4.4596453108169953e-07
AGU B-Disease 1 1.0
have O 0 1.6886248488390265e-07
been O 0 5.156728732913507e-08
reported O 0 5.77174930072033e-08
from O 0 1.35153701563695e-08
non O 0 1.0344939482820337e-06
- O 0 8.087687888291839e-07
Finnish O 0 5.258563760435209e-06
origin O 0 1.596487635424637e-07
, O 0 1.4883285359701404e-07
we O 0 4.97277483191283e-07
diagnosed O 0 0.00038219988346099854
the O 0 6.360523343573732e-07
disorder O 0 0.0069734505377709866
in O 0 9.140444490185473e-08
8 O 0 1.1778269026763155e-06
patients O 0 2.2400779897679968e-08
originating O 0 1.758263934448223e-08
from O 0 1.2615264388671221e-08
3 O 0 2.986746778788074e-07
unrelated O 0 7.97945105546205e-08
families O 0 3.3027476309399617e-09
, O 0 7.35707095245175e-09
all O 0 6.744869551766897e-09
Palestinian O 0 2.5963171879084257e-07
Arabs O 0 2.8174557087368157e-07
from O 0 1.53576884542872e-08
the O 0 4.257720931377662e-08
region O 0 1.7388330775247596e-07
of O 0 5.59377554054663e-07
Jerusalem O 0 5.484892972162925e-05
. O 0 2.1880417989450507e-05

The O 0 9.18518071557628e-06
clinical O 0 0.00014825575635768473
diagnosis O 1 0.5826215147972107
of O 1 0.9027585983276367
AGU B-Disease 1 1.0
is O 0 5.184528617974138e-06
often O 0 1.7876811853057006e-07
difficult O 0 5.510466962732607e-07
, O 0 5.339858688557797e-08
in O 0 1.0320757581894213e-08
particular O 0 1.2580950503604527e-08
early O 0 6.240652794531343e-08
in O 0 4.077073345598592e-09
the O 0 1.1580591596782597e-08
course O 0 7.359235354442717e-08
of O 0 4.18913721489389e-08
the O 0 3.0101892889433657e-07
disease O 0 1.4075328181206714e-05
, O 0 4.189424984701873e-08
and O 0 3.361177647320801e-08
most O 0 1.9158793662654716e-08
of O 0 9.400476841392447e-08
the O 0 8.827142039535829e-08
patients O 0 5.9453174827694966e-08
are O 0 4.73748968943255e-08
diagnosed O 0 4.041541160404449e-06
after O 0 2.5607712927921966e-07
the O 0 4.9353040765254264e-08
age O 0 1.3735231618738908e-07
of O 0 3.1172592684924894e-07
5 O 0 2.8592291982931783e-06
years O 0 1.6295751947836834e-06
. O 0 5.082127245259471e-06

However O 0 6.661959560005926e-06
, O 0 7.595738225063542e-07
since O 0 5.226697794569191e-07
these O 0 7.598028872735085e-08
patients O 0 3.6635025679743194e-08
excrete O 0 3.4307944929423684e-07
early O 0 1.0960711449570226e-07
large O 0 3.0079220891821024e-08
amounts O 0 3.010309512774256e-08
of O 0 8.428108344560314e-08
aspartylglucosamine O 0 4.350473318481818e-06
in O 0 3.8037331506757255e-08
urine O 0 1.5643222184280603e-07
, O 0 3.731300779463709e-08
biochemical O 0 5.127745907884673e-07
screening O 0 1.461132086433281e-07
is O 0 1.262655402456403e-08
easy O 0 1.5162625288667186e-07
by O 0 1.0444391307373735e-07
urine O 0 1.2568896181619493e-06
chromatography O 0 7.56910303607583e-05
. O 0 2.311449406988686e-06
. O 0 7.479471150872996e-06

Detection O 0 5.13632912770845e-05
of O 0 2.7158096145285526e-06
heterozygous O 0 2.482316631358117e-06
carriers O 0 5.181925644137664e-07
of O 0 1.3184468343752087e-06
the O 0 5.906890510232188e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.037832506000995636
ATM O 0 0.43099072575569153
) O 0 6.68404069870121e-08
gene O 0 3.205821030860534e-08
by O 0 4.8700250943056744e-08
G2 O 0 0.0002522687427699566
phase O 0 4.490263381740078e-05
chromosomal O 0 5.648865226248745e-06
radiosensitivity O 0 1.1779216038121376e-05
of O 0 2.32724892157421e-06
peripheral O 0 0.002103013452142477
blood O 0 2.7669042538036592e-05
lymphocytes O 0 8.74867255333811e-05
. O 0 2.0799685444217175e-05

In O 0 0.0004480923234950751
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999997615814209
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.2164451845819713e-06
patients O 0 4.677244191952923e-08
, O 0 1.2215198630372015e-08
mutations O 0 1.5824657140228737e-08
in O 0 1.9802497419618703e-09
a O 0 8.052054134566333e-09
single O 0 7.636847598746499e-09
gene O 0 1.894870216290201e-08
, O 0 1.8696997727829512e-08
ATM O 0 2.6818875085155014e-06
, O 0 2.5317602236896164e-08
result O 0 1.6807155134301865e-07
in O 0 1.4357890165683784e-07
an O 0 1.0322260095563252e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.7983655197895132e-05
embraces O 0 8.048330528254155e-06
a O 0 1.0462794364229921e-07
variety O 0 6.839795219093503e-08
of O 0 1.1589543902346122e-07
clinical O 0 1.5616571999998996e-06
features O 0 2.251532720265459e-07
and O 0 7.949933689133104e-08
manifests O 0 5.460294119075115e-07
extreme O 0 3.1063227652339265e-06
radiosensitivity O 0 1.5844996596570127e-05
and O 0 8.525732653197338e-08
a O 0 6.852656753153497e-08
strong O 0 4.0685387148187147e-07
pre O 0 2.3713448172202334e-05
- O 0 2.4238777314167237e-06
disposition O 0 7.844847459637094e-06
to O 0 1.4501447367365472e-06
malignancy B-Disease 0 0.010305882431566715
. O 0 4.190926119918004e-05

Heterozygotes O 0 0.0001555997005198151
for O 0 8.780533562458004e-07
the O 0 4.5118355274098576e-07
ATM O 0 4.029218416690128e-06
gene O 0 5.4647074421154684e-08
have O 0 9.604291584253133e-09
no O 0 3.6901589339777274e-08
clinical O 0 4.1290914509772847e-07
expression O 0 1.8638520771219191e-07
of O 0 1.3561666492023505e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
but O 0 9.92414584288781e-07
may O 0 6.608285616493959e-07
be O 0 3.075050756251585e-07
cancer B-Disease 0 2.831448455253849e-06
prone O 0 2.39111187738672e-07
with O 0 1.0613073087029079e-08
a O 0 3.807268100786132e-08
moderate O 0 2.7569312806008384e-06
increase O 0 6.179804756811791e-08
in O 0 6.025181420454828e-08
in O 0 2.2124905285636487e-07
vitro O 0 7.643708158866502e-06
radiosensitivity O 0 5.846919157193042e-05
. O 0 1.0989785550918896e-05

We O 0 1.1314093171677087e-05
performed O 0 5.0717562771751545e-06
a O 0 2.8295157790125813e-06
blind O 0 9.400129783898592e-06
chromosomal O 0 1.0145130545424763e-05
analysis O 0 1.5554591072941548e-06
on O 0 2.507931867512525e-06
G2 O 0 0.0009619531338103116
- O 0 1.8484373640603735e-06
phase O 0 8.461339348286856e-06
lymphocytes O 0 5.088458010504837e-07
from O 0 3.321993347071839e-08
7 O 0 1.231403075507842e-06
unrelated O 0 1.80491599621746e-06
A B-Disease 1 0.9999233484268188
- I-Disease 1 0.9996614456176758
T I-Disease 1 1.0
patients O 0 5.594245067186421e-07
, O 0 2.1145261541732907e-07
13 O 0 1.449089950256166e-06
obligate O 0 1.4305420563687221e-06
A B-Disease 1 0.9997863173484802
- I-Disease 1 0.998711109161377
T I-Disease 1 1.0
heterozygotes O 0 0.00011464484123280272
( O 0 7.132434376444508e-08
parents O 0 6.659452989055126e-09
of O 0 1.907667623868292e-08
the O 0 2.8915483341052095e-08
patients O 0 1.8238436538808855e-08
) O 0 1.3272630994265455e-08
, O 0 2.560192235989689e-08
and O 0 5.518229784229334e-08
14 O 0 5.844642601005035e-07
normal O 0 1.5095534422471246e-07
controls O 0 1.5236494732562278e-07
following O 0 9.40323801046361e-08
X O 0 1.3934603657617117e-06
- O 0 5.575157757675697e-08
irradiation O 0 7.500877785560078e-08
with O 0 9.623104979539221e-09
1 O 0 3.0702568665219587e-07
Gy O 0 3.86554984288523e-06
in O 0 6.836792021402971e-09
order O 0 2.310705049524131e-08
to O 0 1.0012517037694124e-08
evaluate O 0 1.5642073947219615e-07
this O 0 2.7970841642854793e-08
cytogenetic O 0 4.650335995393107e-06
method O 0 4.304033041080402e-07
as O 0 4.889440319288951e-08
a O 0 5.290396742907433e-08
tool O 0 2.506195926343935e-07
for O 0 3.2227848834054384e-08
detection O 0 7.165868964875699e-07
of O 0 6.753863885933242e-07
ATM O 0 7.939965871628374e-05
carriers O 0 7.268959961947985e-06
. O 0 1.8334079868509434e-05

Both O 0 4.881093627773225e-05
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
homozygotes O 0 0.07330264896154404
and O 0 9.595887604518794e-07
heterozygotes O 0 8.835461812850554e-06
showed O 0 2.064033139959065e-07
significantly O 0 7.873937590829883e-08
increased O 0 4.1081591461988864e-08
levels O 0 7.679136615479365e-08
of O 0 1.3971181545002764e-07
radiation O 0 8.699332101969048e-05
- O 0 4.44815304945223e-06
induced O 0 3.911633939424064e-06
chromatid O 0 5.822883849759819e-06
damage O 0 1.5651490059553907e-07
relative O 0 7.818475467047392e-08
to O 0 9.329417238745918e-09
that O 0 8.998387812653164e-09
of O 0 1.6570507455071493e-07
normal O 0 1.770385665622598e-06
controls O 0 1.8211156202596612e-05
. O 0 1.3843099623045418e-05

These O 0 8.013185492927732e-07
results O 0 9.450757261220133e-07
show O 0 1.2355904743799329e-07
that O 0 2.6172386924372404e-08
the O 0 4.057712317262485e-07
G2 O 0 0.014958133921027184
- O 0 6.007629508530954e-06
phase O 0 4.481921496335417e-05
chromosomal O 0 4.134290520596551e-06
radiosensitivity O 0 5.758593033533543e-06
assay O 0 4.6977046963547764e-07
can O 0 5.7894866678509516e-09
be O 0 8.567639930845417e-09
used O 0 1.1780135089622945e-08
for O 0 1.4354091248947043e-08
the O 0 3.0070271606064125e-08
detection O 0 8.446701826869685e-07
of O 0 2.327961510673049e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999988079071045
T I-Disease 1 1.0
heterozygotes O 0 0.22595670819282532
. O 0 6.470848165918142e-05

In O 0 3.3810895274655195e-06
combination O 0 1.0853468666027766e-05
with O 0 3.685214551296667e-07
molecular O 0 1.048365083988756e-05
genetic O 0 2.874507742944843e-07
analyses O 0 1.0258077765001872e-07
, O 0 1.6819189596617434e-08
this O 0 3.0494429203997697e-09
test O 0 4.472789427723001e-08
may O 0 9.813203583064478e-09
be O 0 4.755285498703188e-09
of O 0 7.611893337866604e-09
value O 0 7.579282090830475e-09
in O 0 3.3115663544691643e-09
studies O 0 9.614482543440772e-09
of O 0 3.347065202774502e-08
familial B-Disease 0 5.388816362028592e-07
and I-Disease 0 2.0474297457440116e-07
sporadic I-Disease 0 2.2931877538212575e-05
cancers I-Disease 0 0.00032871024450287223
aimed O 0 2.7849523576151114e-06
at O 0 4.117055141250603e-07
determination O 0 1.008210404052079e-07
of O 0 4.8080757153456943e-08
the O 0 2.30098109454957e-08
potential O 0 6.804025076689868e-08
involvement O 0 1.2757109857375326e-07
of O 0 1.6420149506757298e-07
ATM O 0 7.5275734161550645e-06
mutations O 0 2.0966666625099606e-07
in O 0 3.6322759910945024e-08
tumor B-Disease 0 4.810222890228033e-06
risk O 0 8.136790370372182e-07
or O 0 6.302821020653937e-07
development O 0 3.392090320630814e-06
. O 0 1.0719400052039418e-06
. O 0 8.379255632462446e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 6.540637059515575e-06
identification O 0 5.842970836056338e-07
and O 0 8.33182483006567e-08
detection O 0 9.897794370772317e-07
of O 0 4.0238819565274753e-07
founder O 0 3.577112511266023e-05
- O 0 1.0244640407108818e-06
effect O 0 1.6587503637310874e-07
mutations O 0 3.439101092794772e-08
in O 0 8.747759849825343e-09
the O 0 2.956265632292343e-08
ATM O 0 1.7122731605923036e-06
gene O 0 5.312926631972914e-08
in O 0 2.9783441490849327e-08
ethnic O 0 3.2088803436636226e-07
populations O 0 1.1831112942672917e-06
. O 0 1.4283091331890319e-05

To O 0 1.4741995073563885e-06
facilitate O 0 1.4292970718088327e-06
the O 0 1.7885541581108555e-07
evaluation O 0 5.746999249822693e-07
of O 0 6.189549139890005e-07
ATM O 0 0.00031201852834783494
heterozygotes O 0 8.642544344183989e-06
for O 0 1.3161813683382206e-07
susceptibility O 0 1.714521545181924e-06
to O 0 5.4752867129082006e-08
other O 0 2.9863991812817403e-07
diseases O 1 0.5537174344062805
, O 0 5.778247924581592e-08
such O 0 3.314221785899463e-08
as O 0 2.247744760097703e-06
breast B-Disease 0 6.486639904323965e-05
cancer I-Disease 0 1.3152582596376305e-06
, O 0 1.9351382718468813e-08
we O 0 1.068175503604607e-08
have O 0 4.309016699011181e-09
attempted O 0 8.287509700721785e-08
to O 0 5.782897716244406e-09
define O 0 9.60387396276019e-08
the O 0 3.40881207705479e-08
most O 0 9.41838429469044e-09
common O 0 1.0292115604215724e-08
mutations O 0 1.1188959980756863e-08
and O 0 2.9030025050502672e-09
their O 0 4.415031895632637e-09
frequencies O 0 4.69392972490823e-07
in O 0 2.0887355844934063e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.05244394764304161
A B-Disease 1 1.0
- I-Disease 1 0.999052107334137
T I-Disease 1 0.999998927116394
) O 0 8.890318525800467e-08
homozygotes O 0 3.936945063287567e-07
from O 0 9.926909072532908e-09
10 O 0 4.546753729073316e-08
ethnic O 0 9.35948847313739e-08
populations O 0 4.1951264506678854e-07
. O 0 5.839066034241114e-06

Both O 0 2.448801069476758e-06
genomic O 0 1.5343480299634393e-06
mutations O 0 7.495671070500975e-07
and O 0 5.0656094430223675e-08
their O 0 2.5060659325504275e-08
effects O 0 1.2208325870233239e-06
on O 0 5.559192004511715e-07
cDNA O 0 1.4603174349758774e-06
were O 0 1.0810666708493955e-06
characterized O 0 1.4260852367442567e-05
. O 0 3.454383841017261e-05

Protein O 0 6.145677616586909e-05
- O 0 8.819551112537738e-06
truncation O 0 8.042976332944818e-06
testing O 0 3.195964666247164e-07
of O 0 9.208286400053112e-08
the O 0 9.352100249770956e-08
entire O 0 2.5361978828186693e-07
ATM O 0 1.223933395522181e-06
cDNA O 0 2.6520686446929176e-07
detected O 0 1.3350734207051573e-07
92 O 0 1.1244497954976396e-06
( O 0 1.1353336049069185e-07
66 O 0 1.2611507145265932e-06
% O 0 1.4769294409688882e-07
) O 0 2.31764005320656e-07
truncating O 0 7.223046850413084e-06
mutations O 0 5.596550067821227e-07
in O 0 1.9318936494983063e-07
140 O 0 1.890184762487479e-06
mutant O 0 1.1999562048004009e-05
alleles O 0 2.60399428952951e-05
screened O 0 3.443536479608156e-05
. O 0 2.841291279764846e-05

The O 0 2.55706090683816e-05
haplotyping O 0 0.0009184106020256877
of O 0 4.322467248130124e-06
patients O 0 4.5062239450999186e-07
with O 0 4.393135100144718e-08
identical O 0 5.809760068586911e-07
mutations O 0 1.0597582189575405e-07
indicates O 0 3.2948907602303734e-08
that O 0 2.627982054193012e-09
almost O 0 9.395633604469822e-09
all O 0 2.928551401382151e-09
of O 0 4.950300613870695e-09
these O 0 2.2804276245125266e-09
represent O 0 1.246510539232304e-08
common O 0 2.4235159656882388e-08
ancestry O 0 7.393054168858271e-09
and O 0 9.444144133397003e-09
that O 0 5.318672613441322e-09
very O 0 3.604669629453383e-08
few O 0 1.3672904231043503e-07
spontaneously O 0 4.035233871491073e-07
recurring O 0 1.0202792282143491e-06
ATM O 0 1.4681884749734309e-05
mutations O 0 2.8491201646829722e-06
exist O 0 3.469833018243662e-06
. O 0 1.3034036783210468e-05

Assays O 0 3.792420829995535e-05
requiring O 0 1.2854141004936537e-06
minimal O 0 1.884790094663913e-06
amounts O 0 1.6508234068624006e-07
of O 0 9.918395704744398e-08
genomic O 0 1.3112237695622753e-07
DNA O 0 1.0745555556468389e-07
were O 0 1.6143234304877296e-08
designed O 0 8.72541789931347e-08
to O 0 8.80448869367001e-09
allow O 0 2.9133598644648373e-08
rapid O 0 4.939169571116508e-07
screening O 0 1.0919979587242779e-07
for O 0 3.033948559050259e-08
common O 0 2.2048907055705058e-07
ethnic O 0 7.460241135959222e-07
mutations O 0 1.0790748092404101e-05
. O 0 9.824097105592955e-06

These O 0 1.2568859801831422e-06
rapid O 0 5.3945932450005785e-06
assays O 0 2.8113493044656934e-06
detected O 0 1.8759068609597307e-07
mutations O 0 6.864195256639505e-08
in O 0 1.755408973735939e-08
76 O 0 1.8279746427651844e-07
% O 0 2.0310270798518104e-08
of O 0 1.7786649664230936e-07
Costa O 0 1.0285245934937848e-06
Rican O 0 6.387792836903827e-07
patients O 0 2.1609617206763687e-08
( O 0 1.969999985362847e-08
3 O 0 2.1331155153347936e-07
) O 0 1.6580553818812405e-08
, O 0 1.2919822545143234e-08
50 O 0 2.1735361954711152e-08
% O 0 1.0261107519227153e-08
of O 0 6.51862777090173e-08
Norwegian O 0 3.2090074455481954e-06
patients O 0 3.784707303111645e-08
( O 0 1.747791777972907e-08
1 O 0 1.2091672374481277e-07
) O 0 7.27801863220634e-09
, O 0 4.5453814045970375e-09
25 O 0 1.523486048427003e-08
% O 0 3.851027940982021e-09
of O 0 4.6363155092876696e-08
Polish O 0 3.537851443979889e-05
patients O 0 8.925080408062058e-08
( O 0 2.793634479303364e-08
4 O 0 2.5912561341101537e-07
) O 0 1.1078577166756531e-08
, O 0 4.623966987082895e-09
and O 0 8.66744187533186e-09
14 O 0 7.784979771940925e-08
% O 0 5.644478218158611e-09
of O 0 3.942264470424561e-08
Italian O 0 1.0844363714568317e-05
patients O 0 6.936978991234355e-08
( O 0 1.8551673974798177e-08
1 O 0 2.7399204327593907e-07
) O 0 1.4867080011526923e-08
, O 0 1.181181374931839e-08
as O 0 1.7720406475518757e-08
well O 0 1.8004545410121864e-08
as O 0 3.127278702663716e-08
in O 0 1.7340182623115652e-08
patients O 0 2.990006819914015e-08
of O 0 2.1202367861405946e-07
Amish O 0 6.4907526393653825e-06
/ O 0 1.5702857126598246e-05
Mennonite O 0 1.8744327462627552e-05
and O 0 4.0710850157665845e-07
Irish O 0 7.342715434788261e-06
English O 0 3.284923514002003e-05
backgrounds O 0 6.835595559095964e-05
. O 0 5.455601785797626e-05

Additional O 0 6.2284561863634735e-06
mutations O 0 1.6288388451357605e-06
were O 0 2.0036185333083267e-07
observed O 0 2.7978293815067445e-07
in O 0 2.993590442201821e-08
Japanese O 0 7.127850381039025e-07
, O 0 9.417309598802603e-08
Utah O 0 5.513967948900245e-07
Mormon O 0 3.620197048803675e-07
, O 0 1.4000070791553298e-07
and O 0 3.896886369147978e-07
African O 0 7.075841949699679e-06
American O 0 5.7575712162361015e-06
patients O 0 6.960915470699547e-06
. O 0 2.4901102733565494e-05

These O 0 1.2692504469669075e-06
assays O 0 4.303181412979029e-06
should O 0 2.331602360072793e-07
facilitate O 0 3.7890524140493653e-07
screening O 0 1.6567268801281898e-07
for O 0 2.047351586043078e-07
A B-Disease 1 0.9999369382858276
- I-Disease 1 0.9982971549034119
T I-Disease 1 0.9999998807907104
heterozygotes O 0 1.2386251000862103e-05
in O 0 2.4248105745527937e-08
the O 0 2.1770130587128733e-08
populations O 0 2.0560658953172606e-08
studied O 0 4.288926049866859e-07
. O 0 6.192832415763405e-07
. O 0 6.799355105613358e-06

The O 0 4.669322515837848e-05
von B-Disease 1 0.9772714376449585
Hippel I-Disease 1 0.9999723434448242
- I-Disease 1 0.9989637136459351
Lindau I-Disease 1 0.9086449146270752
tumor I-Disease 0 4.9315771320834756e-05
suppressor O 0 1.9624301785370335e-05
gene O 0 1.5537317210601032e-07
is O 0 2.842134527725193e-08
required O 0 6.020506049253527e-08
for O 0 8.43940100025975e-08
cell O 0 1.4807924344495405e-06
cycle O 0 5.072599833511049e-07
exit O 0 6.362264457493438e-07
upon O 0 5.521019375009928e-07
serum O 0 5.71295049667242e-06
withdrawal O 0 1.856608287198469e-05
. O 0 2.8457247026381083e-05

The O 0 5.499507551576244e-06
inactivation O 0 5.8435638493392617e-05
of O 0 2.7581934318732237e-06
the O 0 2.414842583675636e-06
von B-Disease 1 0.998496413230896
Hippel I-Disease 1 0.9999994039535522
- I-Disease 1 0.9999953508377075
Lindau I-Disease 1 0.9999991655349731
( I-Disease 0 8.230183448176831e-05
VHL I-Disease 1 0.9999023675918579
) I-Disease 0 2.6883403734245803e-06
tumor I-Disease 0 2.8594135073944926e-05
suppressor O 0 5.8355781220598146e-05
gene O 0 1.2965759879079997e-06
predisposes O 0 5.559993951465003e-06
affected O 0 2.9492241537809605e-07
individuals O 0 5.164908856158945e-08
to O 0 5.745816267221926e-08
the O 0 1.8009889117820421e-06
human O 1 0.9651384353637695
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 5.148377749719657e-05
is O 0 2.985191827065137e-07
associated O 0 2.031899413168503e-07
with O 0 1.962142590627991e-07
sporadic B-Disease 1 0.9613780379295349
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.2684948444366455
RCC B-Disease 1 1.0
) O 0 7.141975402191747e-06
and O 0 9.874856914393604e-06
brain B-Disease 1 0.8719165325164795
hemangioblastomas I-Disease 0 0.07742519676685333
. O 0 7.699985144427046e-05

VHL O 0 0.01926344446837902
- O 0 0.00013297266559675336
negative O 0 7.777759492455516e-06
786 O 0 7.165149145293981e-05
- O 0 1.599222196091432e-05
0 O 0 7.525936780439224e-06
RCC B-Disease 1 0.9600825309753418
cells O 0 7.479126225007349e-07
are O 0 5.020114102194384e-08
tumorigenic O 0 4.74796470371075e-05
in O 0 4.6046818624745356e-07
nude O 0 6.048895102139795e-06
mice O 0 2.903796882947063e-07
which O 0 1.746032474159165e-08
is O 0 2.1144852979659845e-08
suppressed O 0 3.02751516301214e-07
by O 0 3.10091863298112e-08
the O 0 1.7682634734228486e-07
reintroduction O 0 3.6669744076789357e-06
of O 0 4.453781457414152e-06
VHL B-Disease 1 0.9995699524879456
. O 0 0.00019113892631139606

Remarkably O 0 7.707301119808108e-05
, O 0 2.3148258776473085e-07
this O 0 2.610966198801634e-08
occurs O 0 8.670256335108206e-08
without O 0 6.387524820183899e-08
affecting O 0 5.353269116881165e-08
the O 0 1.2215338074383908e-08
growth O 0 1.7928059037330968e-08
rate O 0 2.7904871302553147e-08
and O 0 1.341884203753807e-08
cell O 0 1.7355378645333985e-07
cycle O 0 2.9625084607687313e-08
profile O 0 1.9200863121682232e-08
of O 0 1.0882133416600936e-08
these O 0 7.926054479412414e-09
cells O 0 6.102230543092446e-08
in O 0 4.1701319730691466e-08
culture O 0 1.5811582443348016e-06
. O 0 3.997419753432041e-06

The O 0 1.1890874702658039e-05
786 O 0 8.316776802530512e-05
- O 0 6.804746135458117e-06
0 O 0 1.794930994947208e-06
cell O 0 3.1925055736792274e-06
line O 0 1.2345873301455867e-06
, O 0 6.481187853069059e-08
like O 0 6.366968108295623e-08
many O 0 3.451745200777623e-08
cancer B-Disease 0 4.568181282138539e-07
cells O 0 1.066315391540229e-07
, O 0 2.433971069137897e-08
fails O 0 1.0573312891892783e-07
to O 0 1.533058657798847e-08
exit O 0 3.1066878136698506e-07
the O 0 7.963242865116626e-08
cell O 0 8.605235279901535e-07
cycle O 0 3.711912199833023e-07
upon O 0 3.244517188250029e-07
serum O 0 2.1259961613395717e-06
withdrawal O 0 1.1156132131873164e-05
. O 0 2.2289907064987347e-05

Here O 0 6.370779374265112e-06
, O 0 2.511464458621049e-07
it O 0 3.162163153547226e-08
is O 0 7.1461445649845245e-09
shown O 0 9.705964032491465e-09
that O 0 4.394381747374609e-09
reintroduction O 0 2.2924571396742977e-07
of O 0 5.685171799996169e-08
the O 0 9.73342366705765e-08
wild O 0 3.730820594682882e-07
- O 0 1.2080370197509183e-06
type O 0 4.42790496890666e-06
VHL B-Disease 0 0.018323631957173347
gene O 0 2.8354702408250887e-07
restores O 0 6.313565563687007e-07
the O 0 2.5920513735400164e-08
ability O 0 7.469824936379155e-08
of O 0 7.645521691301838e-07
VHL O 1 0.9997410178184509
- O 0 0.0005152549128979445
negative O 0 8.953048563853372e-06
RCC B-Disease 1 0.9999977350234985
cancer I-Disease 0 2.016390226344811e-06
cells O 0 6.158342813478157e-08
to O 0 1.4142337967371077e-08
exit O 0 1.693374116484847e-07
the O 0 6.255549322986553e-08
cell O 0 4.5303929141482513e-07
cycle O 0 1.2048070630044094e-07
and O 0 4.5129112891117984e-08
enter O 0 5.784394829788653e-07
G0 O 0 0.00821047741919756
/ O 0 2.210213460784871e-05
quiescence O 0 1.9757551854127087e-05
in O 0 3.817488618551579e-07
low O 0 8.802040611044504e-06
serum O 0 2.250420038762968e-05
. O 0 7.366288173216162e-06

Both O 0 5.667455116054043e-05
VHL O 1 0.9897660613059998
- O 0 7.321314478758723e-05
positive O 0 2.224496029157308e-06
and O 0 3.3926594369404484e-06
VHL O 1 0.9996858835220337
- O 0 6.283093534875661e-05
negative O 0 1.7119841686508153e-06
RCC B-Disease 1 0.9647040367126465
cells O 0 2.828372487329034e-07
exit O 0 3.2913362701947335e-07
the O 0 1.1709999370168589e-07
cell O 0 7.042423817438248e-07
cycle O 0 3.2841811048456293e-07
by O 0 1.0187085308643873e-07
contact O 0 2.331387349840952e-06
inhibition O 0 5.8483910834183916e-05
. O 0 1.7149259292636998e-05

The O 0 2.3850976504036225e-05
cyclin O 0 0.00015361628902610391
- O 0 1.0974652468576096e-05
dependent O 0 2.8421861770766554e-06
kinase O 0 1.4102025488682557e-05
inhibitor O 0 1.1688465747283772e-05
, O 0 2.401040433142043e-07
p27 O 0 7.177289717219537e-06
, O 0 1.3961405898044177e-07
accumulates O 0 3.2593257515145524e-07
upon O 0 4.690672028573317e-08
serum O 0 8.551627672659379e-08
withdrawal O 0 1.529417374968034e-07
, O 0 2.0999479488637007e-08
only O 0 6.441132960333107e-09
in O 0 2.5844768547500507e-09
the O 0 4.832307887170373e-09
presence O 0 2.8112953742720492e-08
of O 0 1.3507154505987273e-07
VHL B-Disease 1 0.9825291633605957
, O 0 8.36682829685742e-08
as O 0 2.5962618721564468e-08
a O 0 9.452704397006073e-09
result O 0 1.2498150070427982e-08
of O 0 2.746695493272e-08
the O 0 2.3896225442854302e-08
stabilization O 0 4.215170008592395e-07
of O 0 3.5016449828617624e-07
the O 0 1.2629224102056469e-06
protein O 0 8.87097394297598e-06
. O 0 7.681738679821137e-06

We O 0 1.780397155926039e-06
propose O 0 1.2575487744470593e-06
that O 0 2.0765915209608465e-08
the O 0 5.831525839994356e-08
loss O 0 6.917608743606252e-07
of O 0 5.73594945763034e-07
wild O 0 1.2805394362658262e-06
- O 0 5.285231054585893e-06
type O 0 2.053146636171732e-05
VHL B-Disease 1 0.9952154159545898
gene O 0 7.311176659641205e-07
results O 0 4.745239721160033e-07
in O 0 3.488152344743867e-08
a O 0 4.9043283212313327e-08
specific O 0 1.0904368963338129e-07
cellular O 0 4.794271262653638e-06
defect O 0 4.195610472379485e-07
in O 0 5.9177580169489374e-08
serum O 0 7.294656256817689e-07
- O 0 2.8924040407218854e-07
dependent O 0 4.787029794783848e-08
growth O 0 8.937532669506254e-08
control O 0 2.0036971193349018e-07
, O 0 4.310580692390431e-08
which O 0 3.5429408740128565e-08
may O 0 3.552536895767844e-07
initiate O 0 4.21991853727377e-06
tumor B-Disease 0 1.41226182677201e-05
formation O 0 2.4964374460978433e-05
. O 0 2.7950958610745147e-05

This O 0 1.6429734159828513e-06
is O 0 2.5178050577778777e-07
corrected O 0 1.3001159686609753e-06
by O 0 2.2257083287513524e-08
the O 0 2.1408226302810363e-08
reintroduction O 0 4.316768240641977e-07
of O 0 7.840622373578299e-08
wild O 0 4.34457177789227e-07
- O 0 3.562073743523797e-06
type O 0 0.00026763638015836477
VHL B-Disease 1 0.9999998807907104
, O 0 5.519565092981793e-05
implicating O 1 0.9894614815711975
VHL B-Disease 1 0.9981160163879395
as O 0 2.440400805880927e-07
the O 0 9.688433522114792e-08
first O 0 7.230701015714658e-08
tumor B-Disease 0 3.387081903838407e-07
suppressor O 0 1.4884692518535303e-06
involved O 0 8.201119072737129e-08
in O 0 1.8974125381987506e-08
the O 0 4.6950844989623874e-08
regulation O 0 1.6604772667960788e-07
of O 0 1.0960356888745082e-07
cell O 0 4.6798322728136554e-07
cycle O 0 1.0967905694769797e-07
exit O 0 1.1325813176199517e-07
, O 0 1.7561960774514773e-08
which O 0 9.03450292355501e-09
is O 0 6.82657619321958e-09
consistent O 0 4.7233960742687486e-08
with O 0 8.951620777963853e-09
its O 0 3.010923776969321e-08
gatekeeper O 0 6.218593853191123e-07
function O 0 8.565666576032527e-08
in O 0 3.0396307693081326e-08
the O 0 2.8685761321867176e-07
kidney O 0 6.10390561632812e-05
. O 0 1.3806953802486532e-06
. O 0 1.822483136493247e-05

Piebaldism B-Disease 1 0.9999998807907104
with O 0 0.0010290106292814016
deafness B-Disease 1 1.0
: O 0 3.02624425785325e-06
molecular O 0 5.489536306413356e-06
evidence O 0 5.323293521541927e-07
for O 0 2.2633518881320924e-07
an O 0 5.15772228482092e-07
expanded O 0 9.910320659400895e-05
syndrome O 1 0.9999957084655762
. O 0 0.0002595741825643927

In O 0 1.5890976783339283e-06
a O 0 1.3099069064992364e-06
South O 0 4.8915571824181825e-06
African O 0 6.064016361051472e-06
girl O 0 2.2404256014851853e-06
of O 0 1.6622562952761655e-06
Xhosa O 0 0.00012096735008526593
stock O 0 2.8160236524854554e-06
with O 0 4.836376774619566e-07
severe O 0 0.2535947263240814
piebaldism B-Disease 1 0.9935799837112427
and O 0 0.00033292945590801537
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 6.851225043646991e-05
identified O 0 1.2395778412610525e-06
a O 0 2.183855087878328e-07
novel O 0 5.450206685964076e-07
missense O 0 5.117494765727315e-06
substitution O 0 2.7453397706267424e-06
at O 0 2.358605570407235e-06
a O 0 2.995649595050054e-07
highly O 0 4.7585089646418055e-07
conserved O 0 4.411111831359449e-07
residue O 0 2.5403176096006064e-07
in O 0 2.5602115982792384e-08
the O 0 5.536299596542449e-08
intracellular O 0 3.0748074664188607e-07
kinase O 0 1.8745960517208005e-07
domain O 0 2.1685837126028673e-08
of O 0 2.6271614217421302e-08
the O 0 2.364023146128602e-07
KIT O 0 0.00014583572919946164
proto O 0 0.0033297594636678696
- O 0 7.275895040947944e-05
oncogene O 0 0.00013757983106188476
, O 0 2.480269813531777e-06
R796G O 0 0.0001733284880174324
. O 0 2.94249093713006e-05

Though O 0 3.411354555282742e-05
auditory B-Disease 0 0.005060375202447176
anomalies I-Disease 0 0.0001449121191399172
have O 0 2.9164661441427597e-07
been O 0 2.307305777549118e-07
observed O 0 4.7282907189583057e-07
in O 0 1.5284578580576635e-07
mice O 0 1.414392272636178e-06
with O 0 1.2465751808576897e-07
dominant O 1 0.9414364099502563
white O 0 5.021612741984427e-05
spotting O 0 0.4727829396724701
( O 0 4.148560037720017e-06
W O 0 0.008939201012253761
) O 0 5.855723017589298e-08
due O 0 1.0428188801370197e-07
to O 0 3.970115969309518e-08
KIT O 0 0.00020835774193983525
mutations O 0 1.1956941307289526e-05
, O 0 2.8522520096885273e-06
deafness B-Disease 1 1.0
is O 0 9.374120679694897e-08
not O 0 3.7685936149500776e-08
typical O 0 5.271179475130339e-07
in O 0 1.9755694324885553e-07
human O 0 2.864581574613112e-06
piebaldism B-Disease 0 0.00021391281916294247
. O 0 2.1724541511503048e-05

Thus O 0 6.9654311118938494e-06
, O 0 4.057758928865951e-07
the O 0 1.7144662933787913e-07
occurrence O 0 3.394711256987648e-06
of O 0 0.0005288089741952717
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 4.887961949862074e-06
this O 0 2.24523304837021e-07
patient O 0 3.99889728441849e-07
extends O 0 2.753226624463423e-07
considerably O 0 2.213898540048831e-07
the O 0 4.759425564770936e-08
phenotypic O 0 1.9005259446203127e-06
range O 0 3.7672680264222436e-07
of O 0 3.5120763186569093e-07
piebaldism B-Disease 0 5.068362042948138e-06
due O 0 3.574872380340821e-07
to O 0 1.2230169943450164e-07
KIT O 0 1.5983026969479397e-05
gene O 0 3.887799095991795e-07
mutation O 0 2.749828524883924e-07
in O 0 3.7273743203058984e-08
humans O 0 2.1669551131253684e-07
and O 0 9.910151277381374e-08
tightens O 0 8.589501021560864e-07
the O 0 8.052717959117217e-08
clinical O 0 4.2238903574798314e-07
similarity O 0 3.04594550470938e-07
between O 0 4.429086288837425e-07
piebaldism B-Disease 0 2.1130408640601672e-05
and O 0 7.807194890574465e-08
the O 0 5.517556189715833e-08
various O 0 6.457594992070881e-08
forms O 0 1.0134396006833413e-06
of O 0 0.00011425195407355204
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
. O 0 3.5808570828521624e-05
. O 0 7.617907976964489e-05

Cycloheximide O 0 0.0007752181263640523
facilitates O 0 9.61941168498015e-06
the O 0 2.806600321036967e-07
identification O 0 3.277644680110825e-07
of O 0 4.567763198792818e-07
aberrant O 0 5.155252438271418e-06
transcripts O 0 3.082201828874531e-06
resulting O 0 5.325827601154742e-07
from O 0 2.1699061392155272e-07
a O 0 6.007791171214194e-07
novel O 0 1.6636488453514175e-06
splice O 0 1.689385862846393e-05
- O 0 2.868843921532971e-06
site O 0 2.3523982406459254e-07
mutation O 0 5.877341209270526e-07
in O 0 2.5397073954991356e-07
COL17A1 O 1 0.982469916343689
in O 0 8.53071583151177e-07
a O 0 1.3056912848696811e-06
patient O 0 1.911158506118227e-06
with O 0 5.4349025049305055e-06
generalized O 1 0.999860405921936
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999939203262329
. O 0 0.000524032162502408

Patients O 0 2.7316096748108976e-05
with O 0 6.398477125912905e-06
generalized O 1 0.9909935593605042
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999974966049194
often O 0 8.128460535772319e-07
show O 0 4.05734084552023e-07
decreased O 0 6.52697622172127e-07
expression O 0 1.8959589453970693e-07
of O 0 3.36229390995868e-07
type O 0 2.5526680474285968e-05
XVII O 1 0.9999908208847046
collagen O 0 4.802646435564384e-05
, O 0 1.659318371594054e-07
a O 0 2.3683151084696874e-07
transmembrane O 0 4.578955667966511e-06
hemidesmosomal O 0 6.213091182871722e-06
protein O 0 3.80558390133956e-07
encoded O 0 1.6877778818980005e-07
by O 0 3.170872560076532e-07
COL17A1 O 0 0.00031006193603388965
. O 0 3.668037606985308e-05

This O 0 3.2039433790487237e-06
report O 0 7.95694006683334e-07
documents O 0 1.2030817515551462e-06
a O 0 4.448758090802585e-07
novel O 0 1.939363755809609e-06
splice O 0 2.1529001969611272e-05
- O 0 2.732032498897752e-06
site O 0 2.704213386550691e-07
mutation O 0 3.1653195264880196e-07
in O 0 1.6013397896585957e-07
COL17A1 O 1 0.7255401611328125
in O 0 2.181431995040839e-07
a O 0 2.1746606648775924e-07
patient O 0 3.614377135363611e-07
with O 0 8.981482437775412e-07
generalized O 1 0.9943755865097046
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999990463256836
, O 0 8.866912253324699e-07
and O 0 1.93944003967772e-07
applies O 0 1.2071855337580928e-07
a O 0 3.424452188482974e-08
new O 0 4.56386182179358e-08
methodology O 0 1.4499038059057057e-07
to O 0 1.563796558912145e-08
define O 0 2.0369905939787714e-07
and O 0 1.6218899645537022e-07
characterize O 0 1.1821368843811797e-06
the O 0 1.9500598114063905e-07
resulting O 0 9.058229011316143e-07
mRNA O 0 3.6357741919346154e-06
splice O 0 9.830207090999465e-06
variants O 0 1.8807944798027165e-05
. O 0 2.3429718567058444e-05

Mutational O 0 0.0004134025948587805
analysis O 0 1.149991567217512e-05
of O 0 7.540966635133373e-06
COL17A1 O 1 0.9947575330734253
identified O 0 1.176800924440613e-05
a O 0 2.337230853299843e-06
maternally O 0 1.03479860626976e-05
inherited O 0 2.6069708837894723e-05
G O 0 0.0006619500345550478
- O 0 2.7391222829464823e-05
to O 0 3.8826709669592674e-07
- O 0 7.970834121806547e-05
T O 0 0.005080632399767637
transversion O 0 2.8993496016482823e-05
at O 0 2.3899173129393603e-07
the O 0 1.8679960689382824e-08
- O 0 4.143808496337442e-08
1 O 0 6.224889403938505e-08
position O 0 2.431002599223575e-07
of O 0 4.923392111777503e-07
exon O 0 9.875826435745694e-06
32 O 0 9.181073437503073e-06
. O 0 1.4616307453252375e-05

This O 0 4.641687610273948e-06
acceptor O 0 8.220275958592538e-06
splice O 0 3.637255576904863e-05
- O 0 1.9092710772383725e-06
site O 0 2.967746581816755e-07
mutation O 0 1.3013523414429073e-07
led O 0 1.3546785737617029e-07
to O 0 3.453391173025011e-08
the O 0 7.605380858421995e-08
formation O 0 9.73154556049849e-07
of O 0 7.777504720252182e-07
aberrant O 0 2.2941856059333077e-06
transcripts O 0 1.734238594508497e-06
present O 0 1.1389318643750812e-07
at O 0 1.0296473647031235e-06
extremely O 0 2.1767841644759756e-06
low O 0 4.3935560825048015e-05
levels O 0 4.808750964002684e-05
. O 0 1.7016958736348897e-05

Based O 0 2.6301781872462016e-06
on O 0 5.860846385985496e-07
our O 0 1.5944138453960477e-07
recent O 0 4.2702779978753824e-08
finding O 0 2.5665315206424566e-07
that O 0 4.939457198815944e-08
cycloheximide O 0 1.9695022274390794e-05
stabilized O 0 1.3066905921732541e-05
mutant O 0 9.40398604143411e-06
COL17A1 O 0 0.0001125042253988795
transcripts O 0 8.093164979072753e-06
in O 0 1.2194217902106175e-07
keratinocytes O 0 2.9410662136797328e-06
homozygous O 0 5.351768663786061e-07
for O 0 4.776850914822717e-08
a O 0 2.2051915493648266e-07
frameshift O 0 1.202759722218616e-05
mutation O 0 4.610047028563713e-07
, O 0 5.100861955043001e-08
the O 0 4.252664353998625e-08
effects O 0 5.89725630106841e-07
of O 0 2.8803142981814744e-07
the O 0 3.462203324033908e-07
splice O 0 2.4649189072079025e-06
- O 0 3.229600338272576e-07
site O 0 6.883677627911311e-08
mutation O 0 4.6532633746210195e-08
on O 0 7.262767809379511e-08
splicing O 0 3.133572192837164e-07
of O 0 1.9033957698866288e-07
COL17A1 O 0 9.334457718068734e-05
transcripts O 0 2.790405233099591e-06
were O 0 1.134909197730849e-07
determined O 0 2.879885983020358e-07
using O 0 2.9551702596108953e-07
reverse O 0 3.6917190300300717e-06
transcriptase O 0 4.897784037893871e-06
polymerase O 0 1.5645894109184155e-06
chain O 0 1.5452012291916617e-07
reaction O 0 1.1350813622357236e-07
of O 0 1.7709434985135886e-07
total O 0 1.8293052050921688e-07
RNA O 0 5.375496812121128e-07
from O 0 4.358099658929859e-08
keratinocytes O 0 2.6674854325392516e-06
incubated O 0 1.0648697070791968e-06
for O 0 1.5903501093816885e-07
2 O 0 3.679209839901887e-06
. O 0 4.762394837598549e-06

5 O 0 1.5186145901679993e-05
h O 0 4.876201273873448e-06
in O 0 4.263962338768579e-08
the O 0 2.3300589901964486e-08
presence O 0 4.410892984196835e-08
or O 0 3.1493783581026946e-08
absence O 0 3.8413324432440277e-07
of O 0 6.24222423084575e-07
10 O 0 2.9477971565938788e-06
microg O 0 0.00010555621702224016
cycloheximide O 0 9.226192196365446e-05
per O 0 5.349739694793243e-06
ml O 0 0.00013556783960666507
. O 0 1.8312672182219103e-05

Using O 0 1.239220750903769e-06
this O 0 8.67497149670271e-08
approach O 0 3.570592923551885e-07
, O 0 9.211905194206338e-08
an O 0 6.468467006470746e-08
abnormally O 0 2.1701164314436028e-06
spliced O 0 3.2101095257530687e-06
transcript O 0 3.512351668177871e-06
was O 0 3.5387409980103257e-07
identified O 0 7.89021896707709e-08
that O 0 9.548181800766997e-09
contains O 0 3.508336376967236e-08
an O 0 1.4436241535520367e-08
extra O 0 1.8803973489411874e-07
264 O 0 2.6643255068847793e-07
bases O 0 7.033933968614292e-08
upstream O 0 9.538828749100503e-08
from O 0 1.3241908014549608e-08
exon O 0 5.381738787946233e-07
32 O 0 2.452289891152759e-07
, O 0 3.758902167305678e-08
resulting O 0 1.9737598222491215e-07
in O 0 6.140842856439122e-08
a O 0 3.1902609975986707e-07
premature O 0 3.7803754366905196e-06
termination O 0 6.9469024310819805e-06
codon O 0 1.9485929442453198e-05
27 O 0 1.2090134987374768e-05
bp O 0 1.1283168532827403e-05
downstream O 0 1.0618376791171613e-06
from O 0 1.2733190146718698e-07
the O 0 1.2201202252981602e-06
cryptic O 0 4.095983240404166e-05
splice O 0 6.856499385321513e-05
site O 0 2.6342160708736628e-05
. O 0 6.537237641168758e-05

Three O 0 3.2342964004783425e-06
other O 0 2.3528177450771182e-07
splice O 0 4.304478352423757e-06
variants O 0 1.2017940207442734e-06
, O 0 1.0121159021991843e-07
including O 0 5.1064297679204174e-08
one O 0 1.1239568387111376e-08
derived O 0 1.4252115931867593e-08
from O 0 7.680188041092606e-09
the O 0 3.4273469395884604e-08
skipping O 0 1.675017387015032e-07
of O 0 7.501807175458453e-08
exon O 0 4.752925804041297e-07
32 O 0 2.1993065502101672e-07
, O 0 6.227146087667279e-08
were O 0 1.619559242271862e-07
also O 0 3.998035253971466e-07
identified O 0 4.569707471091533e-06
. O 0 2.285871232743375e-05

These O 0 6.821294391556876e-07
results O 0 1.092274487746181e-06
indicate O 0 1.5353198534739931e-07
the O 0 1.0672410866163773e-07
usefulness O 0 1.5664691090933047e-06
of O 0 2.9072049301248626e-07
cycloheximide O 0 1.431691362085985e-05
treatment O 0 2.9218642794148764e-07
in O 0 2.210123817292242e-08
evaluating O 0 1.506892459701703e-07
the O 0 2.6102890515744548e-08
abnormal O 0 1.2343055288965843e-07
processing O 0 1.0166839103931125e-07
of O 0 8.224694170166913e-08
mRNA O 0 1.8253126654599328e-07
due O 0 1.03606616619345e-07
to O 0 2.3456435016555588e-08
splice O 0 1.1800192396549392e-06
- O 0 1.286553157342496e-07
site O 0 3.4749575661408016e-08
mutations O 0 4.998063474204173e-08
, O 0 2.104241936251583e-08
because O 0 4.277566034716074e-08
( O 0 2.315585305723289e-07
i O 0 8.13461042525887e-07
) O 0 1.7860759271570714e-07
aberrant O 0 1.2227399110997794e-06
splicing O 0 6.39107099686953e-07
often O 0 4.7886548060205314e-08
generates O 0 1.4152111305065773e-07
a O 0 8.040746024562395e-08
premature O 0 5.724353400182736e-07
termination O 0 1.407263994224195e-06
codon O 0 3.0090952805039706e-06
, O 0 2.4989404323605413e-07
( O 0 1.3740628901359742e-07
ii O 0 4.738681673188694e-05
) O 0 1.1296817348238619e-07
transcripts O 0 6.625272703786322e-07
with O 0 3.677406112956305e-08
premature O 0 1.085211920326401e-06
termination O 0 1.1664474186545704e-06
codons O 0 8.006218763512152e-07
can O 0 3.264171510863889e-08
occur O 0 9.245049881201339e-08
at O 0 3.061406346205331e-07
low O 0 3.62836459544269e-07
or O 0 3.759561550964463e-08
undetectable O 0 4.886983333562966e-07
levels O 0 3.3961054413111924e-08
due O 0 2.8033653620695986e-08
to O 0 1.0878128620106509e-08
nonsense O 0 8.976165304375172e-07
- O 0 1.1464522486903661e-07
mediated O 0 2.521551323297899e-07
mRNA O 0 6.161643995028498e-08
decay O 0 8.221009295539261e-08
, O 0 9.630266362137263e-09
and O 0 1.5925849083942012e-08
( O 0 3.354062982907635e-08
iii O 0 4.534924300969578e-06
) O 0 1.1823218848405759e-08
the O 0 7.4338482036750975e-09
levels O 0 1.680854211372207e-08
of O 0 9.802428202476676e-09
these O 0 7.004236746155357e-09
transcripts O 0 6.077861058884082e-08
can O 0 3.840677997857256e-09
be O 0 2.133481302735163e-08
increased O 0 1.3735979109696927e-07
by O 0 3.287543393071246e-07
cycloheximide O 0 5.510445771506056e-05
. O 0 9.06391505850479e-06

A O 0 2.981118632305879e-05
deletion O 0 2.6852685550693423e-05
mutation O 0 4.2262136048520915e-06
in O 0 4.7156640903267544e-07
COL17A1 O 0 0.10811357200145721
in O 0 3.6909125356032746e-07
five O 0 6.825321747783164e-07
Austrian O 0 1.279663683817489e-05
families O 0 1.194486429767494e-07
with O 0 1.3455564840114675e-06
generalized O 1 0.989843487739563
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9994730353355408
represents O 0 1.001877444650745e-05
propagation O 0 1.398025324306218e-05
of O 0 8.824008546071127e-07
an O 0 5.357283612283936e-07
ancestral O 0 8.481528311676811e-06
allele O 0 0.00010437921446282417
. O 0 4.647519381251186e-05

Patients O 0 3.8208698242669925e-05
with O 0 7.050958174659172e-06
generalized O 1 0.9882882833480835
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999992847442627
, O 0 1.0565295269771013e-06
a O 0 2.1703449704091327e-07
usually O 0 1.3074752303054993e-07
nonlethal O 0 1.0679904335120227e-05
form O 0 1.6478960560561973e-06
of O 0 3.484302942524664e-05
junctional B-Disease 1 0.9999943971633911
epidermolysis I-Disease 1 0.9999991655349731
bullosa I-Disease 1 0.9987049102783203
, O 0 1.959210294444347e-06
have O 0 5.697584128938615e-07
generalized O 0 3.8226997276069596e-05
blistering B-Disease 0 0.009146793745458126
, O 0 0.00021065676992293447
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 0.001119225868023932
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 0.0034640226513147354
and O 0 0.36849743127822876
dental B-Disease 1 0.9999998807907104
abnormalities I-Disease 1 0.9999997615814209
. O 0 0.0009267627028748393

Skin B-Disease 1 0.9999573230743408
fragility I-Disease 0 0.10872786492109299
in O 0 6.578587772310129e-07
most O 0 1.0370547443017131e-07
cases O 0 3.085531474766867e-08
is O 0 5.4481152922392084e-09
due O 0 2.6069852054888543e-08
to O 0 7.593563999819253e-09
mutations O 0 3.7270186936666505e-08
in O 0 5.630478305818087e-09
the O 0 1.9002374784804488e-08
gene O 0 4.7315115381252326e-08
encoding O 0 6.181502953950258e-07
type O 0 1.9767918274737895e-05
XVII O 1 0.999996542930603
collagen O 0 0.01276323664933443
( O 0 2.418174972262932e-06
COL17A1 O 0 0.06490515917539597
) O 0 2.4070570816547843e-06
. O 0 9.880791367322672e-06

Recently O 0 1.7504560673842207e-05
, O 0 6.409651405192562e-07
we O 0 4.6496614913849044e-07
reported O 0 5.558698603636003e-07
five O 0 3.4864535791712115e-07
Austrian O 0 4.304174581193365e-06
families O 0 1.5362880390057398e-07
with O 0 1.204597310788813e-06
generalized O 1 0.9661295413970947
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999998927116394
who O 0 1.6686605022186995e-06
share O 0 7.198019602583372e-07
the O 0 6.016707061462512e-07
same O 0 1.4288459624367533e-06
COL17A1 O 0 0.03946347534656525
mutation O 0 4.28274433943443e-05
. O 0 2.1409228793345392e-05

Affected O 0 6.29694886811194e-06
individuals O 0 2.2478938888070843e-07
in O 0 9.689265567658367e-08
three O 0 1.0404625072624185e-07
families O 0 8.455380395844259e-09
are O 0 9.319387039852245e-09
homozygous O 0 9.315586879665716e-08
for O 0 3.9364937975960856e-08
4003delTC O 0 2.2921385607332923e-06
, O 0 4.9720483730197884e-08
whereas O 0 5.645428302614164e-08
those O 0 1.1576858582884597e-08
in O 0 1.9327924150047693e-08
two O 0 3.052161900995998e-08
others O 0 7.904709775630181e-08
are O 0 1.5638374861737248e-07
compound O 0 1.3831671822117642e-05
heterozygotes O 0 0.00014483323320746422
. O 0 3.795691372943111e-05

To O 0 6.558360041708511e-07
determine O 0 8.777386142355681e-07
if O 0 1.5005510078935913e-07
the O 0 1.1679172473577637e-07
occurrence O 0 3.133195605187211e-07
of O 0 2.0617450502413703e-07
4003delTC O 0 3.7202371458988637e-06
in O 0 4.867220582127629e-08
these O 0 2.3369308266296684e-08
unrelated O 0 1.9588276245485758e-07
families O 0 7.63788143842703e-09
signifies O 0 1.5219850979519833e-07
propagation O 0 4.7533293923152087e-07
of O 0 7.681876468268456e-08
an O 0 1.3707249557626255e-08
ancestral O 0 1.8127600753814477e-07
allele O 0 9.318196703134163e-07
or O 0 1.3748652349931945e-07
a O 0 2.2378920050414308e-07
mutational O 0 8.777362381806597e-06
hot O 0 6.27288955001859e-06
spot O 0 6.562573616974987e-06
, O 0 8.192957778874188e-08
haplotypes O 0 3.166717306157807e-07
were O 0 3.406848847475885e-08
determined O 0 1.1762300999862418e-07
for O 0 4.352342841684731e-08
polymorphisms O 0 1.2929983483900287e-07
both O 0 4.1556017293942205e-08
within O 0 3.025944579349016e-07
and O 0 1.4307672699942486e-06
flanking O 0 0.00032774891587905586
COL17A1 O 1 0.9953782558441162
. O 0 5.4991909564705566e-05

Five O 0 7.193095370894298e-05
intragenic O 0 0.0002752195578068495
polymorphisms O 0 7.108190402504988e-06
were O 0 4.889486717729596e-07
chosen O 0 6.161010901450936e-07
based O 0 3.8434214388871624e-07
on O 0 7.602456548738701e-07
their O 0 1.0770625067380024e-06
informativeness O 0 0.0005547847249545157
. O 0 3.7357571272877976e-05

One O 0 7.866931923672382e-07
of O 0 1.6409097725045285e-07
these O 0 1.970894381031485e-08
, O 0 1.5492316762788505e-08
not O 0 1.1852436365700214e-08
previously O 0 1.1087247742125328e-07
reported O 0 1.9634697423498437e-07
, O 0 1.0285388896136283e-07
was O 0 1.2664670521189691e-06
2988 O 0 1.050358605425572e-05
A O 0 8.788634886514046e-07
or O 0 1.7034878396771092e-07
C O 0 1.2093317309336271e-05
that O 0 1.9733807476995935e-08
introduces O 0 1.4186989005793293e-07
a O 0 1.640664848423512e-08
new O 0 3.267098946935221e-08
restriction O 0 7.311860628078648e-08
site O 0 1.8148011804441921e-07
for O 0 2.049142722171382e-07
Eco0109 O 0 5.311852146405727e-05
I O 0 0.00010414547432446852
. O 0 3.2148585887625813e-05

All O 0 1.3099443094688468e-06
the O 0 4.315664909881889e-07
4003delTC O 0 5.195922312850598e-06
alleles O 0 7.120988243514148e-07
showed O 0 2.219815797843694e-07
the O 0 4.442165391083108e-08
same O 0 6.576775035682658e-08
haplotype O 0 8.203197694456321e-07
for O 0 6.379732298000818e-08
these O 0 1.1998329796369944e-07
five O 0 6.475305553976796e-07
polymorphic O 0 2.1145286154933274e-05
markers O 0 1.5004829947429243e-05
. O 0 2.501699600543361e-05

Fourteen O 0 8.491332118865103e-05
microsatellite O 0 0.0001252149377251044
polymorphisms O 0 6.650348950643092e-06
were O 0 3.7133673913558596e-07
selected O 0 2.643492962306482e-07
based O 0 7.731441797886873e-08
on O 0 5.520914569956403e-08
their O 0 2.7715771011571633e-08
high O 0 1.2634114909815253e-06
heterozygosity O 0 1.4025683412910439e-05
and O 0 4.5814534388455286e-08
their O 0 2.1513546499818403e-08
location O 0 2.8442667598937987e-07
within O 0 4.4457769377004297e-07
10q23 O 0 1.8958311557071283e-05
- O 0 4.942590294376714e-06
q25 O 0 2.9237866328912787e-05
near O 0 2.0101280824746937e-05
COL17A1 O 0 0.009375989437103271
. O 0 0.00011595858813961968

Three O 0 6.740120625181589e-06
families O 0 6.728559469593165e-07
shared O 0 2.648767122082063e-06
microsatellite O 0 0.0001881583739304915
polymorphisms O 0 2.668796878424473e-05
covering O 0 1.7491443941253237e-05
at O 0 3.0628218610218028e-06
most O 0 1.6187192386496463e-07
19 O 0 2.1990119876136305e-06
cM O 0 7.23018047210644e-06
, O 0 9.865868833003333e-08
whereas O 0 1.4125816960586235e-07
the O 0 3.666536230184647e-08
others O 0 2.08574526538996e-08
shared O 0 1.6874713182346568e-08
smaller O 0 2.1555237594839127e-08
regions O 0 3.215840038706119e-08
consistent O 0 3.159745745051623e-07
with O 0 4.5518298463775864e-08
cross O 0 3.1115476417653554e-07
- O 0 2.400525431767164e-07
over O 0 3.8938022584034115e-08
events O 0 2.2322385717643556e-08
during O 0 1.9160035336085457e-08
passage O 0 8.143426377671403e-09
of O 0 8.932398820604703e-09
this O 0 3.035874440726616e-09
mutation O 0 3.778324142444944e-08
through O 0 2.404619259266383e-08
several O 0 9.011255741597779e-08
generations O 0 2.5155973162327427e-06
. O 0 7.852938324504066e-06

These O 0 1.219564069288026e-06
results O 0 1.5378154785139486e-06
indicate O 0 3.030282300642284e-07
that O 0 6.86576626662827e-08
4003delTC O 0 2.8000686143059283e-06
occurs O 0 1.6363529198315518e-07
on O 0 1.0620082235845985e-07
a O 0 5.879326181457145e-08
single O 0 1.562619615924632e-07
ancestral O 0 1.5672491144869127e-06
allele O 0 9.686429621069692e-06
. O 0 2.7942585347773274e-06
. O 0 1.84602577064652e-05

The O 0 2.0786557797691785e-05
haptoglobin O 0 0.0006826466415077448
- O 0 2.4649642000440508e-05
gene O 0 2.3045972739055287e-06
deletion O 0 1.1396230547688901e-05
responsible O 0 8.407695531786885e-06
for O 0 5.2232376219762955e-06
anhaptoglobinemia B-Disease 0 0.3144887387752533
. O 0 0.00020239694276824594

We O 0 3.5142750220984453e-06
have O 0 2.2437302504840773e-07
found O 0 1.5220665261495014e-07
an O 0 9.4245699244766e-08
allelic O 0 6.936793397471774e-06
deletion O 0 2.832204700098373e-06
of O 0 9.044227340382349e-07
the O 0 2.5290630674135173e-06
haptoglobin O 0 0.01955336146056652
( O 0 1.8949732520923135e-06
Hp O 0 7.485907553927973e-05
) O 0 6.434578381231404e-08
gene O 0 3.2333382193883153e-08
from O 0 2.5948212467596932e-08
an O 0 3.0499794689831106e-08
individual O 0 1.4536365711137478e-07
with O 0 9.466326673646108e-07
anhaptoglobinemia B-Disease 0 0.014044736512005329
. O 0 3.4428863727953285e-05

The O 0 4.260689820512198e-05
Hp O 0 0.00022460150648839772
gene O 0 1.8056977069136337e-06
cluster O 0 6.584031780221267e-06
consists O 0 1.0021411753768916e-06
of O 0 4.583835391258617e-07
coding O 0 7.041450089673162e-07
regions O 0 5.591312657315939e-08
of O 0 1.3859325065368466e-07
the O 0 2.7047755679632246e-07
alpha O 0 3.506829216348706e-06
chain O 0 1.1665903087987317e-07
and O 0 1.6754702514276687e-08
beta O 0 3.35743635559993e-07
chain O 0 7.145737868086144e-08
of O 0 3.320517549809665e-08
the O 0 9.53841023942914e-08
haptoglobin O 0 5.537109245778993e-06
gene O 0 1.9834453723888146e-07
( O 0 1.211498954489798e-07
Hp O 0 6.544767529703677e-06
) O 0 3.5688898947228154e-08
and O 0 2.313717395452386e-08
of O 0 1.1665714794162341e-07
the O 0 2.046178337877791e-07
alpha O 0 2.2916140096640447e-06
chain O 0 1.5967313515830028e-07
and O 0 3.2864992505210466e-08
beta O 0 4.95354811391735e-07
chain O 0 1.252578840649221e-07
of O 0 1.1610364225589365e-07
the O 0 1.6283513559756102e-07
haptoglobin O 0 1.5924208128126338e-05
- O 0 7.583795422760886e-07
related O 0 1.2811938177037518e-07
gene O 0 2.2094332052802201e-07
( O 0 2.8369171900521906e-07
Hpr O 0 3.0405257348320447e-05
) O 0 1.5221957028188626e-07
, O 0 6.034186128545116e-08
in O 0 4.340471448927019e-08
tandem O 0 1.8748977481664042e-06
from O 0 6.672652119732447e-08
the O 0 3.3405694921384566e-07
5 O 0 3.5230630146543263e-06
side O 0 1.7835202015703544e-05
. O 0 1.358809822704643e-05

Southern O 0 6.157962343422696e-05
blot O 0 6.521229806821793e-05
and O 0 1.601936901352019e-06
PCR O 0 1.001173586701043e-05
analyses O 0 4.660906824938138e-07
have O 0 2.3715600150353566e-08
indicated O 0 1.1513377984329054e-07
that O 0 8.020998087943099e-09
the O 0 1.9086176195060034e-08
individual O 0 1.5544884490736877e-08
with O 0 4.5446469698617875e-08
anhaptoglobinemia B-Disease 0 2.748697079368867e-05
was O 0 3.9454019429285836e-07
homozygous O 0 8.45098284685264e-08
for O 0 1.0084889368044969e-08
the O 0 1.1558171308934106e-08
gene O 0 2.3955278649623324e-08
deletion O 0 8.853699284827599e-08
and O 0 9.754941743267409e-09
that O 0 3.81667453197565e-09
the O 0 2.6410683418021108e-08
gene O 0 7.789494560483945e-08
deletion O 0 4.915177669317927e-07
was O 0 3.368636214418075e-07
included O 0 1.6244968037426588e-07
at O 0 5.445328383757442e-07
least O 0 4.554861021688339e-08
from O 0 1.0233430991490877e-08
the O 0 5.492461241374258e-08
promoter O 0 3.7494544358196435e-06
region O 0 3.819542655492114e-07
of O 0 7.056265758365043e-07
Hp O 0 3.438447674852796e-05
to O 0 1.801430471459753e-07
Hpr O 0 1.111421897803666e-05
alpha O 0 1.5122493550734362e-06
but O 0 3.300904083403111e-08
not O 0 1.3306266311019499e-08
to O 0 6.689180054308963e-08
Hpr O 0 2.3165750462794676e-05
beta O 0 1.2508600775618106e-05
( O 0 1.8866011259888182e-06
Hpdel O 0 0.0001731179072521627
) O 0 4.988291038898751e-06
. O 0 2.202978612331208e-05

In O 0 8.853376129991375e-07
addition O 0 4.247841332016833e-07
, O 0 1.0898006763682133e-07
we O 0 5.3392376742067427e-08
found O 0 2.35490489330914e-08
seven O 0 7.21405939430042e-08
individuals O 0 7.682971592259946e-09
with O 0 2.9088125685916566e-08
hypohaptoglobinemia B-Disease 0 1.3583175132225733e-05
in O 0 3.969374162693384e-08
three O 0 3.176865348564206e-08
families O 0 3.5744609494514634e-09
, O 0 1.0242588999176405e-08
and O 0 1.2300065854731201e-08
the O 0 2.7226292331761215e-08
genotypes O 0 5.364685762287991e-07
of O 0 4.7970100780503344e-08
six O 0 4.082841797981018e-08
of O 0 1.9209142720910677e-08
the O 0 1.2058112730528592e-08
seven O 0 4.349255888769221e-08
individuals O 0 3.2223406165599044e-09
were O 0 1.510154667982988e-08
found O 0 1.4710108686699641e-08
to O 0 4.077775628275049e-08
be O 0 7.249494728966965e-07
Hp2 O 0 0.06986715644598007
/ O 0 0.034861575812101364
Hpdel O 0 0.09745584428310394
. O 0 8.529018668923527e-05

The O 0 4.637337951862719e-06
phenotypes O 0 1.3585351553047076e-05
and O 0 2.692756311262201e-07
genotypes O 0 9.593138202035334e-06
in O 0 4.924293506292088e-08
one O 0 1.948070327273399e-08
of O 0 4.068243342203459e-08
these O 0 1.30931274711088e-08
three O 0 2.255443298793125e-08
families O 0 9.774385745231484e-09
showed O 0 9.365827935425841e-08
the O 0 6.104535543727252e-08
father O 0 1.0363645941424693e-07
to O 0 2.9360920805743262e-08
be O 0 1.5110441609067493e-07
hypohaptoglobinemic B-Disease 0 0.00012739459634758532
( O 0 8.269775548797043e-07
Hp2 O 0 7.48573656892404e-05
) O 0 1.2839349494697672e-07
and O 0 1.7173053379337944e-07
Hp2 O 0 0.00030884702573530376
/ O 0 2.8914331778651103e-05
Hpdel O 0 0.00014324701623991132
, O 0 9.071613504829656e-08
the O 0 2.863726500379471e-08
mother O 0 4.18294163750943e-08
to O 0 1.6317954987243866e-08
be O 0 8.628139624988762e-08
Hp2 O 0 9.906133527692873e-06
- O 0 4.872413228440564e-07
1 O 0 4.3163936425116844e-07
and O 0 1.3228482487193105e-07
Hp1 O 0 5.720477201975882e-05
/ O 0 2.798888544930378e-06
Hp2 O 0 1.03402908280259e-05
, O 0 1.2416697892092543e-08
one O 0 3.9080187974605e-09
of O 0 7.228739384856908e-09
the O 0 1.1132231136912196e-08
two O 0 9.361681208019945e-09
children O 0 3.6842144890414374e-09
to O 0 6.324023971160386e-09
be O 0 9.8781079316268e-08
hypohaptoglobinemic B-Disease 0 3.2940490200417116e-05
( O 0 5.485300107466173e-07
Hp2 O 0 5.6310109357582405e-05
) O 0 1.2641355340292648e-07
and O 0 1.8417668457004766e-07
Hp2 O 0 0.0002683346683625132
/ O 0 3.020714211743325e-05
Hpdel O 0 0.00016804020560812205
, O 0 7.6811282667677e-08
and O 0 1.611259392575448e-08
the O 0 1.4155884464628343e-08
other O 0 3.950821447773478e-09
child O 0 1.2316029973646891e-08
to O 0 3.762250067040895e-09
be O 0 3.0952161722552773e-08
Hp1 O 0 1.5196431377262343e-05
and O 0 6.767751870029315e-07
Hp1 O 0 0.1871328204870224
/ O 0 0.0003418932610657066
Hpdel O 0 0.001343566575087607
, O 0 1.824216440127202e-07
showing O 0 2.406487169537286e-07
an O 0 8.092241898793873e-08
anomalous O 0 4.314695615903474e-06
inheritance O 0 1.3870541124560987e-06
of O 0 2.1624352939397795e-06
Hp O 0 0.0027576121501624584
phenotypes O 0 1.1158589586557355e-05
in O 0 1.3525344400022732e-07
the O 0 3.883793340264674e-07
child O 0 1.10633629901713e-06
with O 0 1.470465917918773e-06
Hp1 O 0 0.025851929560303688
. O 0 5.8188412367599085e-05

The O 0 3.130437835352495e-05
Hp2 O 0 0.31959372758865356
/ O 0 0.006333553697913885
Hpdel O 0 0.009730189107358456
individuals O 0 2.4219082206400344e-07
had O 0 1.2497177692694095e-07
an O 0 2.8015852748808356e-08
extremely O 0 1.647272540594713e-07
low O 0 4.863916842623439e-07
level O 0 1.6977204495560727e-06
of O 0 4.914718374493532e-07
Hp O 0 3.323751298012212e-05
( O 0 3.1565047464710005e-08
mean O 0 1.150266655258747e-07
+ O 0 2.785228900847869e-07
/ O 0 3.803719152983831e-07
- O 0 2.4291438194268267e-07
SD O 0 4.2690385271271225e-06
= O 0 5.478096340993943e-07
0 O 0 2.034534531958343e-07
. O 0 7.995813433581134e-08
049 O 0 4.1176617742166854e-06
+ O 0 7.79639719894476e-07
/ O 0 8.078714586190472e-07
- O 0 2.7642502686830994e-07
0 O 0 3.653148041848908e-07
. O 0 1.1143684730541281e-07
043 O 0 1.0789400221256074e-05
mg O 0 2.850372220564168e-05
/ O 0 4.141290901316097e-06
ml O 0 1.8853347683034372e-06
; O 0 3.9369744797568273e-08
n O 0 2.0460360872220917e-07
= O 0 3.895422082678124e-07
6 O 0 2.939045771199744e-07
) O 0 8.779937665792659e-09
, O 0 5.048553131103972e-09
compared O 0 6.257098394968352e-09
with O 0 1.442610475521633e-09
the O 0 1.1526732457411981e-08
level O 0 2.4180309310395387e-07
( O 0 1.667789462089786e-08
1 O 0 5.249076551194776e-08
. O 0 1.1008350675467682e-08
64 O 0 1.0561380747731164e-07
+ O 0 1.9761912994908926e-07
/ O 0 2.5446067297707486e-07
- O 0 6.329795354531598e-08
1 O 0 1.1157318624555046e-07
. O 0 4.520311236433372e-08
07 O 0 4.5082324504619464e-06
mg O 0 1.5119007912289817e-05
/ O 0 1.4859546126899659e-06
ml O 0 9.627613053453388e-07
) O 0 1.2901304025092486e-08
obtained O 0 4.501666595047027e-08
from O 0 1.117430858954549e-08
52 O 0 1.7429454146622447e-07
healthy O 0 2.7513630129760713e-07
volunteers O 0 2.6753733095574717e-07
having O 0 4.7633989197493065e-07
phenotype O 0 9.371325177198742e-06
Hp2 O 0 5.013430200051516e-05
, O 0 1.1336695848740419e-07
whereas O 0 2.360125961331505e-07
the O 0 1.1518309150915229e-07
serum O 0 6.186003247421468e-07
Hp O 0 1.6579580233155866e-06
level O 0 1.4733940645328403e-07
of O 0 1.566764140648047e-08
an O 0 5.998759267100695e-09
individual O 0 4.7445585238392596e-09
with O 0 5.604263719760638e-08
Hp1 O 0 0.0003402174625080079
/ O 0 2.5043658752110787e-05
Hpdel O 0 6.431143992813304e-05
was O 0 2.202040377596859e-06
0 O 0 6.71475345370709e-06
. O 0 7.235822977236239e-06

50 O 0 2.4708788259886205e-05
mg O 0 0.0026259678415954113
/ O 0 8.915740181691945e-05
ml O 0 5.9971996961394325e-05
, O 0 1.2334946575265349e-07
which O 0 1.6372606381764854e-08
was O 0 7.772368348923919e-08
approximately O 0 2.3193640785734715e-08
half O 0 1.460769283312402e-08
the O 0 7.477789942811341e-09
level O 0 1.9581422350256616e-07
of O 0 1.2092145595943293e-07
Hp O 0 3.0091009648458567e-06
in O 0 3.552116112359727e-08
control O 0 4.534836648417695e-07
sera O 0 2.537310820116545e-06
from O 0 1.8317050987093353e-08
the O 0 1.7112907357841323e-07
Hp1 O 0 1.5485098629142158e-05
phenotype O 0 1.2706857432931429e-06
( O 0 5.154398152740214e-08
1 O 0 1.2221867962125543e-07
. O 0 2.1844709152674113e-08
26 O 0 2.8538661922539177e-07
+ O 0 2.1150464135644143e-07
/ O 0 1.646609604222249e-07
- O 0 5.304633887703858e-08
0 O 0 6.0014862413027e-08
. O 0 2.269260335197032e-08
33 O 0 4.6471967607430997e-07
mg O 0 1.009308653010521e-05
/ O 0 1.5731806115582003e-06
ml O 0 1.0213871064479463e-06
; O 0 2.1345433864894403e-08
n O 0 1.6433811822480493e-07
= O 0 2.2679930111735302e-07
9 O 0 2.6238720352012024e-07
) O 0 1.8515688537945607e-08
, O 0 2.5159561545251563e-08
showing O 0 2.642343588377116e-07
a O 0 3.491910547381849e-07
gene O 0 1.086454631149536e-06
- O 0 3.3672563404252287e-06
dosage O 0 4.185869693174027e-05
effect O 0 2.991116707562469e-05
. O 0 2.259697430417873e-05

The O 0 5.932816293352516e-06
other O 0 6.216370707079477e-07
allele O 0 1.195874392578844e-05
( O 0 8.873620913618652e-07
Hp2 O 0 4.351185270934366e-05
) O 0 1.1724615234243174e-07
of O 0 1.2670226112732053e-07
individuals O 0 3.561382655448142e-08
with O 0 1.707308285858744e-07
Hp2 O 1 0.9900555610656738
/ O 1 0.5559096932411194
Hpdel O 0 0.09987474977970123
was O 0 3.07477506567011e-07
found O 0 6.278617181720847e-09
to O 0 2.1950619100152835e-09
have O 0 4.176051948689974e-09
, O 0 1.2436607299548541e-08
in O 0 5.041518758019947e-09
all O 0 1.0762042812473283e-08
exons O 0 2.626072443945304e-07
, O 0 1.0125963179064001e-08
no O 0 2.2509222930011674e-08
mutation O 0 6.659328022351474e-08
, O 0 3.086438127297697e-08
by O 0 6.944736696823384e-08
DNA O 0 2.173011353079346e-06
sequencing O 0 6.951521754672285e-06
. O 0 1.0041501809610054e-05

On O 0 1.458946258026117e-06
the O 0 7.736958451687315e-08
basis O 0 7.782351474361349e-08
of O 0 4.960492461236754e-08
the O 0 2.5382730584055935e-08
present O 0 2.4601879644592373e-08
study O 0 1.3084514804972969e-08
, O 0 5.7593414481971195e-09
the O 0 1.1188320492294679e-08
mechanism O 0 3.3603868132559e-07
of O 0 2.0452672799819993e-07
anhaptoglobinemia B-Disease 0 1.075445379683515e-05
and O 0 5.7837169720187376e-08
the O 0 5.469024344506579e-08
mechanism O 0 6.465605224548199e-07
of O 0 1.3341468729777262e-07
anomalous O 0 2.2795602490077727e-06
inheritance O 0 3.2464640753460117e-07
of O 0 6.682465709673124e-07
Hp O 0 0.00014754245057702065
phenotypes O 0 8.604902177467011e-06
were O 0 7.440304443662171e-07
well O 0 1.284639665755094e-06
explained O 0 1.7020527593558654e-05
. O 0 1.4189969988365192e-05

However O 0 4.870786597166443e-06
, O 0 6.505840701720444e-07
the O 0 3.9671229501436756e-07
mechanism O 0 5.4936367632762995e-06
of O 0 1.7079513554563164e-06
hypohaptoglobinemia B-Disease 0 0.0004101382801309228
remains O 0 3.111838304903358e-05
unknown O 0 0.0001588290324434638

ATM O 0 0.00020858793868683279
mutations O 0 1.5109710147953592e-05
and O 0 2.1020773601776455e-06
phenotypes O 0 0.00031007317011244595
in O 0 3.2249579817289487e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 7.179091312536912e-07
in O 0 7.445358818358727e-08
the O 0 1.1213406025945005e-07
British O 0 1.918711859616451e-06
Isles O 0 2.786488039419055e-06
: O 0 4.1233885639258006e-08
expression O 0 3.1429333802179826e-08
of O 0 3.0830722863584015e-08
mutant O 0 1.1439806257840246e-07
ATM O 0 7.865559155106894e-07
and O 0 1.3940352872054973e-08
the O 0 1.7796448759099803e-08
risk O 0 1.4221191690921842e-07
of O 0 2.9875495783926453e-06
leukemia B-Disease 1 1.0
, O 1 0.9999957084655762
lymphoma B-Disease 1 1.0
, O 1 0.9999995231628418
and O 1 0.9999995231628418
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999653100967407
. O 0 0.0012891318183392286

We O 0 3.994771304860478e-06
report O 0 5.217440275373519e-07
the O 0 1.0042318621117374e-07
spectrum O 0 8.762364700487524e-07
of O 0 1.5947134102134441e-07
59 O 0 9.71654117165599e-07
ATM O 0 4.881687345914543e-06
mutations O 0 5.320258651408949e-07
observed O 0 9.868019787973026e-07
in O 0 3.5157431739207823e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999997615814209
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.649192758028221e-07
patients O 0 5.579082440476668e-08
in O 0 2.220120265405967e-08
the O 0 1.905333704144141e-07
British O 0 6.760689302609535e-06
Isles O 0 7.57160087232478e-05
. O 0 2.2640870156465098e-05

Of O 0 1.7703938283375464e-05
51 O 0 2.7295161999063566e-05
ATM O 0 8.867766155162826e-05
mutations O 0 1.7028785350703401e-06
identified O 0 7.020195198492729e-07
in O 0 4.324341418282529e-08
families O 0 2.4727818015435332e-08
native O 0 3.972434114984935e-08
to O 0 1.9271309881219167e-08
the O 0 9.192931571533336e-08
British O 0 2.3601267002959503e-06
Isles O 0 4.548125616565812e-06
, O 0 8.796637018804176e-08
11 O 0 2.408712305168592e-07
were O 0 5.126885582740215e-08
founder O 0 6.449003535635711e-07
mutations O 0 8.849360000340312e-08
, O 0 1.9580351562353826e-08
and O 0 1.646511549324714e-08
2 O 0 1.4506757395338354e-07
of O 0 2.18461693179961e-08
these O 0 9.086225105647827e-09
11 O 0 1.3508211793578084e-07
conferred O 0 2.3832461693018558e-07
a O 0 4.6536449360701226e-08
milder O 0 2.3281234007299645e-06
clinical O 0 9.435646575184364e-07
phenotype O 0 5.224146661930718e-07
with O 0 1.0776955328140048e-08
respect O 0 5.655365242773769e-08
to O 0 3.840562712298379e-08
both O 0 1.020929403239279e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 1.4529698091791943e-05
cellular O 0 0.00010887033567996696
features O 0 6.12024405199918e-06
. O 0 5.902882548980415e-06

We O 0 4.855023234995315e-06
report O 0 6.319540943877655e-07
, O 0 9.089904295933593e-08
in O 0 4.352127191964428e-08
two O 0 1.1485796846955054e-07
A B-Disease 1 0.9964356422424316
- I-Disease 1 0.7203060984611511
T I-Disease 1 0.9999996423721313
families O 0 2.7116580980646177e-08
, O 0 3.0626001290556815e-08
an O 0 2.480684990757709e-08
ATM O 0 2.659628762557986e-06
mutation O 0 3.68476833045861e-07
( O 0 1.8485205544038763e-07
7271T O 0 3.4416650578350527e-06
- O 0 9.306189667768194e-07
- O 0 6.398120717676647e-07
> O 0 1.3597137922261027e-06
G O 0 3.0340090688696364e-06
) O 0 6.466959412421147e-09
that O 0 1.3246068686356693e-09
may O 0 7.0695871379200526e-09
be O 0 1.0123664573313818e-08
associated O 0 1.4514874635551678e-08
with O 0 4.272166176377823e-09
an O 0 4.389330232612565e-09
increased O 0 6.696546250850588e-08
risk O 0 7.145465019675612e-07
of O 0 2.2298390831565484e-05
breast B-Disease 0 0.04930903762578964
cancer I-Disease 0 2.410530441920855e-06
in O 0 3.002144310926269e-08
both O 0 1.7599676027657551e-07
homozygotes O 0 1.211413928103866e-05
and O 0 1.7818993569562736e-07
heterozygotes O 0 3.361307790328283e-06
( O 0 4.148790466729224e-08
relative O 0 1.4550610671903996e-07
risk O 0 7.785097722035061e-08
12 O 0 1.1501536789637612e-07
. O 0 2.219214323417873e-08
7 O 0 2.480349792222114e-07
; O 0 4.470529546551916e-08
P O 0 7.2370235102425795e-06
= O 0 1.3252426924736938e-06
. O 0 1.0172018960474816e-07
0025 O 0 1.758209145918954e-05
) O 0 2.0811315337709857e-08
, O 0 1.0158869301335471e-08
although O 0 1.1387337295332145e-08
there O 0 2.3437161544848095e-08
is O 0 1.2377540770103224e-08
a O 0 3.614997368117656e-08
less O 0 4.774126978190907e-07
severe O 1 0.9988728165626526
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
phenotype O 0 1.5055709354783176e-06
in O 0 3.817715477083539e-09
terms O 0 9.190982197537778e-09
of O 0 1.1510496555899863e-08
the O 0 1.6663936008853852e-08
degree O 0 1.1006502518284833e-06
of O 0 6.485110134235583e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.00012542719196062535

This O 0 1.4220447610568954e-06
mutation O 0 3.3277758575422922e-06
( O 0 9.516282943877741e-07
7271T O 0 2.003162444452755e-05
- O 0 3.5232512800575932e-06
- O 0 1.4992966725912993e-06
> O 0 3.1146403216553153e-06
G O 0 8.738691576581914e-06
) O 0 1.785084258187908e-08
also O 0 4.330934277874121e-09
allows O 0 2.6956139542733126e-09
expression O 0 4.998365721320397e-09
of O 0 8.324339439980122e-09
full O 0 6.159834242680517e-08
- O 0 7.104478783048762e-08
length O 0 4.3783458636426076e-08
ATM O 0 6.193540684762411e-07
protein O 0 6.23243323616407e-08
at O 0 4.3951718708967746e-08
a O 0 1.2135313198768927e-08
level O 0 7.580195671152978e-08
comparable O 0 9.576162796065546e-08
with O 0 5.946561909553338e-09
that O 0 8.710580701176696e-09
in O 0 3.3249349939978856e-08
unaffected O 0 2.1354878754209494e-06
individuals O 0 3.085902733346302e-07
. O 0 7.11537313691224e-06

In O 0 1.1324631259412854e-06
addition O 0 3.6987069051974686e-07
, O 0 1.1932876020637195e-07
we O 0 5.108865508418603e-08
have O 0 1.6135262015382068e-08
studied O 0 7.730363904556725e-07
18 O 0 2.0808020053664222e-06
A B-Disease 1 0.9999794960021973
- I-Disease 1 0.9991182684898376
T I-Disease 1 1.0
patients O 0 9.812140433496097e-08
, O 0 1.2673965876786042e-08
in O 0 7.203057261762069e-09
15 O 0 4.7809891157157836e-08
families O 0 3.171475304597493e-09
, O 0 1.69425042884086e-08
who O 0 3.071123089171124e-08
developed O 0 5.257606062514242e-06
leukemia B-Disease 1 0.999980092048645
, O 0 0.00011949414329137653
lymphoma B-Disease 1 1.0
, O 0 4.270619319868274e-05
preleukemic O 0 0.23071366548538208
T O 0 0.003368521574884653
- O 0 4.6615878090960905e-06
cell O 0 1.265227297153615e-06
proliferation O 0 2.743672439464717e-06
, O 0 2.379825900789001e-07
or O 0 6.787130587326828e-06
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 0.00010170807945542037
mostly O 0 1.0365914704379975e-06
in O 0 5.786718020317494e-07
childhood O 0 1.6506564861629158e-05
. O 0 1.9069793779635802e-05

A O 0 2.5474662834312767e-05
wide O 0 6.180581294756848e-06
variety O 0 6.608015041820181e-07
of O 0 6.048360319255153e-07
ATM O 0 1.6789237633929588e-05
mutation O 0 1.187979279393403e-07
types O 0 9.727410343884912e-08
, O 0 3.8831814208606374e-08
including O 0 7.097558096802459e-08
missense O 0 3.716106220963411e-06
mutations O 0 3.482333283955086e-07
and O 0 8.5050892550953e-08
in O 0 1.4265366132804047e-07
- O 0 5.544374289456755e-06
frame O 0 2.8116333851357922e-05
deletions O 0 7.336705607485783e-07
, O 0 8.378981419809861e-08
were O 0 2.452261753660423e-07
seen O 0 8.073893127402698e-07
in O 0 1.1269303001881781e-07
these O 0 4.212859323615703e-07
patients O 0 2.6262480332661653e-06
. O 0 1.4078523236094043e-05

We O 0 1.1304151712465682e-06
also O 0 7.53780824425121e-08
show O 0 2.0953669022105714e-08
that O 0 3.991069252862189e-09
25 O 0 3.999300801638128e-08
% O 0 8.396784600961382e-09
of O 0 5.5995091230442995e-08
all O 0 1.8126459622180846e-07
A B-Disease 1 0.9999982118606567
- I-Disease 1 0.9998805522918701
T I-Disease 1 1.0
patients O 0 1.4972805217894347e-07
carried O 0 1.3627017381168116e-07
in O 0 6.847522371344894e-08
- O 0 1.5013584970802185e-06
frame O 0 3.294009729870595e-06
deletions O 0 2.6312591216992587e-07
or O 0 5.617994602857834e-08
missense O 0 1.0462679256306728e-06
mutations O 0 8.368424175841938e-08
, O 0 1.2516064629153334e-08
many O 0 3.084329680547171e-09
of O 0 2.3187094910781525e-08
which O 0 8.92133122931682e-09
were O 0 2.567282386678471e-08
also O 0 9.335701101065297e-09
associated O 0 1.9850986632263812e-08
with O 0 1.477390831894354e-08
expression O 0 1.219714818034845e-07
of O 0 6.33245178960351e-07
mutant O 0 8.611157682025805e-06
ATM O 0 5.2070306992391124e-05
protein O 0 8.410397640545852e-06
. O 0 7.662231837457512e-06

The O 0 5.128047632751986e-06
DMPK O 0 0.0005511295748874545
gene O 0 3.3449130114604486e-06
of O 0 1.362156035611406e-05
severely O 1 0.9999995231628418
affected O 1 0.9999998807907104
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9903860092163086
is O 0 3.5095524708594894e-06
hypermethylated O 0 0.00017699776799418032
proximal O 0 1.3008418136450928e-05
to O 0 8.715720412055816e-08
the O 0 3.1691192248217703e-07
largely O 0 1.4587515124730999e-06
expanded O 0 5.125944881001487e-06
CTG O 0 0.0006263651303015649
repeat O 0 6.492078682640567e-05
. O 0 2.7906718969461508e-05

Using O 0 1.2526555110525806e-05
methylation O 0 2.3719554519630037e-05
- O 0 1.0948089766316116e-05
sensitive O 0 2.3703605620539747e-06
restriction O 0 3.0598300782003207e-07
enzymes O 0 4.2612879269654513e-07
, O 0 4.7010615844556014e-08
we O 0 2.8607949786874087e-08
characterized O 0 8.074772495092475e-08
the O 0 3.4835380802178406e-08
methylation O 0 2.0859886262769578e-07
pattern O 0 2.3070639088018652e-07
on O 0 7.609661167862214e-08
the O 0 2.7967162807840396e-08
5 O 0 1.1463374249842673e-07
side O 0 1.426376030622123e-07
of O 0 1.1317477799366316e-07
the O 0 2.0260965527540975e-07
CTG O 0 3.258515789639205e-05
repeat O 0 3.797003387262521e-07
in O 0 3.406322690580055e-08
the O 0 6.888983961061967e-08
DMPK O 0 7.522829491790617e-06
gene O 0 5.342365128058191e-08
of O 0 4.514839702096651e-08
normal O 0 1.229877995001516e-07
individuals O 0 1.083881961960742e-08
and O 0 3.173219553787021e-08
of O 0 3.292331598458986e-07
patients O 0 5.703064402950986e-07
affected O 0 2.3418895125359995e-06
with O 1 0.97423255443573
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.896963335137116e-06
showing O 0 6.092677153901604e-07
expansions O 0 7.209389423223911e-07
of O 0 1.1153126422414061e-07
the O 0 3.0974518949733465e-07
repetitive O 0 4.532183538685786e-06
sequence O 0 3.1576632864016574e-06
. O 0 7.274243671417935e-06

The O 0 1.2849316590290982e-05
gene O 0 3.6154776807961753e-06
segment O 0 2.4439902972517302e-06
analyzed O 0 6.38803669517074e-07
corresponds O 0 4.4129802745374036e-07
to O 0 9.468460859807237e-08
the O 0 6.978143005653692e-07
genomic O 0 6.036931154085323e-06
SacI O 0 0.000306588364765048
- O 0 1.8231645299238153e-05
HindIII O 0 5.930426050326787e-05
fragment O 0 4.824722054763697e-06
carrying O 0 4.885678208665922e-06
exons O 0 1.3467013559420593e-05
11 O 0 8.909047210181598e-06
- O 0 1.050510945788119e-05
15 O 0 1.4572022337233648e-05
. O 0 3.1319188565248623e-05

There O 0 4.962913862982532e-06
is O 0 7.94897687228513e-07
constitutive O 0 9.468148164160084e-06
methylation O 0 2.180239334848011e-06
in O 0 2.5424893124181835e-07
intron O 0 5.362811407394474e-06
12 O 0 1.3044914339843672e-06
at O 0 2.656351512086985e-07
restriction O 0 3.288518257704709e-08
sites O 0 2.821668765307095e-08
of O 0 5.681420844894092e-08
SacII O 0 1.1290939255559351e-05
and O 0 1.990031393006575e-07
HhaI O 0 1.7058488083421253e-05
, O 0 4.645078632847799e-08
localized O 0 3.305094367078709e-07
1 O 0 3.071349112815369e-07
, O 0 3.518589508644254e-08
159 O 0 1.208664599516851e-07
- O 0 9.147682078491925e-08
1 O 0 1.8212925567695493e-07
, O 0 6.021034693048932e-08
232 O 0 4.300988791783311e-07
bp O 0 1.033913918035978e-06
upstream O 0 1.4519088153974735e-07
of O 0 6.942485697436496e-08
the O 0 1.9853644062095555e-07
CTG O 0 0.00013917958131060004
repeat O 0 9.078491984837456e-07
, O 0 2.4066931558763827e-08
whereas O 0 2.9802819767610345e-08
most O 0 4.11226475094395e-09
, O 0 1.9034724907385225e-09
if O 0 1.7185979306333365e-09
not O 0 1.594085419220903e-09
all O 0 3.5387113239693235e-09
, O 0 3.4811784566102233e-09
of O 0 5.725519169885729e-09
the O 0 7.394492129719765e-09
other O 0 2.270527543757339e-09
sites O 0 1.1165190549888848e-08
of O 0 6.707117705673227e-08
SacII O 0 1.1617243217187934e-05
, O 0 1.5101755934665562e-07
HhaI O 0 2.376044176344294e-05
, O 0 1.2042717401072878e-07
and O 0 9.878070272861805e-08
HpaII O 0 1.0740247489593457e-05
in O 0 1.2295116924576632e-08
this O 0 2.5480360044127792e-09
region O 0 2.145331201575118e-08
are O 0 8.04566724355027e-09
unmethylated O 0 1.346402427770954e-06
, O 0 1.8567179793649302e-08
in O 0 8.033507192806155e-09
normal O 0 3.113322577519284e-08
individuals O 0 4.24208224103495e-09
and O 0 1.6189115825682165e-08
most O 0 1.7909055571863064e-08
of O 0 1.4766985145797662e-07
the O 0 6.664740794803947e-07
patients O 0 1.3644485079566948e-06
. O 0 5.344543296814663e-06

In O 0 6.398682330654992e-07
a O 0 1.4978003548549168e-07
number O 0 7.043411898166596e-08
of O 0 3.1781326015334344e-07
young O 0 1.9573650206439197e-05
and O 0 4.619413175532827e-06
severely O 1 0.6410594582557678
affected O 0 6.450848104577744e-07
patients O 0 4.825743715741737e-08
, O 0 2.1145620365814466e-08
however O 0 4.4991942615979497e-08
, O 0 2.137130294954659e-08
complete O 0 6.906824268071432e-08
methylation O 0 5.841678785145632e-08
of O 0 1.8552062996946006e-08
these O 0 6.1786833427390775e-09
restriction O 0 1.8903110188261962e-08
sites O 0 1.9654924798828688e-08
was O 0 9.31775474555252e-08
found O 0 2.267373844233589e-08
in O 0 2.9509926946502674e-08
the O 0 3.7909353522991296e-07
mutated O 0 5.6116932682925835e-06
allele O 0 4.640115366782993e-05
. O 0 2.8277028832235374e-05

In O 0 5.299152689985931e-07
most O 0 6.287319820330595e-08
of O 0 7.07231464502911e-08
these O 0 2.0306705650341428e-08
patients O 0 2.2868489324423535e-08
, O 0 1.5515027484980237e-08
the O 0 4.77726089798125e-08
onset O 0 0.0033801665995270014
of O 0 4.8596168198855594e-05
the O 0 0.09422654658555984
disease O 1 0.9999996423721313
was O 1 0.9998433589935303
congenital O 1 1.0
. O 0 0.017709976062178612

Preliminary O 0 4.8568745114607736e-05
in O 0 2.8577355806191918e-06
vivo O 0 3.3793643524404615e-05
footprinting O 0 4.778014408657327e-05
data O 0 4.2461846305741346e-07
gave O 0 3.54835862026448e-07
evidence O 0 3.1268496059055906e-07
for O 0 9.08595154669456e-08
protein O 0 5.100191060591897e-07
- O 0 4.131773607696232e-07
DNA O 0 1.5666977049022535e-07
contact O 0 7.089142428640116e-08
in O 0 1.5761608906927904e-08
normal O 0 2.1098610147873842e-07
genes O 0 4.466566139171846e-08
at O 0 9.191265348817979e-08
an O 0 1.9182779809057138e-08
Sp1 O 0 3.626804982559406e-06
consensus O 0 6.791603937017499e-07
binding O 0 2.05331929237218e-07
site O 0 1.610455342415662e-07
upstream O 0 1.092314505513059e-07
of O 0 4.22645669573285e-08
the O 0 1.1114922671140448e-07
CTG O 0 0.0001385798241244629
repeat O 0 6.72411431423825e-07
and O 0 3.150796246131904e-08
for O 0 9.211761131666663e-09
a O 0 7.884063180085832e-09
significant O 0 9.475701112648949e-09
reduction O 0 1.9999889744326538e-08
of O 0 1.5092446403741633e-08
this O 0 2.5257971270065127e-09
interaction O 0 2.737448845380186e-08
in O 0 5.554277038299915e-09
cells O 0 2.096150275576747e-08
with O 0 1.0468419908704618e-08
a O 0 1.398299218635657e-07
hypermethylated O 0 1.664435512793716e-05
DMPK O 0 0.00017437964561395347
gene O 0 8.464459142487613e-07
. O 0 6.630613711422484e-07
. O 0 6.742750429111766e-06

The O 0 0.0003170704294461757
hemochromatosis B-Disease 1 0.9999998807907104
gene O 0 4.274118509783875e-06
product O 0 1.1019252497135312e-06
complexes O 0 1.2866111092080246e-06
with O 0 1.2012505123948358e-07
the O 0 4.3792647375084925e-07
transferrin O 0 6.873968231957406e-06
receptor O 0 6.240979928406887e-07
and O 0 3.84403655573351e-08
lowers O 0 1.9502047621244856e-07
its O 0 1.4376970725038518e-08
affinity O 0 5.548731962790043e-08
for O 0 7.340492658158837e-08
ligand O 0 1.6669951037329156e-06
binding O 0 1.6757728644734016e-06
. O 0 3.7253741993481526e-06

We O 0 7.535790700785583e-06
recently O 0 3.84878012482659e-06
reported O 0 6.352302648338082e-07
the O 0 1.0032420760808236e-07
positional O 0 5.627492100757081e-06
cloning O 0 2.3834553530832636e-07
of O 0 7.830011128362457e-08
a O 0 5.085105314606153e-08
candidate O 0 5.056757572674542e-07
gene O 0 3.6052447285328526e-06
for O 0 7.781401654938236e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999978542327881
HFE O 1 0.9999998807907104
. O 0 0.0013119913637638092

The O 0 2.2868764517625095e-06
gene O 0 2.4526548259018455e-07
product O 0 1.7570226873431238e-07
, O 0 8.04416728783508e-08
a O 0 8.181183375199907e-08
member O 0 1.3401223952769215e-07
of O 0 1.5418244458942354e-07
the O 0 2.0009548507005093e-07
major O 0 2.760024926828919e-06
histocompatibility O 0 0.41284045577049255
complex O 0 3.0537275961251e-06
class O 0 4.980216203875898e-07
I O 0 7.420112524414435e-06
- O 0 8.364177688235941e-07
like O 0 3.3054906367624426e-08
family O 0 2.106293983672458e-08
, O 0 3.416492688756989e-08
was O 0 1.8594970185858983e-07
found O 0 1.5812586795505013e-08
to O 0 9.034348380509982e-09
have O 0 2.2266934962544838e-08
a O 0 1.386667634051264e-07
mutation O 0 9.05638046333479e-07
, O 0 1.0193299431193736e-06
Cys O 0 0.05578767880797386
- O 0 2.8098427719669417e-05
282 O 0 6.399954145308584e-06
- O 0 9.240699910151307e-06
- O 0 1.0479703632881865e-05
> O 0 3.2010735594667494e-05
Tyr O 0 0.002423592610284686
( O 0 3.513520141495974e-07
C282Y O 0 3.2005718821892515e-06
) O 0 2.4686395150297358e-08
, O 0 1.26942882872072e-08
in O 0 1.1635609808990921e-08
85 O 0 1.4154325356230402e-07
% O 0 4.537968578688378e-08
of O 0 5.316916258379933e-07
patient O 0 2.5816657398536336e-06
chromosomes O 0 6.908167961228173e-06
. O 0 1.1130679922644049e-05

This O 0 2.018851091634133e-06
mutation O 0 4.125110081076855e-06
eliminates O 0 4.362317667983007e-06
the O 0 2.470854099101416e-07
ability O 0 2.2066262772568734e-07
of O 0 5.148984314473637e-07
HFE O 0 0.00037449703086167574
to O 0 2.141844106517965e-07
associate O 0 2.479049499015673e-06
with O 0 3.568645752238808e-07
beta2 O 0 0.002170911291614175
- O 0 0.0003241643717046827
microglobulin O 0 0.11239227652549744
( O 0 9.083679515242693e-07
beta2m O 0 4.7099074436118826e-05
) O 0 1.0524661320232553e-07
and O 0 1.6774279743003717e-07
prevents O 0 5.584469136010739e-07
cell O 0 5.76978482058621e-06
- O 0 1.5483049082831712e-06
surface O 0 3.5671182558871806e-06
expression O 0 9.544991371512879e-06
. O 0 1.629319194762502e-05

A O 0 1.5705343685112894e-05
second O 0 2.5165186343656387e-06
mutation O 0 4.152068981966295e-07
that O 0 1.618584200002715e-08
has O 0 1.1374464925495431e-08
no O 0 1.641976687949409e-08
effect O 0 2.388279085607792e-07
on O 0 4.741105499306286e-07
beta2m O 0 0.00011667521903291345
association O 0 3.9242453908627795e-07
, O 0 1.8724804817793483e-07
H63D O 0 0.005043123848736286
, O 0 1.7250644646082947e-07
was O 0 2.813275443713792e-07
found O 0 1.7331190704794608e-08
in O 0 1.0622509094559973e-08
eight O 0 6.969936805489851e-08
out O 0 2.3992681619233736e-08
of O 0 1.265822078266865e-07
nine O 0 8.922592655835615e-07
patients O 0 5.439157746423007e-08
heterozygous O 0 1.7609178826205607e-07
for O 0 1.0913544912227735e-07
the O 0 1.075318891707866e-06
C282Y O 0 9.506734204478562e-05
mutant O 0 7.567911961814389e-05
. O 0 4.211137638776563e-05

In O 0 6.886737082822947e-07
this O 0 7.532347012784157e-08
report O 0 5.006306480481726e-08
, O 0 3.793973135657325e-08
we O 0 3.7269622055191576e-08
demonstrate O 0 1.1477244754587446e-07
in O 0 1.0576055586852817e-07
cultured O 0 3.514730906317709e-06
293 O 0 1.7612834426472546e-06
cells O 0 1.3405895060714101e-06
overexpressing O 0 1.8092616301146336e-05
wild O 0 9.069864290722762e-07
- O 0 1.3624176062876359e-06
type O 0 1.1795781347245793e-06
or O 0 2.917236656685418e-07
mutant O 0 2.0528466393443523e-06
HFE O 0 1.4963117791921832e-05
proteins O 0 1.340589683707094e-08
that O 0 3.3682612254892774e-09
both O 0 1.2776001589998032e-08
the O 0 4.239972994923846e-08
wild O 0 1.7362199855597282e-07
- O 0 4.18812703628646e-07
type O 0 1.1560340453797835e-06
and O 0 8.279403118649498e-07
H63D O 1 0.9965453743934631
HFE O 0 0.01701926812529564
proteins O 0 8.94061855660766e-08
form O 0 1.2585012143517815e-07
stable O 0 5.553167170546658e-07
complexes O 0 1.3587904845735466e-07
with O 0 2.3024428585927126e-08
the O 0 1.4230064948606014e-07
transferrin O 0 5.240591235633474e-06
receptor O 0 2.188970938732382e-06
( O 0 2.469930677762022e-07
TfR O 0 2.690066503419075e-05
) O 0 6.835712156316731e-07
. O 0 6.212077551026596e-06

The O 0 1.0231966371065937e-05
C282Y O 0 6.445234612328932e-05
mutation O 0 2.9736013402725803e-06
nearly O 0 6.808594434914994e-07
completely O 0 4.6816353460599203e-07
prevents O 0 1.320665035109414e-07
the O 0 1.2905481128200336e-07
association O 0 9.978547410582905e-08
of O 0 1.621707639287706e-07
the O 0 4.18622590814266e-07
mutant O 0 4.638518930732971e-06
HFE O 0 0.00017853955796454102
protein O 0 1.397419509885367e-06
with O 0 3.3834851365099894e-07
the O 0 4.188636921753641e-06
TfR O 0 0.0061047677882015705
. O 0 5.750231139245443e-05

Studies O 0 9.291147762269247e-06
on O 0 4.0815252759784926e-06
cell O 0 1.7987138562602922e-05
- O 0 2.9012658160354476e-06
associated O 0 6.224592539183504e-07
transferrin O 0 8.320830602315255e-06
at O 0 1.055113784786954e-06
37 O 0 2.945213282146142e-07
degrees O 0 5.548191097659583e-07
C O 0 2.379699253651779e-06
suggest O 0 6.038146693754243e-08
that O 0 8.999503364748307e-09
the O 0 7.72183312847119e-08
overexpressed O 0 2.7987282464891905e-06
wild O 0 3.6475714182415686e-07
- O 0 7.731050004622375e-07
type O 0 1.5281008245437988e-06
HFE O 0 0.0001805039355531335
protein O 0 2.960295262255386e-07
decreases O 0 3.3433515511660516e-08
the O 0 7.1640906540437754e-09
affinity O 0 5.3122175103226255e-08
of O 0 1.3168768475679826e-07
the O 0 4.1711908238539763e-07
TfR O 0 5.132265141583048e-05
for O 0 1.5702637483627768e-06
transferrin O 0 0.0001393963466398418
. O 0 2.315578967682086e-05

The O 0 3.888417631969787e-05
overexpressed O 0 0.00027182057965546846
H63D O 0 0.0002505634620320052
protein O 0 3.1107822451303946e-07
does O 0 4.285640287093884e-09
not O 0 2.0406909495562786e-09
have O 0 1.094002444190778e-09
this O 0 1.0729162003286774e-09
effect O 0 1.844346719792611e-08
, O 0 5.633743693778115e-09
providing O 0 9.723473581857434e-09
the O 0 3.07833514234801e-09
first O 0 2.821188171964195e-09
direct O 0 4.119510954581074e-09
evidence O 0 2.7307686778499374e-08
for O 0 8.078944624401174e-09
a O 0 3.683892657591059e-08
functional O 0 4.804203399544349e-07
consequence O 0 6.44361762169865e-07
of O 0 3.3686555411804875e-07
the O 0 1.4272267208070843e-06
H63D O 0 0.004820144269615412
mutation O 0 1.9739924027817324e-05
. O 0 2.485166442056652e-05

Addition O 0 1.0387912880105432e-05
of O 0 4.554419319902081e-06
soluble O 0 2.878252780647017e-05
wild O 0 2.657790673765703e-06
- O 0 5.790300747321453e-06
type O 0 3.7005720514571294e-05
HFE O 1 0.9999986886978149
/ O 1 0.9968761205673218
beta2m O 0 0.014621458947658539
heterodimers O 0 0.0001196997836814262
to O 0 1.7830721787959192e-07
cultured O 0 2.506143573555164e-06
cells O 0 1.1946767131121305e-07
also O 0 1.4659440772391008e-08
decreased O 0 5.28797556853533e-08
the O 0 1.6395764745880115e-08
apparent O 0 8.320073163758934e-08
affinity O 0 6.223405790706238e-08
of O 0 1.1559541945871388e-07
the O 0 1.8190046091604017e-07
TfR O 0 3.933772859454621e-06
for O 0 2.004197163785193e-08
its O 0 2.2721620140941923e-08
ligand O 0 1.6609521935606608e-07
under O 0 5.7779946160962936e-08
steady O 0 3.5868859526999586e-07
- O 0 1.0783806914105298e-07
state O 0 6.902212579262823e-09
conditions O 0 6.925926498979607e-08
, O 0 2.576455848668502e-08
both O 0 1.6876001041055133e-08
in O 0 3.208151255762459e-08
293 O 0 1.733933174818958e-07
cells O 0 8.768829218297469e-08
and O 0 6.853101552906082e-08
in O 0 3.035117970284773e-07
HeLa O 0 6.587770621990785e-05
cells O 0 1.0640906111802906e-05
. O 0 1.2808723113266751e-05

Furthermore O 0 1.6960431821644306e-05
, O 0 5.925556365582452e-07
at O 0 4.734197034395038e-07
4 O 0 2.9935620204923907e-07
degrees O 0 5.380948664424068e-07
C O 0 4.97746123073739e-06
, O 0 4.863545655098278e-08
the O 0 4.466975056516276e-08
added O 0 3.70752530898244e-07
soluble O 0 4.2714026449175435e-07
complex O 0 1.8947045532513584e-07
of O 0 3.4186936659352796e-07
HFE O 0 0.016204142943024635
/ O 0 4.321440064813942e-05
beta2m O 0 2.2927593818167225e-05
inhibited O 0 1.2975382333024754e-06
binding O 0 4.3038980379606073e-07
of O 0 2.5303174311375187e-07
transferrin O 0 5.072443400422344e-06
to O 0 3.0014291496627266e-07
HeLa O 0 3.8927879359107465e-05
cell O 0 4.686675310949795e-06
TfR O 0 7.86057353252545e-06
in O 0 6.225317150665433e-08
a O 0 1.328735095285083e-07
concentration O 0 4.4066691771149635e-06
- O 0 2.6925763449980877e-06
dependent O 0 9.113563237406197e-07
manner O 0 2.1535081032197922e-05
. O 0 2.6924481062451378e-05

Scatchard O 0 0.00012650051212403923
plots O 0 3.1523647976428038e-06
of O 0 2.840628781086707e-07
these O 0 3.317257579737998e-08
data O 0 5.067348851639508e-08
indicate O 0 5.62216477817401e-08
that O 0 1.9187611499660306e-08
the O 0 1.1712344161196597e-07
added O 0 1.3468364841173752e-06
heterodimer O 0 3.7387389966170304e-06
substantially O 0 2.443227913317969e-07
reduced O 0 9.376874032795968e-08
the O 0 3.179872365421943e-08
affinity O 0 1.0544473383333752e-07
of O 0 5.772618578703259e-07
TfR O 0 3.0774543120060116e-05
for O 0 1.7608737152841059e-06
transferrin O 0 0.0001383011694997549
. O 0 1.7692816982162185e-05

These O 0 1.7326664192296448e-06
results O 0 2.6365219127910677e-06
establish O 0 9.085766805583262e-07
a O 0 2.142890167533551e-07
molecular O 0 1.6378952523155021e-06
link O 0 9.244826628673763e-07
between O 0 7.207141266007966e-07
HFE O 0 0.4374609589576721
and O 0 3.223166515908815e-07
a O 0 1.5065505465372553e-07
key O 0 1.0592191301839193e-06
protein O 0 2.877250437904877e-07
involved O 0 1.3308986979154724e-07
in O 0 2.5421829974447974e-08
iron O 0 2.453027991577983e-05
transport O 0 3.98279371438548e-06
, O 0 7.038617866328423e-08
the O 0 6.99987268149016e-08
TfR O 0 2.1681904399883933e-05
, O 0 1.6489693166477082e-08
and O 0 1.2752409794813957e-08
raise O 0 1.4360937328206091e-08
the O 0 9.223013464065843e-09
possibility O 0 7.785988742625705e-08
that O 0 3.6091534205695552e-09
alterations O 0 9.628543296003045e-08
in O 0 3.46150730301531e-09
this O 0 4.733079705943055e-09
regulatory O 0 6.056914259033874e-08
mechanism O 0 2.973579853460251e-07
may O 0 1.4478099608083994e-08
play O 0 8.60562323623526e-08
a O 0 1.3418381961116665e-08
role O 0 3.465446241079917e-08
in O 0 1.0333462086009604e-08
the O 0 1.4411651250156865e-07
pathogenesis O 1 0.9920507073402405
of O 1 0.5609581470489502
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0016071053687483072
. O 0 0.00010626458242768422

Genomic O 0 1.2671469448832795e-05
organization O 0 1.484080939917476e-06
of O 0 1.6199854826481896e-06
the O 0 3.5776663480646675e-06
UBE3A O 0 0.08327506482601166
/ O 0 0.055425651371479034
E6 O 1 0.9459803104400635
- O 0 8.316023013321683e-05
AP O 0 5.3934858442517e-05
gene O 0 9.965211802409613e-07
and O 0 7.529674235229322e-07
related O 0 1.4705510693602264e-05
pseudogenes O 0 0.00021812701015733182
. O 0 5.0938138883793727e-05

The O 0 3.1497351301368326e-05
UBE3A O 0 0.0007335245609283447
gene O 0 4.916944362776121e-06
encodes O 0 3.0842954856780125e-06
the O 0 1.7861846117739333e-06
E6 O 0 0.0009297546930611134
- O 0 0.00011776795145124197
AP O 0 0.002108865650370717
ubiquitin O 0 0.00023254954430740327
- O 0 1.323956712440122e-05
protein O 0 9.339406119579508e-07
ligase O 0 8.268686997325858e-07
and O 0 6.606119029584079e-08
has O 0 2.4543668430965226e-08
recently O 0 4.606074099910984e-08
been O 0 7.384147071576308e-09
shown O 0 6.025500987050236e-09
to O 0 6.549682574075177e-09
be O 0 8.31867623674043e-08
mutated O 0 1.0407664376543835e-05
in O 0 3.397342879907228e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 8.808576239971444e-05
who O 0 5.324181984178722e-07
lack O 0 2.2656186047242954e-05
15q11 O 0 0.0015187596436589956
- O 0 3.359634501975961e-05
q13 O 0 1.7466090866946615e-05
deletions O 0 4.131421064812457e-06
or O 0 7.059039717205451e-07
chromosome O 0 5.263084403850371e-06
15 O 0 5.591030458163004e-06
paternal O 0 5.0248694606125355e-05
uniparental B-Disease 1 0.6894298195838928
disomy I-Disease 0 0.34716102480888367
. O 0 0.0004528378776740283

Previous O 0 7.732935773674399e-05
UBE3A O 0 0.0006071780226193368
cDNA O 0 6.915247467986774e-06
analysis O 0 4.541038265415409e-07
has O 0 6.745013791942256e-08
shown O 0 6.474737546113829e-08
a O 0 1.157083673319903e-07
coding O 0 6.061190447326226e-07
region O 0 2.1683257500626496e-07
of O 0 3.3356607787027315e-07
approximately O 0 7.848879590710567e-07
2 O 0 9.966390280169435e-06
. O 0 8.433770744886715e-06

6 O 0 0.0001784619380487129
kb O 0 0.0002651082177180797
and O 0 9.339780149275612e-07
a O 0 5.29936528437247e-07
3 O 0 2.4720259261812316e-06
- O 0 1.6895249927983969e-06
untranslated O 0 1.4724973880220205e-05
region O 0 4.620742970473657e-07
( O 0 3.1537970812678395e-07
UTR O 0 4.594971323967911e-05
) O 0 1.393764677004583e-07
of O 0 2.337783087114076e-07
< O 0 6.284518349275459e-06
50 O 0 5.823633841828268e-07
bp O 0 2.4739670152484905e-06
, O 0 1.06341701666679e-07
whereas O 0 2.721737075717101e-07
Northern O 0 4.113860256893531e-07
analysis O 0 1.750151028545588e-07
has O 0 3.8454594175618695e-08
indicated O 0 1.319619968853658e-07
mRNA O 0 1.895609926805264e-07
sizes O 0 1.396730624492193e-07
of O 0 1.3249719188479503e-07
5 O 0 1.726906134535966e-06
- O 0 2.9188581720518414e-06
8 O 0 1.258127849723678e-05
kb O 0 0.0004141248355153948
. O 0 2.3546617740066722e-05

We O 0 2.057393658105866e-06
have O 0 8.878033241899175e-08
analyzed O 0 1.634757325064129e-07
additional O 0 6.873916191807439e-08
cDNA O 0 2.4055717062765325e-07
clones O 0 1.5927861340969685e-07
and O 0 1.7147680608786686e-08
provide O 0 2.06870858221464e-08
evidence O 0 3.384614188917112e-08
for O 0 1.7705609423046553e-08
an O 0 1.743872424242454e-08
additional O 0 2.758125106083753e-07
0 O 0 5.373715794121381e-06
. O 0 5.783959295513341e-06

5 O 0 5.338176561053842e-05
kb O 0 0.00012707756832242012
of O 0 2.9279801765369484e-06
5 O 0 7.137399734347127e-06
- O 0 3.2946506962616695e-06
UTR O 0 5.263716229819693e-05
and O 0 3.6469450037657225e-07
> O 0 3.0474059258267516e-06
2 O 0 2.1080679744045483e-06
kb O 0 1.040169081534259e-05
of O 0 5.529259965442179e-07
3 O 0 1.0956204278045334e-05
- O 0 1.859603071352467e-05
UTR O 0 0.0010670130141079426
. O 0 3.0523675377480686e-05

We O 0 1.4162360457703471e-06
have O 0 7.510598010185277e-08
established O 0 1.6980818884348992e-07
the O 0 4.4868109227991226e-08
genomic O 0 2.2973638635903626e-07
organization O 0 8.651540639448285e-08
of O 0 3.5631978789751884e-07
UBE3A O 0 9.74588401732035e-05
and O 0 3.289283938556764e-07
the O 0 2.8079466574126855e-07
sequence O 0 3.8278531633295643e-07
of O 0 2.0498575850069756e-06
intron O 0 9.772686462383717e-05
- O 0 0.00014008526341058314
exon O 0 5.43978858331684e-05
borders O 0 7.567846296296921e-06
. O 0 6.87553983880207e-05

We O 0 3.1985152872948674e-06
have O 0 3.740807130725443e-07
also O 0 2.6252436668983137e-07
mapped O 0 6.589218060071289e-07
two O 0 1.7744547164966207e-07
highly O 0 1.1848840131278848e-06
homologous O 0 1.2500316870500683e-06
processed O 0 9.251697292711469e-07
pseudogenes O 0 4.176152287982404e-06
, O 0 4.918159106637177e-07
UBE3AP1 O 0 0.0003435458638705313
and O 0 7.97026132204337e-07
UBE3AP2 O 0 0.0009544515633024275
, O 0 6.009251762861822e-08
to O 0 7.339971297426473e-09
chromosomes O 0 1.7920537942472947e-08
2 O 0 5.6407465365282405e-08
and O 0 1.4067977005538523e-08
21 O 0 2.064107889054867e-07
, O 0 1.7236182259239285e-08
respectively O 0 7.414451630438634e-08
, O 0 1.2177605590579788e-08
and O 0 9.509686371700354e-09
determined O 0 4.789112040270993e-08
their O 0 2.4871898318679087e-08
genomic O 0 6.588263090634427e-07
organization O 0 1.6206405462071416e-06
. O 0 1.236152820638381e-05

These O 0 4.808809990208829e-07
results O 0 2.9357684638853243e-07
will O 0 1.7365138660352386e-08
form O 0 1.2617284994576039e-08
the O 0 5.28760990547994e-09
basis O 0 9.802352707311002e-09
for O 0 2.0532822109231574e-09
studies O 0 3.1490823282354086e-09
of O 0 1.0256488991444712e-08
mutation O 0 7.218299202804701e-08
and O 0 1.8043431282421807e-07
imprinting O 0 7.0434107328765094e-06
of O 0 9.835438504524063e-06
UBE3A O 1 0.6587837934494019
. O 0 0.0001022530414047651

Mutation O 0 6.793213833589107e-05
spectrum O 0 7.97214888734743e-05
and O 0 4.551523034024285e-06
genotype O 0 0.00010478370677446947
- O 0 7.18435476301238e-05
phenotype O 0 1.8363756680628285e-05
analyses O 0 8.306561767312814e-07
in O 0 7.792613132551196e-07
Cowden B-Disease 1 0.9999370574951172
disease I-Disease 1 0.7382346391677856
and O 0 7.666925375815481e-05
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.627041223808192e-05
two O 0 5.5669184803264216e-05
hamartoma B-Disease 1 0.9999978542327881
syndromes I-Disease 1 0.9123055934906006
with O 0 0.00012434755626600236
germline O 1 0.9999947547912598
PTEN O 1 0.9998867511749268
mutation O 0 0.0002909214817918837
. O 0 7.936241308925673e-05

The O 0 7.319877477129921e-05
tumour B-Disease 1 0.9999988079071045
suppressor O 0 0.0013475315645337105
gene O 0 1.2353209058346692e-05
PTEN O 0 0.0006296797073446214
, O 0 6.56282793443097e-07
which O 0 2.0632577957258036e-07
maps O 0 7.473557275261555e-07
to O 0 1.0981611922034062e-06
10q23 O 0 0.0002198217116529122
. O 0 6.548356031998992e-05

3 O 0 2.4718452550587244e-05
and O 0 1.170897689917183e-06
encodes O 0 1.5114823099793284e-06
a O 0 3.3645329722276074e-07
403 O 0 7.361003326877835e-07
amino O 0 1.5119494491955265e-06
acid O 0 1.1636740282483515e-06
dual O 0 8.510543011652771e-06
specificity O 0 2.0771536583197303e-05
phosphatase O 0 0.06839792430400848
( O 0 8.553109296371986e-07
protein O 0 9.532405442769232e-07
tyrosine O 0 2.7613359634415247e-06
phosphatase O 0 7.844203537388239e-06
; O 0 5.33643778055648e-08
PTPase O 0 1.426791277481243e-05
) O 0 3.866161790710976e-08
, O 0 1.9416676266814648e-08
was O 0 8.707795018381148e-08
shown O 0 2.349498728904109e-08
recently O 0 2.510089203155985e-08
to O 0 6.6443925916814806e-09
play O 0 1.2860084552812623e-07
a O 0 4.6976285972277765e-08
broad O 0 6.236946319404524e-07
role O 0 8.146434424816107e-07
in O 0 3.173117306687345e-07
human O 0 4.258896751707653e-06
malignancy B-Disease 0 0.0006788716418668628
. O 0 2.8119069611420855e-05

Somatic O 0 0.003179639345034957
PTEN O 0 0.0013434335123747587
deletions O 0 9.573817806085572e-06
and O 0 2.460618020450056e-07
mutations O 0 3.2786107340143644e-07
were O 0 1.1911670583231171e-07
observed O 0 2.352927879201161e-07
in O 0 9.141368195741961e-08
sporadic B-Disease 0 0.02020110748708248
breast I-Disease 1 0.999996542930603
, I-Disease 1 0.7557389140129089
brain I-Disease 1 1.0
, I-Disease 1 0.856688916683197
prostate I-Disease 1 1.0
and I-Disease 1 0.9998248219490051
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9990013241767883
cell O 0 0.00990747008472681
lines O 0 1.1195908200534177e-06
and O 0 7.861946471621195e-08
in O 0 2.1876191524938804e-08
several O 0 3.3088909390244226e-08
primary O 0 2.543993559811497e-06
tumours B-Disease 1 0.9999998807907104
such O 0 4.632930199477414e-07
as O 0 8.211555541492999e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999998807907104
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9996579885482788

In O 0 1.2223958947288338e-06
addition O 0 1.6318691677952302e-06
, O 0 1.402042357767641e-06
PTEN O 0 0.007455871440470219
was O 0 1.8844306168830371e-06
identified O 0 1.5208100023755833e-07
as O 0 3.4361310241592946e-08
the O 0 5.5113087427116625e-08
susceptibility O 0 6.340428626572248e-07
gene O 0 1.3870736381704774e-07
for O 0 1.2687904415997764e-07
two O 0 1.579929084982723e-05
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9998621940612793
( O 0 4.996065399609506e-06
CD B-Disease 0 0.00017127323371823877
; O 0 1.3267436997921322e-06
MIM O 0 0.00040931024705059826
158350 O 0 1.776922908902634e-05
) O 0 2.665321687800315e-07
and O 0 4.870196903539181e-07
Bannayan B-Disease 0 0.0009205806418322027
- I-Disease 0 0.00031799834687262774
Zonana I-Disease 1 0.9976022839546204
( I-Disease 0 2.991363999171881e-06
BZS I-Disease 0 0.0006658002967014909
) I-Disease 0 1.085915982912411e-06
or I-Disease 0 1.5431734254889307e-06
Ruvalcaba I-Disease 0 0.0010466299718245864
- I-Disease 0 0.00011203329631825909
Riley I-Disease 0 0.002267411444336176
- I-Disease 1 0.763953685760498
Smith I-Disease 1 0.9998729228973389
syndrome I-Disease 1 1.0
( O 0 0.19001685082912445
MIM O 1 0.9999935626983643
153480 O 0 0.05343962833285332
) O 0 1.6548869098187424e-05
. O 0 4.499178976402618e-05

Constitutive O 0 9.654146560933441e-05
DNA O 0 5.216338195168646e-06
from O 0 3.8789701761743345e-07
37 O 0 2.7259918624622514e-06
CD B-Disease 0 6.663026852038456e-06
families O 0 1.5313118240101176e-07
and O 0 3.249434428198583e-07
seven O 0 3.1556073736282997e-06
BZS B-Disease 0 0.00031629574368707836
families O 0 2.3375758928523283e-07
was O 0 3.105232508460176e-06
screened O 0 2.8089614261261886e-06
for O 0 2.374720679654274e-06
germline O 0 0.0051341913640499115
PTEN O 0 0.11822795122861862
mutations O 0 0.0002988480555359274
. O 0 0.00011771629215218127

PTEN O 0 0.001123821479268372
mutations O 0 5.739337666454958e-06
were O 0 5.68444477266894e-07
identified O 0 2.182353853186214e-07
in O 0 3.143904692137767e-08
30 O 0 1.8300188742159662e-07
of O 0 1.70897308748863e-07
37 O 0 1.921236844282248e-06
( O 0 1.4671655890197144e-07
81 O 0 5.779988896392751e-07
% O 0 5.8143662329257495e-08
) O 0 3.9661653516986917e-08
CD B-Disease 0 1.0387567499492434e-06
families O 0 8.61733084889238e-09
, O 0 1.4722178143244946e-08
including O 0 2.4686158894837718e-08
missense O 0 1.0669749599401257e-06
and O 0 7.616849018177163e-08
nonsense O 0 2.458852122799726e-06
point O 0 3.556781109637086e-07
mutations O 0 1.4959287852889247e-07
, O 0 5.8629762378359374e-08
deletions O 0 7.577187943752506e-07
, O 0 1.9846885379593004e-07
insertions O 0 2.3994664388737874e-06
, O 0 4.016647210391966e-07
a O 0 6.324291916826041e-07
deletion O 0 1.0185284736508038e-05
/ O 0 2.7058847990701906e-05
insertion O 0 5.688789769919822e-06
and O 0 2.383396804361837e-06
splice O 0 5.419661465566605e-05
site O 0 1.0423478670418262e-05
mutations O 0 4.281878864276223e-05
. O 0 5.313032670528628e-05

These O 0 4.6719614488210937e-07
mutations O 0 6.73813417506608e-07
were O 0 8.985580279841088e-08
scattered O 0 1.279719867852691e-07
over O 0 1.3183520763959677e-07
the O 0 9.233278319698002e-08
entire O 0 2.592628050024359e-07
length O 0 8.757663749747735e-08
of O 0 1.6110419664983056e-07
PTEN O 0 0.00010485306847840548
, O 0 4.03156725781173e-08
with O 0 1.16242970804592e-08
the O 0 2.3474560961744828e-08
exception O 0 3.2841928288007693e-08
of O 0 2.4977580892482365e-08
the O 0 2.226544815187026e-08
first O 0 3.899629064108012e-08
, O 0 3.7393160567944506e-08
fourth O 0 4.936175059810921e-07
and O 0 1.9307113063860015e-07
last O 0 2.2668089059152408e-06
exons O 0 2.8491109333117492e-05
. O 0 8.676543075125664e-06

A O 0 3.9844875573180616e-05
hot O 0 4.040417115902528e-05
spot O 0 1.9038447135244496e-05
for O 0 7.877089842622809e-07
PTEN O 0 4.429441105457954e-05
mutation O 0 3.8614493291788676e-07
in O 0 7.933891765787848e-08
CD B-Disease 0 3.120902192677022e-06
was O 0 4.030383990993869e-07
identified O 0 1.255983335113342e-07
in O 0 4.694046040754074e-08
exon O 0 7.626522346981801e-07
5 O 0 2.1714609488299175e-07
that O 0 1.4097442324612075e-08
contains O 0 3.7300484478919316e-08
the O 0 7.90095597835716e-08
PTPase O 0 6.04165416007163e-06
core O 0 1.7970361341212993e-06
motif O 0 2.1727161936269113e-07
, O 0 9.599090411427369e-09
with O 0 5.767399446909849e-09
13 O 0 5.48316663184778e-08
of O 0 3.140153381764321e-08
30 O 0 1.1824914025737598e-07
( O 0 1.8450082350796038e-08
43 O 0 1.1680019440518663e-07
% O 0 2.158860468171042e-08
) O 0 2.3946004290564815e-08
CD B-Disease 0 1.4600682334275916e-06
mutations O 0 3.2004024319576274e-07
identified O 0 1.649444953955026e-07
in O 0 9.800300659890127e-08
this O 0 5.025536893299432e-07
exon O 0 4.420242476044223e-05
. O 0 2.0700206732726656e-05

Seven O 0 1.0129371730727144e-05
of O 0 1.3329123476069071e-06
30 O 0 1.6439059891126817e-06
( O 0 2.1779108294595062e-07
23 O 0 3.8278787428680516e-07
% O 0 2.4900426609519855e-08
) O 0 1.494857215789125e-08
were O 0 2.091944573123783e-08
within O 0 3.627360456448514e-08
the O 0 2.9419558345011865e-08
core O 0 1.0510914307815256e-06
motif O 0 1.310040147473046e-07
, O 0 9.415797919132274e-09
the O 0 1.0380576398461017e-08
majority O 0 1.304106245214598e-08
( O 0 2.4248382857194883e-08
five O 0 3.0816028839808496e-08
of O 0 3.3373243724099666e-08
seven O 0 7.40246832720004e-08
) O 0 4.387555652130004e-09
of O 0 8.628399328358682e-09
which O 0 7.955785363833456e-09
were O 0 7.878068686295592e-08
missense O 0 2.4366945581277832e-06
mutations O 0 5.370761755330022e-07
, O 0 8.491749525774139e-08
possibly O 0 4.89405920234276e-07
pointing O 0 4.505437232182885e-07
to O 0 2.3345251065620687e-08
the O 0 6.086712289743446e-08
functional O 0 2.8692630849036505e-07
significance O 0 2.3352117750619072e-07
of O 0 1.7471609226049623e-07
this O 0 7.610212549025164e-08
region O 0 2.020866077145911e-06
. O 0 1.2339150089246687e-05

Germline O 0 0.03077075257897377
PTEN O 0 0.000991051085293293
mutations O 0 5.107684955873992e-06
were O 0 3.793105349814141e-07
identified O 0 2.708148940655519e-07
in O 0 3.335555476269292e-08
four O 0 8.882928170805826e-08
of O 0 2.2537561505941994e-07
seven O 0 2.024502236963599e-06
( O 0 2.6493128757465456e-07
57 O 0 1.900040274449566e-06
% O 0 3.813358659954247e-07
) O 0 1.0646596138030873e-06
BZS B-Disease 0 0.000455521687399596
families O 0 1.3590539538199664e-06
studied O 0 5.6698601838434115e-05
. O 0 4.132514732191339e-05

Interestingly O 0 5.3024741646368057e-05
, O 0 7.43881457765383e-07
none O 0 4.811722646991257e-07
of O 0 7.468770490959287e-08
these O 0 1.543338790099824e-08
mutations O 0 1.2242621494351624e-07
was O 0 1.902528339314813e-07
observed O 0 1.3504811136044736e-07
in O 0 5.20406757686942e-08
the O 0 7.466718443538412e-07
PTPase O 0 0.00048182878526858985
core O 0 0.0002618313592392951
motif O 0 5.354910535970703e-05
. O 0 1.7468008081777953e-05

It O 0 8.502548780597863e-07
is O 0 9.531989775268812e-08
also O 0 2.727499470722705e-08
worthy O 0 2.2598578652832657e-07
of O 0 4.3763083823478155e-08
note O 0 7.749734010076281e-08
that O 0 5.560923277414531e-09
a O 0 2.0706746539644882e-08
single O 0 2.9043441429621453e-08
nonsense O 0 5.532973545996356e-07
point O 0 1.835235821090464e-07
mutation O 0 7.915587474371932e-08
, O 0 8.401995188478395e-08
R233X O 0 2.4623016088298755e-06
, O 0 7.496029041931251e-08
was O 0 1.2131036442042387e-07
observed O 0 5.0341899537897916e-08
in O 0 8.192016842656358e-09
the O 0 3.562463390949233e-08
germline O 0 2.424464810246718e-06
DNA O 0 1.3876478988095187e-07
from O 0 1.7289323750446783e-08
two O 0 6.095076798828813e-08
unrelated O 0 3.4785992397701193e-07
CD B-Disease 0 3.7341171719162958e-06
families O 0 8.321295297264442e-08
and O 0 4.0890930108616885e-07
one O 0 1.3477140328177484e-06
BZS B-Disease 0 0.0019701181445270777
family O 0 7.321556495298864e-06
. O 0 3.747306618606672e-05

Genotype O 0 0.0008936520898714662
- O 0 6.298450898611918e-05
phenotype O 0 5.8920895753544755e-06
studies O 0 1.8940541224310437e-07
were O 0 6.02594028009662e-08
not O 0 9.797979316772398e-09
performed O 0 3.356059607995121e-08
on O 0 4.37493170579728e-08
this O 0 1.4005835602404204e-08
small O 0 3.2447054820750054e-08
group O 0 1.3818004163113073e-07
of O 0 2.04047205443203e-06
BZS B-Disease 0 0.03148382902145386
families O 0 5.2437408157857135e-06
. O 0 3.480174927972257e-05

However O 0 1.972930840565823e-05
, O 0 4.8784199861984234e-06
genotype O 0 6.40426660538651e-05
- O 0 1.1312582500977442e-05
phenotype O 0 5.947488716628868e-06
analysis O 0 5.009974870517908e-07
inthe O 0 4.732418801722815e-06
group O 0 6.762494564327426e-08
of O 0 2.055301990822045e-07
CD B-Disease 0 1.1717963388946373e-05
families O 0 1.9266604311951596e-08
revealed O 0 1.455351110735137e-07
two O 0 1.4511440937781117e-08
possible O 0 5.2263093408555505e-08
associations O 0 2.2652040243542615e-08
worthy O 0 1.7460581602790626e-07
of O 0 8.01352442181269e-08
follow O 0 1.0994212118475843e-07
- O 0 2.897318154282402e-07
up O 0 7.688414171980185e-08
in O 0 3.9587433775523095e-08
independent O 0 3.3435244972679357e-07
analyses O 0 4.254898158251308e-06
. O 0 1.9637818695628084e-05

The O 0 3.065951659664279e-06
first O 0 1.4022508594280225e-06
was O 0 1.813688413676573e-06
an O 0 6.818289932652988e-08
association O 0 2.102080429722264e-07
noted O 0 1.291167421868522e-07
in O 0 2.7247022416077016e-08
the O 0 5.23800522955753e-08
group O 0 5.42723022078917e-08
of O 0 3.415412095364445e-07
CD B-Disease 0 0.00020823838713113219
families O 0 2.922931514603988e-07
with O 0 2.49116728809895e-05
breast B-Disease 1 0.9999972581863403
disease I-Disease 1 0.9998177886009216
. O 0 0.00039769752766005695

A O 0 5.0966496019100305e-06
correlation O 0 1.2383277407934656e-06
was O 0 4.7079979026420915e-07
observed O 0 7.845678595685968e-08
between O 0 3.018911343133368e-08
the O 0 2.396121701053744e-08
presence O 0 1.3459245451485913e-07
/ O 0 1.8137749293600791e-06
absence O 0 6.690858072033734e-07
of O 0 3.722011001627834e-07
a O 0 4.958009753863735e-07
PTEN O 0 4.786022691405378e-05
mutation O 0 1.236652593661347e-07
and O 0 1.696882989676851e-08
the O 0 3.216864641331085e-08
type O 0 4.852597612625686e-07
of O 0 1.2097525541321374e-06
breast O 0 0.00010865170042961836
involvement O 0 3.7655474443454295e-05
( O 0 1.6763690382504137e-06
unaffected O 0 1.501538008596981e-05
versus O 0 0.010955143719911575
benign O 0 0.3619096279144287
versus O 1 0.7494595050811768
malignant O 1 0.9681613445281982
) O 0 9.355271686217748e-06
. O 0 2.6572697606752627e-05

Specifically O 0 2.854889089576318e-06
and O 0 2.7136945845995797e-07
more O 0 4.5545395011004075e-08
directly O 0 3.2471756838958754e-08
, O 0 4.302900080688232e-08
an O 0 3.6532242120301817e-08
association O 0 2.1266197336444748e-07
was O 0 5.128474640514469e-07
also O 0 2.1085490686800767e-08
observed O 0 2.933041720609708e-08
between O 0 1.159559825936185e-08
the O 0 1.0374855641259728e-08
presence O 0 1.386678949444331e-08
of O 0 1.0473436873326136e-07
a O 0 8.448458288512484e-07
PTEN O 1 0.8650906682014465
mutation O 0 0.0038284023758023977
and O 1 0.6093358397483826
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999990463256836
. O 0 0.01387555617839098

Secondly O 0 7.98038745415397e-05
, O 0 8.281203349724819e-07
there O 0 9.777185994153115e-08
appeared O 0 2.38838396171559e-07
to O 0 2.770250517869499e-08
be O 0 9.295779079820932e-08
an O 0 1.7506233973563212e-07
interdependent O 0 0.00012542503827717155
association O 0 4.1228466329812363e-07
between O 0 5.495598998095375e-07
mutations O 0 3.707885980475112e-07
upstream O 0 1.6248982603883633e-07
and O 0 2.2050752335189827e-08
within O 0 7.424739578709705e-08
the O 0 1.5194689240161097e-07
PTPase O 0 2.314691482752096e-05
core O 0 5.779262210126035e-06
motif O 0 5.267591518531844e-07
, O 0 3.38640937513901e-08
the O 0 4.3333823640523406e-08
core O 0 6.793663942517014e-07
motif O 0 7.493370191014037e-08
containing O 0 1.9316463095719882e-08
the O 0 5.4592872444914065e-09
majority O 0 7.081098818417786e-09
of O 0 4.3788048742499086e-08
missense O 0 7.038751164145651e-07
mutations O 0 1.2205863697545283e-07
, O 0 2.0370327646901387e-08
and O 0 1.950866490574299e-08
the O 0 3.820004579324632e-08
involvement O 0 2.0017144208850368e-07
of O 0 8.799187867225555e-08
all O 0 4.31516262722198e-08
major O 0 2.4948377586042625e-07
organ O 0 4.2807761928997934e-05
systems O 0 0.0001994640042539686
( O 0 7.400724371109391e-07
central O 0 3.968238161178306e-06
nervous O 0 1.0219239811704028e-05
system O 0 5.698882887372747e-05
, O 0 8.583621092839167e-05
thyroid O 1 1.0
, O 1 0.5057833194732666
breast O 1 0.9999998807907104
, O 1 0.9934954643249512
skin O 1 1.0
and O 1 0.9999985694885254
gastrointestinal O 1 1.0
tract O 1 0.9978315234184265
) O 0 2.948614928754978e-05
. O 0 6.706198473693803e-05

However O 0 4.398209057399072e-06
, O 0 3.455935484453221e-07
these O 0 3.489662958600093e-08
observations O 0 1.2361678614070115e-07
would O 0 9.560827685106688e-09
need O 0 1.1549576406366668e-08
to O 0 4.3307610830822796e-09
be O 0 1.4438829687435373e-08
confirmed O 0 4.77880099936101e-08
by O 0 9.231566622247556e-09
studying O 0 5.114149459473083e-08
a O 0 1.6164154459374913e-08
larger O 0 4.87991833608703e-08
number O 0 4.052993318737208e-08
of O 0 3.838739814909786e-07
CD B-Disease 0 2.4270479116239585e-05
families O 0 1.730089024931658e-06
. O 0 1.1293868737993762e-05

Molecular O 1 0.9988914132118225
defects O 1 0.9789537787437439
leading O 0 2.5645189452916384e-05
to O 0 2.363984776820871e-07
human O 0 1.1200949074918753e-06
complement B-Disease 0 3.176666723447852e-05
component I-Disease 1 0.999998927116394
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.2519078040895693e-07
an O 0 2.9272181123474184e-08
African O 0 1.4762015325686662e-06
- O 0 5.880951903236564e-07
American O 0 2.449326359510451e-07
family O 0 4.128209241116565e-07
. O 0 5.263149432721548e-06

Complement B-Disease 0 0.0010990165174007416
component I-Disease 1 0.9999911785125732
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.00012049580254824832
C6D B-Disease 1 0.9999867677688599
) O 0 1.0293900913893594e-06
was O 0 3.100332378380699e-06
diagnosed O 0 1.931154429257731e-06
in O 0 3.237225953967027e-08
a O 0 8.062184519985749e-08
16 O 0 5.35127867351548e-07
- O 0 1.8889815578404523e-07
year O 0 3.267447823418479e-08
- O 0 1.0021805962878716e-07
old O 0 3.0761478342355986e-07
African O 0 1.5904743122518994e-06
- O 0 5.987228632875485e-07
American O 0 1.9167973164258e-07
male O 0 8.571256330469623e-06
with O 0 0.00026657036505639553
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.008354351855814457

The O 0 7.992144674062729e-06
patients O 0 2.8357749215501826e-06
father O 0 1.4757595181436045e-06
and O 0 5.241133749223081e-07
two O 0 8.51010099722771e-07
brothers O 0 1.0980336810462177e-05
also O 0 2.817095889895427e-07
had O 0 1.1091548230979242e-06
C6D B-Disease 1 0.9769192337989807
, O 0 1.2038056240726291e-07
but O 0 4.683403886929227e-08
gave O 0 1.3639954943300836e-07
no O 0 9.475723317109441e-08
history O 0 3.3074306315938884e-07
of O 0 3.835186817013891e-06
meningitis B-Disease 1 1.0
or O 0 1.1973921573371626e-05
other O 0 3.3126530070148874e-06
neisserial B-Disease 1 0.8921747803688049
infection I-Disease 0 0.012958730570971966
. O 0 3.8948379369685426e-05

By O 0 2.6211935164610622e-06
using O 0 2.681864316400606e-06
exon O 0 8.911230906960554e-06
- O 0 1.1867206239912775e-06
specific O 0 1.3136758525433834e-07
polymerase O 0 1.5271392612703494e-06
chain O 0 4.486794296099106e-07
reaction O 0 3.9865031453700794e-07
( O 0 2.0744862183619261e-07
PCR O 0 4.621788320946507e-06
) O 0 1.623405125883437e-07
/ O 0 1.4544701798513415e-06
single O 0 3.3668374044282245e-07
- O 0 9.77080730990565e-07
strand O 0 3.3893530826389906e-07
conformation O 0 1.4388291447176016e-07
polymorphism O 0 1.4572857764960645e-07
as O 0 6.4429763746431945e-09
a O 0 1.3750089067343652e-08
screening O 0 1.7344847336175917e-08
step O 0 5.5799340259454766e-08
and O 0 1.8010315017136236e-08
nucleotide O 0 6.859836787498352e-08
sequencing O 0 2.2224758922106957e-08
of O 0 1.121370196699445e-08
target O 0 5.759970989061003e-08
exons O 0 4.2515941345300234e-07
, O 0 1.381288594615171e-08
we O 0 1.0329186395097167e-08
determined O 0 3.3083228601071824e-08
that O 0 7.57103180148988e-09
the O 0 7.450956474031045e-08
proband O 0 1.2380382031551562e-05
was O 0 4.1529324334987905e-07
a O 0 1.2743807076276426e-07
compound O 0 6.100660243646416e-07
heterozygote O 0 3.7298534607543843e-06
for O 0 2.595604087218817e-07
two O 0 1.0613648555590771e-06
C6 O 1 0.9673864245414734
gene O 0 7.462856046913657e-06
mutations O 0 1.3380577001953498e-05
. O 0 1.7120597476605326e-05

The O 0 4.346355581219541e-06
first O 0 1.7181060911752866e-06
, O 0 4.2281746459593705e-07
1195delC O 0 5.295215487421956e-06
located O 0 1.2302358243232447e-07
in O 0 3.038912055330911e-08
exon O 0 4.5933705905554234e-07
7 O 0 4.3740391220126185e-07
, O 0 3.1504779229862834e-08
is O 0 1.0613619316757195e-08
a O 0 1.818768424755035e-08
novel O 0 3.397563119733604e-08
mutation O 0 4.685708887564033e-08
, O 0 1.714974118272039e-08
while O 0 2.0984344928365317e-08
the O 0 3.1829301860852866e-08
second O 0 1.7101289984111645e-07
, O 0 8.891810665545563e-08
1936delG O 0 1.53707492245303e-06
in O 0 4.424981980832854e-08
exon O 0 4.113911415970506e-07
12 O 0 2.815758364249632e-07
, O 0 3.94082846355559e-08
has O 0 1.8009764346516022e-08
been O 0 2.8811049546106915e-08
described O 0 6.358072823786642e-08
before O 0 9.482014462491861e-08
to O 0 3.035841444898324e-08
cause O 0 1.0336606237615342e-06
C6D B-Disease 1 0.5677568316459656
in O 0 2.0839941328176792e-07
an O 0 1.0634879998860924e-07
unrelated O 0 1.6059077552199597e-06
African O 0 6.174919690238312e-06
- O 0 3.174574885633774e-06
American O 0 8.236890494117688e-07
individual O 0 2.059892949546338e-06
. O 0 1.9832797988783568e-05

Both O 0 4.225999873597175e-06
mutations O 0 4.050091320095817e-06
result O 0 1.2199666343803983e-06
in O 0 2.4907677698138286e-07
premature O 0 6.307893272605725e-06
termination O 0 1.4752663446415681e-05
codons O 0 1.0967464731947985e-05
and O 0 4.562997219181852e-06
C6 O 1 0.9950809478759766
null O 0 0.00011470104800537229
alleles O 0 4.846085357712582e-05
. O 0 3.9266571548068896e-05

Allele O 0 8.670916577102616e-05
- O 0 2.994600890815491e-06
specific O 0 1.2675204175138788e-07
PCR O 0 1.7250478094865684e-06
indicated O 0 2.1092333213346137e-07
that O 0 1.4667606684781731e-08
the O 0 1.1749688155759941e-07
probands O 0 3.4096698072971776e-05
two O 0 2.8296864229560015e-07
brothers O 0 3.853859652735991e-06
also O 0 1.9891017188911064e-07
inherited O 0 1.2394240229696152e-06
the O 0 1.996703957729551e-07
1195delC O 0 1.7225324882019777e-06
mutation O 0 5.168791261667138e-08
from O 0 8.647247362603139e-09
their O 0 1.3935222753502785e-08
heterozygous O 0 3.512742807743052e-07
mother O 0 5.429342309071217e-08
and O 0 7.734804796655226e-08
the O 0 1.460083183246752e-07
1936delG O 0 2.6448194603290176e-06
mutation O 0 1.0166781549969528e-07
from O 0 1.9844701881766014e-08
their O 0 5.362650412621406e-08
homozygous O 0 2.9434372663672548e-06
father O 0 3.0219155178201618e-06
. O 0 4.455034741113195e-06
. O 0 3.8376718293875456e-05

PAX6 O 1 0.6342073082923889
mutations O 0 0.0013231515185907483
reviewed O 0 0.0005940503324382007
. O 0 0.0002525040472391993

Mutations O 0 2.4433436919935048e-05
in O 0 9.535960430184787e-07
PAX6 O 0 0.014468942768871784
are O 0 1.15560709446072e-07
responsible O 0 7.242487640723994e-07
for O 0 1.0909695191685387e-07
human O 0 9.028775593833416e-07
aniridia B-Disease 1 0.9999998807907104
and O 0 1.9753170477088133e-07
have O 0 2.387235475964644e-08
also O 0 1.4052395691521724e-08
been O 0 1.638032287587521e-08
found O 0 8.669227113955458e-09
in O 0 1.830171925121249e-08
patients O 0 8.216775881919602e-08
with O 0 3.538322346230416e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 0.0006610078271478415
with O 1 0.9999637603759766
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.007638168055564165
with O 0 8.477545634377748e-05
autosomal B-Disease 1 0.9999918937683105
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 3.2821690183482133e-06
and O 0 8.718744197722117e-07
with O 0 4.027869181300048e-06
isolated B-Disease 0 0.060524675995111465
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0023348594550043344

No O 0 8.16222745925188e-06
locus O 0 9.425874850421678e-06
other O 0 1.79551321366489e-07
than O 0 2.2105923846993392e-07
chromosome O 0 1.4092879609961528e-06
11p13 O 0 3.258373226344702e-06
has O 0 8.278962582153326e-08
been O 0 1.9057334554872796e-07
implicated O 0 3.36546145263128e-06
in O 0 3.805805590673117e-07
aniridia B-Disease 1 0.9999998807907104
, O 0 1.7550744360050885e-06
and O 0 1.628683435228595e-06
PAX6 O 1 0.9996790885925293
is O 0 5.754579390782055e-08
clearly O 0 4.816079268721296e-08
the O 0 2.6618383941467982e-08
major O 0 9.07396753291323e-08
, O 0 1.3858751479745024e-08
if O 0 7.910588628590176e-09
not O 0 1.3632341477887167e-08
only O 0 4.724171276393463e-08
, O 0 1.695764382247944e-07
gene O 0 1.249924366675259e-06
responsible O 0 7.590129371237708e-06
. O 0 2.393893555563409e-05

Twenty O 0 0.0001143919289461337
- O 0 1.0122072126250714e-05
eight O 0 8.326953775394941e-07
percent O 0 1.9486320468331542e-07
of O 0 2.1673086791906826e-07
identified O 0 1.035898662848922e-06
PAX6 O 0 0.00010063374065794051
mutations O 0 9.787977433006745e-07
are O 0 1.6638345812225452e-07
C O 0 0.00031785527244210243
- O 0 1.7503676644992083e-05
T O 0 8.81842333910754e-06
changes O 0 1.889113150355115e-07
at O 0 3.916614161880716e-07
CpG O 0 9.893349215417402e-07
dinucleotides O 0 9.91951878859254e-07
, O 0 1.966306228950998e-08
20 O 0 3.5837672385241603e-08
% O 0 4.9674393487464386e-09
are O 0 6.282462550188939e-09
splicing O 0 2.0756635876750806e-07
errors O 0 2.565320187386533e-07
, O 0 1.5650677198664198e-08
and O 0 9.450829452362086e-09
more O 0 4.762465533048044e-09
than O 0 6.6058891690090604e-09
30 O 0 4.600367020657359e-08
% O 0 1.3340980764553478e-08
are O 0 2.3749098687630976e-08
deletion O 0 6.751777732461051e-07
or O 0 2.150813571688559e-07
insertion O 0 3.90826653529075e-06
events O 0 4.010490556538571e-06
. O 0 1.8815300791175105e-05

There O 0 4.148295374761801e-06
is O 0 3.464974440703372e-07
a O 0 3.0991745347819233e-07
noticeably O 0 2.7659455099637853e-06
elevated O 0 1.1166700460307766e-05
level O 0 6.930035283403413e-07
of O 0 8.358374259387347e-08
mutation O 0 6.928383555759865e-08
in O 0 8.633898040955046e-09
the O 0 2.230119200419267e-08
paired O 0 9.478940654616963e-08
domain O 0 4.035421596881861e-08
compared O 0 1.4468438003234496e-08
with O 0 2.9806783707897466e-09
the O 0 1.2759368672732307e-08
rest O 0 4.1123378480278916e-08
of O 0 7.073501961940565e-08
the O 0 2.1899971613947855e-07
gene O 0 1.5745569044156582e-06
. O 0 5.107265678816475e-06

Increased O 0 7.713713785051368e-06
mutation O 0 2.646630946401274e-06
in O 0 1.7997717804973945e-07
the O 0 3.0244504500842595e-07
homeodomain O 0 7.200970230769599e-06
is O 0 6.566246213424165e-08
accounted O 0 8.61943902918938e-08
for O 0 1.5203799108576277e-08
by O 0 5.964694338445042e-08
the O 0 3.079681789586175e-07
hypermutable O 0 7.879384065745398e-05
CpG O 0 5.210418385104276e-05
dinucleotide O 0 9.190103446599096e-05
in O 0 9.966181551135378e-07
codon O 0 2.19017547351541e-05
240 O 0 2.590589429019019e-05
. O 0 2.3658152713323943e-05

Very O 0 4.245445779815782e-06
nearly O 0 4.799019279744243e-07
all O 0 5.426288041121552e-08
mutations O 0 8.771405646257335e-08
appear O 0 7.56817613023486e-08
to O 0 2.229974782608224e-08
cause O 0 3.4149039151998295e-07
loss O 0 1.0623815569488215e-06
of O 0 1.8164044490731612e-07
function O 0 1.4401443593214935e-07
of O 0 5.262198499167425e-08
the O 0 5.472478292745109e-08
mutant O 0 4.436179494859971e-07
allele O 0 4.007494567304093e-07
, O 0 1.3030620138465565e-08
and O 0 7.242650923444671e-09
more O 0 4.051909474611648e-09
than O 0 6.9111707468039185e-09
80 O 0 2.3815143634919878e-08
% O 0 9.503666298371627e-09
of O 0 6.91729198365465e-08
exonic O 0 4.331240234023426e-06
substitutions O 0 5.588475460172049e-07
result O 0 2.3318402497807256e-07
in O 0 1.6101128608170256e-07
nonsense O 0 1.5051708942337427e-05
codons O 0 4.7175668441923335e-05
. O 0 1.1593270755838603e-05

In O 0 1.7784286683308892e-06
a O 0 4.3126038917762344e-07
gene O 0 1.8576997717900667e-07
with O 0 2.3755667655223078e-08
such O 0 5.146078052575831e-08
extraordinarily O 0 1.7579155837665894e-06
high O 0 6.257858444769226e-07
sequence O 0 5.5217462602286105e-08
conservation O 0 8.877893975522966e-09
throughout O 0 2.452549940912263e-09
evolution O 0 3.4978057783519034e-08
, O 0 4.0024126235493895e-09
there O 0 3.309621465774626e-09
are O 0 4.804488806797735e-09
presumed O 0 2.503615803561843e-07
undiscovered O 0 1.8896639630838763e-06
missense O 0 1.4130264389677905e-06
mutations O 0 1.711484856059542e-07
, O 0 2.211270633267759e-08
these O 0 8.431802811514899e-09
are O 0 5.723510554389577e-09
hypothesized O 0 8.229386594393873e-08
to O 0 3.946716731206834e-09
exist O 0 2.299971768593423e-08
in O 0 1.504832525256461e-08
as O 0 5.645632938922063e-08
- O 0 3.139674618068966e-07
yet O 0 2.6380635631539917e-07
unidentified O 0 2.5332610675832257e-06
phenotypes O 0 8.595528015575837e-06
. O 0 1.9815520317933988e-06
. O 0 1.4476780052063987e-05

Genetic O 0 3.7847399653401226e-05
heterogeneity O 0 3.265284249209799e-05
and O 0 1.1021355703633162e-06
penetrance O 0 2.9300357709871605e-05
analysis O 0 5.440381301013986e-07
of O 0 7.434310873577488e-07
the O 0 1.2957922308487468e-06
BRCA1 O 0 8.163780148606747e-05
and O 0 3.5103291793348035e-06
BRCA2 O 0 0.0029066698625683784
genes O 0 7.198388630058616e-06
in O 0 1.0480962373549119e-05
breast B-Disease 1 0.9998711347579956
cancer I-Disease 1 0.6166766881942749
families O 0 3.60401736543281e-06
. O 0 9.304311970481649e-05

The O 0 0.02084694802761078
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.5052766799926758
Consortium O 0 0.0016383999027311802
. O 0 4.871290730079636e-05

The O 0 3.400261221031542e-06
contribution O 0 2.619554379634792e-06
of O 0 3.2919558634603163e-06
BRCA1 O 0 6.243839743547142e-05
and O 0 2.801008804453886e-06
BRCA2 O 0 0.3056996166706085
to O 0 4.867478855885565e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9931637644767761
assessed O 0 6.208684226294281e-06
by O 0 5.083650833626052e-08
linkage O 0 6.920458872627933e-07
and O 0 4.8310294431530565e-08
mutation O 0 1.0757552360018963e-07
analysis O 0 4.451597490628956e-08
in O 0 1.673298655191502e-08
237 O 0 9.936460543258363e-08
families O 0 4.803563768973618e-09
, O 0 8.073245183481959e-09
each O 0 3.3239693220110667e-09
with O 0 7.099829613110842e-09
at O 0 4.226775445204112e-07
least O 0 5.085571075369444e-08
four O 0 4.411279874716456e-08
cases O 0 2.484297745297681e-08
of O 0 5.633638693325338e-07
breast B-Disease 0 0.0018534429837018251
cancer I-Disease 0 1.0779261174320709e-05
, O 0 1.0945544914875427e-07
collected O 0 6.300525257074696e-08
by O 0 7.190705986204193e-08
the O 0 4.085353793925606e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999997615814209
Linkage O 0 0.0025965969543904066
Consortium O 0 0.0002731444837991148
. O 0 2.5606674171285704e-05

Families O 0 1.1645867061815807e-06
were O 0 5.534688511943386e-07
included O 0 1.5384404150609043e-07
without O 0 7.375367516715414e-08
regard O 0 1.0567002561856498e-07
to O 0 1.2192153953094476e-08
the O 0 3.0375787218872574e-08
occurrence O 0 6.348548140522325e-07
of O 0 1.1207594980078284e-05
ovarian B-Disease 1 1.0
or I-Disease 0 0.003686649492010474
other I-Disease 0 3.771592309931293e-05
cancers I-Disease 1 0.9999551773071289
. O 0 9.165458322968334e-05

Overall O 0 0.0033081150613725185
, O 0 0.00011863107647513971
disease O 0 0.2938503623008728
was O 0 7.761694178043399e-06
linked O 0 1.3208405107434373e-06
to O 0 7.172926075327268e-08
BRCA1 O 0 1.3692900893147453e-06
in O 0 2.42151063645224e-08
an O 0 9.821479629579244e-09
estimated O 0 2.859218461992441e-08
52 O 0 1.0879647049932828e-07
% O 0 1.239641811423553e-08
of O 0 3.941385173789058e-08
families O 0 1.221012091434659e-08
, O 0 2.3260936288238554e-08
to O 0 1.6900095545224758e-08
BRCA2 O 0 6.212897005752893e-07
in O 0 2.7311955363984453e-08
32 O 0 1.4339374843075348e-07
% O 0 9.213413143527305e-09
of O 0 2.9792815325890842e-08
families O 0 4.337589398772934e-09
, O 0 9.463221317673742e-09
and O 0 7.321877770749552e-09
to O 0 3.6568683636772903e-09
neither O 0 2.2987876491242787e-08
gene O 0 1.273308747329338e-08
in O 0 6.428111376521883e-09
16 O 0 9.704616132921728e-08
% O 0 1.888800937877022e-08
( O 0 2.6833346211674325e-08
95 O 0 1.397999227492619e-07
% O 0 4.025712030397699e-08
confidence O 0 1.093314608624496e-06
interval O 0 2.8431161354092183e-06
[ O 0 1.7093819906222052e-06
CI O 0 1.4770669622521382e-05
] O 0 7.170004892032011e-07
6 O 0 3.9520182326668873e-07
% O 0 3.3123384923783306e-08
- O 0 1.2069415333826328e-07
28 O 0 2.1001486061322794e-07
% O 0 4.130086850295811e-08
) O 0 5.033268379861511e-08
, O 0 7.32623917087949e-08
suggesting O 0 4.1446708110015607e-07
other O 0 1.6659176083066995e-07
predisposition O 0 8.74359375302447e-06
genes O 0 2.598596211100812e-06
. O 0 1.0554011169006117e-05

The O 0 1.6652837757646921e-06
majority O 0 5.549927095671592e-07
( O 0 3.206821475032484e-07
81 O 0 9.719682338982238e-07
% O 0 7.59437810415875e-08
) O 0 1.1418900669468712e-07
of O 0 9.619656111681252e-07
the O 0 0.004478211980313063
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.2791025483238627e-07
were O 0 1.4917986845830455e-07
due O 0 3.5524524832908355e-07
to O 0 3.185019536999789e-08
BRCA1 O 0 1.6446587096652365e-06
, O 0 2.4444810620138924e-08
with O 0 9.496871733460921e-09
most O 0 1.4886089694243765e-08
others O 0 6.068802349545876e-08
( O 0 3.954222904667404e-08
14 O 0 2.9872481377424265e-07
% O 0 3.9734494805543363e-08
) O 0 7.65223333587528e-08
due O 0 6.96574943503947e-07
to O 0 6.98697306233953e-07
BRCA2 O 0 0.00024139409651979804
. O 0 2.277467865496874e-05

Conversely O 0 2.628690162964631e-05
, O 0 4.969678570887481e-07
the O 0 1.1467824378996738e-07
majority O 0 6.864954116281297e-08
of O 0 2.6331520075473236e-07
families O 0 2.61767780784794e-08
with O 0 1.4264441006162087e-07
male B-Disease 0 0.18710272014141083
and I-Disease 1 0.6071703433990479
female I-Disease 1 0.9999912977218628
breast I-Disease 1 0.9980687499046326
cancer I-Disease 0 0.0020111247431486845
were O 0 8.331894605362322e-07
due O 0 8.816598892735783e-06
to O 0 3.963398000905727e-07
BRCA2 O 0 7.96490057837218e-05
( O 0 5.399665496952366e-07
76 O 0 3.285410457465332e-06
% O 0 5.428331633083872e-07
) O 0 1.796121068764478e-06
. O 0 1.0973541975545231e-05

The O 0 6.290634246397531e-06
largest O 0 1.5228112033582875e-06
proportion O 0 6.772826282031019e-07
( O 0 1.658239483504076e-07
67 O 0 4.859911086896318e-07
% O 0 3.100859302662684e-08
) O 0 2.0660746002931774e-08
of O 0 3.003874127216477e-08
families O 0 3.3534341969954085e-09
due O 0 2.705339952058239e-08
to O 0 3.721632557684984e-09
other O 0 3.378169299850242e-09
genes O 0 9.30879817673258e-09
was O 0 3.445732943418989e-08
found O 0 4.474186354741505e-09
in O 0 6.797925777846103e-09
families O 0 5.181600926107421e-09
with O 0 1.4883989152281174e-08
four O 0 2.444672873025411e-07
or O 0 9.067738915291557e-08
five O 0 1.943567156104109e-07
cases O 0 8.002328399925318e-08
of O 0 7.508100679842755e-06
female O 1 0.9874241948127747
breast B-Disease 1 0.9904114603996277
cancer I-Disease 0 0.0015469453064724803
only O 0 7.472634024452418e-06
. O 0 2.9902752430643886e-05

These O 0 1.0811110087161069e-06
estimates O 0 7.314907861655229e-07
were O 0 1.7737559687702742e-07
not O 0 6.05975714051965e-08
substantially O 0 3.5265921383142995e-07
affected O 0 5.666270297410847e-08
either O 0 4.5695060180150904e-08
by O 0 2.1533949734475755e-08
changing O 0 7.012460656596886e-08
the O 0 2.8763993853431202e-08
assumed O 0 3.147724214613845e-07
penetrance O 0 1.3820628055327688e-06
model O 0 2.1038673025941534e-07
for O 0 5.24730445761179e-08
BRCA1 O 0 4.583376380651316e-07
or O 0 2.395833931245761e-08
by O 0 1.9269396744903133e-08
including O 0 5.346238296510819e-08
or O 0 2.942119294857548e-07
excluding O 0 5.200056875764858e-06
BRCA1 O 0 1.2656988474191166e-05
mutation O 0 2.2956737666390836e-06
data O 0 4.8671649892639834e-06
. O 0 1.539451659482438e-05

Among O 0 4.429396085470216e-06
those O 0 2.569085779668967e-07
families O 0 1.3590820913123025e-07
with O 0 2.745944698290259e-07
disease O 0 1.3434302672976628e-05
due O 0 1.006932166092156e-06
to O 0 6.048878731235163e-08
BRCA1 O 0 1.045242811414937e-06
that O 0 9.253355415239639e-09
were O 0 3.581792284990115e-08
tested O 0 7.310048033559724e-08
by O 0 4.749991511232565e-09
one O 0 4.31047197935186e-09
of O 0 1.823833173375533e-08
the O 0 2.1390510696051024e-08
standard O 0 7.51119912933973e-08
screening O 0 1.5873688141709863e-08
methods O 0 4.0286693092639325e-08
, O 0 8.060244027774388e-09
mutations O 0 1.8272906743277417e-08
were O 0 1.4275566506682935e-08
detected O 0 3.4179397090383645e-08
in O 0 8.877063528700546e-09
the O 0 3.2800610227923244e-08
coding O 0 1.5653310470042925e-07
sequence O 0 2.0179985682489132e-08
or O 0 6.4846346070623895e-09
splice O 0 6.100415106402579e-08
sites O 0 7.356916409406722e-09
in O 0 2.9839548609800204e-09
an O 0 4.6396921860036855e-09
estimated O 0 2.166748025445031e-08
63 O 0 1.6775399558355275e-07
% O 0 5.3585608839057386e-08
( O 0 1.0691052665379175e-07
95 O 0 6.911330387993075e-07
% O 0 1.666524696020133e-07
CI O 0 3.100605317740701e-05
51 O 0 1.3785718238068512e-06
% O 0 1.2944863669872575e-07
- O 0 8.951519134825503e-07
77 O 0 5.690883426723303e-07
% O 0 3.283498415385111e-07
) O 0 1.2791456356353592e-06
. O 0 1.3097521332383621e-05

The O 0 3.822446615231456e-06
estimated O 0 7.090359304129379e-07
sensitivity O 0 8.633520565126673e-07
was O 0 2.9613400442940474e-07
identical O 0 5.8828820925782566e-08
for O 0 1.0484905388352672e-08
direct O 0 3.497966005738817e-08
sequencing O 0 2.6944130127048993e-07
and O 0 5.9116207040688096e-08
other O 0 1.6210333342314698e-07
techniques O 0 2.2423781047109514e-05
. O 0 1.2765967767336406e-05

The O 0 1.1925011676794384e-05
penetrance O 0 0.00024463949375785887
of O 0 1.3726495126320515e-05
BRCA2 O 0 0.00012285778939258307
was O 0 2.570571041360381e-06
estimated O 0 1.837251346614721e-07
by O 0 4.466003744596492e-08
maximizing O 0 1.2264362112546223e-06
the O 0 1.723858957802804e-07
LOD O 0 6.974974530749023e-05
score O 0 1.8570934798844974e-06
in O 0 2.533572569518583e-07
BRCA2 O 0 1.192819581774529e-05
- O 0 9.853322353592375e-07
mutation O 0 5.8144880910049324e-08
families O 0 7.217208608523151e-09
, O 0 2.16619433501819e-08
over O 0 4.965604105677812e-08
all O 0 6.486504844360752e-08
possible O 0 1.1072852430515923e-06
penetrance O 0 4.211503255646676e-05
functions O 0 7.521940005972283e-06
. O 0 1.0191250112256967e-05

The O 0 2.7802025215351023e-06
estimated O 0 5.326010068529285e-07
cumulative O 0 1.3732339994021459e-06
risk O 0 6.135293801889929e-07
of O 0 1.9466126559564145e-06
breast B-Disease 0 1.7104721337091178e-05
cancer I-Disease 0 1.946247039086302e-06
reached O 0 1.3102417142363265e-06
28 O 0 1.3998618442201405e-06
% O 0 4.295511857321799e-08
( O 0 3.616555943608546e-08
95 O 0 2.3181573283181933e-07
% O 0 4.985001211821327e-08
CI O 0 7.471750450349646e-06
9 O 0 4.887854743174103e-07
% O 0 2.1675251815622687e-08
- O 0 6.929269602551358e-08
44 O 0 4.1473349199350196e-08
% O 0 7.267309865000016e-09
) O 0 5.516416656803358e-09
by O 0 3.950052729351228e-09
age O 0 2.3078948530041998e-08
50 O 0 1.7158312104470497e-08
years O 0 5.9664326812480795e-09
and O 0 7.681842717488507e-09
84 O 0 6.81921292766674e-08
% O 0 1.231227209075314e-08
( O 0 1.650287551058227e-08
95 O 0 1.815337640209691e-07
% O 0 5.105962586071655e-08
CI O 0 6.59075385556207e-06
43 O 0 3.7122697449376574e-07
% O 0 4.901766104126182e-08
- O 0 1.3718475599944213e-07
95 O 0 1.2690166784068424e-07
% O 0 1.2613724287291461e-08
) O 0 1.4253448199497143e-08
by O 0 1.527425652625425e-08
age O 0 2.703205268517195e-07
70 O 0 6.7222356392449e-07
years O 0 1.1052721902160556e-06
. O 0 7.830756658222526e-06

The O 0 8.519687253283337e-05
corresponding O 1 0.9076727628707886
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.00016799727745819837
were O 0 6.469512754847528e-06
0 O 0 4.0239210647996515e-05
. O 0 1.850991975516081e-05

4 O 0 1.79776889126515e-05
% O 0 9.011201882458408e-07
( O 0 3.8974772564870364e-07
95 O 0 1.0141193342860788e-06
% O 0 1.4485632959804207e-07
CI O 0 9.992704690375831e-06
0 O 0 3.366914427260781e-07
% O 0 2.0270176648296e-08
- O 0 5.4233183277574426e-08
1 O 0 4.9663523071785676e-08
% O 0 4.348249760255385e-09
) O 0 3.1295144253817853e-09
by O 0 2.186616665511565e-09
age O 0 1.2045998865062302e-08
50 O 0 8.23445400754963e-09
years O 0 5.683954640289812e-09
and O 0 8.743305635050547e-09
27 O 0 1.1213577266744323e-07
% O 0 1.0984231302302305e-08
( O 0 1.0625467616875994e-08
95 O 0 9.31416508365146e-08
% O 0 1.5943294684461762e-08
CI O 0 1.6073404367489275e-06
0 O 0 1.7459200307712308e-07
% O 0 1.68227813901467e-08
- O 0 4.7328477137398295e-08
47 O 0 5.000838143587316e-08
% O 0 1.385816972288012e-08
) O 0 1.4088114674848384e-08
by O 0 2.270152066330411e-08
age O 0 3.426550279073126e-07
70 O 0 7.143652283048141e-07
years O 0 9.058609293788322e-07
. O 0 7.3438773142697755e-06

The O 0 9.0643306975835e-06
lifetime O 0 3.40563383360859e-05
risk O 0 3.893809116561897e-05
of O 0 0.04834360256791115
breast B-Disease 1 0.9999719858169556
cancer I-Disease 0 0.00735397357493639
appears O 0 4.0865120354283135e-07
similar O 0 6.50160458803839e-08
to O 0 2.3016438532863503e-08
the O 0 1.1132934929491967e-07
risk O 0 2.44767278445579e-07
in O 0 5.561276594789888e-08
BRCA1 O 0 8.571220746489416e-07
carriers O 0 6.49313989242728e-08
, O 0 2.468046211845376e-08
but O 0 1.4033164852378377e-08
there O 0 1.5049989698923127e-08
was O 0 3.644837676120005e-08
some O 0 3.3475930916182506e-09
suggestion O 0 6.435928412429348e-08
of O 0 8.015542363182249e-08
a O 0 9.452635651996388e-08
lower O 0 5.342558893062233e-07
risk O 0 4.0912385657065897e-07
in O 0 9.400440603712923e-08
BRCA2 O 0 2.059254711639369e-06
carriers O 0 1.6798132662643184e-07
< O 0 1.5396981325466186e-06
50 O 0 9.160270764141387e-08
years O 0 8.467892342878258e-08
of O 0 3.4434339113431633e-07
age O 0 7.400381946354173e-06
. O 0 1.1476393410703167e-05

Eye B-Disease 1 0.9918168187141418
movement I-Disease 0 0.00047528877621516585
abnormalities I-Disease 0 0.0063175312243402
correlate O 0 1.4178712035572971e-06
with O 0 2.386163941991981e-07
genotype O 0 4.129993976675905e-05
in O 0 9.355719612358371e-07
autosomal O 1 0.8101447224617004
dominant O 1 0.9999995231628418
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999997615814209
. O 0 0.0007989933365024626

We O 0 1.297986636927817e-05
compared O 0 7.17727562005166e-06
horizontal O 0 0.0006199231138452888
eye O 0 0.0004793705593328923
movements O 0 1.0751039553724695e-05
( O 0 2.9890143196098506e-06
visually O 0 4.807021923625143e-06
guided O 0 1.1503052519401535e-05
saccades O 0 0.0001894072483992204
, O 0 6.629734912166896e-07
antisaccades O 0 1.432643421139801e-05
, O 0 6.129082663619556e-08
and O 0 5.801461000487507e-08
smooth O 0 6.036029276401678e-07
pursuit O 0 9.550532240609755e-07
) O 0 2.3452363606679683e-08
in O 0 7.531051338105499e-09
control O 0 7.143216862459667e-08
subjects O 0 5.41087786132266e-07
( O 0 5.6657086133782286e-08
n O 0 2.954164131097059e-07
= O 0 9.562379545968724e-07
14 O 0 2.7129289037475246e-07
) O 0 1.85601329860674e-08
and O 0 2.579769997623771e-08
patients O 0 1.36405349238089e-08
with O 0 7.635172494246945e-09
three O 0 3.0007363704953605e-08
forms O 0 1.0073492262563377e-07
of O 0 7.399376613648201e-07
autosomal O 0 6.369379843818024e-05
dominant O 0 0.4293050467967987
cerebellar B-Disease 1 0.9999974966049194
ataxias I-Disease 0 0.4195144772529602
type I-Disease 0 0.00025236737565137446
I I-Disease 0 0.0002912936906795949
spinocerebellar B-Disease 0 0.0007787136128172278
ataxias I-Disease 0 3.475829726085067e-05
1 I-Disease 0 1.0096399591930094e-06
and I-Disease 0 9.151557378572761e-08
2 I-Disease 0 9.107376968131575e-07
( O 0 1.0576096087788756e-07
SCA1 B-Disease 0 6.967803074076073e-06
, O 0 8.055729239231368e-08
n O 0 2.0864480632099003e-07
= O 0 3.096326679496997e-07
11 O 0 2.1780147108074743e-07
; O 0 4.3992983478347014e-08
SCA2 B-Disease 0 9.757829502632376e-06
, O 0 7.010106628513313e-08
n O 0 3.4053232411679346e-07
= O 0 4.06943911457347e-07
10 O 0 1.645805838279557e-07
) O 0 6.117006989825313e-08
and O 0 4.4764337303604407e-07
SCA3 B-Disease 1 0.9999998807907104
/ O 0 0.00021160999312996864
Machado B-Disease 0 1.6829890228109434e-05
- I-Disease 0 3.626818624979933e-06
Joseph I-Disease 0 0.0003212563751731068
disease I-Disease 0 0.008963359519839287
( O 0 5.057175258116331e-06
MJD B-Disease 1 1.0
) O 0 5.767990387539612e-07
( O 0 1.9986968879948108e-07
n O 0 1.2174386938568205e-06
= O 0 3.454838861216558e-06
16 O 0 3.7137924664421007e-06
) O 0 9.038942039296671e-07
. O 0 7.299469416466309e-06

In O 0 1.3026095984969288e-05
SCA1 B-Disease 0 0.0015853961231186986
, O 0 3.202116658940213e-06
saccade O 0 4.34777102782391e-05
amplitude O 0 1.555836934130639e-05
was O 0 1.046753027367231e-06
significantly O 0 3.924888858364284e-07
increased O 0 2.220686212695e-07
, O 0 1.3714421243093966e-07
resulting O 0 1.0590969168333686e-06
in O 0 5.784720542578725e-07
hypermetria B-Disease 0 0.00019028139649890363
. O 0 2.046741974481847e-05

The O 0 1.3622040569316596e-05
smooth O 0 6.017392297508195e-05
pursuit O 0 5.854010669281706e-05
gain O 0 0.00010040226334240288
was O 0 0.00011888769222423434
decreased O 0 0.00012838738621212542
. O 0 2.9337128580664285e-05

In O 0 1.527863605588209e-05
SCA2 B-Disease 0 0.0018044449388980865
, O 0 4.8455963224114385e-06
saccade O 0 0.00010537791240494698
velocity O 0 4.268034172127955e-05
was O 0 2.333757402084302e-05
markedly O 0 9.103404590860009e-05
decreased O 0 5.224838241701946e-05
. O 0 3.0659186450066045e-05

The O 0 1.7660418052400928e-06
percentage O 0 9.519523018752807e-07
of O 0 4.132301967274543e-07
errors O 0 7.532269592047669e-06
in O 0 1.613825304502825e-07
antisaccades O 0 8.479291864205152e-05
was O 0 7.493512157452642e-07
greatly O 0 9.640174880587438e-08
increased O 0 5.5912483531983526e-08
and O 0 4.274352605193599e-08
was O 0 2.895445447848033e-07
significantly O 0 1.0245152992638396e-07
correlated O 0 1.1254320497755543e-07
with O 0 3.2178157027829e-08
age O 0 1.0986873348883819e-05
at O 0 0.00022295756207313389
disease O 0 0.0036108989734202623
onset O 0 0.14182674884796143
. O 0 4.1596777009544894e-05

In O 0 9.995869731938e-07
addition O 0 5.647872853842273e-07
, O 0 9.3862333017114e-08
a O 0 5.2540947592660814e-08
correlation O 0 9.041315962576846e-08
between O 0 5.6600701014986043e-08
smooth O 0 3.25826903235793e-07
pursuit O 0 2.752428542862617e-07
gain O 0 1.526770887494422e-07
and O 0 2.0144529599974703e-08
the O 0 1.6282886150520426e-08
number O 0 2.188470382691321e-08
of O 0 2.838405634975061e-07
trinucleotide O 0 6.878426211187616e-05
repeats O 0 4.140817054576473e-06
was O 0 3.3873768643388757e-06
found O 0 2.524138153603417e-06
. O 0 2.0424367903615348e-05

In O 0 6.299166125245392e-05
SCA3 B-Disease 1 0.9999997615814209
, O 0 1.7702672266750596e-05
gaze B-Disease 0 0.02038179151713848
- I-Disease 0 0.014984706416726112
evoked I-Disease 0 0.002267303643748164
nystagmus I-Disease 1 0.997071385383606
was O 0 3.427335286687594e-06
often O 0 7.488598186000672e-08
present O 0 1.1631898644282046e-07
as O 0 1.0097519265173105e-07
was O 0 1.0758429880297626e-06
saccade O 0 9.806218258745503e-06
hypometria O 0 1.4791236026212573e-05
and O 0 4.0349681285078987e-07
smooth O 0 3.933071639039554e-06
pursuit O 0 9.299250450567342e-06
gain O 0 1.2197816431580577e-05
was O 0 2.2208896552911028e-05
markedly O 0 3.215949982404709e-05
decreased O 0 2.3012544261291623e-05
. O 0 1.2585179320012685e-05

Three O 0 4.7862536121101584e-06
major O 0 2.2063472897571046e-06
criteria O 0 2.1225441741989926e-06
, O 0 7.21478841114731e-07
saccade O 0 1.4954075595596805e-05
amplitude O 0 3.593025439840858e-06
, O 0 1.8569592441508576e-07
saccade O 0 2.799790991048212e-06
velocity O 0 2.3620812044100603e-06
, O 0 7.181851202631151e-08
and O 0 3.780667157116113e-08
presence O 0 1.195011805066315e-07
of O 0 6.078893193262047e-07
gaze B-Disease 0 0.0005189189687371254
- I-Disease 0 6.603262590942904e-05
evoked I-Disease 0 3.149590702378191e-05
nystagmus I-Disease 0 0.00041449052514508367
, O 0 9.063001016329508e-08
permitted O 0 5.54346364367575e-08
the O 0 2.501209728222875e-08
correct O 0 9.743025941588712e-08
assignment O 0 8.456594002836937e-08
of O 0 2.480770078250316e-08
90 O 0 4.782128826263943e-08
% O 0 7.812673175067175e-09
of O 0 2.417615618810487e-08
the O 0 6.351685044592159e-08
SCA1 B-Disease 0 2.386094092798885e-05
, O 0 1.3390206277108518e-08
90 O 0 2.1598243193921007e-08
% O 0 4.0863068484497944e-09
of O 0 2.468022763935096e-08
the O 0 9.322589278326632e-08
SCA2 B-Disease 0 6.976058648433536e-05
, O 0 4.3136978433722106e-08
and O 0 2.9268775847413053e-08
93 O 0 1.477495743529289e-07
% O 0 9.658815969260104e-09
of O 0 4.266573938593865e-08
the O 0 8.225777037296211e-08
patients O 0 7.549375879989384e-08
with O 0 8.604146728430351e-08
SCA3 B-Disease 1 1.0
to O 0 4.6044135615375126e-08
their O 0 3.09554089028552e-08
genetically O 0 2.213917298377055e-07
confirmed O 0 1.1337333916117132e-07
patient O 0 5.457519947071887e-08
group O 0 5.1924175181738974e-08
and O 0 4.540262921182148e-08
, O 0 3.3922340492154035e-08
therefore O 0 6.380364681035644e-08
, O 0 6.146971287535052e-08
may O 0 7.689440906233358e-08
help O 0 1.8130573664620897e-07
orient O 0 2.09130175790051e-05
diagnoses O 0 3.0014602998562623e-06
of O 0 6.82385746131331e-07
SCA1 B-Disease 0 0.08209958672523499
, O 0 7.888997970439959e-07
SCA2 B-Disease 0 0.1058502122759819
, O 0 3.4039658203255385e-07
and O 0 1.094535264201113e-06
SCA3 B-Disease 1 1.0
at O 0 2.623641876198235e-06
early O 0 6.309749096544692e-07
clinical O 0 1.2192780332043185e-06
stages O 0 2.30840942094801e-06
of O 0 8.847434287417855e-07
the O 0 3.6536048355628736e-06
diseases O 0 0.004844014532864094
. O 0 2.7371961550670676e-06
. O 0 1.7508033124613576e-05

Genetic O 0 4.131315108679701e-06
basis O 0 9.090039725379029e-07
and O 0 3.591216284348775e-07
molecular O 0 8.925027032091748e-06
mechanism O 0 0.0001386985240969807
for O 0 5.909668470849283e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9991037249565125

Ventricular B-Disease 1 0.9999998807907104
fibrillation I-Disease 1 0.9999837875366211
causes O 0 2.7635103833745234e-05
more O 0 2.858589311927062e-07
than O 0 1.4307261153589934e-07
300 O 0 2.2954672829200717e-07
, O 0 5.475463993320773e-08
000 O 0 3.7759400584036484e-07
sudden O 0 6.437942374759587e-07
deaths O 0 9.496168473788202e-08
each O 0 1.938681215563065e-08
year O 0 2.2687840939283888e-08
in O 0 3.364743861311581e-08
the O 0 2.6313270495847974e-07
USA O 0 7.235692009999184e-06
alone O 0 2.2547094431502046e-06
. O 0 9.650653737480752e-06

In O 0 1.71955196037743e-06
approximately O 0 5.387819328461774e-07
5 O 0 5.635675393023121e-07
- O 0 1.4944045290121721e-07
12 O 0 5.5121702757787716e-08
% O 0 4.388133412192019e-09
of O 0 1.0019050478149438e-08
these O 0 3.586329899718521e-09
cases O 0 4.4635490858979665e-09
, O 0 1.8932904133350803e-09
there O 0 2.967766921102566e-09
are O 0 2.5076618559438657e-09
no O 0 7.805407875594028e-08
demonstrable O 0 0.00013811810640618205
cardiac O 0 0.05612301826477051
or O 0 1.496820800639398e-06
non O 0 0.12708908319473267
- O 0 0.003421131521463394
cardiac O 0 0.0001076318440027535
causes O 0 4.098477646152787e-08
to O 0 6.514064398999153e-09
account O 0 5.346052489585418e-09
for O 0 4.2671084443668406e-09
the O 0 1.2951576700004352e-08
episode O 0 4.86675624244981e-08
, O 0 5.686665804915947e-09
which O 0 4.3951189354629605e-09
is O 0 5.409905412534499e-09
therefore O 0 4.910852524631082e-08
classified O 0 1.71608405707957e-07
as O 0 1.6425160538346972e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9999854564666748
IVF B-Disease 1 1.0
) O 0 4.192048800177872e-05
. O 0 5.983740629744716e-05

A O 0 1.5231788893288467e-05
distinct O 0 4.965930202160962e-06
group O 0 1.7494963913122774e-06
of O 0 2.5217770598828793e-05
IVF B-Disease 1 1.0
patients O 0 3.663003553810995e-07
has O 0 1.5282649812320415e-08
been O 0 1.0789583448911344e-08
found O 0 4.7339465680806825e-09
to O 0 2.9717999172618192e-09
present O 0 1.57873341066761e-08
with O 0 1.924420089949308e-08
a O 0 4.437723930550419e-07
characteristic O 0 0.0005305252270773053
electrocardiographic O 0 0.1623505800962448
pattern O 0 0.00021643980289809406
. O 0 1.947604505403433e-05

Because O 0 9.685178383733728e-07
of O 0 7.105210215740954e-07
the O 0 1.5626254423750652e-07
small O 0 2.1949206896465512e-08
size O 0 1.6902738764201786e-08
of O 0 2.7355278930940585e-08
most O 0 1.3339427340497423e-08
pedigrees O 0 5.329897234673808e-08
and O 0 9.794056232692583e-09
the O 0 2.7359090992717938e-08
high O 0 1.1543561413418502e-06
incidence O 0 5.999042400617327e-07
of O 0 1.6322817941727408e-07
sudden B-Disease 0 8.110008820949588e-06
death I-Disease 0 5.2958662308810744e-06
, O 0 7.777261856745099e-08
however O 0 5.962100857459518e-08
, O 0 2.5552647997528766e-08
molecular O 0 1.551962043322419e-07
genetic O 0 2.2070151928232917e-08
studies O 0 1.5871084002583302e-08
of O 0 8.251028305039654e-08
IVF B-Disease 1 0.5412905216217041
have O 0 1.279780459384483e-08
not O 0 1.2994977538482999e-08
yet O 0 1.6623594945031073e-07
been O 0 3.956185423703573e-07
done O 0 2.739972615017905e-06
. O 0 1.1673949302348774e-05

Because O 0 5.8854515373241156e-05
IVF B-Disease 1 0.9999765157699585
causes O 0 0.00018745748093351722
cardiac O 1 0.9963919520378113
rhythm O 1 0.9997660517692566
disturbance O 1 0.9975789189338684
, O 0 4.891669505013851e-07
we O 0 1.934240572154522e-07
investigated O 0 4.5634700995833555e-07
whether O 0 7.17081931611574e-08
malfunction O 0 4.513269686867716e-06
of O 0 1.6361374832740694e-07
ion O 0 6.1434711824404076e-06
channels O 0 3.1478114692617964e-07
could O 0 4.690859611855558e-08
cause O 0 3.092985707553453e-07
the O 0 2.0032996417285176e-07
disorder O 0 5.321553999237949e-06
by O 0 2.393189468818946e-08
studying O 0 1.746399647117869e-07
mutations O 0 5.718537465781992e-08
in O 0 2.520394204452714e-08
the O 0 2.3138238702813396e-07
cardiac O 0 2.8094998924643733e-05
sodium O 0 2.312890865141526e-05
channel O 0 1.4949426258681342e-05
gene O 0 4.937012818118092e-06
SCN5A O 0 0.0005751308635808527
. O 0 4.011943383375183e-05

We O 0 2.253382945127669e-06
have O 0 1.8626953135481017e-07
now O 0 2.937947272130259e-07
identified O 0 3.873772413953702e-07
a O 0 2.476768656833883e-07
missense O 0 9.519909326627385e-06
mutation O 0 1.7412703527952544e-06
, O 0 3.2163745800062316e-07
a O 0 5.888197165404563e-07
splice O 0 1.0132782335858792e-05
- O 0 1.4222415529729915e-06
donor O 0 5.968608718376345e-08
mutation O 0 2.0561292046750168e-07
, O 0 4.9547811187267143e-08
and O 0 7.36429086600765e-08
a O 0 1.644378215814868e-07
frameshift O 0 2.8224355901329545e-06
mutation O 0 7.768277754394148e-08
in O 0 1.580984232418814e-08
the O 0 4.673195519444562e-08
coding O 0 4.084949694060924e-07
region O 0 1.1166195434952897e-07
of O 0 2.9493449460460397e-07
SCN5A O 0 0.05249873176217079
in O 0 3.355240778546431e-07
three O 0 1.8666925143406843e-06
IVF B-Disease 1 0.7064197063446045
families O 0 1.1483829212011187e-06
. O 0 9.178376785712317e-06

We O 0 1.3891059325032984e-06
show O 0 2.1597176669274631e-07
that O 0 1.2237865831821182e-08
sodium O 0 2.6782936402014457e-07
channels O 0 7.19484916089641e-08
with O 0 1.6591719997904875e-08
the O 0 1.0773486280868383e-07
missense O 0 2.3267584765562788e-06
mutation O 0 3.3069417781916854e-07
recover O 0 6.027768222338636e-07
from O 0 3.417665794813729e-08
inactivation O 0 2.836234671121929e-06
more O 0 3.1295400049202726e-08
rapidly O 0 8.772175164040164e-08
than O 0 1.0653716131514557e-08
normal O 0 1.9506284587578193e-08
and O 0 6.841683664049469e-09
that O 0 3.880329391137138e-09
the O 0 4.662707198122007e-08
frameshift O 0 2.5079655188164907e-06
mutation O 0 9.742877438156938e-08
causes O 0 3.27057811944087e-08
the O 0 1.6886755105360862e-08
sodium O 0 1.1787129494678084e-07
channel O 0 6.180936651389857e-08
to O 0 5.52674839227052e-09
be O 0 2.9549577007514927e-08
non O 0 1.01014938991284e-06
- O 0 2.7661119474942097e-06
functional O 0 1.2757704098476097e-05
. O 0 8.614148100605235e-06

Our O 0 2.957006927317707e-06
results O 0 8.584162287661457e-07
indicate O 0 1.5653878904231533e-07
that O 0 2.4374694262974117e-08
mutations O 0 2.069520519398793e-07
in O 0 6.541270636262198e-08
cardiac O 0 6.1124569583626e-06
ion O 0 4.8796136979945004e-05
- O 0 1.0304695933882613e-05
channel O 0 1.3968077894332964e-07
genes O 0 2.6398785379910805e-09
contribute O 0 1.8471515428331031e-09
to O 0 1.5193675206859325e-09
the O 0 5.8316338424901915e-09
risk O 0 5.721603457686797e-08
of O 0 3.9551704844598135e-07
developing O 0 6.31741713732481e-05
IVF B-Disease 1 0.9999552965164185
. O 0 1.0356546908951714e-06
. O 0 4.975059709977359e-06

Molecular O 0 5.386392513173632e-05
heterogeneity O 0 3.809365807683207e-05
in O 0 1.0564599506324157e-06
mucopolysaccharidosis B-Disease 0 0.00037686110590584576
IVA I-Disease 0 0.14609938859939575
in O 0 3.931493210984627e-07
Australia O 0 6.250909905247681e-07
and O 0 7.250809375136669e-08
Northern O 0 4.7580462592122785e-07
Ireland O 0 2.01197030946787e-06
: O 0 2.338922655553688e-07
nine O 0 3.848115852633782e-07
novel O 0 1.9224982850118977e-07
mutations O 0 2.8058107659489906e-07
including O 0 2.2490991113954806e-07
T312S O 0 1.1123676813440397e-05
, O 0 1.0421965157547675e-07
a O 0 6.385770490169307e-08
common O 0 7.301241566892713e-08
allele O 0 5.203933710618003e-07
that O 0 1.595144638599777e-08
confers O 0 1.3274981256472529e-06
a O 0 1.3917153864895226e-06
mild O 0 0.05789266526699066
phenotype O 0 0.005958814173936844
. O 0 4.5014276111032814e-05

Mucopolysaccharidosis B-Disease 1 0.5398247838020325
IVA I-Disease 1 0.9999898672103882
( O 0 0.0003580133488867432
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 1.9437279661360662e-06
is O 0 1.8805837953550508e-07
an O 0 2.82512132798729e-07
autosomal B-Disease 1 0.9244689345359802
recessive I-Disease 1 0.9999973773956299
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9396731853485107
by O 0 6.280964953475632e-06
a O 0 4.456255919649266e-05
genetic B-Disease 1 0.9999896287918091
defect I-Disease 1 0.9992527365684509
in O 0 1.1205082728338311e-06
N O 0 8.805545076029375e-05
- O 0 2.314395533176139e-05
acetylgalactosamine O 0 4.653852738556452e-05
- O 0 6.286657935561379e-06
6 O 0 2.3583723304909654e-05
- O 0 1.3571444469562266e-05
sulfate O 0 0.00011311955313431099
sulfatase O 1 0.626957356929779
( O 0 2.062800604107906e-06
GALNS O 0 0.004191643558442593
) O 0 3.442331490077777e-06
. O 0 1.5114552297745831e-05

Previous O 0 8.341160537383985e-06
studies O 0 6.493486921499425e-07
of O 0 3.777524852921488e-07
patients O 0 9.666671019203932e-08
from O 0 3.267098946935221e-08
a O 0 1.2526840009741136e-07
British O 0 3.391786094653071e-06
- O 0 3.1591448532708455e-06
Irish O 0 1.0731357633630978e-06
population O 0 9.34976096544915e-09
showed O 0 2.7250141698687003e-08
that O 0 4.986957513608559e-09
the O 0 5.399815705686706e-08
I113F O 0 9.462220305067603e-07
mutation O 0 7.066893914497996e-08
is O 0 5.421919357928573e-09
the O 0 1.0372995795648876e-08
most O 0 6.954954390181456e-09
common O 0 2.345343830256752e-08
single O 0 2.6728683266696862e-08
mutation O 0 1.482854088408203e-07
among O 0 4.6113396479086077e-07
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 1.0
patients O 0 5.792675892735133e-06
and O 0 6.116074473538902e-07
produces O 0 2.459396228005062e-06
a O 0 1.0385150517322472e-06
severe O 0 0.05721328780055046
clinical O 0 0.019910071045160294
phenotype O 0 0.0006364082801155746
. O 0 1.2049593351548538e-05

We O 0 4.52811764262151e-06
studied O 0 5.567427706409944e-06
mutations O 0 5.877307103219209e-07
in O 0 5.7318377599813175e-08
the O 0 1.8724750816545566e-07
GALNS O 0 3.962566188420169e-05
gene O 0 9.164622838397918e-08
from O 0 3.366631418089128e-08
23 O 0 1.2282786201467388e-06
additional O 0 1.943073812071816e-06
MPS B-Disease 1 0.9999986886978149
IVA I-Disease 1 1.0
patients O 0 3.165168607210944e-07
( O 0 3.2103063318800196e-08
15 O 0 5.2667470384903936e-08
from O 0 4.449387969174268e-09
Australia O 0 2.260318510138859e-08
, O 0 7.996755257977384e-09
8 O 0 5.744161413190341e-08
from O 0 3.6550136250923515e-09
Northern O 0 6.091229920457408e-08
Ireland O 0 1.7459667844832438e-07
) O 0 1.711849684227218e-08
, O 0 1.0893471902306828e-08
with O 0 1.0139395101305126e-08
various O 0 6.897253967963479e-08
clinical O 0 9.529856470180675e-06
phenotypes O 0 8.119704580167308e-05
( O 0 3.190035897659982e-07
severe O 0 0.0020875053014606237
, O 0 1.9351021762759046e-07
16 O 0 3.835066024748812e-07
cases O 0 1.40207765397804e-08
; O 0 1.0748626877443712e-08
intermediate O 0 1.4187153283273801e-06
, O 0 1.925323367402143e-08
4 O 0 1.7046872358150722e-07
cases O 0 1.3361428408131815e-08
; O 0 1.5384719276312353e-08
mild O 0 3.018200004589744e-06
, O 0 1.0767877256512293e-07
3 O 0 1.2825657904613763e-06
cases O 0 2.09326813660482e-07
) O 0 2.818716211550054e-07
. O 0 4.432628884387668e-06

We O 0 3.6373619423102355e-06
found O 0 2.7184037776351033e-07
two O 0 6.876827285395848e-08
common O 0 9.493940922311594e-08
mutations O 0 8.128765216497413e-08
that O 0 7.080072528253822e-09
together O 0 1.2093929413481419e-08
accounted O 0 6.188344769952892e-08
for O 0 1.6184916518113823e-08
32 O 0 1.1734056215573219e-07
% O 0 9.160337377522865e-09
of O 0 4.2036244707333026e-08
the O 0 5.388231016922873e-08
44 O 0 1.9035066145534074e-07
unrelated O 0 2.0343851758752862e-07
alleles O 0 1.8560103853815235e-07
in O 0 4.655793262031693e-08
these O 0 2.0479531315231725e-07
patients O 0 1.4053581480766297e-06
. O 0 8.153038834279869e-06

One O 0 2.8956078494957183e-06
is O 0 1.3771170870313654e-07
the O 0 1.975997179215483e-07
T312S O 0 9.086936188396066e-06
mutation O 0 9.427892564417562e-07
, O 0 6.843148270263555e-08
a O 0 9.36632744696908e-08
novel O 0 2.6809922815118625e-07
mutation O 0 4.5183116981206695e-07
found O 0 1.291962945515479e-07
exclusively O 0 6.815376991653466e-07
in O 0 5.739046855524066e-07
milder O 0 0.008341945707798004
patients O 0 2.6879972210736014e-05
. O 0 5.031664113630541e-05

The O 0 3.5493303585099056e-06
other O 0 1.8070709018047637e-07
is O 0 6.743959346522388e-08
the O 0 1.1174675762504194e-07
previously O 0 3.186621029271919e-07
described O 0 6.443740971917578e-07
I113F O 0 8.895031896827277e-06
that O 0 1.6958369997155387e-07
produces O 0 4.040010935568716e-06
a O 0 4.590183380059898e-06
severe O 1 0.9906203746795654
phenotype O 1 0.9939916729927063
. O 0 0.00011842219828395173

The O 0 1.072638769983314e-05
I113F O 0 5.195266203372739e-05
and O 0 1.1652099374259706e-06
T312S O 0 1.4128867405815981e-05
mutations O 0 2.921061650340562e-07
accounted O 0 1.359633046149611e-07
for O 0 2.5875165121647115e-08
8 O 0 6.18528360973869e-07
( O 0 3.857705266341327e-08
18 O 0 7.196344853355185e-08
% O 0 8.504663639996579e-09
) O 0 8.310522048304847e-09
and O 0 1.6870659536039057e-08
6 O 0 7.681954912186484e-07
( O 0 2.1419948481593565e-08
14 O 0 6.946194019974428e-08
% O 0 6.7090466515651315e-09
) O 0 8.28504109762207e-09
of O 0 4.797275821033509e-08
44 O 0 3.9359164816232806e-07
unrelated O 0 9.135343930211093e-07
alleles O 0 1.9026186919290922e-06
, O 0 1.305622731706535e-06
respectively O 0 2.4730430595809594e-05
. O 0 2.489856160536874e-05

The O 0 2.987925427078153e-06
relatively O 0 1.260601152353047e-06
high O 0 2.4695070806046715e-06
residual O 0 9.175715604214929e-06
GALNS O 0 0.00013571864110417664
activity O 0 2.0262683619876043e-07
seen O 0 1.1097107233126735e-07
when O 0 3.26275859663383e-08
the O 0 4.9806288870968274e-08
T312S O 0 1.600658720235515e-06
mutant O 0 6.054448817849334e-07
cDNA O 0 7.633995551259432e-07
is O 0 6.806310182128072e-08
overexpressed O 0 1.4071364375922712e-06
in O 0 5.0399542317336454e-08
mutant O 0 7.550253258159501e-07
cells O 0 1.20539084491611e-07
provides O 0 2.7731793750263023e-08
an O 0 3.3267917309842687e-09
explanation O 0 4.5280518889967425e-08
for O 0 2.280206778948468e-08
the O 0 2.0686560731064674e-07
mild O 1 0.758515477180481
phenotype O 0 0.000537695421371609
in O 0 7.66264705021058e-08
patients O 0 1.7859289158650427e-08
with O 0 2.0639555842194568e-08
this O 0 1.0030756669721086e-07
mutation O 0 2.8571414532052586e-06
. O 0 3.651246743174852e-06

The O 0 1.1722954695869703e-06
distribution O 0 2.0329615324499173e-07
and O 0 3.230181988556069e-08
relative O 0 1.006473553388787e-07
frequencies O 0 2.2684625378133205e-07
of O 0 2.2933265952929105e-08
the O 0 2.98065145898363e-08
I113F O 0 1.1391070984245744e-06
and O 0 6.162948551491354e-08
T312S O 0 1.5797670585016022e-06
mutations O 0 9.70685647416758e-08
in O 0 1.748215083807736e-08
Australia O 0 6.953020204036875e-08
corresponded O 0 4.0875715257016054e-08
to O 0 4.681418808161197e-09
those O 0 4.2783310227889615e-09
observed O 0 1.6635228305972305e-08
in O 0 6.119665219017634e-09
Northern O 0 1.312025688093854e-07
Ireland O 0 3.6341234022074786e-07
and O 0 1.6217393650208578e-08
are O 0 2.6738000702408726e-09
unique O 0 4.5411785443150166e-09
to O 0 1.0847851505957351e-09
these O 0 1.4051235730505596e-09
two O 0 1.8777401855629705e-09
populations O 0 3.0446192234023783e-09
, O 0 3.819194294152339e-09
suggesting O 0 8.788348715427219e-09
that O 0 1.1319550852206817e-09
both O 0 4.6238968209877385e-09
mutations O 0 2.569290913356781e-08
were O 0 1.716354880443305e-08
probably O 0 3.795340930423663e-08
introduced O 0 2.8836282695010595e-08
to O 0 6.350156400714013e-09
Australia O 0 4.6566103861778174e-08
by O 0 1.5643127682096747e-08
Irish O 0 3.6867331232315337e-07
migrants O 0 5.785912904343604e-08
during O 0 1.0321686971792587e-07
the O 0 1.2727605280815624e-07
19th O 0 4.643440661311615e-06
century O 0 1.930179314513225e-05
. O 0 1.8566684957477264e-05

Haplotype O 0 0.0002625760971568525
analysis O 0 8.296164196508471e-06
using O 0 3.5228783872298663e-06
6 O 0 1.2095151760149747e-05
RFLPs O 0 5.3391846449812874e-05
provides O 0 1.6109099476580013e-07
additional O 0 5.856594498254708e-08
data O 0 3.219190958247964e-08
that O 0 3.3875124927362776e-09
the O 0 4.404671827273887e-08
I113F O 0 1.1392363603590638e-06
mutation O 0 1.1199855265431324e-07
originated O 0 7.475127006273397e-08
from O 0 2.9326891137770872e-08
a O 0 2.168495427667949e-07
common O 0 1.4991765056038275e-06
ancestor O 0 1.5286026609828696e-05
. O 0 2.154654066544026e-05

The O 0 3.5122343433613423e-06
other O 0 3.729998923063249e-07
9 O 0 3.8026053061912535e-06
novel O 0 3.7380470985226566e-07
mutations O 0 2.030694474797201e-07
identified O 0 1.1018479995072994e-07
in O 0 1.594368903568011e-08
these O 0 4.765493599734327e-08
23 O 0 1.2737189081235556e-06
patients O 0 6.895820092722715e-08
were O 0 5.324146457041934e-08
each O 0 1.4802396641755422e-08
limited O 0 7.995234341251489e-08
to O 0 3.90047745213451e-08
a O 0 2.7476866648612486e-07
single O 0 1.3840162864653394e-06
family O 0 1.5996439515220118e-06
. O 0 1.2548507584142499e-05

These O 0 7.090325198078062e-07
data O 0 4.075513402312936e-07
provide O 0 1.0274742123783653e-07
further O 0 5.883431697384367e-08
evidence O 0 1.529175364112234e-07
for O 0 3.4860441644468665e-08
extensive O 0 5.69681844808656e-07
allelic O 0 1.2481777048378717e-05
heterogeneity O 0 1.1751469173759688e-05
in O 0 6.375207135533856e-07
MPS B-Disease 1 0.9999620914459229
IVA I-Disease 1 0.9999998807907104
in O 0 2.2599439830628398e-07
British O 0 2.732493840085226e-06
- O 0 1.5554101082670968e-06
Irish O 0 9.031996910380258e-07
patients O 0 2.044007096912992e-08
and O 0 8.518853178429708e-09
provide O 0 1.8605359031198532e-08
evidence O 0 2.0334262273991044e-08
for O 0 4.716740775734252e-09
their O 0 4.55766580031991e-09
transmission O 0 3.5073267667939945e-07
to O 0 1.0430452057619277e-08
Australia O 0 6.381508654840218e-08
by O 0 1.3811384924622416e-08
British O 0 3.353551676354982e-07
- O 0 4.364517565136339e-07
Irish O 0 6.734671273989079e-07
migrants O 0 3.871013802836387e-07
. O 0 6.334602176139015e-07
. O 0 8.144125786202494e-06

Identification O 0 7.1778572419134434e-06
of O 0 4.380093287181808e-06
constitutional O 0 8.438879012828693e-05
WT1 O 1 0.9249245524406433
mutations O 0 7.054421985230874e-06
, O 0 2.7674630587171123e-07
in O 0 6.404641084145624e-08
patients O 0 6.894373427712708e-08
with O 0 1.1465538563015798e-07
isolated O 0 5.312054418027401e-05
diffuse B-Disease 1 0.9999998807907104
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.0941217826475622e-06
and O 0 1.4024755046193604e-07
analysis O 0 1.0432286501327326e-07
of O 0 3.608980136959872e-07
genotype O 0 2.4288725398946553e-05
/ O 0 1.3804893569613341e-05
phenotype O 0 2.0809884517802857e-06
correlations O 0 3.6148287563264603e-07
by O 0 1.2180207953349509e-08
use O 0 2.2857197023995468e-08
of O 0 1.0473836198343633e-07
a O 0 3.0231240089051425e-07
computerized O 0 4.0148570406017825e-06
mutation O 0 2.933698851848021e-06
database O 0 3.837447366095148e-06
. O 0 1.3243418834463228e-05

Constitutional O 0 2.6739915483631194e-05
mutations O 0 1.9614292341429973e-06
of O 0 6.080910566197417e-07
the O 0 5.871671646673349e-07
WT1 O 0 0.0007148358272388577
gene O 0 6.187283361214213e-07
, O 0 2.3101108581613516e-07
encoding O 0 4.935369815939339e-06
a O 0 1.1688928225339623e-06
zinc O 0 0.0009483455796726048
- O 0 0.00013635633513331413
finger O 0 3.4454681099305162e-06
transcription O 0 6.770488880647463e-07
factor O 0 3.4244530411342566e-07
involved O 0 1.7593517043223983e-07
in O 0 1.1678594091790728e-07
renal O 1 0.9999574422836304
and O 0 7.836666554794647e-06
gonadal O 1 0.999998927116394
development O 0 3.099564492003992e-05
, O 0 4.477005788317001e-08
are O 0 4.661638186576056e-09
found O 0 1.0662701832586663e-08
in O 0 1.3760137029805719e-08
most O 0 2.1918959092204204e-08
patients O 0 4.229303129932305e-08
with O 0 2.832229597515834e-07
Denys B-Disease 1 0.9999774694442749
- I-Disease 1 0.9999997615814209
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.794228196144104
DDS B-Disease 1 1.0
) O 0 1.2127003401474212e-06
, O 0 2.1225108071121213e-07
or O 0 1.3173457773518749e-06
diffuse B-Disease 1 0.998792290687561
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.00046590849524363875
DMS B-Disease 1 0.9999967813491821
) O 0 2.0637280329083296e-07
associated O 0 1.4353467747696413e-07
with O 0 2.2400293175905972e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 8.398177305934951e-05
/ O 1 0.998920202255249
or O 0 4.896590326097794e-05
Wilms B-Disease 1 0.9999982118606567
tumor I-Disease 0 0.00018291184096597135
( O 0 3.9802948776923586e-06
WT B-Disease 1 0.9999997615814209
) O 0 1.6241054254351184e-05
. O 0 3.575860682758503e-05

Most O 0 5.641618827212369e-06
mutations O 0 1.9027520465897396e-05
in O 0 3.1950762604537886e-06
DDS B-Disease 1 1.0
patients O 0 5.843594863108592e-06
lie O 0 2.2308906864054734e-06
in O 0 1.6428906235432805e-07
exon O 0 1.5285598919945187e-06
8 O 0 1.1009085483237868e-06
or O 0 2.0063205852238752e-07
exon O 0 1.5449049897142686e-06
9 O 0 1.5231946690619225e-06
, O 0 2.6458616275704117e-07
encoding O 0 4.6362902139662765e-06
zinc O 0 3.209901842637919e-05
finger O 0 8.653775694256183e-06
2 O 0 2.5982963052229024e-05
or O 0 1.2201504659969942e-06
zinc O 0 1.2916940249851905e-05
finger O 0 1.3522367225959897e-06
3 O 0 1.159645989901037e-06
, O 0 4.364571282167162e-08
respectively O 0 1.286679349732367e-07
, O 0 9.950661628010948e-09
with O 0 5.6707438744751926e-09
a O 0 2.8089425896382636e-08
hot O 0 5.713794166695152e-07
spot O 0 1.5554575156784267e-06
( O 0 1.2388906611704442e-07
R394W O 0 1.5948152167766239e-06
) O 0 7.347495767362489e-08
in O 0 1.4134603532056644e-07
exon O 0 5.2267059800215065e-06
9 O 0 1.475273438700242e-05
. O 0 1.3973602108308114e-05

We O 0 5.283749487716705e-06
analyzed O 0 1.7590307379578007e-06
a O 0 1.3052364522536664e-07
series O 0 2.5230835376532923e-07
of O 0 1.5930869778912893e-07
24 O 0 9.727917813506792e-07
patients O 0 4.532700259574085e-08
, O 0 4.6271104281458975e-08
10 O 0 1.894635914823084e-07
with O 0 8.57982698221349e-08
isolated B-Disease 0 7.0000851337681524e-06
DMS I-Disease 1 0.9999994039535522
( O 0 7.6173364504938945e-06
IDMS B-Disease 1 0.920152485370636
) O 0 1.0861546684282075e-07
, O 0 5.0098790893571277e-08
10 O 0 1.5137442233026377e-07
with O 0 1.076241602504524e-07
DDS B-Disease 1 0.9999998807907104
, O 0 9.190213745569054e-08
and O 0 4.740987691320697e-08
4 O 0 1.0551327704888536e-06
with O 0 3.777942936267209e-07
urogenital B-Disease 1 0.9986757636070251
abnormalities I-Disease 1 0.9906136989593506
and O 0 2.129137828887906e-05
/ O 1 0.9851790070533752
or O 0 0.0005907542654313147
WT B-Disease 1 1.0
. O 0 9.537898586131632e-05

We O 0 3.1243656849255785e-05
report O 0 1.752881689753849e-05
WT1 O 0 0.0007160425884649158
heterozygous O 0 7.586945230286801e-06
mutations O 0 1.2588255913215107e-06
in O 0 1.6480832698562153e-07
16 O 0 2.0705444967461517e-06
patients O 0 1.427731461944859e-07
, O 0 1.1114497766584464e-07
4 O 0 1.2512243756646058e-06
of O 0 2.6426411636748526e-07
whom O 0 1.2336646477706381e-06
presented O 0 8.343372428498697e-06
with O 0 5.651026185660157e-06
IDMS B-Disease 1 0.9996532201766968
. O 0 0.00019611476454883814

One O 0 1.091462399926968e-05
male O 0 8.629852345620748e-06
and O 0 9.164776884063031e-07
two O 0 2.707327439566143e-06
female O 0 9.721657261252403e-05
IDMS B-Disease 1 0.9999880790710449
patients O 0 6.676447810605168e-06
with O 0 1.2034722203679848e-05
WT1 O 1 0.9999997615814209
mutations O 0 0.48632556200027466
underwent O 1 0.8792186975479126
normal O 0 0.00022066631936468184
puberty O 0 0.07576389610767365
. O 0 5.913795030210167e-05

Two O 0 7.723842827545013e-06
mutations O 0 6.8965955506428145e-06
associated O 0 1.4230975011741975e-06
with O 0 4.031621756439563e-07
IDMS B-Disease 1 0.9952417612075806
are O 0 4.3607272459667e-08
different O 0 2.4586492841649488e-08
from O 0 2.7409544856027424e-08
those O 0 5.51601999632112e-08
described O 0 8.759290039961343e-07
in O 0 1.7766893734005862e-06
DDS B-Disease 1 1.0
patients O 0 8.390501170651987e-05
. O 0 5.71015989407897e-05

No O 0 3.5154524084646255e-05
WT1 O 0 0.002664525294676423
mutations O 0 5.689462341251783e-06
were O 0 6.866603712296637e-07
detected O 0 5.644216685141146e-07
in O 0 5.98785661054535e-08
the O 0 1.9952688035118626e-07
six O 0 1.7335871689283522e-06
other O 0 4.848628805120825e-07
IDMS B-Disease 1 0.9999933242797852
patients O 0 7.835178053028358e-07
, O 0 1.6253601131666073e-07
suggesting O 0 3.643944808118249e-07
genetic O 0 2.566318642038823e-07
heterogeneity O 0 3.392277676539379e-06
of O 0 3.0788291951466817e-06
this O 0 3.405515371923684e-06
disease O 0 0.0901319682598114
. O 0 4.7909357817843556e-05

We O 0 1.969182994798757e-05
analyzed O 0 1.9271332348580472e-05
genotype O 0 8.55819380376488e-05
/ O 0 9.661863441579044e-05
phenotype O 0 1.911261642817408e-05
correlations O 0 4.528873887466034e-06
, O 0 7.893982711948411e-08
on O 0 4.609264081523179e-08
the O 0 7.198277973685663e-09
basis O 0 1.4604739639878517e-08
of O 0 1.8031727222478366e-08
the O 0 3.350194432982789e-08
constitution O 0 9.386788235588028e-08
of O 0 1.51584032437313e-07
a O 0 3.740364888926706e-07
WT1 O 0 5.147926276549697e-05
mutation O 0 4.0078501228890673e-07
database O 0 1.0873548461631799e-07
of O 0 3.2011473649617983e-07
84 O 0 4.945909950038185e-06
germ O 0 0.004046998918056488
- O 0 7.311059744097292e-05
line O 0 7.132867722248193e-06
mutations O 0 3.5596860925579676e-07
, O 0 2.6785686557673216e-08
to O 0 7.01992552976094e-09
compare O 0 3.606815113244011e-08
the O 0 1.4137968129546152e-08
distribution O 0 1.5894411120598306e-08
and O 0 6.08129058221607e-09
type O 0 6.53438760878089e-08
of O 0 3.1130195310424824e-08
mutations O 0 2.2843291702656643e-08
, O 0 4.7186574647639645e-09
according O 0 2.2447088632304713e-09
to O 0 5.065664332448705e-09
the O 0 5.048806173135745e-08
different O 0 5.437237859950983e-07
symptoms O 0 0.00026691981474868953
. O 0 2.9620863642776385e-05

This O 0 1.3294782092998503e-06
demonstrated O 0 7.877827556512784e-06
( O 0 4.0094863607009756e-07
1 O 0 2.103102133332868e-06
) O 0 1.1751963313599845e-07
the O 0 7.436956650508364e-08
association O 0 5.1226628272615926e-08
between O 0 4.811314013863921e-08
mutations O 0 4.54366784197191e-08
in O 0 1.4865888076087685e-08
exons O 0 2.5393995883860043e-07
8 O 0 2.1578689768375625e-07
and O 0 4.5025419836974834e-08
9 O 0 8.007410201571474e-07
and O 0 2.2271740363066783e-07
DMS B-Disease 0 0.0437038317322731
; O 0 1.6612136732874205e-07
( O 0 7.409912683442599e-08
2 O 0 7.792479550516873e-07
) O 0 2.730497605796245e-08
among O 0 2.4649413177257884e-08
patients O 0 2.826543621381461e-08
with O 0 7.985845940083891e-08
DMS B-Disease 1 0.8867961168289185
, O 0 6.209781133748038e-08
a O 0 3.329408571062231e-08
higher O 0 5.956509241400454e-08
frequency O 0 2.208999347885765e-07
of O 0 6.17482101006317e-08
exon O 0 1.3465920289945643e-07
8 O 0 6.785828787769788e-08
mutations O 0 2.533494303236239e-08
among O 0 2.6031194977349514e-08
46 O 0 4.2076996464857075e-07
, O 0 4.7040305162227014e-07
XY O 0 0.012796914204955101
patients O 0 2.0831576819091424e-07
with O 0 1.2582947306327696e-07
female O 0 1.269957579097536e-06
phenotype O 0 1.963289605555474e-06
than O 0 5.7367600447832956e-08
among O 0 5.3429051405373684e-08
46 O 0 7.054119919303048e-07
, O 0 4.0564395931141917e-07
XY O 0 0.12491773068904877
patients O 0 8.515997507174689e-08
with O 0 2.9727084793762515e-08
sexual O 0 7.434006192852394e-07
ambiguity O 0 1.6359362007278833e-06
or O 0 3.920564495274448e-07
male O 0 6.980446300985932e-07
phenotype O 0 1.6223091279243818e-06
; O 0 5.70113414255502e-08
and O 0 1.2215272704452218e-07
( O 0 1.060198897562259e-07
3 O 0 3.6623296750804e-07
) O 0 5.725388607658033e-09
statistically O 0 6.718702483254901e-09
significant O 0 8.581885424518987e-09
evidence O 0 3.1204027806097656e-08
that O 0 4.38952296732964e-09
mutations O 0 4.8066272739788474e-08
in O 0 3.749392973873e-08
exons O 0 1.5042003269627457e-06
8 O 0 1.0905009730777238e-06
and O 0 1.6912582623263006e-07
9 O 0 7.531239702984749e-07
preferentially O 0 3.012969500559848e-07
affect O 0 1.535252494022643e-07
amino O 0 1.9147110208450613e-07
acids O 0 2.312896718592583e-08
with O 0 8.280459873333257e-09
different O 0 2.3520186687164824e-08
functions O 0 2.4079750460259675e-07
. O 0 3.7487140502889815e-07
. O 0 3.5674449918587925e-06

The O 0 2.269835749757476e-05
185delAG O 0 0.00011675767746055499
BRCA1 O 0 1.0023783033830114e-05
mutation O 0 6.156294602988055e-07
originated O 0 1.5066368064253766e-07
before O 0 1.3878860727345455e-07
the O 0 1.842996333323299e-08
dispersion O 0 4.987530815014907e-07
of O 0 7.690994863196465e-08
Jews O 0 1.3374922502862319e-07
in O 0 1.8024920223069785e-08
the O 0 2.725835379635555e-08
diaspora O 0 4.039842238512392e-08
and O 0 3.2297510443868305e-08
is O 0 1.7634462778914894e-08
not O 0 1.5421854016040015e-08
limited O 0 2.737922102369339e-07
to O 0 8.776004278843175e-07
Ashkenazim O 0 0.0018804112914949656
. O 0 5.3435251174960285e-05

The O 0 1.269690619665198e-05
185delAG O 0 4.212616113363765e-05
mutation O 0 1.7530923059894121e-06
in O 0 1.5627387028871453e-07
BRCA1 O 0 1.609038235983462e-06
is O 0 3.2386953563445786e-08
detected O 0 8.999232647965982e-08
in O 0 3.7107401595903866e-08
Ashkenazi O 0 3.5489983929437585e-06
Jews O 0 6.874866471662244e-07
both O 0 2.315598521818174e-07
in O 0 3.9107356997192255e-07
familial B-Disease 1 0.8459198474884033
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.007864505052566528
in O 0 8.548877303837799e-07
the O 0 5.371679208110436e-07
general O 0 7.135849386941118e-07
population O 0 1.2737051235944818e-07
. O 0 6.307899639068637e-06

All O 0 9.477343155595008e-06
tested O 0 1.1647104656731244e-05
Ashkenazi O 0 1.09167376649566e-05
mutation O 0 5.435205707726709e-07
carriers O 0 1.3683902011507598e-07
share O 0 6.646079953043227e-08
the O 0 1.1022179791098097e-07
same O 0 2.3358576584087132e-07
allelic O 0 2.6953151973430067e-05
pattern O 0 8.688193702255376e-06
at O 0 6.458977168222191e-06
the O 0 1.826676111704728e-06
BRCA1 O 0 5.068520476925187e-05
locus O 0 3.815655873040669e-05
. O 0 2.5383189495187253e-05

Our O 0 5.799419795948779e-06
previous O 0 1.9731378415599465e-06
study O 0 2.2948653111143358e-07
showed O 0 1.478266824506136e-07
that O 0 9.829538072381183e-09
this O 0 1.4440097118040285e-08
Ashkenazi O 0 1.2459636309358757e-06
mutation O 0 1.8694917969241942e-07
also O 0 2.4359497530213048e-08
occurs O 0 3.835913986449668e-08
in O 0 1.3841606971709552e-08
Iraqi O 0 1.0302210284862667e-06
Jews O 0 5.091044954497193e-07
with O 0 6.458752466187434e-08
a O 0 3.731066442469455e-07
similar O 0 1.570976678522129e-06
allelic O 0 0.00047786932555027306
pattern O 0 0.00032460413058288395
. O 0 7.406260556308553e-05

We O 0 1.7065804058802314e-06
extended O 0 7.597238322887279e-07
our O 0 7.786969291601054e-08
analysis O 0 4.346129500731877e-08
to O 0 1.2486616185469757e-08
other O 0 2.230987128370998e-08
non O 0 3.5577582480073033e-07
- O 0 4.959948682881077e-07
Ashkenazi O 0 1.2327144531809608e-06
subsets O 0 3.465268605395977e-07
354 O 0 3.997097621777357e-07
of O 0 5.54257546525605e-08
Moroccan O 0 2.405480472589261e-06
origin O 0 1.981377124593564e-07
, O 0 1.854354252373014e-07
200 O 0 6.792892577323073e-07
Yemenites O 0 2.8464683055062778e-05
and O 0 5.196122856432339e-07
150 O 0 1.4722381820320152e-06
Iranian O 0 8.27205349196447e-06
Jews O 0 1.6368790966225788e-05
. O 0 2.1465695681399666e-05

Heteroduplex O 0 0.0002585126494523138
analysis O 0 4.07777906730189e-06
complemented O 0 2.6746845378511352e-06
by O 0 7.555167513828565e-08
direct O 0 1.2021581596854958e-07
DNA O 0 3.7247167483656085e-07
sequencing O 0 2.508261900402431e-07
of O 0 2.2170402758092678e-07
abnormally O 0 2.517449956940254e-06
migrating O 0 2.1981345810218045e-07
bands O 0 1.5351778301919694e-06
were O 0 9.184113309856912e-07
employed O 0 1.3704337106901221e-05
. O 0 1.65033543453319e-05

Four O 0 5.014233011024771e-06
of O 0 1.0415541282782215e-06
Moroccan O 0 9.96731159830233e-06
origin O 0 1.364813897453132e-07
( O 0 3.504497314565924e-08
1 O 0 7.793447309722978e-08
. O 0 5.951304782314537e-09
1 O 0 4.416145671370941e-08
% O 0 7.850375460805026e-09
) O 0 1.0158869301335471e-08
and O 0 1.2627614509597151e-08
none O 0 6.491740123237832e-08
of O 0 6.922360284988827e-08
the O 0 8.547127094971074e-08
Yemenites O 0 1.3588487490778789e-05
or O 0 6.099810434534447e-08
Iranians O 0 5.194180516809865e-07
was O 0 2.277534321137864e-07
a O 0 5.468659125540398e-08
carrier O 0 1.6326835350355395e-07
of O 0 2.278900979035825e-07
the O 0 9.346106253360631e-07
185delAG O 0 4.48281061835587e-05
mutation O 0 1.6135210898937657e-05
. O 0 1.9682947822730057e-05

BRCA1 O 0 0.0002318972401553765
allelic O 0 7.811043906258419e-05
patterns O 0 1.0305894875273225e-06
were O 0 2.3509473123795033e-07
determined O 0 1.6028859306516097e-07
for O 0 2.430167356237689e-08
four O 0 4.490209803975631e-08
of O 0 2.1054745502624428e-08
these O 0 4.850425394664626e-09
individuals O 0 1.6448408191038766e-09
and O 0 5.5087201467074465e-09
for O 0 9.981475201925605e-09
12 O 0 9.312495308222424e-08
additional O 0 3.406342230505288e-08
non O 0 4.0222894881480897e-07
- O 0 4.2943079847646004e-07
Ashkenazi O 0 1.3134344953869004e-06
185delAG O 0 1.770309722815e-06
mutation O 0 3.0231240089051425e-07
carriers O 0 3.715340426424518e-07
who O 0 1.8351375956626725e-06
had O 0 0.23748469352722168
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.6925443410873413

Six O 0 4.027007526019588e-05
non O 0 9.943194891093299e-05
- O 0 3.3154858101624995e-05
Ashkenazi O 0 1.0690053386497311e-05
individuals O 0 4.0408128398894405e-08
shared O 0 8.653207572706378e-08
the O 0 4.634848238538325e-08
common O 0 2.0528982247469685e-07
Ashkenazi O 0 1.03915390354814e-05
haplotype O 0 2.6457375952304574e-06
, O 0 8.90703617528743e-08
four O 0 1.0217090817832286e-07
had O 0 7.271042790080173e-08
a O 0 6.421826981295453e-08
closely O 0 7.018267922376253e-08
related O 0 1.821761514975151e-07
pattern O 0 1.6039166439441033e-06
, O 0 8.995319689120151e-08
and O 0 3.7761555660154045e-08
the O 0 4.812883602767215e-08
rest O 0 9.520869781454167e-08
( O 0 2.6452626755713027e-08
n O 0 1.2551198835808464e-07
= O 0 2.2584141845527483e-07
6 O 0 1.445721693471569e-07
) O 0 9.449729887478497e-09
displayed O 0 9.117738386521523e-08
a O 0 1.0690625629194983e-07
distinct O 0 1.318996396548755e-06
BRCA1 O 0 3.612287764553912e-05
allelic O 0 0.00014328514225780964
pattern O 0 0.00010256670793751255
. O 0 3.515573189361021e-05

We O 0 6.761688837286783e-06
conclude O 0 7.399881269520847e-06
that O 0 7.034162052832471e-08
the O 0 2.760714608029957e-07
185delAG O 0 1.2944734407938085e-05
BRCA1 O 0 4.6262771320471074e-06
mutation O 0 3.002451194333844e-07
occurs O 0 5.029851735116608e-08
in O 0 1.0128415439680793e-08
some O 0 1.6472245789600493e-08
non O 0 6.221755484148161e-07
- O 0 4.016899879388802e-07
Ashkenazi O 0 4.924871177536261e-07
populations O 0 6.460056045654028e-09
at O 0 6.512749450848787e-08
rates O 0 2.0745723361415003e-08
comparable O 0 4.848846302252241e-08
with O 0 1.1864015547757845e-08
that O 0 2.7736872354466868e-08
of O 0 1.0918100770140882e-06
Ashkenazim O 0 0.012963696382939816
. O 0 3.0456334570772015e-05

The O 0 1.6443842696389765e-06
majority O 0 4.542584406408423e-07
of O 0 4.381871576697449e-07
Jewish O 0 1.977561169042019e-06
185delAG O 0 1.0891958481806796e-05
mutation O 0 5.045865236752434e-07
carriers O 0 1.6817287473713805e-07
have O 0 2.2007432320947373e-08
a O 0 9.318252125467552e-08
common O 0 2.556386675678368e-07
allelic O 0 2.1076673874631524e-05
pattern O 0 1.9821870864689117e-06
, O 0 7.502379872903475e-08
supporting O 0 2.1487348078608193e-07
the O 0 1.1872565863768614e-07
founder O 0 1.343899498351675e-06
effect O 0 1.52038055034609e-07
notion O 0 1.8314889871362539e-07
, O 0 2.4826162459135048e-08
but O 0 1.1948836586839207e-08
dating O 0 3.310828944336208e-08
the O 0 1.1162826218935606e-08
mutations O 0 1.3760767636483706e-08
origin O 0 9.722731952876984e-09
to O 0 8.580199661878396e-09
an O 0 1.7300804344699827e-08
earlier O 0 2.097018523272709e-07
date O 0 8.943549119067029e-07
than O 0 1.6307322425745951e-07
currently O 0 3.6216229659657984e-07
estimated O 0 9.219601793120091e-07
. O 0 6.4881410253292415e-06

However O 0 7.5990524237568025e-06
, O 0 5.465530534820573e-07
the O 0 1.798515825157665e-07
different O 0 1.649772229939117e-07
allelic O 0 1.2636749488592613e-05
pattern O 0 5.50128061149735e-06
at O 0 2.409275566606084e-06
the O 0 2.7697336690835073e-07
BRCA1 O 0 1.342118139291415e-06
locus O 0 4.367661290416436e-07
even O 0 1.4183993535255013e-08
in O 0 4.814607379444169e-09
some O 0 4.6001189524247366e-09
Jewish O 0 4.6007968990124937e-08
mutation O 0 5.837301486621982e-08
carriers O 0 4.6362803374222494e-08
, O 0 3.972926521100817e-08
might O 0 3.2428122409555726e-08
suggest O 0 6.679044872726081e-08
that O 0 1.0719880982890118e-08
the O 0 6.223346105116434e-08
mutation O 0 2.858133996141987e-07
arose O 0 1.0222748869637144e-06
independently O 0 6.242271979317593e-07
. O 0 1.002044655251666e-06
. O 0 1.065150627255207e-05

Crystal O 0 0.032189976423978806
structure O 0 0.00010903655493166298
of O 0 3.458263381617144e-05
the O 0 0.00014032643230166286
hemochromatosis B-Disease 1 1.0
protein O 0 0.00020670965022873133
HFE O 1 0.7677298188209534
and O 0 7.674641722132947e-08
characterization O 0 1.3668589815551968e-07
of O 0 5.139221315175746e-08
its O 0 4.031621259059648e-08
interaction O 0 2.622471129143378e-07
with O 0 2.3369182144961087e-07
transferrin O 0 2.535812382120639e-05
receptor O 0 1.5688681742176414e-05
. O 0 3.1992049116524868e-06

HFE O 1 0.7213378548622131
is O 0 4.491148956731195e-06
an O 0 1.2639079614018556e-06
MHC O 0 0.28214895725250244
- O 0 0.0005539663834497333
related O 0 1.5140877849262324e-06
protein O 0 3.421802148295683e-07
that O 0 8.263072892589207e-09
is O 0 9.355612284878134e-09
mutated O 0 7.016046055241532e-08
in O 0 2.7558579418496265e-08
the O 0 7.448028327416978e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9998431205749512

HFE O 0 0.0026828027330338955
binds O 0 9.47745138546452e-06
to O 0 9.950947514880681e-07
transferrin O 0 3.0493618396576494e-05
receptor O 0 1.0563517207629047e-05
( O 0 5.042930979470839e-07
TfR O 0 1.9659535610117018e-05
) O 0 6.576311051276207e-08
and O 0 4.2751029383225614e-08
reduces O 0 1.09515589485909e-07
its O 0 2.60596113577094e-08
affinity O 0 1.3574486956713372e-07
for O 0 1.352863279180383e-07
iron O 0 0.0014238335425034165
- O 0 1.7011829186230898e-05
loaded O 0 1.5540059621343971e-06
transferrin O 0 1.78623686224455e-05
, O 0 1.0672936241462594e-06
implicating O 0 0.00029208793421275914
HFE O 1 0.9995598196983337
in O 0 1.6802354366518557e-05
iron O 1 0.9999855756759644
metabolism O 1 0.988956868648529
. O 0 2.9908285796409473e-05

The O 0 5.0595092034200206e-05
2 O 0 0.00023634350509382784
. O 0 8.17406180431135e-05

6 O 0 0.0002704951330088079
A O 0 6.516063149319962e-05
crystal O 0 0.0009888125350698829
structure O 0 4.978369906893931e-05
of O 0 7.010707577137509e-06
HFE O 1 0.9658005237579346
reveals O 0 9.552152278047288e-07
the O 0 6.311253741841938e-08
locations O 0 1.837968142126556e-07
of O 0 3.6052995255886344e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 9.867300832411274e-05
and O 0 2.4878124804672552e-06
a O 0 2.2012193312548334e-06
patch O 0 2.4225919332820922e-05
of O 0 6.444327482313383e-06
histidines O 0 7.119801739463583e-05
that O 0 1.739998367611406e-08
could O 0 3.70400101701307e-08
be O 0 5.3930225618614713e-08
involved O 0 1.7827032650075125e-07
in O 0 2.387878339504823e-07
pH O 0 0.00011820582585642114
- O 0 9.730054443934932e-06
dependent O 0 1.3683657016372308e-06
interactions O 0 4.050979441672098e-06
. O 0 1.639411311771255e-05

We O 0 4.3597310650511645e-06
also O 0 4.960890009897412e-07
demonstrate O 0 5.516192800314457e-07
that O 0 2.1752498469140846e-07
soluble O 0 1.6941241483436897e-05
TfR O 0 0.00014647400530520827
and O 0 1.0064060234071803e-06
HFE O 0 0.002045492408797145
bind O 0 5.865336447641312e-07
tightly O 0 4.0250600363833655e-07
at O 0 2.1309074327291455e-07
the O 0 4.213433513200471e-08
basic O 0 1.9693167985224136e-07
pH O 0 6.869131539133377e-07
of O 0 3.415515692495319e-08
the O 0 2.0347259876984936e-08
cell O 0 6.541158370509947e-08
surface O 0 4.397133679390208e-08
, O 0 8.555359976014643e-09
but O 0 5.4043569619466325e-09
not O 0 6.8010646003813235e-09
at O 0 2.1919235848599783e-07
the O 0 9.960558600141667e-08
acidic O 0 4.304823050915729e-06
pH O 0 2.6921094104181975e-05
of O 0 3.1415186185768107e-06
intracellular O 0 2.0223667888785712e-05
vesicles O 0 4.224995427648537e-05
. O 0 1.4854918845230713e-05

TfR O 0 0.008455256000161171
HFE O 0 0.00533119635656476
stoichiometry O 0 5.605609840131365e-05
( O 0 1.5529823258475517e-06
2 O 0 3.6639435165852774e-06
1 O 0 2.2636334051640006e-06
) O 0 1.0541013750753336e-07
differs O 0 2.3702108364886953e-07
from O 0 6.560762955132304e-08
TfR O 0 1.2007197256025393e-05
transferrin O 0 3.638416956164292e-06
stoichiometry O 0 1.5135032072066679e-06
( O 0 7.748566588361427e-08
2 O 0 2.7454552764538676e-07
2 O 0 2.689401981115225e-07
) O 0 1.504181135203453e-08
, O 0 9.839330239458377e-09
implying O 0 4.1571475151158666e-08
a O 0 1.156467632767999e-08
different O 0 6.169309507697562e-09
mode O 0 4.389165439988574e-07
of O 0 4.1907998848955685e-08
binding O 0 1.0552279405828813e-07
for O 0 9.728486105586853e-08
HFE O 0 0.00011814317986136302
and O 0 3.9093933423828275e-07
transferrin O 0 7.15974692866439e-06
to O 0 1.4869281983465044e-07
TfR O 0 1.0518101589696016e-05
, O 0 3.403692616643639e-08
consistent O 0 8.034583487415148e-08
with O 0 1.211845201964934e-08
our O 0 3.72912367652134e-08
demonstration O 0 3.938116606150288e-07
that O 0 2.7105977906671797e-08
HFE O 0 0.0003410500939935446
, O 0 5.444668431664468e-07
transferrin O 0 1.2301717106311116e-05
, O 0 2.2492578466426494e-07
and O 0 2.6996525548383943e-07
TfR O 0 2.511514503567014e-05
form O 0 8.107998610284994e-07
a O 0 6.881760441501683e-07
ternary O 0 3.850795837934129e-05
complex O 0 5.647530633723363e-05
. O 0 1.8779843230731785e-05

Identification O 0 8.046536095207557e-06
of O 0 1.8505186289985431e-06
three O 0 4.396052304400655e-07
novel O 0 1.8304203308616707e-07
mutations O 0 1.955048389845615e-07
and O 0 4.3418623363322695e-08
a O 0 5.871951813674059e-08
high O 0 3.161487995839707e-07
frequency O 0 7.188052109086129e-07
of O 0 9.926893795864089e-08
the O 0 6.510551742167081e-08
Arg778Leu O 0 2.3278120352188125e-05
mutation O 0 2.3037790697344462e-07
in O 0 6.518130390986698e-08
Korean O 0 9.040899385581724e-06
patients O 0 5.766939921159064e-07
with O 0 1.8445124396748724e-06
Wilson B-Disease 0 0.15863710641860962
disease I-Disease 1 0.9977954626083374
. O 0 9.715152555145323e-05

Four O 0 2.0283254343667068e-05
mutations O 0 6.491576186817838e-06
- O 0 5.404990588431247e-06
- O 0 2.625556817292818e-06
R778L O 0 7.311076387850335e-06
, O 0 1.9893141711690987e-07
A874V O 0 7.383202500932384e-06
, O 0 2.5635887368480326e-07
L1083F O 0 4.367175733932527e-06
, O 0 2.047355422973851e-07
and O 0 1.5405397846279811e-07
2304delC O 0 6.5715357777662575e-06
- O 0 6.672652261840994e-07
- O 0 1.5750856618979014e-07
in O 0 2.2178348046963947e-08
the O 0 1.2340512967057293e-07
copper O 0 1.007757327897707e-05
- O 0 4.811512098967796e-06
transporting O 0 8.428999080933863e-07
enzyme O 0 2.8071249857930525e-07
, O 0 7.806152524381105e-08
P O 0 4.0177092159865424e-05
- O 0 2.8079034564143512e-06
type O 0 4.787011675944086e-06
ATPase O 0 7.822619954822585e-05
( O 0 1.3775398599591426e-07
ATP7B O 0 6.605995440622792e-05
) O 0 2.5396676761602066e-08
, O 0 1.260857640517088e-08
were O 0 2.5220339594511643e-08
identified O 0 9.85168995271124e-08
in O 0 7.085235864678907e-08
Korean O 0 7.879021723056212e-06
Patients O 0 2.747917278611567e-06
with O 0 2.8200979613757227e-06
Wilson B-Disease 1 0.6129302382469177
disease I-Disease 1 0.9965072274208069
. O 0 0.00013151222083251923

Arg778Leu O 0 0.004374890588223934
, O 0 1.528645952930674e-06
the O 0 3.51654364294518e-07
most O 0 4.654772567391774e-08
frequently O 0 4.633018235722375e-08
reported O 0 3.8747248964909886e-08
mutation O 0 3.2781976244677935e-08
of O 0 2.611025884391438e-08
this O 0 9.707278536552622e-09
enzyme O 0 1.4698993311412778e-07
, O 0 2.1321225673887056e-08
was O 0 1.2362139045762888e-07
found O 0 1.3890931960247599e-08
in O 0 1.0904531499988934e-08
six O 0 1.0697254282376889e-07
of O 0 2.3348242450538237e-07
eight O 0 1.0478117928869324e-06
unrelated O 0 3.653691749150312e-07
patients O 0 2.001057275435869e-08
studied O 0 1.4173883755574934e-07
, O 0 2.2950288780521078e-08
an O 0 1.002795979587745e-08
allele O 0 2.1721071163938177e-07
frequency O 0 6.725391017425864e-07
of O 0 3.6667887570729363e-07
37 O 0 7.131228812795598e-06
. O 0 1.129847987613175e-05

5 O 0 1.4327867575048003e-05
% O 0 5.283439463710238e-07
, O 0 2.0853164528489287e-07
which O 0 4.475768022871307e-08
is O 0 1.2908319746429697e-08
considerably O 0 5.595547847292437e-08
higher O 0 3.5634279527130275e-08
than O 0 6.834067534100541e-09
those O 0 3.0884448332102465e-09
in O 0 6.903213112252615e-09
other O 0 1.1769422769702942e-08
Asian O 0 3.4625068678906246e-07
populations O 0 2.51576011578436e-07
. O 0 2.716711151151685e-06

The O 0 1.8302019952898263e-06
novel O 0 1.0300245776306838e-06
single O 0 3.406427424579306e-07
nucleotide O 0 7.688441314712691e-07
deletion O 0 1.0631853228915134e-06
, O 0 2.4337353465853084e-07
2304delC O 0 1.0711137292673811e-05
, O 0 3.6041544149156834e-07
was O 0 1.556861434437451e-06
found O 0 1.4021102856531797e-07
in O 0 1.9704816622834187e-07
one O 0 1.0403608712294954e-06
patient O 0 6.533660780405626e-06
. O 0 2.77919079962885e-05

Since O 0 6.71315319777932e-06
a O 0 8.546554113308957e-07
mutation O 0 1.0757198651845101e-06
at O 0 1.795819684957678e-06
cDNA O 0 4.483351858652895e-06
nucleotide O 0 7.843791536288336e-06
2302 O 0 0.00029848498525097966
( O 0 5.681566790372017e-07
2302insC O 0 1.0337559615436476e-05
) O 0 1.0228126967604112e-07
had O 0 9.84023387218258e-08
been O 0 7.194287121592424e-08
previously O 0 1.4711096696373716e-07
described O 0 1.265183584564511e-07
, O 0 3.061297704221033e-08
this O 0 1.5610964965162566e-08
region O 0 7.194930873311023e-08
of O 0 1.33708667249266e-07
the O 0 3.46547352592097e-07
ATP7B O 0 0.0049903057515621185
gene O 0 1.38494286261448e-07
may O 0 5.0542595886327035e-08
be O 0 8.62932481027201e-08
susceptible O 0 8.336799055541633e-07
to O 0 1.3974100454561267e-07
gene O 0 5.550516561925178e-06
rearrangements O 0 0.37558266520500183
causing O 1 0.9866188168525696
Wilson B-Disease 1 0.9832619428634644
disease I-Disease 1 0.9998114705085754
. O 0 0.0002923060383182019

Disruption O 0 0.00014608848141506314
of O 0 3.882933015120216e-06
splicing O 0 5.654670076182811e-06
regulated O 0 3.2164604135687114e-07
by O 0 5.297748018051607e-08
a O 0 2.7667900326378003e-07
CUG O 0 0.0008012123871594667
- O 0 1.1146506949444301e-05
binding O 0 3.7426666494866367e-06
protein O 0 2.212655272160191e-05
in O 0 1.3525047506846022e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.002349724993109703

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999967813491821
DM B-Disease 1 1.0
) O 0 1.3493315236701164e-05
is O 0 1.6115460255150538e-07
caused O 0 3.0026143349459744e-07
by O 0 3.331435038944619e-08
a O 0 1.4554217386830715e-07
CTG O 0 2.077112003462389e-05
expansion O 0 3.9340400803666853e-07
in O 0 1.6646749756432655e-08
the O 0 2.15818545257207e-08
3 O 0 2.3120549030863913e-07
untranslated O 0 1.5812910305612604e-06
region O 0 8.079302205032945e-08
of O 0 2.399564209554228e-07
the O 0 2.8961685529793613e-06
DM B-Disease 1 1.0
gene O 0 2.3377695470117033e-05
. O 0 2.1232495782896876e-05

One O 0 9.548961315886118e-06
model O 0 1.1519497093104292e-05
of O 0 3.820156052825041e-05
DM B-Disease 1 1.0
pathogenesis O 1 0.9996505975723267
suggests O 0 4.3521356474229833e-07
that O 0 1.280627781596877e-08
RNAs O 0 1.8283999736468104e-07
from O 0 1.4922990843047046e-08
the O 0 1.562890084016999e-08
expanded O 0 6.72185791472657e-08
allele O 0 1.127495750097296e-07
create O 0 2.962423728547492e-08
a O 0 2.4245146335033496e-08
gain O 0 1.9616055624283035e-07
- O 0 1.777657558932333e-07
of O 0 7.878308849740279e-08
- O 0 1.3058215131422912e-07
function O 0 1.508824531981645e-08
mutation O 0 8.391997319279199e-09
by O 0 2.2782538078303105e-09
the O 0 1.1865328275462161e-08
inappropriate O 0 3.3294785595217036e-08
binding O 0 2.439897528461188e-08
of O 0 2.562224210578279e-08
proteins O 0 6.322842249772975e-09
to O 0 2.111788788283775e-08
the O 0 4.5262817138791434e-07
CUG O 0 0.0018575909780338407
repeats O 0 3.865292092086747e-05
. O 0 1.2214486559969373e-05

Data O 0 1.5341798643930815e-05
presented O 0 6.808231773902662e-06
here O 0 2.8519588113340433e-07
indicate O 0 1.459838188111462e-07
that O 0 2.9264478840218544e-08
the O 0 1.1858896442618061e-07
conserved O 0 9.08170420643728e-07
heterogeneous O 0 6.961566214158665e-06
nuclear O 0 3.586926686693914e-05
ribonucleoprotein O 0 0.0005741127533838153
, O 0 1.862684371189971e-06
CUG O 0 0.0002457897935528308
- O 0 3.3374503800587263e-06
binding O 0 6.289670864134678e-07
protein O 0 5.745125122302852e-07
( O 0 1.851248043749365e-07
CUG O 0 0.00020870051230303943
- O 0 4.796667781192809e-06
BP O 0 1.4460526472248603e-05
) O 0 7.198006102271393e-08
, O 0 5.5528182940633997e-08
may O 0 2.2441498970238172e-07
mediate O 0 2.3998416054382687e-06
the O 0 2.830269352216419e-07
trans O 0 2.0986701656511286e-06
- O 0 3.533146468726045e-07
dominant O 0 5.409123104982427e-07
effect O 0 2.3676241767134343e-07
of O 0 1.7099577576118463e-07
the O 0 2.929662912265485e-07
RNA O 0 3.375155529283802e-06
. O 0 2.8760784971382236e-06

CUG O 1 0.9990682005882263
- O 0 0.16269466280937195
BP O 0 0.000555359001737088
was O 0 2.225939169875346e-06
found O 0 4.1589480304082826e-08
to O 0 1.1682665501666634e-08
bind O 0 2.4554859479053448e-08
to O 0 2.015813471700767e-08
the O 0 1.3794897313346155e-07
human O 0 1.4758411452930886e-06
cardiac O 0 0.21716739237308502
troponin O 1 0.8545699119567871
T O 0 0.007451958488672972
( O 0 3.5225386341153353e-07
cTNT O 0 4.7091748456296045e-06
) O 0 5.422925397624567e-08
pre O 0 6.004577812745993e-07
- O 0 2.2683887834773486e-07
messenger O 0 3.8649974953841593e-07
RNA O 0 2.887933590045577e-07
and O 0 4.126512109792202e-08
regulate O 0 5.583735074310425e-08
its O 0 6.296657062421218e-08
alternative O 0 1.6800213415990584e-06
splicing O 0 1.4379294952959754e-05
. O 0 7.716805157542694e-06

Splicing O 0 7.694501255173236e-05
of O 0 8.352400982403196e-06
cTNT O 0 0.0004056843463331461
was O 0 3.0529819923685864e-05
disrupted O 0 0.00018492626259103417
in O 0 9.477198545937426e-06
DM B-Disease 1 1.0
striated O 1 0.9892041087150574
muscle O 0 0.00016420046449638903
and O 0 3.866007602937316e-07
in O 0 7.043318106525476e-08
normal O 0 1.2280730743441381e-07
cells O 0 5.7375480366772535e-08
expressing O 0 3.948826687860674e-08
transcripts O 0 2.4042162749537965e-07
that O 0 2.2644609742883404e-08
contain O 0 7.584952754768892e-07
CUG O 0 0.0007615689537487924
repeats O 0 3.587487663025968e-05
. O 0 1.6772368326201104e-05

Altered O 0 1.7689711967250332e-05
expression O 0 1.3779712162431679e-06
of O 0 6.798174467803619e-07
genes O 0 5.272501653053041e-07
regulated O 0 8.882926181286166e-07
posttranscriptionally O 0 9.583812243363354e-06
by O 0 7.117131985978631e-07
CUG O 1 0.6755489110946655
- O 0 0.0001634240325074643
BP O 0 3.2917188946157694e-05
therefore O 0 5.530609996640123e-07
may O 0 2.9315407346075517e-07
contribute O 0 5.229859425526229e-07
to O 0 1.3214402088124189e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9999650716781616
. O 0 3.659498361230362e-06
. O 0 1.2468082786654122e-05

Identification O 0 5.569387212744914e-06
of O 0 1.4646606132373563e-06
a O 0 6.525507387777907e-07
novel O 0 8.309223744618066e-07
nonsense O 0 4.426279701874591e-06
mutation O 0 7.172952223299944e-07
and O 0 1.6387390644467814e-07
a O 0 2.741985554166604e-07
missense O 0 3.3059338875318645e-06
substitution O 0 7.470251262020611e-07
in O 0 8.973454157512606e-08
the O 0 2.469572564223199e-07
vasopressin O 0 7.300430297618732e-06
- O 0 1.8479472601029556e-06
neurophysin O 0 7.131350685085636e-06
II O 0 0.00016400018648710102
gene O 0 6.141674901982697e-08
in O 0 1.2967124263241203e-08
two O 0 4.8658748141861e-08
Spanish O 0 3.612086175053264e-06
kindreds O 0 2.5492498025414534e-05
with O 0 2.1491910047188867e-06
familial B-Disease 1 0.9481209516525269
neurohypophyseal I-Disease 1 0.9999998807907104
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999960660934448
. O 0 0.000960423843935132

Familial B-Disease 1 0.9998859167098999
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9532045722007751
FNDI B-Disease 1 1.0
) O 0 6.51817572361324e-06
is O 0 1.6384689160986454e-07
an O 0 2.1840237707237975e-07
autosomal B-Disease 1 0.9999873638153076
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999078512191772
by O 0 0.0007028412073850632
deficiency O 1 0.9999954700469971
in O 0 2.096571734000463e-06
the O 0 5.686537770088762e-05
antidiuretic O 0 0.12133514136075974
hormone O 0 2.81607990473276e-05
arginine O 0 2.3852455342421308e-05
vasopressin O 0 1.3149887308827601e-05
( O 0 5.035049639445788e-07
AVP O 0 2.2551337679033168e-05
) O 0 6.514774497645703e-08
encoded O 0 6.244749073403e-08
by O 0 4.7187139529114575e-08
the O 0 3.153833176838816e-07
AVP O 0 0.00016358974971808493
- O 0 1.0386129360995255e-05
neurophysin O 0 0.00021170280524529517
II O 1 0.9999991655349731
( O 0 1.8249755157739855e-05
AVP O 0 0.028086135163903236
- O 0 3.206505789421499e-05
NPII O 0 0.0006123981438577175
) O 0 3.971896660459606e-07
gene O 0 7.519570885961002e-07
on O 0 2.7005507945432328e-06
chromosome O 0 2.4969565856736153e-05
20p13 O 0 0.0002382975653745234
. O 0 5.440468157758005e-05

In O 0 6.784197807974124e-07
this O 0 5.595195773366868e-08
study O 0 6.70858852913625e-08
, O 0 3.32165122074457e-08
we O 0 4.43852350429097e-08
analyzed O 0 7.955409841997607e-08
two O 0 1.7420207498730633e-08
families O 0 6.807345798165443e-09
with O 0 5.231355615364919e-08
FNDI B-Disease 1 0.9999915361404419
using O 0 2.207508202900499e-07
direct O 0 1.3535162679545465e-07
automated O 0 1.1837997817565338e-06
fluorescent O 0 5.363648369893781e-07
, O 0 1.7033912058650458e-08
solid O 0 2.2219465733996913e-07
phase O 0 2.3528361907665385e-06
, O 0 3.176483787115103e-08
single O 0 3.13538919272105e-08
- O 0 5.328982766172885e-08
stranded O 0 3.975313944692971e-08
DNA O 0 4.20410586343678e-08
sequencing O 0 1.2573507035540388e-07
of O 0 1.2629810441922018e-07
PCR O 0 1.6276870155707e-05
- O 0 3.1207029678625986e-05
amplified O 0 5.090871491120197e-05
AVP O 0 0.004685321357101202
- O 0 9.240394865628332e-05
NPII O 0 0.00459498493000865
DNA O 0 6.254966137930751e-05
. O 0 1.9410441382206045e-05

In O 0 1.3435715118248481e-06
one O 0 1.453708762255701e-07
of O 0 1.4682181870284694e-07
the O 0 1.3795488484902307e-07
families O 0 4.300012435010103e-08
, O 0 1.0492371416148671e-07
affected O 0 1.483156779613637e-07
individuals O 0 2.470862980885613e-08
presented O 0 4.060937044414459e-07
a O 0 8.148029451149341e-08
novel O 0 1.8031269632956537e-07
nonsense O 0 6.934683369763661e-07
mutation O 0 1.2343784305812733e-07
in O 0 3.664760228616615e-08
exon O 0 3.834290680515551e-07
3 O 0 1.4385068425326608e-07
of O 0 3.305679641130155e-08
the O 0 2.571085211400259e-08
gene O 0 2.342290450485507e-08
, O 0 2.096114393168591e-08
consisting O 0 6.596913948442307e-08
in O 0 1.4681742044331259e-08
a O 0 7.612593577732696e-08
G O 0 1.73536864167545e-06
to O 0 6.115408979212589e-08
T O 0 8.176522896974348e-06
transition O 0 1.7277776578339399e-06
at O 0 7.200861773526412e-07
nucleotide O 0 3.63651196266801e-07
2101 O 0 2.550416184021742e-06
, O 0 1.551854822423593e-08
which O 0 5.519321444324987e-09
produces O 0 1.3703851386992483e-08
a O 0 1.6850206563390202e-08
stop O 0 5.3470341043748704e-08
signal O 0 2.372495089275617e-07
in O 0 4.931925801088255e-08
codon O 0 1.6641772617731476e-06
82 O 0 2.162925966331386e-06
( O 0 1.3202032960180077e-06
Glu O 0 0.0008421879610978067
) O 0 1.1501496146593126e-06
of O 0 8.802124284557067e-06
NPII O 0 0.11520463228225708
. O 0 0.00013847627269569784

The O 0 1.709558637230657e-05
premature O 0 4.002908826805651e-05
termination O 0 2.637001125549432e-05
eliminates O 0 8.180430995707866e-06
part O 0 2.215049477172215e-07
of O 0 1.622101990506053e-07
the O 0 2.461416102050862e-07
C O 0 4.319471190683544e-05
- O 0 7.743173568997008e-07
terminal O 0 6.997269110797788e-07
domain O 0 4.4195839876692844e-08
of O 0 9.696179148477313e-08
NPII O 0 0.00011751599959097803
, O 0 6.685034747988539e-08
including O 0 4.186453494980924e-08
a O 0 6.050932910284246e-08
cysteine O 0 2.600852440082235e-07
residue O 0 1.3507181506611232e-07
in O 0 7.689700431967594e-09
position O 0 1.5010978415830323e-07
85 O 0 1.8045633964902663e-07
, O 0 1.383500780605118e-08
which O 0 3.8773255717217125e-09
could O 0 8.18327094975757e-09
be O 0 9.068479300822219e-09
involved O 0 2.2045789194180543e-08
in O 0 8.445193877548718e-09
the O 0 5.300537608832201e-08
correct O 0 1.1972731499554357e-06
folding O 0 1.624411925149616e-05
of O 0 7.839274189791468e-07
the O 0 3.5048028621531557e-06
prohormone O 0 0.05695214495062828
. O 0 2.17230299313087e-05

In O 0 1.9290084765088977e-06
the O 0 1.1053776916014613e-06
second O 0 1.5833174984436482e-06
family O 0 6.119586259956122e-08
, O 0 4.64915572706559e-08
a O 0 6.627573867490355e-08
G279A O 0 1.1825867431980441e-06
substitution O 0 3.037892213342275e-07
at O 0 1.9616167890035285e-07
position O 0 2.1310130193796795e-07
- O 0 4.1212263823808826e-08
1 O 0 2.2966709423144493e-08
of O 0 4.231148764688442e-09
the O 0 3.5110858664921807e-09
signal O 0 7.592900885811105e-08
peptide O 0 5.3556586721015265e-08
was O 0 2.1112452230909184e-08
observed O 0 2.6695207822058364e-08
in O 0 1.2966851592466355e-08
all O 0 6.277087294392913e-08
affected O 0 3.2988782550091855e-07
individuals O 0 6.202891995599202e-07
. O 0 1.0342854693590198e-05

This O 0 2.336161287530558e-06
missense O 0 4.2225703509757295e-05
mutation O 0 4.384004569146782e-06
, O 0 8.479947837258806e-07
which O 0 9.492887897977198e-07
replaces O 0 0.11159354448318481
Ala O 0 0.0019312623189762235
with O 0 8.376766800211044e-07
Thr O 0 0.000706569233443588
, O 0 2.2665528831566917e-07
is O 0 4.8593175705491376e-08
frequent O 0 1.5476285852855654e-07
among O 0 1.5591571127515635e-06
FNDI B-Disease 1 1.0
patients O 0 1.245184307663294e-06
and O 0 1.3160847345261573e-07
is O 0 2.7434179372676226e-08
thought O 0 4.406991038763408e-08
to O 0 7.70535191207955e-09
reduce O 0 3.5064097403392225e-08
the O 0 2.2659211396103274e-08
efficiency O 0 1.5509323247897555e-07
of O 0 4.265035968842312e-08
cleavage O 0 2.32417619372427e-07
by O 0 4.765112038285224e-08
signal O 0 2.130256234522676e-06
peptidases O 0 1.6876900190254673e-05
. O 0 1.9187905309081543e-06
. O 0 1.2914340913994238e-05

Genetic O 0 3.391101927263662e-05
heterogeneity O 0 8.91776435310021e-05
of O 0 5.7069642934948206e-05
Saethre B-Disease 1 0.9999992847442627
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.9182782580173807e-06
due O 0 8.331947356055025e-06
to O 0 2.753762373686186e-07
TWIST O 0 0.2739306390285492
and O 0 9.734267223393545e-06
FGFR O 1 0.999448835849762
mutations O 0 2.8372323868097737e-05
. O 0 1.1396361514925957e-05

Thirty O 0 0.0006789020844735205
- O 0 7.609414024045691e-05
two O 0 4.1424345909035765e-07
unrelated O 0 6.423616127904097e-07
patients O 0 5.454543838823156e-08
with O 0 3.849693896995632e-08
features O 0 6.307415105766268e-07
of O 0 7.852676390029956e-06
Saethre B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.5899980780886835e-06
a O 0 9.088922183764225e-07
common O 0 8.705270374775864e-06
autosomal B-Disease 0 0.007871313020586967
dominant I-Disease 1 0.8466134071350098
condition I-Disease 0 0.0005622183089144528
of O 0 0.008642821572721004
craniosynostosis B-Disease 1 0.9999998807907104
and O 0 0.05581127852201462
limb B-Disease 1 0.9999979734420776
anomalies I-Disease 0 0.057451147586107254
, O 0 3.672776642815734e-07
were O 0 3.223643147975963e-07
screened O 0 2.4865312298061326e-07
for O 0 2.5695653604884683e-08
mutations O 0 9.580474369386138e-08
in O 0 4.486768290234977e-08
TWIST O 0 9.07216381165199e-05
, O 0 1.8263798438056256e-06
FGFR2 O 1 0.8090636134147644
, O 0 1.9356773464096477e-06
and O 0 4.36451500718249e-06
FGFR3 O 1 0.7687699198722839
. O 0 3.775774166570045e-05

Nine O 0 3.91933172068093e-05
novel O 0 3.255670890212059e-06
and O 0 7.259526455527521e-07
three O 0 4.3152206785634917e-07
recurrent O 0 6.77818479744019e-06
TWIST O 0 0.00010488187399460003
mutations O 0 1.2013791774734273e-06
were O 0 2.861996222236485e-07
found O 0 1.1547642486675613e-07
in O 0 1.718221085411642e-07
12 O 0 1.1236052159802057e-05
families O 0 1.4737202036485542e-06
. O 0 2.3664557375013828e-05

Seven O 0 1.8111744793714024e-05
families O 0 2.626826471896493e-07
were O 0 1.3817081878642057e-07
found O 0 3.058461572891247e-08
to O 0 1.722523812475174e-08
have O 0 2.9142769975010197e-08
the O 0 2.490057795512257e-07
FGFR3 O 0 0.04664057120680809
P250R O 0 1.7932450646185316e-05
mutation O 0 2.9944359880573757e-07
, O 0 2.9625931929899707e-08
and O 0 3.089465394623403e-08
one O 0 1.8604401574862095e-08
individual O 0 9.724753446960221e-09
was O 0 7.802609758300605e-08
found O 0 4.093951844197363e-09
to O 0 7.790307954280706e-09
have O 0 3.023106032173928e-08
an O 0 1.376392191332343e-07
FGFR2 O 0 0.00351027213037014
VV269 O 0 0.0002808373828884214
- O 0 3.843960803351365e-05
270 O 0 1.5573454220429994e-05
deletion O 0 6.152527203084901e-05
. O 0 3.230849688407034e-05

To O 0 7.314573053918139e-07
date O 0 2.0982838577765506e-06
, O 0 1.5130052588574472e-07
our O 0 9.36756094915836e-08
detection O 0 3.2388163617724786e-07
rate O 0 9.42514475354983e-08
for O 0 3.102350021322309e-08
TWIST O 0 1.0728699635365047e-05
or O 0 2.3707534069217218e-07
FGFR O 0 4.44238175987266e-05
mutations O 0 1.1572248581614986e-07
is O 0 1.1153334256164271e-08
68 O 0 8.925641736823309e-08
% O 0 1.2960991391253174e-08
in O 0 2.5295301853134333e-08
our O 0 4.5185097974353994e-07
Saethre B-Disease 1 0.9944601058959961
- I-Disease 1 0.9996225833892822
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
patients O 0 7.937090913401335e-07
, O 0 1.0934193284128924e-07
including O 0 1.680582357721505e-07
our O 0 3.841420550543262e-07
five O 0 2.748499241533864e-07
patients O 0 6.313035783023224e-08
elsewhere O 0 1.4266073833368864e-07
reported O 0 1.9905608894532634e-07
with O 0 1.95537097624765e-07
TWIST O 0 0.0021456654649227858
mutations O 0 3.293577901786193e-05
. O 0 1.4786469364480581e-05

More O 0 7.4372542258061e-07
than O 0 1.5731220059933548e-07
35 O 0 1.945030163597039e-07
different O 0 1.7471084134967896e-08
TWIST O 0 1.206513843499124e-06
mutations O 0 5.08202226967569e-08
are O 0 3.283852967328471e-09
now O 0 2.1423176121970755e-08
known O 0 3.816305138570897e-08
in O 0 2.893087369670866e-08
the O 0 1.333194177277619e-07
literature O 0 1.8970220025948947e-06
. O 0 7.195629677880788e-06

The O 0 5.920246167079313e-06
most O 0 3.0449291443801485e-07
common O 0 5.063861294729577e-07
phenotypic O 0 1.21952116387547e-05
features O 0 4.456210547232331e-07
, O 0 3.779578605644929e-08
present O 0 2.309431756941649e-08
in O 0 3.5605933756954755e-09
more O 0 2.132971577140097e-09
than O 0 5.032689820438918e-09
a O 0 1.3968246115325655e-08
third O 0 4.903018790969327e-08
of O 0 3.755820543460686e-08
our O 0 4.6842615120112896e-08
patients O 0 1.661480730774656e-08
with O 0 1.9497578662708293e-08
TWIST O 0 1.5576957594021223e-05
mutations O 0 3.4732485687527515e-07
, O 0 6.977877831104706e-08
are O 0 4.749250948066219e-08
coronal B-Disease 0 0.0020041302777826786
synostosis I-Disease 0 7.807282963767648e-05
, O 0 6.000009875606338e-07
brachycephaly B-Disease 0 2.354956086492166e-05
, O 0 1.2048041071466287e-06
low B-Disease 0 0.002811359940096736
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 0.006171913351863623
facial B-Disease 1 1.0
asymmetry I-Disease 1 0.999748170375824
, O 0 1.2351748409855645e-05
ptosis B-Disease 1 0.9931408762931824
, O 0 5.778143531642854e-06
hypertelorism B-Disease 1 0.7659246325492859
, O 0 1.5657775520594441e-06
broad B-Disease 0 0.00024258090707007796
great I-Disease 1 0.654840350151062
toes I-Disease 0 0.020771898329257965
, O 0 2.052044237643713e-06
and O 0 5.116313786857063e-06
clinodactyly B-Disease 0 0.0031214074697345495
. O 0 3.277285577496514e-05

Significant O 0 6.934942211955786e-05
intra O 0 0.0008060037507675588
- O 0 0.00010726585605880246
and O 0 1.8325440578337293e-06
interfamilial O 0 0.00028370070504024625
phenotypic O 0 5.826169945066795e-05
variability O 0 7.774310688546393e-06
is O 0 3.139919613204256e-08
present O 0 2.3732253495722944e-08
for O 0 2.7680426839538086e-08
either O 0 2.560676080065605e-07
TWIST O 0 0.0001064701791619882
mutations O 0 3.883259068970801e-06
or O 0 1.6680113503753091e-06
FGFR O 0 0.0049666897393763065
mutations O 0 2.477095404174179e-05
. O 0 1.6158415746758692e-05

The O 0 3.3647138479864225e-06
overlap O 0 7.96621861809399e-07
in O 0 6.047424960797798e-08
clinical O 0 8.265399173978949e-07
features O 0 1.0565047858790422e-07
and O 0 2.5433859462964392e-08
the O 0 1.1872505645271758e-08
presence O 0 2.7502444766014378e-08
, O 0 1.3174039636965063e-08
in O 0 3.993048558470491e-09
the O 0 5.464204644312076e-09
same O 0 5.2203885658741456e-09
genes O 0 6.433606536404568e-09
, O 0 4.593709412858971e-09
of O 0 1.6077535747172078e-08
mutations O 0 2.9755049979485193e-08
for O 0 4.660304586678876e-09
more O 0 4.4940975385543425e-09
than O 0 1.2342979971435852e-08
one O 0 2.987184899438944e-08
craniosynostotic B-Disease 0 4.258709850546438e-06
condition I-Disease 0 3.466785756245372e-07
- O 0 8.103872062292794e-08
such O 0 1.1281922951411616e-08
as O 0 1.1783397724229872e-07
Saethre B-Disease 0 4.2551913793431595e-05
- I-Disease 0 3.2005323191697244e-06
Chotzen I-Disease 0 6.250517617445439e-05
, I-Disease 0 2.949893200820952e-07
Crouzon I-Disease 0 0.00012513618275988847
, I-Disease 0 3.2578526543147746e-07
and I-Disease 0 8.696688382769935e-07
Pfeiffer I-Disease 0 0.001033227308653295
syndromes I-Disease 0 2.4621847842354327e-05
- O 0 6.677522605968989e-07
support O 0 5.637465960717236e-08
the O 0 6.744666336544469e-08
hypothesis O 0 1.566167213695735e-07
that O 0 1.0063982536223648e-08
TWIST O 0 4.148991592956008e-06
and O 0 1.2251614123215404e-07
FGFRs O 0 7.819779057172127e-06
are O 0 5.625293564293088e-09
components O 0 4.4417586053668856e-08
of O 0 1.7253384498872038e-08
the O 0 8.029370945905612e-09
same O 0 1.0122583660177042e-08
molecular O 0 1.8628765019457205e-07
pathway O 0 7.055096062913435e-08
involved O 0 2.1583293374760615e-08
in O 0 6.586740042280326e-09
the O 0 5.024807947506815e-08
modulation O 0 5.751815115218051e-05
of O 0 6.15533281234093e-05
craniofacial O 1 1.0
and O 0 0.13203805685043335
limb O 1 0.999998927116394
development O 0 3.064118209294975e-05
in O 0 1.317594211514006e-07
humans O 0 6.11346138157387e-07
. O 0 2.990682901327091e-07
. O 0 3.798705392910051e-06

Mutation O 0 1.9388833607081324e-05
analysis O 0 5.7482666306896135e-06
of O 0 3.233627285226248e-05
UBE3A O 1 0.9999997615814209
in O 1 0.9999628067016602
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9999169111251831
. O 0 0.011295409873127937

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9980448484420776
AS B-Disease 1 1.0
) O 0 1.7430797925044317e-06
is O 0 7.951830127694848e-08
caused O 0 4.330622971338016e-07
by O 0 1.8032713455795601e-07
chromosome O 0 2.4543774088670034e-06
15q11 O 0 9.11638835532358e-06
- O 0 2.2931815237825504e-06
q13 O 0 2.669180503289681e-06
deletions O 0 3.095216527526645e-07
of O 0 1.1923911813482846e-07
maternal O 0 1.2877278265932546e-07
origin O 0 9.260279654199621e-08
, O 0 9.578683091149287e-08
by O 0 1.1711194503050137e-07
paternal O 0 5.58098372493987e-06
uniparental B-Disease 1 0.9999202489852905
disomy I-Disease 1 0.9999972581863403
( O 0 0.16503173112869263
UPD B-Disease 1 1.0
) O 0 2.5140238903986756e-06
15 O 0 2.3756674636388198e-06
, O 0 1.585889748412228e-07
by O 0 2.0310508830334584e-07
imprinting O 0 0.00022427346266340464
defects O 0 0.00195313710719347
, O 0 2.1736570943176048e-07
and O 0 1.156410647240591e-07
by O 0 4.986864965417226e-08
mutations O 0 1.9697262132467586e-07
in O 0 1.2200324306377297e-07
the O 0 1.021845037030289e-06
UBE3A O 0 0.004431921988725662
gene O 0 2.1728417777922004e-05
. O 0 3.827401451417245e-05

UBE3A O 0 0.014451825991272926
encodes O 0 6.340471736621112e-05
a O 0 9.151780432148371e-06
ubiquitin O 0 0.00011125772289233282
- O 0 4.6481931349262595e-05
protein O 0 4.697759322880302e-06
ligase O 0 7.1276181188295595e-06
and O 0 5.966389835521113e-07
shows O 0 2.942143510153983e-06
brain O 0 0.0013767449418082833
- O 0 9.79208925855346e-06
specific O 0 1.5350328794738743e-06
imprinting O 0 0.00010682805441319942
. O 0 3.448314964771271e-05

Here O 0 4.129292574361898e-05
we O 0 5.486584086611401e-06
describe O 0 2.0607851183740422e-05
UBE3A O 0 0.001645312295295298
coding O 0 4.519821231951937e-05
- O 0 9.758807209436782e-06
region O 0 4.354859299837699e-07
mutations O 0 4.868274459113309e-07
detected O 0 1.9896404523933597e-07
by O 0 8.344292723450053e-08
SSCP O 0 3.981759800808504e-05
analysis O 0 1.7475592528626294e-07
in O 0 4.67269636317269e-08
13 O 0 1.9703772977663903e-06
AS B-Disease 1 0.9947066903114319
individuals O 0 2.012057223055308e-07
or O 0 8.476777679788938e-07
families O 0 1.0241592462989502e-06
. O 0 8.692353731021285e-06

Two O 0 7.085477591317613e-06
identical O 0 7.486807589884847e-06
de O 0 3.344960350659676e-05
novo O 0 1.9465645891614258e-05
5 O 0 6.1401788116199896e-06
- O 0 4.2712172216852196e-06
bp O 0 4.775744400831172e-06
duplications O 0 7.3933069870690815e-06
in O 0 2.6325619728595484e-07
exon O 0 1.846538225436234e-06
16 O 0 1.1185843504790682e-06
were O 0 5.759047212450241e-07
found O 0 1.4935653780412395e-06
. O 0 1.6968408090178855e-05

Among O 0 2.351840294068097e-06
the O 0 4.213698900912277e-07
other O 0 4.144559184737773e-08
11 O 0 2.0728347749354725e-07
unique O 0 3.282877969468245e-08
mutations O 0 5.8198363461769986e-08
, O 0 2.7635167043627007e-08
8 O 0 2.9801464052070514e-07
were O 0 6.8118424678687e-08
small O 0 4.016278865037748e-08
deletions O 0 1.8802663248607132e-07
or O 0 4.7294005156572894e-08
insertions O 0 4.153795885031286e-07
predicted O 0 3.471139393695921e-07
to O 0 3.3385212816483545e-08
cause O 0 7.58634200792585e-07
frameshifts O 0 9.124071948463097e-05
, O 0 1.4691370608943544e-07
1 O 0 7.191748068180459e-07
was O 0 1.5151221077758237e-07
a O 0 1.1089041684897438e-08
mutation O 0 6.2020730773326704e-09
to O 0 2.5594093511216442e-09
a O 0 1.9166908060697097e-08
stop O 0 7.110077149263816e-08
codon O 0 6.028055850038072e-07
, O 0 4.264092368089223e-08
1 O 0 1.6799189950233995e-07
was O 0 1.2130597326631687e-07
a O 0 2.5230541211840318e-08
missense O 0 3.25811384982444e-07
mutation O 0 3.814914961708382e-08
, O 0 1.2643085689489908e-08
and O 0 1.647281244743226e-08
1 O 0 2.636896283547685e-07
was O 0 1.6173767392047012e-07
predicted O 0 1.3436006440770143e-07
to O 0 1.4026795724930707e-08
cause O 0 6.544266284436162e-08
insertion O 0 2.893185069297033e-07
of O 0 4.1456118538008013e-07
an O 0 3.135569102141744e-07
isoleucine O 0 0.00012295330816414207
in O 0 1.2156144180153206e-07
the O 0 3.4546303595561767e-07
hect O 0 4.831656042370014e-06
domain O 0 2.4561938971601194e-07
of O 0 1.138389933430517e-07
the O 0 2.5182853846672515e-07
UBE3A O 0 4.341515159467235e-05
protein O 0 3.324643671476224e-07
, O 0 3.7246167039484135e-08
which O 0 1.7317905331992733e-08
functions O 0 9.158926417285329e-08
in O 0 5.044590167813112e-08
E2 O 0 1.751224226609338e-05
binding O 0 9.813841188588412e-07
and O 0 6.546344479829713e-07
ubiquitin O 0 2.4374836357310414e-05
transfer O 0 1.950702971953433e-05
. O 0 2.430543099762872e-05

Eight O 0 6.708334240101976e-06
of O 0 4.4453952341427794e-07
the O 0 1.0119074289605123e-07
cases O 0 3.272668536169476e-08
were O 0 2.955149369654464e-08
familial O 0 6.025538255016727e-07
, O 0 1.4913378265646315e-07
and O 0 1.8092470099873026e-07
five O 0 6.05264119712956e-07
were O 0 6.195738819769758e-07
sporadic O 0 5.117066757520661e-05
. O 0 3.098976594628766e-05

In O 0 1.7543331978231436e-06
two O 0 5.71454620512668e-07
familial O 0 4.861700290348381e-06
cases O 0 3.0796113037467876e-07
and O 0 9.114278753941107e-08
one O 0 5.913943823543377e-08
sporadic O 0 1.7714614841679577e-06
case O 0 1.4707100035593612e-06
, O 0 3.160915298394684e-07
mosaicism O 0 4.572154284687713e-05
for O 0 2.6758453941511107e-07
UBE3A O 0 0.0003241826198063791
mutations O 0 4.905343757855007e-07
was O 0 1.9279806906524755e-07
detected O 0 6.881944614178792e-08
in O 0 1.1492157447889895e-08
the O 0 2.8138597230054074e-08
mother O 0 1.4077263799094908e-08
of O 0 8.847588617300062e-08
three O 0 1.7891579773277044e-07
AS B-Disease 1 0.9999897480010986
sons O 0 6.242439849302173e-05
, O 0 5.815442349899058e-08
in O 0 1.1990318959931301e-08
the O 0 3.168284834487167e-08
maternal O 0 1.0621804591437467e-07
grandfather O 0 1.2157117623701197e-07
of O 0 1.2585059039338375e-07
two O 0 9.33582882112205e-08
AS B-Disease 1 0.9998775720596313
first O 0 4.5296067696654063e-07
cousins O 0 3.5727694580600655e-07
, O 0 3.286687189074655e-08
and O 0 4.2632223085092846e-08
in O 0 2.0152022273123293e-08
the O 0 6.659556817112389e-08
mother O 0 5.8336059538532936e-08
of O 0 1.954750104005143e-07
an O 0 2.462000736613845e-07
AS B-Disease 1 0.9999979734420776
daughter O 0 0.000615382450632751
. O 0 0.00011703055497491732

The O 0 1.119602529797703e-06
frequencies O 0 8.876888273334771e-07
with O 0 1.909258529053659e-08
which O 0 6.787483020076479e-09
we O 0 1.052614262420093e-08
detected O 0 1.966249740803505e-08
mutations O 0 2.0089199637141064e-08
were O 0 2.1737104560770604e-08
5 O 0 1.661985322698456e-07
( O 0 1.790403558743492e-08
14 O 0 6.01916312348294e-08
% O 0 5.677280423554976e-09
) O 0 4.142969078912984e-09
of O 0 1.7282829389841936e-08
35 O 0 6.67204176352243e-08
in O 0 5.476328279740983e-09
sporadic O 0 1.3827838074575993e-07
cases O 0 1.4001161119381322e-08
and O 0 2.3235971369217623e-08
8 O 0 5.40318410457985e-07
( O 0 2.4076205917822335e-08
80 O 0 3.013796501249999e-08
% O 0 5.304337857836572e-09
) O 0 6.9240875255616174e-09
of O 0 2.1687986517804347e-08
10 O 0 1.0698111196916216e-07
in O 0 5.57460424488454e-08
familial O 0 1.154648998635821e-06
cases O 0 3.4156042261201947e-07
. O 0 9.061624837158888e-07
. O 0 1.2184481420263182e-05

The O 0 0.0004142981197219342
hemochromatosis B-Disease 1 0.9999995231628418
845 O 0 0.0006872863741591573
G O 0 0.0008118010009638965
- O 0 3.4384705941192806e-05
- O 0 6.521676823467715e-06
> O 0 2.261579084006371e-06
A O 0 2.213206045098559e-07
and O 0 5.058155849724244e-08
187 O 0 1.8051331096557988e-07
C O 0 2.2350091057887767e-06
- O 0 5.032683247918612e-07
- O 0 3.497276281905215e-07
> O 0 1.049001525643689e-06
G O 0 1.7015360072036856e-06
mutations O 0 1.0809341688400309e-07
: O 0 3.4247786828700555e-08
prevalence O 0 2.474882023761893e-07
in O 0 2.735058579617089e-08
non O 0 1.2356981642369647e-06
- O 0 2.6711820737546077e-06
Caucasian O 0 4.054790679219877e-06
populations O 0 2.4151097477442818e-06
. O 0 1.120869637816213e-05

Hemochromatosis B-Disease 1 0.9999927282333374
, O 0 3.224069587304257e-05
the O 0 0.00018328335136175156
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9999998807907104
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 4.107809218112379e-06
leads O 0 2.9273242034832947e-06
, O 0 7.944780122670636e-08
if O 0 8.357960012972399e-08
untreated O 0 3.936152097594459e-06
, O 0 7.846636407293772e-08
to O 0 3.054186095141631e-07
progressive O 1 0.9999880790710449
iron B-Disease 1 1.0
overload I-Disease 1 0.9999961853027344
and O 0 0.00017789330740924925
premature B-Disease 0 0.008500403724610806
death I-Disease 0 0.0006631753640249372
. O 0 4.5649096136912704e-05

The O 0 0.00011147074837936088
hemochromatosis B-Disease 1 1.0
gene O 0 1.7078818927984685e-05
, O 0 2.0645245513151167e-06
HFE O 1 0.9999778270721436
, O 0 1.7663954849922447e-06
recently O 0 7.143311790969165e-07
has O 0 2.9494900743998187e-08
been O 0 2.640463847569663e-08
identified O 0 7.682550062781957e-08
, O 0 3.085554922677147e-08
and O 0 2.991444247868458e-08
characterization O 0 1.5792127783242904e-07
of O 0 7.741918750525656e-08
this O 0 7.924239930900967e-09
gene O 0 2.038906288248654e-08
has O 0 3.3968809987072746e-09
shown O 0 4.734524328142697e-09
that O 0 1.9533379358449565e-09
it O 0 2.635727636146612e-09
contains O 0 8.640289372863208e-09
two O 0 3.1552691570624347e-09
mutations O 0 9.437823855762417e-09
that O 0 1.751037537189859e-09
result O 0 4.4106066354743234e-08
in O 0 6.139730146514921e-08
amino O 0 3.601103628625424e-07
acid O 0 1.8438090876315982e-07
substitutions O 0 7.565087116745417e-07
- O 0 6.171054565129452e-07
cDNA O 0 1.2192524536658311e-06
nucleotides O 0 8.362406447304238e-07
845 O 0 1.874340000540542e-06
G O 0 3.0622784379374934e-06
- O 0 8.011618888303929e-07
- O 0 6.291123213486571e-07
> O 0 9.820563491302892e-07
A O 0 7.420109682243492e-07
( O 0 1.1089088047810947e-07
C282Y O 0 2.0346426481410163e-06
) O 0 2.035207380401971e-08
and O 0 3.129080283770236e-08
187 O 0 1.0342970568899545e-07
C O 0 2.0283653157093795e-06
- O 0 4.540419240584015e-07
- O 0 5.514493750524707e-07
> O 0 2.826751142492867e-06
G O 0 2.823127397277858e-05
( O 0 8.110225735435961e-07
H63D O 0 0.00135875737760216
) O 0 1.637444029256585e-06
. O 0 8.503647222823929e-06

Although O 0 0.001280112424865365
hemochromatosis B-Disease 1 1.0
is O 0 1.006964794214582e-06
common O 0 6.178733542583359e-07
in O 0 1.2789708137006528e-07
Caucasians O 0 5.245846296020318e-06
, O 0 2.7583516271079134e-07
affecting O 0 6.076458589632239e-07
> O 0 1.2833587561544846e-06
= O 0 7.432389566019992e-07
1 O 0 3.863335393816669e-07
/ O 0 3.627440605669108e-07
300 O 0 2.8290029874256106e-08
individuals O 0 1.2012563166408086e-09
of O 0 1.1033113089808921e-08
northern O 0 4.4655099173951385e-08
European O 0 7.568537085944627e-08
origin O 0 2.2776248442824e-08
, O 0 5.396940228052927e-09
it O 0 1.717998188155434e-09
has O 0 1.6146982639853036e-09
not O 0 3.0075417711827868e-09
been O 0 6.816934572384525e-09
recognized O 0 1.4904669498605472e-08
in O 0 1.4216305466163703e-08
other O 0 6.199415025776034e-08
populations O 0 7.919526865407533e-07
. O 0 9.728865734359715e-06

The O 0 6.042846507625654e-06
present O 0 7.847576739550277e-07
study O 0 1.4810197512815648e-07
used O 0 1.0357026525298352e-07
PCR O 0 5.508530648512533e-06
and O 0 4.3975578023491835e-07
restriction O 0 6.279781814555463e-07
- O 0 8.725598377168353e-07
enzyme O 0 1.0726449772846536e-07
digestion O 0 4.969716371761024e-08
to O 0 9.653474464244027e-09
analyze O 0 6.576938460511883e-08
the O 0 1.9987838939528046e-08
frequency O 0 3.3711654623402865e-07
of O 0 1.080037748124596e-07
the O 0 1.8158571890580788e-07
845 O 0 4.498620455706259e-06
G O 0 1.1596755030041095e-05
- O 0 1.7240707848031889e-06
- O 0 4.811452072317479e-07
> O 0 7.130325343496224e-07
A O 0 1.6282442061310576e-07
and O 0 4.28545483543985e-08
187 O 0 9.023106173344786e-08
C O 0 1.0466920912222122e-06
- O 0 2.509618468593544e-07
- O 0 2.1297940122622094e-07
> O 0 9.942704082277487e-07
G O 0 2.548585371187073e-06
mutations O 0 2.438851254282781e-07
in O 0 8.425119091270972e-08
HLA O 0 4.866997642238857e-06
- O 0 1.9750646629290713e-07
typed O 0 6.423529441690334e-08
samples O 0 5.4477831135102406e-09
from O 0 5.384725110246791e-09
non O 0 3.277304188031849e-07
- O 0 3.5176105939171975e-07
Caucasian O 0 2.409187800367363e-07
populations O 0 2.710907942571339e-08
, O 0 5.5925280406654565e-08
comprising O 0 4.491730294375884e-07
Australian O 0 3.6518420074571623e-06
Aboriginal O 0 5.432200396171538e-07
, O 0 3.7198034874563746e-08
Chinese O 0 7.871699381212238e-08
, O 0 8.610680168885665e-08
and O 0 4.3484473621902e-07
Pacific O 0 2.304175177414436e-05
Islanders O 0 0.00028107682010158896
. O 0 2.066025263047777e-05

Results O 0 2.7524269171408378e-05
showed O 0 2.2722890662407735e-06
that O 0 9.934488787166629e-08
the O 0 2.6382093665233697e-07
845 O 0 6.417973054340109e-06
G O 0 5.378252171794884e-05
- O 0 2.0649124053306878e-05
- O 0 4.0491022446076386e-06
> O 0 1.9565231923479587e-06
A O 0 2.611479885672452e-07
mutation O 0 8.946076945903769e-08
was O 0 3.478863774830643e-08
present O 0 6.474191849292765e-09
in O 0 2.669738430327584e-09
these O 0 2.0675163803218766e-09
populations O 0 8.322736277932563e-09
( O 0 7.680378111274422e-09
allele O 0 3.876210996622831e-08
frequency O 0 8.25411419214106e-08
0 O 0 3.4723274922043856e-08
. O 0 4.649383988919453e-09
32 O 0 4.7703679229016416e-08
% O 0 5.811037429026555e-09
) O 0 1.0838799191503767e-08
, O 0 1.172423047535176e-08
and O 0 1.3555129463327376e-08
, O 0 1.7648225991706568e-08
furthermore O 0 4.8693379994801944e-08
, O 0 6.786214701293147e-09
it O 0 3.2880962397285884e-09
was O 0 3.409813587040844e-08
always O 0 2.4357406758213074e-08
seen O 0 7.5640201657734e-08
in O 0 2.206383697966885e-08
conjunction O 0 4.2716550296972855e-07
with O 0 2.1328918364815763e-07
HLA O 0 9.187070827465504e-05
haplotypes O 0 2.129807398887351e-06
common O 0 1.9398230222122947e-07
in O 0 1.0957743512562956e-07
Caucasians O 0 3.2255418318527518e-06
, O 0 1.1426939749981102e-07
suggesting O 0 3.216423749563546e-07
that O 0 8.599683809507042e-08
845 O 0 5.018686806579353e-06
G O 0 2.161466545658186e-05
- O 0 8.789918865659274e-06
- O 0 3.3578317015781067e-06
> O 0 1.2274236951270723e-06
A O 0 1.8411732582990226e-07
may O 0 2.102962071148795e-08
have O 0 4.357822991352123e-09
been O 0 5.848230788529918e-09
introduced O 0 1.2004231386697484e-08
into O 0 2.7481930064965354e-09
these O 0 2.162980905495715e-09
populations O 0 1.068462740505538e-08
by O 0 5.3140716715915914e-08
Caucasian O 0 6.365557510434883e-06
admixture O 0 4.5107441110303625e-05
. O 0 3.0340259399963543e-05

187 O 0 3.635747270891443e-05
C O 0 8.540210546925664e-05
- O 0 1.055687062034849e-05
- O 0 3.890928837790852e-06
> O 0 5.199065071792575e-06
G O 0 1.0285952157573774e-05
was O 0 2.390867734902713e-07
present O 0 2.0721127924616667e-08
at O 0 6.776025429644505e-08
an O 0 5.900364641320266e-09
allele O 0 1.281190264990073e-07
frequency O 0 2.7380292522138916e-07
of O 0 2.442612867525895e-07
2 O 0 5.829328983963933e-06
. O 0 6.8911122070858255e-06

68 O 0 1.5410145351779647e-05
% O 0 3.958815852911357e-07
in O 0 7.648804967175238e-08
the O 0 8.532597917110252e-08
two O 0 5.755116916361658e-08
populations O 0 4.275453235891291e-08
analyzed O 0 3.994719577349315e-07
( O 0 1.5177252521425544e-07
Australian O 0 1.3187586773710791e-05
Aboriginal O 0 3.0655512546218233e-06
and O 0 4.74428532015736e-07
Chinese O 0 2.1045807443442754e-06
) O 0 1.9550666365830693e-06
. O 0 1.5739529771963134e-05

In O 0 3.2943962651188485e-06
the O 0 1.5585891333103064e-06
Australian O 0 6.633784778387053e-06
Aboriginal O 0 1.14885938273801e-06
samples O 0 7.159530213129983e-08
, O 0 7.559577852589427e-08
187 O 0 2.2353708573064068e-07
C O 0 4.360541879577795e-06
- O 0 1.5870848528720671e-06
- O 0 1.2510776059571072e-06
> O 0 3.533952167344978e-06
G O 0 1.724702633509878e-05
was O 0 1.0781852921581958e-07
found O 0 2.7769520016818205e-09
to O 0 2.325724279828023e-09
be O 0 1.1519260212367044e-08
associated O 0 7.963759429685524e-08
with O 0 2.0922483656704571e-07
HLA O 0 0.0180504210293293
haplotypes O 0 2.1657829165633302e-06
common O 0 1.2847384311953647e-07
in O 0 4.044490964361103e-08
Caucasians O 0 7.726752642156498e-07
, O 0 1.843207186880136e-08
suggesting O 0 2.043601554646557e-08
that O 0 4.206132775408378e-09
it O 0 6.4224003892832116e-09
was O 0 8.325152833776883e-08
introduced O 0 1.5611686876582098e-07
by O 0 5.80110679493373e-08
recent O 0 6.981445039855316e-07
admixture O 0 3.775507502723485e-05
. O 0 2.464277895342093e-05

In O 0 2.2141293811728247e-06
the O 0 7.681948090976221e-07
Chinese O 0 1.884141767050096e-07
samples O 0 5.498928956626514e-08
analyzed O 0 1.4150572269500117e-07
, O 0 4.2553825352342756e-08
187 O 0 1.6964938254204753e-07
C O 0 2.2870815428177593e-06
- O 0 7.392717975562846e-07
- O 0 3.126608021375432e-07
> O 0 7.948385700728977e-07
G O 0 3.2337443371943664e-06
was O 0 1.2169994079158641e-07
present O 0 1.555924278306975e-08
in O 0 8.673015194915479e-09
association O 0 1.4377162571577173e-08
with O 0 7.071205399000746e-09
a O 0 2.734839554818791e-08
wide O 0 1.2750760447488574e-07
variety O 0 1.4969450035096088e-07
of O 0 6.382312562891457e-07
HLA O 0 4.520105358096771e-05
haplotypes O 0 6.559042162734841e-07
, O 0 1.6662632162933733e-08
showing O 0 1.5026298427756046e-08
this O 0 1.8780124122486086e-09
mutation O 0 4.816986365341336e-09
to O 0 1.843019958869263e-09
be O 0 8.44474268291151e-09
widespread O 0 5.26830454816718e-08
and O 0 3.015182414856099e-08
likely O 0 1.560088236374213e-07
to O 0 4.11272189637657e-08
predate O 0 9.98287532638642e-07
the O 0 6.925120743517255e-08
more O 0 4.842219780698542e-08
genetically O 0 2.8243994165677577e-07
restricted O 0 2.5483541321591474e-07
845 O 0 4.199691829853691e-06
G O 0 2.061217492155265e-05
- O 0 9.480146218265872e-06
- O 0 4.089922185812611e-06
> O 0 6.068170023354469e-06
A O 0 3.326056230434915e-06
mutation O 0 6.983035746088717e-06
. O 0 8.611658813606482e-06

Genotype O 0 0.0019051297567784786
- O 0 0.00022258181707002223
phenotype O 0 9.410746861249208e-05
correlations O 0 4.25004109274596e-05
in O 0 9.574730938766152e-06
attenuated B-Disease 1 0.9982307553291321
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999996423721313
. O 0 0.012462329119443893

Germ O 1 0.9647650718688965
- O 0 0.00045083221630193293
line O 0 7.677797839278355e-06
mutations O 0 7.046454584269668e-07
of O 0 3.59419345841161e-07
the O 0 2.4559454914196976e-07
tumor B-Disease 0 8.091428753687069e-06
suppressor O 0 2.7014189981855452e-05
APC O 0 4.960198111803038e-06
are O 0 1.796749984350754e-07
implicated O 0 1.7925509382621385e-05
in O 0 2.0849277007073397e-06
attenuated B-Disease 1 0.9981856942176819
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9999927282333374
AAPC B-Disease 1 1.0
) O 0 4.45943851445918e-06
, O 0 2.721482701417699e-07
a O 0 1.831157163678654e-07
variant O 0 1.6436724763480015e-05
of O 0 3.971971818828024e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9111480116844177
FAP B-Disease 1 0.9960895776748657
) O 0 2.263478199893143e-05
. O 0 8.350375719601288e-05

AAPC B-Disease 1 0.9999992847442627
is O 0 1.9757326299441047e-06
recognized O 0 2.9573720894404687e-07
by O 0 4.645415430104549e-08
the O 0 6.660839346750436e-08
occurrence O 0 2.8244451755199407e-07
of O 0 2.413777906440373e-07
< O 0 1.1615935363806784e-05
100 O 0 2.6119034828298027e-06
colonic B-Disease 0 0.00011203777830814943
adenomas I-Disease 0 3.570347325876355e-05
and O 0 9.859040517312678e-08
a O 0 1.1028950552827155e-07
later O 0 6.510774710477563e-07
onset O 1 0.9873625040054321
of O 1 0.9999938011169434
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.740585947933141e-06
age O 0 4.0307941162609495e-06
> O 0 4.660921149479691e-06
40 O 0 3.4151776162616443e-07
years O 0 3.7571822986137704e-07
) O 0 7.039946581244294e-07
. O 0 6.929586561454926e-06

The O 0 2.531913196435198e-06
aim O 0 2.973927394123166e-06
of O 0 3.1869038252807513e-07
this O 0 4.4067054005836326e-08
study O 0 8.066522383387564e-08
was O 0 1.369668325423845e-07
to O 0 3.95062720315309e-08
assess O 0 1.9633325791801326e-06
genotype O 0 2.8124029995524324e-05
- O 0 2.293907709827181e-05
phenotype O 0 2.3006487026577815e-05
correlations O 0 2.6109368263860233e-05
in O 0 6.174519512569532e-06
AAPC B-Disease 1 0.9999998807907104
families O 0 4.178801646048669e-06
. O 0 1.9983657693956047e-05

By O 0 4.862993591814302e-06
protein O 0 7.425075182254659e-06
- O 0 2.743722006925964e-06
truncation O 0 6.638727882091189e-06
test O 0 3.255981255279039e-06
( O 0 7.27799374544702e-07
PTT O 0 1.5339997844421305e-05
) O 0 7.62206653348585e-08
assay O 0 4.397167572278704e-07
, O 0 3.6442951767412524e-08
the O 0 5.5272256105354245e-08
entire O 0 2.6142109277316194e-07
coding O 0 4.016302170839481e-07
region O 0 7.877287089286256e-08
of O 0 1.0023430974115399e-07
the O 0 1.6447638984118385e-07
APC B-Disease 0 1.7148174720205134e-06
gene O 0 1.507293490021766e-07
was O 0 3.0739425938008935e-07
screened O 0 2.6868411850955454e-07
in O 0 4.051014812489484e-08
affected O 0 7.605250118558615e-08
individuals O 0 2.3258275305693132e-08
from O 0 2.4465177261845383e-07
11 O 0 0.014988417737185955
AAPC B-Disease 1 1.0
kindreds O 0 0.020858723670244217
, O 0 3.574402285266842e-07
and O 0 1.5843748712995875e-07
their O 0 6.863566426318357e-08
phenotypic O 0 1.3831513570039533e-05
differences O 0 4.21362938141101e-06
were O 0 5.28733789906255e-06
examined O 0 2.8636846764129587e-05
. O 0 1.8162076230510138e-05

Five O 0 2.5301093046437018e-05
novel O 0 9.927583050739486e-06
germ O 0 0.0011299593606963754
- O 0 7.121804810594767e-05
line O 0 2.1831021513207816e-05
APC B-Disease 0 1.1431356142566074e-05
mutations O 0 1.1415299923100974e-06
were O 0 6.056238817109261e-07
identified O 0 1.5050555930429255e-06
in O 0 1.3508846450349665e-06
seven O 0 3.7781766877742484e-05
kindreds O 0 0.0025220790412276983
. O 0 9.769201278686523e-05

Mutations O 0 2.065806620521471e-05
were O 0 2.2014671685610665e-06
located O 0 5.684325401489332e-07
in O 0 3.5593320291127384e-08
three O 0 3.461766695522783e-08
different O 0 1.8020692493792012e-08
regions O 0 2.481626637518275e-08
of O 0 1.1273785816001691e-07
the O 0 1.2044601760408113e-07
APC B-Disease 0 6.327887263068988e-07
gene O 0 4.0243303800480135e-08
( O 0 1.9423085362291204e-08
1 O 0 1.4011091309384938e-07
) O 0 2.057183934311979e-08
at O 0 7.721862260723356e-08
the O 0 2.0588482030348132e-08
5 O 0 9.993517835482635e-08
end O 0 2.237998728560342e-07
spanning O 0 2.78632910521992e-07
exons O 0 1.2589285347530677e-07
4 O 0 5.442032247060524e-08
and O 0 7.811034485882828e-09
5 O 0 4.788691754242791e-08
, O 0 1.575196151293312e-08
( O 0 7.0480989933230376e-09
2 O 0 6.155982390509962e-08
) O 0 6.934171459249683e-09
within O 0 2.167500134930833e-08
exon O 0 9.546254631231932e-08
9 O 0 1.2146514904998185e-07
, O 0 2.6398696562068835e-08
and O 0 2.425161937935627e-08
( O 0 3.634777812067114e-08
3 O 0 2.91609637770307e-07
) O 0 1.9684263108388222e-08
at O 0 5.085891174871904e-08
the O 0 2.4305149892711597e-08
3 O 0 3.291242194336519e-07
distal O 0 1.0526925962039968e-06
end O 0 2.7465077323540754e-07
of O 0 2.0061176542185422e-07
the O 0 3.8341809727171494e-07
gene O 0 1.927421408254304e-06
. O 0 6.617798135266639e-06

Variability O 0 6.862876762170345e-05
in O 0 2.910400667133217e-07
the O 0 1.5528236474438017e-07
number O 0 3.4733216125459876e-07
of O 0 0.03176679089665413
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.000298235536320135
most O 0 3.6874009623488746e-08
apparent O 0 2.0430059066711692e-07
in O 0 1.5184904000875576e-08
individuals O 0 3.5872673720405146e-09
with O 0 6.5703025242669355e-09
mutations O 0 4.569871947524007e-08
in O 0 1.4166121609093807e-08
region O 0 8.124409589527204e-08
1 O 0 3.596724582166644e-06
, O 0 1.0338099087903174e-07
and O 0 3.723821748735645e-07
upper O 0 0.06437109410762787
- O 1 0.5916339755058289
gastrointestinal O 0 0.005204790737479925
manifestations O 0 0.001128871226683259
were O 0 5.671746521329624e-07
more O 0 8.968491727046057e-08
severe O 0 1.8221509890281595e-05
in O 0 2.989043537127145e-07
them O 0 7.676184168303735e-07
. O 0 1.200590304506477e-05

In O 0 1.0309444178346894e-06
individuals O 0 9.700433878379044e-08
with O 0 5.894416688079218e-08
mutations O 0 2.3140137273003347e-07
in O 0 1.777690705750956e-08
either O 0 5.716552919921014e-08
region O 0 6.934624252608046e-08
2 O 0 4.920678975395276e-07
or O 0 1.596447418705793e-08
region O 0 2.94647080067989e-08
3 O 0 1.0676829020894729e-07
, O 0 9.015722390870451e-09
the O 0 9.953812885044044e-09
average O 0 1.6990528095561785e-08
number O 0 1.7821855990973745e-08
of O 0 8.89462654640738e-08
adenomas B-Disease 0 1.0635863873176277e-05
tended O 0 1.3552238442571252e-07
to O 0 1.5135718456349423e-08
be O 0 2.6423784049711685e-08
lower O 0 1.1259259480311812e-07
than O 0 9.641698106577223e-09
those O 0 2.2315307379727756e-09
in O 0 1.8998598250163923e-09
individuals O 0 1.0990848231529071e-09
with O 0 3.393396896811396e-09
mutations O 0 1.534266935721007e-08
in O 0 4.024512278988368e-09
region O 0 1.5409534981358775e-08
1 O 0 1.7834753407441895e-07
, O 0 1.4730042074972971e-08
although O 0 3.8904470756051523e-08
age O 0 3.14788962896273e-07
at O 0 1.3625527799376869e-06
diagnosis O 0 5.836338004883146e-06
was O 0 1.2547480991997872e-06
similar O 0 2.150129830624792e-06
. O 0 1.5157324014580809e-05

In O 0 1.1136615285067819e-05
all O 0 1.6236965166172013e-05
AAPC B-Disease 1 0.9999997615814209
kindreds O 0 0.0003877484705299139
, O 0 6.189142141010961e-07
a O 0 2.8504931037787173e-07
predominance O 0 3.5628788737085415e-06
of O 0 1.0602252586977556e-05
right O 1 0.9470887780189514
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999949932098389
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9998339414596558
sparing O 0 5.050200707046315e-05
was O 0 2.0142233552178368e-05
observed O 0 2.4456539904349484e-05
. O 0 5.789886199636385e-05

No O 0 0.00010434508294565603
desmoid B-Disease 1 0.9970136880874634
tumors I-Disease 1 1.0
were O 0 2.5590459244995145e-06
found O 0 2.5134002612503537e-07
in O 0 1.751894416202049e-07
these O 0 8.952099506132072e-07
kindreds O 0 0.000604857224971056
. O 0 4.629542672773823e-05

Our O 0 2.6676152629079297e-06
data O 0 1.2696269777734415e-06
suggest O 0 2.3288509964913828e-07
that O 0 4.9977867178085944e-08
, O 0 2.9554547609222936e-07
in O 0 4.649319862437551e-07
AAPC B-Disease 1 1.0
families O 0 3.878000498502843e-08
, O 0 3.032548434589444e-08
the O 0 1.9547924168250574e-08
location O 0 3.829254424658757e-08
of O 0 6.943876229570378e-08
the O 0 2.6569668420961534e-07
APC B-Disease 0 8.479231837554835e-06
mutation O 0 1.0814264896907844e-06
may O 0 8.869026828506321e-07
partially O 0 3.587420678741182e-06
predict O 0 1.963416934813722e-06
specific O 0 1.4559010423909058e-06
phenotypic O 0 0.00026415998581796885
expression O 0 5.0339298468315974e-05
. O 0 4.0555340092396364e-05

This O 0 5.34866103407694e-07
should O 0 1.7234677329724946e-07
help O 0 8.763077374851491e-08
in O 0 3.39556791573159e-08
the O 0 7.661317624751973e-08
design O 0 1.0747272654043627e-06
of O 0 8.756074407756387e-07
tailored O 0 3.248407438150025e-06
clinical O 0 1.3143117030267604e-05
- O 0 5.481531843543053e-06
management O 0 1.7551296878082212e-06
protocols O 0 2.997572664753534e-06
in O 0 1.8249327382591218e-08
this O 0 1.0262281691097996e-08
subset O 0 4.629590932836436e-07
of O 0 5.131312263984e-07
FAP B-Disease 0 3.4376113035250455e-05
patients O 0 7.911080501799006e-07
. O 0 2.5745700895640766e-06
. O 0 2.318205952178687e-05

Wilms B-Disease 1 0.9968043565750122
' I-Disease 0 3.964712959714234e-05
tumor I-Disease 0 1.0249554179608822e-05
1 O 0 4.956636985298246e-06
and O 0 1.1419514294175315e-06
Dax O 0 0.24222934246063232
- O 0 3.3277822240052046e-06
1 O 0 1.048034505402029e-06
modulate O 0 4.6940908760007005e-07
the O 0 7.2133993000989e-08
orphan O 0 2.8089431225453154e-07
nuclear O 0 6.947432211745763e-07
receptor O 0 1.168257540484774e-06
SF O 0 6.31873044767417e-05
- O 0 3.8899466403563565e-07
1 O 0 2.5529197955620475e-07
in O 0 2.014702538133406e-08
sex O 0 9.590345939614053e-08
- O 0 1.0857507959372015e-07
specific O 0 3.3502711715982514e-08
gene O 0 2.3615648103714193e-07
expression O 0 1.4131761645330698e-06
. O 0 6.60265004626126e-06

Products O 0 9.684988071967382e-06
of O 0 6.743238827766618e-06
steroidogenic O 0 0.00011617218842729926
factor O 0 2.815913603626541e-06
1 O 0 5.273655915516429e-06
( O 0 8.598500471634907e-07
SF O 0 0.0008119285921566188
- O 0 1.5204285546133178e-06
1 O 0 1.207237914968573e-06
) O 0 1.0389474169869573e-07
and O 0 4.161670688063168e-07
Wilms B-Disease 0 0.003150754841044545
tumor I-Disease 0 3.4740412502287654e-06
1 O 0 7.0279647843563e-06
( O 0 9.409003496330115e-07
WT1 O 0 6.11884897807613e-05
) O 0 3.9251951022833964e-08
genes O 0 1.9183000077305223e-08
are O 0 5.411350478823351e-09
essential O 0 1.0849993259398616e-07
for O 0 8.076143842572492e-08
mammalian O 0 5.037902155891061e-06
gonadogenesis O 0 8.320687811647076e-06
prior O 0 7.26702864994877e-07
to O 0 1.6605547159542766e-07
sexual O 0 4.497788268054137e-06
differentiation O 0 7.755318802082911e-05
. O 0 2.8751090212608688e-05

In O 0 3.7389313547464553e-06
males O 0 4.877163974015275e-06
, O 0 1.8134618358089938e-06
SF O 1 0.9900222420692444
- O 0 1.3610978385258932e-05
1 O 0 3.1236324957717443e-06
participates O 0 2.265876446472248e-07
in O 0 1.649998004893405e-08
sexual O 0 6.382531125836977e-08
development O 0 8.001549645086925e-08
by O 0 1.8346071328778635e-08
regulating O 0 6.304539823531741e-08
expression O 0 2.8871999901980416e-08
of O 0 1.101513902312945e-07
the O 0 5.135889864504861e-07
polypeptide O 0 2.0572193534462713e-05
hormone O 0 9.391868843522388e-06
Mullerian O 0 0.00016329114441759884
inhibiting O 0 7.451434157701442e-06
substance O 0 1.0403119631519075e-05
( O 0 4.5344831960392185e-06
MIS O 0 0.024582866579294205
) O 0 6.229739483387675e-06
. O 0 2.9929627999081276e-05

Here O 0 3.417690095375292e-06
, O 0 2.937683802883839e-07
we O 0 1.281456718515983e-07
show O 0 1.9268374273906375e-07
that O 0 1.2631545587282744e-07
WT1 O 0 0.0010659836698323488
- O 0 8.88733848114498e-05
KTS O 0 0.0025264397263526917
isoforms O 0 1.1740088666556403e-05
associate O 0 2.8225649657542817e-06
and O 0 3.4948726579386857e-07
synergize O 0 1.8060980437439866e-05
with O 0 7.013724143689615e-07
SF O 0 0.2795778214931488
- O 0 3.0957824037614046e-06
1 O 0 4.593615869907808e-07
to O 0 6.944233632566466e-08
promote O 0 1.6925343970797257e-06
MIS O 0 0.0004882418143097311
expression O 0 8.272621016658377e-06
. O 0 9.627791769162286e-06

In O 0 4.787139459949685e-06
contrast O 0 6.190367912495276e-06
, O 0 2.297099626957788e-06
WT1 O 0 0.006882258225232363
missense O 0 2.397860043856781e-05
mutations O 0 2.543241407693131e-06
, O 0 2.0746998075082956e-07
associated O 0 2.634191957895382e-07
with O 0 3.4365643841738347e-07
male B-Disease 0 0.0005040389369241893
pseudohermaphroditism I-Disease 1 1.0
in O 0 2.4133914848789573e-05
Denys B-Disease 1 0.9999990463256836
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.560205868780031e-06
fail O 0 4.407051619637059e-06
to O 0 3.179090413141239e-07
synergize O 0 2.457837763358839e-05
with O 0 2.046283270829008e-06
SF O 1 0.9999920129776001
- O 0 0.00029850576538592577
1 O 0 4.102570892428048e-05
. O 0 1.2479467841330916e-05

Additionally O 0 1.211728340422269e-05
, O 0 5.495064669958083e-07
the O 0 3.425367651743727e-07
X O 0 2.5681854822323658e-05
- O 0 4.330430783738848e-06
linked O 0 7.759080062896828e-07
, O 0 5.908058753334444e-08
candidate O 0 5.204633453104179e-07
dosage O 0 1.621738738322165e-05
- O 0 5.497231995832408e-06
sensitive O 0 1.3188165439714794e-06
sex O 0 2.407444412710902e-07
- O 0 4.957512942382891e-07
reversal O 0 1.0255450888507767e-06
gene O 0 5.16484476520418e-07
, O 0 7.525123351115326e-07
Dax O 1 0.9768627882003784
- O 0 9.618035619496368e-06
1 O 0 2.151083663193276e-06
, O 0 2.0177509441055008e-07
antagonizes O 0 4.0108234315994196e-06
synergy O 0 1.5229215932777151e-06
between O 0 4.1821439822342654e-07
SF O 0 0.0003243526443839073
- O 0 4.390074082039064e-07
1 O 0 2.374905960778051e-07
and O 0 6.67079476102117e-08
WT1 O 0 8.217077993322164e-05
, O 0 2.5513054779935374e-08
most O 0 5.772781364044022e-09
likely O 0 1.3785119712395044e-08
through O 0 4.092632455154899e-09
a O 0 1.5143081455448737e-08
direct O 0 5.8106635947297036e-08
interaction O 0 1.7922729966812767e-07
with O 0 2.2836435675799294e-07
SF O 1 0.9958986639976501
- O 0 2.4411821868852712e-05
1 O 0 8.725651241547894e-06
. O 0 6.844826202723198e-06

We O 0 1.4167266272124834e-05
propose O 0 1.395233630319126e-05
that O 0 1.024635935209517e-06
WT1 O 0 0.0008168360800482333
and O 0 6.395243872248102e-06
Dax O 1 0.9999009370803833
- O 0 3.063855183427222e-05
1 O 0 2.460137466187007e-06
functionally O 0 9.876861213342636e-07
oppose O 0 1.1495878027290019e-07
each O 0 2.1030704289159985e-08
other O 0 1.1597766302884338e-08
in O 0 3.928835567990063e-08
testis O 0 2.7578410026762867e-06
development O 0 1.9102333226328483e-07
by O 0 1.645845060238571e-07
modulating O 0 7.682851901336107e-06
SF O 0 0.0021251472644507885
- O 0 2.905191877289326e-06
1 O 0 3.872955858241767e-06
- O 0 4.143099886277923e-06
mediated O 0 2.176832094846759e-05
transactivation O 0 3.892724635079503e-05
. O 0 1.2603920822584769e-06
. O 0 9.634377420297824e-06

A O 0 9.872421651380137e-05
mouse O 0 9.54947063291911e-06
model O 0 6.311774541245541e-06
for O 0 1.8952818209072575e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999998807907104
- O 1 0.999997615814209
centre O 1 0.9986937642097473
mutations O 0 7.488520350307226e-05
. O 0 2.0356173990876414e-05

Imprinting O 0 0.00022856115538161248
in O 0 1.7607073914405191e-06
the O 0 2.73011301032966e-06
15q11 O 0 6.080794264562428e-05
- O 0 1.3699959708901588e-05
q13 O 0 1.3854352800990455e-05
region O 0 3.2217806733569887e-07
involves O 0 2.7835139349008386e-07
an O 0 3.1810731826453775e-08
imprinting O 0 3.1474201023229398e-06
centre O 0 0.003066737437620759
( O 0 1.1174893188581336e-06
IC O 1 0.6920182704925537
) O 0 1.4818178328823706e-07
, O 0 4.635493411342395e-08
mapping O 0 7.745729391217537e-08
in O 0 8.341568324965465e-09
part O 0 2.071259253000335e-08
to O 0 1.3614724458932415e-08
the O 0 6.035659794179082e-08
promoter O 0 3.4181823593826266e-06
and O 0 1.8748463048723352e-07
first O 0 9.561175602357253e-07
exon O 0 6.463475074269809e-06
of O 0 3.2458556233905256e-06
SNRPN O 0 0.017132682725787163
. O 0 7.748400093987584e-05

Deletion O 0 0.0001002491990220733
of O 0 5.995289484417299e-06
this O 0 1.399616166963824e-06
IC O 0 0.2616737484931946
abolishes O 0 4.869452095590532e-05
local O 0 1.0862225963137462e-06
paternally O 0 2.2451717995863874e-06
derived O 0 1.0090049329392059e-07
gene O 0 8.327805289809476e-08
expression O 0 1.2735581833567267e-07
and O 0 1.1279355760507315e-07
results O 0 4.036702648591017e-06
in O 0 1.7732631022226997e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 0.0014394301688298583
. O 0 8.14554441603832e-05

We O 0 2.312327069375897e-06
have O 0 1.3463146331105236e-07
created O 0 5.769844619862852e-07
two O 0 9.389044208774067e-08
deletion O 0 7.988433594618982e-07
mutations O 0 4.5723916741735593e-07
in O 0 8.868267542538888e-08
mice O 0 7.613361390212958e-07
to O 0 7.179030347970183e-08
understand O 0 2.9444277970469557e-05
PWS B-Disease 1 1.0
and O 0 1.6079536635515979e-06
the O 0 2.5240390755243425e-07
mechanism O 0 2.7393086838856107e-06
of O 0 2.5796083491513855e-07
this O 0 4.066948235958989e-07
IC O 0 0.001939226407557726
. O 0 2.9915418053860776e-05

Mice O 0 0.0009041890734806657
harbouring O 0 0.0034417605493217707
an O 0 4.031708613183582e-06
intragenic O 0 0.0002518942637834698
deletion O 0 1.6740999853936955e-05
in O 0 6.524424520648608e-07
Snrpn O 0 0.001731269177980721
are O 0 3.3506043450870493e-07
phenotypically O 0 4.0486862417310476e-05
normal O 0 5.977233286103001e-07
, O 0 4.580780199603396e-08
suggesting O 0 8.185241995306569e-08
that O 0 7.17281389839286e-09
mutations O 0 5.9304021249317884e-08
of O 0 7.527879830604434e-08
SNRPN O 0 2.9507691579055972e-05
are O 0 1.2501153001664989e-08
not O 0 1.6946447800592068e-08
sufficient O 0 3.6112589896220015e-07
to O 0 5.176689796826395e-07
induce O 0 0.0002369628637097776
PWS B-Disease 1 1.0
. O 0 0.00070024817250669

Mice O 0 4.224886652082205e-05
with O 0 3.15402559181166e-07
a O 0 4.036900520532072e-07
larger O 0 6.672181029898638e-07
deletion O 0 2.4031373868638184e-06
involving O 0 9.090343269235746e-07
both O 0 2.3356550116204744e-07
Snrpn O 0 0.00014593325613532215
and O 0 2.484507035660499e-07
the O 0 6.428751930798171e-07
putative O 0 0.00012537649308796972
PWS O 1 1.0
- O 0 0.19503550231456757
IC O 0 0.4344806969165802
lack O 0 2.881847194657894e-06
expression O 0 5.448964657261968e-07
of O 0 3.101832817264949e-07
the O 0 1.763951615885162e-07
imprinted O 0 6.571470407834568e-07
genes O 0 2.3950693162078096e-07
Zfp127 O 0 7.87278258940205e-05
( O 0 6.094380182730674e-07
mouse O 0 1.191338014905341e-06
homologue O 0 8.14141549199121e-06
of O 0 7.552024499091203e-07
ZNF127 O 0 0.02700565941631794
) O 0 7.452142085639935e-07
, O 0 1.1943843674089294e-06
Ndn O 0 0.003588452935218811
and O 0 1.2246082405908965e-06
Ipw O 0 0.000625617045443505
, O 0 5.281781909616257e-07
and O 0 2.477583791460347e-07
manifest O 0 1.681465505498636e-06
several O 0 6.025147740729153e-07
phenotypes O 0 2.70894706773106e-05
common O 0 9.08492711459985e-06
to O 0 3.477103018667549e-05
PWS B-Disease 1 1.0
infants O 1 0.9999624490737915
. O 0 0.00021882611326873302

These O 0 4.7295040417338896e-07
data O 0 2.435193380279088e-07
demonstrate O 0 8.025607911577026e-08
that O 0 6.2004290590778055e-09
both O 0 7.446037564307062e-09
the O 0 1.902493274030803e-08
position O 0 2.2058141269098996e-07
of O 0 7.465879292567479e-08
the O 0 8.128005646312886e-08
IC O 0 5.06616233906243e-05
and O 0 1.4178339391435202e-08
its O 0 6.197732993484806e-09
role O 0 2.9747161178761417e-08
in O 0 4.280412024826319e-09
the O 0 1.3011595356715588e-08
coordinate O 0 2.546555499804981e-08
expression O 0 1.5210529724640764e-08
of O 0 1.6606412245323554e-08
genes O 0 4.013275045622322e-09
is O 0 2.666954435071034e-09
conserved O 0 2.4189438008193065e-08
between O 0 2.9213003571726404e-08
mouse O 0 1.0535708128145416e-07
and O 0 1.7362259185915718e-08
human O 0 3.341451559890629e-08
, O 0 1.0663434579782916e-08
and O 0 7.2919141835825485e-09
indicate O 0 1.7544516950351863e-08
that O 0 6.8753296389445495e-09
the O 0 5.7455423529972904e-08
mouse O 0 2.935264262760029e-07
is O 0 1.0589535470728606e-08
a O 0 9.436257997208486e-09
suitable O 0 1.0024731977864576e-07
model O 0 1.0157206276062425e-07
system O 0 7.683590297347109e-08
in O 0 5.798094893094685e-09
which O 0 3.1273483802607416e-09
to O 0 7.046244476782704e-09
investigate O 0 5.993260998593541e-08
the O 0 2.235246476800512e-08
molecular O 0 3.095904332894861e-07
mechanisms O 0 3.3588457881705835e-07
of O 0 5.696069393934522e-08
imprinting O 0 3.5244269724898913e-07
in O 0 6.727191248501185e-09
this O 0 5.328705032781045e-09
region O 0 3.727502217998335e-08
of O 0 9.939871858932747e-08
the O 0 2.329530843780958e-07
genome O 0 2.386539392773557e-07
. O 0 3.027936656962993e-07
. O 0 6.1084651861165185e-06

Mutations O 0 4.774300577992108e-06
of O 0 9.652287644712487e-07
the O 0 4.801486852556991e-07
ATM O 0 1.3086771105008665e-05
gene O 0 1.7656886086570012e-07
detected O 0 3.6463745800574543e-07
in O 0 4.529403554442979e-07
Japanese O 1 0.9994463324546814
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 2.022081389441155e-05
: O 0 9.005294288044752e-08
possible O 0 1.5829793653665547e-07
preponderance O 0 1.4522898936775164e-06
of O 0 8.412722252160165e-08
the O 0 7.302230642380891e-08
two O 0 9.893644659086931e-08
founder O 0 4.1604903344705235e-06
mutations O 0 1.8556930854174425e-06
4612del165 O 0 2.865779970306903e-05
and O 0 4.454546342458343e-06
7883del5 O 0 0.000406732433475554
. O 0 5.52092315047048e-05

The O 0 3.0839466489851475e-05
ATM O 0 0.17966710031032562
( O 0 3.637838381109759e-05
A O 1 0.9999991655349731
- O 1 0.9999884366989136
T O 1 1.0
, O 0 1.332162582912133e-06
mutated O 0 1.2094066050849506e-06
) O 0 1.4512251311771251e-07
gene O 0 3.3218481121366494e-07
on O 0 6.946087296455516e-07
human O 0 1.4764464140171185e-06
chromosome O 0 1.5891486327745952e-05
11q22 O 0 0.00012381251144688576
. O 0 3.5163244319846854e-05

3 O 0 1.3863207641406916e-05
has O 0 2.5294272631981585e-07
recently O 0 3.2233387514679634e-07
been O 0 6.473256064509769e-08
identified O 0 6.220711412652236e-08
as O 0 1.643766012193737e-08
the O 0 2.2328432436324874e-08
gene O 0 4.918454976632347e-08
responsible O 0 1.2275356198188092e-07
for O 0 3.9615308367046964e-08
the O 0 6.171330824145116e-07
human O 0 0.0036431162152439356
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.5382512831129134e-05
. O 0 1.5343450286309235e-05

In O 0 1.0322232810722198e-06
order O 0 4.129693707000115e-07
to O 0 2.685229105736653e-08
define O 0 3.452562111760926e-07
the O 0 6.662364171461377e-08
types O 0 3.41786233093444e-07
of O 0 5.768051323684631e-06
disease O 0 0.010789177380502224
- O 0 9.204226444126107e-06
causing O 0 2.93220546154771e-06
ATM O 0 0.00015418023394886404
mutations O 0 5.471794111144845e-07
in O 0 9.616797314038195e-08
Japanese O 0 3.182215368724428e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 0 1.8188278261277446e-07
as O 0 2.3369622681457258e-08
well O 0 8.019911845735805e-09
as O 0 5.29531041237874e-09
to O 0 4.178235091245597e-09
look O 0 2.3447800145959263e-08
for O 0 1.1343028738508565e-08
possible O 0 1.9010138885278138e-07
mutational O 0 4.172943590674549e-06
hotspots O 0 1.5848479506530566e-06
, O 0 5.6996341868398304e-08
reverse O 0 3.583125476325222e-07
- O 0 3.232358096738608e-07
transcribed O 0 7.056118533910194e-08
RNA O 0 5.276721637414994e-08
derived O 0 1.1906021057939142e-08
from O 0 1.1169280611511567e-08
ten O 0 1.4147389038043912e-07
patients O 0 2.7167416760676133e-08
belonging O 0 8.371872439738581e-08
to O 0 3.8077256903079615e-08
eight O 0 8.059852802944079e-07
unrelated O 0 1.6579563180130208e-06
Japanese O 0 3.147299503325485e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999918937683105
T I-Disease 1 1.0
families O 0 3.5923971353213346e-08
was O 0 1.777366094302124e-07
analyzed O 0 4.411212373156559e-08
for O 0 6.976783595291636e-09
mutations O 0 3.4835647255704316e-08
by O 0 1.2008857019907282e-08
the O 0 4.038624723534667e-08
restriction O 0 1.4625095445808256e-07
endonuclease O 0 3.0798923944530543e-06
fingerprinting O 0 2.5240610739274416e-06
method O 0 5.010633230995154e-06
. O 0 1.1312000424368307e-05

As O 0 3.1353140457213158e-06
has O 0 2.464387307554716e-07
been O 0 8.915450422364302e-08
reported O 0 6.929202811534196e-08
by O 0 1.5147298526585473e-08
others O 0 2.7482782272159056e-08
, O 0 2.5621655908025787e-08
mutations O 0 6.655137951838697e-08
that O 0 8.693584518937314e-09
lead O 0 1.6633505595109455e-07
to O 0 1.1912386099766081e-07
exon O 0 4.362692379800137e-06
skipping O 0 1.4533761714119464e-06
or O 0 7.37435428277422e-08
premature O 0 4.899378041045566e-07
protein O 0 1.615580771385794e-07
truncation O 0 2.351912144149537e-06
were O 0 1.2598401610830479e-07
also O 0 7.772487009560791e-08
predominant O 0 1.283136043639388e-06
in O 0 1.023858970938818e-07
our O 0 7.457239803443372e-07
mutants O 0 3.0273929951363243e-05
. O 0 8.955123121268116e-06

Six O 0 3.650226517493138e-06
different O 0 1.4046760554720095e-07
mutations O 0 2.873748599085957e-07
were O 0 1.1720043602281294e-07
identified O 0 1.5391198360248382e-07
on O 0 1.9637843706732383e-07
12 O 0 5.152235758032475e-07
of O 0 2.233214360103375e-07
the O 0 4.4149842892693414e-07
16 O 0 7.155200819397578e-06
alleles O 0 1.2900431102025323e-05
examined O 0 2.3590562705066986e-05
. O 0 2.0903464246657677e-05

Four O 0 1.2527725630206987e-05
were O 0 1.7433208086004015e-06
deletions O 0 7.619392818014603e-06
involving O 0 2.103084170812508e-06
a O 0 3.8945532310208364e-07
loss O 0 4.999273187422659e-06
of O 0 1.9140568383591017e-06
a O 0 8.160515676536306e-07
single O 0 8.178607231457136e-07
exon O 0 2.4405969725194154e-06
exon O 0 1.2585542208398692e-06
7 O 0 9.231707736034878e-07
, O 0 2.0258394783922995e-07
exon O 0 2.1785867829748895e-06
16 O 0 1.643645759941137e-06
, O 0 3.5172215007150953e-07
exon O 0 2.9890200039517367e-06
33 O 0 2.4783121261862107e-06
or O 0 1.0451630032548564e-06
exon O 0 2.2387070202967152e-05
35 O 0 1.8083059330820106e-05
. O 0 3.261761230533011e-05

The O 0 2.7352523375157034e-06
others O 0 3.3462549708929146e-07
were O 0 3.5138285170432937e-07
minute O 0 2.7625264920061454e-06
deletions O 0 1.654973857512232e-06
, O 0 2.778665475489106e-07
4649delA O 0 4.265998086339096e-06
in O 0 1.3806834431306925e-07
exon O 0 2.562117970228428e-06
33 O 0 1.6140313618961954e-06
and O 0 7.809940711922536e-07
7883del5 O 0 2.798680361593142e-05
in O 0 1.4024074062035652e-06
exon O 0 3.2856532925507054e-05
55 O 0 1.4557396752934437e-05
. O 0 2.449358180456329e-05

The O 0 5.352122570911888e-06
mutations O 0 6.291858426266117e-06
4612del165 O 0 2.427485196676571e-05
and O 0 4.2199727090519445e-07
7883del5 O 0 1.1255667232035194e-05
were O 0 1.983642050618073e-07
found O 0 2.8221476711109972e-08
in O 0 9.210777918156055e-09
more O 0 1.1787101961147073e-08
than O 0 1.5112439299969083e-08
two O 0 1.848685826644214e-08
unrelated O 0 4.885496807105483e-08
families O 0 4.599548741879289e-09
; O 0 1.0393216065551769e-08
44 O 0 4.78299568840157e-08
% O 0 2.3480069444303808e-08
( O 0 3.076645782584819e-08
7 O 0 2.382355432928307e-07
of O 0 7.25659248246302e-08
16 O 0 3.3320299053229974e-07
) O 0 8.623776359684143e-09
of O 0 1.6954595949414397e-08
the O 0 1.9600266298880342e-08
mutant O 0 1.6011931336379348e-07
alleles O 0 1.0530524718888046e-07
had O 0 3.807093662544503e-08
one O 0 1.578736430474237e-08
of O 0 4.883997206661661e-08
the O 0 1.2548697725378588e-07
two O 0 5.482925189426169e-07
mutations O 0 7.267406544997357e-06
. O 0 1.3654842405230738e-05

The O 0 6.953616775717819e-06
4612del165 O 0 1.7007709175231867e-05
mutations O 0 3.020772396666871e-07
in O 0 1.439947450165846e-08
three O 0 1.1505228769692621e-08
different O 0 8.721103839093303e-09
families O 0 4.847401147145547e-09
were O 0 1.9301767295587524e-08
all O 0 1.641597791035565e-08
ascribed O 0 1.1092874530049812e-07
to O 0 1.3547942323555162e-08
the O 0 4.217694993258192e-08
same O 0 1.75133649804593e-07
T O 0 4.717661431641318e-05
- O 0 3.4096656236215495e-06
- O 0 6.013964934936666e-07
> O 0 3.5541060583454964e-07
A O 0 1.0747645973196995e-07
substitution O 0 1.421197310946809e-07
at O 0 1.1847591707692118e-07
the O 0 5.3108195174900175e-08
splice O 0 5.333171770871559e-07
donor O 0 3.095103906503027e-08
site O 0 3.127798038349283e-07
in O 0 2.8964976195311465e-07
intron O 0 3.758659295272082e-05
33 O 0 4.274828461348079e-05
. O 0 5.3198516980046406e-05

Microsatellite O 0 0.002451659645885229
genotyping O 0 0.0003901429590769112
around O 0 3.30887360178167e-06
the O 0 6.357042252602696e-07
ATM O 0 2.6412721126689576e-05
locus O 0 1.7412687611795263e-06
also O 0 3.743783238974174e-08
indicated O 0 6.571634258989434e-08
that O 0 1.0124978189196554e-08
a O 0 6.573689859123988e-08
common O 0 3.427301749070466e-07
haplotype O 0 7.724535862507764e-06
was O 0 4.0813088730828895e-07
shared O 0 3.8295393522957966e-08
by O 0 9.500404019036068e-09
the O 0 3.152178607024325e-08
mutant O 0 3.625320630362694e-07
alleles O 0 2.4580310764577007e-07
in O 0 7.69498598174323e-08
both O 0 4.82763994114066e-07
mutations O 0 1.1608924978645518e-05
. O 0 1.1641174751275685e-05

This O 0 6.635332852056308e-07
suggests O 0 3.755161799290363e-07
that O 0 2.109848296072414e-08
these O 0 2.966919332436646e-08
two O 0 7.41621875022247e-08
founder O 0 1.521099875390064e-06
mutations O 0 2.4817316557346203e-07
may O 0 8.035748066959059e-08
be O 0 4.562329891655281e-08
predominant O 0 9.840118764259387e-07
among O 0 8.779858262641937e-08
Japanese O 0 1.6746801065892214e-06
ATM O 0 2.3762027922202833e-05
mutant O 0 1.0484531230758876e-05
alleles O 0 1.1763521797547583e-05
. O 0 1.4056602594791912e-05

W474C O 0 0.001117826672270894
amino O 0 3.935549466405064e-05
acid O 0 3.941941031371243e-06
substitution O 0 1.8490842421670095e-06
affects O 0 1.9244353666181269e-07
early O 0 1.040992501089022e-07
processing O 0 8.569131182412093e-08
of O 0 2.110242824926445e-08
the O 0 2.8883347269470505e-08
alpha O 0 2.1108793646362756e-07
- O 0 2.9130099221674755e-08
subunit O 0 5.737110342352025e-08
of O 0 2.3152137984538967e-08
beta O 0 2.539542549584439e-07
- O 0 1.529055708715532e-07
hexosaminidase O 0 1.2717003983198083e-06
A O 0 2.1506906477952725e-07
and O 0 6.104325933620203e-08
is O 0 3.7284408449522743e-08
associated O 0 1.645005625050544e-07
with O 0 4.089467324774887e-07
subacute O 1 0.999691367149353
G B-Disease 1 0.9998812675476074
( I-Disease 0 8.510502993885893e-06
M2 I-Disease 0 0.0008407831192016602
) I-Disease 0 1.3542293118007365e-06
gangliosidosis I-Disease 0 9.373651846544817e-05
. O 0 2.034449062193744e-05

Mutations O 0 1.9891404008376412e-05
in O 0 9.831638863033731e-07
the O 0 1.471541963837808e-06
HEXA O 0 0.0006424139137379825
gene O 0 5.109713470119459e-07
, O 0 9.079541740675268e-08
encoding O 0 2.2029236390608276e-07
the O 0 1.0947757544954584e-07
alpha O 0 9.306739343628578e-07
- O 0 7.504841903482884e-08
subunit O 0 1.5430100575031247e-07
of O 0 3.626869116146736e-08
beta O 0 7.036529723336571e-07
- O 0 3.645825472631259e-07
hexosaminidase O 0 2.353112449782202e-06
A O 0 8.506742119607225e-07
( O 0 1.7266133056637045e-07
Hex O 0 1.0149630725209136e-05
A O 0 5.862786451871216e-07
) O 0 4.234945549796976e-08
, O 0 3.460155895140815e-08
that O 0 2.090608219873502e-08
abolish O 0 1.6589116285103955e-06
Hex O 0 1.2242579032317735e-05
A O 0 7.900712830632983e-07
enzyme O 0 4.1126207861452713e-07
activity O 0 6.957025675546902e-07
cause O 0 0.0010083598317578435
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 1 0.8064377307891846
TSD B-Disease 1 1.0
) O 0 1.1426508308431949e-06
, O 0 1.2617387312729988e-07
the O 0 3.2767852076176496e-07
fatal O 0 6.66147461743094e-05
infantile B-Disease 0 5.053511358710239e-06
form I-Disease 0 3.0573247045140306e-07
of I-Disease 0 2.8791055228793994e-06
G I-Disease 0 0.4148683547973633
( I-Disease 0 9.688448017186602e-07
M2 I-Disease 0 7.649347389815375e-05
) I-Disease 0 3.0871009926158877e-07
gangliosidosis I-Disease 0 5.999831046210602e-06
, I-Disease 0 2.784570369840367e-07
Type I-Disease 0 6.008454874972813e-06
1 I-Disease 0 1.4092453056946397e-05
. O 0 1.0166758329432923e-05

Less O 0 0.0002337352343602106
severe O 1 0.999943733215332
, O 0 0.0004205112636554986
subacute O 1 1.0
( O 0 0.00017181529256049544
juvenile O 1 0.8538762927055359
- O 0 4.866007293458097e-05
onset O 1 0.9997960925102234
) O 0 1.5838900253584143e-06
and O 0 1.0339797881897539e-05
chronic O 1 0.9999984502792358
( O 0 4.87562247144524e-05
adult O 0 3.69479603250511e-05
- O 0 6.9582210926455446e-06
onset O 0 0.0009835322853177786
) O 0 5.298475613813025e-08
variants O 0 2.919691439728922e-07
are O 0 6.434330401816624e-09
characterized O 0 5.2138339867724426e-08
by O 0 7.925011757947686e-09
a O 0 2.2169171387531605e-08
broad O 0 3.370364822785632e-07
spectrum O 0 1.3555279565480305e-06
of O 0 6.903940175106982e-08
clinical O 0 5.869113124390424e-07
manifestations O 0 1.0975968507409561e-06
and O 0 1.7428282816922547e-08
are O 0 7.596113071883792e-09
associated O 0 2.6739490621707773e-08
with O 0 1.4506571055505901e-08
residual O 0 8.033630933823588e-07
levels O 0 4.100949411167676e-07
of O 0 6.171943027766247e-07
Hex O 0 2.726878119574394e-05
A O 0 1.4591536228181212e-06
enzyme O 0 7.464610689567053e-07
activity O 0 1.6232206689892337e-06
. O 0 3.7911991057626437e-06

We O 0 1.6276000678772107e-05
identified O 0 1.0502604709472507e-05
a O 0 3.7472166241059313e-06
1422 O 0 0.0004378522571641952
G O 0 0.0004446225066203624
- O 0 7.975297921802849e-05
- O 0 2.4627366656204686e-05
> O 0 2.652861257956829e-05
C O 0 0.00018957869906444103
( O 0 1.338520689841971e-07
amino O 0 2.105715992684054e-07
acid O 0 1.1564030444333184e-07
W474C O 0 6.4476319039386e-07
) O 0 9.459178329507267e-09
substitution O 0 6.470416735737672e-08
in O 0 1.0368248481995579e-08
the O 0 1.3381576735582712e-08
first O 0 2.6722105417320563e-08
position O 0 1.884772728999451e-07
of O 0 1.365529982422231e-07
exon O 0 7.493283646908822e-07
13 O 0 2.228665607617586e-07
of O 0 2.1642043179781467e-07
HEXA O 0 0.0001419911568518728
of O 0 1.7808459062962356e-07
a O 0 2.315786247208962e-07
non O 0 2.0434436009963974e-06
- O 0 1.1211475339223398e-06
Jewish O 0 1.284906716136902e-06
proband O 0 0.00024740121443755925
who O 0 6.092555508985242e-07
manifested O 0 9.65553135756636e-06
a O 0 2.3003110527497483e-06
subacute O 0 0.0861978754401207
variant O 0 0.0001627461751922965
of O 0 4.4756601710105315e-05
G B-Disease 1 0.9944650530815125
( I-Disease 0 5.6577664508949965e-06
M2 I-Disease 0 0.0007398643647320569
) I-Disease 0 4.127648026042152e-06
gangliosidosis I-Disease 0 0.0002623838372528553
. O 0 2.596354352135677e-05

On O 0 8.08265212981496e-06
the O 0 1.4057804946787655e-06
second O 0 3.0258545393735403e-06
maternally O 0 6.884694812470116e-06
inherited O 0 5.5367499953717925e-06
allele O 0 5.742146186094033e-06
, O 0 2.0783555498837814e-07
we O 0 1.5109000628399372e-07
identified O 0 4.642337216864689e-07
the O 0 3.901780019077705e-07
common O 0 0.023599248379468918
infantile O 1 0.9999996423721313
disease O 1 0.9983612895011902
- O 0 0.0063241315074265
causing O 0 0.00020099690300412476
4 O 0 0.01294428389519453
- O 0 4.0016187995206565e-05
bp O 0 2.642200342961587e-06
insertion O 0 1.2287202935112873e-06
, O 0 3.8949505665186734e-07
+ O 0 4.613240434991894e-06
TATC O 0 0.00030583725310862064
1278 O 0 0.00010279857815476134
, O 0 4.843328156312054e-07
in O 0 4.787057150679175e-07
exon O 0 1.2165624866611324e-05
11 O 0 1.666352545726113e-05
. O 0 3.0407607482629828e-05

Pulse O 0 0.0011157112894579768
- O 0 4.89159683638718e-05
chase O 0 6.551686965394765e-06
analysis O 0 7.523644853790756e-07
using O 0 7.360105200859834e-07
proband O 0 5.4964017181191593e-05
fibroblasts O 0 2.6472268928046105e-06
revealed O 0 6.932527298886271e-07
that O 0 1.9654398997204225e-08
the O 0 7.443343008617376e-08
W474C O 0 2.438172941765515e-06
- O 0 3.005963549185253e-07
containing O 0 1.0548254181230732e-07
alpha O 0 9.344118439003068e-07
- O 0 1.5586680035539757e-07
subunit O 0 2.2762576179502503e-07
precursor O 0 2.8185013434267603e-07
was O 0 6.451315925914969e-08
normally O 0 4.206182779853407e-08
synthesized O 0 1.1214775952339551e-07
, O 0 1.4020402616665706e-08
but O 0 1.2267054039227787e-08
not O 0 1.3447281510536868e-08
phosphorylated O 0 2.856766343484196e-07
or O 0 3.1972657410506145e-08
secreted O 0 4.9639655941291494e-08
, O 0 2.6460904578584632e-08
and O 0 4.3525421489221117e-08
the O 0 1.9082614244325669e-07
mature O 0 1.7182421743200393e-06
lysosomal O 0 8.11072823125869e-06
alpha O 0 2.6023310510936426e-06
- O 0 2.8430380893951224e-07
subunit O 0 9.718413593873265e-07
was O 0 3.3490385931145283e-07
not O 0 9.143845147718821e-08
detected O 0 3.820168785750866e-06
. O 0 1.4341647329274565e-05

When O 0 6.39968538962421e-06
the O 0 2.158207507818588e-06
W474C O 0 1.622831041458994e-05
- O 0 1.115988766287046e-06
containing O 0 5.061166916675575e-07
alpha O 0 4.696921678259969e-06
- O 0 4.529598243152577e-07
subunit O 0 1.9806602722383104e-06
was O 0 7.475168786186259e-07
transiently O 0 2.839842636603862e-06
co O 0 8.018116091079719e-07
- O 0 1.4513939561311417e-07
expressed O 0 1.748925448907812e-08
with O 0 1.0133304861881243e-08
the O 0 3.8078564301713413e-08
beta O 0 3.2252327741844056e-07
- O 0 4.452616408912036e-08
subunit O 0 5.827689619763987e-08
to O 0 3.340978382837534e-09
produce O 0 5.4263399107412624e-08
Hex O 0 7.238570105982944e-06
A O 0 1.23632162285503e-06
( O 0 2.7129158297611866e-07
alphabeta O 0 1.1074583198933396e-05
) O 0 1.0065426891969764e-07
in O 0 9.195245809223707e-08
COS O 0 7.599320269946475e-06
- O 0 7.504555128434731e-07
7 O 0 3.6227561395207886e-07
cells O 0 8.018722752467511e-08
, O 0 1.2361545564942844e-08
the O 0 2.5186833951806875e-08
mature O 0 1.5215671567148092e-07
alpha O 0 4.724964242086571e-07
- O 0 4.4573237545364464e-08
subunit O 0 9.915748222510956e-08
was O 0 1.846198038890634e-08
present O 0 8.011258323392667e-09
, O 0 4.633811112597641e-09
but O 0 6.177999445355908e-09
its O 0 6.407264940833102e-09
level O 0 3.3394260867680714e-07
was O 0 9.521087918074045e-08
much O 0 1.3773449936138604e-08
lower O 0 2.5821428550898418e-08
than O 0 4.726160796053591e-09
that O 0 1.8013019964513433e-09
from O 0 4.753780036281796e-09
normal O 0 7.606424645700827e-08
alpha O 0 4.2095419416909863e-07
- O 0 9.772823972298283e-08
subunit O 0 2.3579640640036814e-07
transfections O 0 6.181467711030564e-07
, O 0 6.777134409219343e-09
although O 0 7.57574003529271e-09
higher O 0 3.1064473660080694e-08
than O 0 9.701244252369179e-09
in O 0 4.5208694565701535e-09
those O 0 5.944702508031696e-09
cells O 0 2.82531456008428e-08
transfected O 0 2.1875112565794552e-07
with O 0 5.138709013863263e-09
an O 0 1.0506486347594546e-08
alpha O 0 9.045685942510318e-07
- O 0 2.668648448889144e-07
subunit O 0 7.628732987541298e-07
associated O 0 3.3180361924678436e-07
with O 0 9.939319625118515e-07
infantile O 0 0.3129356801509857
TSD B-Disease 1 0.9991393089294434
. O 0 8.688943489687517e-05

Furthermore O 0 1.1601654477999546e-05
, O 0 4.4053317083125876e-07
the O 0 1.153872588588456e-07
precursor O 0 5.342405984265497e-07
level O 0 3.437678799400601e-07
of O 0 6.486479975365e-08
the O 0 5.7718814616691816e-08
W474C O 0 1.2865460803368478e-06
alpha O 0 1.1669836794681032e-06
- O 0 1.0950430606726513e-07
subunit O 0 2.6174137701673317e-07
was O 0 4.0718532545724884e-08
found O 0 3.7169931577096804e-09
to O 0 2.4892101713192005e-09
accumulate O 0 3.0012511587074187e-08
in O 0 7.687882330742468e-09
comparison O 0 1.0422695595480036e-08
to O 0 9.598632999541223e-09
the O 0 4.387207042100272e-08
normal O 0 2.3419605099661567e-07
alpha O 0 1.407511035722564e-06
- O 0 2.415436028968543e-07
subunit O 0 1.4701603276989772e-06
precursor O 0 1.479702632423141e-06
levels O 0 2.0722986846521962e-06
. O 0 3.920634298992809e-06

We O 0 5.168395546206739e-06
conclude O 0 9.13092662813142e-06
that O 0 1.721852811442659e-07
the O 0 9.503304454483441e-07
1422 O 0 0.0003224493993911892
G O 0 0.00012814557703677565
- O 0 2.204685370088555e-05
- O 0 3.8066475553932833e-06
> O 0 1.3624409120893688e-06
C O 0 2.096985781463445e-06
mutation O 0 2.155692158112288e-08
is O 0 1.8559275227758576e-09
the O 0 3.8086822584659785e-09
cause O 0 4.5947373905619315e-08
of O 0 5.890213401471556e-07
Hex B-Disease 1 0.7435691356658936
A I-Disease 1 0.7474019527435303
enzyme I-Disease 1 0.9999985694885254
deficiency I-Disease 1 0.99998939037323
in O 0 1.9979039223017026e-07
the O 0 7.416105631818937e-07
proband O 0 0.00014952839410398155
. O 0 1.0748588465503417e-05

The O 0 5.591457465925487e-06
resulting O 0 8.359110324818175e-06
W474C O 0 2.4633731300127693e-05
substitution O 0 3.328902721477789e-06
clearly O 0 6.522856779156427e-07
interferes O 0 2.482011041138321e-07
with O 0 5.4625395762286644e-08
alpha O 0 1.894837851068587e-06
- O 0 1.9099164205726993e-07
subunit O 0 2.2286570811047568e-07
processing O 0 5.4917805414334e-08
, O 0 4.332528558137483e-09
but O 0 2.7853437334357523e-09
because O 0 2.3352633160556024e-09
the O 0 6.2079905660539225e-09
base O 0 5.486513998675946e-08
substitution O 0 2.8393776574375806e-07
falls O 0 3.1404471201312845e-07
at O 0 1.1950629641432897e-07
the O 0 2.0237223452568287e-08
first O 0 3.659291181179469e-08
position O 0 2.101318727909529e-07
of O 0 1.6180139539301308e-07
exon O 0 9.661690683060442e-07
13 O 0 2.740479772000981e-07
, O 0 6.441185007588501e-08
aberrant O 0 5.04959132285876e-07
splicing O 0 7.940369641801226e-07
may O 0 1.3097228190872556e-07
also O 0 4.1894729463365366e-08
contribute O 0 8.392017036840116e-08
to O 0 1.2070783839135402e-07
Hex B-Disease 0 0.011633415706455708
A I-Disease 0 0.00019054280710406601
deficiency I-Disease 0 0.0021546378266066313
in O 0 7.508535304623365e-08
this O 0 1.2427625506461482e-07
proband O 0 1.6366213458240964e-05
. O 0 8.785433465163806e-07
. O 0 9.251527444575913e-06

Two O 0 5.508194590220228e-06
frequent O 0 6.033777026459575e-06
missense O 0 0.0002676108852028847
mutations O 0 0.00021097698481753469
in O 0 0.00019321759464219213
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9939992427825928

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.580862438771874e-05
an O 0 0.016464930027723312
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9997639060020447
by O 0 2.3212078303913586e-05
early O 1 0.9999197721481323
childhood O 1 0.9999998807907104
deafness B-Disease 1 1.0
and O 1 0.9999998807907104
goiter B-Disease 1 1.0
. O 1 0.9999017715454102

A O 0 1.5368377717095427e-05
century O 0 3.896621365129249e-06
after O 0 4.202991306101467e-07
its O 0 2.4773799012223208e-08
recognition O 0 1.1426853063767339e-07
as O 0 4.2296264268770756e-07
a O 0 1.7868132999865338e-06
syndrome O 0 0.0018206145614385605
by O 0 1.6068285901837953e-07
Vaughan O 0 0.033364906907081604
Pendred O 1 0.6592511534690857
, O 0 2.1480751399849396e-07
the O 0 2.3954348193910846e-07
disease O 0 2.0245793166395742e-06
gene O 0 3.8584568073929404e-07
( O 0 5.067377628620306e-07
PDS O 1 0.6118216514587402
) O 0 4.357181637715257e-07
was O 0 1.3257116506792954e-06
mapped O 0 3.522027895996871e-07
to O 0 2.0630943708965788e-07
chromosome O 0 1.2993216842005495e-05
7q22 O 0 0.00012334257189650089
- O 0 0.0001458540791645646
q31 O 0 0.0006612365250475705
. O 0 6.391350325429812e-05

1 O 0 1.734141551423818e-05
and O 0 9.77832087301067e-07
, O 0 4.183197006568662e-07
recently O 0 3.152970009523415e-07
, O 0 5.264657687575891e-08
found O 0 2.5058939812083736e-08
to O 0 4.442809142801707e-08
encode O 0 3.762847882171627e-07
a O 0 1.4112609960648115e-06
putative O 0 4.512512168730609e-05
sulfate O 0 0.002591499127447605
transporter O 0 0.008138464763760567
. O 0 8.36077451822348e-05

We O 0 2.2083725070842775e-06
performed O 0 3.344359811308095e-07
mutation O 0 1.3427271028376708e-07
analysis O 0 6.449815259657043e-08
of O 0 1.8050297967420192e-07
the O 0 4.867127927354886e-07
PDS B-Disease 0 0.016776537522673607
gene O 0 2.992072438701143e-07
in O 0 3.472089105116538e-08
patients O 0 2.3783368163776686e-08
from O 0 4.827870370149867e-08
14 O 0 3.1689787647337653e-06
Pendred B-Disease 0 4.402540434966795e-05
families O 0 1.1324956084024507e-08
originating O 0 2.3158895245956046e-08
from O 0 1.0825451646212514e-08
seven O 0 4.932565644821807e-08
countries O 0 6.3078577916542145e-09
and O 0 3.9588265110523935e-08
identified O 0 1.783733836191459e-07
all O 0 1.6071089703473262e-07
mutations O 0 3.752752718355623e-06
. O 0 8.691798939253204e-06

The O 0 2.7101691557618324e-06
mutations O 0 1.2454432862796239e-06
include O 0 2.1683857198695478e-07
three O 0 1.220290783976452e-07
single O 0 7.272943491898332e-08
base O 0 6.366725529005635e-07
deletions O 0 1.9180386061634636e-06
, O 0 2.9668069601029856e-07
one O 0 1.8323170536405087e-07
splice O 0 1.6514690059921122e-06
site O 0 3.879621317537385e-07
mutation O 0 2.342599287885605e-07
and O 0 3.099440561982192e-07
10 O 0 4.806471679330571e-06
missense O 0 0.0001867122045950964
mutations O 0 8.952425559982657e-05
. O 0 5.8687444834504277e-05

One O 0 1.0011181075242348e-05
missense O 0 6.861863221274689e-05
mutation O 0 7.288645520020509e-06
( O 0 1.7495915471954504e-06
L236P O 0 5.459114981931634e-05
) O 0 2.42474612832666e-07
was O 0 2.680220347883733e-07
found O 0 1.4660754388273745e-08
in O 0 7.017154413091475e-09
a O 0 3.251501468071183e-08
homozygous O 0 1.7884569558646035e-07
state O 0 1.214969547191913e-08
in O 0 2.614230254494032e-08
two O 0 1.3085143280022749e-07
consanguineous O 0 4.095612894161604e-06
families O 0 1.3478660854104874e-08
and O 0 3.7751185288925626e-08
in O 0 3.524399261323197e-08
a O 0 7.069590424180205e-08
heterozygous O 0 7.605772367469399e-08
state O 0 1.03760626757321e-08
in O 0 1.9721239752357178e-08
five O 0 6.816911479745613e-08
additional O 0 1.6280066006402194e-07
non O 0 6.099151960370364e-06
- O 0 1.269935273739975e-05
consanguineous O 0 2.9062422981951386e-05
families O 0 1.4614347492170054e-06
. O 0 1.2352949852356687e-05

Another O 0 2.6316149160265923e-05
missense O 0 9.775464423000813e-05
mutation O 0 9.580028745403979e-06
( O 0 2.3385641725326423e-06
T416P O 0 6.185033998917788e-05
) O 0 3.126730234725983e-07
was O 0 4.0850900973055104e-07
found O 0 3.261955683342421e-08
in O 0 1.7820259046175124e-08
a O 0 4.0800863132517406e-08
homozygous O 0 2.360279154345335e-07
state O 0 1.3374840790447706e-08
in O 0 1.6150995207908636e-08
one O 0 2.44447644348611e-08
family O 0 5.40729550024821e-09
and O 0 1.422425199848476e-08
in O 0 1.5496011585014458e-08
a O 0 4.8648445272192475e-08
heterozygous O 0 1.6368991850868042e-07
state O 0 2.138557597675117e-08
in O 0 7.379475874813579e-08
four O 0 1.0004787327488884e-06
families O 0 4.519419007920078e-07
. O 0 8.024696398933884e-06

Pendred B-Disease 0 0.006010041106492281
patients O 0 3.4185311506007565e-06
in O 0 2.165789965147269e-07
three O 0 4.714935357696959e-07
non O 0 5.987034001009306e-06
- O 0 5.289758973958669e-06
consanguineous O 0 4.6133154683047906e-06
families O 0 2.0782714216238674e-08
were O 0 3.9941934204534846e-08
shown O 0 4.3108190794782786e-08
to O 0 2.4641797935487375e-08
be O 0 1.0248788129274544e-07
compound O 0 1.3536043752537807e-06
heterozygotes O 0 8.73430872161407e-06
for O 0 4.413384431245504e-07
L236P O 0 3.726224531419575e-05
and O 0 4.700443696492584e-06
T416P O 0 0.0002482807612977922
. O 0 3.7485002394532785e-05

In O 0 9.896377832774306e-07
total O 0 4.06533899877104e-07
, O 0 7.802907475706888e-08
one O 0 1.3515525587592947e-08
or O 0 8.259700479129606e-09
both O 0 5.874189579202493e-09
of O 0 8.22737344918778e-09
these O 0 1.5159604682679628e-09
mutations O 0 1.1081535689072552e-08
were O 0 1.0607304368193127e-08
found O 0 7.550553071666855e-09
in O 0 8.835307596655184e-09
nine O 0 1.0996938470952955e-07
of O 0 5.990255402821276e-08
the O 0 1.4861301167456986e-07
14 O 0 1.8214642523162183e-06
families O 0 2.393662725808099e-07
analyzed O 0 4.833508683077525e-06
. O 0 1.1774779522966128e-05

The O 0 1.8928168401544099e-06
identification O 0 9.387572958985402e-07
of O 0 6.917305199749535e-07
two O 0 5.149819344296702e-07
frequent O 0 1.1591495194807067e-06
PDS B-Disease 0 0.0024421201087534428
mutations O 0 1.4863259139019647e-06
will O 0 1.898066557259881e-07
facilitate O 0 6.044727456355758e-07
the O 0 2.716519702516962e-07
molecular O 0 4.764405821333639e-05
diagnosis O 0 0.023778334259986877
of O 1 0.8536548018455505
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.841167688369751

Insertional O 0 0.0004032237338833511
mutation O 0 4.9228469833906274e-06
by O 0 4.608319557064533e-07
transposable O 0 4.3330073822289705e-05
element O 0 6.481771379185375e-06
, O 0 7.40381608466123e-07
L1 O 0 0.0004353862314019352
, O 0 2.402281893409963e-07
in O 0 1.1917431663732714e-07
the O 0 7.548612757091178e-07
DMD B-Disease 1 0.9999998807907104
gene O 0 6.766622391296551e-07
results O 0 1.1121745728814858e-06
in O 0 3.673235653423035e-07
X B-Disease 1 0.9884436726570129
- I-Disease 1 0.9993345141410828
linked I-Disease 1 0.9243769645690918
dilated I-Disease 1 0.9722729921340942
cardiomyopathy I-Disease 1 1.0
. O 0 0.05754634365439415

X B-Disease 1 0.9986479878425598
- I-Disease 1 0.9999376535415649
linked I-Disease 1 0.9955472946166992
dilated I-Disease 1 0.999940037727356
cardiomyopathy I-Disease 1 1.0
( O 1 0.9811336994171143
XLDCM B-Disease 1 1.0
) O 0 1.787960400179145e-06
is O 0 7.287217584917016e-08
a O 0 9.783753540659745e-08
clinical O 0 1.1973895652772626e-06
phenotype O 0 1.9888429960701615e-06
of O 0 3.197922069375636e-07
dystrophinopathy B-Disease 0 8.487665763823316e-05
which O 0 3.5570245415783575e-08
is O 0 9.432550740484658e-09
characterized O 0 4.583070278840751e-08
by O 0 2.6580485368299378e-08
preferential O 0 1.2714360764221055e-06
myocardial B-Disease 0 0.08410339802503586
involvement I-Disease 0 1.6675087408657419e-06
without O 0 1.001238700837348e-07
any O 0 5.059255769879201e-08
overt O 0 6.826591061326326e-07
clinical O 0 5.966986464045476e-06
signs O 0 4.0442180761601776e-05
of O 1 0.9933565258979797
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9993888139724731

To O 0 6.519138082694553e-07
date O 0 1.714150357656763e-06
, O 0 1.1620056739047868e-07
several O 0 4.292457234100766e-08
mutations O 0 1.763248604902401e-07
in O 0 6.835386301418112e-08
the O 0 9.825876986724325e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.29837629199028015
, O 0 0.0005615350091829896
DMD O 1 1.0
, O 0 1.0475229146322818e-06
have O 0 3.494765010714218e-08
been O 0 2.868619475293599e-08
identified O 0 4.166840383845738e-08
in O 0 1.0401405958759824e-08
patients O 0 2.205272942035208e-08
with O 0 7.627112807995218e-08
XLDCM B-Disease 1 0.9999957084655762
, O 0 2.2214530304154323e-07
but O 0 2.588385328294862e-08
a O 0 2.4342497795259987e-08
pathogenic O 0 3.4254262004651537e-07
correlation O 0 6.56989200820135e-08
of O 0 4.8450655043552615e-08
these O 0 3.8739639052209895e-08
cardiospecific O 0 4.310192252887646e-06
mutations O 0 3.859244372961257e-07
in O 0 1.1029246138605231e-07
DMD O 1 0.9999996423721313
with O 0 2.2166342716900544e-07
the O 0 8.836354368213506e-07
XLDCM B-Disease 1 0.9941826462745667
phenotype O 0 7.107641067705117e-06
has O 0 4.349421800498021e-08
remained O 0 3.1730567684462585e-07
to O 0 6.216192360852801e-08
be O 0 8.931148158808355e-07
elucidated O 0 0.00013268415932543576
. O 0 1.5120939679036383e-05

We O 0 5.948225862084655e-06
report O 0 3.7815834730281495e-07
here O 0 7.680908709062351e-08
the O 0 2.3152978201324004e-08
identification O 0 4.9886821784639324e-08
of O 0 5.754974452543138e-08
a O 0 1.0295045882457998e-07
unique O 0 2.3629840484318265e-07
de O 0 1.1558186997717712e-05
novo O 0 5.328719907993218e-06
L1 O 0 1.746980706229806e-05
insertion O 0 9.996555263569462e-07
in O 0 1.0714140330492228e-07
the O 0 2.2302113222849584e-07
muscle O 0 2.5767194529180415e-06
exon O 0 2.562259624028229e-06
1 O 0 1.0629723874444608e-06
in O 0 1.6436349881132628e-07
DMD O 1 0.9999998807907104
in O 0 1.0677929651592422e-07
three O 0 1.9144735574627703e-07
XLDCM B-Disease 0 0.00145479547791183
patients O 0 5.2452232779387487e-08
from O 0 1.8217054531532995e-08
two O 0 7.39260599402769e-08
unrelated O 0 7.336544740610407e-07
Japanese O 0 3.4269462503289105e-06
families O 0 1.4365315337272477e-06
. O 0 1.2644585694943089e-05

The O 0 6.450475666497368e-06
insertion O 0 8.892267032933887e-06
was O 0 2.0208003661537077e-06
a O 0 3.350473036789481e-07
5 O 0 1.0442205393701443e-06
- O 0 6.003329531267809e-07
truncated O 0 4.151954158260196e-07
form O 0 1.3608291737909894e-07
of O 0 3.160119490530633e-07
human O 0 2.4777963858468866e-07
L1 O 0 1.4858545000606682e-05
inversely O 0 1.2149438362030196e-06
integrated O 0 8.839068073029921e-07
in O 0 1.548829864361778e-08
the O 0 2.9288990788245428e-08
5 O 0 2.1971347052840429e-07
- O 0 1.743100028761546e-07
untranslated O 0 1.4842026985206758e-06
region O 0 7.037315441493774e-08
in O 0 2.889028927199888e-08
the O 0 7.827846104646596e-08
muscle O 0 6.88018531036505e-07
exon O 0 7.185516324170749e-07
1 O 0 2.1854717147107294e-07
, O 0 1.95640748046344e-08
which O 0 5.156106208659139e-09
affected O 0 6.149772246999419e-09
the O 0 4.517637375300865e-09
transcription O 0 1.5917224871486724e-08
or O 0 3.1724312066216953e-09
the O 0 7.057515905017908e-09
stability O 0 1.620354908027366e-07
of O 0 3.751911137328534e-08
the O 0 4.372311934730533e-08
muscle O 0 1.574267258774853e-07
form O 0 5.4175700370251434e-08
of O 0 3.0160111919030896e-07
dystrophin O 0 3.7560607779596467e-06
transcripts O 0 1.894263732538093e-07
but O 0 1.8900503384600142e-09
not O 0 1.6938684899159284e-09
that O 0 2.1846655595680886e-09
of O 0 3.5030268463742686e-08
the O 0 1.805250207098652e-07
brain O 0 2.2526015527546406e-05
or O 0 2.8914001859448035e-07
Purkinje O 0 0.0020498838275671005
cell O 0 3.253014028814505e-06
form O 0 1.452933844348081e-07
, O 0 3.012469207419599e-08
probably O 0 3.966014006095975e-08
due O 0 4.741240999805996e-08
to O 0 6.056889212402439e-09
its O 0 6.7228040911970766e-09
unique O 0 4.0843371351684254e-08
site O 0 1.1639554742259861e-07
of O 0 3.344605374877574e-07
integration O 0 2.6138917746720836e-05
. O 0 1.886940844997298e-05

We O 0 2.490727638360113e-06
speculate O 0 1.1408095588194556e-06
that O 0 2.869051485276941e-08
this O 0 1.401120730548655e-08
insertion O 0 2.013523925370464e-07
of O 0 1.881577702533832e-07
an O 0 9.76790417439588e-08
L1 O 0 0.00012656566104851663
sequence O 0 1.3084771808280493e-06
in O 0 6.723704473188263e-07
DMD O 1 1.0
is O 0 1.1397597887707889e-07
responsible O 0 1.1957688172969938e-07
for O 0 7.1877139795617495e-09
some O 0 2.7353805887031513e-09
of O 0 9.86138726233321e-09
the O 0 8.614684965380093e-09
population O 0 2.2822288503476784e-09
of O 0 2.683232125377799e-08
Japanese O 0 8.098284638435871e-07
patients O 0 2.1248500559067907e-07
with O 0 4.804816740033857e-07
XLDCM B-Disease 0 0.34059542417526245
. O 0 3.3016585803125054e-06
. O 0 1.1939680007344577e-05

Severe O 0 0.34107938408851624
early O 0 0.026117034256458282
- O 1 0.9998549222946167
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.6671724915504456
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.999932050704956
red O 1 0.9999991655349731
hair O 1 0.9999799728393555
pigmentation O 1 0.9998877048492432
caused O 0 2.027029768214561e-05
by O 0 7.89393482136802e-07
POMC O 1 0.9822806715965271
mutations O 0 5.930643965257332e-06
in O 0 7.253713079080626e-07
humans O 0 1.2585922377184033e-05
. O 0 1.1669563718896825e-05

Sequential O 0 6.87872088747099e-05
cleavage O 0 1.0424671927466989e-05
of O 0 8.505509185852134e-07
the O 0 3.34113366307065e-07
precursor O 0 1.1829815775854513e-06
protein O 0 1.669634741574555e-07
pre O 0 1.6106838529594825e-06
- O 0 1.5661046290915692e-06
pro O 0 0.0002232025726698339
- O 0 0.00010225566802546382
opiomelanocortin O 0 0.0014529692707583308
( O 0 2.4932185169745935e-06
POMC O 0 0.000990835833363235
) O 0 3.6449873164201563e-07
generates O 0 7.970641036081361e-07
the O 0 7.77616207869869e-07
melanocortin O 0 0.00015350236208178103
peptides O 0 6.431623660319019e-06
adrenocorticotrophin O 0 8.251288818428293e-05
( O 0 2.6275881737092277e-06
ACTH O 0 0.00019576743943616748
) O 0 1.7347581433568848e-06
, O 0 3.4237416457472136e-06
melanocyte O 0 0.2974235415458679
- O 0 0.0011158866109326482
stimulating O 0 0.0002018599770963192
hormones O 0 2.601412916192203e-06
( O 0 3.290206507244875e-07
MSH O 0 8.702924969838932e-05
) O 0 7.872420582089035e-08
alpha O 0 6.327078949652787e-07
, O 0 1.596666621139775e-08
beta O 0 9.824518798495774e-08
and O 0 7.45866035600784e-09
gamma O 0 2.1273216077588586e-07
as O 0 7.900621490364301e-09
well O 0 5.8555977844321205e-09
as O 0 1.0329777033746268e-08
the O 0 2.3008624339126982e-08
opioid O 0 9.589887213223847e-07
- O 0 3.3560823453626654e-07
receptor O 0 3.014699814229971e-07
ligand O 0 9.694068694443558e-07
beta O 0 6.396634489647113e-06
- O 0 9.047187631949782e-06
endorphin O 0 0.00019805008196271956
. O 0 1.519862053100951e-05

While O 0 4.464506673684809e-06
a O 0 7.855574040149804e-07
few O 0 2.1583505827038607e-07
cases O 0 1.310484947225632e-07
of O 0 6.55067879051785e-07
isolated O 0 7.076196925481781e-05
ACTH B-Disease 1 0.9999984502792358
deficiency I-Disease 1 0.9999051094055176
have O 0 2.8483029268500104e-07
been O 0 4.2218161411256006e-07
reported O 0 9.193543064611731e-07
( O 0 1.179494915959367e-06
OMIM O 0 0.11897046118974686
201400 O 0 7.312990055652335e-05
) O 0 2.0211578544149233e-07
, O 0 9.615219198622071e-08
an O 0 1.6023510340801295e-07
inherited O 0 0.20692899823188782
POMC O 1 1.0
defect O 0 0.2690659165382385
has O 0 2.497363311704248e-07
not O 0 3.438871587491121e-08
been O 0 1.2086381673270807e-07
described O 0 2.3235114099406928e-07
so O 0 1.0594449406653439e-07
far O 0 1.4994482171459822e-06
. O 0 8.88959584699478e-06

Recent O 0 5.744386271544499e-06
studies O 0 1.2777203437508433e-06
in O 0 2.17739369645642e-07
animal O 0 2.279916202496679e-07
models O 0 7.895048952377692e-07
elucidated O 0 4.745448222820414e-06
a O 0 8.757396585679089e-08
central O 0 1.976004853077029e-07
role O 0 2.3763693945966224e-07
of O 0 4.60315874306616e-07
alpha O 0 3.4218788641737774e-05
- O 0 7.678047040826641e-06
MSH O 0 0.0009163622162304819
in O 0 3.851823748846073e-08
the O 0 7.355559006327894e-08
regulation O 0 1.228437440659036e-07
of O 0 3.176089791168124e-08
food O 0 1.1759010654088797e-08
intake O 0 2.540152088670311e-08
by O 0 3.855062935542719e-09
activation O 0 4.379523232955762e-08
of O 0 4.9745150221269796e-08
the O 0 1.90731171301195e-07
brain O 0 4.063934738951502e-06
melanocortin O 0 4.73983891424723e-05
- O 0 6.5705057750165e-07
4 O 0 9.41220719141711e-07
- O 0 3.4383279512439913e-07
receptor O 0 3.397197474441782e-07
( O 0 1.2059267362474202e-07
MC4 O 0 6.0412825405364856e-05
- O 0 1.2925141845698818e-06
R O 0 9.463709034207568e-07
; O 0 5.861366147996705e-08
refs O 0 1.9010298046850949e-06
3 O 0 3.037509941350436e-07
- O 0 7.960631620562708e-08
5 O 0 5.1715332460844365e-08
) O 0 4.211422766076112e-09
and O 0 6.540869179616493e-09
the O 0 2.2240703501097414e-08
linkage O 0 5.306607704369526e-07
of O 0 3.5230425510235364e-07
human O 0 7.60929708576441e-07
obesity B-Disease 0 0.00013088319974485785
to O 0 1.890743739352274e-08
chromosome O 0 1.1028236457377716e-07
2 O 0 1.534416753656842e-07
in O 0 1.771533852945595e-08
close O 0 9.92842714708786e-08
proximity O 0 2.0151259150225087e-07
to O 0 4.094157191047998e-08
the O 0 3.0730544153811934e-07
POMC O 0 0.0005764244124293327
locus O 0 1.4836167565590586e-06
, O 0 6.770147109591562e-08
led O 0 8.761941217017011e-08
to O 0 1.4009442494966606e-08
the O 0 2.306280144637185e-08
proposal O 0 4.8840341548839206e-08
of O 0 8.077006441453705e-08
an O 0 4.151402777097246e-08
association O 0 1.8755562791739067e-07
of O 0 8.269528734672349e-06
POMC O 1 0.9999997615814209
with O 0 0.0002510129997972399
human O 0 0.45920461416244507
obesity B-Disease 1 0.9999998807907104
. O 0 6.745161226717755e-05

The O 0 2.4491630483680638e-06
dual O 0 6.5908293436223175e-06
role O 0 1.3359259583012317e-06
of O 0 2.540589321142761e-06
alpha O 0 0.0006915108533576131
- O 0 0.00021360140817705542
MSH O 1 0.9916113018989563
in O 0 2.0507418696524837e-07
regulating O 0 8.996561291496619e-07
food O 0 1.0583280385390026e-07
intake O 0 4.6983095103314554e-07
and O 0 1.7139235808372177e-07
influencing O 0 6.150634362711571e-06
hair O 0 7.278794510057196e-05
pigmentation O 0 0.00037433268153108656
predicts O 0 8.32016667118296e-07
that O 0 1.5340649639483672e-08
the O 0 9.093302111295998e-08
phenotype O 0 1.7927685576069052e-06
associated O 0 1.0351160284471916e-07
with O 0 4.650636853398282e-08
a O 0 3.9441792409888876e-07
defect O 0 5.21431411470985e-06
in O 0 6.535297529808304e-07
POMC O 1 0.9745046496391296
function O 0 1.5256240430971957e-06
would O 0 2.3752025413159572e-07
include O 0 2.2430465378420195e-06
obesity B-Disease 1 0.9999953508377075
, O 0 7.702054745095666e-07
alteration O 0 3.574115544324741e-05
in O 0 2.2205515506357187e-06
pigmentation O 1 0.9999884366989136
and O 0 0.07129179686307907
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999995231628418
. O 0 0.00021962686150800437

The O 0 4.468084625841584e-06
observation O 0 8.778006304055452e-06
of O 0 8.694747748450027e-07
these O 0 2.1553084650349774e-07
symptoms O 0 9.927914106810931e-06
in O 0 1.2742749788685614e-07
two O 0 2.6948833919959725e-07
probands O 0 1.0880298759730067e-05
prompted O 0 1.7516622108360025e-07
us O 0 2.0785726917438296e-08
to O 0 5.719647422353091e-09
search O 0 5.7656645680026486e-08
for O 0 3.006820747941674e-08
mutations O 0 2.3640907897970465e-07
within O 0 2.51112908244977e-07
their O 0 5.996469099045498e-07
POMC O 0 0.0015913365641608834
genes O 0 1.4490757166640833e-05
. O 0 2.4154036509571597e-05

Patient O 0 1.561749195388984e-05
1 O 0 6.106928140070522e-06
was O 0 8.373730793209688e-07
found O 0 1.6274531944304726e-08
to O 0 1.0306004050164574e-08
be O 0 2.59827821480485e-08
a O 0 6.118640527574826e-08
compound O 0 5.163633431948256e-07
heterozygote O 0 2.61977402260527e-06
for O 0 5.2712493925355375e-08
two O 0 4.437948319946372e-08
mutations O 0 7.939856772054554e-08
in O 0 4.4813287303213656e-08
exon O 0 1.0261653642373858e-06
3 O 0 9.916473118209979e-07
( O 0 1.4261038927543268e-07
G7013T O 0 4.52089489044738e-06
, O 0 1.752128326870661e-07
C7133delta O 0 8.278406312456354e-06
) O 0 7.728065298806541e-08
which O 0 2.6339348480064473e-08
interfere O 0 9.132498490771468e-08
with O 0 2.0151214030761366e-08
appropriate O 0 1.1207377070832081e-07
synthesis O 0 5.671243457072705e-07
of O 0 3.2738833510848053e-07
ACTH O 0 3.644988464657217e-05
and O 0 1.4014622138347477e-06
alpha O 0 0.0001242396974703297
- O 0 5.2125556976534426e-05
MSH O 0 0.027989014983177185
. O 0 2.1613159333355725e-05

Patient O 0 3.093560735578649e-05
2 O 0 1.82461863005301e-05
was O 0 2.764827513601631e-06
homozygous O 0 8.895531777852739e-07
for O 0 5.5830000178502814e-08
a O 0 7.999566520311419e-08
mutation O 0 1.6771976163454383e-07
in O 0 7.993892836566374e-08
exon O 0 1.5487242990275263e-06
2 O 0 2.3887055249360856e-06
( O 0 2.607910971619276e-07
C3804A O 0 8.374885510420427e-06
) O 0 1.9731800193767413e-07
which O 0 4.3854166165147035e-07
abolishes O 0 5.233255433267914e-05
POMC O 0 0.0014842678792774677
translation O 0 8.320798224303871e-05
. O 0 6.013876190991141e-05

These O 0 8.806051710052998e-07
findings O 0 6.586716949641414e-07
represent O 0 1.5138321884933248e-07
the O 0 1.0098097646960014e-07
first O 0 1.1914521991229776e-07
examples O 0 1.1092154750258487e-07
of O 0 3.0063966960369726e-07
a O 0 9.72104544416652e-07
genetic B-Disease 1 0.9955626726150513
defect I-Disease 1 0.9314773082733154
within O 0 8.095852308542817e-07
the O 0 6.31224111202755e-07
POMC O 0 0.0002312573924427852
gene O 0 1.1741085614858093e-07
and O 0 3.831738482062974e-08
define O 0 1.8759301667614636e-07
a O 0 1.3631229478505702e-07
new O 0 2.2022272787580732e-06
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.8996601104736328
resulting O 0 3.6981534776714398e-06
in O 0 2.8755059133800387e-07
early O 0 0.00021259443019516766
- O 1 0.9894607663154602
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9540058970451355
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9999804496765137
red O 1 0.9999992847442627
hair O 1 0.999919056892395
pigmentation O 1 0.999836802482605
. O 0 3.880634267261485e-06
. O 0 1.3685960766451899e-05

A O 0 4.5916338422102854e-05
European O 0 5.0821694458136335e-05
multicenter O 0 0.004104158375412226
study O 0 3.892595486831851e-06
of O 0 0.00028034969000145793
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.3509438758774195e-06
classification O 0 6.570894584001508e-07
of O 0 1.8881891605815326e-07
105 O 0 2.615013556805934e-07
mutations O 0 3.4809346516340156e-08
and O 0 9.043295889910041e-09
a O 0 2.462356896160145e-08
general O 0 5.6573828288719596e-08
system O 0 6.793677442828994e-08
for O 0 4.421278632094072e-08
genotype O 0 5.442664701149624e-07
- O 0 2.5331422648378066e-07
based O 0 1.071536672725415e-07
prediction O 0 4.555687610263703e-06
of O 0 7.52486766941729e-06
metabolic O 1 0.9999651908874512
phenotype O 0 0.006495074834674597
. O 0 4.780339077115059e-05

Phenylketonuria B-Disease 1 0.9999923706054688
( O 0 0.00023635274555999786
PKU B-Disease 1 0.9999511241912842
) O 0 5.982062702969415e-06
and O 0 1.4900421774655115e-05
mild B-Disease 1 0.9999998807907104
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.999717652797699
MHP B-Disease 1 1.0
) O 0 3.1479364679398714e-06
are O 0 5.328687961991818e-07
allelic B-Disease 1 0.9991262555122375
disorders I-Disease 1 0.9610472917556763
caused O 0 7.181906198638899e-07
by O 0 4.41266010398067e-08
mutations O 0 5.9002207564162745e-08
in O 0 1.471647870232573e-08
the O 0 8.556898478673247e-08
gene O 0 3.192287749698153e-07
encoding O 0 5.888994110136991e-06
phenylalanine O 0 5.591301669483073e-05
hydroxylase O 0 0.0003820011916104704
( O 0 1.438915751350578e-05
PAH O 1 0.9999767541885376
) O 0 5.360955128708156e-06
. O 0 1.842518940975424e-05

Previous O 0 5.132597834744956e-06
studies O 0 4.1363077230016643e-07
have O 0 4.447396051432406e-08
suggested O 0 2.68611842102473e-07
that O 0 2.3164197671121656e-08
the O 0 1.0409745954120808e-07
highly O 0 1.4911971675246605e-06
variable O 0 2.4420158297289163e-05
metabolic O 1 0.8364303112030029
phenotypes O 0 0.0002979758137371391
of O 0 0.01997341588139534
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999825954437256
correlate O 0 2.3034917830955237e-05
with O 0 4.238558540237136e-05
PAH O 1 1.0
genotypes O 1 0.8604779839515686
. O 0 6.60563018755056e-05

We O 0 4.240185717208078e-06
identified O 0 1.3751971437159227e-06
both O 0 3.5992357538816577e-07
causative O 0 4.858960892306641e-06
mutations O 0 2.4251564809674164e-06
in O 0 4.794028996002453e-07
686 O 0 5.563261947827414e-05
patients O 0 5.332917680789251e-07
from O 0 2.206975580065773e-07
seven O 0 3.1113984277908457e-06
European O 0 1.8795484720612876e-05
centers O 0 6.783216122130398e-06
. O 0 7.463617293979041e-06

On O 0 2.378102180955466e-06
the O 0 1.9979860610419564e-07
basis O 0 2.1732653010531067e-07
of O 0 8.772208559548744e-08
the O 0 7.758741560337512e-08
phenotypic O 0 2.869779791581095e-06
characteristics O 0 1.3683630868399632e-06
of O 0 1.7916661363415187e-06
297 O 0 1.6994868929032236e-05
functionally O 0 2.434765519865323e-05
hemizygous O 0 1.846001214289572e-05
patients O 0 7.077766639440597e-08
, O 0 3.6932711111603567e-08
105 O 0 1.5415804455187754e-07
of O 0 3.8865753282379956e-08
the O 0 2.261698384131705e-08
mutations O 0 2.3349617350731933e-08
were O 0 1.4054942987229424e-08
assigned O 0 2.3437875640297534e-08
to O 0 6.82657619321958e-09
one O 0 2.014883193623973e-08
of O 0 7.723836148443297e-08
four O 0 3.314298169243557e-07
arbitrary O 0 1.3774285889667226e-06
phenotype O 0 1.749673356243875e-05
categories O 0 6.830799520685105e-06
. O 0 2.309302544745151e-05

We O 0 3.965185442211805e-06
proposed O 0 1.9772330688283546e-06
and O 0 2.65308045754864e-07
tested O 0 4.6867816649864835e-07
a O 0 3.7994261958829156e-08
simple O 0 6.61624426356866e-08
model O 0 5.724878349155915e-08
for O 0 1.4915590540454104e-08
correlation O 0 6.426176923923776e-08
between O 0 1.1303682612151533e-07
genotype O 0 2.5307085707027e-06
and O 0 4.342641375387757e-07
phenotypic O 0 4.6565692173317075e-05
outcome O 0 4.455321322893724e-05
. O 0 3.188673508702777e-05

The O 0 6.94792288413737e-06
observed O 0 5.114918621984543e-06
phenotype O 0 9.81633274932392e-06
matched O 0 8.364177688235941e-07
the O 0 2.5912362389135524e-07
predicted O 0 1.7013185242831241e-06
phenotype O 0 1.4947009958632407e-06
in O 0 2.8911015803601003e-08
79 O 0 1.4907377021700086e-07
% O 0 1.104913849303557e-08
of O 0 3.278272586726416e-08
the O 0 1.915967118293338e-08
cases O 0 1.7269748298076593e-08
, O 0 8.278217222823514e-09
and O 0 6.939768315561423e-09
in O 0 3.7241107975205523e-09
only O 0 3.897069777991646e-09
5 O 0 4.531213804170875e-08
of O 0 2.7494422738527646e-08
184 O 0 1.178091437736839e-07
patients O 0 1.2507568314390483e-08
was O 0 5.361187760399844e-08
the O 0 3.169614615217142e-08
observed O 0 9.789054189468516e-08
phenotype O 0 2.1393066163000185e-07
more O 0 6.475957992080339e-09
than O 0 4.915695406282339e-09
one O 0 4.9518780187440825e-09
category O 0 1.7107172567421003e-08
away O 0 1.6602326624592934e-08
from O 0 7.212144215174021e-09
that O 0 3.951810612079498e-08
expected O 0 2.978724523927667e-06
. O 0 1.3419551578408573e-05

Among O 0 3.319385768918437e-06
the O 0 5.929439907959022e-07
seven O 0 4.581907830925047e-07
contributing O 0 1.5342659764883138e-07
centers O 0 6.393972995510921e-08
, O 0 1.4384541557888042e-08
the O 0 1.3786222829992312e-08
proportion O 0 2.5888692078979147e-08
of O 0 4.624824967436325e-08
patients O 0 1.725483222969615e-08
for O 0 1.162411944477526e-08
whom O 0 5.87583954825277e-08
the O 0 6.377955941161417e-08
observed O 0 2.1761751156645914e-07
phenotype O 0 2.588953975646291e-07
did O 0 2.2027718316053324e-08
not O 0 1.4256193558992436e-08
match O 0 6.13669840276998e-07
the O 0 1.0045633302979695e-07
predicted O 0 8.69495465849468e-07
phenotype O 0 1.6480328213219764e-06
was O 0 3.5519101970749034e-07
4 O 0 2.5015683036144765e-07
% O 0 5.653240719993846e-08
- O 0 1.530733584331756e-07
23 O 0 2.427286744932644e-07
% O 0 7.422658399036663e-08
( O 0 1.5517903761974594e-07
P O 0 2.9774077120237052e-05
< O 0 4.6578147703257855e-06
. O 0 1.3227952422312228e-07
0001 O 0 0.00018596864538267255
) O 0 4.9256271950071095e-08
, O 0 1.948055405875948e-08
suggesting O 0 4.689553634307231e-08
that O 0 4.729379998735794e-09
differences O 0 5.513400935797108e-08
in O 0 7.658362832785315e-09
methods O 0 2.930038967008386e-08
used O 0 5.753412413156411e-09
for O 0 7.617165564965944e-09
mutation O 0 6.864744506174247e-08
detection O 0 9.768357358552748e-07
or O 0 1.0499477554049008e-07
phenotype O 0 1.1149101055707433e-06
classification O 0 2.0583443927080225e-07
may O 0 3.5272169185418534e-08
account O 0 6.421383424992655e-09
for O 0 4.804974640393311e-09
a O 0 1.0480806444945756e-08
considerable O 0 7.539835422676333e-08
proportion O 0 1.1444826242268391e-07
of O 0 9.018647233460797e-07
genotype O 0 9.309221059083939e-05
- O 0 5.202365719014779e-05
phenotype O 0 8.359634375665337e-05
inconsistencies O 0 5.968529512756504e-05
. O 0 3.7489153328351676e-05

Our O 0 4.23513392888708e-06
data O 0 5.388579893406131e-07
indicate O 0 3.1616747264706646e-07
that O 0 7.981871164020049e-08
the O 0 1.917765985126607e-06
PAH O 1 0.999996542930603
- O 0 8.771286957198754e-06
mutation O 0 5.689998943125829e-07
genotype O 0 1.024017592499149e-06
is O 0 3.494312039720171e-08
the O 0 6.678178010588454e-08
main O 0 6.298140533544938e-07
determinant O 0 4.524056294030743e-06
of O 0 1.658930614212295e-06
metabolic O 0 0.43834584951400757
phenotype O 0 9.600019438948948e-06
in O 0 9.400978484563893e-08
most O 0 1.6610408692940837e-07
patients O 0 3.316882839499158e-06
with O 0 0.1433480978012085
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.002700434997677803

In O 0 1.798517473616812e-06
the O 0 3.694684096444689e-07
present O 0 1.5784088702730514e-07
study O 0 7.141854752035215e-08
, O 0 2.4387668773329096e-08
the O 0 3.783300073223472e-08
classification O 0 2.6930669605462754e-07
of O 0 4.05605646847107e-07
105 O 0 1.9217633962398395e-05
PAH O 1 0.9999632835388184
mutations O 0 2.0259901134522806e-07
may O 0 1.6678564307426313e-08
allow O 0 1.2790386527683495e-08
the O 0 1.4950567006621895e-08
prediction O 0 2.0299199832152226e-07
of O 0 3.220855404606482e-08
the O 0 7.258336154336575e-08
biochemical O 0 1.7978828736886499e-06
phenotype O 0 1.5355951745732455e-06
in O 0 5.5393627462763106e-08
> O 0 1.6238058151429868e-06
10 O 0 2.4337512627425895e-07
, O 0 6.902636329186862e-08
000 O 0 2.73578990572787e-07
genotypes O 0 7.593587270093849e-07
, O 0 3.0735140654769566e-08
which O 0 8.604864376593468e-09
may O 0 1.978200891983306e-08
be O 0 1.5284165044704423e-08
useful O 0 5.035803596342703e-08
for O 0 1.2310251484848322e-08
the O 0 6.380437866937427e-08
management O 0 1.1337964451740845e-06
of O 0 2.5550416467012838e-06
hyperphenylalaninemia B-Disease 1 0.9999996423721313
in O 0 1.594238938196213e-06
newborns O 0 1.1816424375865608e-05
. O 0 1.0334257240174338e-05

Somatic O 0 0.0002568978816270828
instability O 0 2.2300027922028676e-05
of O 0 4.498946509556845e-06
the O 0 3.8026960282877553e-06
CTG O 0 0.37316471338272095
repeat O 0 1.8628301404532976e-05
in O 0 4.195582334887149e-07
mice O 0 1.919601345434785e-06
transgenic O 0 1.597795971974847e-06
for O 0 2.5288531446676643e-07
the O 0 0.00025074221775867045
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.5334482415928505e-05
is O 0 5.690411697401032e-08
age O 0 4.46642971496658e-08
dependent O 0 7.774885624201033e-09
but O 0 4.025103805815888e-09
not O 0 3.287324856771079e-09
correlated O 0 2.1025170937605253e-08
to O 0 4.925267749200657e-09
the O 0 2.888356931407543e-08
relative O 0 4.4468322357715806e-07
intertissue O 0 6.492251031886553e-06
transcription O 0 8.621425990895659e-07
levels O 0 7.658365461793437e-07
and O 0 9.328794590146572e-07
proliferative O 0 0.07470547407865524
capacities O 0 0.0004258275148458779
. O 0 2.342243715247605e-05

A O 0 0.00023565180890727788
( O 0 2.8341064535197802e-05
CTG O 0 0.006216580048203468
) O 0 1.833045644161757e-06
nexpansion O 0 2.217089058831334e-05
in O 0 1.176920179091212e-07
the O 0 1.2579839392401482e-07
3 O 0 1.3512982377505978e-06
- O 0 1.1002242672475404e-06
untranslated O 0 8.58572093420662e-06
region O 0 5.848579576195334e-07
( O 0 3.1776232845004415e-07
UTR O 0 7.405885844491422e-05
) O 0 1.3702850765184849e-07
of O 0 3.176320433340152e-07
the O 0 1.5631114820280345e-06
DM O 1 0.9999997615814209
protein O 0 2.3078193862602348e-06
kinase O 0 8.72829502895911e-07
gene O 0 7.39434042884568e-08
( O 0 7.213152031226855e-08
DMPK O 0 7.441792695317417e-05
) O 0 7.846037419767526e-08
is O 0 4.2983231196558336e-08
responsible O 0 3.830051582554006e-07
for O 0 1.4705865396535955e-06
causing O 1 0.9999997615814209
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999974966049194
DM B-Disease 1 1.0
) O 0 4.045977402711287e-05
. O 0 1.6251278793788515e-05

Major O 0 2.1804264179081656e-05
instability O 0 3.411244324524887e-05
, O 0 4.0394036204816075e-07
with O 0 4.588002866512397e-08
very O 0 5.477062359204865e-08
large O 0 3.2923463066936165e-08
expansions O 0 2.39815250324682e-07
between O 0 4.4621806694067345e-08
generations O 0 4.036022005493578e-08
and O 0 1.1778809039242333e-08
high O 0 8.325978484435836e-08
levels O 0 3.9836788090497066e-08
of O 0 5.286906556989379e-08
somatic O 0 3.685619276438956e-06
mosaicism O 0 1.8975099010276608e-05
, O 0 5.559600779747598e-08
is O 0 3.408382909242391e-08
observed O 0 3.9260982021005475e-07
in O 0 2.6298295097149094e-07
patients O 0 2.1069122340122703e-06
. O 0 1.547053034300916e-05

There O 0 3.0799685646343278e-06
is O 0 2.1714939180128567e-07
a O 0 1.8715877558861393e-07
good O 0 3.0523662530868023e-07
correlation O 0 2.9702607662329683e-07
between O 0 1.2564073870180437e-07
repeat O 0 2.619251802116196e-07
size O 0 7.3668331879162e-08
( O 0 1.8847451599413034e-08
at O 0 5.369139444155735e-08
least O 0 1.1693946255775245e-08
in O 0 1.0628406599266782e-08
leucocytes O 0 1.7117833976953989e-06
) O 0 4.2580456494079044e-08
, O 0 5.9214837477838955e-08
clinical O 0 1.121389232139336e-06
severity O 0 1.935310137923807e-06
and O 0 2.1438734165712958e-07
age O 0 2.101075324389967e-06
of O 0 6.098162884882186e-06
onset O 1 0.9940352439880371
. O 0 4.3796222598757595e-05

The O 0 2.632867472129874e-05
trinucleotide O 0 0.0009187213145196438
repeat O 0 3.309957173769362e-05
instability O 0 1.777011129888706e-05
mechanisms O 0 0.00032681753509677947
involved O 0 2.141014192602597e-06
in O 0 1.1274220241830335e-06
DM B-Disease 1 1.0
and O 0 1.6789494111435488e-05
other O 0 1.7150694020529045e-06
human O 0 0.00013196797226555645
genetic B-Disease 1 0.9999994039535522
diseases I-Disease 1 0.9999969005584717
are O 0 8.540918372546003e-08
unknown O 0 6.683353149128379e-06
. O 0 9.978515663533472e-06

We O 0 5.7490997278364375e-06
studied O 0 1.0809731065819506e-05
somatic O 0 1.7337595636490732e-05
instability O 0 2.6178859116043895e-06
by O 0 2.1504936853489198e-07
measuring O 0 2.3472703105653636e-05
the O 0 9.211709652845457e-07
CTG O 0 0.019702516496181488
repeat O 0 1.3364916640057345e-06
length O 0 1.5863690805417718e-07
at O 0 9.976739079320396e-08
several O 0 1.60069788535111e-08
ages O 0 1.0089048885220109e-07
in O 0 1.2723764264421789e-08
various O 0 2.6551045806399998e-08
tissues O 0 2.614011407331418e-07
of O 0 3.2556195606048277e-07
transgenic O 0 2.817286031131516e-06
mice O 0 3.243449668843823e-07
carrying O 0 2.3611256949607196e-07
a O 0 3.0691649044456426e-07
( O 0 5.392831212702731e-07
CTG O 0 0.001037435489706695
) O 0 4.00281976453698e-07
55expansion O 0 1.0613764970912598e-05
surrounded O 0 1.0780798902487732e-06
by O 0 5.948096415409054e-08
45 O 0 3.191088637777284e-07
kb O 0 8.724869076104369e-06
of O 0 2.1744905609466514e-07
the O 0 4.613741566572571e-07
human O 0 2.4990383735712385e-06
DM B-Disease 1 1.0
region O 0 1.2277714631636627e-06
, O 0 1.1246906694850622e-07
using O 0 1.8538592883032834e-07
small O 0 3.6804763681175245e-07
- O 0 4.200248895358527e-06
pool O 0 5.416074145614402e-06
PCR O 0 3.188521441188641e-05
. O 0 1.001117198029533e-05

These O 0 1.8784037365549011e-06
mice O 0 1.8452566337145981e-06
have O 0 2.613691663100326e-08
been O 0 2.769584916961776e-08
shown O 0 1.4043473051117417e-08
to O 0 1.0117758186822812e-08
reproduce O 0 2.3407368132666306e-07
the O 0 5.5977256607775416e-08
intergenerational O 0 7.02194256518851e-07
and O 0 5.2757453516960595e-08
somatic O 0 1.303044200540171e-06
instability O 0 4.1147708884636813e-07
of O 0 1.7953387043689872e-07
the O 0 1.5082454751791374e-07
55 O 0 1.295494485020754e-06
CTG O 0 8.867174619808793e-05
repeat O 0 9.741053190737148e-07
suggesting O 0 2.063659110262961e-07
that O 0 8.897303338528673e-09
surrounding O 0 1.074268638490139e-07
sequences O 0 1.0635042002604678e-07
and O 0 6.064104240977031e-08
the O 0 7.84117517582672e-08
chromatin O 0 1.4228519376047188e-06
environment O 0 3.393257088646351e-07
are O 0 2.4592685221591637e-08
involved O 0 1.7111780437062407e-07
in O 0 1.701054372915678e-07
instability O 0 3.903553806594573e-05
mechanisms O 0 0.026639051735401154
. O 0 3.8203856092877686e-05

As O 0 1.4005536286276765e-06
observed O 0 6.749465910615982e-07
in O 0 3.1570525749202716e-08
some O 0 1.2698913920416999e-08
of O 0 8.690820862966575e-08
the O 0 1.1451988513044853e-07
tissues O 0 1.4855111203360138e-06
of O 0 4.4700296712107956e-05
DM B-Disease 1 1.0
patients O 0 2.621468411234673e-06
, O 0 5.748501763491731e-08
there O 0 2.3374392199571048e-08
is O 0 7.841530980101652e-09
a O 0 2.1206853162425432e-08
tendency O 0 4.406671649803684e-08
for O 0 2.1892386570243616e-08
repeat O 0 2.554848776981089e-07
length O 0 8.327932476959177e-08
and O 0 4.1029753816701486e-08
somatic O 0 1.1988291817033314e-06
mosaicism O 0 2.206825001849211e-06
to O 0 6.715614730978814e-09
increase O 0 6.604806035426236e-09
with O 0 4.84899143060602e-09
the O 0 2.5022593774792767e-08
age O 0 1.61461045422584e-07
of O 0 2.435151316149131e-07
the O 0 9.199164878737065e-07
mouse O 0 8.753538168093655e-06
. O 0 5.592545221588807e-06

Furthermore O 0 1.3497266081685666e-05
, O 0 4.118523690976872e-07
we O 0 1.1523066234531143e-07
observed O 0 6.569603527850632e-08
no O 0 2.494744144598826e-08
correlation O 0 1.489044194613598e-07
between O 0 1.0628026103631782e-07
the O 0 1.3862297976174887e-07
somatic O 0 4.850714503845666e-06
mutation O 0 6.31563068509422e-07
rate O 0 4.1686539020702185e-07
and O 0 4.276330400898587e-07
tissue O 0 2.8040074539603665e-05
proliferation O 0 9.490186494076625e-05
capacity O 0 0.00017313835269305855
. O 0 2.3324648282141425e-05

The O 0 6.295879757090006e-06
somatic O 0 5.476844307850115e-05
mutation O 0 1.2132973097322974e-06
rates O 0 2.222807182761244e-07
in O 0 1.36102062953114e-08
different O 0 1.0624251700619425e-08
tissues O 0 9.200947914678181e-08
were O 0 2.5176266404969283e-08
also O 0 8.621984015633188e-09
not O 0 4.705427603113321e-09
correlated O 0 1.8871048723667627e-08
to O 0 2.6238549111212706e-09
the O 0 1.694214901704072e-08
relative O 0 1.0455717074364657e-06
inter O 0 0.15708623826503754
- O 0 1.7146522850453039e-06
tissue O 0 9.52797307718356e-08
difference O 0 6.759425019708942e-08
in O 0 5.599334773620512e-09
transcriptional O 0 7.646179511766604e-08
levels O 0 1.797517157342554e-08
of O 0 9.693401636923227e-09
the O 0 1.0386973059439697e-08
three O 0 1.2300300333834002e-08
genes O 0 1.6846607664433577e-08
( O 0 5.5567703327596973e-08
DMAHP O 0 5.2275790949352086e-05
, O 0 2.134120791197347e-07
DMPK O 0 0.00011915712093468755
and O 0 1.8906793286532775e-07
59 O 0 7.864434223847638e-07
) O 0 5.1558238567395165e-08
surrounding O 0 2.0960028734862135e-07
the O 0 3.693426720019488e-07
repeat O 0 6.454838967329124e-06
. O 0 2.0718539417430293e-06
. O 0 1.603683085704688e-05

A O 0 6.28661218797788e-05
novel O 0 1.3906055755796842e-05
missense O 0 8.685704960953444e-05
mutation O 0 3.2809173262648983e-06
in O 0 2.564953263117786e-07
patients O 0 1.86978240890312e-07
from O 0 1.6575405936691823e-07
a O 0 2.1277669475239236e-06
retinoblastoma B-Disease 1 0.7487397789955139
pedigree O 0 9.291405149269849e-06
showing O 0 1.4827794529992389e-06
only O 0 2.0580125692504225e-07
mild O 0 2.1727464627474546e-05
expression O 0 4.868799123869394e-07
of O 0 5.974138730380218e-07
the O 0 1.573293047840707e-06
tumor B-Disease 0 7.993601320777088e-05
phenotype O 0 7.034216105239466e-05
. O 0 2.296724596817512e-05

We O 0 1.284243921872985e-06
have O 0 9.013869117779905e-08
used O 0 1.4174101181652077e-07
single O 0 4.159539912507171e-07
strand O 0 9.899927135847975e-07
conformation O 0 3.319435109006008e-07
polymorphism O 0 1.16664153892998e-07
analysis O 0 2.8450363842580373e-08
to O 0 5.9197304835834075e-09
study O 0 1.698515106340892e-08
the O 0 4.285013588400943e-08
27 O 0 7.132461519177014e-07
exons O 0 7.381586897281522e-07
of O 0 1.0127570249096607e-07
the O 0 1.4332512421333377e-07
RB1 O 0 2.4266753825941123e-05
gene O 0 1.047225808292751e-07
in O 0 1.7801946583517747e-08
individuals O 0 1.1051310089271738e-08
from O 0 2.197337600762239e-08
a O 0 1.1796316812251462e-07
family O 0 5.336590902516036e-08
showing O 0 6.299155188571604e-07
mild O 0 0.00024525393382646143
expression O 0 2.1889122763241176e-06
of O 0 5.149616299604531e-06
the O 0 9.321413017460145e-06
retinoblastoma B-Disease 1 0.9656175971031189
phenotype O 0 0.000929393689148128
. O 0 2.903494350903202e-05

In O 0 1.455670599170844e-06
this O 0 1.6733025631765486e-07
family O 0 6.600110680210491e-08
affected O 0 8.026740516697828e-08
individuals O 0 1.6422804449689465e-08
developed O 0 1.0858268524316372e-06
unilateral B-Disease 0 0.0001288228522753343
tumors I-Disease 1 1.0
and O 0 2.3265342861122917e-06
, O 0 7.354436348805393e-08
as O 0 1.5781131068592913e-08
a O 0 9.966731440158583e-09
result O 0 1.8362944942396098e-08
of O 0 5.178343442935329e-08
linkage O 0 3.363769565112307e-07
analysis O 0 5.1657167432495044e-08
, O 0 2.6670779362802932e-08
unaffected O 0 2.9864105499655125e-07
mutation O 0 7.848657190834274e-08
carriers O 0 7.440560523264139e-08
were O 0 9.126229372213857e-08
also O 0 8.910843263265633e-08
identified O 0 2.680496322682302e-07
within O 0 3.455981527622498e-07
the O 0 9.424647373634798e-07
pedigree O 0 4.373099000076763e-05
. O 0 3.517978257150389e-05

A O 0 8.048560630413704e-06
single O 0 9.421888194083294e-07
band O 0 2.6682564566726796e-06
shift O 0 1.5360769793915097e-06
using O 0 9.087691523745889e-07
SSCP O 0 0.0014908675802871585
was O 0 1.5595303466398036e-06
identified O 0 1.8261675904795993e-07
in O 0 5.732209729103488e-08
exon O 0 4.852676624977903e-07
21 O 0 2.8241569793863164e-07
which O 0 1.7420472175899704e-08
resulted O 0 2.411332218343887e-07
in O 0 3.483744137611211e-08
a O 0 1.8774389332065766e-07
missense O 0 2.511009824957e-06
mutation O 0 5.611680649053596e-07
converting O 0 2.1005582766520092e-06
a O 0 7.057652737785247e-07
cys O 0 0.00022582011297345161
- O 0 1.2055696970492136e-05
- O 0 9.304848390456755e-06
> O 0 1.009450170386117e-05
arg O 0 4.8264064389513806e-06
at O 0 3.6005198467137234e-07
nucleotide O 0 2.1038532338479854e-07
position O 0 5.560024760598026e-07
28 O 0 1.2353281135801808e-06
in O 0 1.9463550415821373e-07
the O 0 1.5631949281669222e-06
exon O 0 3.606958853197284e-05
. O 0 1.7479105736128986e-05

The O 0 7.22697450328269e-06
mutation O 0 6.7654491431312636e-06
destroyed O 0 1.4890505553921685e-05
an O 0 6.425074161597877e-07
NdeI O 0 0.0001478094345657155
restriction O 0 7.3121991590596735e-06
enzyme O 0 8.630831871414557e-06
site O 0 5.6151461649278644e-06
. O 0 2.433400550216902e-05

Analysis O 0 6.377485078701284e-06
of O 0 1.8763037132885074e-06
all O 0 4.334663969984831e-07
family O 0 4.8909885919101725e-08
members O 0 3.40762227324376e-08
demonstrated O 0 2.369272920077492e-07
that O 0 3.604373688403939e-08
the O 0 2.919953203672776e-07
missense O 0 2.1109442968736403e-05
mutation O 0 5.512261850526556e-06
co O 0 8.654873818159103e-05
- O 0 0.0004134449700359255
segregated O 0 2.1337473299354315e-06
with O 0 1.430048115480531e-07
patients O 0 1.1808489261966315e-06
with O 0 1.2887877346656751e-05
tumors B-Disease 1 1.0
or O 0 0.04078040271997452
who O 0 1.241091922565829e-06
, O 0 8.830409115034854e-08
as O 0 1.4104273304837989e-08
a O 0 6.528891205448417e-09
result O 0 1.4211831711463674e-08
of O 0 3.6259077518252525e-08
linkage O 0 2.515090784527274e-07
analysis O 0 5.626874255426628e-08
had O 0 4.006989939853156e-08
been O 0 4.4564735901531094e-08
predicted O 0 2.3058890974425594e-07
to O 0 1.9338026291393362e-08
carry O 0 2.3461699072413467e-07
the O 0 6.820155817877094e-07
predisposing O 0 4.589944001054391e-05
mutation O 0 2.5710472982609645e-05
. O 0 3.401787398615852e-05

These O 0 8.334874905813194e-07
observations O 0 9.072407465282595e-07
point O 0 2.934838789769856e-07
to O 0 3.7509380490519106e-08
another O 0 1.0449890908148518e-07
region O 0 8.501764625634678e-08
of O 0 2.1988662979310902e-07
the O 0 3.2560325280428515e-07
RB1 O 0 6.591101555386558e-05
gene O 0 6.709139199756464e-08
where O 0 3.188532815556755e-08
mutations O 0 3.2887566447925565e-08
only O 0 1.0785098147891858e-08
modify O 0 3.0541826845364994e-08
the O 0 8.12178679865383e-09
function O 0 8.434601461715374e-09
of O 0 1.0244152193195077e-08
the O 0 9.878442064348292e-09
gene O 0 1.4365157063878087e-08
and O 0 1.198940502433743e-08
raise O 0 2.2396463350560225e-08
important O 0 1.6751156906025244e-08
questions O 0 2.403647059168179e-08
for O 0 1.386308756679e-08
genetic O 0 9.879520490585492e-08
counseling O 0 8.017010344474329e-08
in O 0 7.213341479683777e-09
families O 0 3.2034233043987115e-09
with O 0 1.5707676936926873e-08
these O 0 7.852805339325641e-08
distinctive O 0 7.21017886462505e-06
phenotypes O 0 5.0440932682249695e-05
. O 0 2.10692223845399e-06
. O 0 1.104351304093143e-05

Maternal B-Disease 0 0.00029862363589927554
disomy I-Disease 0 0.273600310087204
and O 0 0.09844221919775009
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9999279975891113
with O 0 1.4970082702348009e-05
gamete O 0 0.0004689800553023815
complementation O 0 0.00013899311306886375
in O 0 2.0079392371030735e-08
a O 0 2.4866634973363944e-08
case O 0 4.704281764134066e-08
of O 0 6.273484132179874e-08
familial O 0 1.0012537359216367e-06
translocation O 0 1.0307792308594799e-06
( O 0 8.956286734473906e-08
3 O 0 4.171572811628721e-07
; O 0 3.254064040447702e-08
15 O 0 3.3989962844316324e-07
) O 0 7.706854177058631e-08
( O 0 9.562108971294947e-08
p25 O 0 4.682689905166626e-06
; O 0 8.827697683955193e-08
q11 O 0 3.59753062184609e-06
. O 0 1.64432321980712e-07
2 O 0 3.844817911158316e-06
) O 0 1.1000479389622342e-06
. O 0 1.0960594408970792e-05

Maternal B-Disease 0 0.003781384788453579
uniparental I-Disease 1 0.9998759031295776
disomy I-Disease 1 0.999943733215332
( I-Disease 0 0.0022684193681925535
UPD I-Disease 1 1.0
) I-Disease 0 2.5984968488046434e-06
for I-Disease 0 2.386075266258558e-07
chromosome I-Disease 0 9.103626439355139e-07
15 I-Disease 0 2.8943355800947757e-07
is O 0 2.6997726720878745e-08
responsible O 0 8.925590577746334e-08
for O 0 1.3235569973346628e-08
an O 0 5.74681013887357e-09
estimated O 0 1.122851145396453e-08
30 O 0 2.9898814091211534e-08
% O 0 8.318497890513754e-09
of O 0 4.349405102743731e-08
cases O 0 1.077334275123576e-07
of O 0 0.00010917577310465276
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999997615814209
PWS B-Disease 1 1.0
) O 0 5.4126376198837534e-05
. O 0 2.546994983276818e-05

We O 0 5.7846709751174785e-06
report O 0 4.024898885290895e-07
on O 0 1.5378388695808098e-07
an O 0 3.252878855164454e-08
unusual O 0 1.6667058844177518e-07
case O 0 3.098678007518174e-07
of O 0 4.228077727930213e-07
maternal B-Disease 0 2.3494908418797422e-06
disomy I-Disease 0 0.0003163240908179432
15 I-Disease 0 3.763999984585098e-06
in O 0 4.2655162246774125e-07
PWS B-Disease 1 1.0
that O 0 3.3507888019812526e-08
is O 0 9.028628511487113e-09
most O 0 6.458023005251334e-09
consistent O 0 7.47190540550946e-08
with O 0 1.4326137609543821e-08
adjacent O 0 1.0658883553560372e-07
- O 0 7.363700404994233e-08
1 O 0 1.1248901898852637e-07
segregation O 0 1.4999801578596816e-07
of O 0 2.0027833613767143e-08
a O 0 2.8448139843817444e-08
paternal O 0 9.212818952164525e-08
t O 0 5.533627813747444e-07
( O 0 3.988263230780831e-08
3 O 0 1.838573098211782e-07
; O 0 2.514790331531458e-08
15 O 0 1.731604726273872e-07
) O 0 4.264677855303489e-08
( O 0 5.343720488326653e-08
p25 O 0 1.6306805719068507e-06
; O 0 3.0985063403932145e-08
q11 O 0 4.478662845031067e-07
. O 0 8.246682448032061e-09
2 O 0 8.188895606053848e-08
) O 0 1.0880970791049549e-08
with O 0 2.017344158389278e-08
simultaneous O 0 8.125019803628675e-07
maternal O 0 3.071907485718839e-06
meiotic O 0 0.0001164240384241566
nondisjunction O 0 9.380822302773595e-05
for O 0 1.5724006061645923e-06
chromosome O 0 8.844221156323329e-06
15 O 0 1.1468438970041461e-05
. O 0 2.4006150852073915e-05

The O 0 9.284380212193355e-06
patient O 0 4.269181317795301e-06
( O 0 7.445819960594235e-07
J O 0 2.0609775674529374e-05
. O 0 1.0076644230139209e-07
B O 0 1.435687750017678e-06
. O 0 3.44293411558283e-08
) O 0 1.9254958516512488e-08
, O 0 2.188378545042724e-08
a O 0 5.009267312061638e-08
17 O 0 4.727610303234542e-07
- O 0 3.5506604945112485e-07
year O 0 7.729893525265652e-08
- O 0 5.538643677027721e-07
old O 0 1.411053744959645e-06
white O 0 7.065148110996233e-07
male O 0 1.4311997347249417e-06
with O 0 9.047384992300067e-07
PWS B-Disease 1 1.0
, O 0 2.194629360019462e-06
was O 0 4.776376840709418e-07
found O 0 7.692223746857962e-09
to O 0 4.379495877060435e-09
have O 0 1.676502847658412e-08
47 O 0 2.7598724727795343e-07
chromosomes O 0 8.090157876949888e-08
with O 0 2.649150587785698e-08
a O 0 1.58407885919587e-07
supernumerary O 0 1.3504940397979226e-05
, O 0 1.465768519892663e-07
paternal O 0 6.876643396935833e-07
der O 0 0.001003412064164877
( O 0 2.7545422653929563e-07
15 O 0 5.086822625344212e-07
) O 0 4.5869356313232856e-08
consisting O 0 5.053719576153526e-08
of O 0 9.232062581077116e-08
the O 0 2.1202832556355133e-07
short O 0 1.5334454701587674e-06
arm O 0 4.1643459553597495e-05
and O 0 8.342150863427378e-07
the O 0 2.7444784791441634e-06
proximal O 1 0.8994928002357483
long O 0 7.26776715964661e-06
arm O 0 8.823751704767346e-05
of O 0 1.0445369298395235e-05
chromosome O 0 1.3577579920820426e-05
15 O 0 7.57443785914802e-06
, O 0 9.031178365148662e-07
and O 0 4.803140200237976e-06
distal O 1 0.9986464381217957
chromosome O 1 0.8859680891036987
arm O 1 0.9832186102867126
3p O 1 0.9999864101409912
. O 0 0.00043573477887548506

The O 0 1.664538649492897e-05
t O 0 1.3008876521780621e-05
( O 0 2.5513986656733323e-07
3 O 0 4.5974024942552205e-07
; O 0 2.1742909694921764e-08
15 O 0 1.3604760340513167e-07
) O 0 1.2098105628410849e-08
was O 0 3.3904743901302936e-08
present O 0 9.444468318520194e-09
in O 0 3.924415015177374e-09
the O 0 7.682268154951544e-09
balanced O 0 5.481890497094355e-08
state O 0 4.235791717377424e-09
in O 0 6.315056477745884e-09
the O 0 3.849186924753667e-08
patients O 0 7.155367143241165e-08
father O 0 4.4820941980106e-07
and O 0 6.518230293295346e-07
a O 0 5.5790783335396554e-06
sister O 0 4.665948654292151e-05
. O 0 6.397697143256664e-05

Fluorescent O 0 0.00010384114284534007
in O 0 7.927067713353608e-07
situ O 0 3.924487828044221e-06
hybridization O 0 4.0649939592185547e-07
analysis O 0 1.9465629463866208e-07
demonstrated O 0 5.150339461579279e-07
that O 0 5.334514696642145e-08
the O 0 8.802273896435509e-07
PWS B-Disease 1 1.0
critical O 0 1.6648467862978578e-05
region O 0 6.049122021067888e-07
resided O 0 3.1838780500947905e-07
on O 0 7.261576939754377e-08
the O 0 2.338875226826076e-08
derivative O 0 1.464164540720958e-07
chromosome O 0 5.2933241789787644e-08
3 O 0 3.9920074357269186e-08
and O 0 3.7618410608786235e-09
that O 0 1.6443044703606802e-09
there O 0 7.80466091754306e-09
was O 0 4.2910166087040125e-08
no O 0 1.2873994315043547e-08
deletion O 0 1.1358187634868955e-07
of O 0 1.3394887332651706e-07
the O 0 1.0129673455594457e-06
PWS B-Disease 1 1.0
region O 0 2.644080950631178e-06
on O 0 6.460711574618472e-07
the O 0 1.2899845103220287e-07
normal O 0 3.0255583283178566e-07
pair O 0 4.19335833612422e-07
of O 0 7.159447932281182e-07
15s O 0 0.00012157468154327944
present O 0 5.161403464626346e-07
in O 0 8.334112067132082e-07
J O 0 0.0005843101534992456
. O 0 3.5268629289930686e-05

B O 0 0.004345029592514038
. O 0 0.0003520854515954852

Methylation O 0 3.867943451041356e-05
analysis O 0 3.7296540540410206e-06
at O 0 4.154677299084142e-06
exon O 0 3.4115714697691146e-06
alpha O 0 1.188616579383961e-06
of O 0 1.1366932284317954e-07
the O 0 9.494393538034274e-08
small O 0 8.282911068135945e-08
nuclear O 0 9.635103197069839e-06
ribonucleoprotein O 0 0.00045181874884292483
- O 0 3.97702797272359e-06
associated O 0 4.992332947040268e-07
polypeptide O 0 5.9643293752742466e-06
N O 0 5.794599019282032e-06
( O 0 1.9505172588196729e-07
SNRPN O 0 0.00010210259642917663
) O 0 4.466370029376776e-08
gene O 0 4.0874859053019463e-08
showed O 0 7.710295335527917e-08
a O 0 4.8527692086963725e-08
pattern O 0 4.259329102751508e-07
characteristic O 0 6.968447223698604e-07
of O 0 2.9819281621712435e-07
only O 0 5.367378008713786e-08
the O 0 6.48309139705816e-08
maternal O 0 1.7541347574479005e-07
chromosome O 0 3.686511718115071e-07
15 O 0 5.048979687671817e-07
in O 0 3.735224538559123e-07
J O 0 0.0005214100820012391
. O 0 2.8118425689172e-05

B O 0 0.006746286991983652
. O 0 0.0005296659655869007

Maternal B-Disease 0 0.00024053690140135586
disomy I-Disease 0 0.0009691469022072852
was O 0 7.2458151407772675e-06
confirmed O 0 9.490308343629295e-07
by O 0 2.3052780306898057e-07
polymerase O 0 3.343525577292894e-06
chain O 0 3.350156987380615e-07
reaction O 0 1.567876921626521e-07
analysis O 0 1.884141767050096e-07
of O 0 4.253265046827437e-07
microsatellite O 0 8.040137799980585e-06
repeats O 0 1.7907335632116883e-06
at O 0 5.2605730616051e-07
the O 0 1.8110803523541108e-07
gamma O 0 6.675276836176636e-06
- O 0 1.509503022134595e-06
aminobutyric O 0 8.910058568289969e-06
acid O 0 1.9434055502642877e-06
receptor O 0 3.6394997096067527e-06
beta3 O 0 1.89419042726513e-05
subunit O 0 8.871853424352594e-06
( O 0 9.66554239312245e-07
GABRB3 O 0 0.00023642707674298435
) O 0 3.455115347605897e-06
locus O 0 8.109467307804152e-05
. O 0 3.289525193395093e-05

A O 0 9.21370810829103e-05
niece O 0 5.9561913076322526e-05
( O 0 8.499549153384578e-07
B O 0 3.4722427244560095e-06
. O 0 3.145584059893736e-08
B O 0 3.4578803820295434e-07
. O 0 1.0007896733554844e-08
) O 0 6.4340848204835766e-09
with O 0 5.4128368454087195e-09
45 O 0 4.181066870501127e-08
chromosomes O 0 2.832361012394813e-08
and O 0 5.366965982744887e-09
the O 0 7.0108128191748165e-09
derivative O 0 4.2449983084225096e-08
3 O 0 4.004987630423784e-08
but O 0 4.1322829602563615e-09
without O 0 1.3487481353990916e-08
the O 0 3.338075416081665e-08
der O 0 2.654389936651569e-05
( O 0 5.8230117616631105e-08
15 O 0 2.376568914996824e-07
) O 0 2.2324430304365706e-08
demonstrated O 0 1.461455525486599e-07
a O 0 8.416220964591048e-08
phenotype O 0 8.316692401422188e-07
consistent O 0 1.6991477025385393e-07
with O 0 1.711337205279051e-08
that O 0 1.4890804145295533e-08
reported O 0 9.986163007624782e-08
for O 0 8.33745232853289e-08
haploinsufficiency O 0 9.380017218063585e-06
of O 0 1.356808411401289e-06
distal O 0 6.57435302855447e-05
3 O 0 7.967886631377041e-05
p O 0 0.00016951285942923278
. O 0 2.038922320934944e-05

Uniparental B-Disease 1 0.9999997615814209
disomy I-Disease 1 0.9998527765274048
associated O 0 5.488248461915646e-06
with O 0 7.203746577033598e-07
unbalanced O 0 3.162577559123747e-05
segregation O 0 5.170555141376099e-06
of O 0 4.64484855910996e-07
non O 0 1.812774280551821e-05
- O 0 2.1415313312900253e-05
Robertsonian O 0 0.001174531877040863
translocations O 0 7.444715720339445e-06
has O 0 4.062319547415427e-08
been O 0 4.516682849953213e-08
reported O 0 3.9570522858412005e-08
previously O 0 3.268769432906993e-08
but O 0 8.729275968732964e-09
has O 0 4.542720866140826e-09
not O 0 2.223695894087996e-09
, O 0 3.501903211855506e-09
to O 0 2.439198398818121e-09
our O 0 1.6586247042482682e-08
knowledge O 0 9.661398792104592e-08
, O 0 1.8650197830538673e-08
been O 0 1.8899720899412387e-08
observed O 0 4.0981571913789594e-08
in O 0 2.0684916890445493e-08
a O 0 1.5053871038617217e-07
case O 0 1.9875385532941436e-06
of O 0 3.317114897072315e-05
PWS B-Disease 1 1.0
. O 0 0.0003987635427620262

Furthermore O 0 1.9936736862291582e-05
, O 0 8.946910270424269e-07
our O 0 3.383582054539147e-07
findings O 0 1.8742456120435236e-07
are O 0 9.802839429084997e-09
best O 0 6.020517417937299e-08
interpreted O 0 1.2015368611173471e-07
as O 0 1.0228225022501647e-07
true O 0 1.504569013377477e-06
gamete O 0 2.1215213564573787e-05
complementation O 0 0.00010413673589937389
resulting O 0 4.0818058550939895e-06
in O 0 1.4560204135705135e-06
maternal B-Disease 0 0.00017768904217518866
UPD I-Disease 1 1.0
15 I-Disease 0 0.002847377909347415
and O 0 0.0009500581072643399
PWS B-Disease 1 1.0

Schwartz B-Disease 0 0.4419425129890442
- I-Disease 1 0.9997909665107727
Jampel I-Disease 1 0.9999948740005493
syndrome I-Disease 1 0.9997492432594299
type I-Disease 0 0.0002052877825917676
2 I-Disease 0 0.00018559381715022027
and O 0 4.842957878281595e-06
Stuve B-Disease 1 0.9999910593032837
- I-Disease 1 0.9999645948410034
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999915361404419
: O 0 5.430221676760993e-07
a O 0 1.825194289040155e-07
case O 0 1.3009044153022842e-07
for O 0 5.054895524381209e-08
" O 0 4.650832465813437e-07
lumping O 0 2.784910066111479e-06
" O 0 4.844320756092202e-06
. O 0 1.201761006086599e-05

Recent O 0 3.3033970794349443e-06
studies O 0 1.1467062677184003e-06
demonstrated O 0 1.6399975493186503e-06
the O 0 1.7452941847295733e-07
existence O 0 2.3324162157223327e-07
of O 0 1.8127825285318977e-07
a O 0 1.2001146387774497e-07
genetically O 0 2.7257942747382913e-07
distinct O 0 7.542956836914527e-08
, O 0 3.324534958437653e-08
usually O 0 2.420748579368137e-08
lethal O 0 2.0444990411760955e-07
form O 0 6.81688518966439e-08
of O 0 1.301567067457654e-07
the O 0 3.150190082124027e-07
Schwartz B-Disease 0 8.215895650209859e-05
- I-Disease 0 0.0025973976589739323
Jampel I-Disease 1 0.9999606609344482
syndrome I-Disease 1 0.9999903440475464
( O 0 6.951388968445826e-06
SJS B-Disease 1 0.9998080134391785
) O 0 1.0098730172103387e-06
of O 0 7.518935035477625e-06
myotonia B-Disease 1 0.9999980926513672
and O 0 0.0008735737064853311
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 0.9999998807907104
, O 0 4.0500034970136767e-07
which O 0 5.296171678992323e-08
we O 0 9.181804472291333e-08
called O 0 5.861774070581305e-07
SJS B-Disease 0 0.00023463505203835666
type I-Disease 0 1.0507614206289873e-05
2 I-Disease 0 3.831594221992418e-05
. O 0 1.688372685748618e-05

This O 0 5.510085884452565e-06
disorder O 1 0.7999035716056824
is O 0 1.9967725961578253e-07
reminiscent O 0 8.084455657808576e-06
of O 0 8.979375820672431e-07
another O 0 1.072278450919839e-06
rare O 0 4.95321728521958e-07
condition O 0 1.6328593801517854e-06
, O 0 1.7854766554137314e-07
the O 0 8.904656851882464e-07
Stuve B-Disease 1 0.9999003410339355
- I-Disease 1 0.9999468326568604
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00020577592658810318
SWS B-Disease 1 0.9999748468399048
) O 0 2.6058998514599807e-07
, O 0 9.185026783598005e-08
which O 0 5.901391730844807e-08
comprises O 0 4.6635881290058023e-07
campomelia B-Disease 0 1.1476841791591141e-05
at O 0 6.434996180360031e-07
birth O 0 5.625027483802114e-07
with O 0 1.2870013961219229e-06
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 0.00943703856319189
contractures B-Disease 1 0.9999973773956299
, O 0 1.891528313535673e-06
and O 0 6.247911983336962e-07
early B-Disease 0 9.483454959990922e-06
death I-Disease 0 2.8373595341690816e-05
. O 0 1.5688934581703506e-05

To O 0 1.0352104027333553e-06
test O 0 1.349150466012361e-06
for O 0 5.635713407059484e-08
possible O 0 4.893274763162481e-07
nosologic O 0 1.7097805539378896e-05
identity O 0 1.8954546021632268e-07
between O 0 3.66368141158091e-07
these O 0 1.8640848509221541e-07
disorders O 0 0.00013892687275074422
, O 0 3.24202673596119e-08
we O 0 3.088805300421882e-08
reviewed O 0 5.649176770816666e-08
the O 0 5.923525225881576e-09
literature O 0 2.8512673111436015e-08
and O 0 6.074821534696184e-09
obtained O 0 2.4827629729884393e-08
a O 0 9.424691249648731e-09
follow O 0 1.4696001748859544e-08
- O 0 5.153877324914902e-08
up O 0 1.0376399295353167e-08
of O 0 1.9829039743513022e-08
the O 0 1.4257770963865823e-08
only O 0 1.2308232655300344e-08
two O 0 2.065243265292338e-08
surviving O 0 3.2487776024936466e-07
patients O 0 1.0273895512113995e-08
, O 0 1.0938611794131248e-08
one O 0 2.4575333767984375e-08
with O 0 5.4045969477556355e-08
SJS B-Disease 0 0.00011759938206523657
type I-Disease 0 2.110477907990571e-06
2 I-Disease 0 1.1320549901938648e-06
at O 0 1.1814656630804166e-07
age O 0 1.656854031750754e-08
10 O 0 1.2193781984137786e-08
years O 0 6.680877184805922e-09
and O 0 7.129901558045049e-09
another O 0 4.240587614390279e-08
with O 0 8.551220531671788e-08
SWS B-Disease 0 0.0002598071878310293
at O 0 1.6666485862515401e-06
age O 0 1.1584256753849331e-06
7 O 0 6.129894245532341e-06
years O 0 2.8842719075328205e-06
. O 0 8.076965968939476e-06

Patients O 0 1.7503543858765624e-05
reported O 0 1.1993815860478207e-06
as O 0 2.4951208388301893e-07
having O 0 8.521616905454721e-07
either O 0 9.626791324990336e-06
neonatal O 1 0.9999986886978149
SJS B-Disease 1 0.9999995231628418
or O 0 0.0001306299673160538
SWS B-Disease 1 0.8974596261978149
presented O 0 8.038375085561711e-07
a O 0 4.949000853571306e-08
combination O 0 2.712980631258688e-07
of O 0 2.858788263893075e-07
a O 0 4.96366794777714e-07
severe O 0 0.005160827189683914
, O 0 3.4397751278447686e-06
prenatal O 0 0.0004021477361675352
- O 0 0.01568065769970417
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.7869594693183899
with O 1 0.9995681643486023
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 0 0.22627422213554382
feeding O 0 0.00024771352764219046
difficulties O 0 0.0001996546779992059
, O 0 3.6582869711310195e-07
tendency O 0 2.483805872088851e-07
to O 0 7.971267024231565e-08
hyperthermia B-Disease 0 0.37019506096839905
, O 0 1.3143099408807757e-07
and O 0 4.0900360431805893e-08
frequent O 0 3.482402277654728e-08
death O 0 3.098606953244598e-07
in O 0 4.2659149102064475e-08
infancy O 0 2.1303517314663623e-06
) O 0 3.2898292090521863e-08
with O 0 2.1228462543376736e-08
a O 0 1.385147641030926e-07
distinct O 0 4.062857442477252e-06
campomelic B-Disease 1 0.9718838930130005
- I-Disease 1 0.9989584684371948
metaphyseal I-Disease 1 0.9999526739120483
skeletal I-Disease 1 0.9999997615814209
dysplasia I-Disease 1 1.0
. O 0 0.001241576741449535

The O 0 2.2538861230714247e-06
similarity O 0 1.0772391760838218e-06
of O 0 6.789188091715914e-07
the O 0 4.100378419025219e-07
clinical O 0 8.445907951681875e-06
and O 0 2.676651718047651e-07
radiographic O 0 0.0007401059265248477
findings O 0 1.501783799540135e-06
is O 0 4.342823345382385e-08
so O 0 1.1674780253656536e-08
extensive O 0 6.490811443882194e-08
that O 0 1.0666811434134615e-08
these O 0 1.3692165623524488e-07
disorders O 0 0.02590593881905079
appear O 0 1.0162555241777227e-07
to O 0 2.049151781591263e-08
be O 0 3.711405582862426e-08
a O 0 1.5672222275497916e-07
single O 0 5.274342242955754e-07
entity O 0 8.433722541667521e-06
. O 0 1.9216224245610647e-05

The O 0 2.8908427793794544e-06
follow O 0 1.4015998885952285e-06
- O 0 1.835471834965574e-06
up O 0 1.3974447199416318e-07
observation O 0 4.6180821300367825e-07
of O 0 7.772664645244731e-08
an O 0 1.4940077619485237e-08
identical O 0 1.9510234494646284e-07
and O 0 6.783551498301676e-08
unique O 0 2.502892471056839e-07
pattern O 0 2.617543395899702e-05
of O 0 0.2610905170440674
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 6.798764502491395e-07
the O 0 4.246407456776069e-07
two O 0 8.690654595966407e-08
patients O 0 2.4814326593514124e-08
( O 0 1.624671241984288e-08
one O 0 1.697303986247789e-08
with O 0 2.7408654901250884e-08
SJS B-Disease 0 4.1947605495806783e-05
type I-Disease 0 6.709228159706981e-07
2 I-Disease 0 6.459922587964684e-07
, O 0 1.1931459376057774e-08
one O 0 8.021961761528473e-09
with O 0 3.0280919105507564e-08
SWS B-Disease 0 0.00016001457697711885
) O 0 4.501666595047027e-08
surviving O 0 3.907693439941795e-07
beyond O 0 2.169883401847983e-07
infancy O 0 3.6681493043033697e-07
adds O 0 6.922201833958752e-08
to O 0 7.773787835674284e-09
the O 0 1.1757956386304613e-08
evidence O 0 3.0641196246961044e-08
in O 0 1.1981905245761482e-08
favor O 0 1.404655876058314e-07
of O 0 3.947276354665519e-07
identity O 0 2.296742422913667e-06
. O 0 1.555066046421416e-05

The O 0 6.95191920385696e-06
hypothesis O 0 9.682992640591692e-06
that O 0 6.843839059911261e-07
SWS B-Disease 0 0.000527694181073457
and O 0 2.0484544620558154e-06
SJS B-Disease 0 0.11506595462560654
type I-Disease 0 1.4106222806731239e-05
2 I-Disease 0 4.4364728637447115e-06
are O 0 1.1489351692262062e-08
the O 0 1.9838420683981894e-08
same O 0 9.978641912766761e-08
disorder O 0 2.766048510238761e-06
should O 0 3.422858796398032e-08
be O 0 6.27092404670293e-08
testable O 0 1.3990437537358957e-06
by O 0 3.003060555784032e-08
molecular O 0 6.46021817374276e-07
methods O 0 1.3944455758974073e-06
. O 0 1.1000269068972557e-06
. O 0 9.446700460102875e-06

A O 0 0.0001012137727229856
mouse O 0 1.0288023077009711e-05
model O 0 2.381660806349828e-06
of O 0 3.4683409921854036e-06
severe O 1 0.9999990463256836
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9999886751174927
defects O 1 0.9999964237213135
in O 0 1.4329043551697396e-05
hemostasis O 1 0.9993674159049988
and O 0 0.00040503405034542084
thrombosis B-Disease 1 0.9999963045120239
. O 0 0.0012419037520885468

von B-Disease 0 0.1309283822774887
Willebrand I-Disease 1 0.9984411597251892
factor I-Disease 0 0.0004456325841601938
( I-Disease 0 5.629850784316659e-05
vWf I-Disease 1 0.9968235492706299
) I-Disease 0 0.0014030273305252194
deficiency I-Disease 1 1.0
causes O 1 0.9999643564224243
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.026446443051099777
humans O 0 0.0003392552025616169
. O 0 1.664329283812549e-05

We O 0 5.5142600103863515e-06
generated O 0 1.7755477301761857e-06
a O 0 5.507336027221754e-07
mouse O 0 5.865917955816258e-07
model O 0 2.2770737473365443e-07
for O 0 2.4708535661943642e-08
this O 0 1.8629256359758983e-08
disease O 0 9.200386585916931e-08
by O 0 1.2884507682997537e-08
using O 0 9.103229103857302e-08
gene O 0 5.216360250415164e-07
targeting O 0 4.355176315584686e-06
. O 0 9.806705747905653e-06

vWf B-Disease 0 0.12215180695056915
- I-Disease 1 0.9979598522186279
deficient I-Disease 0 0.2251325398683548
mice O 0 1.0530547115195077e-05
appeared O 0 1.1026022548321635e-06
normal O 0 3.957592866754567e-07
at O 0 2.335175963708025e-07
birth O 0 4.425539401609058e-08
; O 0 1.4524594860176876e-08
they O 0 2.4442620372155943e-08
were O 0 1.983623292289849e-07
viable O 0 5.629886345559498e-06
and O 0 2.346087512705708e-06
fertile O 0 8.536619861843064e-05
. O 0 3.2592892239335924e-05

Neither O 0 0.00021513762476388365
vWf O 0 0.001366835436783731
nor O 0 0.0001682605070527643
vWf O 0 0.0011165044270455837
propolypeptide O 0 0.0011150733334943652
( O 0 1.397484174958663e-05
von B-Disease 0 0.007414244581013918
Willebrand I-Disease 1 0.7234441041946411
antigen O 0 4.694558083429001e-05
II O 1 0.9984763264656067
) O 0 1.3142647503627813e-07
were O 0 8.257971728653501e-08
detectable O 0 6.526509537252423e-07
in O 0 2.2560371348845365e-08
plasma O 0 1.412211531715002e-06
, O 0 5.229280830576499e-08
platelets O 0 2.2279536437963543e-07
, O 0 1.679367400697629e-08
or O 0 1.8162999992910045e-08
endothelial O 0 1.504398312590638e-07
cells O 0 3.009069615700355e-08
of O 0 2.7106134226073664e-08
the O 0 1.0710156317372821e-07
homozygous O 0 2.75463389698416e-06
mutant O 0 2.6498375518713146e-05
mice O 0 3.092278348049149e-05
. O 0 1.5727211575722322e-05

The O 0 5.4048494348535314e-05
mutant O 0 0.004003592766821384
mice O 0 0.0014839653158560395
exhibited O 0 0.00010338210995541885
defects O 0 0.10327093303203583
in O 0 1.2243513083376456e-06
hemostasis O 0 0.1580241471529007
with O 0 5.460268539536628e-07
a O 0 1.356655729978229e-06
highly O 0 0.00029576587257906795
prolonged O 1 0.9972378015518188
bleeding O 1 0.9819064140319824
time O 0 2.7050305106968153e-06
and O 0 6.736116802130709e-07
spontaneous O 0 1.3318486708158161e-05
bleeding O 0 1.0630661563482136e-05
events O 0 1.2843440799770178e-07
in O 0 1.3558800304735996e-08
approximately O 0 3.436268514178664e-08
10 O 0 6.477949199279465e-08
% O 0 6.875070113210313e-08
of O 0 9.88733063422842e-07
neonates O 0 5.272910129860975e-05
. O 0 2.364870124438312e-05

As O 0 2.791616452668677e-06
in O 0 2.6782811346492963e-07
the O 0 4.018397987692879e-07
human O 0 6.172431312734261e-07
disease O 0 7.278770794982847e-07
, O 0 2.015759648088533e-08
the O 0 5.242743128519578e-08
factor O 0 2.0712164428005053e-07
VIII O 0 0.2508954405784607
level O 0 1.8312250631424831e-06
in O 0 9.474671713860516e-09
these O 0 1.3055646341797456e-08
mice O 0 9.986467830458423e-08
was O 0 2.6260492447249817e-08
reduced O 0 3.783913271604433e-08
strongly O 0 1.4310489682145544e-08
as O 0 5.8261306890017295e-09
a O 0 5.872565100872862e-09
result O 0 6.798341001257313e-09
of O 0 1.0866950894694583e-08
the O 0 9.332478789758625e-09
lack O 0 7.728758077973907e-08
of O 0 4.7293912786017245e-08
protection O 0 2.888968992920127e-07
provided O 0 3.4127941717088106e-07
by O 0 4.369019563910115e-07
vWf O 0 5.71148339076899e-05
. O 0 2.208007572335191e-05

Defective O 1 0.9966134428977966
thrombosis B-Disease 1 0.9987640380859375
in O 0 8.29312648420455e-06
mutant O 0 0.000278669991530478
mice O 0 9.898220014292747e-06
was O 0 9.470733175476198e-07
also O 0 4.280144949575515e-08
evident O 0 2.665029228410276e-07
in O 0 3.355220812295556e-08
an O 0 1.942623484296746e-08
in O 0 3.605191878364167e-08
vivo O 0 1.5705363693996333e-06
model O 0 1.9122232970403275e-06
of O 0 6.030720396665856e-05
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 0.018832892179489136

In O 0 1.0181388461205643e-06
this O 0 1.1856419490641201e-07
model O 0 8.636361599201337e-07
, O 0 2.1238430747416714e-07
the O 0 4.577431127472664e-07
exteriorized O 0 8.342464570887387e-05
mesentery O 0 0.00016350756050087512
was O 0 4.4495700421975926e-06
superfused O 0 2.526822754589375e-05
with O 0 3.886331114699715e-07
ferric O 0 0.2190801203250885
chloride O 0 2.1273299353197217e-05
and O 0 5.148272066435311e-07
the O 0 1.7958660691874684e-07
accumulation O 0 6.62145112073631e-07
of O 0 4.693558253165975e-07
fluorescently O 0 7.558830020570895e-06
labeled O 0 5.276193633108051e-07
platelets O 0 8.441338650300168e-07
was O 0 3.3077111538659665e-07
observed O 0 2.8458836709432944e-07
by O 0 3.5769730288848223e-07
intravital O 0 0.00010728221968747675
microscopy O 0 0.0004323152534198016
. O 0 3.139005639241077e-05

We O 0 5.180416337680072e-06
conclude O 0 6.792220574425301e-06
that O 0 7.141827751411256e-08
these O 0 1.5880054604622273e-07
mice O 0 1.946289785337285e-06
very O 0 3.71738167359581e-07
closely O 0 2.6513703232922126e-06
mimic O 0 0.25392138957977295
severe O 1 0.9999959468841553
human O 1 0.9982994198799133
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 2.8542410746013047e-06
will O 0 8.955756669593029e-08
be O 0 1.2674159499681537e-08
very O 0 8.906386739226946e-09
useful O 0 1.6055901497225022e-08
for O 0 6.669240271151011e-09
investigating O 0 5.381791368108679e-08
the O 0 7.313140315545752e-09
role O 0 5.6746305432398e-08
of O 0 1.2731270260246674e-07
vWf O 0 6.5471836023789365e-06
in O 0 1.6522488976988825e-07
normal O 0 4.779918072017608e-06
physiology O 0 4.6742505219299346e-05
and O 0 4.175775529802195e-07
in O 0 4.450663482202799e-07
disease O 0 6.581394700333476e-06
models O 0 4.490699211601168e-06
. O 0 1.307542902395653e-06
. O 0 7.485215519409394e-06

Oral O 0 0.002211971441283822
contraceptives O 0 0.000488072051666677
and O 0 1.204480099659122e-06
the O 0 8.807211315797758e-07
risk O 0 3.385834861546755e-05
of O 1 0.9981541037559509
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9998329877853394

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999988079071045
Clinical O 1 0.9649298787117004
Study O 0 1.3259178558655549e-05
Group O 0 2.0160567146376707e-05
. O 0 3.0190636607585475e-05

BACKGROUND O 0 0.0002606599300634116
Women O 0 5.610205334960483e-06
with O 0 1.2108682767575374e-07
mutations O 0 2.7837154448207e-07
in O 0 3.791534908259564e-08
either O 0 1.1086381590530436e-07
the O 0 2.308311763954407e-07
BRCA1 O 0 3.0755659281567205e-06
or O 0 1.217229339545156e-07
the O 0 9.865566852340635e-08
BRCA2 O 0 1.71314854924276e-06
gene O 0 6.683530529016934e-08
have O 0 1.5920594620411066e-08
a O 0 1.0121294735654374e-07
high O 0 4.177857135800878e-06
lifetime O 0 5.297316420183051e-06
risk O 0 0.00017890389426611364
of O 1 0.9998602867126465
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.12158641964197159

Oral O 0 0.007740473840385675
contraceptives O 0 0.140459343791008
protect O 0 4.429808905115351e-05
against O 1 0.9999822378158569
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.9499877857451793e-07
general O 0 1.3181149824958993e-06
, O 0 3.266052317485446e-08
but O 0 9.084458518771044e-09
it O 0 2.897647677357895e-09
is O 0 1.747544220442876e-09
not O 0 1.6898219490357747e-09
known O 0 7.495897236253768e-09
whether O 0 1.703924112916866e-08
they O 0 1.706835384140959e-08
also O 0 6.289022991268212e-08
protect O 0 2.6379905193607556e-07
against O 0 1.1859832738991827e-05
hereditary B-Disease 1 0.9998233914375305
forms I-Disease 0 0.32103127241134644
of I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.05812812224030495

METHODS O 0 4.909246854367666e-05
We O 0 1.0013024621002842e-05
enrolled O 0 8.4037528722547e-06
207 O 0 5.897407845623093e-06
women O 0 1.252135007234756e-06
with O 0 6.699920049868524e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.978475084906677e-06
161 O 0 7.081412150000688e-07
of O 0 1.324399647728569e-07
their O 0 2.9109326504794808e-08
sisters O 0 5.733226089432719e-07
as O 0 8.30128925599638e-08
controls O 0 5.04106026255613e-07
in O 0 3.345858701209181e-08
a O 0 1.1422865497934254e-07
case O 0 8.908903055271367e-07
- O 0 1.74971830801951e-06
control O 0 2.111971753038233e-06
study O 0 1.810175490390975e-06
. O 0 7.504629138566088e-06

All O 0 3.4961567507707514e-06
the O 0 8.726813121029409e-07
patients O 0 3.0714221566086053e-07
carried O 0 1.4411595827823476e-07
a O 0 1.1353617423992546e-07
pathogenic O 0 2.1152816316316603e-06
mutation O 0 1.6064853980424232e-07
in O 0 3.686437111127816e-08
either O 0 3.4064990472870704e-07
BRCA1 O 0 1.9935558157158084e-05
( O 0 3.701586308579863e-07
179 O 0 1.1990476878054324e-06
women O 0 3.085885111886455e-07
) O 0 1.0183588727841197e-07
or O 0 3.83011723670279e-07
BRCA2 O 0 3.634225140558556e-05
( O 0 9.915783039105008e-07
28 O 0 2.8690172257483937e-05
women O 0 4.364598225947702e-06
) O 0 2.209387957918807e-06
. O 0 1.5753781553939916e-05

The O 0 5.125749794387957e-06
control O 0 4.835472736886004e-06
women O 0 3.5934257880398945e-07
were O 0 1.0170389685981718e-07
enrolled O 0 6.578079592145514e-08
regardless O 0 2.747581007156441e-08
of O 0 2.9634353637675304e-08
whether O 0 1.5435714928457855e-08
or O 0 1.3304489954180099e-08
not O 0 9.887114238438244e-09
they O 0 1.9011004326330294e-08
had O 0 1.2154730200109043e-07
either O 0 1.1883910246979212e-06
mutation O 0 1.065366086550057e-05
. O 0 1.9823874026769772e-05

Lifetime O 0 2.5833458494162187e-05
histories O 0 3.0622347821918083e-06
of O 0 1.4387745750354952e-06
oral O 0 2.221154500148259e-05
- O 0 2.974628159790882e-06
contraceptive O 0 9.14082534109184e-07
use O 0 2.846458535543661e-08
were O 0 5.0761030934154405e-08
obtained O 0 9.879690310299338e-08
by O 0 2.509725405275276e-08
interview O 0 1.0820667029065589e-07
or O 0 1.9065002021534383e-08
by O 0 1.1955265222240996e-08
written O 0 2.1009535444704852e-08
questionnaire O 0 3.142088544905164e-08
and O 0 1.5158310162632915e-08
were O 0 5.166445760096394e-08
compared O 0 1.3741508553266613e-07
between O 0 1.103778970446001e-07
patients O 0 3.0063159073279166e-08
and O 0 4.789869834098681e-08
control O 0 5.036868969909847e-06
women O 0 2.6029044875031104e-07
, O 0 2.972668688983049e-08
after O 0 8.218155045369713e-08
adjustment O 0 1.0216623280712156e-07
for O 0 1.02975743487832e-08
year O 0 9.850332993721622e-09
of O 0 4.7575376527220214e-08
birth O 0 1.8206030460987677e-07
and O 0 6.619500254601007e-07
parity O 0 4.269369310350157e-05
. O 0 1.5437957699759863e-05

RESULTS O 0 0.00011236334103159606
The O 0 4.039583473058883e-06
adjusted O 0 6.700814992655069e-06
odds O 0 7.387541700154543e-06
ratio O 0 1.6359535948140547e-05
for O 0 0.000508974539116025
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.7652372719112464e-07
with O 0 1.2922459546871323e-08
any O 0 1.6268295155441592e-08
past O 0 2.1414802375829822e-08
use O 0 1.5744900494496505e-08
of O 0 1.7727244028264977e-07
oral O 0 5.002897523809224e-06
contraceptives O 0 7.5779921644425485e-06
was O 0 3.0861785944580333e-06
0 O 0 8.831805644149426e-06
. O 0 8.331026037922129e-06

5 O 0 1.4745659427717328e-05
( O 0 1.0602843758533709e-06
95 O 0 1.855813366091752e-06
percent O 0 2.1044833431460575e-07
confidence O 0 1.128349254031491e-06
interval O 0 7.616702077939408e-07
, O 0 1.876151323187969e-08
0 O 0 6.009103259430049e-08
. O 0 4.129951047815439e-09
3 O 0 1.3185376346314115e-08
to O 0 2.9827369463220066e-09
0 O 0 6.420210496571599e-08
. O 0 2.1689558593607217e-08
8 O 0 8.124453643176821e-07
) O 0 4.4305059532234736e-07
. O 0 4.727109626401216e-06

The O 0 3.5566049518820364e-06
risk O 0 1.574186171637848e-06
decreased O 0 5.386884254221513e-07
with O 0 2.005669408333688e-08
increasing O 0 2.871942328397381e-08
duration O 0 1.5297354138965602e-07
of O 0 1.5194377311900098e-08
use O 0 1.527993731542665e-08
( O 0 2.8118208206251438e-08
P O 0 1.058391035257955e-06
for O 0 8.702692788631339e-09
trend O 0 5.3928477683484743e-08
, O 0 8.224612990659352e-09
< O 0 1.0365939573375726e-07
0 O 0 5.429342309071217e-08
. O 0 8.447916144405099e-09
001 O 0 7.630079039699922e-07
) O 0 9.704390180331757e-09
; O 0 3.2650850911863927e-09
use O 0 7.009341995711793e-09
for O 0 1.4056309893817343e-08
six O 0 3.962430028536801e-08
or O 0 5.242080103329272e-09
more O 0 2.745960792083224e-09
years O 0 7.54650830714354e-09
was O 0 3.3196688065117996e-08
associated O 0 7.366366183703121e-09
with O 0 3.956771355007049e-09
a O 0 2.590598136009703e-08
60 O 0 7.702578130874826e-08
percent O 0 1.0338591494019056e-07
reduction O 0 6.331533768388908e-07
in O 0 3.322884367662482e-07
risk O 0 9.721428796183318e-06
. O 0 1.6890362530830316e-05

Oral O 0 0.0008209933876059949
- O 0 9.63545753620565e-05
contraceptive O 0 1.5283430911949836e-05
use O 0 7.216467565740459e-07
protected O 0 5.2546285587595776e-05
against O 1 0.9999926090240479
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 5.734899559683981e-07
for O 0 1.595550003230528e-07
carriers O 0 6.328346557893383e-08
of O 0 1.9727305300420994e-07
the O 0 2.4255419361907116e-07
BRCA1 O 0 1.8284712268723524e-06
mutation O 0 1.5160630084665172e-07
( O 0 3.4258569314715714e-08
odds O 0 4.3163402096979553e-07
ratio O 0 1.1966893964654446e-07
, O 0 1.3942958787538373e-08
0 O 0 4.224877159231255e-08
. O 0 4.658224916909148e-09
5 O 0 1.9903344750105134e-08
; O 0 4.272663112203645e-09
95 O 0 4.648340024004938e-08
percent O 0 1.708082564277902e-08
confidence O 0 2.2447362368893664e-07
interval O 0 2.3907719537419325e-07
, O 0 1.3373666618576863e-08
0 O 0 3.022229577709368e-08
. O 0 1.6038753658520477e-09
3 O 0 6.970505506131985e-09
to O 0 1.572886487721803e-09
0 O 0 3.143245308478981e-08
. O 0 3.5291534139503256e-09
9 O 0 1.1237386132734173e-07
) O 0 9.573784431893273e-09
and O 0 6.882191261325943e-09
for O 0 7.650100108946845e-09
carriers O 0 1.7874315361154913e-08
of O 0 3.447192042926872e-08
the O 0 1.4062186437513446e-07
BRCA2 O 0 4.414454906509491e-06
mutation O 0 3.572711761989922e-07
( O 0 6.156053444783538e-08
odds O 0 5.509174343387713e-07
ratio O 0 1.7145495689874224e-07
, O 0 2.292653178415094e-08
0 O 0 6.558585852189935e-08
. O 0 4.350091398208633e-09
4 O 0 3.715137708582006e-08
; O 0 5.473362651997604e-09
95 O 0 7.06379452708461e-08
percent O 0 2.3466862231202867e-08
confidence O 0 1.6637741850900056e-07
interval O 0 2.918522170602955e-07
, O 0 7.218433850653128e-09
0 O 0 2.736728532681809e-08
. O 0 3.3525580089843743e-09
2 O 0 1.739563693092805e-08
to O 0 3.1944724643295785e-09
1 O 0 7.537175861216383e-08
. O 0 4.353903904075196e-08
1 O 0 8.223422014452808e-07
) O 0 5.9975667454637e-07
. O 0 6.047222541383235e-06

CONCLUSIONS O 0 0.00022986630210652947
Oral O 0 0.0016914254520088434
- O 0 6.787748861825094e-05
contraceptive O 0 4.699529199569952e-06
use O 0 7.499289012002919e-08
may O 0 7.369938970214207e-08
reduce O 0 9.703505554625735e-08
the O 0 7.322551454080894e-08
risk O 0 1.4588893009204185e-06
of O 0 0.19972024857997894
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.042820016067708e-07
women O 0 1.6590367124535987e-07
with O 0 2.961457745698226e-08
pathogenic O 0 4.36894197264337e-06
mutations O 0 1.728481464624565e-07
in O 0 4.67199257059292e-08
the O 0 5.96483118897595e-07
BRCA1 O 0 5.24846363987308e-05
or O 0 1.6627684090053663e-05
BRCA2 O 0 0.0012499842559918761
gene O 0 0.0002675555006135255

A O 0 4.6263387048384175e-05
Japanese O 0 2.8521530111902393e-05
family O 0 1.0821156593010528e-06
with O 0 1.803646341613785e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.0834415888894e-06
a O 0 1.1046599865949247e-06
codon O 0 4.848360731557477e-06
291 O 0 1.8855021153285634e-06
deletion O 0 1.3625267456518486e-06
: O 0 1.025359850359564e-07
a O 0 7.467687623829988e-08
clinical O 0 1.354752612314769e-06
, O 0 1.687388504478804e-07
biochemical O 0 4.429665204952471e-05
, O 0 1.1020104011549847e-06
pathological O 0 0.00014091776392888278
, O 0 5.252712753645028e-07
and O 0 9.969812708732206e-07
genetic O 0 1.0070310054288711e-05
report O 0 2.749647137534339e-06
. O 0 1.9484219592413865e-05

We O 0 6.880008641019231e-06
report O 0 6.703868393742596e-07
a O 0 3.2822333650983637e-07
Japanese O 0 1.9291646822239272e-06
family O 0 5.760667818321963e-07
with O 0 1.4816549082752317e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9999817609786987
ALD B-Disease 1 1.0
) O 0 7.403004360639898e-07
with O 0 4.8144258357751823e-08
a O 0 1.0709196374136809e-07
three O 0 7.278021740830809e-08
base O 0 2.8660332418439793e-07
pair O 0 1.0172711881750729e-06
deletion O 0 2.9292345971043687e-06
( O 0 3.806861741395551e-07
delGAG O 0 8.828968020679895e-06
291 O 0 6.484717687271768e-07
) O 0 4.526497576762267e-08
in O 0 1.0581705112144846e-07
the O 0 4.204637662041932e-06
ALD B-Disease 1 1.0
gene O 0 0.00011023010301869363
. O 0 6.16387915215455e-05

A O 0 1.2939426596858539e-05
variety O 0 1.2934167443745537e-06
of O 0 4.925369125885481e-07
phenotypes O 0 5.13686791236978e-06
were O 0 1.9553225172330713e-07
observed O 0 1.913940508302403e-07
within O 0 1.5895660965270508e-07
this O 0 1.022730771182978e-07
family O 0 6.89737817083369e-07
. O 0 1.1151493708894122e-05

While O 0 9.069138286577072e-06
the O 0 2.7454757400846574e-06
proband O 0 0.00042955923709087074
( O 0 3.2422872209281195e-07
patient O 0 1.1894597662376327e-07
1 O 0 1.3428542615656625e-06
) O 0 1.0626769864074959e-07
was O 0 2.618877203985903e-07
classified O 0 8.905524850888469e-08
as O 0 4.281173460185528e-08
having O 0 1.3043940327861492e-07
a O 0 1.2745800859192968e-07
rare O 0 1.832582796623683e-07
intermediate O 0 1.0766203558887355e-05
type O 0 1.9971887468273053e-06
of O 0 8.958334092312725e-07
adult O 0 4.309185442252783e-06
cerebral O 0 0.0005726074450649321
and O 0 1.2656532817345578e-06
cerebello O 1 0.8777860403060913
- O 0 0.00035665699397213757
brain O 0 4.894375706498977e-06
stem O 0 2.388597977187601e-07
forms O 0 1.3203954551954666e-07
, O 0 5.4158345363930493e-08
his O 0 9.028184422277263e-08
younger O 0 8.280293513962533e-06
brother O 0 1.8994633137481287e-05
( O 0 1.9511460891408205e-07
patient O 0 8.53285797575154e-08
2 O 0 1.6604501524852822e-06
) O 0 7.082722675022524e-08
and O 0 1.592731422306315e-07
nephew O 0 9.235680772690102e-05
( O 0 2.663408054104366e-07
patient O 0 2.13452381103707e-07
3 O 0 2.0330735424067825e-06
) O 0 1.3555688838096103e-07
had O 0 4.742209114283469e-07
a O 0 3.100613412243547e-06
childhood O 0 0.002495063468813896
ALD B-Disease 1 1.0
type O 1 0.999790608882904
. O 0 0.000745920930057764

Another O 0 8.189261279767379e-05
nephew O 0 0.004095152486115694
( O 0 2.7487506031320663e-06
patient O 0 1.1023436172763468e-06
4 O 0 3.932719209842617e-06
) O 0 1.0010343487465434e-07
of O 0 1.5007270803835127e-07
patient O 0 1.638142208548743e-07
1 O 0 1.5577554677292937e-06
was O 0 5.513321070793609e-07
classified O 0 1.0782881076920603e-07
as O 0 6.06014936010979e-08
having O 0 3.127374270661676e-07
an O 0 2.221332238150353e-07
adolescent O 0 1.026025438477518e-05
form O 0 2.1526824639295228e-05
. O 0 7.912008004495874e-05

The O 0 9.82126766757574e-06
tau O 0 3.566492523532361e-05
level O 0 3.8638286241621245e-06
in O 0 1.2084456102456897e-07
the O 0 2.1701669083995512e-07
cerebrospinal O 0 2.004075940931216e-05
fluid O 0 8.801415242487565e-05
( O 0 5.444904672913253e-06
CSF O 1 0.9997283816337585
) O 0 1.5197312563941523e-07
in O 0 2.8106466487543003e-08
patient O 0 4.638403083845333e-08
1 O 0 2.761725852451491e-07
was O 0 1.6703083360880555e-07
as O 0 1.2438363228284288e-08
high O 0 5.4878537270042216e-08
as O 0 6.695087151342705e-09
that O 0 3.872189235920587e-09
of O 0 5.710461081775975e-08
patients O 0 2.410904471616959e-07
with O 0 4.719042863143841e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9997960925102234
( O 0 3.362715460752952e-06
AD B-Disease 0 0.0004320052976254374
) O 0 1.7909555936057586e-06
. O 0 7.610089596710168e-06

His O 0 5.603530371445231e-05
brain O 0 0.00014505299623124301
magnetic O 0 0.00011613387323450297
resonance O 0 0.0005567696061916649
image O 0 0.0001715829857857898
( O 0 1.06863026303472e-05
MRI O 1 0.9939579963684082
) O 0 8.05197032605065e-07
showed O 0 4.322430413594702e-06
abnormalities B-Disease 0 0.020294934511184692
in I-Disease 0 1.7961640708108462e-07
the I-Disease 0 9.632159390093875e-07
bilateral I-Disease 0 0.026668790727853775
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9999412298202515
and O 0 3.314354034955613e-05
brain O 0 0.026416517794132233
stem O 0 1.0948693898171769e-06
, O 0 2.0312787896159534e-08
but O 0 9.643813747572949e-09
not O 0 6.6778702567660275e-09
in O 0 1.8472830376481397e-08
the O 0 2.2039175462396088e-07
cerebral O 0 0.2825436592102051
white O 0 7.50712445096724e-07
matter O 0 5.401834073381906e-07
, O 0 3.2507887937072155e-08
where O 0 1.5389240104468627e-08
marked O 0 9.366614506234328e-08
reductions O 0 3.190419306520198e-07
of O 0 2.1452642329222726e-07
the O 0 4.346436810465093e-07
cerebral O 0 3.269135413574986e-05
blood O 0 1.4172370299547765e-07
flow O 0 1.3045730895555607e-07
and O 0 2.0824782609452086e-07
oxygen O 0 1.4274063460106845e-06
metabolism O 0 2.515607093300787e-06
were O 0 7.23431554661147e-08
clearly O 0 1.783403860144972e-07
demonstrated O 0 3.5379750329411763e-07
by O 0 8.664967054983208e-08
positron O 0 1.912130301207071e-06
emission O 0 1.7930301510205027e-06
tomography O 0 6.141924586700043e-06
( O 0 6.598015147574188e-07
PET O 0 3.5161187952326145e-06
) O 0 1.1942818218813045e-06
. O 0 8.831410013954155e-06

In O 0 1.4457617680818657e-06
patients O 0 2.1565440988524642e-07
2 O 0 8.426065392086457e-07
and O 0 6.705825228436879e-08
3 O 0 5.03823400777037e-07
, O 0 2.3514175495620293e-08
the O 0 2.3863067966090057e-08
autopsy O 0 1.9597040079588623e-07
findings O 0 1.2845129049310344e-07
showed O 0 5.313220867719792e-07
massive O 0 0.00024906007456593215
demyelination B-Disease 1 1.0
of I-Disease 1 0.5666897296905518
the I-Disease 0 0.13091644644737244
cerebral I-Disease 1 0.9999963045120239
white I-Disease 0 4.097304554306902e-06
matter I-Disease 0 4.5306521201382566e-07
with O 0 2.9372348109291124e-08
sparing O 0 2.432020380638278e-07
of O 0 1.5126893515571282e-07
the O 0 4.881626978203712e-07
U O 1 0.5598987340927124
- O 0 0.00010588073200779036
fibers O 0 1.272221993531275e-06
, O 0 2.675933963303123e-08
compatible O 0 2.8352511094453803e-07
with O 0 8.95693297309208e-09
the O 0 3.1427298097241874e-08
findings O 0 2.496096556114935e-07
of O 0 1.0594989134915522e-06
childhood O 0 0.0005405087722465396
ALD B-Disease 1 1.0
. O 0 0.0007052230648696423

Oleic O 0 0.00841866061091423
and O 0 5.2365707233548164e-05
erucic O 1 0.9740195274353027
acids O 0 1.6483063518535346e-05
( O 0 2.567939418440801e-06
Lorenzos O 0 0.00014191505033522844
Oil O 0 2.4370897335757036e-06
) O 0 4.697790245700162e-08
were O 0 3.5627756744816e-08
administered O 0 1.6722106366273692e-08
to O 0 3.880255228239093e-09
patients O 0 4.0989682759118296e-09
1 O 0 5.269992442435978e-08
and O 0 1.3649722241382278e-08
4 O 0 1.0102373693143818e-07
, O 0 6.480912695394636e-09
but O 0 5.285855753101032e-09
sufficient O 0 6.475232083857918e-08
effectiveness O 0 4.014923717932106e-07
was O 0 3.98641930132726e-07
not O 0 1.012589052606927e-07
obtained O 0 2.285080199726508e-06
. O 0 6.1658574850298464e-06

The O 0 3.339972181493067e-06
findings O 0 1.2173051118224976e-06
in O 0 5.00714705253813e-08
this O 0 1.9309316812154975e-08
family O 0 1.2649310043855166e-08
suggest O 0 3.012825189330215e-08
that O 0 2.0447128434852857e-08
delGAG291 O 0 2.0622339889087016e-06
is O 0 1.938847660198917e-08
part O 0 2.545516331053932e-08
of O 0 4.272934006621654e-08
the O 0 6.871713509326582e-08
cause O 0 4.973120439899503e-07
of O 0 4.122018708585529e-06
Japanese O 0 0.08916857093572617
ALD B-Disease 1 1.0
with O 0 7.4834665610978846e-06
phenotypic O 0 0.000780660193413496
variations O 0 6.41454680589959e-05
. O 0 3.600470881792717e-05

Moreover O 0 8.841700037010014e-06
, O 0 1.7491366577360168e-07
although O 0 6.58646612805569e-08
the O 0 2.7569305061092564e-08
scale O 0 2.108239840481474e-07
of O 0 3.6696217620146854e-08
the O 0 1.7541104568863375e-08
study O 0 1.3176502555722891e-08
is O 0 2.8820816844188357e-09
limited O 0 2.2479275330056225e-08
, O 0 1.254137149686585e-08
there O 0 1.0573893760579267e-08
is O 0 7.31113214413881e-09
a O 0 2.5882963328172082e-08
possibility O 0 3.21185638085808e-07
that O 0 2.86138970295724e-08
PET O 0 2.579505178346153e-07
can O 0 7.489197884069654e-08
detect O 0 2.851808631021413e-06
an O 0 3.1861017646406253e-07
insidious B-Disease 0 0.0013776773121207952
lesion I-Disease 0 0.00021431049390230328
which O 0 2.6739550662568945e-07
is O 0 9.150963364845666e-08
undetectable O 0 2.081764705508249e-06
by O 0 8.763161218894311e-08
computed O 0 1.1785526794483303e-06
tomogram O 0 3.684722105390392e-05
( O 0 5.725358391828195e-07
CT O 1 0.5909530520439148
) O 0 1.026359655043052e-07
or O 0 5.0745249779993173e-08
MRI O 0 2.5696592729218537e-06
analysis O 0 5.685920001496925e-08
, O 0 2.3465563714353266e-08
and O 0 1.0187392263105721e-08
that O 0 2.1169821451394455e-09
the O 0 6.012620179518535e-09
higher O 0 4.3206643596249705e-08
level O 0 1.2985468345050322e-07
of O 0 4.420814647687621e-08
tau O 0 1.7304756738667493e-07
reflects O 0 1.0568590447235238e-08
the O 0 8.272314389046187e-09
process O 0 1.1678537958914603e-07
of O 0 4.3725080445256026e-07
neuronal B-Disease 0 0.0004308378556743264
degeneration I-Disease 1 0.9999908208847046
in O 0 1.9045673980144784e-05
ALD B-Disease 1 1.0
. O 0 0.00045665379730053246

Lorenzos O 0 0.0006213350570760667
Oil O 0 7.700205060245935e-06
should O 0 8.942511442455725e-08
be O 0 2.564258139159392e-08
given O 0 2.0087091101572696e-08
in O 0 8.439332788157117e-09
the O 0 3.9632539028389147e-08
early O 0 5.020712592340715e-07
stage O 0 4.1644675548013765e-06
. O 0 1.1697492254825193e-06
. O 0 8.148592314682901e-06

Nonsense O 0 0.00010899353219429031
mutation O 0 3.801604634645628e-06
in O 0 2.4419421151833376e-07
exon O 0 2.033666760326014e-06
4 O 0 8.955446446634596e-07
of O 0 1.9917249005629856e-07
human O 0 1.4032393380603025e-07
complement O 0 5.997463858875562e-07
C9 O 1 0.9161857962608337
gene O 0 1.0433679165089416e-07
is O 0 9.490769059539161e-09
the O 0 2.642338081670914e-08
major O 0 1.627441577056743e-07
cause O 0 9.201287980431516e-07
of O 0 3.029507297469536e-06
Japanese O 0 0.0010090266587212682
complement B-Disease 1 0.9973852038383484
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999988079071045
. O 0 0.00013301985745783895

Deficiency B-Disease 1 0.998237133026123
of I-Disease 0 2.2448813979281113e-05
the I-Disease 0 8.467990483040921e-06
ninth I-Disease 0 3.766247391467914e-05
component I-Disease 0 1.3525088888854953e-06
of I-Disease 0 4.055101499034208e-07
human I-Disease 0 2.3998225628929504e-07
complement I-Disease 0 1.8600410385261057e-06
( O 0 1.5699522464274196e-06
C9 O 1 0.9999978542327881
) O 0 1.7329280410649517e-07
is O 0 3.213313704009124e-08
the O 0 4.9186141382051574e-08
most O 0 9.057661287670271e-08
common O 0 1.817167503759265e-05
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.0808908257331495e-07
Japan O 0 1.6729133278658992e-07
but O 0 2.1857255561030797e-08
is O 0 8.009394925068136e-09
rare O 0 3.0930561223385666e-08
in O 0 1.2601364396402914e-08
other O 0 3.984666463452413e-08
countries O 0 2.037798765286425e-07
. O 0 5.518831130757462e-06

We O 0 5.040636551711941e-06
studied O 0 2.373416691625607e-06
the O 0 2.048925864528428e-07
molecular O 0 1.2925869441460236e-06
basis O 0 9.539926395518705e-07
of O 0 1.4782704056415241e-05
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9998908042907715
in O 0 5.580076845035364e-07
four O 0 2.4147664134943625e-06
Japanese O 0 6.523717456730083e-05
C9 B-Disease 1 1.0
- I-Disease 0 0.436857670545578
deficient I-Disease 0 6.389363261405379e-05
patients O 0 1.6219195231315098e-07
who O 0 1.4089033584241406e-07
had O 0 8.929913747124374e-06
suffered O 1 0.9999978542327881
from O 1 0.9983900785446167
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.10510094463825226

Direct O 0 1.0161940735997632e-05
sequencing O 0 1.4554383596987464e-05
of O 0 3.986992851423565e-06
amplified O 0 5.048173989052884e-05
C9 O 0 0.0035406809765845537
cDNA O 0 6.414545623556478e-06
and O 0 3.485087347598892e-07
DNA O 0 1.3418940625342657e-06
revealed O 0 7.9771507444093e-07
a O 0 2.7518117917679774e-07
nonsense O 0 7.130568974389462e-06
substitution O 0 8.318536856677383e-06
( O 0 1.8821946241587284e-06
CGA O 0 9.094338020076975e-05
- O 0 2.147296618204564e-05
- O 0 1.4860742339806166e-05
> O 0 1.7798163753468543e-05
TGA O 0 2.7179989046999253e-05
) O 0 1.372278148892292e-07
at O 0 5.214301381784026e-07
codon O 0 8.240725151154038e-07
95 O 0 4.6118984187160095e-07
in O 0 5.4284306827412365e-08
exon O 0 5.368380584513943e-07
4 O 0 4.6915846496631275e-07
in O 0 4.7028823502159867e-08
the O 0 2.3451744368685468e-07
four O 0 3.4248193969688145e-06
C9 B-Disease 1 0.999982476234436
- I-Disease 0 0.000978871830739081
deficient I-Disease 0 4.864271977567114e-05
individuals O 0 1.983421952900244e-06
. O 0 1.7198395653394982e-05

An O 0 1.3483037037076429e-05
allele O 0 5.524251901078969e-05
- O 0 8.014890227059368e-06
specific O 0 3.683384193209349e-07
polymerase O 0 5.264585524855647e-06
chain O 0 1.9961518660238653e-07
reaction O 0 1.5230567385060567e-07
system O 0 2.746046732227114e-07
designed O 0 1.7399162288711523e-07
to O 0 1.2300253260377758e-08
detect O 0 1.5876450731866498e-07
exclusively O 0 2.1629407598311445e-08
only O 0 4.291791810828727e-09
one O 0 2.243155217129811e-09
of O 0 6.0165317172788946e-09
the O 0 8.427895714646638e-09
normal O 0 2.005811161609472e-08
and O 0 8.210975899203277e-09
mutant O 0 9.333728456795143e-08
alleles O 0 2.7680112424377512e-08
indicated O 0 2.0594725924638624e-08
that O 0 3.2515683479061863e-09
all O 0 5.180810447313888e-09
the O 0 1.0327058319603566e-08
four O 0 1.642750468988652e-08
patients O 0 6.336508651116901e-09
were O 0 1.4156343652871328e-08
homozygous O 0 7.593914830295034e-08
for O 0 1.2969844753740745e-08
the O 0 1.6893197951617367e-08
mutation O 0 5.606561970239454e-08
in O 0 1.7179466738070914e-08
exon O 0 2.741120113114448e-07
4 O 0 1.1983327397047105e-07
and O 0 8.66445049041431e-09
that O 0 3.3039952995750355e-09
the O 0 1.3583857594312576e-08
parents O 0 8.991027478089109e-09
of O 0 8.437324794385859e-08
patient O 0 1.9390905947602732e-07
2 O 0 2.9157504286558833e-06
were O 0 2.8383562948874896e-06
heterozygous O 0 2.3824470190447755e-05
. O 0 2.259076791233383e-05

The O 0 4.292237917979946e-06
common O 0 2.5034275950019946e-06
mutation O 0 1.2805418236894184e-06
at O 0 8.379954579140758e-07
codon O 0 1.7770910289982567e-06
95 O 0 1.0098374332301319e-06
in O 0 6.564393117969303e-08
exon O 0 4.914240321340912e-07
4 O 0 1.844734356382105e-07
might O 0 4.0252363220361076e-08
be O 0 3.8107554445332426e-08
responsible O 0 1.8537707546784077e-07
for O 0 4.373813311531194e-08
most O 0 2.4030151735132677e-07
Japanese O 0 0.00047498580534011126
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999319314956665
. O 0 5.328379302227404e-06
. O 0 1.621877891011536e-05

BRCA1 O 0 2.4046452381298877e-05
required O 0 8.562136031287082e-07
for O 0 2.9874303208998754e-07
transcription O 0 4.049056315125199e-06
- O 0 2.873293169614044e-06
coupled O 0 3.4025613331323257e-06
repair O 0 7.769470357743558e-06
of O 0 6.682971161353635e-06
oxidative O 0 0.43509966135025024
DNA O 0 6.895560363773257e-05
damage O 0 0.0003023195604328066
. O 0 5.185183908906765e-05

The O 0 0.0002356336044613272
breast B-Disease 1 0.9999357461929321
and I-Disease 1 0.9918532967567444
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9987658262252808
gene O 0 0.0001567914878251031
BRCA1 O 0 0.0009385438752360642
encodes O 0 7.655395165784284e-06
a O 0 2.240660478491918e-06
zinc O 0 0.00010461407509865239
finger O 0 7.543965693912469e-06
protein O 0 9.707390518087777e-07
of O 0 5.553813480219105e-07
unknown O 0 2.3368340862361947e-06
function O 0 2.9597129014291568e-06
. O 0 8.184823855117429e-06

Association O 0 3.511686372803524e-05
of O 0 8.037485713430215e-06
the O 0 3.21271863867878e-06
BRCA1 O 0 7.78100911702495e-06
protein O 0 5.327356689122098e-07
with O 0 6.349347358991508e-08
the O 0 2.5742164666553435e-07
DNA O 0 1.6753190266172169e-06
repair O 0 2.366645048823557e-06
protein O 0 1.1005747637682362e-06
Rad51 O 0 1.6225772924371995e-05
and O 0 4.8640096395047294e-08
changes O 0 6.551572084845247e-08
in O 0 1.0694679808409546e-08
the O 0 2.064837545390219e-08
phosphorylation O 0 4.946603837652219e-08
and O 0 1.6463953755874172e-08
cellular O 0 2.505263978491712e-07
localization O 0 6.733496320521226e-07
of O 0 4.860095970116163e-08
the O 0 4.195342384605283e-08
protein O 0 8.587898037148989e-08
after O 0 1.1582395842424376e-07
exposure O 0 2.1397779903509218e-07
to O 0 2.9073261131884465e-08
DNA O 0 1.10292626231967e-06
- O 0 1.1778155339925434e-06
damaging O 0 2.6403615720482776e-06
agents O 0 3.766480460853927e-08
are O 0 7.925706313471892e-09
consistent O 0 1.6881740805274603e-07
with O 0 1.879331890108915e-08
a O 0 6.33600407695667e-08
role O 0 2.635772489156807e-07
for O 0 1.5594396529650112e-07
BRCA1 O 0 4.0426898522127885e-06
in O 0 2.703870336517866e-07
DNA O 0 5.995032552164048e-06
repair O 0 4.458696275833063e-05
. O 0 3.237412965972908e-05

Here O 0 8.017849722818937e-06
, O 0 2.5392520797140605e-07
it O 0 3.356936417731049e-08
is O 0 1.455612697043307e-08
shown O 0 5.0181991895215106e-08
that O 0 2.7416707126803885e-08
mouse O 0 5.86816724990058e-07
embryonic O 0 1.3941037195763784e-06
stem O 0 1.3441917872114573e-06
cells O 0 1.1521982514750562e-06
deficient B-Disease 0 9.747800504555926e-07
in I-Disease 0 5.401834712870368e-08
BRCA1 I-Disease 0 1.3443226407616748e-06
are O 0 2.9052195316126017e-08
defective O 0 1.3556287967730896e-06
in O 0 2.0217509444364623e-08
the O 0 1.9369293724480485e-08
ability O 0 1.448285047445097e-08
to O 0 9.120379118598976e-09
carry O 0 5.295434490903972e-08
out O 0 4.905151484990711e-08
transcription O 0 9.50899789131654e-07
- O 0 6.500072800008638e-07
coupled O 0 1.1972034599239123e-06
repair O 0 1.2589599691636977e-06
of O 0 4.095294059425214e-07
oxidative O 0 3.099679815932177e-05
DNA O 0 1.5232992609526264e-06
damage O 0 4.8771221372589935e-06
, O 0 1.5265030128830404e-07
and O 0 1.0586570908799331e-07
are O 0 7.476296559616458e-08
hypersensitive O 0 4.085922682861565e-06
to O 0 1.6757186926952272e-07
ionizing O 0 0.00020923968986608088
radiation O 0 6.972972914809361e-05
and O 0 6.864941042294959e-07
hydrogen O 0 8.083175998763181e-06
peroxide O 0 0.00018135046411771327
. O 0 2.0498891899478622e-05

These O 0 8.60568661664729e-07
results O 0 9.550732329444145e-07
suggest O 0 3.699694559600175e-07
that O 0 1.881513185253425e-07
BRCA1 O 0 6.531536200782284e-06
participates O 0 1.0013941391662229e-06
, O 0 7.528784351507056e-08
directly O 0 5.842369432684791e-08
or O 0 6.414873610083305e-08
indirectly O 0 1.7067091562239511e-07
, O 0 2.7859348605829837e-08
in O 0 3.604463216788645e-08
transcription O 0 9.337304049950035e-07
- O 0 9.909921345752082e-07
coupled O 0 1.8261221157445107e-06
repair O 0 3.220292001060443e-06
of O 0 1.5554797982986202e-06
oxidative O 0 0.00011342694779159501
DNA O 0 3.762897677006549e-06
damage O 0 7.010192348388955e-06
. O 0 1.04185608051921e-06
. O 0 9.92205514194211e-06

Truncation O 0 0.00039155848207883537
mutations O 0 1.565416096127592e-05
in O 0 5.131199714014656e-07
the O 0 5.460689749270387e-07
transactivation O 0 5.2736697398358956e-05
region O 0 1.041720906869159e-06
of O 0 1.9388182863622205e-06
PAX6 O 0 0.06628082692623138
result O 0 1.7840872033048072e-06
in O 0 3.2995671972457785e-07
dominant O 0 0.00012136087752878666
- O 0 6.502585620182799e-06
negative O 0 1.6823781834318652e-06
mutants O 0 3.65641426469665e-05
. O 0 1.540447374281939e-05

PAX6 O 0 0.019731594249606133
is O 0 1.673024712545157e-06
a O 0 7.554963872280496e-07
transcription O 0 7.273303026522626e-07
factor O 0 2.0125486344113597e-07
with O 0 4.883167648017661e-08
two O 0 5.86966741877859e-08
DNA O 0 6.07337085511972e-07
- O 0 4.623400684522494e-07
binding O 0 2.1944021000308567e-07
domains O 0 4.7048203555277723e-07
( O 0 6.918585881976469e-08
paired O 0 2.2169132307681139e-07
box O 0 2.2998672477569926e-07
and O 0 1.0648236070665007e-07
homeobox O 0 6.253358606045367e-06
) O 0 8.695197806218857e-08
and O 0 1.6717042683467298e-07
a O 0 6.249622401810484e-07
proline O 0 1.755436278472189e-05
- O 0 1.5233867088682018e-05
serine O 0 2.2876965886098333e-05
- O 0 1.179271475848509e-05
threonine O 0 3.1290528568206355e-05
( O 0 1.3451317499857396e-06
PST O 1 0.9870561361312866
) O 0 1.581483957124874e-06
- O 0 7.894537702668458e-06
rich O 0 6.29102396487724e-06
transactivation O 0 0.00025699884281493723
domain O 0 3.173093864461407e-05
. O 0 2.8865815693279728e-05

PAX6 O 1 0.9999692440032959
regulates O 0 0.0004479659837670624
eye O 0 0.03952014818787575
development O 0 1.468804657633882e-05
in O 0 3.038153124634846e-07
animals O 0 1.5183724144662847e-07
ranging O 0 9.210365874423587e-07
from O 0 7.998772844075575e-08
jellyfish O 0 1.4893906552515546e-07
to O 0 5.145773585013558e-08
Drosophila O 0 1.6683389958416228e-06
to O 0 2.7566895255404233e-07
humans O 0 1.3274462617118843e-05
. O 0 2.6069359591929242e-05

Heterozygous O 0 2.7911617507925257e-05
mutations O 0 3.490173639875138e-06
in O 0 1.877011044371102e-07
the O 0 2.776578185148537e-07
human O 0 5.561371381190838e-07
PAX6 O 0 0.0001988531439565122
gene O 0 1.1378385522675671e-07
result O 0 1.3613042426641186e-07
in O 0 4.0281239677142366e-08
various O 0 1.1331355409538446e-07
phenotypes O 0 7.0499631874554325e-06
, O 0 2.0805627798381465e-07
including O 0 2.6355087356932927e-06
aniridia B-Disease 1 1.0
, O 0 5.200292434892617e-05
Peters B-Disease 1 0.9999997615814209
anomaly I-Disease 1 0.9999982118606567
, O 0 2.4351520551135764e-06
autosomal B-Disease 0 0.003406735137104988
dominant I-Disease 1 0.9998657703399658
keratitis I-Disease 1 0.9999997615814209
, O 0 7.294973784155445e-06
and O 0 1.960398913070094e-05
familial B-Disease 1 0.9991351962089539
foveal I-Disease 1 0.9999998807907104
dysplasia I-Disease 1 1.0
. O 0 0.10419604927301407

It O 0 3.9782199223736825e-07
is O 0 4.729111680035203e-08
believed O 0 9.336701367601563e-08
that O 0 1.271265404056976e-08
the O 0 7.473986585182502e-08
mutated O 0 5.785233838651038e-07
allele O 0 1.4858370604997617e-06
of O 0 6.32797195976309e-07
PAX6 O 0 0.008935759775340557
produces O 0 4.440166776475962e-07
an O 0 3.0746281964866284e-08
inactive O 0 5.804249667562544e-07
protein O 0 8.290274990940816e-07
and O 0 5.177000730327563e-07
aniridia B-Disease 1 0.9999998807907104
is O 0 1.4970120787438645e-07
caused O 0 4.346428283952264e-07
due O 0 8.719500783627154e-07
to O 0 2.9623936370626325e-07
genetic O 0 9.057875104190316e-06
haploinsufficiency O 0 0.0003623699303716421
. O 0 2.5626683054724708e-05

However O 0 5.426378265838139e-06
, O 0 6.176741749186476e-07
several O 0 1.628466179681709e-07
truncation O 0 5.172636065253755e-06
mutations O 0 3.3636376883805497e-07
have O 0 2.8299634635686743e-08
been O 0 2.3461536713398345e-08
found O 0 9.089242247739548e-09
to O 0 8.676622087477881e-09
occur O 0 3.6707206163555384e-08
in O 0 3.215269828160672e-08
the O 0 1.3710484836337855e-07
C O 0 0.00866480078548193
- O 0 6.951355771889212e-06
terminal O 0 2.3187110400613165e-06
half O 0 1.236761022482824e-07
of O 0 2.2069144733904977e-07
PAX6 O 0 0.03416517749428749
in O 0 1.219139136310332e-07
patients O 0 1.0162167285443502e-07
with O 0 1.6902021116038668e-07
Aniridia B-Disease 1 0.9999996423721313
resulting O 0 1.5104016028999467e-06
in O 0 3.930409420149772e-08
mutant O 0 1.8140761426366225e-07
proteins O 0 4.05835987038472e-09
that O 0 1.6440597772060528e-09
retain O 0 1.2324751708092663e-07
the O 0 6.525469586904364e-08
DNA O 0 2.8011666586280626e-07
- O 0 4.7843187189755554e-08
binding O 0 2.07831121201707e-08
domains O 0 2.146178346151828e-08
but O 0 1.0716446396941137e-08
have O 0 9.702501913011474e-09
lost O 0 4.448350807706447e-07
most O 0 2.303967328032286e-08
of O 0 1.291450502094449e-07
the O 0 5.496710286934103e-07
transactivation O 0 5.805538603453897e-05
domain O 0 5.108045115775894e-06
. O 0 9.431738362764008e-06

It O 0 2.3590145303842291e-07
is O 0 2.5876646603251174e-08
not O 0 7.399035162336531e-09
clear O 0 4.219803173555192e-08
whether O 0 4.313056223281819e-08
such O 0 5.328027086193288e-08
mutants O 0 5.8006362451124005e-06
really O 0 7.540855904153432e-07
behave O 0 1.2663291215631034e-07
as O 0 6.691911380585225e-08
loss O 0 7.445883056789171e-07
- O 0 2.918282859809551e-07
of O 0 2.1699827357224422e-07
- O 0 6.506504632852739e-07
function O 0 1.3185419334149628e-07
mutants O 0 6.549316822201945e-07
as O 0 7.283646397127086e-08
predicted O 0 1.3745049045610358e-06
by O 0 7.97998097823438e-07
haploinsufficiency O 0 0.0002790451399050653
. O 0 3.120000474154949e-05

Contrary O 0 4.2719666453194804e-06
to O 0 8.271402407444839e-08
this O 0 1.720806430682842e-08
theory O 0 3.0199512934814265e-07
, O 0 2.4283650645884336e-08
our O 0 2.5885434240535687e-08
data O 0 3.922583147186742e-08
showed O 0 2.7339634556255987e-08
that O 0 2.279818556161217e-09
these O 0 6.709993449760532e-09
mutants O 0 3.59894073653777e-07
are O 0 8.616360958058067e-09
dominant O 0 7.043982463983411e-07
- O 0 1.2711871022474952e-07
negative O 0 3.33226104487494e-08
in O 0 2.972861423700124e-08
transient O 0 7.151027716645331e-07
transfection O 0 1.4621318769059144e-06
assays O 0 2.9216440111667907e-07
when O 0 3.862705000301503e-08
they O 0 1.963326923259956e-08
are O 0 5.255938972936747e-08
coexpressed O 0 6.546902113768738e-06
with O 0 2.3663736214984965e-07
wild O 0 3.636751671365346e-06
- O 0 2.1145046048332006e-05
type O 0 0.00013127029524184763
PAX6 O 1 0.9973992109298706
. O 0 6.997365562710911e-05

We O 0 8.37250070162554e-07
found O 0 9.030233627527195e-08
that O 0 1.6134768188180715e-08
the O 0 8.93434588533637e-08
dominant O 0 7.956053195812274e-06
- O 0 3.5435701306596457e-07
negative O 0 4.042509260671068e-08
effects O 0 2.740926561273227e-07
result O 0 5.688534443493154e-08
from O 0 9.871586215126626e-09
the O 0 1.8444346494561614e-08
enhanced O 0 1.3112700969486468e-07
DNA O 0 2.8389218087454537e-08
binding O 0 1.911681479782601e-08
ability O 0 2.0652866083992194e-08
of O 0 8.997104572472381e-08
these O 0 1.547367531884447e-07
mutants O 0 1.638364301470574e-05
. O 0 6.917562586750137e-06

Kinetic O 0 4.7543431719532236e-05
studies O 0 1.24529128697759e-06
of O 0 5.842837254022015e-07
binding O 0 9.40199754495552e-07
and O 0 2.340250233601182e-07
dissociation O 0 1.5423714785356424e-06
revealed O 0 3.814126330325962e-07
that O 0 1.2538309057674724e-08
various O 0 4.622408411592005e-08
truncation O 0 2.577306531748036e-06
mutants O 0 8.570624459025566e-07
have O 0 2.7322794693418473e-08
3 O 0 3.626171292125946e-07
- O 0 1.4643265444647113e-07
5 O 0 2.1925696103153314e-07
- O 0 1.1381315800917946e-07
fold O 0 5.089850674266927e-08
higher O 0 4.27394510893464e-08
affinity O 0 1.299378826757902e-08
to O 0 4.303120082482792e-09
various O 0 1.681825700927675e-08
DNA O 0 7.809548208115302e-08
- O 0 1.904185076284648e-08
binding O 0 1.130708504604172e-08
sites O 0 1.4284745830650536e-08
when O 0 7.365242638002201e-09
compared O 0 1.2837410245936098e-08
with O 0 7.009649749534219e-09
the O 0 7.55590221501734e-08
wild O 0 1.3195059409554233e-06
- O 0 6.120810667198384e-06
type O 0 5.143510497873649e-05
PAX6 O 1 0.9696149230003357
. O 0 3.5589324397733435e-05

These O 0 7.813390539013199e-07
results O 0 1.504230453974742e-06
provide O 0 1.1436195990199849e-07
a O 0 6.01381557885361e-08
new O 0 8.492332170817463e-08
insight O 0 3.754657029730879e-07
into O 0 1.0524054516736214e-08
the O 0 1.1654889497947352e-08
role O 0 4.264840924861346e-08
of O 0 2.1735948507739522e-07
mutant O 0 8.604491995356511e-06
PAX6 O 0 0.0016090727876871824
in O 0 1.223721028509317e-06
causing O 0 0.00012679651263169944
aniridia B-Disease 1 0.9999985694885254
. O 0 1.5743478797958232e-05
. O 0 3.4777927794493735e-05

Reversal O 0 0.0005594381364062428
of O 0 0.00045959081035107374
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.09979945421218872
excellent O 1 0.7608846426010132
neuropsychologic O 0 0.28839975595474243
outcome O 0 1.3090040738461539e-05
in O 0 1.4795854497151595e-07
very B-Disease 0 5.136340632816427e-07
- I-Disease 0 6.104412477725418e-06
long I-Disease 0 2.531044174247654e-06
- I-Disease 0 0.004781621508300304
chain I-Disease 0 0.0009355570073239505
acyl I-Disease 1 0.7806103825569153
- I-Disease 1 0.9999927282333374
coenzyme I-Disease 1 0.9999871253967285
A I-Disease 1 0.9999628067016602
dehydrogenase I-Disease 1 0.9673892855644226
deficiency I-Disease 1 0.9320594668388367
. O 0 1.766649802448228e-05

Very B-Disease 0 0.00010350629599997774
- I-Disease 0 0.0007267686305567622
long I-Disease 0 5.246487125987187e-05
- I-Disease 0 0.4169272184371948
chain I-Disease 0 0.002789375837892294
acyl I-Disease 0 0.02702256105840206
- I-Disease 1 0.999052107334137
coenzyme I-Disease 1 0.906104326248169
A I-Disease 0 0.014905410818755627
dehydrogenase I-Disease 0 2.1062187443021685e-05
( I-Disease 0 9.52677055465756e-07
VLCAD I-Disease 1 0.9999617338180542
) I-Disease 0 4.977162006980507e-06
deficiency I-Disease 1 0.6882470846176147
is O 0 1.502779412021482e-07
a O 0 1.0090325304190628e-06
disorder O 0 0.0071893418207764626
of O 0 4.708349024440395e-06
fatty O 0 1.6520455119461985e-06
acid O 0 4.0037969029071974e-07
beta O 0 2.4861947167664766e-07
oxidation O 0 4.106623663346909e-08
that O 0 7.105438459831248e-09
reportedly O 0 1.267656983827692e-07
has O 0 1.3342023486018206e-08
high O 0 2.4569717993472295e-07
rates O 0 2.074060745371753e-07
of O 0 6.02033424002002e-07
morbidity O 0 2.4305871193064377e-05
and O 0 1.4408425386136514e-06
mortality O 0 4.7932211600709707e-05
. O 0 1.4368917618412524e-05

We O 0 2.256826292068581e-06
describe O 0 8.566782980778953e-07
the O 0 2.532538587729505e-07
outcome O 0 9.670457075117156e-07
of O 0 1.6042685047068517e-07
a O 0 1.1105873198857807e-07
5 O 0 4.378187270503986e-07
- O 0 2.553224192070047e-07
year O 0 6.241629080250277e-08
- O 0 3.671148363082466e-07
old O 0 1.7101190223911544e-06
girl O 0 2.502833240214386e-06
with O 0 3.2017727789934725e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 6.01555848334101e-06
was O 0 3.982971975347027e-06
first O 0 7.113387567869722e-08
seen O 0 5.828256277595756e-08
at O 0 9.75254508261969e-08
5 O 0 7.541316904280393e-08
months O 0 3.4371471002714316e-08
of O 0 2.9590298211701338e-08
age O 0 1.9376541615656606e-07
with O 0 3.2021151241679036e-07
severe O 1 0.9999871253967285
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999997615814209
hepatomegaly B-Disease 1 1.0
, O 1 0.9999998807907104
encephalopathy B-Disease 1 1.0
, O 0 4.3843356252182275e-05
and O 0 0.00011177676060469821
hypotonia B-Disease 1 0.9998961687088013
. O 0 0.00015568427625112236

Biochemical O 0 0.00038632721407338977
studies O 0 3.395082239876501e-05
indicated O 1 0.9785888195037842
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.08862564712762833
by O 0 3.2040762221186014e-07
a O 0 2.9806034262946923e-07
stable O 0 2.4885052880563308e-06
yet O 0 7.299416893147281e-07
inactive O 0 7.73186911828816e-06
enzyme O 0 9.397987923875917e-06
. O 0 4.997128144168528e-06

Molecular O 0 5.2406212489586323e-05
genetic O 0 1.928827941810596e-06
analysis O 0 6.950812121431227e-07
of O 0 6.664041620751959e-07
her O 0 4.649359937047848e-07
VLCAD O 1 0.9948838353157043
gene O 0 2.689778739295434e-06
revealed O 0 7.692659892200027e-06
a O 0 1.6102108020277228e-06
T1372C O 0 8.537132816854864e-05
( O 0 2.2827277916803723e-06
F458L O 0 3.0619681638199836e-05
) O 0 5.25699192621687e-07
missense O 0 9.171053534373641e-06
mutation O 0 1.9611636616900796e-06
and O 0 8.171473382390104e-07
a O 0 5.826461347169243e-06
1668 O 0 0.018950415775179863
ACAG O 1 0.9929540753364563
1669 O 0 0.003157478990033269
splice O 0 0.0002092464710585773
site O 0 2.418040094198659e-05
mutation O 0 0.00010288644261891022
. O 0 0.00010443358041811734

After O 0 1.205016906169476e-05
initial O 0 3.3857813832582906e-06
treatment O 0 3.4206575492135016e-06
with O 0 2.9844747473362077e-07
intravenous O 0 1.7887921785586514e-05
glucose O 0 6.078219666960649e-05
and O 0 3.2742863709245285e-07
carnitine O 0 0.00016590251470915973
, O 0 5.205536623975604e-08
the O 0 4.175289447516661e-08
patient O 0 5.783099155109994e-08
has O 0 1.1686209333561237e-08
thrived O 0 3.744665946214809e-07
on O 0 7.120581813069293e-08
a O 0 4.6307654599786474e-08
low O 0 1.4706257616126095e-06
- O 0 1.5985153822839493e-06
fat O 0 8.67429889694904e-07
diet O 0 2.411872515040159e-07
supplemented O 0 1.1004807021208762e-07
with O 0 3.7880294456726915e-08
medium O 0 2.5167415515170433e-05
- O 0 1.8910251355919172e-06
chain O 0 3.3904007068485953e-07
triglyceride O 0 1.0887800954151317e-06
oil O 0 8.254127124018851e-07
and O 0 2.926750255483057e-07
carnitine O 0 2.8901185942231677e-05
and O 0 2.5681990223347384e-07
avoidance O 0 1.5154548236750998e-05
of O 0 3.937079327442916e-06
fasting O 0 9.698954090708867e-05
. O 0 1.2779001735907514e-05

Her O 0 8.69785581016913e-05
ventricular O 1 0.9998481273651123
hypertrophy O 1 0.9993752837181091
resolved O 0 5.8156452723778784e-05
significantly O 0 5.725036089643254e-07
over O 0 1.001958978008588e-07
1 O 0 1.9122803962545731e-07
year O 0 1.6383760126359448e-08
, O 0 1.796907156403904e-08
and O 0 8.032254328327326e-08
cognitively O 0 0.00014294411812443286
, O 0 3.0208408219323246e-08
she O 0 1.0375925008077047e-08
is O 0 7.379894917391994e-09
in O 0 5.4425379758527015e-09
the O 0 3.165566653251517e-08
superior O 0 5.416823569248663e-06
range O 0 2.850658574971021e-06
for O 0 5.732592285312421e-07
age O 0 9.416459761268925e-06
. O 0 1.4534479305439163e-05

Clinical O 0 5.530497583094984e-05
recognition O 0 2.1090345398988575e-05
of O 1 0.9979482293128967
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 9.054980978362437e-07
important O 0 6.51723510713964e-08
because O 0 5.499670940878332e-09
it O 0 1.714907660321785e-09
is O 0 2.9742153184741937e-09
one O 0 3.2004858763201582e-09
of O 0 2.5231262412717115e-08
the O 0 9.221380992130435e-08
few O 0 3.8577650229854044e-07
directly O 0 1.0200924407399725e-06
treatable O 1 0.9913941025733948
causes O 0 1.4341510905069299e-05
of O 0 0.0007008530665189028
cardiomyopathy B-Disease 1 1.0
in O 0 2.298218896612525e-05
children O 0 1.4266007610785891e-06
. O 0 1.916773271659622e-06
. O 0 1.9089700799668208e-05

Cloning O 0 1.331882958766073e-05
of O 0 9.729346857056953e-07
a O 0 3.090983398124081e-07
novel O 0 3.970487796323141e-07
member O 0 2.6902151262220286e-07
of O 0 3.3027120593942527e-07
the O 0 2.9046080385342066e-07
low O 0 9.074415174836759e-06
- O 0 4.976430773240281e-06
density O 0 1.1481758974696277e-06
lipoprotein O 0 7.053715671645477e-05
receptor O 0 1.480387982155662e-05
family O 0 1.198726408802031e-06
. O 0 8.100168997771107e-06

A O 0 1.639376932871528e-05
gene O 0 2.0661516373365885e-06
encoding O 0 4.930754585075192e-06
a O 0 6.88441218699154e-07
novel O 0 1.1249035196669865e-06
transmembrane O 0 8.882782822183799e-06
protein O 0 6.308605975391401e-07
was O 0 2.6258746288476686e-07
identified O 0 5.415029136202065e-08
by O 0 1.5222225258071376e-08
DNA O 0 6.673161578873987e-08
sequence O 0 2.1566053831634235e-08
analysis O 0 3.1115948928572834e-08
within O 0 6.170417776729664e-08
the O 0 2.0806619716040586e-07
insulin B-Disease 0 0.0002043905114987865
- I-Disease 0 0.0008510982734151185
dependent I-Disease 0 0.00012030510697513819
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 7.048706174828112e-05
IDDM B-Disease 1 0.9929941296577454
) O 0 8.81085725268349e-07
locus O 0 7.926547368697356e-06
IDDM4 O 0 0.0001359125308226794
on O 0 1.0166631909669377e-05
chromosome O 0 6.305565329967067e-05
11q13 O 0 0.0003685185220092535
. O 0 6.932984251761809e-05

Based O 0 3.757802005566191e-06
on O 0 4.835736149289005e-07
its O 0 9.08158597212605e-08
chromosomal O 0 8.775125479587587e-07
position O 0 1.0898095297307009e-06
, O 0 4.234719597207004e-08
this O 0 8.878910051635103e-09
gene O 0 3.3559249601466945e-08
is O 0 7.923711464741245e-09
a O 0 2.595603376676081e-08
candidate O 0 1.919427745633584e-07
for O 0 2.0519685506315e-07
conferring O 0 6.6514462560007814e-06
susceptibility O 0 0.00012296841305214912
to O 0 8.847502613207325e-06
diabetes B-Disease 1 0.999783456325531
. O 0 0.00022065851953811944

The O 0 5.99678787693847e-06
gene O 0 1.7996411543208524e-06
, O 0 7.771195100758632e-07
termed O 0 4.051767973578535e-06
low O 0 9.829353984969202e-06
- O 0 6.362055501085706e-06
density O 0 5.725194114347687e-07
lipoprotein O 0 5.897840765101137e-06
receptor O 0 6.116306963122042e-07
related O 0 7.704208826453396e-08
protein O 0 5.5185982006378254e-08
5 O 0 1.8517529554173962e-07
( O 0 4.462946989747252e-08
LRP5 O 0 2.3665596017963253e-05
) O 0 3.917454094448658e-08
, O 0 3.181291674536624e-08
encodes O 0 5.765917521216579e-08
a O 0 3.206108445397149e-08
protein O 0 1.0596307475907452e-07
of O 0 3.2184271958612953e-07
1615 O 0 9.206980030285195e-05
amino O 0 1.2453576800908195e-06
acids O 0 1.1147171363745656e-07
that O 0 1.0587737797607133e-08
contains O 0 3.281913762975819e-08
conserved O 0 9.517891896848596e-08
modules O 0 8.081953239980066e-08
which O 0 1.7705903410103474e-09
are O 0 1.2715897224069295e-09
characteristic O 0 2.2117347953098943e-08
of O 0 2.180911451432621e-08
the O 0 4.350450311108034e-08
low O 0 5.899950679122412e-07
- O 0 4.099021850834106e-07
density O 0 1.02030114135232e-07
lipoprotein O 0 7.980285772646312e-06
( O 0 3.0508238069160143e-07
LDL O 0 1.2857027286372613e-05
) O 0 5.469754000841931e-07
receptor O 0 3.7342667837947374e-06
family O 0 6.780161925235006e-07
. O 0 7.261767223099014e-06

These O 0 2.0959198536729673e-06
modules O 0 8.583493581681978e-06
include O 0 2.2076535799442354e-07
a O 0 1.377469089902661e-07
putative O 0 1.0318659633412608e-06
signal O 0 1.4942619372959598e-06
peptide O 0 3.402661263862683e-07
for O 0 3.738695397714764e-08
protein O 0 1.5059242741699563e-07
export O 0 1.0655224258471208e-07
, O 0 5.2634835157050475e-08
four O 0 1.1228473795199534e-07
epidermal O 0 6.238082619347551e-07
growth O 0 9.036040182763827e-08
factor O 0 3.250590623338212e-07
( O 0 1.9224945901896717e-07
EGF O 0 7.2869497671490535e-06
) O 0 9.906409559334861e-08
repeats O 0 3.853433554468211e-07
with O 0 3.972191464640673e-08
associated O 0 4.335817607170611e-07
spacer O 0 2.9105635803716723e-06
domains O 0 5.186043381399941e-07
, O 0 1.392509147990495e-07
three O 0 1.28426563605899e-07
LDL O 0 1.4139499171506031e-06
- O 0 8.316406479025318e-07
receptor O 0 4.400590682962502e-07
( O 0 1.005600438475085e-07
LDLR O 0 3.0315417461679317e-05
) O 0 6.700634713752152e-08
repeats O 0 1.6397584090555029e-07
, O 0 2.2168283209111905e-08
a O 0 5.211686371353608e-08
single O 0 1.7965530219044012e-07
transmembrane O 0 4.305184575059684e-06
spanning O 0 8.837719747134543e-07
domain O 0 1.7538069130296208e-07
, O 0 5.918502665736014e-08
and O 0 1.2246299263551919e-07
a O 0 3.294765633654606e-07
cytoplasmic O 0 7.271517915796721e-06
domain O 0 7.0146802499948535e-06
. O 0 7.936955626064446e-06

The O 0 6.973632935114438e-06
encoded O 0 1.159614953394339e-06
protein O 0 3.606874088291079e-07
has O 0 2.2320426396049697e-08
a O 0 3.5115899521542815e-08
unique O 0 5.3275392986051884e-08
organization O 0 9.422628721722504e-08
of O 0 2.600395987428783e-07
EGF O 0 4.7554090997437015e-05
and O 0 3.0321672284117085e-07
LDLR O 0 0.0011372024891898036
repeats O 0 9.574515615895507e-07
; O 0 5.362067412306715e-08
therefore O 0 1.9017828378764534e-07
, O 0 1.934583622187347e-07
LRP5 O 0 0.00010505434329388663
likely O 0 4.0987990246321715e-07
represents O 0 1.3216451577591215e-07
a O 0 3.838248829879376e-08
new O 0 5.320958607057946e-08
category O 0 1.6472694142066757e-07
of O 0 2.783731360977981e-07
the O 0 8.973947842605412e-07
LDLR O 0 0.002263053320348263
family O 0 2.8344122711132513e-06
. O 0 1.0976410521834623e-05

Both O 0 1.3507401490642224e-05
human O 0 4.907387392449891e-06
and O 0 2.938924126283382e-06
mouse O 0 1.6305051758536138e-05
LRP5 O 0 0.027965355664491653
cDNAs O 0 4.822573464480229e-05
have O 0 9.894549890532289e-08
been O 0 5.8125479540649394e-08
isolated O 0 9.553193791589365e-08
and O 0 3.8316361639090246e-08
the O 0 7.670543311633082e-08
encoded O 0 6.190670376327034e-08
mature O 0 6.345025838072615e-08
proteins O 0 4.288387867035226e-09
are O 0 2.0442283421573393e-09
95 O 0 6.036707844714329e-08
% O 0 1.1348655348797365e-08
identical O 0 7.56438041094043e-08
, O 0 1.6270218949898663e-08
indicating O 0 7.611460262069158e-08
a O 0 3.320878505519431e-08
high O 0 2.60745821378805e-07
degree O 0 3.375955941464781e-07
of O 0 9.205231066289343e-08
evolutionary O 0 9.85343490356172e-07
conservation O 0 2.3326029463532905e-07
. O 0 2.038996314013275e-07
. O 0 3.4332795166847063e-06

The O 0 1.895070272439625e-05
APC B-Disease 0 5.509668335434981e-05
variants O 0 8.763393452682067e-06
I1307K O 0 1.7879376173368655e-05
and O 0 2.677987254173786e-07
E1317Q O 0 7.704796189500485e-06
are O 0 8.081953239980066e-08
associated O 0 2.6651819098333362e-06
with O 0 0.3222707211971283
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 5.0023983931168914e-05
but O 0 8.319469912976274e-08
not O 0 1.3070546422966345e-08
always O 0 4.525366747998305e-08
with O 0 3.119486180480635e-08
a O 0 2.3627158896033507e-07
family O 0 1.9643705684302404e-07
history O 0 3.5183186355425278e-06
. O 0 1.6071233403636143e-05

Classical O 0 0.0019058079924434423
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9617860913276672
FAP B-Disease 1 0.9995036125183105
) O 0 1.9749224975385005e-06
is O 0 2.518667372441996e-07
a O 0 6.051418495189864e-07
high O 0 0.00039952623774297535
- O 1 0.5704218149185181
penetrance O 1 0.9999966621398926
autosomal B-Disease 1 0.9999980926513672
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.6620523929595947
that O 0 4.831619548895105e-08
predisposes O 0 6.772006599931046e-07
to O 0 3.2094000346205576e-08
hundreds O 0 1.6185262552426138e-07
or O 0 8.049953237332375e-08
thousands O 0 6.375341286002367e-07
of O 0 0.02394154481589794
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999996423721313
carcinoma I-Disease 1 1.0
and O 0 8.365613552996365e-07
that O 0 1.8352089625750523e-08
results O 0 1.5889598614649003e-07
from O 0 2.8830507758925705e-08
truncating O 0 1.4443038480749237e-06
mutations O 0 1.1245104758472735e-07
in O 0 4.265215025611724e-08
the O 0 3.9879631685835193e-07
APC B-Disease 0 1.5630648704245687e-05
gene O 0 7.480020485672867e-06
. O 0 1.7076670701499097e-05

A O 0 3.575492883101106e-05
variant O 0 8.61494627315551e-05
of O 0 1.3519232197722886e-05
FAP B-Disease 0 0.0033000607509166002
is O 0 5.624627192446496e-06
attenuated B-Disease 1 0.8269230723381042
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999983310699463
coli I-Disease 1 0.9986085295677185
, O 0 2.1040509636804927e-06
which O 0 2.008506783113262e-07
results O 0 1.0684026392482338e-06
from O 0 1.6748047926284926e-07
germ O 0 0.002184916054829955
- O 0 7.431819085468305e-06
line O 0 9.79737251327606e-07
mutations O 0 1.1895199492073516e-07
in O 0 7.85726594898506e-09
the O 0 1.4828393624100045e-08
5 O 0 6.492780357802985e-08
and O 0 2.1701229258042076e-08
3 O 0 1.2763875645305234e-07
regions O 0 2.0288432267534517e-08
of O 0 8.748031632421771e-08
the O 0 4.463666414267209e-07
APC B-Disease 0 8.708850145922042e-06
gene O 0 3.4317376957915258e-06
. O 0 1.3878843674319796e-05

Attenuated B-Disease 1 0.9999698400497437
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999604225158691
patients O 0 2.95334325528529e-06
have O 0 2.065405482198912e-07
" O 0 2.8409965580067364e-06
multiple O 0 0.0006559466128237545
" O 1 0.9999970197677612
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 3.0436128781730076e-06
typically O 0 7.434460513877639e-08
fewer O 0 3.188855046687422e-08
than O 0 8.318371769178157e-09
100 O 0 4.577758261348208e-08
) O 0 7.764275444799296e-09
without O 0 3.143041382713818e-08
the O 0 6.302472144170679e-08
florid O 0 7.317103154491633e-06
phenotype O 0 2.485076038283296e-06
of O 0 4.1932543126677047e-07
classical O 0 1.4750553418707568e-05
FAP B-Disease 0 0.00013199768727645278
. O 0 1.808236811484676e-05

Another O 0 2.0709823729703203e-05
group O 0 2.593456429167418e-06
of O 0 2.2111225916887634e-06
patients O 0 7.204681651273859e-07
with O 0 2.3401297255531972e-07
multiple O 0 0.0002900853578466922
adenomas B-Disease 1 0.9769355058670044
has O 0 8.950565444365566e-08
no O 0 4.7322874507926826e-08
mutations O 0 4.7795850832699216e-08
in O 0 1.3264935816437173e-08
the O 0 4.210059501019714e-08
APC B-Disease 0 7.066839771141531e-07
gene O 0 7.941886082107885e-08
, O 0 2.6454646473439425e-08
and O 0 2.526362230526047e-08
their O 0 4.0498637332575527e-08
phenotype O 0 1.3434165566650336e-06
probably O 0 1.7424368081719876e-07
results O 0 1.3931453679560946e-07
from O 0 2.4748720406364555e-08
variation O 0 5.735118406846595e-07
at O 0 4.34430631912619e-07
a O 0 5.3582741799118594e-08
locus O 0 3.6088800925426767e-07
, O 0 3.994444597310576e-08
or O 0 4.039541678935166e-08
loci O 0 4.569418763367139e-07
, O 0 4.43615384426721e-08
elsewhere O 0 1.5081202775490965e-07
in O 0 7.696835524484413e-08
the O 0 4.792291861122067e-07
genome O 0 1.6512925640199683e-06
. O 0 4.595149675878929e-06

Recently O 0 1.1615371477091685e-05
, O 0 5.000781015951361e-07
however O 0 5.921461365687719e-07
, O 0 1.825210063088889e-07
a O 0 2.1605684707992623e-07
missense O 0 3.3220842396985972e-06
variant O 0 4.647259174817009e-06
of O 0 2.0193556338199414e-06
APC B-Disease 0 5.4271404223982245e-05
( O 0 8.842221745908319e-07
I1307K O 0 3.650035796454176e-05
) O 0 1.7149683628758794e-07
was O 0 1.990593290202014e-07
described O 0 7.216095809781109e-08
that O 0 6.9748145037351605e-09
confers O 0 1.0853697318680133e-07
an O 0 1.0511336689944528e-08
increased O 0 8.965669451299618e-08
risk O 0 2.7591747766564367e-06
of O 1 0.99982088804245
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0001423615321982652
including O 0 3.252192300351453e-06
multiple O 0 2.397508069407195e-05
adenomas B-Disease 0 0.008236892521381378
, O 0 4.240098689933802e-07
in O 0 8.225076726375846e-07
Ashkenazim O 0 0.0013686006423085928
. O 0 2.8243715860298835e-05

We O 0 2.716788685575011e-06
have O 0 1.207171607120472e-07
studied O 0 7.018555265858595e-07
a O 0 9.252088517541779e-08
set O 0 1.2680342820203805e-07
of O 0 1.8023584402726556e-07
164 O 0 9.495205972598342e-07
patients O 0 9.755689234225429e-08
with O 0 2.1583299769645237e-07
multiple O 1 0.999993085861206
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9990949630737305
/ I-Disease 1 1.0
or I-Disease 1 0.7629271149635315
carcinoma I-Disease 1 1.0
and O 0 6.682950015601818e-07
analyzed O 0 8.690826689417008e-07
codons O 0 1.969701088455622e-06
1263 O 0 2.377467717451509e-05
- O 0 5.120023615745595e-06
1377 O 0 6.648203998338431e-05
( O 0 6.047644660611695e-07
exon O 0 3.6846561215497786e-06
15G O 0 6.403183306247229e-06
) O 0 5.1433989511906475e-08
of O 0 9.910831977322232e-08
the O 0 1.7105384131355095e-07
APC B-Disease 0 1.6607494899290032e-06
gene O 0 2.0557351376737643e-07
for O 0 1.5382511264760979e-07
germ O 0 0.2126254439353943
- O 0 0.0008011413738131523
line O 0 0.00014419372018892318
variants O 0 0.0007276036776602268
. O 0 3.2170573831535876e-05

Three O 0 1.516494285169756e-05
patients O 0 7.984838248376036e-07
with O 0 6.606899916050679e-08
the O 0 2.991293399645656e-07
I1307K O 0 3.827002274192637e-06
allele O 0 8.131818276524427e-07
were O 0 4.617861648625876e-08
detected O 0 8.426597730704088e-08
, O 0 3.3167637525366445e-08
each O 0 3.100794288002362e-08
of O 0 4.827193151868414e-07
Ashkenazi O 0 5.71717755519785e-05
descent O 0 4.882555003860034e-05
. O 0 4.183754208497703e-05

Four O 0 4.54345099569764e-05
patients O 0 2.4834059786371654e-06
had O 0 9.104563787332154e-07
a O 0 1.5513525113419746e-06
germ O 0 0.11715671420097351
- O 0 0.00036775460466742516
line O 0 6.304165435722098e-05
E1317Q O 0 0.00012377204257063568
missense O 0 7.84002349973889e-06
variant O 0 1.9157864699081983e-06
of O 0 3.563361019587319e-07
APC O 0 6.091503905736317e-07
that O 0 9.284824464828034e-09
was O 0 7.541360247387274e-08
not O 0 6.889822490308006e-09
present O 0 2.1666156868604958e-08
in O 0 1.1939746968891995e-08
controls O 0 1.479531732684336e-07
; O 0 1.9107119442196563e-08
one O 0 7.114090205817547e-09
of O 0 1.0045840603822853e-08
these O 0 6.481617464970668e-09
individuals O 0 4.8446007205882324e-09
had O 0 1.7901644611129086e-08
an O 0 8.83357209602309e-09
unusually O 0 8.077699931163806e-08
large O 0 4.912613604801663e-08
number O 0 6.516340533835319e-08
of O 0 5.480384857037279e-07
metaplastic B-Disease 0 9.525554196443409e-05
polyps I-Disease 0 4.222390089125838e-06
of I-Disease 0 8.180510349120595e-07
the I-Disease 0 2.2912074655323522e-06
colorectum I-Disease 0 0.0003695785126183182
. O 0 2.3890177544672042e-05

There O 0 1.985391918424284e-06
is O 0 7.022352122021402e-08
increasing O 0 8.569605114416845e-08
evidence O 0 1.1512104691746572e-07
that O 0 8.5186409037874e-09
there O 0 3.317605390407152e-08
exist O 0 1.4709469553508825e-07
germ O 0 4.105733023607172e-05
- O 0 2.2922304196981713e-06
line O 0 3.8199834762053797e-07
variants O 0 2.6799366992236173e-07
of O 0 1.3528244835470105e-07
the O 0 1.2748499500503385e-07
APC B-Disease 0 3.9450782196581713e-07
gene O 0 1.433712704113077e-08
that O 0 4.398800879101827e-09
predispose O 0 1.2419427264376282e-07
to O 0 1.3150640576498063e-08
the O 0 4.7202625808040466e-08
development O 0 2.8782605454580334e-07
of O 0 9.953045037036645e-07
multiple O 1 0.999994158744812
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999996423721313
carcinoma I-Disease 1 1.0
, O 0 1.279493289985112e-06
but O 0 5.9098056226503104e-08
without O 0 1.0377354442425712e-07
the O 0 7.932802503773928e-08
florid O 0 4.130554316361668e-06
phenotype O 0 7.521966267631797e-07
of O 0 1.329689638396303e-07
classical O 0 1.8701243789109867e-06
FAP B-Disease 0 9.126139048021287e-06
, O 0 3.65970329596621e-08
and O 0 3.105677492953873e-08
possibly O 0 1.6383766876515438e-07
with O 0 5.1638153308886103e-08
importance O 0 6.988098903093487e-06
for O 1 0.5354917645454407
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 6.948777695470199e-07
in O 0 1.7963760257089234e-08
the O 0 4.215121762740637e-08
general O 0 1.4276579918259813e-07
population O 0 2.7211237707547298e-08
. O 0 7.327811317736632e-07
. O 0 1.0595782441669144e-05

Genomic O 0 2.1336381905712187e-05
structure O 0 9.970011888071895e-06
of O 0 5.687948942068033e-06
the O 0 0.00011599442223086953
human O 1 0.9999654293060303
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 0.00014691911928821355
gene O 0 1.9807735952781513e-05
. O 0 1.7377553376718424e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999997615814209
CLD B-Disease 1 1.0
) O 0 5.8899827308778185e-06
is O 0 9.545416901346471e-08
caused O 0 1.4145066984383448e-07
by O 0 1.619529221841276e-08
mutations O 0 3.473195064884749e-08
in O 0 6.745950464903672e-09
a O 0 2.3879414001726218e-08
gene O 0 7.323166073547327e-08
which O 0 4.874727466130935e-08
encodes O 0 6.426348591048736e-07
an O 0 3.082020612055203e-07
intestinal O 0 0.0003611132560763508
anion O 0 0.0009662621305324137
transporter O 0 0.0049713365733623505
. O 0 3.65523956133984e-05

We O 0 4.49516846856568e-06
report O 0 6.467047910518886e-07
here O 0 1.2545706340461038e-07
the O 0 3.258952219198363e-08
complete O 0 6.773635163881409e-08
genomic O 0 7.587182437873707e-08
organization O 0 5.118950952009982e-08
of O 0 1.1297614577188142e-07
the O 0 2.1470550848334824e-07
human O 0 9.096839335143159e-07
CLD B-Disease 0 0.0007806660723872483
gene O 0 5.805849809803476e-07
which O 0 9.945295431634804e-08
spans O 0 1.2899209878014517e-06
approximately O 0 1.7055897671980347e-07
39kb O 0 5.111671271151863e-06
, O 0 9.159345637499428e-08
and O 0 1.8727715200839157e-07
comprises O 0 9.302329431193357e-07
21 O 0 3.3077094485634007e-06
exons O 0 2.582126580819022e-05
. O 0 7.184576134022791e-06

All O 0 2.088133078359533e-05
exon O 0 9.855425014393404e-05
/ O 0 2.9910339435446076e-05
intron O 0 2.6852942028199323e-05
boundaries O 0 1.0626876019159681e-06
conform O 0 1.0210599157289835e-06
to O 0 1.9884681989879027e-07
the O 0 2.1064522570668487e-06
GT O 1 0.9989798665046692
/ O 0 0.12582284212112427
AG O 1 0.9995461106300354
rule O 0 6.203145312611014e-05
. O 0 3.7337871617637575e-05

An O 0 1.1161197335241013e-06
analysis O 0 5.004435479349922e-07
of O 0 3.6089144828110875e-07
the O 0 2.2948499633912434e-07
putative O 0 2.495878106856253e-06
promoter O 0 8.124012310872786e-06
region O 0 3.9326184264609765e-07
sequence O 0 3.4182076547040197e-07
shows O 0 1.4847447005195136e-07
a O 0 2.852606257874868e-07
putative O 0 1.2095971214876045e-05
TATA O 0 0.012256915681064129
box O 0 1.8367553593634511e-06
and O 0 2.054004681895094e-07
predicts O 0 7.191213171608979e-07
multiple O 0 1.903740809439114e-07
transcription O 0 2.1521719872907852e-07
factor O 0 1.7389807283052505e-07
binding O 0 3.1347138929049834e-07
sites O 0 6.703388635287411e-07
. O 0 6.70800773150404e-06

The O 0 5.212002179177944e-06
genomic O 0 3.253256181778852e-06
structure O 0 1.8573645093056257e-06
was O 0 2.8074219926566e-07
determined O 0 9.19789471254262e-08
using O 0 3.077326837797045e-08
DNA O 0 1.1679395583996666e-07
from O 0 8.009547691756325e-09
several O 0 1.2797316983892415e-08
sources O 0 4.6037026635303846e-08
including O 0 4.039410583800418e-08
multiple O 0 2.7028906401938e-07
large O 0 8.971740612651047e-07
- O 0 1.8982411347678863e-05
insert O 0 1.6576211692154175e-06
libaries O 0 7.539671969425399e-06
and O 0 7.896376530425187e-08
genomic O 0 3.262852601437771e-07
DNA O 0 2.7246326794738707e-07
from O 0 1.570813310536323e-07
Finnish O 0 0.0033251193817704916
CLD B-Disease 1 0.9999829530715942
patients O 0 8.898544365365524e-06
and O 0 3.398462240511435e-06
controls O 0 0.0001699895365163684
. O 0 4.3241070670774207e-05

Exon O 0 0.00029445503605529666
- O 0 9.053349458554294e-06
specific O 0 2.4962821498775156e-07
primers O 0 3.118295808235416e-06
developed O 0 5.127931785864348e-07
in O 0 1.6433991945064008e-08
this O 0 3.6270129122328854e-09
study O 0 5.071639108678028e-09
will O 0 5.4231499291290675e-09
facilitate O 0 3.553051186599987e-08
mutation O 0 3.5148868704482084e-08
screening O 0 3.956644789582242e-08
studies O 0 3.346043442320479e-08
of O 0 7.105155930275942e-08
patients O 0 1.5617584381288907e-07
with O 0 2.7258852242084686e-07
the O 0 3.3647713280515745e-05
disease O 1 0.9883702993392944
. O 0 5.837114076712169e-05

Genomic O 0 1.4453604308073409e-05
sequencing O 0 5.2079130909987725e-06
of O 0 1.962877831829246e-06
a O 0 7.740803994238377e-06
BAC O 1 0.9998747110366821
clone O 0 0.00038745772326365113
H O 1 1.0
_ O 0 3.919460596080171e-06
RG364P16 O 0 1.116925704991445e-05
revealed O 0 3.198296951723023e-07
the O 0 1.924126458163755e-08
presence O 0 2.90292643256862e-08
of O 0 6.007395114693281e-08
another O 0 1.1551541945209465e-07
, O 0 4.6418545451842874e-08
highly O 0 1.257788397879267e-07
homologous O 0 8.437019261009482e-08
gene O 0 2.6169690414690194e-08
3 O 0 1.21762283811222e-07
of O 0 7.165842674794476e-08
the O 0 1.5382084939119522e-07
CLD B-Disease 0 0.0015628017717972398
gene O 0 1.6799317847926432e-07
, O 0 2.1060449384435742e-08
with O 0 8.866014589159477e-09
a O 0 1.7589112388805006e-08
similar O 0 2.695903233984609e-08
genomic O 0 1.4873806719606364e-07
structure O 0 6.129387202236103e-07
, O 0 3.5429678746368154e-08
recently O 0 1.084916476656872e-07
identified O 0 7.349191832872748e-08
as O 0 9.477458462470167e-08
the O 0 1.922714318425278e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 2.4017097530304454e-05
( O 0 5.1944753067800775e-06
PDS B-Disease 1 0.9846551418304443
) O 0 1.0128399026143597e-06
. O 0 1.6640470903439564e-06
. O 0 1.5766616343171336e-05

The O 0 2.0312601918703876e-05
APCI1307K O 1 0.6965731978416443
allele O 0 7.732773519819602e-05
and O 0 2.4230896542576374e-06
cancer B-Disease 0 1.894428896775935e-05
risk O 0 6.287763767431898e-07
in O 0 6.131163843292597e-08
a O 0 1.2260427695309772e-07
community O 0 6.049409506658776e-08
- O 0 8.002923834737885e-08
based O 0 1.5729144209331025e-08
study O 0 3.408291959772214e-08
of O 0 2.467813828843646e-07
Ashkenazi O 0 3.751389522221871e-05
Jews O 0 2.7664344088407233e-05
. O 0 2.9222617740742862e-05

Mutations O 0 2.5481464035692625e-05
in O 0 1.3993226275488269e-06
APC O 0 8.83606026036432e-06
are O 0 1.573095147477943e-07
classically O 0 2.1138592273928225e-05
associated O 0 7.572290314783459e-07
with O 0 4.742996225104434e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999711513519287
FAP B-Disease 1 0.9999773502349854
) O 0 1.3219998891145224e-06
, O 0 3.854763974686648e-07
a O 0 1.3803663705402869e-06
highly O 0 0.0019388941582292318
penetrant O 1 0.9999998807907104
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.980156660079956
by O 0 1.2711953786492813e-05
multiple O 1 0.7849262356758118
intestinal O 1 0.9999914169311523
polyps B-Disease 0 0.001129954238422215
and O 0 4.954979431204265e-07
, O 0 2.571571258158656e-07
without O 0 3.3513552466502006e-07
surgical O 0 6.192488217493519e-05
intervention O 0 5.927437996433582e-06
, O 0 1.5069156233948888e-07
the O 0 1.541921363923393e-07
development O 0 5.060842340753879e-06
of O 1 0.9952468276023865
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.2340746521949768
CRC B-Disease 1 0.99636310338974
) O 0 5.238017820374807e-06
. O 0 2.3690728994552046e-05

APC B-Disease 0 0.00031095778103917837
is O 0 1.7365821349812904e-06
a O 0 3.053215323234326e-06
tumour O 1 0.9999982118606567
- O 0 2.452943954267539e-05
suppressor O 0 1.1269360584265087e-05
gene O 0 1.7806081586968503e-07
, O 0 8.628304470903458e-08
and O 0 3.1111085263546556e-07
somatic O 0 0.002849103417247534
loss O 0 0.0010038017062470317
occurs O 0 2.9125685614417307e-05
in O 0 1.6971451259450987e-05
tumours B-Disease 1 1.0
. O 0 0.0015151787083595991

The O 0 2.7043575755669735e-05
germline O 0 0.001091770245693624
T O 0 0.00012996539589948952
- O 0 2.2522358449350577e-06
to O 0 8.416702712565893e-08
- O 0 1.4740378446731484e-06
A O 0 1.4082507959756185e-06
transversion O 0 4.2851468606386334e-05
responsible O 0 5.992541787236405e-07
for O 0 6.008541220126062e-08
the O 0 2.7449365802567627e-07
APC O 0 3.5933167055191007e-06
I1307K O 0 7.710846148256678e-06
allele O 0 1.527625840935798e-06
converts O 0 1.0158606755794608e-06
the O 0 1.4893977606789122e-07
wild O 0 2.2022113910225016e-07
- O 0 1.2941950444655959e-07
type O 0 5.476727693576322e-08
sequence O 0 3.7983753031767264e-08
to O 0 1.9421639407823932e-08
a O 0 7.118802045624761e-07
homopolymer O 1 0.9003807306289673
tract O 0 0.0003321596886962652
( O 0 2.8476858915382763e-06
A8 O 0 0.0656995102763176
) O 0 6.832610210949497e-08
that O 0 1.8166049997603295e-08
is O 0 5.895181587334264e-08
genetically O 0 1.0405275361335953e-06
unstable O 0 2.9771294066449627e-05
and O 0 2.53650023296359e-06
prone O 0 7.003225618973374e-05
to O 0 9.712770179248764e-07
somatic O 0 0.0044497353956103325
mutation O 0 2.9141134291421622e-05
. O 0 1.924309071910102e-05

The O 0 2.5052235287148505e-05
I1307K O 0 0.00014112470671534538
allele O 0 3.056746209040284e-05
was O 0 3.960820322390646e-06
found O 0 2.777136955955939e-07
in O 0 4.631167200841446e-07
6 O 0 4.054165037814528e-05
. O 0 2.9100865504005924e-05

1 O 0 1.0446166015753988e-05
% O 0 4.5280907556843886e-07
of O 0 1.0320529781893129e-06
unselected O 0 9.746450814418495e-05
Ashkenazi O 0 1.1410128536226694e-05
Jews O 0 1.0050930541183334e-06
and O 0 1.1410126177224811e-07
higher O 0 3.82672169507714e-07
proportions O 0 7.833108952581824e-07
of O 0 6.987306164774054e-07
Ashkenazim O 0 0.003055406268686056
with O 0 2.0246727672201814e-07
family O 0 5.534050728783768e-08
or O 0 5.163214211734157e-08
personal O 0 1.81361770046351e-07
histories O 0 3.252193607750087e-07
of O 0 3.5135644793626852e-06
CRC B-Disease 1 0.5053050518035889
( O 0 1.4765676041861298e-06
ref O 0 2.6624215024639852e-05
. O 0 2.0665679301146156e-07
2 O 0 3.873155492328806e-06
) O 0 1.461341412323236e-06
. O 0 1.2876623259217013e-05

To O 0 1.6419976418546867e-06
evaluate O 0 4.323452685639495e-06
the O 0 3.485625654775504e-07
role O 0 7.254170100168267e-07
of O 0 1.2961828588231583e-06
I1307K O 0 3.6223154893377796e-05
in O 0 1.8456670147770637e-07
cancer B-Disease 0 1.9258432075730525e-06
, O 0 1.7866109658370988e-07
we O 0 2.365416804650522e-07
genotyped O 0 8.916161277738865e-06
5 O 0 1.4557815575244604e-06
, O 0 3.93169614198996e-07
081 O 0 3.229183130315505e-05
Ashkenazi O 0 6.156761628517415e-06
volunteers O 0 7.05882371221378e-07
in O 0 2.0681373769093625e-07
a O 0 6.268598440328788e-07
community O 0 1.6958869082372985e-06
survey O 0 8.54466634336859e-06
. O 0 4.233343861415051e-05

Risk O 0 5.0350969104329124e-05
of O 0 0.00012763972335960716
developing O 1 0.9999998807907104
colorectal B-Disease 1 1.0
, I-Disease 1 0.9968773126602173
breast I-Disease 1 0.9979650974273682
and I-Disease 0 4.438025825947989e-06
other I-Disease 0 6.512221943921759e-07
cancers I-Disease 0 0.09327409416437149
were O 0 5.703945475943328e-07
compared O 0 7.479839041479863e-07
between O 0 9.15515954602597e-07
genotyped O 0 2.165514524676837e-05
I1307K O 0 2.2955950953473803e-06
carriers O 0 4.240806106281525e-08
and O 0 3.87818523961414e-08
non O 0 3.2367907465413737e-07
- O 0 6.880711111989513e-08
carriers O 0 1.2307152630341989e-08
and O 0 5.35819033586904e-09
their O 0 9.331909467391597e-09
first O 0 1.2860648723744816e-07
- O 0 2.8526170581244514e-07
degree O 0 1.7527728459754144e-06
relatives O 0 1.7106605127992225e-06
. O 0 5.4840520533616655e-06

Sperm O 0 1.995482853089925e-05
DNA O 0 5.848808541486505e-06
analysis O 0 1.7520192159281578e-06
in O 0 7.304068390112661e-07
a O 0 1.0465310879226308e-05
Friedreich B-Disease 1 0.999915361404419
ataxia I-Disease 1 0.9999998807907104
premutation O 1 0.9994292855262756
carrier O 0 1.838317075453233e-05
suggests O 0 3.1249437597580254e-06
both O 0 8.167242526724294e-07
meiotic O 0 2.691405825316906e-05
and O 0 4.692582535881229e-07
mitotic O 0 3.6090218600293156e-06
expansion O 0 1.1524158480824553e-06
in O 0 1.2024207762806327e-07
the O 0 4.6477640580633306e-07
FRDA B-Disease 0 0.0004430824192240834
gene O 0 5.5327122936432716e-06
. O 0 9.701470844447613e-06

Friedreich B-Disease 1 0.9999994039535522
ataxia I-Disease 1 1.0
is O 0 1.321350737271132e-05
usually O 0 9.684900987849687e-07
caused O 0 7.258446999003354e-07
by O 0 1.897173795839535e-08
an O 0 4.923351504260154e-09
expansion O 0 1.1215202988523743e-07
of O 0 2.0808543865769025e-07
a O 0 5.995165111016831e-07
GAA O 0 4.725235339719802e-05
trinucleotide O 0 1.4235443813959137e-05
repeat O 0 6.905704594828421e-07
in O 0 7.079278674382294e-08
intron O 0 6.72034502713359e-07
1 O 0 3.218638937596552e-07
of O 0 2.85481064565829e-07
the O 0 8.794470431894297e-07
FRDA B-Disease 0 0.0013727268669754267
gene O 0 1.550978049635887e-05
. O 0 2.487226447556168e-05

Occasionally O 0 2.8772512450814247e-05
, O 0 1.2902629578093183e-06
a O 0 1.2022204600725672e-06
fully O 0 1.4553040728060296e-06
expanded O 0 5.623654146802437e-07
allele O 0 9.132904779107776e-07
has O 0 1.7538562602226193e-08
been O 0 8.836116727195531e-09
found O 0 3.5721028357471596e-09
to O 0 7.850240457685231e-09
arise O 0 7.709486027351886e-08
from O 0 1.227545709525657e-08
a O 0 4.5486185484833186e-08
premutation O 0 1.7895315522764577e-06
of O 0 1.8297954795798432e-07
100 O 0 4.876522439190012e-07
or O 0 1.6277971326417173e-07
less O 0 1.5432027566930628e-06
triplet O 0 0.00010980837396346033
repeats O 0 3.4927161323139444e-05
. O 0 1.4125864254310727e-05

We O 0 3.0674959816678893e-06
have O 0 2.1899803925862216e-07
examined O 0 9.472016131439887e-07
the O 0 6.290439102940582e-08
sperm O 0 7.813481062157734e-08
DNA O 0 1.894877925678884e-07
of O 0 2.616325787130336e-07
a O 0 1.68634733199724e-06
premutation O 0 0.00039932539220899343
carrier O 0 5.1526512834243476e-05
. O 0 6.043178655090742e-05

This O 0 5.4395691222453024e-06
mans O 0 0.0001927825651364401
leucocyte O 0 5.894685455132276e-05
DNA O 0 2.3511988729296718e-06
showed O 0 3.615563173298142e-07
one O 0 4.442097534251843e-08
normal O 0 2.2758949569379183e-07
allele O 0 5.669037363986718e-07
and O 0 6.554859055540874e-08
one O 0 4.735700898095274e-08
allele O 0 5.272672183309624e-07
of O 0 2.9051594196971564e-07
approximately O 0 6.665852652076865e-07
100 O 0 1.4754808717043488e-06
repeats O 0 1.5385607184725814e-05
. O 0 9.140701877186075e-06

His O 0 9.291254173149355e-06
sperm O 0 2.0864131329290103e-06
showed O 0 5.354448830985348e-07
an O 0 6.876761915464158e-08
expanded O 0 2.559943652613583e-07
allele O 0 6.058878625481157e-07
in O 0 2.61488839470303e-08
a O 0 9.437593462280347e-08
tight O 0 1.1535913699844969e-06
range O 0 3.019671339643537e-06
centering O 0 1.988128133234568e-06
on O 0 9.596640637710152e-08
a O 0 2.9748639107651798e-08
size O 0 3.444799645535568e-08
of O 0 1.0222373703072662e-07
approximately O 0 1.2248266330061597e-06
320 O 0 8.419715413765516e-06
trinucleotide O 0 0.00017032604955602437
repeats O 0 4.010742486570962e-05
. O 0 2.484121432644315e-05

His O 0 4.011912824353203e-05
affected O 0 1.3670060070580803e-05
son O 0 4.817489752895199e-05
has O 0 4.5710839913226664e-07
repeat O 0 2.5740396267792676e-06
sizes O 0 2.1201044546614867e-06
of O 0 2.2181704935064772e-06
1040 O 0 0.0001835670555010438
and O 0 2.7899022825295106e-06
540 O 0 5.565697210840881e-05
. O 0 1.2514828995335847e-05

These O 0 3.01081229281408e-07
data O 0 2.1783782244710892e-07
suggest O 0 3.8914414801638486e-08
that O 0 5.924655432920645e-09
expansion O 0 1.3936143261616962e-07
occurs O 0 2.667490051067034e-08
in O 0 4.895960525885812e-09
two O 0 8.482161639733476e-09
stages O 0 1.0204237099742386e-07
, O 0 4.168738243492953e-09
the O 0 9.559332880826332e-09
first O 0 1.7634967264257284e-08
during O 0 4.610785353520441e-08
meiosis O 0 5.01922386320075e-07
followed O 0 6.03378325081394e-08
by O 0 1.590902876102973e-08
a O 0 9.463622063776711e-08
second O 0 1.2776289395333151e-06
mitotic O 0 1.7266938812099397e-05
expansion O 0 3.5990564356325194e-05
. O 0 3.03477263514651e-05

We O 0 1.8170401290262816e-06
also O 0 1.5673566622353974e-07
show O 0 8.919055716205548e-08
that O 0 8.503674209237033e-09
in O 0 1.804993132736854e-08
all O 0 3.995168640358315e-08
informative O 0 4.23423529127831e-07
carrier O 0 2.408856971669593e-07
father O 0 3.852191525766102e-07
to O 0 6.462818902264189e-08
affected O 0 2.949935833385098e-07
child O 0 5.360687396205321e-07
transmissions O 0 3.3223343507415848e-06
, O 0 3.5667802933403436e-08
with O 0 1.1681306588684492e-08
the O 0 4.149423915578154e-08
notable O 0 7.301687077188035e-08
exception O 0 3.576413121209043e-08
of O 0 3.643614121529026e-08
the O 0 8.943585783072194e-08
premutation O 0 3.150603333779145e-06
carrier O 0 3.011725482338079e-07
, O 0 6.107283923029172e-08
the O 0 8.34076061551059e-08
expansion O 0 7.071592449392483e-07
size O 0 4.997086193725409e-07
decreases O 0 9.890028422887553e-07
. O 0 8.579161203670083e-07
. O 0 9.15467808226822e-06

The O 0 9.184664122585673e-06
R496H O 0 3.192750955349766e-05
mutation O 0 2.297189439559588e-06
of O 0 1.2946582046424737e-06
arylsulfatase O 0 0.00014117734099272639
A O 0 4.105467724002665e-06
does O 0 2.840124864178506e-07
not O 0 1.0235460194962798e-06
cause O 0 0.02065981924533844
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 0.0003697363717947155

Deficiency B-Disease 1 0.9982776641845703
of I-Disease 0 7.381955947494134e-05
arylsulfatase I-Disease 1 0.998997151851654
A I-Disease 0 0.010895464569330215
( O 0 1.0642855158948805e-05
ARSA O 0 0.09429622441530228
) O 0 7.959384333844355e-07
enzyme O 0 1.7714377236188739e-06
activity O 0 1.8171614328821306e-06
causes O 0 7.502501830458641e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0005641636671498418
MLD B-Disease 1 1.0
) O 0 2.0984416551073082e-05
. O 0 5.065452205599286e-05

A O 0 8.000426532817073e-06
number O 0 8.366714610019699e-07
of O 0 1.8988988585988409e-06
ARSA O 0 0.0006485171616077423
gene O 0 1.0378001888966537e-06
mutations O 0 1.209930360346334e-06
responsible O 0 1.994284502870869e-06
for O 0 2.7020889774576062e-06
MLD B-Disease 1 1.0
have O 0 1.0735574278442073e-06
been O 0 1.2371802995403414e-06
identified O 0 5.804465672554215e-06
. O 0 1.2323934242886025e-05

Recently O 0 1.0833127817022614e-05
, O 0 6.062982720322907e-07
the O 0 3.3373629548805184e-07
R496H O 0 7.0214532570389565e-06
mutation O 0 4.833089519706846e-07
of O 0 8.451650046481518e-07
ARSA O 0 0.23365691304206848
was O 0 1.5459986570931505e-06
proposed O 0 1.2368035129384225e-07
to O 0 1.3097348094959216e-08
be O 0 2.3715871932949995e-08
a O 0 5.892932719575583e-08
cause O 0 3.2468386734763044e-07
of O 0 7.677373105252627e-06
MLD B-Disease 1 1.0
( O 0 3.7940528727631317e-06
Draghia O 0 6.98273433954455e-05
et O 0 9.114171916735359e-06
al O 0 4.019492735096719e-06
. O 0 8.244389704259447e-08
, O 0 1.8266902657160244e-07
1997 O 0 1.6286880963889416e-06
) O 0 3.009052306879312e-06
. O 0 2.6427987904753536e-05

We O 0 5.292528840072919e-06
have O 0 4.2093091678907513e-07
investigated O 0 2.7737487471313216e-06
the O 0 2.7113432565784024e-07
R496H O 0 5.841672646056395e-06
mutation O 0 3.007807549693098e-07
and O 0 3.632567313616164e-08
found O 0 2.101193885550856e-08
this O 0 1.1161230162315405e-08
mutation O 0 8.621231017968967e-08
at O 0 1.0904889080620705e-07
a O 0 2.094124162965727e-08
relatively O 0 1.9482783386592928e-08
high O 0 1.1725095561132548e-07
frequency O 0 1.9659054828480294e-07
in O 0 1.95870275554455e-09
an O 0 1.689647755043211e-09
African O 0 1.7472917335226157e-08
American O 0 4.7188914997775555e-09
population O 0 6.274735731004455e-10
( O 0 4.567273226285806e-09
f O 0 1.5091504224074015e-07
= O 0 1.1169902336405357e-07
0 O 0 7.697643411574973e-08
. O 0 1.0868836497479606e-08
09 O 0 4.4771169882551476e-07
, O 0 5.100083555475976e-08
n O 0 6.473588882727199e-07
= O 0 1.7889207128973794e-06
61 O 0 1.444314762011345e-06
subjects O 0 3.945223852497293e-06
) O 0 1.4234097989174188e-06
. O 0 1.4123802429821808e-05

The O 0 4.681467908085324e-05
ARSA O 0 0.002174016321077943
enzyme O 0 2.4307205421791878e-06
activity O 0 3.7085118265167694e-07
in O 0 2.2846167624379632e-08
subjects O 0 1.342728239706048e-07
with O 0 1.3029427314847908e-08
and O 0 2.4517515129218737e-08
without O 0 6.69728663638125e-08
the O 0 4.412340359749578e-08
R496H O 0 1.0766558489194722e-06
mutation O 0 5.467689234706086e-08
was O 0 5.2496872626761615e-08
determined O 0 7.225695952683964e-08
and O 0 3.003530579803737e-08
found O 0 2.4630002926073757e-08
to O 0 3.0161139363826805e-08
be O 0 2.1356517265758157e-07
normal O 0 3.005507551279152e-06
. O 0 7.537616056652041e-06

It O 0 1.138468519457092e-06
is O 0 1.2077761368800566e-07
therefore O 0 2.9727775086030306e-07
concluded O 0 4.866821541327226e-07
that O 0 1.8257335199223235e-08
the O 0 1.3314141256159928e-07
R496H O 0 4.6684126573381945e-06
mutation O 0 3.896157920735277e-07
of O 0 4.824211146114976e-07
ARSA O 0 0.0001757985446602106
does O 0 5.3608712136110626e-08
not O 0 2.4597468950560142e-08
negatively O 0 4.162082589687088e-08
influence O 0 4.463687375277914e-08
the O 0 2.9374476184784726e-08
activity O 0 9.753066620987738e-08
of O 0 2.4277079546664027e-07
ARSA O 0 0.0827198475599289
and O 0 1.2589957520958706e-07
is O 0 3.4868019582745546e-08
not O 0 4.784957496895004e-08
a O 0 5.159316742719966e-07
cause O 0 2.6115145374205895e-05
of O 0 0.0026716915890574455
MLD B-Disease 1 1.0

Down O 0 7.176329381763935e-05
- O 0 1.662869908614084e-05
regulation O 0 3.633167580119334e-06
of O 0 2.3955769847816555e-06
transmembrane O 0 0.00013638507516589016
carbonic O 1 0.8967260122299194
anhydrases O 0 0.002270745113492012
in O 0 4.09431277148542e-06
renal B-Disease 1 1.0
cell I-Disease 1 0.9999997615814209
carcinoma I-Disease 1 1.0
cell O 0 0.00013457750901579857
lines O 0 5.180704647500534e-07
by O 0 7.379124156159378e-08
wild O 0 5.478409548231866e-07
- O 0 3.723317831827444e-06
type O 0 3.305683276266791e-05
von B-Disease 1 0.9994736313819885
Hippel I-Disease 1 0.9999980926513672
- I-Disease 1 0.9997898936271667
Lindau I-Disease 1 0.9992308616638184
transgenes O 0 0.003183123655617237
. O 0 0.0001411202538292855

To O 0 3.924206794181373e-06
discover O 0 3.5060934351349715e-06
genes O 0 7.849283747418667e-07
involved O 0 9.542172847432084e-07
in O 0 4.7442580353163066e-07
von B-Disease 0 0.4550948441028595
Hippel I-Disease 1 0.9999984502792358
- I-Disease 1 0.9999964237213135
Lindau I-Disease 1 0.9999996423721313
( O 0 5.637092181132175e-05
VHL B-Disease 1 0.9999939203262329
) O 0 4.48210766990087e-06
- O 0 9.712484461488202e-05
mediated O 0 0.0009327901643700898
carcinogenesis O 1 0.5158336758613586
, O 0 3.176796212756017e-07
we O 0 4.932311412630952e-07
used O 0 5.156117367732804e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 0 0.17414513230323792
lines O 0 2.3894415789982304e-05
stably O 0 8.934941433835775e-05
transfected O 0 8.28261545393616e-06
with O 0 1.5836710076655436e-07
wild O 0 2.0045199562446214e-06
- O 0 1.1492526027723216e-05
type O 0 0.00046940211905166507
VHL O 1 0.9999995231628418
- O 0 0.10532400012016296
expressing O 0 1.530592271592468e-05
transgenes O 0 0.0004177141236141324
. O 0 3.1680021493230015e-05

Large O 0 2.1599540559691377e-05
- O 0 1.7718835806590505e-05
scale O 0 9.030627552419901e-06
RNA O 0 1.604751901140844e-06
differential O 0 2.0402364953042706e-06
display O 0 2.7236845312472724e-07
technology O 0 3.3490931627966347e-07
applied O 0 6.449298695088146e-08
to O 0 4.412043619339556e-09
these O 0 8.603748824498325e-09
cell O 0 1.8953008407152083e-07
lines O 0 3.528926129092724e-08
identified O 0 4.096734684821968e-08
several O 0 1.9984559784802514e-08
differentially O 0 3.171416835812124e-07
expressed O 0 2.8941249397007596e-08
genes O 0 3.470003662187082e-08
, O 0 1.793749859757554e-08
including O 0 2.5498655631395195e-08
an O 0 6.628610549341829e-08
alpha O 0 6.356324320222484e-06
carbonic O 0 0.00022300305136013776
anhydrase O 0 0.00020817962649744004
gene O 0 8.71865324825194e-07
, O 0 7.823060741429799e-07
termed O 0 2.7846450393553823e-05
CA12 O 0 0.010949209332466125
. O 0 5.5757485824869946e-05

The O 0 9.345819307782222e-06
deduced O 0 8.22767924546497e-06
protein O 0 3.7392950957837456e-07
sequence O 0 1.5215918836020137e-07
was O 0 2.722842964431038e-07
classified O 0 8.812859420004315e-08
as O 0 3.4889971800566855e-08
a O 0 5.6077816168453865e-08
one O 0 6.318336431831995e-08
- O 0 1.238889922205999e-06
pass O 0 8.310697694469127e-07
transmembrane O 0 0.004151472356170416
CA O 0 0.0002142216544598341
possessing O 0 0.0001029443446896039
an O 0 3.925615317257325e-07
apparently O 0 1.704628516563389e-06
intact O 0 3.274697064625798e-06
catalytic O 0 1.723196419334272e-06
domain O 0 3.064105271732842e-07
in O 0 7.646354305279601e-08
the O 0 4.527007035903807e-07
extracellular O 0 8.710302608960774e-06
CA O 0 3.031235064554494e-05
module O 0 0.0002369845606153831
. O 0 5.001668614568189e-05

Reintroduced O 0 0.00011339581396896392
wild O 0 9.91436536423862e-06
- O 0 1.2946315109729767e-05
type O 0 1.617076304682996e-05
VHL B-Disease 1 0.6503189206123352
strongly O 0 1.5603917518092203e-06
inhibited O 0 1.2113411003156216e-06
the O 0 6.061478785568397e-08
overexpression O 0 3.14077965413162e-07
of O 0 1.0887203671927637e-07
the O 0 1.4297617667580198e-07
CA12 O 0 5.197644350118935e-05
gene O 0 1.1040989988941874e-07
in O 0 3.67651544763703e-08
the O 0 3.5463119729683967e-07
parental O 0 3.0181916372384876e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.999849796295166
lines O 0 0.00025896262377500534
. O 0 7.606627332279459e-05

Similar O 0 2.933405312433024e-06
results O 0 3.205676421202952e-06
were O 0 4.938779056828935e-07
obtained O 0 6.757381356692349e-07
with O 0 3.600636375722388e-07
CA9 O 0 0.4995395839214325
, O 0 5.383576535678003e-07
encoding O 0 2.9749260193057125e-06
another O 0 4.6919157625779917e-07
transmembrane O 0 1.036613048199797e-05
CA O 0 2.255406343465438e-06
with O 0 9.229457020865084e-08
an O 0 1.360022139351713e-07
intact O 0 4.268659722583834e-06
catalytic O 0 9.65459275903413e-06
domain O 0 5.9157650866836775e-06
. O 0 9.282964128942695e-06

Although O 0 2.0318038878031075e-06
both O 0 2.7816722081297485e-07
domains O 0 5.919835075474111e-07
of O 0 3.000699280164554e-07
the O 0 3.733094899871503e-07
VHL B-Disease 0 0.0001409271644661203
protein O 0 2.249532400355747e-07
contribute O 0 3.150591965095373e-08
to O 0 9.449134807937298e-09
regulation O 0 8.275252127987187e-08
of O 0 1.0089491553344487e-07
CA12 O 0 0.00012351959594525397
expression O 0 1.7497438875579974e-07
, O 0 4.861375302311899e-08
the O 0 9.669289369185208e-08
elongin O 0 3.399843080842402e-06
binding O 0 2.1089114454753144e-07
domain O 0 1.51016692484518e-07
alone O 0 6.62004353557677e-08
could O 0 1.846203900868204e-07
effectively O 0 4.0645509216119535e-06
regulate O 0 5.008932475902839e-06
CA9 O 0 0.0054047591984272
expression O 0 3.49532492691651e-05
. O 0 3.240164733142592e-05

We O 0 3.82857360818889e-05
mapped O 0 5.091439379611984e-05
CA12 O 0 0.0014769749250262976
and O 0 9.877267984848004e-06
CA9 O 1 0.6809603571891785
loci O 0 1.2513349247456063e-05
to O 0 5.361188755159674e-07
chromosome O 0 4.369983798824251e-06
bands O 0 1.1101411473646294e-05
15q22 O 0 7.702893344685435e-05
and O 0 6.798492904636078e-06
17q21 O 0 0.0002898744132835418
. O 0 4.387280569062568e-05

2 O 0 3.208962516509928e-05
respectively O 0 8.52141783980187e-06
, O 0 5.497816459865135e-07
regions O 0 5.001487011213612e-07
prone O 0 1.7161002006105264e-06
to O 0 7.26024751429577e-08
amplification O 0 1.6623227566014975e-05
in O 0 2.1108571957029199e-07
some O 0 5.676638465956785e-07
human O 0 1.2032404811179731e-05
cancers B-Disease 0 0.12271355092525482
. O 0 2.0577530449372716e-05

Additional O 0 3.051480234717019e-06
experiments O 0 5.31866533037828e-07
are O 0 1.1883153128167123e-08
needed O 0 3.635117451494807e-08
to O 0 9.117648858136818e-09
define O 0 4.1141031914548876e-08
the O 0 2.0433247982509783e-08
role O 0 8.9699291550005e-08
of O 0 2.2874341709666624e-07
CA O 0 3.5344376101420494e-06
IX O 0 0.021278103813529015
and O 0 4.879216248809826e-07
CA O 0 1.3679397852683906e-05
XII O 0 0.2028813511133194
enzymes O 0 2.857433685221622e-07
in O 0 2.5209663689906847e-08
the O 0 3.257597569472637e-08
regulation O 0 9.341653139927075e-08
of O 0 6.028998456031331e-08
pH O 0 1.809750756365247e-06
in O 0 2.8787704664523517e-08
the O 0 6.813310449160781e-08
extracellular O 0 5.269811822472548e-07
microenvironment O 0 1.234488422596769e-06
and O 0 2.9623446806681386e-08
its O 0 2.188286707394127e-08
potential O 0 2.2546052491634327e-07
impact O 0 1.8472533156455029e-06
on O 0 2.0452646367630223e-06
cancer B-Disease 0 2.1294283214956522e-05
cell O 0 2.684774335648399e-05
growth O 0 6.194643901835661e-06
. O 0 1.9906283341697417e-05

A O 0 1.2416029676387552e-05
gene O 0 2.944675316030043e-06
encoding O 0 8.817683010420296e-06
a O 0 1.4305038575912477e-06
transmembrane O 0 1.1811567674158141e-05
protein O 0 1.0241709560432355e-06
is O 0 4.721739088608956e-08
mutated O 0 3.924319855741487e-07
in O 0 8.381682903291221e-08
patients O 0 7.856622801227786e-07
with O 0 0.00020887330174446106
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999996423721313
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 0.00019728865299839526
. O 0 7.63028219807893e-05

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9878016114234924
WFS B-Disease 1 0.9999998807907104
; O 0 8.314825390698388e-05
OMIM O 1 0.9999693632125854
222300 O 0 0.020357206463813782
) O 0 7.364275234067463e-07
is O 0 2.8134041940575116e-07
an O 0 8.123291763695306e-07
autosomal B-Disease 1 0.9999985694885254
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 5.9483281802386045e-06
by O 0 4.184976774013194e-07
young O 0 4.23394885729067e-05
- O 0 0.0024149396922439337
onset O 1 0.9999994039535522
non O 1 0.9999990463256836
- O 1 0.9999948740005493
immune O 1 0.9998724460601807
insulin B-Disease 1 0.9999864101409912
- I-Disease 1 0.998761773109436
dependent I-Disease 0 0.19550317525863647
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999667406082153
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.004636732861399651

Linkage O 0 5.321622666087933e-05
to O 0 7.043881851132028e-07
markers O 0 1.5627879292878788e-06
on O 0 1.4601781685996684e-06
chromosome O 0 3.975848812842742e-06
4p O 0 0.0007782139582559466
was O 0 4.530182650341885e-06
confirmed O 0 1.1026254469470587e-06
in O 0 2.359257393891312e-07
five O 0 1.1900457366209594e-06
families O 0 7.481216357518861e-07
. O 0 1.4853742868581321e-05

On O 0 2.6450313725945307e-06
the O 0 2.737533293384331e-07
basis O 0 4.2651134890547837e-07
of O 0 1.0535502497077687e-06
meiotic O 0 0.0031323290895670652
recombinants O 1 0.8983319997787476
and O 0 3.396069951122627e-05
disease O 1 0.6103883981704712
- O 0 9.259614307666197e-05
associated O 0 1.588655095474678e-06
haplotypes O 0 9.71232930169208e-06
, O 0 3.1345643947133794e-07
the O 0 1.081220375453995e-06
WFS B-Disease 1 0.9240289330482483
gene O 0 4.5584940266962803e-07
was O 0 3.238269812300132e-07
localized O 0 3.1938532174535794e-07
to O 0 4.954790355782279e-08
a O 0 1.0265295031786081e-06
BAC O 1 0.9940908551216125
/ O 0 0.0010384459747001529
P1 O 0 0.0010861787013709545
contig O 0 1.015070483845193e-05
of O 0 2.034278452356375e-07
less O 0 1.7817480113535566e-07
than O 0 4.225755674269749e-07
250 O 0 3.887016191583825e-06
kb O 0 0.00019614447955973446
. O 0 2.9607394026243128e-05

Mutations O 0 1.609089486009907e-05
in O 0 3.8380736100407375e-07
a O 0 3.805399160228262e-07
novel O 0 9.317041076428723e-07
gene O 0 9.059472745320818e-07
( O 0 1.226785911967454e-06
WFS1 O 0 0.008199174888432026
) O 0 4.0777334220365447e-07
encoding O 0 1.5250217302309466e-06
a O 0 2.473607878528128e-07
putative O 0 1.9818166947516147e-06
transmembrane O 0 2.5654157980170567e-06
protein O 0 9.611736118131375e-08
were O 0 2.8205439761563866e-08
found O 0 1.607643262957481e-08
in O 0 1.2339377519765549e-08
all O 0 2.637916729497647e-08
affected O 0 5.801461000487507e-08
individuals O 0 1.3760767636483706e-08
in O 0 6.689001708082287e-08
six O 0 6.2110052567732055e-06
WFS B-Disease 1 0.9996359348297119
families O 0 4.207683446111332e-08
, O 0 3.9606920410051316e-08
and O 0 2.1986874543244994e-08
these O 0 1.1870534777358444e-08
mutations O 0 1.3459013814554055e-07
were O 0 1.0439192976718914e-07
associated O 0 3.428871195865213e-07
with O 0 7.647053053005948e-07
the O 0 0.001087348093278706
disease O 1 0.9999932050704956
phenotype O 1 0.8953823447227478
. O 0 6.233683961909264e-05

WFS1 O 0 0.0021570913959294558
appears O 0 1.6640962030578521e-06
to O 0 1.2835994311899412e-07
function O 0 2.1367071667555138e-07
in O 0 2.9807139867443766e-08
survival O 0 7.658803156118665e-07
of O 0 2.9154290359656443e-07
islet O 0 2.111323283315869e-06
beta O 0 3.157753781124484e-06
- O 0 1.0315197869203985e-06
cells O 0 3.021169732164708e-07
and O 0 2.7189039997210784e-07
neurons O 0 6.8824565460090525e-06
. O 0 1.4221519677448669e-06
. O 0 1.3337858945305925e-05

Stable O 0 0.0001284925965592265
interaction O 0 4.105874722881708e-06
between O 0 5.11952237047808e-07
the O 0 1.0276348660909207e-07
products O 0 7.651226496818708e-08
of O 0 8.537286078080797e-08
the O 0 1.1864461413324534e-07
BRCA1 O 0 2.8140800623077666e-06
and O 0 2.752678085471416e-07
BRCA2 O 0 5.548462922888575e-06
tumor B-Disease 0 1.9348892692505615e-06
suppressor O 0 2.2369752059603343e-06
genes O 0 1.5638165962172934e-07
in O 0 1.6504300504038838e-07
mitotic O 0 6.965364264033269e-06
and O 0 3.5963028039986966e-06
meiotic O 0 0.0006759062525816262
cells O 0 0.00012025177420582622
. O 0 6.234926695469767e-05

BRCA1 O 0 0.0005415502237156034
and O 0 3.815453510469524e-06
BRCA2 O 0 2.1736044800491072e-05
account O 0 1.3857567182640196e-07
for O 0 4.383969454124781e-08
most O 0 2.1490745183427862e-08
cases O 0 1.1878166894518927e-08
of O 0 3.235583534433317e-08
familial O 0 6.169253765619942e-07
, O 0 1.5154053301102977e-07
early O 0 2.0905139535898343e-05
onset O 1 0.9999988079071045
breast B-Disease 1 0.999945878982544
and I-Disease 1 0.9965505599975586
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.106730441184482e-06
encode O 0 2.8543558983074035e-07
products O 0 7.129442280984222e-08
that O 0 1.049216713511214e-08
each O 0 1.6340223396582587e-08
interact O 0 7.354576325724338e-08
with O 0 1.956213964149356e-07
hRAD51 O 0 2.9866443583159707e-05
. O 0 7.364314569713315e-06

Results O 0 2.2924425138626248e-05
presented O 0 4.637908659788081e-06
here O 0 3.0466949851870595e-07
show O 0 1.23124749507042e-07
that O 0 5.39213793615545e-08
BRCA1 O 0 3.36010589307989e-06
and O 0 9.835447372097406e-07
BRCA2 O 0 5.2046925702597946e-05
coexist O 0 3.322043085063342e-06
in O 0 1.005936098863458e-07
a O 0 1.6253352441708557e-07
biochemical O 0 2.9397006073850207e-06
complex O 0 1.1043429367418867e-05
and O 0 4.6207517812035803e-07
colocalize O 0 5.7990095228888094e-05
in O 0 1.3554772237966972e-07
subnuclear O 0 1.3857721569365822e-05
foci O 0 7.223859938676469e-06
in O 0 7.824621661711717e-08
somatic O 0 2.3380891889246413e-06
cells O 0 1.1756346651736749e-07
and O 0 2.6699384036987794e-08
on O 0 7.459787099151072e-08
the O 0 4.0326515460265e-08
axial O 0 3.771916112782492e-07
elements O 0 6.276691806306189e-07
of O 0 1.4632854572482756e-06
developing O 0 2.440544449200388e-05
synaptonemal O 0 0.0002910851617343724
complexes O 0 1.6391126337111928e-05
. O 0 1.0924601156148128e-05

Like O 0 5.0626753363758326e-05
BRCA1 O 0 0.0003268680302426219
and O 0 1.9713870642590337e-05
RAD51 O 1 0.9905713796615601
, O 0 1.0286766155331861e-05
BRCA2 O 0 8.725577936274931e-05
relocates O 0 8.520329174643848e-06
to O 0 5.022000664212101e-07
PCNA O 0 0.00012038646673317999
+ O 0 1.5992443422874203e-06
replication O 0 1.8050280914394534e-07
sites O 0 4.129629971316717e-08
following O 0 8.961447406363732e-08
exposure O 0 2.0954712454113178e-07
of O 0 2.2465094673407293e-07
S O 0 1.3829389899910893e-05
phase O 0 4.397538577904925e-05
cells O 0 4.0823715607984923e-07
to O 0 1.0359455870911916e-07
hydroxyurea O 0 2.870807293220423e-05
or O 0 3.197374780938844e-06
UV O 0 0.29173368215560913
irradiation O 0 0.00012819947733078152
. O 0 1.690183489699848e-05

Thus O 0 2.5109349735430442e-05
, O 0 4.312013516027946e-06
BRCA1 O 0 1.1760515917558223e-05
and O 0 9.582408893038519e-07
BRCA2 O 0 1.1599685421970207e-05
participate O 0 7.995163286977913e-07
, O 0 1.16621990287058e-07
together O 0 6.706899569053348e-08
, O 0 4.573813683350636e-08
in O 0 2.2941360811046252e-08
a O 0 7.63245324719719e-08
pathway O 0 5.005389880352595e-07
( O 0 6.293270615742586e-08
s O 0 2.6163507982346346e-07
) O 0 1.810831129489543e-08
associated O 0 2.0114582000019254e-08
with O 0 9.47246725502282e-09
the O 0 2.626800643668048e-08
activation O 0 1.5752463866647304e-07
of O 0 1.738705464049417e-07
double O 0 8.5835563368164e-07
- O 0 3.193352313246578e-06
strand O 0 6.178179319249466e-07
break O 0 8.500400667799113e-07
repair O 0 4.438770702108741e-06
and O 0 9.23877166769671e-07
/ O 0 7.108513091225177e-05
or O 0 1.184410621135612e-06
homologous O 0 7.831324182916433e-06
recombination O 0 1.0112982636201195e-05
. O 0 8.617466846772004e-06

Dysfunction O 0 0.011572943069040775
of O 0 2.739191359069082e-06
this O 0 9.437557224600823e-08
pathway O 0 3.612075261116843e-07
may O 0 3.0247154114704244e-08
be O 0 1.9394764905200645e-08
a O 0 2.2445899361400734e-08
general O 0 7.857884298800855e-08
phenomenon O 0 1.2461805454222485e-07
in O 0 7.714424654636787e-09
the O 0 1.0184517229561152e-08
majority O 0 1.8984227523333175e-08
of O 0 8.97008334277416e-08
cases O 0 1.0615587342499566e-07
of O 0 2.0924808268318884e-06
hereditary B-Disease 1 0.9999997615814209
breast I-Disease 1 0.9999916553497314
and I-Disease 1 0.9999681711196899
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0001887596445158124
. O 0 9.896173287415877e-05

A O 0 3.848296182695776e-05
novel O 0 1.237794913322432e-05
Arg362Ser O 0 7.30503088561818e-05
mutation O 0 2.0122811292822007e-06
in O 0 1.5075967496613885e-07
the O 0 3.555916237019119e-07
sterol O 0 1.636128217796795e-05
27 O 0 1.0626526091073174e-05
- O 0 1.631650229683146e-05
hydroxylase O 0 3.16164550895337e-05
gene O 0 4.495381631386408e-07
( O 0 2.9968757075948815e-07
CYP27 O 0 0.0003458979190327227
) O 0 1.0123205385070833e-07
: O 0 4.08036626708963e-08
its O 0 1.2054548470530335e-08
effects O 0 1.1286877565908071e-07
on O 0 8.024674258422237e-08
pre O 0 1.0038045274995966e-06
- O 0 2.0377676435145986e-07
mRNA O 0 5.557909048548026e-07
splicing O 0 8.949999710239354e-07
and O 0 1.5175385215115966e-07
enzyme O 0 1.3616537444249843e-06
activity O 0 3.480139412204153e-06
. O 0 1.0192891750193667e-05

A O 0 1.7950706023839302e-05
novel O 0 4.739057658298407e-06
C O 0 1.2274575965420809e-05
to O 0 6.950514119807849e-08
A O 0 2.5471391040809976e-07
mutation O 0 1.12804642071751e-07
in O 0 2.048784430996875e-08
the O 0 6.979434630238757e-08
sterol O 0 1.578922137923655e-06
27 O 0 2.088525434373878e-06
- O 0 2.319177610843326e-06
hydroxylase O 0 6.127311280579306e-06
gene O 0 2.0458291771774384e-07
( O 0 2.0705371639451187e-07
CYP27 O 0 0.0006108691450208426
) O 0 1.2768039425736788e-07
was O 0 2.3243246971560438e-07
identified O 0 1.0802890670902343e-07
by O 0 5.0926956873809104e-08
sequencing O 0 9.487475267633272e-07
amplified O 0 2.298986373716616e-06
CYP27 O 0 0.00010570458834990859
gene O 0 1.9639509218905005e-07
products O 0 9.439141024358833e-08
from O 0 2.4367304618522212e-08
a O 0 8.985065846900397e-08
patient O 0 1.6982890826966468e-07
with O 0 6.872132871649228e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 4.985568375559524e-05
CTX B-Disease 1 0.9995437264442444
) O 0 4.286535840947181e-06
. O 0 1.3245162335806526e-05

The O 0 1.0281274626322556e-05
mutation O 0 8.490082109346986e-06
changed O 0 3.5834609661833383e-06
the O 0 2.4315736482094508e-06
adrenodoxin O 0 8.436022471869364e-05
cofactor O 0 2.3064987544785254e-05
binding O 0 1.4616368844144745e-06
residue O 0 3.0249975679907948e-06
362Arg O 0 7.946081495902035e-06
to O 0 2.9076292662466585e-07
362Ser O 0 2.4406841475865804e-05
( O 0 2.261591816932196e-06
CGT O 0 0.0002641650498844683
362Arg O 0 1.5170859114732593e-05
to O 0 3.677546942526533e-07
AGT O 0 0.002035252982750535
362Ser O 0 2.3250229787663557e-05
) O 0 1.7432680010642798e-07
, O 0 5.79783225873598e-08
and O 0 9.563805036805206e-08
was O 0 1.472878579988901e-06
responsible O 0 2.0047189082106343e-06
for O 0 6.600330948458577e-07
deficiency O 0 0.006231135223060846
in O 0 9.448868354411388e-08
the O 0 1.5205139902718656e-07
sterol O 0 1.5101480812518275e-06
27 O 0 1.4913648556102999e-06
- O 0 6.369841116793395e-07
hydroxylase O 0 1.3978582273921347e-06
activity O 0 4.256218844034265e-08
, O 0 9.08615671590951e-09
as O 0 6.00683147666814e-09
confirmed O 0 1.1075112382741281e-08
by O 0 2.274016530634526e-09
expression O 0 1.4843222650995358e-08
of O 0 6.078138881093764e-08
mutant O 0 3.3782427522055514e-07
cDNA O 0 4.251067196037184e-07
into O 0 2.9139056323401746e-07
COS O 0 2.8696631488855928e-05
- O 0 5.101152055431157e-06
1 O 0 7.69220514484914e-06
cells O 0 1.2687127309618518e-05
. O 0 1.0669662515283562e-05

Quantitative O 0 1.4529698091791943e-05
analysis O 0 1.1565402928681578e-06
showed O 0 4.27706424943608e-07
that O 0 1.660846926654358e-08
the O 0 4.792017449517516e-08
expression O 0 7.44447845590912e-08
of O 0 2.182268588057923e-07
CYP27 O 0 2.2566675397683866e-05
gene O 0 9.674712941887265e-08
mRNA O 0 1.7812570263231464e-07
in O 0 2.158448886291353e-08
the O 0 9.312104509717756e-08
patient O 0 3.157688297505956e-07
represented O 0 1.1410761544539127e-06
52 O 0 2.51343626587186e-05
. O 0 3.5247678169980645e-05

5 O 0 6.552711511176312e-06
% O 0 4.777333515448845e-07
of O 0 3.59951059181185e-07
the O 0 5.116296506457729e-07
normal O 0 3.549881967046531e-06
level O 0 3.9926460885908455e-05
. O 0 9.99924486677628e-06

As O 0 2.2405324671126436e-06
the O 0 3.243279707021429e-07
mutation O 0 5.550753030547639e-07
occurred O 0 1.5170551250776043e-06
at O 0 4.5994460151632666e-07
the O 0 8.428236952795487e-08
penultimate O 0 3.721241228049621e-06
nucleotide O 0 2.0609587636499782e-07
of O 0 1.2091327050711698e-07
exon O 0 9.35663877044135e-07
6 O 0 1.7221695998159703e-06
( O 0 1.5089173643900722e-07
- O 0 3.004332995715231e-07
2 O 0 2.452336502756225e-07
position O 0 5.465926733450033e-07
of O 0 2.818783571001404e-07
exon O 0 2.2706535673933104e-06
6 O 0 2.0100983419979457e-06
- O 0 6.339727178783505e-07
intron O 0 1.8543327087172656e-06
6 O 0 1.7151070323961903e-06
splice O 0 1.6116149481604225e-06
site O 0 2.0740786510486942e-07
) O 0 1.3992751846103602e-08
of O 0 3.038077522887761e-08
the O 0 3.626703204417936e-08
gene O 0 9.659409272444464e-08
, O 0 3.879894450165011e-08
we O 0 3.7776036521108836e-08
hypothesized O 0 2.689401981115225e-07
that O 0 8.098290926739082e-09
the O 0 4.1082216739596333e-08
mutation O 0 1.5146207488214714e-07
may O 0 1.2727034004456073e-07
partially O 0 6.890323334118875e-07
affect O 0 9.12649014139788e-08
the O 0 5.303005323753496e-08
normal O 0 8.670141227185013e-08
splicing O 0 1.4397322445347527e-07
efficiency O 0 1.2311242869600392e-07
in O 0 1.5439072242884322e-08
exon O 0 1.6826608373321505e-07
6 O 0 8.467811341006382e-08
and O 0 1.1069705152522147e-08
cause O 0 3.297663297985309e-08
alternative O 0 1.6767849331245088e-07
splicing O 0 2.0002566714083514e-07
elsewhere O 0 3.65127377222052e-08
, O 0 1.0171509856604644e-08
which O 0 6.161865240272846e-09
resulted O 0 1.2698048124093475e-07
in O 0 3.218497113266494e-08
decreased O 0 6.96251504450629e-07
transcript O 0 1.4004119748278754e-06
in O 0 6.187908496713135e-08
the O 0 6.220005843715626e-07
patient O 0 4.588608135236427e-06
. O 0 1.6913138097152114e-05

Transfection O 0 0.0005229615489952266
of O 0 1.0549644684942905e-05
constructed O 0 9.862654405878857e-05
minigenes O 0 0.00020843962556682527
, O 0 1.7269918828333175e-07
with O 0 3.446915997074029e-08
or O 0 6.300393096125845e-08
without O 0 6.56130154652601e-08
the O 0 2.490840600444244e-08
mutation O 0 5.707706307589433e-08
, O 0 1.4849875995537332e-08
into O 0 4.3381870540315504e-08
COS O 0 5.240881364443339e-06
- O 0 3.100064134287095e-07
1 O 0 1.317232403152957e-07
cells O 0 9.285692215144081e-09
confirmed O 0 1.3284330968588165e-08
that O 0 2.9264852763333238e-09
the O 0 3.352790045596521e-08
mutant O 0 1.0414606776976143e-06
minigene O 0 7.133561666705646e-06
was O 0 2.7489869580676896e-07
responsible O 0 6.695319854088666e-08
for O 0 1.0790859761300453e-08
a O 0 2.2520216802490722e-08
mRNA O 0 1.2324035481015017e-07
species O 0 1.339562238911185e-08
alternatively O 0 2.428986363156582e-07
spliced O 0 9.95660457192571e-07
at O 0 4.429838043051859e-07
an O 0 7.739526353134352e-08
activated O 0 6.9614334279322065e-06
cryptic O 0 4.588253432302736e-06
5 O 0 1.639894321669999e-06
splice O 0 2.0193094769638265e-06
site O 0 7.891074460530945e-07
88 O 0 2.2096278371463995e-06
bp O 0 3.21728680319211e-06
upstream O 0 2.3038977303713182e-07
from O 0 2.4600096182325615e-08
the O 0 4.8512053041349645e-08
3 O 0 3.959975174439023e-07
end O 0 7.725168984507036e-07
of O 0 9.128002602665219e-07
exon O 0 1.3614092495117802e-05
6 O 0 1.4910441677784547e-05
. O 0 9.2060699898866e-06

Our O 0 1.9856495327985613e-06
data O 0 4.411961924688512e-07
suggest O 0 7.360751652640829e-08
that O 0 1.3814677402024245e-08
the O 0 4.1135379547085904e-08
C O 0 1.2760434628944495e-06
to O 0 1.0856053833663282e-08
A O 0 1.1659975740485606e-07
mutation O 0 5.3251010712074276e-08
at O 0 1.524886528159186e-07
the O 0 5.530959157340476e-08
penultimate O 0 1.4030910051587853e-06
nucleotide O 0 5.669145863862468e-08
of O 0 2.654117281508661e-08
exon O 0 1.4182727170464204e-07
6 O 0 7.692769798950394e-08
of O 0 3.703506479268981e-08
the O 0 6.558924070532157e-08
CYP27 O 0 3.4244741982547566e-05
gene O 0 9.693073366179306e-08
not O 0 3.02803435658916e-08
only O 0 1.270429805799722e-07
causes O 0 1.0345974033043603e-06
the O 0 5.259800559542782e-07
deficiency B-Disease 0 4.553661710815504e-05
in I-Disease 0 3.6538025938170904e-08
the I-Disease 0 7.661975587325287e-08
sterol I-Disease 0 9.767397841642378e-07
27 I-Disease 0 9.873997441900428e-07
- I-Disease 0 6.591216106244246e-07
hydroxylase I-Disease 0 1.0850029639186687e-06
activity I-Disease 0 8.791587902123865e-08
, O 0 1.9756857483343992e-08
but O 0 1.8364554321692594e-08
also O 0 3.067435017101161e-08
partially O 0 9.92956330492234e-08
leads O 0 1.3550682353979937e-08
to O 0 3.6160159311293683e-09
alternative O 0 7.687313541282492e-08
pre O 0 6.395997615982196e-07
- O 0 9.735725114978777e-08
mRNA O 0 1.3050112102064304e-07
splicing O 0 1.963063311904989e-07
of O 0 7.659870959741966e-08
the O 0 2.190224819287323e-07
gene O 0 3.011710759892594e-06
. O 0 8.593978236604016e-06

To O 0 2.7729262797038245e-07
our O 0 2.3202053966997482e-07
knowledge O 0 5.050636104897421e-07
, O 0 2.9027047432350628e-08
this O 0 9.21265819187056e-09
is O 0 6.447451017521644e-09
the O 0 1.3467559512037042e-08
first O 0 3.8181397599146294e-08
report O 0 1.4724059305137871e-08
regarding O 0 6.5301257734518e-08
effects O 0 1.6821651627196843e-07
on O 0 1.1208572914256365e-07
pre O 0 5.836561172145593e-07
- O 0 1.0150389329055542e-07
mRNA O 0 8.004572293884848e-08
splicing O 0 4.6254161389924775e-08
of O 0 1.0197463318206701e-08
a O 0 1.4885295662736553e-08
mutation O 0 3.912338897293921e-08
at O 0 1.351041447605894e-07
the O 0 4.1884902657329803e-08
- O 0 1.7077529435027827e-07
2 O 0 1.1657650844654199e-07
position O 0 2.166194832398105e-07
of O 0 1.0685793938591814e-07
a O 0 2.3868673793003836e-07
5 O 0 2.6704688025347423e-06
splice O 0 1.2963921108166687e-05
site O 0 4.670220278057968e-06
. O 0 1.449379760742886e-05

ATM O 0 0.0006488247308880091
germline O 0 0.000330964830936864
mutations O 0 6.281006790231913e-06
in O 0 7.018321070972888e-07
classical O 1 0.9514645338058472
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0020471280440688133
in O 0 3.8260574797277513e-07
the O 0 8.135936582220893e-07
Dutch O 0 0.23971031606197357
population O 0 5.634508966068097e-07
. O 0 5.678615707438439e-06

Germline O 0 0.0004886016831733286
mutations O 0 2.8564822969201487e-06
in O 0 1.1129050392355566e-07
the O 0 1.9084725977336348e-07
ATM O 0 4.429041382536525e-06
gene O 0 6.932085483413175e-08
are O 0 1.0061142141637447e-08
responsible O 0 1.304513403965757e-07
for O 0 1.353490546307512e-07
the O 0 0.0019246091833338141
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.2804280635900795e-05
. O 0 2.7222738935961388e-05

In O 0 2.136891680493136e-06
our O 0 4.89134322378959e-07
study O 0 1.1554076451147921e-07
, O 0 4.486614102461317e-08
we O 0 3.291630790158706e-08
have O 0 1.1984374381768248e-08
determined O 0 1.0616518864026148e-07
the O 0 7.437240157059932e-08
ATM O 0 3.6876160720566986e-06
mutation O 0 1.648514000862633e-07
spectrum O 0 5.01574049849296e-07
in O 0 2.681615463018261e-08
19 O 0 5.61294939416257e-07
classical O 0 1.3440787370200269e-05
A B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999191761016846
T I-Disease 1 1.0
patients O 0 9.989039995161875e-08
, O 0 1.6952849790641267e-08
including O 0 6.935970908727995e-09
some O 0 3.866712727784716e-09
immigrant O 0 1.3838993950798795e-08
populations O 0 6.06195094121631e-09
, O 0 4.5953920668750925e-09
as O 0 6.550382458669901e-09
well O 0 6.750197734106678e-09
as O 0 1.2942883209632328e-08
12 O 0 7.140764779478559e-08
of O 0 9.338197060060338e-08
Dutch O 0 9.69814027484972e-06
ethnic O 0 3.8404169799832744e-07
origin O 0 2.421765884719207e-06
. O 0 2.2442007320933044e-05

Both O 0 4.180838459433289e-06
the O 0 8.005349059203581e-07
protein O 0 9.41565417633683e-07
truncation O 0 1.05512835943955e-05
test O 0 2.725510967138689e-06
( O 0 7.748978987365263e-07
PTT O 0 2.1165236830711365e-05
) O 0 7.111921718205849e-08
and O 0 3.147144411741465e-08
the O 0 5.590117879705758e-08
restriction O 0 1.645391591864609e-07
endonuclease O 0 3.9431815821444616e-06
fingerprinting O 0 3.834341896435944e-06
( O 0 4.929536885356356e-07
REF O 0 5.700567999156192e-05
) O 0 6.152460940711535e-08
method O 0 1.5327158564559795e-07
were O 0 5.5866753001510006e-08
used O 0 1.600896126774387e-08
and O 0 1.8470151630367582e-08
compared O 0 2.6125103858021248e-08
for O 0 3.7679157571801625e-09
their O 0 2.71900568726835e-09
detection O 0 1.3311817781413993e-07
efficiency O 0 1.2681503847034037e-07
, O 0 1.4293986438929096e-08
identifying O 0 7.939523527511483e-08
76 O 0 9.214014085046074e-08
% O 0 5.412795545112203e-09
and O 0 9.7027239576164e-09
60 O 0 3.507118506718143e-08
% O 0 5.277352777000033e-09
of O 0 3.0039199572229336e-08
the O 0 7.844137428492104e-08
mutations O 0 5.159463967174815e-07
, O 0 5.529607847165607e-07
respectively O 0 1.4630476471211296e-05
. O 0 1.8259659555042163e-05

Most O 0 3.659372623587842e-06
patients O 0 6.796923344154493e-07
were O 0 1.9836799936001626e-07
found O 0 6.75045797038365e-08
to O 0 4.8587430967472756e-08
be O 0 6.628565643040929e-07
compound O 0 2.7841218980029225e-05
heterozygote O 0 0.0005795444012619555
. O 0 8.894630445865914e-05

Seventeen O 0 2.1632831703755073e-05
mutations O 0 1.0553321772022173e-06
were O 0 1.4863654484997824e-07
distinct O 0 9.135372636137618e-08
, O 0 3.349951782638527e-08
of O 0 5.021148297146283e-08
which O 0 2.2565105339822367e-08
10 O 0 7.399899715210267e-08
were O 0 7.198678986242157e-08
not O 0 8.508302329346407e-08
reported O 0 1.2694767974608112e-06
previously O 0 4.023097517347196e-06
. O 0 2.294878868269734e-05

Mutations O 0 2.0339077309472486e-05
are O 0 3.718076584391383e-07
small O 0 5.682645110027806e-07
deletions O 0 3.4312824936932884e-06
or O 0 7.586037895634945e-07
point O 0 3.4982112993020564e-06
mutations O 0 3.444383992246003e-06
frequently O 0 7.682269824726973e-07
affecting O 0 4.795533186552348e-06
splice O 0 2.1254054445307702e-05
sites O 0 5.954321295575937e-06
. O 0 2.68608819169458e-05

Moreover O 0 5.5383454309776425e-05
, O 0 5.877436706214212e-06
a O 0 4.937375251756748e-06
16 O 0 5.7155917602358386e-05
. O 0 3.222999657737091e-05

7 O 0 0.00025060499319806695
- O 0 6.108453817432746e-05
kb O 0 0.00010652887431206182
genomic O 0 1.3054645933152642e-06
deletion O 0 1.0508769037187449e-06
of O 0 1.9447371357728116e-07
the O 0 9.590584681973269e-08
3 O 0 3.37571748332266e-07
end O 0 1.327286298646868e-07
of O 0 2.2467874671860955e-08
the O 0 1.6858498597116522e-08
gene O 0 1.97385894296076e-08
, O 0 9.337749240501125e-09
most O 0 6.441354560848822e-09
likely O 0 2.9445157423424462e-08
a O 0 1.2169294016928234e-08
result O 0 3.1018174695418566e-08
of O 0 4.488951077519232e-08
recombination O 0 7.047940897564331e-08
between O 0 2.721943914707481e-08
two O 0 3.444339569114163e-08
LINE O 0 2.0404991118994076e-06
elements O 0 1.620838474991615e-06
, O 0 4.1096097902482143e-07
was O 0 2.611637000882183e-06
identified O 0 5.315082489687484e-06
. O 0 1.0206753358943388e-05

The O 0 2.5122792521869997e-06
most O 0 1.5903378880466335e-07
frequently O 0 6.735962898574144e-08
found O 0 2.7349592812697665e-08
mutation O 0 1.77096538322985e-07
, O 0 5.0500773340900196e-08
identified O 0 1.6908244049318455e-07
in O 0 4.66942680077409e-08
three O 0 1.9732159728391707e-07
unrelated O 0 1.5045102372823749e-06
Turkish O 0 3.0079909265623428e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999942779541016
T I-Disease 1 1.0
individuals O 0 1.2303215157771774e-07
, O 0 1.2428704110334365e-07
was O 0 3.233279812775436e-07
previously O 0 3.885774546574794e-08
described O 0 1.503203073127679e-08
to O 0 3.491605449212898e-09
be O 0 2.090181716596362e-08
a O 0 8.97487453244139e-08
Turkish O 0 1.042702751874458e-05
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999045133590698
T I-Disease 1 1.0
founder O 0 0.09672395139932632
mutation O 0 3.563585414667614e-05
. O 0 1.3413231499725953e-05

The O 0 2.3410989342664834e-06
presence O 0 1.236678940585989e-06
of O 0 7.37964398922486e-07
a O 0 6.214094128154102e-07
founder O 0 4.589461696014041e-06
mutation O 0 3.1470850103687553e-07
among O 0 3.28986047293256e-08
relatively O 0 3.356372957341591e-08
small O 0 8.761285030800536e-09
ethnic O 0 1.2337377341964384e-08
population O 0 2.4677249133020496e-09
groups O 0 3.3534726107120605e-09
in O 0 6.396788432283529e-09
Western O 0 1.078434124224259e-07
Europe O 0 1.8427103043450188e-07
could O 0 2.4162186917919826e-08
indicate O 0 3.448606022971035e-08
a O 0 4.6036497280965705e-08
high O 0 2.4506582008143596e-07
carrier O 0 1.8558812087121623e-07
frequency O 0 9.461579111302854e-07
in O 0 2.543235488872142e-08
such O 0 5.64161801719365e-08
communities O 0 7.893663678260054e-07
. O 0 7.136793556128396e-06

In O 0 9.97766846921877e-07
patients O 0 1.8104742594005074e-07
of O 0 1.522779342622016e-07
Dutch O 0 5.422742833616212e-05
ethnic O 0 3.425144612378972e-08
origin O 0 5.4949030214856975e-08
, O 0 1.7336942548240586e-08
however O 0 2.2719627068568116e-08
, O 0 1.073936406470466e-08
no O 0 1.7368220639468746e-08
significant O 0 1.0251427795537893e-07
founder O 0 1.7631825812713942e-06
effect O 0 5.346973352970963e-07
could O 0 1.4260197644944128e-07
be O 0 3.0843142440062365e-07
identified O 0 4.917638307233574e-06
. O 0 1.5962828911142424e-05

The O 0 4.414674094732618e-06
observed O 0 2.1377497887442587e-06
genetic O 0 6.89609578330419e-07
heterogeneity O 0 2.7742723887058673e-06
including O 0 1.7936990559519472e-07
the O 0 1.625919736625292e-07
relative O 0 7.631338121427689e-07
high O 0 6.327505161607405e-06
percentage O 0 3.2232770763584995e-07
of O 0 3.4698553008638555e-07
splice O 0 4.502491719904356e-06
- O 0 2.93931492478805e-07
site O 0 6.3531999217048e-08
mutations O 0 7.097990817328537e-08
had O 0 3.3426886147935875e-08
no O 0 9.357221131267579e-08
reflection O 0 1.651785623835167e-06
on O 0 1.0754439472293598e-06
the O 0 2.3962741124705644e-06
phenotype O 0 0.0001810154935810715
. O 0 2.122241676261183e-05

All O 0 2.9854131753381807e-06
patients O 0 6.924974513822235e-07
manifested O 0 2.406972271273844e-06
classical O 0 7.836696568119805e-06
A B-Disease 1 0.9999562501907349
- I-Disease 1 0.9332032799720764
T I-Disease 1 0.9999978542327881
and O 0 7.985509000718594e-07
increased O 0 1.9417827843426494e-06
cellular O 0 1.110167613660451e-05
radioresistant O 0 9.729014891490806e-06
DNA O 0 2.3441687062586425e-06
synthesis O 0 6.144982762634754e-06
. O 0 5.420621619123267e-06

Determination O 0 1.791501563275233e-05
of O 0 1.8123328118235804e-06
the O 0 2.39729274653655e-07
genomic O 0 3.2403642080680584e-07
structure O 0 3.6863394825559226e-07
of O 0 2.0292348779094027e-07
the O 0 1.7480059000263282e-07
COL4A4 O 0 0.00047060675569809973
gene O 0 9.916901433371095e-08
and O 0 4.9738225982309814e-08
of O 0 6.201791507010057e-07
novel O 0 5.0822823141061235e-06
mutations O 0 0.005947606172412634
causing O 1 0.9997087121009827
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999988079071045

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.0072770146653056145
a O 0 0.00038753688568249345
progressive O 1 0.9999998807907104
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.8661295175552368
by O 0 2.6306865038350224e-05
glomerular B-Disease 1 0.9975905418395996
basement I-Disease 1 0.9969064593315125
membrane I-Disease 0 0.16984155774116516
abnormalities I-Disease 1 0.9044634103775024
and O 0 2.880792635551188e-07
associated O 0 2.282940272380074e-07
with O 0 8.81528023910505e-08
mutations O 0 3.9285586694859376e-07
in O 0 4.485553262156827e-08
either O 0 1.7867591850517783e-07
the O 0 3.152600243083725e-07
COL4A3 O 0 0.2577826678752899
or O 0 7.783331312793962e-08
the O 0 9.21789933272521e-08
COL4A4 O 0 1.3049821063759737e-05
gene O 0 3.0292820696331546e-08
, O 0 9.410106471818835e-09
which O 0 7.299024495921458e-09
encode O 0 4.94186949140385e-08
the O 0 3.743005194678517e-08
alpha3 O 0 4.303981768316589e-06
and O 0 1.8860276895793504e-07
alpha4 O 0 2.742211836448405e-05
type O 0 4.611670374288224e-05
IV O 1 0.9999998807907104
collagen O 0 0.15187007188796997
chains O 0 4.070513114129426e-06
, O 0 1.0680877267077449e-06
respectively O 0 7.739459761069156e-06
. O 0 9.804834917304106e-06

To O 0 9.859272722678725e-07
date O 0 2.9417842597467825e-06
, O 0 1.2619119615919772e-07
mutation O 0 1.496515267263021e-07
screening O 0 7.92091867651834e-08
in O 0 7.383936129201629e-09
the O 0 1.7879703051448814e-08
two O 0 1.534041516038087e-08
genes O 0 1.7764095971983807e-08
has O 0 9.661597744070605e-09
been O 0 2.4290876865507016e-08
hampered O 0 4.644936666409194e-07
by O 0 1.9693727537628547e-08
the O 0 5.51097230072628e-08
lack O 0 2.9321753913791326e-07
of O 0 4.2385340748296585e-07
genomic O 0 8.833093261273461e-07
structure O 0 4.4056437218387146e-06
information O 0 1.4804338661633665e-06
. O 0 9.166821655526292e-06

We O 0 5.823183528264053e-06
report O 0 5.076195748188184e-07
here O 0 1.6964146709597117e-07
the O 0 5.1429573488803726e-08
complete O 0 1.465407848399991e-07
characterization O 0 2.493503359346505e-07
of O 0 8.284190755603049e-08
the O 0 6.502435212496493e-08
48 O 0 2.5237912382181094e-07
exons O 0 6.111910693107347e-07
of O 0 8.827377939724101e-08
the O 0 1.8058219097838446e-07
COL4A4 O 0 0.00012338234228082
gene O 0 1.7777560401555093e-07
, O 0 3.5135329312652175e-08
a O 0 3.371656731587791e-08
comprehensive O 0 2.0666625744070188e-07
gene O 0 5.2439830255934794e-08
screen O 0 2.6974493039233494e-07
, O 0 3.930334457891149e-08
and O 0 2.3583570651908303e-08
the O 0 2.3188951203678698e-08
subsequent O 0 6.790826745373124e-08
detection O 0 2.513544359317166e-07
of O 0 5.9549645214929114e-08
10 O 0 1.5738393699393782e-07
novel O 0 9.644386267382288e-08
mutations O 0 1.4496356470772298e-07
in O 0 7.252551625924752e-08
eight O 0 7.798935257596895e-06
patients O 0 2.9030623409198597e-05
diagnosed O 1 0.9970904588699341
with O 0 0.27128028869628906
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999611377716064

Furthermore O 0 2.224647869297769e-05
, O 0 8.240787678914785e-07
we O 0 3.504832477574382e-07
identified O 0 7.472788183804369e-07
a O 0 2.71236729076918e-07
glycine O 0 1.8380660549155436e-06
to O 0 1.2437135410436895e-07
alanine O 0 1.3079232985546696e-06
substitution O 0 1.2666373550018761e-06
in O 0 1.2943678484589327e-07
the O 0 3.7838054822714184e-07
collagenous O 0 5.1856040954589844e-05
domain O 0 1.1256801002446082e-07
that O 0 9.128384270695733e-09
is O 0 1.7175469935182264e-08
apparently O 0 1.92674548316063e-07
silent O 0 6.93414051511354e-07
in O 0 3.871910436714643e-08
the O 0 6.424877341260071e-08
heterozygous O 0 4.312838370879035e-07
carriers O 0 2.6881377834797604e-07
, O 0 2.743573190855386e-07
in O 0 5.193769538891502e-07
11 O 0 2.1559450033237226e-05
. O 0 2.5214067136403173e-05

5 O 0 2.517567736504134e-06
% O 0 9.482231888569004e-08
of O 0 6.067991620284374e-08
all O 0 1.6144989345434624e-08
control O 0 5.680554338027832e-08
individuals O 0 8.065303092053e-09
, O 0 2.374221352852146e-08
and O 0 1.9663398020952627e-08
in O 0 1.3285699651532923e-08
one O 0 2.300445700598175e-08
control O 0 9.690503333104061e-08
individual O 0 2.564942747085297e-08
homozygous O 0 2.3207010713122145e-07
for O 0 6.811335850898104e-08
this O 0 1.250244565653702e-07
glycine O 0 4.65268703919719e-06
substitution O 0 1.7114540241891518e-05
. O 0 1.80723855010001e-05

There O 0 1.0594666264296393e-06
has O 0 6.064358615276433e-08
been O 0 3.663691217070664e-08
no O 0 2.5415671345285773e-08
previous O 0 4.609053050330658e-08
finding O 0 7.745803287662056e-08
of O 0 3.578016460892286e-08
a O 0 8.560016340197762e-08
glycine O 0 2.9276435498104547e-07
substitution O 0 1.6704198912975698e-07
that O 0 6.351149384187238e-09
is O 0 4.213913662454161e-09
not O 0 3.705765916350856e-09
associated O 0 2.1371549863147266e-08
with O 0 8.348174596051194e-09
any O 0 5.178264217420292e-08
obvious O 0 6.772807523702795e-07
phenotype O 0 3.5928369470639154e-06
in O 0 1.5698100241934299e-07
homozygous O 0 4.256099146004999e-06
individuals O 0 5.783292067462753e-07
. O 0 1.415295173501363e-05

Founder O 0 0.004974347539246082
BRCA1 O 0 0.0002388036227785051
and O 0 4.463719051273074e-06
BRCA2 O 0 3.3394404454156756e-05
mutations O 0 2.552206979089533e-06
in O 0 4.0582659721621894e-07
French O 0 0.32664743065834045
Canadian O 1 0.9993970394134521
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.492619963362813e-05
. O 0 0.00030611667898483574

We O 0 1.7551096789247822e-06
have O 0 1.6801433844193525e-07
identified O 0 5.268615836939716e-07
four O 0 1.9928820904624445e-07
mutations O 0 1.7511477778953122e-07
in O 0 2.9392186462473546e-08
each O 0 3.077514776350654e-08
of O 0 6.238367973310233e-07
the O 0 1.450065610697493e-05
breast B-Disease 1 0.8984940052032471
cancer I-Disease 0 0.02858327515423298
- O 0 9.186879469780251e-05
susceptibility O 0 2.52263157562993e-06
genes O 0 1.9942794438065903e-07
, O 0 2.0301310144077434e-07
BRCA1 O 0 3.2311916129401652e-06
and O 0 4.6357320115930634e-07
BRCA2 O 0 4.1114140913123265e-05
, O 0 1.6909889666294475e-07
in O 0 9.461997052540028e-08
French O 1 0.5040006637573242
Canadian O 1 0.6451655030250549
breast B-Disease 1 0.9999363422393799
cancer I-Disease 1 0.9995236396789551
and O 1 0.9998093247413635
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5284301753126783e-06
from O 0 3.148939185848576e-06
Quebec O 0 0.0009200896020047367
. O 0 9.142326598521322e-05

To O 0 2.0660609152400866e-06
identify O 0 5.579354819928994e-06
founder O 0 5.1020786486333236e-05
effects O 0 6.152691639726982e-05
, O 0 7.691448900004616e-07
we O 0 2.715685809562274e-07
examined O 0 7.5346451922087e-07
independently O 0 1.2161119400388998e-07
ascertained O 0 1.443165160708304e-06
French O 0 1.1896431715285871e-05
Canadian O 0 3.9522701626992784e-06
cancer B-Disease 0 1.1477467296572286e-06
families O 0 1.013289896434344e-08
for O 0 8.0413720127126e-09
the O 0 1.2799366899685083e-08
distribution O 0 1.9404904350039942e-08
of O 0 4.9521922562689724e-08
these O 0 4.0156049152528794e-08
eight O 0 1.6429279412477626e-06
mutations O 0 5.879667696717661e-06
. O 0 1.0548176760494243e-05

Mutations O 0 5.649958893627627e-06
were O 0 6.36957395272475e-07
found O 0 7.913927646541197e-08
in O 0 3.738067988479088e-08
41 O 0 3.971813384850975e-07
of O 0 7.502593462049845e-07
97 O 0 2.181724448746536e-05
families O 0 1.5877433270361507e-06
. O 0 1.4907399418007117e-05

Six O 0 9.612882422516122e-06
of O 0 1.1894420595126576e-06
eight O 0 5.167589165466779e-07
mutations O 0 1.823131157152602e-07
were O 0 1.3213150396040874e-07
observed O 0 3.5293311384521076e-07
at O 0 1.8312110796614434e-06
least O 0 1.2220765484016738e-06
twice O 0 1.0612418918753974e-05
. O 0 9.819468687055632e-06

The O 0 1.740017432894092e-05
BRCA1 O 0 0.00010519487113924697
C4446T O 0 5.67174720345065e-05
mutation O 0 2.903114818764152e-06
was O 0 7.169157356656797e-07
the O 0 3.908982648681558e-08
most O 0 1.0206997025363762e-08
common O 0 3.415873806034142e-08
mutation O 0 8.941641027604419e-08
found O 0 2.374366303570241e-08
, O 0 3.090213951395526e-08
followed O 0 8.548561680754574e-08
by O 0 6.331473656473463e-08
the O 0 6.216002930159448e-07
BRCA2 O 0 6.905700865900144e-05
8765delAG O 0 7.605452265124768e-05
mutation O 0 1.8625421944307163e-05
. O 0 1.5863595763221383e-05

Together O 0 1.4404536159418058e-06
, O 0 9.41878326443657e-08
these O 0 1.612726130417741e-08
mutations O 0 5.2094303981675694e-08
were O 0 2.2599518700872068e-08
found O 0 9.959529201353234e-09
in O 0 7.158435177956335e-09
28 O 0 2.120216606726899e-07
of O 0 9.204352835467944e-08
41 O 0 3.563265806860727e-07
families O 0 1.110589042951915e-08
identified O 0 5.348370279989467e-08
to O 0 2.144095923028999e-08
have O 0 1.1014991940783148e-07
a O 0 1.4677536910312483e-06
mutation O 0 1.684876042418182e-05
. O 0 3.3451484341640025e-05

The O 0 8.807749054540182e-07
odds O 0 1.589816179148329e-06
of O 0 1.5948532450238417e-07
detection O 0 4.107125732843997e-07
of O 0 4.003758391490919e-08
any O 0 2.7156486837043303e-08
of O 0 1.037003301007644e-07
the O 0 8.052656141899206e-08
four O 0 3.7443624023580924e-07
BRCA1 O 0 2.5855783860606607e-06
mutations O 0 1.0947074997602613e-06
was O 0 3.4363617942290148e-06
18 O 0 1.8744487533695064e-05
. O 0 2.9080778404022567e-05

7x O 0 0.00145079439971596
greater O 0 3.934189408028033e-06
if O 0 3.0421426799875917e-07
one O 0 4.259702635067697e-08
or O 0 1.9649602833737845e-08
more O 0 6.232918181581226e-09
cases O 0 2.895488826482051e-08
of O 0 8.68762163008796e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.8265599212318193e-06
also O 0 9.963028446691169e-08
present O 0 8.925284333827221e-08
in O 0 7.498574206010744e-08
the O 0 4.239944928485784e-07
family O 0 1.3269562941786717e-06
. O 0 1.2932902791362721e-05

The O 0 2.6461691504664486e-06
odds O 0 4.56031284556957e-06
of O 0 3.3882835737131245e-07
detection O 0 8.951262771006441e-07
of O 0 1.4526651170854166e-07
any O 0 5.8799763280603656e-08
of O 0 1.777084719378763e-07
the O 0 2.8843413701906684e-07
four O 0 1.0194505648541963e-06
BRCA2 O 0 1.2178614269942045e-05
mutations O 0 2.2329468265525065e-06
was O 0 6.232972282305127e-06
5 O 0 1.8033135347650386e-05
. O 0 2.3423554011969827e-05

3x O 0 0.00017952077905647457
greater O 0 1.0664816727512516e-06
if O 0 7.880984043140415e-08
there O 0 4.996214286734357e-08
were O 0 7.29230649199053e-08
at O 0 1.8025508552454994e-07
least O 0 5.156826787811042e-08
five O 0 6.741373681506957e-08
cases O 0 4.455921143176056e-08
of O 0 9.110904102271888e-07
breast B-Disease 0 0.009217727929353714
cancer I-Disease 0 1.8460292267263867e-05
in O 0 2.4579421165071835e-07
the O 0 3.0531396078004036e-06
family O 0 1.829751681725611e-06
. O 0 1.4224276128516067e-05

Interestingly O 0 6.982481136219576e-05
, O 0 5.407266598922433e-07
the O 0 2.1089637414206663e-07
presence O 0 3.7174598332967435e-07
of O 0 2.3612321911059553e-06
a O 0 8.548301593691576e-06
breast B-Disease 0 0.001186206005513668
cancer I-Disease 0 1.3904252227803227e-05
case O 0 1.4541969903802965e-06
< O 0 8.05436593509512e-06
36 O 0 4.7656618562541553e-07
years O 0 3.250949731636865e-08
of O 0 2.9453019578795647e-08
age O 0 7.713795469044271e-08
was O 0 6.10724910643512e-08
strongly O 0 1.8432142923074935e-08
predictive O 0 9.788176669189852e-08
of O 0 1.3635046869353573e-08
the O 0 6.103252569999995e-09
presence O 0 1.0370126979353245e-08
of O 0 1.3687682098861842e-08
any O 0 1.2854855846455848e-08
of O 0 6.62203945012152e-08
the O 0 9.715709126112415e-08
eight O 0 7.940301429698593e-07
mutations O 0 2.1754540284746327e-06
screened O 0 3.7265185710566584e-06
. O 0 7.759252184769139e-06

Carriers O 0 2.491366785761784e-06
of O 0 3.2059685395324777e-07
the O 0 6.446359179790306e-08
same O 0 2.983535196676712e-08
mutation O 0 6.325377910343377e-08
, O 0 9.473677842208872e-09
from O 0 8.146238350548174e-09
different O 0 1.0291958396635437e-08
families O 0 6.2619815999198636e-09
, O 0 1.4424847094574034e-08
shared O 0 3.857079988733858e-08
similar O 0 5.741313557905414e-08
haplotypes O 0 2.811821673276427e-07
, O 0 1.1512077513486929e-08
indicating O 0 2.48803928570851e-08
that O 0 4.339136605580052e-09
the O 0 2.023818801433208e-08
mutant O 0 1.8326666406665026e-07
alleles O 0 1.0056426447135891e-07
were O 0 3.034544704405562e-08
likely O 0 3.459872033317879e-08
to O 0 1.4704863104952892e-08
be O 0 1.7662031837062386e-08
identical O 0 7.910184507409213e-08
by O 0 1.4598278141875198e-08
descent O 0 1.496937755973704e-07
for O 0 2.519769282116613e-08
a O 0 4.137434927997674e-08
mutation O 0 7.935451407092842e-08
in O 0 2.5846704332366244e-08
the O 0 2.0710268699986045e-07
founder O 0 1.190043712995248e-05
population O 0 5.24490360476193e-07
. O 0 1.1282286322966684e-05

The O 0 1.2843283911934122e-06
identification O 0 7.504883683395747e-07
of O 0 8.369108286387927e-07
common O 0 4.569271823129384e-06
BRCA1 O 0 5.313700967235491e-05
and O 0 1.0616868166835047e-06
BRCA2 O 0 4.922912921756506e-06
mutations O 0 1.5106768103123613e-07
will O 0 2.688631894898208e-08
facilitate O 0 9.316475058085416e-08
carrier O 0 7.206110552715472e-08
detection O 0 6.475775080616586e-07
in O 0 5.926138868517228e-08
French O 0 0.49494704604148865
Canadian O 1 0.7322679162025452
breast B-Disease 1 0.9999830722808838
cancer I-Disease 1 0.9999244213104248
and O 1 0.9998528957366943
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.8637201467063278e-05
. O 0 0.0001241807040059939

Are O 0 7.851792361179832e-06
Dp71 O 0 0.0007936182664707303
and O 0 8.416383934672922e-06
Dp140 O 0 0.00044026155956089497
brain O 0 0.00038209857302717865
dystrophin O 0 0.0001127799550886266
isoforms O 0 1.3375703929341398e-05
related O 0 6.156939775792125e-07
to O 0 2.971943899865437e-07
cognitive B-Disease 1 0.9989840388298035
impairment I-Disease 1 0.999998927116394
in O 0 0.18505248427391052
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999958276748657

Molecular O 0 8.782249642536044e-05
study O 0 2.2130611796455923e-06
and O 0 2.8825954245803587e-07
neuropsychological O 0 6.325900358206127e-06
analysis O 0 2.596987940250983e-07
were O 0 1.6574948347169993e-07
performed O 0 1.8020800496287848e-07
concurrently O 0 2.9000440804338723e-07
on O 0 2.155935447945012e-07
49 O 0 1.0525068319111597e-06
patients O 0 7.105650183802936e-07
with O 0 9.423957817489281e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999997615814209
DMD B-Disease 1 1.0
) O 0 2.7608385266830737e-07
in O 0 9.437301606851634e-09
order O 0 2.3312770380812253e-08
to O 0 4.5644776847098e-09
find O 0 3.211114574241947e-08
a O 0 3.089076372475574e-08
molecular O 0 3.432535606862075e-07
explanation O 0 1.2147522454597492e-07
for O 0 3.4269351800730874e-08
the O 0 3.2645954206600436e-07
cognitive B-Disease 1 0.934694230556488
impairment I-Disease 0 0.1645735800266266
observed O 0 1.0574417501629796e-06
in O 0 5.095586743664171e-07
most O 0 1.0483581718290225e-05
DMD B-Disease 1 1.0
patients O 0 0.00017400129581801593
. O 0 6.639549974352121e-05

Complete O 0 7.152812941058073e-06
analysis O 0 7.317956942642923e-07
of O 0 6.680471074105299e-07
the O 0 8.037960697038216e-07
dystrophin O 0 4.662239734898321e-05
gene O 0 5.303905368236883e-07
was O 0 3.062986309032567e-07
performed O 0 3.379150470550485e-08
to O 0 9.763876818169592e-09
define O 0 1.1483058415251435e-07
the O 0 6.351745440724699e-08
localization O 0 2.6454954422661103e-06
of O 0 1.0838471808938266e-07
deletions O 0 3.0863503752698307e-07
and O 0 7.908720789373547e-08
duplications O 0 2.2005037862982135e-06
in O 0 3.568753825788917e-08
relation O 0 1.7747272806900583e-07
to O 0 4.2018207579985756e-08
the O 0 3.6838443406850274e-07
different O 0 7.067593742249301e-06
DMD B-Disease 1 1.0
promoters O 0 0.0019949842244386673
. O 0 4.701054058386944e-05

Qualitative O 0 1.6791318557807244e-05
analysis O 0 1.3490488299794379e-06
of O 0 6.56127610909607e-07
the O 0 7.951994120958261e-07
Dp71 O 0 0.00012529641389846802
transcript O 0 1.6659922721373732e-06
and O 0 2.0564149494362027e-08
testing O 0 4.576047274440498e-08
for O 0 1.2822873429740866e-08
the O 0 1.1475751016121194e-08
specific O 0 1.5206699899295018e-08
first O 0 5.328087837597195e-08
exon O 0 3.5977666357212e-07
of O 0 5.7533938502274395e-08
Dp140 O 0 2.189365432059276e-06
were O 0 1.2324481701853074e-07
also O 0 1.492655457013825e-07
carried O 0 1.0920954309767694e-06
out O 0 1.5939667719067074e-06
. O 0 9.131554179475643e-06

Neuropsychological O 0 0.0009539251332171261
analysis O 0 1.4443353393289726e-05
assessed O 0 1.4619346075050998e-05
verbal O 0 2.838731961674057e-05
and O 0 2.8124809432483744e-06
visuospatial O 0 0.0005211567040532827
intelligence O 0 5.677798071701545e-06
, O 0 6.224527169251814e-07
verbal O 0 5.962141585769132e-05
memory O 1 0.8687635660171509
, O 0 4.011236796941375e-06
and O 0 4.304223693907261e-06
reading O 0 0.0014621266163885593
skills O 0 0.3948085308074951
. O 0 0.00010122969979420304

Comparison O 0 1.1201173947483767e-05
of O 0 5.629269253404345e-06
molecular O 0 2.803831193887163e-05
and O 0 8.186910349650134e-07
psychometric O 0 2.6685729608288966e-05
findings O 0 4.863425147050293e-07
demonstrated O 0 4.5811910354132124e-07
that O 0 2.3365476664594098e-08
deletions O 0 6.288633471740468e-07
and O 0 1.144937797903367e-07
duplications O 0 3.0223620797187323e-06
that O 0 3.0757892233168604e-08
were O 0 7.706854177058631e-08
localized O 0 9.94692527456209e-07
in O 0 5.822112214559638e-08
the O 0 1.087630678853202e-07
distal O 0 6.0944421420572326e-06
part O 0 9.453825811078787e-08
of O 0 1.6735771168896463e-07
the O 0 6.454011014511707e-08
gene O 0 4.8314259259996106e-08
seemed O 0 1.1182799397602139e-07
to O 0 2.2048061154578136e-08
be O 0 4.832642375163232e-08
preferentially O 0 4.0864304651222483e-07
associated O 0 6.959295433262014e-07
with O 0 4.9343861974193715e-06
cognitive B-Disease 1 0.9999997615814209
impairment I-Disease 1 0.999996542930603
. O 0 0.00010695189848775044

Two O 0 1.4626850315835327e-05
altered O 0 1.2984756722289603e-05
Dp71 O 0 0.00013213910278864205
transcripts O 0 1.1060525139328092e-05
and O 0 2.3153425843247533e-07
two O 0 2.12222545314944e-07
deleted O 0 1.0763417321868474e-06
Dp140 O 0 1.2591077620527358e-06
DNA O 0 1.938515481469949e-07
sequences O 0 7.433184379124214e-08
were O 0 4.503263539845648e-08
found O 0 3.9333190926527095e-08
in O 0 7.676690927382879e-08
four O 0 2.632582209116663e-06
patients O 0 6.670554739685031e-06
with O 0 0.0020386800169944763
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 1 0.9993935823440552

These O 0 9.269210181628296e-07
findings O 0 5.553309847527998e-07
suggest O 0 1.79877304162801e-07
that O 0 1.606420241273554e-08
some O 0 1.388343484620691e-08
sequences O 0 4.699869293744996e-08
located O 0 3.0232904180138576e-08
in O 0 9.330769934479122e-09
the O 0 3.891055300186963e-08
distal O 0 1.0318236718376284e-06
part O 0 4.6564149869254834e-08
of O 0 5.986166229376977e-08
the O 0 4.3200131472076464e-08
gene O 0 4.533565345354873e-08
and O 0 2.9753289609857347e-08
, O 0 3.265815706754438e-08
in O 0 1.3593187908611526e-08
particular O 0 8.69892957666707e-08
, O 0 1.1144620515324277e-07
some O 0 1.7211812064488186e-07
DMD B-Disease 1 0.9999991655349731
isoforms O 0 6.828038294770522e-06
expressed O 0 7.70102062119804e-08
in O 0 2.5726304642148534e-08
the O 0 7.561582293647007e-08
brain O 0 1.0910637229244458e-06
may O 0 3.5291417788130275e-08
be O 0 1.4017996541326738e-08
related O 0 2.2915646269439094e-08
to O 0 1.531343229999038e-08
the O 0 3.2272143357658933e-07
cognitive B-Disease 1 0.9999624490737915
impairment I-Disease 1 0.9986720085144043
associated O 0 2.2189108221937204e-06
with O 0 8.866127245710231e-06
DMD B-Disease 1 1.0
. O 0 2.76344708254328e-05
. O 0 3.3797921787481755e-05

I1307K O 0 0.000591700489167124
APC O 0 8.81076994119212e-05
and O 0 1.2405936331560952e-06
hMLH1 O 0 8.369400347874034e-06
mutations O 0 3.111090904894809e-07
in O 0 1.789751458147748e-08
a O 0 6.681950281972604e-08
non O 0 8.191017855097016e-07
- O 0 7.41166502393753e-07
Jewish O 0 1.8047698802092782e-07
family O 0 3.916893831501511e-08
with O 0 1.5673940367832984e-07
hereditary B-Disease 1 0.9999998807907104
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999539852142334

We O 0 3.4870497529482236e-06
describe O 0 1.630375777494919e-06
a O 0 5.317758109413262e-07
French O 0 2.0292231056373566e-05
Canadian O 0 2.1112844478921033e-05
hereditary B-Disease 1 0.9999814033508301
non I-Disease 1 0.9999996423721313
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999815225601196
HNPCC B-Disease 1 1.0
) O 0 4.494984295888571e-06
kindred O 0 2.992249392264057e-05
which O 0 1.951920438614252e-07
carries O 0 4.78217486943322e-07
a O 0 3.687376590733038e-07
novel O 0 1.8439003497405793e-06
truncating O 0 2.1691728761652485e-05
mutation O 0 4.205423465464264e-06
in O 0 2.174464725612779e-06
hMLH1 O 0 0.00038358569145202637
. O 0 8.162690210156143e-05

Interestingly O 0 3.731580000021495e-05
, O 0 1.2068671821907628e-06
the O 0 7.640338708370109e-07
I1307K O 0 2.0516981749096885e-05
APC O 0 1.1512346645758953e-05
polymorphism O 0 2.443111952743493e-06
, O 0 8.751703006737444e-08
associated O 0 2.652811481596018e-08
with O 0 7.004250957010072e-09
an O 0 6.401890573215496e-09
increased O 0 7.527204815005462e-08
risk O 0 6.765603757230565e-06
of O 1 0.9999945163726807
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.074931090755854e-06
is O 0 2.439702129208854e-08
also O 0 9.466651462730624e-09
present O 0 1.848114550284663e-08
in O 0 1.6956535731083022e-08
this O 0 5.485687637474257e-08
family O 0 5.386575594457099e-07
. O 0 7.568964974780101e-06

The O 0 9.442970622330904e-06
I1307K O 0 0.00010048223339254037
polymorphism O 0 5.299251370161073e-06
has O 0 6.992733148081243e-08
previously O 0 1.1846586289721017e-07
only O 0 1.5492819471774055e-08
been O 0 2.528642539800785e-08
identified O 0 6.932957319349953e-08
in O 0 1.6480949938113554e-08
individuals O 0 1.9994779165699583e-08
of O 0 4.512799591793737e-07
self O 0 4.109798828721978e-05
- O 0 7.978591020219028e-05
reported O 0 2.5755277874850435e-06
Ashkenazi O 0 1.9275303202448413e-05
Jewish O 0 3.247459517297102e-06
origins O 0 2.9857050321879797e-05
. O 0 5.073505963082425e-05

In O 0 1.6581050203967607e-06
addition O 0 5.837267735842033e-07
, O 0 4.9823963621520306e-08
in O 0 8.491534586596572e-09
this O 0 5.653377765924006e-09
family O 0 6.752232550866211e-09
, O 0 9.341490248004902e-09
there O 0 1.2129088844403668e-08
appears O 0 1.464172338927483e-08
to O 0 3.747747001625612e-09
be O 0 1.1026065394048601e-08
no O 0 1.9361351633051527e-08
relationship O 0 3.127803438474075e-08
between O 0 8.404446560916767e-08
the O 0 1.3440337909287337e-07
I1307K O 0 1.8167282860304113e-06
polymorphism O 0 1.0354418833458112e-07
and O 0 6.280521880341894e-09
the O 0 6.055445034292006e-09
presence O 0 1.7489721670926883e-08
or O 0 4.485074001081557e-08
absence O 0 1.4196614301908994e-06
of O 0 3.3852129490696825e-06
cancer B-Disease 0 5.244266503723338e-05
. O 0 1.5969917512848042e-06
. O 0 1.3506924915418494e-05

Identification O 0 6.6634779614105355e-06
of O 0 1.6762875247877673e-06
a O 0 4.340798795965384e-07
novel O 0 3.345820687172818e-07
mutation O 0 2.396942875293462e-07
of O 0 2.8447115596463846e-07
the O 0 5.934322189204977e-07
CPO O 0 6.803281576139852e-05
gene O 0 3.5266191389382584e-07
in O 0 1.0832127372850664e-07
a O 0 1.0009099469243665e-06
Japanese O 0 0.00017067005683202296
hereditary B-Disease 1 0.9999995231628418
coproporphyria I-Disease 1 0.999438464641571
family O 0 1.6108426279970445e-05
. O 0 5.528172187041491e-05

Hereditary B-Disease 1 0.9999943971633911
coproporphyria I-Disease 1 0.9999978542327881
( O 0 0.019610455259680748
HCP B-Disease 1 1.0
) O 0 4.034608991787536e-06
is O 0 3.717385368418036e-07
an O 0 7.789909091115987e-07
autosomal B-Disease 1 0.9999945163726807
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 0.01077931746840477
by O 0 2.3211380266729975e-06
a O 0 3.3134281693492085e-05
deficiency B-Disease 1 0.9946789741516113
of I-Disease 0 0.11657068133354187
coproporphyrinogen I-Disease 1 0.999983549118042
oxidase I-Disease 0 0.0002826914715114981
( O 0 4.189920446151518e-07
CPO O 0 2.5533327061566524e-05
) O 0 4.72719996480464e-08
caused O 0 1.3587981584350928e-07
by O 0 2.0315306770157804e-08
a O 0 5.194338825731393e-08
mutation O 0 1.9191203648460942e-07
in O 0 5.745673803403406e-08
the O 0 6.801429890401778e-07
CPO O 0 0.0003211691218893975
gene O 0 1.5718933354946785e-05
. O 0 2.3373213480226696e-05

Only O 0 1.7313549278696883e-06
11 O 0 1.0454799621584243e-06
mutations O 0 1.1076679840016368e-07
of O 0 5.3272753319788535e-08
the O 0 3.5176231705236205e-08
gene O 0 5.7819079302134924e-08
have O 0 2.8158890330587383e-08
been O 0 1.368690476510892e-07
reported O 0 7.71781230923807e-07
in O 0 2.290984639330418e-06
HCP B-Disease 1 1.0
patients O 0 0.00010885517986025661
. O 0 0.00013012299314141273

We O 0 5.71531563764438e-06
report O 0 6.925595243956195e-07
another O 0 4.4789021558244713e-07
mutation O 0 8.339088708453346e-07
in O 0 1.3555005295984301e-07
a O 0 9.94237211671134e-07
Japanese O 0 5.3195577493170276e-05
family O 0 1.2209071428515017e-05
. O 0 4.645676017389633e-05

Polymerase O 0 0.00042288866825401783
chain O 0 2.453861088724807e-05
reaction O 0 1.0222144737781491e-05
- O 0 1.427953702659579e-05
single O 0 8.316668527186266e-07
strand O 0 1.5949126463965513e-06
conformational O 0 7.09299683876452e-07
polymorphism O 0 7.316477876884164e-07
and O 0 2.2788459119738036e-08
direct O 0 6.358558124475167e-08
sequence O 0 1.0467145727943716e-07
analyses O 0 1.0017487284130766e-07
demonstrated O 0 3.0686177865391073e-07
a O 0 1.9379720583856397e-07
C O 0 3.9764099710737355e-06
to O 0 7.201494156561239e-08
T O 0 1.5360008092102362e-06
substitution O 0 1.7886598868699366e-07
in O 0 2.7851804418332904e-08
exon O 0 1.4758987276763946e-07
1 O 0 5.3246541398266345e-08
of O 0 3.261427039547016e-08
the O 0 7.152378600494558e-08
CPO O 0 3.1490624223806662e-06
gene O 0 6.918981654280287e-08
at O 0 1.5660926067084802e-07
nucleotide O 0 1.2319276265770895e-07
position O 0 2.48243225087208e-07
85 O 0 2.5480795784460497e-07
, O 0 6.913045780265747e-08
which O 0 5.09118081026827e-08
lies O 0 3.179487748639076e-07
in O 0 2.9635032205987955e-08
the O 0 1.1628049634282434e-07
putative O 0 1.496786467214406e-06
presequence O 0 5.982296443107771e-06
for O 0 1.7196948931541556e-07
targeting O 0 1.6108266436276608e-06
to O 0 7.238172088364081e-07
mitochondria O 0 2.49596378125716e-05
. O 0 2.3392212824546732e-05

This O 0 1.2554172599266167e-06
mutation O 0 9.047152502716926e-07
changes O 0 3.8100361621218326e-07
the O 0 1.7913296801452816e-07
codon O 0 1.3889151659896015e-06
for O 0 7.563674131461084e-08
glutamine O 0 6.583326239706366e-07
to O 0 3.626447409033062e-08
a O 0 1.652523167194886e-07
termination O 0 3.4118868370569544e-06
codon O 0 1.10553992271889e-05
at O 0 3.456249032751657e-06
amino O 0 1.8812470443663187e-06
acid O 0 1.6206221289394307e-06
position O 0 1.2655539649131242e-05
29 O 0 5.6441604101564735e-05
. O 0 1.7564729205332696e-05

MaeI O 0 0.00036867131711915135
restriction O 0 2.7281555503577692e-06
analysis O 0 9.161282150671468e-07
showed O 0 7.299917683667445e-07
two O 0 1.012447938819605e-07
other O 0 2.870201143423401e-08
carriers O 0 8.352939318001518e-08
in O 0 4.927844798885417e-08
the O 0 4.452098210094846e-07
family O 0 7.081708872647141e-07
. O 0 6.826182470831554e-06

The O 0 1.1240703315706924e-05
C O 0 0.04591962322592735
- O 0 0.00016582517127972096
T O 0 3.5228189517511055e-05
mutation O 0 2.0290083568852424e-07
is O 0 1.4937569403628004e-08
located O 0 2.4054999769873575e-08
within O 0 2.736728532681809e-08
a O 0 2.8671042429095905e-08
recently O 0 1.314141968578042e-07
proposed O 0 1.4989463181791507e-07
putative O 0 3.295444344075804e-07
alternative O 0 5.495855930348625e-07
translation O 0 6.970534514039173e-07
initiation O 0 1.827756364036759e-06
codon O 0 5.832164788444061e-06
( O 0 5.917114549447433e-07
TIC O 0 9.324791790277231e-06
- O 0 6.898226843077282e-07
1 O 0 6.110431058914401e-07
) O 0 6.317179668258177e-08
, O 0 3.3384704778427476e-08
supporting O 0 1.510460663212143e-07
that O 0 4.9592529194342205e-08
TIC O 0 4.2594083424774e-06
- O 0 3.7925991591691854e-07
1 O 0 3.077664700867899e-07
is O 0 1.3126859599310592e-08
the O 0 2.7061087592983313e-08
real O 0 1.32111381390132e-06
TIC O 0 4.5838232836104e-06
rather O 0 1.980092605435857e-07
than O 0 3.688618051000958e-07
TIC O 0 1.1617786185524892e-05
- O 0 1.5928301309031667e-06
2 O 0 2.8828694667026866e-06
. O 0 7.852091243876202e-07
. O 0 5.898599738429766e-06

Human B-Disease 0 2.0657633285736665e-05
complement I-Disease 0 6.79329241393134e-05
factor I-Disease 0 0.0010077721672132611
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 1 0.9361043572425842
with O 1 0.9999985694885254
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999998807907104

This O 0 1.026960376293573e-06
study O 0 4.786988370142353e-07
reports O 0 3.5067481007899914e-07
on O 0 3.278072995271941e-07
six O 0 3.3540089816597174e-07
cases O 0 1.7591705159247795e-07
of O 0 2.531109203118831e-06
deficiency B-Disease 1 0.9537774324417114
in I-Disease 0 1.549387462773666e-07
the I-Disease 0 2.028720018643071e-07
human I-Disease 0 7.69310730674988e-08
complement I-Disease 0 3.6178397522235173e-07
regulatory I-Disease 0 3.1935118727233203e-07
protein I-Disease 0 2.764229236618121e-07
Factor I-Disease 0 9.011889119392436e-07
H I-Disease 1 0.9999755620956421
( O 0 4.999130851501832e-07
FH O 0 0.00013420767209026963
) O 0 2.5858390984012658e-08
in O 0 9.861424565826837e-09
the O 0 2.162598633503876e-08
context O 0 2.856853313915053e-07
of O 0 6.072878591112385e-07
an O 0 9.676726222096477e-06
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.9995324611663818

Five O 0 2.9804975838487735e-06
of O 0 4.2323941329414083e-07
the O 0 1.5236436468057946e-07
cases O 0 5.7433943823070877e-08
were O 0 6.653767314901415e-08
observed O 0 1.111203999926147e-07
in O 0 2.6927272855914453e-08
children O 0 4.6853159574311576e-08
presenting O 0 2.837165311575518e-06
with O 0 0.00015019903366919607
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.17832976579666138
. O 0 0.00022042701311875135

Two O 0 1.7735864048518124e-06
of O 0 1.1955787613260327e-06
the O 0 1.0481825256647426e-06
children O 0 3.4515153402026044e-07
exhibited O 0 4.153290774411289e-06
a O 0 1.3862148989574052e-05
homozygous O 0 0.27202901244163513
deficiency O 1 0.9958518743515015
characterized O 0 1.7187173853017157e-06
by O 0 7.727314255134843e-08
the O 0 1.1789411757945345e-07
absence O 0 6.534637009281141e-07
of O 0 2.3006877825082483e-07
the O 0 8.349068991719832e-08
150 O 0 1.5108295770005498e-07
- O 0 1.7600062562905805e-07
kD O 0 9.797026905289385e-07
form O 0 1.7796210727283324e-08
of O 0 4.383309004651892e-08
Factor O 0 3.854131875868916e-07
H O 1 0.7235909104347229
and O 0 1.6407964764653116e-08
the O 0 1.031499152759352e-08
presence O 0 1.5353354143599063e-08
, O 0 1.4237932610683401e-08
upon O 0 4.684529386622671e-08
immunoblotting O 0 7.23443179140304e-07
, O 0 2.8097728588249993e-08
of O 0 4.408739684436114e-08
the O 0 6.99088005262638e-08
42 O 0 6.675663257738051e-07
- O 0 7.077887289597129e-07
kD O 0 1.1163314411533065e-05
Factor O 0 1.705890440462099e-06
H O 1 0.7279084324836731
- O 0 1.3247890819911845e-06
like O 0 5.496412214256452e-08
protein O 0 8.742976120856838e-08
1 O 0 5.496485186995415e-07
( O 0 7.061773743544109e-08
FHL O 0 1.078580226021586e-05
- O 0 1.151118169673282e-07
1 O 0 1.0096979963236663e-07
) O 0 1.4974597561945302e-08
and O 0 2.375154295464199e-08
other O 0 4.526186714315372e-08
FH O 0 0.00019530059944372624
- O 0 9.841170367508312e-07
related O 0 2.1920594406310556e-07
protein O 0 4.0304223603016e-07
( O 0 2.9309146043488e-07
FHR O 0 0.000183239157195203
) O 0 6.745437985955505e-07
bands O 0 2.395450974290725e-05
. O 0 1.9150636944686994e-05

Southern O 0 3.732046388904564e-05
blot O 0 1.8128072042600252e-05
and O 0 4.1967390984609665e-07
PCR O 0 1.2502748631959548e-06
analysis O 0 8.020023045673952e-08
of O 0 7.096961951447156e-08
DNA O 0 2.617039456254133e-07
of O 0 1.3588035585598846e-07
one O 0 6.766713056549634e-08
patient O 0 1.9406574836011714e-07
with O 0 3.484143462628708e-07
homozygous O 0 0.03734368458390236
deficiency O 1 0.9982989430427551
ruled O 0 7.410601483570645e-06
out O 0 2.0846234960458787e-08
the O 0 8.19414136543628e-09
presence O 0 1.6347611264677653e-08
of O 0 5.4379231784196236e-08
a O 0 3.890691502306254e-08
large O 0 6.130497354206454e-08
deletion O 0 2.407664965176082e-07
of O 0 1.3842391410889832e-07
the O 0 4.1448407728239545e-07
FH O 0 0.006526891607791185
gene O 0 1.562464433391142e-07
as O 0 8.326058065222242e-08
the O 0 2.1081231693642621e-07
underlying O 0 0.00028959321207366884
defect O 0 0.00012961415632162243
for O 0 1.0217047019978054e-05
the O 0 0.001503723906353116
deficiency O 1 0.9999992847442627
. O 0 0.00021027146431151778

The O 0 4.811167855223175e-06
other O 0 4.585667454648501e-07
four O 0 7.164570661188918e-07
children O 0 1.1383638565121146e-07
presented O 0 8.853054964674811e-07
with O 0 1.1620394388955901e-06
heterozygous O 0 0.004636759404093027
deficiency O 1 0.9986523985862732
and O 0 9.104685432248516e-07
exhibited O 0 3.293318741270923e-06
a O 0 3.280919145254302e-07
normal O 0 5.390594424170558e-07
immunoblotting O 0 2.8821164050896186e-06
pattern O 0 2.3532845716545125e-07
of O 0 6.410666486544869e-08
proteins O 0 1.581319075683041e-08
of O 0 1.2120096926082624e-07
the O 0 1.171043891190493e-06
FH O 0 0.43818700313568115
family O 0 2.545968982303748e-06
. O 0 9.82282199402107e-06

Factor B-Disease 1 0.6773523092269897
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999961853027344
is O 0 2.3061443243932445e-07
the O 0 2.3705973717369488e-07
only O 0 9.001238936434675e-07
complement B-Disease 1 0.9999995231628418
deficiency I-Disease 1 1.0
associated O 0 5.20408502779901e-06
with O 0 1.392303965985775e-05
HUS B-Disease 1 1.0
. O 0 0.000201885006390512

These O 0 8.442216312687378e-07
observations O 0 1.284843051507778e-06
suggest O 0 5.670313498740143e-07
a O 0 2.2139934685583285e-07
role O 0 3.9566455711792514e-07
for O 0 5.376332410378382e-07
FH O 1 0.9986959099769592
and O 0 4.72405417895061e-06
/ O 0 0.021647661924362183
or O 0 2.296343836860615e-06
FH O 0 0.0053659649565815926
receptors O 0 5.765576247540594e-07
in O 0 4.9136730240206816e-08
the O 0 1.3278737753807945e-07
pathogenesis O 0 0.0003099062596447766
of O 0 5.727642019337509e-06
idiopathic O 1 0.9999943971633911
HUS B-Disease 1 1.0
. O 0 7.245146116474643e-05
. O 0 9.191269055008888e-05

Further O 0 2.4285075141960988e-06
evidence O 0 8.199060061997443e-07
for O 0 9.251911592400575e-08
a O 0 1.274714946930544e-07
major O 0 3.70267372318267e-07
ancient O 0 4.311709290050203e-06
mutation O 0 0.0002174245601054281
underlying O 1 0.9999854564666748
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.0004345060442574e-05
linkage O 0 0.00019074860028922558
disequilibrium O 0 9.92612331174314e-05
studies O 0 2.4773569862190925e-07
in O 0 3.2271707084419177e-08
the O 0 1.3632411821618007e-07
Japanese O 0 1.962205715244636e-06
population O 0 1.3210227223225957e-07
. O 0 5.023465746489819e-06

The O 1 0.9978554844856262
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999884366989136
DM B-Disease 1 1.0
) O 0 1.5304548242056626e-06
mutation O 0 3.8179510397640115e-07
is O 0 3.3563217982646165e-08
an O 0 3.623004474206937e-08
unstable O 0 1.1767448995669838e-05
( O 0 1.2496394674599287e-06
CTG O 0 0.0009702019742690027
) O 0 1.0727145394184845e-07
n O 0 3.349256019191671e-07
repeat O 0 2.2446334924097755e-07
, O 0 2.1634772195966434e-08
present O 0 2.8517893824187013e-08
at O 0 1.0579667275578686e-07
a O 0 1.1855081361034081e-08
copy O 0 2.3729084475121454e-08
number O 0 1.0523955040753208e-08
of O 0 4.041915246943972e-08
5 O 0 3.021619363607897e-07
- O 0 2.113566495154373e-07
37 O 0 2.189949128705848e-07
repeats O 0 2.9599340223285253e-07
on O 0 8.177813271004197e-08
normal O 0 6.526116891336642e-08
chromosomes O 0 2.8162650878016393e-08
but O 0 1.2644075120249454e-08
amplified O 0 1.8654809252893756e-07
to O 0 2.2037845326394745e-08
50 O 0 2.32559528967613e-07
- O 0 6.591574788217258e-07
3000 O 0 1.761496832841658e-06
copies O 0 5.740546384913614e-07
on O 0 3.978727363573853e-06
DM B-Disease 1 0.9999903440475464
chromosomes O 0 4.038506085635163e-05
. O 0 1.7834556274465285e-05

Previous O 0 1.5539926607743837e-05
findings O 0 4.397169050207594e-06
in O 0 3.8866312479513e-07
Caucasian O 0 2.1997798285156023e-06
populations O 0 2.0020219437810738e-07
of O 0 2.0222310013195965e-06
a O 0 0.00026767540839500725
DM B-Disease 1 1.0
founder O 1 0.9987871050834656
chromosome O 0 5.307363153406186e-06
raise O 0 1.5435634281857347e-07
a O 0 5.464019281475885e-08
question O 0 7.73024737554806e-08
about O 0 1.3493683503895681e-08
the O 0 1.8918115074484376e-08
molecular O 0 2.3886684630269883e-07
events O 0 4.1407272277638185e-08
involved O 0 4.8380282891002935e-08
in O 0 2.6032635602746268e-08
the O 0 8.227314651776396e-08
expansion O 0 2.5204817575286143e-06
mutation O 0 8.671778232383076e-06
. O 0 9.290580237575341e-06

To O 0 3.513423735057586e-06
investigate O 0 4.405081199365668e-06
whether O 0 1.1636784620350227e-06
a O 0 2.7553014660952613e-06
founder O 0 5.267743472359143e-05
chromosome O 0 4.530372734734556e-06
for O 0 5.591801937043783e-07
the O 0 1.7305560504610185e-06
DM B-Disease 1 1.0
mutation O 0 3.6766772382179624e-07
exists O 0 3.2464260613096485e-08
in O 0 3.3587408410085118e-09
the O 0 7.709364702179755e-09
Japanese O 0 7.194066853344339e-08
population O 0 3.163609374468024e-09
, O 0 2.1732128985263444e-08
we O 0 1.2920307312924706e-07
genotyped O 0 6.279257831920404e-06
families O 0 5.566009164681418e-08
using O 0 1.884184825939883e-07
polymorphic O 0 2.298640083608916e-06
markers O 0 5.192784442442644e-07
near O 0 1.0559169822954573e-06
the O 0 4.953344614477828e-07
( O 0 1.1641735682133003e-06
CTG O 0 0.0002698102907743305
) O 0 2.0909118347844924e-07
n O 0 1.0111316441907547e-06
repeat O 0 1.2770295825248468e-06
region O 0 5.143575663169031e-07
and O 0 6.744306233485986e-07
constructed O 0 1.783237894414924e-05
haplotypes O 0 6.110952381277457e-05
. O 0 2.3238790163304657e-05

Six O 0 1.035516288538929e-05
different O 0 8.686666888024774e-07
haplotypes O 0 6.400759502867004e-06
were O 0 3.629374987212941e-07
found O 0 2.2516807973715913e-07
and O 0 1.8036616893368773e-06
DM B-Disease 1 1.0
alleles O 0 1.4585452845494729e-05
were O 0 2.0368090645206394e-06
always O 0 1.9103022168565076e-06
haplotype O 0 3.268128784839064e-05
A O 0 3.211635339539498e-05
. O 0 3.298135197837837e-05

To O 0 6.982749596318172e-07
find O 0 3.777892345624423e-07
an O 0 2.1861758625618677e-08
origin O 0 4.722171098592298e-08
of O 0 1.761782897347075e-07
the O 0 5.468471044878243e-07
( O 0 1.5318025816668523e-06
CTG O 0 0.0007400233880616724
) O 0 1.6074201880655892e-07
n O 0 4.156787838383025e-07
repeat O 0 4.312784938065306e-07
mutation O 0 8.039857135599959e-08
and O 0 1.012795181054571e-08
to O 0 6.818325903878986e-09
investigate O 0 4.004063569595928e-08
the O 0 1.8069497897954534e-08
mechanism O 0 1.467291497192491e-07
of O 0 1.955202577619275e-08
the O 0 5.66435476301308e-09
expansion O 0 2.7669553759324117e-08
mutation O 0 9.63794732911083e-09
in O 0 1.6315612194617302e-09
the O 0 2.956478617477387e-09
Japanese O 0 4.245742957209586e-08
population O 0 1.1077916362012274e-09
we O 0 6.672064678525658e-09
have O 0 8.654622796200329e-09
studied O 0 3.185433286034822e-07
90 O 0 2.759474853064603e-07
Japanese O 0 3.500440470816102e-06
DM B-Disease 1 0.9999998807907104
families O 0 2.3392014725232002e-07
comprising O 0 1.093265609597438e-06
190 O 0 6.6722577685141e-07
affected O 0 2.3828597761621495e-07
and O 0 2.2735413551799866e-07
130 O 0 2.21919026444084e-06
unaffected O 0 7.3182754931622185e-06
members O 0 3.040795718334266e-06
. O 0 1.9123244783258997e-05

The O 0 3.726461500264122e-06
results O 0 1.5462552482858882e-06
suggest O 0 3.012030163063173e-07
that O 0 1.5675652775826165e-08
a O 0 4.792099872474864e-08
few O 0 4.730221192517092e-08
common O 0 7.4484837853106e-08
ancestral O 0 1.0676992445723954e-07
mutations O 0 7.46627790704224e-08
in O 0 1.365883761650366e-08
both O 0 4.4260200837697994e-08
Caucasian O 0 1.15480872864282e-06
and O 0 1.1358057605548311e-07
Japanese O 0 6.100363520999963e-07
populations O 0 9.383060550760547e-09
have O 0 3.120496527841965e-09
originated O 0 8.133942408505845e-09
by O 0 3.6240530576492347e-09
expansion O 0 2.5992546781594683e-08
of O 0 1.753762646217183e-08
an O 0 6.687659759307962e-09
ancestral O 0 5.1380553145463637e-08
n O 0 2.085413797203728e-07
= O 0 3.2336345157091273e-07
5 O 0 1.3432214984732127e-07
repeat O 0 7.874703555899032e-08
to O 0 1.385177483825828e-08
n O 0 3.2987017561936227e-07
= O 0 8.225554779528466e-07
19 O 0 1.1371251957825734e-06
- O 0 6.619449663958221e-07
37 O 0 1.018798457153025e-06
copies O 0 1.6107944702525856e-06
. O 0 6.184833182487637e-06

These O 0 1.171285248346976e-06
data O 0 8.289326274280029e-07
support O 0 5.710471100428549e-07
multistep O 0 9.096196663449518e-06
models O 0 3.514100853863056e-06
of O 0 1.0730559552030172e-06
triplet O 0 1.3459631190926302e-05
repeat O 0 4.793864150087757e-07
expansion O 0 1.9054789390793303e-07
that O 0 4.091867733535537e-09
have O 0 4.674593157005802e-09
been O 0 1.6084591436538176e-08
proposed O 0 5.3556789225694956e-08
for O 0 3.6131776681713745e-08
both O 0 6.167071546769876e-07
DM B-Disease 1 1.0
and O 0 1.3745489923167042e-05
Friedreichs B-Disease 1 0.963639497756958
ataxia I-Disease 1 0.9795320630073547
. O 0 4.749174422613578e-06
. O 0 1.9165236153639853e-05

The O 0 1.966118816199014e-06
molecular O 0 4.793777407030575e-06
basis O 0 2.987885864058626e-06
of O 0 0.006901425775140524
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.5400551944821927e-07
the O 0 1.1308146241617578e-07
western O 0 8.108655720207025e-07
Cape O 0 1.3237056009529624e-05
, O 0 2.9316919381017215e-07
South O 0 2.314764969923999e-06
Africa O 0 1.5014004929980729e-05
. O 0 1.7043770640157163e-05

Deficiency B-Disease 1 0.9935727119445801
of I-Disease 0 1.2158908248238731e-05
the I-Disease 0 3.241416834498523e-06
sixth I-Disease 0 2.0729406969621778e-05
component I-Disease 0 1.0060491604235722e-06
of I-Disease 0 1.990107278970754e-07
human I-Disease 0 6.463953639013198e-08
complement I-Disease 0 8.300764875457389e-07
( O 0 4.148791958868969e-07
C6 O 1 0.9999827146530151
) O 0 5.0463992096183574e-08
has O 0 1.1697315116521168e-08
been O 0 2.1199449307118812e-08
reported O 0 2.2470102223337562e-08
in O 0 2.887898142844847e-09
a O 0 5.6928510794307385e-09
number O 0 4.644022055799724e-09
of O 0 1.7526522455568738e-08
families O 0 2.6715620826678332e-09
from O 0 6.74571909442534e-09
the O 0 3.267965098530112e-08
western O 0 4.376843207865022e-07
Cape O 0 1.3931049579696264e-05
, O 0 4.179018446848204e-07
South O 0 3.449903715591063e-06
Africa O 0 1.2932644494867418e-05
. O 0 9.66975130722858e-06

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9983173608779907
is O 0 7.319310952880187e-07
endemic O 0 1.847924835374215e-07
in O 0 3.135412995902698e-08
the O 0 1.4866235176214104e-07
Cape O 0 4.449252173799323e-06
and O 0 2.8074373048525558e-08
almost O 0 3.4602084753032614e-08
all O 0 1.1082909701087829e-08
pedigrees O 0 9.014608082225095e-08
of O 0 1.5904394956578471e-07
total O 0 2.3802986106602475e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.6135594705701806e-05
C6Q0 O 1 0.9892450571060181
) O 0 3.07223650963806e-08
have O 0 7.215887443123847e-09
been O 0 2.318015290825315e-08
ascertained O 0 5.881187234990648e-07
because O 0 6.324461310214247e-08
of O 0 2.310488525836263e-06
recurrent O 1 0.9199126362800598
disease O 1 0.997776448726654
. O 0 0.00013385889178607613

We O 0 2.47585967372288e-06
have O 0 2.158393783702195e-07
sequenced O 0 8.412351348852098e-07
the O 0 1.1384279474668801e-07
expressed O 0 1.205220740985169e-07
exons O 0 1.6270053038169863e-06
of O 0 2.4881632043616264e-07
the O 0 4.8611394731779e-07
C6 O 1 0.7720405459403992
gene O 0 8.253909555833161e-08
from O 0 1.800121474104799e-08
selected O 0 1.3500600459792622e-07
cases O 0 3.0069237766383594e-08
and O 0 2.8324043555016942e-08
have O 0 2.2853924974697293e-08
found O 0 7.344176111701017e-08
three O 0 2.4145674615283497e-07
molecular O 0 0.012491410598158836
defects O 0 0.058221861720085144
leading O 0 1.1247458132856991e-05
to O 0 1.6430175264758873e-07
total O 0 6.038600986357778e-06
deficiency O 1 0.9999680519104004
879delG O 0 0.011694541200995445
, O 0 2.262335385694314e-07
which O 0 2.098546580953098e-08
is O 0 9.777965992441295e-09
the O 0 2.6667015262660243e-08
common O 0 1.1914271880186789e-07
defect O 0 6.406724537555419e-07
in O 0 3.186526598142336e-08
the O 0 1.5102648376341676e-07
Cape O 0 5.791024250356713e-06
and O 0 9.25034200349728e-08
hitherto O 0 6.48613422526978e-07
unreported O 0 1.6246936240804644e-07
, O 0 2.576470414794585e-08
and O 0 6.455574919073115e-08
1195delC O 0 1.9306996819068445e-06
and O 0 5.129917468593703e-08
1936delG O 0 2.05775472750247e-06
, O 0 4.089365290838032e-08
which O 0 9.849958182428509e-09
have O 0 8.580673949154516e-09
been O 0 3.3489168771438926e-08
previously O 0 1.4634107969868637e-07
reported O 0 1.4446052887251426e-07
in O 0 1.1128010157790413e-07
African O 0 9.255313671019394e-06
- O 0 8.788888408162165e-06
Americans O 0 2.664836074472987e-06
. O 0 1.7181395378429443e-05

We O 0 2.6855470878217602e-06
also O 0 1.882317093304664e-07
show O 0 7.603102858411148e-08
that O 0 1.0581358900196847e-08
the O 0 7.784252176179507e-08
879delG O 0 5.8250166148354765e-06
and O 0 5.37838332093088e-07
1195delC O 0 0.00017287986702285707
defects O 0 1.289048304897733e-05
are O 0 4.678743081854009e-08
associated O 0 1.7812705266351259e-07
with O 0 2.935073837306845e-07
characteristic O 1 0.9999760389328003
C6 O 1 1.0
/ O 1 0.9999995231628418
C7 O 1 0.9999771118164062
region O 0 5.044465183345892e-07
DNA O 0 3.251527118663944e-07
marker O 0 2.9669061518688977e-07
haplotypes O 0 5.802367581964063e-07
, O 0 3.178477570031646e-08
although O 0 5.6078885535271183e-08
small O 0 4.757310634317946e-08
variations O 0 4.214285809212015e-07
were O 0 8.830996875985875e-07
observed O 0 6.9609686761396006e-06
. O 0 1.0627266419760417e-05

The O 0 1.7231341189472005e-05
1936delG O 0 0.0003299070231150836
defect O 0 6.171483255457133e-05
was O 0 2.6382019768789178e-06
observed O 0 4.490424032610463e-07
only O 0 7.49175583791839e-08
once O 0 1.2554970396649878e-07
in O 0 2.157448619755087e-08
the O 0 8.26479436000227e-08
Cape O 0 3.3448586691520177e-06
, O 0 3.259468073224525e-08
but O 0 1.873648081129886e-08
its O 0 2.7660531642936803e-08
associated O 0 1.9919110627597547e-07
haplotype O 0 2.60525121120736e-06
could O 0 2.0844176162881922e-07
be O 0 6.095577305131883e-07
deduced O 0 1.5898716810625046e-05
. O 0 1.5457684639841318e-05

The O 0 2.273685140607995e-06
data O 0 5.472346629176172e-07
from O 0 7.175115257496145e-08
the O 0 7.342522678754904e-08
haplotypes O 0 7.84804115028237e-07
indicate O 0 1.0528275140586629e-07
that O 0 1.881422839744573e-08
these O 0 5.008732628652979e-08
three O 0 2.263496412524546e-07
molecular O 0 0.006956435739994049
defects O 0 0.00011328406253596768
account O 0 1.1227681540049161e-07
for O 0 2.2697804524796084e-07
the O 0 1.01456237189268e-06
defects O 0 3.7224101106403396e-05
in O 0 2.8885827063618308e-08
all O 0 2.7255545376192458e-08
the O 0 3.904526479914239e-08
38 O 0 5.244773433332739e-07
unrelated O 0 4.4585058844859304e-07
C6Q0 O 0 2.2050848201615736e-05
individuals O 0 1.2883574207478432e-08
we O 0 3.951245020061833e-08
have O 0 1.9479141855072157e-08
studied O 0 5.895277013223676e-07
from O 0 7.585460082282225e-08
the O 0 7.327957973757293e-07
Cape O 0 8.064084977377206e-05
. O 0 2.108495573338587e-05

We O 0 2.6375278139312286e-06
have O 0 2.0101029463148734e-07
also O 0 1.0750865442332724e-07
observed O 0 4.0885899466047704e-07
the O 0 3.1271596867554763e-07
879delG O 0 1.1806635484390426e-05
defect O 0 2.2806518700235756e-06
in O 0 2.8505775162557256e-07
two O 0 1.7150251778730308e-06
Dutch O 1 0.9999997615814209
C6 B-Disease 1 1.0
- I-Disease 1 0.9999985694885254
deficient I-Disease 1 0.9999984502792358
kindreds O 0 5.985497773508541e-05
, O 0 6.59996004515051e-08
but O 0 3.6521583979265415e-08
the O 0 1.284277857394045e-07
879delG O 0 6.644674613198731e-06
defect O 0 1.0207571676801308e-06
in O 0 5.839250150074804e-08
the O 0 1.8010663893619494e-07
Cape O 0 4.721820459963055e-06
probably O 0 1.1615779982321328e-07
did O 0 1.3907819784719777e-08
not O 0 6.132284458004733e-09
come O 0 1.3059805681336911e-08
from O 0 1.3952056399091362e-08
The O 0 1.9246996885158296e-07
Netherlands O 0 1.231253827427281e-05
. O 0 1.1372162589395884e-06
. O 0 6.995680450927466e-06

Complement B-Disease 1 0.9999994039535522
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.156093200435862e-05
seven O 0 5.558456905419007e-06
further O 0 1.406104956913623e-06
molecular O 0 0.0002631545066833496
defects O 0 2.8172913516755216e-05
and O 0 2.4166939738279325e-07
their O 0 2.2031461810456676e-07
associated O 0 2.928971980509232e-06
marker O 0 1.3267957001517061e-05
haplotypes O 0 8.21143839857541e-05
. O 0 3.925863711629063e-05

Seven O 0 2.06266668101307e-05
further O 0 1.9566575701901456e-06
molecular O 0 6.3958905229810625e-06
bases O 0 4.133935817662859e-06
of O 0 0.4299929141998291
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 8.551334758521989e-06
described O 0 3.939762609661557e-05
. O 0 1.8356508007855155e-05

All O 0 1.776747012627311e-06
these O 0 2.5343649667775026e-07
new O 0 1.1089432518929243e-06
molecular O 0 0.00010196775110671297
defects O 0 2.7143127226736397e-05
involve O 0 8.239939006671193e-07
single O 0 3.182669843226904e-07
- O 0 1.2643130276046577e-06
nucleotide O 0 1.7213930902926222e-07
events O 0 5.4743885868902e-08
, O 0 1.3033751855573428e-08
deletions O 0 1.30094903738609e-07
and O 0 2.0168979375512208e-08
substitutions O 0 1.863707979055107e-07
, O 0 1.7074800240379773e-08
some O 0 4.9722168604660055e-09
of O 0 2.4309043666903563e-08
which O 0 1.3417612798605205e-08
alter O 0 2.1318504650480463e-07
splice O 0 7.431086146425514e-07
sites O 0 9.677241763483835e-08
, O 0 1.1111806230701404e-07
and O 0 2.0097003528007917e-07
others O 0 1.177227204607334e-06
codons O 0 5.50020340597257e-05
. O 0 3.1794941605767235e-05

They O 0 5.797577955490851e-07
are O 0 5.457686924614791e-08
distributed O 0 7.672811364045629e-08
along O 0 7.15999490807917e-08
the O 0 1.8296455550625979e-07
C7 O 0 0.009011741727590561
gene O 0 1.675659575539612e-07
, O 0 3.138620030540551e-08
but O 0 2.0336008432764174e-08
predominantly O 0 5.180200801646606e-08
towards O 0 2.064592194983561e-07
the O 0 2.6158468813264335e-07
3 O 0 4.913869361189427e-06
end O 0 1.2097840226488188e-05
. O 0 1.6500664060004056e-05

All O 0 2.8065676360711223e-06
were O 0 7.33774811578769e-07
found O 0 1.7199606361373299e-07
in O 0 1.1080039286071042e-07
compound O 0 5.129862074682023e-06
heterozygous O 0 7.529196409450378e-06
individuals O 0 1.8911441657110117e-06
. O 0 2.9640132197528146e-05

The O 0 0.0002810733567457646
C6 O 1 1.0
/ O 1 0.9999594688415527
C7 O 1 0.9999613761901855
marker O 0 4.9531066906638443e-05
haplotypes O 0 2.3320888431044295e-05
associated O 0 1.3112517081026454e-06
with O 0 1.0899873359448975e-06
most O 0 3.535388896125369e-05
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999302625656128
are O 0 9.942031056198175e-07
tabulated O 0 1.4264551282394677e-05
. O 0 2.0738029888889287e-06
. O 0 1.416326813341584e-05

A O 0 7.412760896841064e-05
genome O 0 4.483125394472154e-06
- O 0 2.947580696854857e-06
wide O 0 9.333377875009319e-07
search O 0 4.6667247488585417e-07
for O 0 1.912920595259493e-07
chromosomal O 0 1.895003515528515e-05
loci O 0 2.898802085837815e-05
linked O 0 6.27070912742056e-05
to O 0 2.3877421426732326e-06
mental O 1 0.9999780654907227
health O 0 4.21782533521764e-05
wellness O 0 3.7317295209504664e-05
in O 0 1.1475209049649493e-07
relatives O 0 1.335226329501893e-07
at O 0 8.892843652574811e-07
high O 0 8.367740520043299e-06
risk O 0 6.535835836984916e-06
for O 0 0.0004913634620606899
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 3.0689939194417093e-06
the O 0 1.385661789754522e-06
Old O 0 3.639986607595347e-05
Order O 0 8.08680761110736e-06
Amish O 0 6.40208600088954e-05
. O 0 1.5371879271697253e-05

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999862909317017
BPAD B-Disease 1 1.0
; O 1 0.9999958276748657
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 2.9242075470392592e-05
is O 0 1.4950660442991648e-07
characterized O 0 1.0591237042945068e-07
by O 0 1.749295819308827e-08
episodes O 0 1.6029747484935797e-07
of O 0 4.2726449578367465e-07
mania B-Disease 0 3.6456938687479123e-05
and O 0 1.0794718718898366e-06
/ O 0 0.042016271501779556
or O 0 4.490236733545316e-06
hypomania B-Disease 0 0.4587114155292511
interspersed O 0 7.477164558622462e-07
with O 0 4.759743532645189e-08
periods O 0 2.356341610720847e-06
of O 0 3.3992466796917142e-06
depression B-Disease 0 0.001989413984119892
. O 0 2.0721361579489894e-05

Compelling O 0 3.326313890283927e-05
evidence O 0 3.6714532143378165e-06
supports O 0 1.1582699244172545e-06
a O 0 2.7759242016145436e-07
significant O 0 2.3644831514957332e-07
genetic O 0 3.4238976809319865e-07
component O 0 6.704635779897217e-07
in O 0 5.633156163753483e-08
the O 0 9.489469476875456e-08
susceptibility O 0 1.4636441392212873e-06
to O 0 3.002293453846505e-07
develop O 0 0.00042514310916885734
BPAD B-Disease 1 1.0
. O 0 0.00042663695057854056

To O 0 7.899040497250098e-07
date O 0 2.182577645726269e-06
, O 0 1.3624158157199417e-07
however O 0 1.5929593644159468e-07
, O 0 8.795345252110565e-08
linkage O 0 4.829398676520213e-07
studies O 0 5.1492691000021296e-08
have O 0 1.571109464748588e-08
attempted O 0 2.7491964260661916e-07
only O 0 3.752927213440671e-08
to O 0 3.0182434329617536e-08
identify O 0 1.9953068886024994e-07
chromosomal O 0 4.153667305217823e-06
loci O 0 2.26413840209716e-06
that O 0 4.616760662656816e-08
cause O 0 5.817128112539649e-07
or O 0 1.1061225535513586e-07
increase O 0 5.35698703174603e-08
the O 0 7.291472314818748e-08
risk O 0 3.8253133993748634e-07
of O 0 4.593309768097242e-06
developing O 0 0.08034185320138931
BPAD B-Disease 1 1.0
. O 0 8.15675375633873e-05

To O 0 5.34474054347811e-07
determine O 0 3.8644628830297734e-07
whether O 0 5.166839756043373e-08
there O 0 3.4524628489407405e-08
could O 0 4.0862854433498796e-08
be O 0 4.511172946308761e-08
protective O 0 5.197595100980834e-07
alleles O 0 1.956714186235331e-07
that O 0 7.843894422876474e-09
prevent O 0 5.447941830993841e-08
or O 0 1.8998026263261636e-08
reduce O 0 4.596192582084768e-08
the O 0 2.1129331173597166e-08
risk O 0 6.429621635106741e-08
of O 0 2.7174317551725835e-07
developing O 0 0.00023493413755204529
BPAD B-Disease 1 1.0
, O 0 2.78506906425946e-08
similar O 0 3.0113991300595444e-09
to O 0 1.794693615941867e-09
what O 0 2.551197031408492e-09
is O 0 2.088674122546763e-09
observed O 0 9.027905534253478e-09
in O 0 6.866994084475664e-09
other O 0 1.234027706686902e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.6646276296560245e-07
we O 0 1.546877541613867e-07
used O 0 1.0577684861345915e-06
mental O 1 0.890357494354248
health O 0 4.001959496235941e-06
wellness O 0 2.4803433916531503e-05
( O 0 3.929817182779516e-08
absence O 0 2.338530009637907e-07
of O 0 2.437409705180471e-07
any O 0 1.1169065601279726e-06
psychiatric B-Disease 1 0.7813337445259094
disorder I-Disease 0 0.2260276973247528
) O 0 3.0246982873904926e-07
as O 0 2.116251067718622e-07
the O 0 2.2351704842549225e-07
phenotype O 0 2.3336185677180765e-06
in O 0 4.170299305883418e-08
our O 0 2.2158501167268696e-07
genome O 0 2.423927867312159e-07
- O 0 5.35287142611196e-07
wide O 0 1.2670529940805864e-06
linkage O 0 2.801361233650823e-06
scan O 0 3.989818651461974e-06
of O 0 3.654688498500036e-07
several O 0 1.30135120457453e-07
large O 0 2.5631146627347334e-07
multigeneration O 0 1.651561979088001e-05
Old O 0 6.747735824319534e-06
Order O 0 1.6827456192913814e-06
Amish O 0 6.058646249584854e-06
pedigrees O 0 1.3810615655529546e-06
exhibiting O 0 1.045915837494249e-06
an O 0 1.1897150642425913e-07
extremely O 0 3.795243628701428e-06
high O 0 0.0006720827077515423
incidence O 0 0.09885033965110779
of O 0 0.045057427138090134
BPAD B-Disease 1 1.0
. O 0 0.00047917134361341596

We O 0 1.3273777312861057e-06
have O 0 8.381362448517393e-08
found O 0 5.866477437166395e-08
strong O 0 1.2657822878736624e-07
evidence O 0 2.0788034760244045e-07
for O 0 6.002699137752643e-08
a O 0 1.3086440731058246e-07
locus O 0 8.504827633259993e-07
on O 0 4.610099608726159e-07
chromosome O 0 2.0208140085742343e-06
4p O 0 7.59933318477124e-05
at O 0 3.7769229948025895e-06
D4S2949 O 0 1.250024070031941e-05
( O 0 2.003756236490517e-07
maximum O 0 2.601745336505701e-06
GENEHUNTER O 0 6.227326957741752e-05
- O 0 1.8565534674053197e-06
PLUS O 0 2.2854658254800597e-06
nonparametric O 0 5.78854496779968e-06
linkage O 0 8.26294865419186e-07
score O 0 3.054861963391886e-07
= O 0 4.09427485692504e-07
4 O 0 2.0898454522466636e-07
. O 0 2.667418819157774e-08
05 O 0 2.5901838398567634e-06
, O 0 1.0853118226350489e-07
P O 0 4.1777616388571914e-06
= O 0 5.207860453992907e-07
5 O 0 1.4159833483518014e-07
. O 0 1.503469881924957e-08
22 O 0 8.275331708773592e-08
x O 0 1.111034393375121e-07
10 O 0 7.286035952347447e-08
( O 0 1.957445050493334e-08
- O 0 5.789864587768534e-08
4 O 0 2.1269241301524744e-07
) O 0 3.443840412842292e-08
; O 0 9.667371614341391e-08
SIBPAL O 0 2.238728484371677e-05
Pempirical O 0 9.170003977487795e-06
value O 0 8.375114646241855e-08
< O 0 7.950189342409431e-07
3 O 0 1.6613641662388545e-07
x O 0 1.9174811427546956e-07
10 O 0 1.2293644147121086e-07
( O 0 2.701225376711136e-08
- O 0 9.641315301678333e-08
5 O 0 1.4714197504872573e-07
) O 0 1.9030885312076862e-08
) O 0 1.532409754645414e-08
and O 0 1.9315246291284893e-08
suggestive O 0 2.8699827225864283e-07
evidence O 0 1.3722126368520549e-07
for O 0 3.240364065959511e-08
a O 0 1.0153216578601132e-07
locus O 0 1.0324399681849172e-06
on O 0 7.195891384981223e-07
chromosome O 0 2.4957328150776448e-06
4q O 0 2.3420874640578404e-05
at O 0 2.4549156023567775e-06
D4S397 O 0 1.1698179150698707e-05
( O 0 2.9811803869961295e-07
maximum O 0 2.7473824957269244e-06
GENEHUNTER O 0 7.60822367738001e-05
- O 0 1.2561621360873687e-06
PLUS O 0 1.3894543826609151e-06
nonparametric O 0 2.670285539352335e-06
linkage O 0 5.05227433222899e-07
score O 0 1.7744649483120156e-07
= O 0 2.2090308959832328e-07
3 O 0 9.389258792680266e-08
. O 0 1.6279594561297017e-08
29 O 0 1.674435878840086e-07
, O 0 3.839303275299244e-08
P O 0 2.6802254069480114e-06
= O 0 3.6243872614249995e-07
2 O 0 1.390830277614441e-07
. O 0 9.65767377181237e-09
57 O 0 6.259332963054476e-08
x O 0 1.0978433095942819e-07
10 O 0 1.2547478434044024e-07
( O 0 4.627021965575295e-08
- O 0 1.0228146152257978e-07
3 O 0 1.4227431677227287e-07
) O 0 3.533533288191393e-08
; O 0 8.408872531617817e-08
SIBPAL O 0 4.15571266785264e-05
Pempirical O 0 1.0103208296641242e-05
value O 0 1.708847747750042e-07
< O 0 8.397522606173879e-07
1 O 0 2.5089101995945384e-07
x O 0 3.7314578094083117e-07
10 O 0 1.2652161274218088e-07
( O 0 3.3672094446046685e-08
- O 0 5.385754775488749e-08
3 O 0 5.6751716215330816e-08
) O 0 7.802919199662028e-09
) O 0 2.7801634328028513e-09
that O 0 3.851065244475649e-09
are O 0 1.4358144895254554e-08
linked O 0 1.5591645023960155e-06
to O 0 6.239998242563161e-07
mental O 1 0.9998193383216858
health O 0 0.0003554408031050116
wellness O 0 0.0013825551141053438
. O 0 4.269133205525577e-05

These O 0 7.566457611574151e-07
findings O 0 4.340028851856914e-07
are O 0 2.774258689441922e-08
consistent O 0 2.2879140715303947e-07
with O 0 2.0814928447521197e-08
the O 0 3.949768156985556e-08
hypothesis O 0 6.910250505143267e-08
that O 0 1.7443206878908768e-09
certain O 0 7.0886527758773354e-09
alleles O 0 9.107917975370583e-08
could O 0 3.446469065693236e-08
prevent O 0 6.307872268962456e-08
or O 0 1.951923600529426e-08
modify O 0 5.42200488951039e-08
the O 0 1.4893218214240278e-08
clinical O 0 2.9438004389703565e-07
manifestations O 0 2.4401849714195123e-06
of O 0 1.5600926417391747e-06
BPAD B-Disease 1 1.0
and O 0 4.201011734039639e-07
perhaps O 0 4.7449503881580313e-07
other O 0 2.0686916002432554e-07
related O 0 0.00024973394465632737
affective B-Disease 1 0.9999986886978149
disorders I-Disease 1 0.9999990463256836
. O 0 0.00030568212969228625

Segregation O 0 0.04519680142402649
distortion O 1 0.9999380111694336
in O 0 0.06241152063012123
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.42527681589126587

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999966621398926
DM B-Disease 1 1.0
) O 0 1.356606026092777e-05
is O 0 1.4652486868271808e-07
an O 0 6.766339311070624e-08
autosomal B-Disease 0 0.12771517038345337
dominant I-Disease 1 0.9999971389770508
disease I-Disease 0 0.4980665147304535
which O 0 7.289344239325146e-08
, O 0 1.926851389555395e-08
in O 0 6.210252756488899e-09
the O 0 1.4396920100523403e-08
typical O 0 1.1657539999987421e-07
pedigree O 0 1.6439673800050514e-07
, O 0 1.777361902099983e-08
shows O 0 1.541997285414709e-08
a O 0 2.8795831497063773e-08
three O 0 1.0464471245086315e-07
generation O 0 4.224593794788234e-06
anticipation O 0 1.7862181266536936e-05
cascade O 0 5.283218342810869e-05
. O 0 1.4687052498629782e-05

This O 0 1.0875056659642723e-06
results O 0 6.676778866676614e-06
in O 0 1.7856718841358088e-06
infertility B-Disease 1 0.9999074935913086
and O 1 0.9999896287918091
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999986886978149
CDM B-Disease 1 0.9999992847442627
) O 0 1.2217765288369264e-07
with O 0 1.7688968512175052e-08
the O 0 7.645187594107483e-08
disappearance O 0 1.0547787496761885e-06
of O 0 2.0293425677664345e-06
DM B-Disease 1 1.0
in O 0 5.419078661361709e-07
that O 0 3.903053027443093e-07
pedigree O 0 2.100760320900008e-05
. O 0 2.256660991406534e-05

The O 0 2.9333409656828735e-06
concept O 0 1.511088839833974e-06
of O 0 1.1223906994928257e-06
segregation O 0 8.890876415534876e-06
distortion O 0 4.054980672663078e-05
, O 0 7.389730427576069e-08
where O 0 2.9553127944836888e-08
there O 0 1.6122985613264973e-08
is O 0 9.493122732351367e-09
preferential O 0 2.4982114155136514e-07
transmission O 0 1.1650532769635902e-06
of O 0 4.109679707653413e-08
the O 0 3.5462672798303174e-08
larger O 0 4.418917853854509e-08
allele O 0 3.1503282116318587e-07
at O 0 2.4744713300606236e-07
the O 0 2.443875644075888e-07
DM B-Disease 1 1.0
locus O 0 1.4012804285812308e-06
, O 0 2.8361776926999482e-08
has O 0 9.622297625355714e-09
been O 0 8.667044859578255e-09
put O 0 4.819056442784131e-08
forward O 0 2.282905597894569e-07
to O 0 4.151213062186798e-08
explain O 0 2.7191453000341426e-07
partially O 0 2.92145443836489e-07
the O 0 7.689747860695206e-08
maintenance O 0 8.298018769892224e-07
of O 0 2.205358896389953e-06
DM B-Disease 1 1.0
in O 0 3.128752439351956e-07
the O 0 3.4442155083524995e-07
population O 0 1.9455606548035576e-07
. O 0 4.521864866546821e-06

In O 0 3.2645816645526793e-06
a O 0 1.5517564406763995e-06
survey O 0 7.357950266850821e-07
of O 0 3.033465191037976e-06
DM B-Disease 1 1.0
in O 0 4.613829105437617e-07
Northern O 0 2.3055733890942065e-06
Ireland O 0 3.0083406272751745e-06
, O 0 4.872213139606174e-07
59 O 0 2.239895593447727e-06
pedigrees O 0 3.4462370877008652e-06
were O 0 2.212584377048188e-06
ascertained O 0 0.00010657277016434819
. O 0 3.775197910727002e-05

Sibships O 0 0.00016493973089382052
where O 0 3.566672432953055e-07
the O 0 4.615607096525309e-08
status O 0 4.943509779309352e-08
of O 0 3.3109994745927906e-08
all O 0 1.0840535580314281e-08
the O 0 1.3691963118844797e-08
members O 0 1.879403477289543e-08
had O 0 2.9637746479238558e-08
been O 0 3.043668783675457e-08
identified O 0 6.8520428442298e-08
were O 0 6.124688667341616e-08
examined O 0 1.2047082975641388e-07
to O 0 1.0785263349077923e-08
determine O 0 9.875055440033975e-08
the O 0 8.729596601142475e-08
transmission O 0 1.1443900802987628e-05
of O 0 7.809210842424363e-07
the O 0 2.7946236969000893e-06
DM B-Disease 1 1.0
expansion O 0 1.6103100278996862e-05
from O 0 5.645321010661064e-08
affected O 0 5.416516657419379e-08
parents O 0 1.1263883159529087e-08
to O 0 3.223559374987417e-08
their O 0 2.944763650702953e-07
offspring O 0 8.226228601415642e-06
. O 0 1.086794782167999e-05

Where O 0 6.793048669351265e-06
the O 0 2.5126480522885686e-06
transmitting O 0 0.00015230565622914582
parent O 0 4.23196843257756e-06
was O 0 6.137118361948524e-06
male O 0 4.050284587719943e-06
, O 0 2.0742995729960967e-06
58 O 0 4.928643465973437e-05
. O 0 3.732825643965043e-05

3 O 0 4.8124802560778335e-06
% O 0 1.909499331986808e-07
of O 0 1.654896664149419e-07
the O 0 7.193421680540268e-08
offspring O 0 1.0787777426912726e-07
were O 0 9.974722559036309e-08
affected O 0 8.964148179302356e-08
, O 0 2.1153686802222182e-08
and O 0 1.9075148571801037e-08
in O 0 1.2714231445443147e-08
the O 0 1.6182632123218355e-08
case O 0 3.563897266189997e-08
of O 0 2.864819137471386e-08
a O 0 8.322612643496541e-08
female O 0 5.603514523500053e-07
transmitting O 0 1.787037581379991e-05
parent O 0 8.154548822858487e-07
, O 0 1.0359609632359934e-06
68 O 0 1.3772808415524196e-05
. O 0 2.2982867449172772e-05

7 O 0 6.36331969872117e-05
% O 0 5.004071681469213e-06
were O 0 4.9095970098278485e-06
affected O 0 1.6539939679205418e-05
. O 0 3.027944330824539e-05

Studies O 0 2.4817583835101686e-05
on O 0 8.023670488910284e-06
meiotic O 0 0.00018209120025858283
drive O 0 1.2320666428422555e-05
in O 0 1.9147817056364147e-06
DM B-Disease 1 1.0
have O 0 1.8841741677988466e-07
shown O 0 1.7345318781281094e-07
increased O 0 1.4493689093342255e-07
transmission O 0 8.802936690699426e-07
of O 0 2.6162103594629116e-08
the O 0 2.138288479613948e-08
larger O 0 3.3440660018868584e-08
allele O 0 2.8098273219256953e-07
at O 0 2.7473723207549483e-07
the O 0 2.5352181864946033e-07
DM B-Disease 1 0.9999958276748657
locus O 0 1.8332083300265367e-06
in O 0 1.5685320420288917e-07
non O 0 1.1776947758335155e-05
- O 0 0.0001985113776754588
DM O 1 1.0
heterozygotes O 0 6.589593249373138e-05
for O 0 2.7740502446249593e-06
CTGn O 0 0.0007784019107930362
. O 0 2.5722491045598872e-05

This O 0 8.10013091268047e-07
study O 0 2.5184752416862466e-07
provides O 0 6.911529482067635e-08
further O 0 6.882942926722535e-08
evidence O 0 1.2092237966498942e-07
that O 0 2.713008129262562e-08
the O 0 5.527941766558797e-07
DM B-Disease 1 1.0
expansion O 0 4.874523256148677e-06
tends O 0 6.008610284879978e-07
to O 0 9.937255640579679e-08
be O 0 5.107316383146099e-07
transmitted O 0 2.6568327484710608e-06
preferentially O 0 5.3725275392935146e-06
. O 0 6.264997864491306e-06

Diagnosis O 1 0.9998204112052917
of O 1 0.971662700176239
hemochromatosis B-Disease 1 1.0
. O 1 0.8367490172386169

If O 0 0.00011682171316351742
untreated O 1 0.9994959831237793
, O 0 0.0005184825859032571
hemochromatosis B-Disease 1 1.0
can O 0 0.0001155965801444836
cause O 1 0.9646434783935547
serious O 1 0.999948263168335
illness O 0 0.31374460458755493
and O 0 3.0522264182764047e-07
early B-Disease 0 5.265881100058323e-06
death I-Disease 0 3.557110630936222e-06
, O 0 2.628705253471253e-08
but O 0 2.4218199001779794e-08
the O 0 1.0395282146191676e-07
disease O 0 1.5339617220888613e-06
is O 0 2.0042048021196024e-08
still O 0 8.06261510888362e-08
substantially O 0 1.0320383125872468e-06
under O 0 1.037981201079674e-05
- O 1 0.6241387128829956
diagnosed O 0 0.004720328841358423
. O 0 1.9474076907499693e-05

The O 0 4.8279207476298325e-06
cornerstone O 0 5.493398930411786e-05
of O 0 6.384090056599234e-07
screening O 0 2.981487341457978e-07
and O 0 7.891483022604007e-08
case O 0 2.9926400202384684e-07
detection O 0 1.3043421631664387e-06
is O 0 3.539172155342385e-08
the O 0 6.36589945202104e-08
measurement O 0 1.1850240753119579e-06
of O 0 9.558185638525174e-07
serum O 0 5.711523044737987e-06
transferrin O 0 1.3735137144976761e-05
saturation O 0 5.425012204796076e-06
and O 0 4.679997402945446e-07
the O 0 1.2172749848105013e-06
serum O 0 1.3415329704002943e-05
ferritin O 0 0.00013823113113176078
level O 0 5.060700641479343e-05
. O 0 1.4612851373385638e-05

Once O 0 9.564427273289766e-06
the O 0 9.881986215987126e-07
diagnosis O 0 6.740249955328181e-05
is O 0 1.844090320446412e-07
suspected O 0 3.752759766939562e-06
, O 0 3.677911877275619e-07
physicians O 0 4.367719554920768e-07
must O 0 1.3917829733145481e-07
use O 0 4.2981838532796246e-07
serum O 0 9.322630830865819e-06
ferritin O 0 0.0003619145427364856
levels O 0 3.3965330658247694e-05
and O 0 3.7136236642254516e-05
hepatic O 1 0.9999997615814209
iron O 1 0.9993709921836853
stores O 0 2.508692659830558e-06
on O 0 1.5570277582810377e-06
liver O 0 2.9601728783745784e-06
biopsy O 0 6.446783231695008e-07
specimens O 0 7.144102198708424e-08
to O 0 1.9168151510484677e-08
assess O 0 4.6649802243337035e-07
patients O 0 2.34139250210319e-08
for O 0 2.160854428723269e-08
the O 0 6.046202827292291e-08
presence O 0 7.091501856848481e-07
of O 0 1.9187602447345853e-05
iron B-Disease 1 0.9999985694885254
overload I-Disease 1 0.9995914101600647
. O 0 0.00013557817146647722

Liver O 1 0.534380316734314
biopsy O 0 0.002711511915549636
is O 0 2.3710269658749894e-07
also O 0 2.122247089175744e-08
used O 0 6.663391172168076e-09
to O 0 3.970129558439339e-09
establish O 0 1.9338468604246373e-08
the O 0 8.596924949699769e-09
presence O 0 3.0591905897381366e-08
or O 0 2.2009617239859836e-08
absence O 0 3.425975023674255e-07
of O 0 6.134545174063533e-07
cirrhosis B-Disease 1 0.9988757967948914
, O 0 5.696004024002832e-08
which O 0 1.9326227729266066e-08
can O 0 2.9216346675298155e-08
affect O 0 8.659808941047231e-07
prognosis O 0 0.00013297368423081934
and O 0 4.193720997136552e-06
management O 0 0.00022885815997142345
. O 0 5.3689360356656834e-05

A O 0 1.7234660845133476e-05
DNA O 0 7.3811188485706225e-06
- O 0 1.7641581280258833e-06
based O 0 8.903656834036155e-08
test O 0 3.037336000488722e-07
for O 0 3.975071294348709e-08
the O 0 9.702432635094738e-08
HFE O 0 0.00022084101510699838
gene O 0 7.196852891411254e-08
is O 0 3.76863473761091e-09
commercially O 0 1.9792423699982464e-08
available O 0 4.998232050468232e-09
, O 0 1.5104132389254232e-09
but O 0 1.2314872455121417e-09
its O 0 2.0079153895125046e-09
place O 0 2.0223604124680605e-08
in O 0 3.8106224842238134e-09
the O 0 1.6645511635715593e-08
diagnosis O 0 8.075655387074221e-06
of O 0 8.044786227401346e-06
hemochromatosis B-Disease 1 1.0
is O 0 1.0347929446652415e-06
still O 0 6.370873961714096e-07
being O 0 2.8358047075016657e-06
evaluated O 0 1.4832270608167164e-05
. O 0 1.529963265056722e-05

Currently O 0 3.478025973890908e-06
, O 0 1.902588167013164e-07
the O 0 4.913756868063501e-08
most O 0 1.4782279400549214e-08
useful O 0 6.617936065822505e-08
role O 0 3.241254020736051e-08
for O 0 7.422471082207949e-09
this O 0 3.6672760383993364e-09
test O 0 4.562834376997671e-08
is O 0 3.4353755395954977e-09
in O 0 1.6048300466309229e-09
the O 0 1.3612439175858526e-08
detection O 0 9.390295190314646e-07
of O 0 4.021337190351915e-06
hemochromatosis B-Disease 1 1.0
in O 0 2.956165303658054e-07
the O 0 1.7334950541680882e-07
family O 0 1.9733130685040123e-08
members O 0 1.4510057155803224e-08
of O 0 7.754480435551159e-08
patients O 0 2.4182796209970547e-08
with O 0 1.3711668245264264e-08
a O 0 1.9251476146564528e-07
proven O 0 5.401716407504864e-05
case O 0 1.2908019471069565e-06
of O 0 4.4081193664169405e-06
the O 0 3.15914730890654e-05
disease O 0 0.18500523269176483
. O 0 3.349471080582589e-05

It O 0 9.285321311836015e-07
is O 0 3.096314742379036e-07
crucial O 0 2.8655626920226496e-06
to O 0 2.7201074317417806e-06
diagnose O 1 0.9999984502792358
hemochromatosis B-Disease 1 1.0
before O 1 0.9999960660934448
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.07145217061042786
because O 0 4.662103492591996e-06
phlebotomy O 1 0.9972342848777771
therapy O 0 0.005714045371860266
can O 0 1.1588842880883021e-06
avert O 1 0.9428675770759583
serious O 1 0.9999998807907104
chronic O 1 1.0
disease O 1 0.9941101670265198
and O 0 1.0367818248369076e-07
can O 0 8.55782378295089e-09
even O 0 9.239951914707945e-09
lead O 0 3.683288696265663e-08
to O 0 1.6593524776453705e-08
normal O 0 3.754825286250707e-07
life O 0 2.2034109292690118e-07
expectancy O 0 6.037433877281728e-07
. O 0 4.42497395169994e-07
. O 0 5.767529273725813e-06

Prevalence O 0 5.915193833061494e-05
of O 0 3.4568390674394323e-06
the O 0 3.1420038340002066e-06
I1307K O 0 5.130738645675592e-05
APC B-Disease 0 1.088875978894066e-05
gene O 0 2.781953298836015e-07
variant O 0 8.854761404109013e-07
in O 0 3.6319228513548296e-08
Israeli O 0 4.982634322914237e-07
Jews O 0 2.8170180144115875e-07
of O 0 8.713692523087957e-08
differing O 0 1.3348773109100875e-07
ethnic O 0 8.73865886319436e-08
origin O 0 3.8980758176876407e-07
and O 0 1.870418714133848e-06
risk O 0 0.04950378090143204
for O 1 0.9999922513961792
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.7779766321182251

BACKGROUND O 0 0.00010490728163858876
& O 0 3.751146505237557e-05
AIMS O 0 1.2342268746579066e-05
Israeli O 0 1.8653561255632667e-06
Jews O 0 3.3551253864061437e-07
of O 0 1.0471200084793963e-07
European O 0 3.7335010460992635e-07
birth O 0 8.250509608842549e-08
, O 0 3.0306981813055245e-08
i O 0 5.995696028548991e-08
. O 0 1.6977505623572142e-08
e O 0 5.0810140095336465e-08
. O 0 2.022252232336541e-08
, O 0 4.527412755805926e-08
Ashkenazim O 0 2.8269963877392e-05
, O 0 6.317227274621473e-08
have O 0 3.642238510792595e-08
the O 0 7.703054052399239e-07
highest O 1 0.9999804496765137
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 2.0795857835764764e-06
of O 0 7.061370155270197e-08
any O 0 4.4222822737083334e-08
Israeli O 0 6.772019673917384e-07
ethnic O 0 3.5501255979397683e-07
group O 0 2.0562247300404124e-06
. O 0 1.3602258150058333e-05

The O 0 1.7694201233098283e-05
I1307K O 0 0.00014231292880140245
APC B-Disease 0 3.067936995648779e-05
gene O 0 1.54426572862576e-06
variant O 0 1.3242232853372116e-05
was O 0 1.9296853679406922e-06
found O 0 1.5044140866393718e-07
in O 0 3.982984253525501e-07
6 O 0 0.00011615535186138004
. O 0 4.08338601118885e-05

1 O 0 3.888587798428489e-06
% O 0 1.4825657501660316e-07
of O 0 1.3667455789345695e-07
American O 0 1.6143518166700233e-07
Jews O 0 3.672927277875715e-07
, O 0 9.151504087867579e-08
28 O 0 5.374799911805894e-07
% O 0 3.405952497814724e-08
of O 0 1.1508570452178901e-07
their O 0 1.099678797800152e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.157578092010226e-05
, O 0 1.0109563675086974e-07
but O 0 2.103607954495601e-08
not O 0 1.4395848957349244e-08
in O 0 3.5787877550319536e-08
non O 0 1.0807202670548577e-06
- O 0 2.3630950636288617e-06
Jews O 0 5.146528110344661e-06
. O 0 1.4322266906674486e-05

We O 0 1.629900543775875e-05
assessed O 0 1.6261481505353004e-05
the O 0 9.405135870110826e-07
I1307K O 0 8.746195817366242e-06
prevalence O 0 7.36374147436436e-07
in O 0 2.6573287570386128e-08
Israeli O 0 3.585723220567161e-07
Jews O 0 1.1586305959099263e-07
of O 0 3.595564379565985e-08
differing O 0 5.111457923590024e-08
ethnic O 0 5.7914000706205115e-08
origin O 0 3.561968071608135e-07
and O 0 1.7092386315198382e-06
risk O 0 0.006849877070635557
for O 1 0.9999613761901855
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.6259576678276062

METHODS O 0 1.1827585694845766e-05
DNA O 0 2.0899958599329693e-06
samples O 0 1.2599974752447451e-07
from O 0 4.164822442476179e-08
500 O 0 2.6016013521257264e-07
unrelated O 0 1.190140608287038e-07
Jews O 0 1.592573539710429e-07
of O 0 9.594884176067353e-08
European O 0 1.072969894266862e-06
or O 0 6.97314135322813e-08
non O 0 5.820091359964863e-07
- O 0 7.615410879679985e-08
European O 0 4.943868603390911e-08
origin O 0 1.6063989249914812e-08
, O 0 3.6371339273699732e-09
with O 0 1.9099093417906943e-09
or O 0 6.229281535041764e-09
without O 0 1.1373922248480994e-08
a O 0 8.479622337631554e-09
personal O 0 3.279911098275079e-08
and O 0 1.048642914724951e-07
/ O 0 2.393989598203916e-05
or O 0 8.864378031603337e-08
family O 0 1.5994677582398253e-08
history O 0 7.48167394704069e-08
of O 0 3.5940493603447976e-07
neoplasia B-Disease 1 0.8465243577957153
, O 0 3.5071462889391114e-07
were O 0 2.4767615514065255e-07
examined O 0 4.0084083252622804e-07
for O 0 3.795920378024675e-08
the O 0 9.184255844729705e-08
I1307K O 0 3.5480913993524155e-06
variant O 0 1.2864491054642713e-06
by O 0 4.0651176647088505e-08
the O 0 9.973752668201996e-08
allele O 0 9.665302513894858e-07
- O 0 3.552841860710032e-07
specific O 0 9.190021188487663e-08
oligonucleotide O 0 2.2803629690315574e-05
( O 0 8.046843049669405e-07
ASO O 0 0.0011190855875611305
) O 0 1.7854709994935547e-06
method O 0 2.5974984964705072e-05
. O 0 2.8998638299526647e-05

RESULTS O 0 4.3991200072923675e-05
In O 0 9.032953016685497e-07
persons O 0 5.130984845891362e-07
at O 0 1.2318636208874523e-06
average O 0 2.777340739612555e-07
risk O 0 2.134038368239999e-06
for O 0 0.00701484689489007
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 9.366412086819764e-06
I1307K O 0 5.482199776452035e-05
was O 0 5.744072950619739e-07
found O 0 5.3474213501658596e-08
in O 0 1.482845704003921e-07
5 O 0 5.124351901031332e-06
. O 0 9.91093384072883e-06

0 O 0 7.953518434078433e-06
% O 0 2.7791054435510887e-07
of O 0 4.769767656398471e-07
120 O 0 9.318560501014872e-07
European O 0 2.173680741179851e-06
and O 0 8.764445738052018e-07
1 O 0 1.2404231711116154e-05
. O 0 9.962180229194928e-06

6 O 0 1.336352670477936e-05
% O 0 3.079015300500032e-07
of O 0 2.777878478354978e-07
188 O 0 4.7266772185139416e-07
non O 0 8.209192401409382e-07
- O 0 3.357090747613256e-07
European O 0 2.4499664164068236e-07
Jews O 0 3.742452179267275e-07
( O 0 7.422048753369381e-08
P O 0 4.155505394010106e-06
= O 0 8.276679182017688e-07
0 O 0 2.5619610255489533e-07
. O 0 8.302286857997387e-08
08 O 0 7.346826350840274e-06
) O 0 1.3000403669138905e-06
. O 0 1.0264051525155082e-05

It O 0 5.236614470049972e-06
occurred O 0 2.004913221753668e-05
in O 0 2.1579564872808987e-06
15 O 0 3.253137765568681e-05
. O 0 4.7079451178433374e-05

4 O 0 1.399436587234959e-05
% O 0 4.577321703891357e-07
of O 0 7.696907573517819e-07
52 O 0 2.1649734662787523e-06
Ashkenazi O 0 5.341119049262488e-06
Israelis O 0 2.5808337795751868e-06
with O 0 3.1110076292861777e-07
familial O 0 1.8781491235131398e-05
cancer B-Disease 0 0.00011749537225114182
( O 0 1.3304104413691675e-06
P O 0 0.0051548718474805355
= O 0 3.424100896154414e-06
0 O 0 3.7313259326765547e-07
. O 0 2.8688599940096537e-08
02 O 0 1.2990611821805942e-06
) O 0 1.765337565018399e-08
and O 0 2.0544900891650286e-08
was O 0 5.916877299227963e-08
not O 0 9.850821491852457e-09
detected O 0 7.543331292936273e-08
in O 0 2.360386730515529e-08
51 O 0 6.749788212800922e-07
non O 0 1.3287291267261025e-06
- O 0 7.88415434271883e-07
European O 0 8.468100531899836e-07
Jews O 0 1.1294700925645884e-06
at O 0 2.380493697273778e-06
increased O 0 2.9357170205912553e-06
cancer B-Disease 0 4.792416439158842e-05
risk O 0 8.18081298348261e-06
. O 0 1.854569563874975e-05

Colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9999995231628418
occurred O 0 0.01145214308053255
personally O 0 6.334230874927016e-06
or O 0 1.9599001177539321e-07
in O 0 4.6027281541682896e-08
the O 0 3.590945141240809e-08
families O 0 4.990516000447087e-09
of O 0 6.044611922106924e-08
13 O 0 4.168868485976418e-07
of O 0 2.753567969193682e-07
20 O 0 8.167289706761949e-07
Ashkenazi O 0 3.561523271855549e-06
I1307K O 0 2.7492671961226733e-06
carriers O 0 6.358230564273981e-08
, O 0 3.588787933495041e-08
8 O 0 1.8145883018405584e-07
of O 0 6.793793261294923e-08
whom O 0 1.4256171709803311e-07
also O 0 4.5828254968682813e-08
had O 0 5.4811902572282634e-08
a O 0 6.228785309758678e-08
personal O 0 1.9305674925362837e-07
or O 0 1.5835290412269387e-07
family O 0 1.0721112175815506e-07
history O 0 5.651882020174526e-07
of O 0 4.587400781019824e-06
noncolonic O 1 0.5092476606369019
neoplasia B-Disease 1 0.9999895095825195
. O 0 0.0005111044156365097

CONCLUSIONS O 0 6.820632552262396e-05
The O 0 1.0096042387885973e-05
I1307K O 0 0.00017715277499519289
APC O 0 4.9312431656289846e-05
variant O 0 1.5994844943634234e-05
may O 0 3.9529643913738255e-07
represent O 0 1.745592044244404e-07
a O 0 1.6628479215796688e-07
susceptibility O 0 9.382488883602491e-07
gene O 0 2.759587971468136e-07
for O 0 7.145437734834559e-07
colorectal B-Disease 1 1.0
, I-Disease 0 4.807003733731108e-06
or I-Disease 0 5.186864768802479e-07
other I-Disease 0 3.883248211877799e-08
, I-Disease 0 1.0200151479011765e-07
cancers I-Disease 0 4.742109467770206e-06
in O 0 3.090537958883033e-08
Ashkenazi O 0 4.869802069151774e-06
Jews O 0 9.039036967806169e-07
, O 0 1.967854217355125e-07
and O 0 2.7693030801856366e-07
partially O 0 3.0302469440357527e-06
explains O 0 2.2272355693075951e-07
the O 0 1.6272058189770178e-07
higher O 0 6.161930741654942e-06
incidence O 0 0.012777368538081646
of O 1 0.9988105297088623
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.943633141214377e-07
European O 0 1.1156174878124148e-05
Israelis O 0 1.8485274267732166e-05
. O 0 4.309415089664981e-06

Systematic O 0 2.0301678887335584e-05
analysis O 0 2.4927737740654266e-06
of O 0 3.841317720798543e-06
coproporphyrinogen O 1 0.7610446214675903
oxidase O 0 0.005920474883168936
gene O 0 2.1262992959236726e-05
defects O 0 0.0003450971853453666
in O 0 9.337874189441209e-07
hereditary B-Disease 1 0.9999967813491821
coproporphyria I-Disease 1 0.9998142123222351
and O 0 2.8672284315689467e-05
mutation O 0 6.370600749505684e-05
update O 0 0.00011949132021982223
. O 0 4.040763815282844e-05

Hereditary B-Disease 1 0.9999774694442749
coproporphyria I-Disease 1 0.9999585151672363
( O 0 0.0004847929230891168
HC B-Disease 1 1.0
) O 0 5.699324447050458e-06
is O 0 2.4843885171321745e-07
an O 0 3.6044946227775654e-07
acute O 1 0.9999994039535522
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.7805630564689636
autosomal O 1 0.9999954700469971
dominant O 1 0.9999957084655762
inheritance O 0 0.0001342231553280726
caused O 0 1.596482252352871e-05
by O 0 3.3199862059518637e-07
deficient B-Disease 0 1.0278401987307006e-06
activity I-Disease 0 2.1112035142323293e-07
of I-Disease 0 8.124019927890913e-07
coproporphyrinogen I-Disease 0 0.0002719372569117695
III I-Disease 1 0.9999871253967285
oxidase I-Disease 0 6.088708323659375e-05
( O 0 1.921499006130034e-06
CPO O 0 0.00011557099787751213
) O 0 3.047705149583635e-06
. O 0 1.2518457879195921e-05

Clinical O 0 0.0013237225357443094
manifestations O 0 0.017764657735824585
of O 0 2.497051900718361e-05
the O 0 2.4830485926941037e-05
disease O 0 0.09512262046337128
are O 0 7.53706075329319e-08
characterized O 0 9.726192047310178e-07
by O 0 1.6976753158814972e-07
acute O 1 0.9957022070884705
attacks O 0 0.0774436891078949
of O 1 1.0
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 3.856025159620913e-06
precipitated O 0 8.220064046327025e-05
by O 0 1.7153739406694513e-07
drugs O 0 1.01438922683883e-06
, O 0 4.901396550849313e-07
fasting O 0 1.72840736922808e-05
, O 0 2.9841558557563985e-07
cyclical O 0 0.00014308035315480083
hormonal O 0 0.00041948872967623174
changes O 0 8.08960794529412e-06
, O 0 2.5877990992739797e-05
or O 0 0.07470250874757767
infectious B-Disease 1 0.9999970197677612
diseases I-Disease 1 0.9998977184295654
. O 0 8.376518962904811e-05

Skin O 1 0.9999995231628418
photosensitivity O 1 0.9999980926513672
may O 0 3.534927236614749e-05
also O 0 1.1238516890443861e-06
be O 0 4.7300591177190654e-07
present O 0 1.9319538751005894e-06
. O 0 1.3575301636592485e-05

The O 0 6.8789918259426486e-06
seven O 0 4.625602286978392e-06
exons O 0 1.4173360796121415e-05
, O 0 3.059812740957568e-07
the O 0 3.788449021158158e-07
exon O 0 4.559582066576695e-06
/ O 0 3.972611921199132e-06
intron O 0 3.102467871940462e-06
boundaries O 0 2.5917850621226535e-07
and O 0 6.60813483932543e-08
part O 0 6.44623625589702e-08
of O 0 1.5769161620937666e-07
3 O 0 5.802909868179995e-07
noncoding O 0 4.74860797794463e-07
sequence O 0 2.9720281347067612e-08
of O 0 5.869499730692951e-08
the O 0 1.4649803858901578e-07
CPO O 0 6.69785049467464e-06
gene O 0 6.643469419032044e-08
were O 0 1.1054729043280531e-07
systematically O 0 3.8977557892394543e-07
analyzed O 0 1.2264368365322298e-07
by O 0 1.5552002352592353e-08
an O 0 4.581461965358358e-08
exon O 0 1.6458135405628127e-06
- O 0 1.2090237078155042e-06
by O 0 2.155386482627364e-07
- O 0 1.7223785107489675e-05
exon O 0 2.1839518012711778e-05
denaturing O 0 0.00017809306154958904
gradient O 0 0.0001600762188900262
gel O 0 0.00010210054460912943
electrophoresis O 0 3.266857311245985e-05
( O 0 8.325961289301631e-07
DGGE O 0 9.679403592599556e-05
) O 0 1.0779015013895332e-07
strategy O 0 3.0958926799939945e-07
followed O 0 8.416301966462925e-08
by O 0 7.724598738434452e-09
direct O 0 2.1031304697771702e-08
sequencing O 0 1.7245791639197705e-07
in O 0 2.7877156583144824e-08
seven O 0 4.5326356712394045e-07
unrelated O 0 1.7772927094483748e-06
heterozygous O 0 3.3953656384255737e-06
HC B-Disease 1 0.986613929271698
patients O 0 1.7730675949678698e-07
from O 0 6.308365385621073e-08
France O 0 4.662138962885365e-06
, O 0 1.2437276097898575e-07
Holland O 0 4.865187747782329e-06
, O 0 7.645625288432711e-08
and O 0 8.83687860664395e-08
Czech O 0 6.562416729138931e-06
Republic O 0 2.355425567657221e-05
. O 0 2.1933861717116088e-05

Seven O 0 1.750015508150682e-05
novel O 0 1.7565647567607812e-06
mutations O 0 7.616804396093357e-07
and O 0 1.4150869276363665e-07
two O 0 1.234903521663e-07
new O 0 3.845467233531963e-07
polymorphisms O 0 1.9587562292144867e-06
were O 0 2.042543655988993e-06
detected O 0 1.7266445865971036e-05
. O 0 2.5884581191348843e-05

Among O 0 2.1188209302636096e-06
these O 0 1.0822812868127585e-07
mutations O 0 2.213980820897632e-07
two O 0 4.6564149869254834e-08
are O 0 4.6024471345162965e-08
missense O 0 8.08881304692477e-06
( O 0 5.42531438441074e-07
G197W O 0 1.1800095307989977e-05
, O 0 2.2106620178874437e-07
W427R O 0 3.960174581152387e-06
) O 0 3.417027016894281e-08
, O 0 1.6357873278138868e-08
two O 0 1.2363832624373572e-08
are O 0 1.7366927451689662e-08
nonsense O 0 2.798992682073731e-06
( O 0 1.7136946439677558e-07
Q306X O 0 5.776314083050238e-06
, O 0 1.0437302222499056e-07
Q385X O 0 3.1036665859573986e-06
) O 0 4.0356681552111695e-08
, O 0 2.2038433300508586e-08
two O 0 1.4074686305320938e-08
are O 0 5.98046945299302e-09
small O 0 3.778000134957438e-08
deletions O 0 6.053270453776349e-07
( O 0 1.448324269404111e-07
662de14bp O 0 4.814192379853921e-06
; O 0 1.6148260328918695e-07
1168del3bp O 0 8.265776159532834e-06
removing O 0 1.2045284165651537e-06
a O 0 2.0036053172134416e-07
glycine O 0 9.28329370708525e-07
at O 0 3.54483432829511e-07
position O 0 6.283124207584478e-07
390 O 0 5.694346896234492e-07
) O 0 3.31064597958175e-08
, O 0 1.8652508870786733e-08
and O 0 1.689384454550691e-08
one O 0 1.7055368672913573e-08
is O 0 1.2882297006910903e-08
a O 0 5.3996096482933353e-08
splicing O 0 7.369699233095162e-07
mutation O 0 4.4141756916360464e-07
( O 0 3.0506726034218445e-07
IVS1 O 0 0.00015628816618118435
- O 0 7.946793630253524e-06
15c O 0 1.852035529736895e-05
- O 0 2.651190925462288e-06
- O 0 1.4366931964104879e-06
> O 0 3.638576572484453e-06
g O 0 7.90921660609456e-07
) O 0 3.092831946105434e-08
which O 0 1.021221684993634e-08
creates O 0 7.715856042977975e-08
a O 0 6.268018637456407e-08
new O 0 1.2062049847827438e-07
acceptor O 0 7.812525950612326e-07
splice O 0 1.4083317182667088e-05
site O 0 2.7867617973242886e-06
. O 0 1.0303388989996165e-05

The O 0 5.054547727922909e-06
pathological O 0 6.326491529762279e-06
significance O 0 9.9713997769868e-07
of O 0 3.239613306504907e-07
the O 0 1.456081406558951e-07
point O 0 3.9841430066189787e-07
mutations O 0 3.5937202369495935e-07
G197W O 0 3.07460391013592e-06
, O 0 1.3179800362195238e-07
W427R O 0 4.144447757425951e-06
, O 0 4.0538594703320996e-08
and O 0 3.96093362553529e-08
the O 0 6.055019952100338e-08
in O 0 6.24374862923105e-08
- O 0 6.851656735307188e-07
frame O 0 1.6702252878530999e-06
deletion O 0 4.999998850507836e-07
390delGly O 0 7.432389566019992e-07
were O 0 3.40534818121796e-08
assessed O 0 9.776888276746831e-08
by O 0 3.926346359151012e-09
their O 0 3.71729069748028e-09
respective O 0 5.995044460860299e-08
expression O 0 8.106778892624789e-08
in O 0 1.7315064937406532e-08
a O 0 3.191562925053404e-08
prokaryotic O 0 1.5047972112824937e-07
system O 0 8.217872959903616e-08
using O 0 1.1091837848198338e-07
site O 0 4.339590304880403e-07
- O 0 1.7436084362998372e-06
directed O 0 1.9604531189543195e-06
mutagenesis O 0 0.0004938779165968299
. O 0 8.121733844745904e-05

These O 0 1.1934507710975595e-06
mutations O 0 1.9501487713569077e-06
resulted O 0 1.5385151073132874e-06
in O 0 5.887113374569708e-08
the O 0 9.283306212637399e-08
absence O 0 1.3814461681249668e-06
or O 0 1.2728308718124026e-07
a O 0 9.856614724412793e-08
dramatic O 0 1.3269499277157593e-06
decrease O 0 6.966772616578965e-07
of O 0 4.560599791147979e-06
CPO O 0 0.0003573359572328627
activity O 0 1.4447196917899419e-05
. O 0 2.144359859812539e-05

The O 0 5.0388289309921674e-06
two O 0 9.797073516892851e-07
polymorphisms O 0 1.012519192045147e-06
were O 0 1.5906306316537666e-07
localized O 0 6.117334123700857e-07
in O 0 5.5932325437879626e-08
noncoding O 0 3.575172513592406e-07
part O 0 3.9123612793900975e-08
of O 0 4.132379771704109e-08
the O 0 2.5599479869242714e-08
gene O 0 3.2460857113392194e-08
1 O 0 1.7720093126172287e-07
) O 0 3.376509027930297e-08
a O 0 9.486320351470567e-08
C O 0 1.818207420001272e-05
/ O 0 6.242603831196902e-06
G O 0 7.257876404764829e-06
polymorphism O 0 5.83455744163075e-07
in O 0 1.8068462281917164e-08
the O 0 8.839171528052248e-08
promotor O 0 2.104088525811676e-05
region O 0 5.852295430486265e-07
, O 0 4.357480634098465e-07
142 O 0 1.5197934999378049e-06
bp O 0 1.7652183714744751e-06
upstream O 0 1.4775972090319556e-07
from O 0 1.9140932394634547e-08
the O 0 5.827467575159062e-08
transcriptional O 0 9.728149734655744e-07
initiation O 0 9.630653039494064e-07
site O 0 5.191031391404977e-07
( O 0 2.0841035563989863e-07
- O 0 1.028646238410147e-06
142C O 0 8.517688911524601e-06
/ O 0 7.023415491858032e-06
G O 0 3.0285769753390923e-05
) O 0 6.98228461715189e-08
, O 0 1.4773344325647031e-08
and O 0 2.401511522975852e-08
2 O 0 4.493182927944872e-07
) O 0 3.4541685067779326e-08
a O 0 9.090319963434013e-08
6 O 0 1.3483657994584064e-06
bp O 0 2.7780213258665754e-06
deletion O 0 7.807818747096462e-07
polymorphism O 0 3.7742444192190305e-07
in O 0 1.1193486137983655e-08
the O 0 2.300252610609732e-08
3 O 0 2.663067846242484e-07
noncoding O 0 4.966821620655537e-07
part O 0 4.54806361460669e-08
of O 0 1.0756588153526536e-07
the O 0 2.3188383124761458e-07
CPO O 0 2.360501093789935e-05
gene O 0 5.240568725639605e-07
, O 0 4.3285544393256714e-07
574 O 0 5.651510946336202e-06
bp O 0 3.895837380696321e-06
downstream O 0 2.6852092105400516e-07
of O 0 6.33582288855905e-08
the O 0 3.193633446585409e-08
last O 0 3.6779322698521355e-08
base O 0 5.436274364001292e-08
of O 0 3.1262466393400246e-08
the O 0 5.090675969654512e-08
normal O 0 2.2022997825388302e-07
termination O 0 1.0775186183309415e-06
codon O 0 3.3129972507595085e-06
( O 0 4.842690941586625e-07
+ O 0 4.794198048330145e-06
574 O 0 1.0949759598588571e-05
delATTCTT O 0 3.172951255692169e-05
) O 0 1.9112387690256583e-06
. O 0 1.0397743608336896e-05

Five O 0 3.5045908589381725e-05
intragenic O 0 0.00028015111456625164
dimorphisms O 0 6.74123948556371e-05
are O 0 8.43376852799338e-08
now O 0 9.580254811680788e-08
well O 0 6.575107391881829e-08
characterized O 0 1.0579989861980721e-07
and O 0 3.274685411724931e-08
the O 0 3.410802307257654e-08
high O 0 2.846888094154565e-07
degree O 0 3.857271906326787e-07
of O 0 1.4512845325498347e-07
allelic O 0 5.156216047907947e-06
heterogeneity O 0 3.6848493891739054e-06
in O 0 1.4226563394004188e-07
HC B-Disease 1 0.9996306896209717
is O 0 6.876040714587361e-08
demonstrated O 0 1.0838719788353046e-07
with O 0 1.4861749164651883e-08
seven O 0 1.866382781656739e-08
new O 0 4.243497997435952e-09
different O 0 1.773446500763498e-09
mutations O 0 8.375989679620943e-09
making O 0 4.182237667293975e-09
a O 0 8.722984112807808e-09
total O 0 2.1092811053335936e-08
of O 0 1.9309615595375362e-07
nineteen O 0 1.6563000826863572e-05
CPO O 0 0.000278983439784497
gene B-Disease 0 1.5932333553791977e-05
defects I-Disease 0 6.43382518319413e-05
reported O 0 9.445370210414694e-07
so O 0 1.8647286026407528e-07
far O 0 6.640320862061344e-07
. O 0 1.2480709301598836e-06
. O 0 1.2521419193944894e-05

Coincidence O 0 9.510579548077658e-05
of O 0 3.1065596886037383e-06
two O 0 7.875452183725429e-07
novel O 0 2.815408834067057e-06
arylsulfatase O 0 2.9715985874645412e-05
A O 0 2.899039600379183e-06
alleles O 0 1.8313472764930339e-06
and O 0 4.781805387210625e-07
mutation O 0 1.6846049675223185e-06
459 O 0 5.304358182911528e-06
+ O 0 4.918239028484095e-06
1G O 0 0.0002444629790261388
> O 0 3.5185232718504267e-06
A O 0 4.0775310594654e-07
within O 0 1.518352092944042e-07
a O 0 1.486249203708212e-07
family O 0 7.660558054567446e-08
with O 0 7.662675329811464e-07
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999998807907104
: O 0 9.278133461521065e-07
molecular O 0 1.5191819784377003e-06
basis O 0 6.302394126578292e-07
of O 0 9.450487254980544e-07
phenotypic O 0 0.00013794739788863808
heterogeneity O 0 0.00020926383149344474
. O 0 6.885342008899897e-05

In O 0 2.7930971100431634e-06
a O 0 8.668038731229899e-07
family O 0 1.1273914424236864e-07
with O 0 7.34232727950257e-08
three O 0 1.3351206007428118e-07
siblings O 0 6.579804789907939e-07
, O 0 6.021344489681724e-08
one O 0 2.6699893851400702e-08
developed O 0 2.829157779160596e-07
classical O 0 6.573403425136348e-06
late O 0 0.0013093188172206283
infantile O 1 0.9999071359634399
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.692588375590276e-05
MLD B-Disease 1 1.0
) O 0 5.321212483977433e-07
, O 0 1.459195146935599e-07
fatal O 0 7.254976480908226e-06
at O 0 1.1898869161086623e-06
age O 0 3.5501153661243734e-07
5 O 0 3.940693886761437e-07
years O 0 4.37748575166097e-08
, O 0 2.358091677479024e-08
with O 0 5.4048545194973485e-08
deficient O 0 7.514046046708245e-06
arylsulfatase O 0 5.669984602718614e-05
A O 0 8.883664122549817e-06
( O 0 1.0108625474458677e-06
ARSA O 0 0.00019125742255710065
) O 0 1.2063040344401088e-07
activity O 0 2.3094939649581647e-07
and O 0 1.1874026739633337e-07
increased O 0 1.4242326642488479e-06
galactosylsulfatide O 0 0.0029535156209021807
( O 0 9.412886356585659e-06
GS O 1 0.9999998807907104
) O 0 1.8463867945683887e-06
excretion O 0 2.7095982659375295e-05
. O 0 7.376432222372387e-06

The O 0 6.7392784330877475e-06
two O 0 8.232712502831419e-07
other O 0 1.6190449514397187e-07
siblings O 0 1.782475010259077e-06
, O 0 2.86699275875435e-07
apparently O 0 1.846819941420108e-06
healthy O 0 9.744957196744508e-07
at O 0 1.6427259197371313e-06
12 O 0 7.371302217507036e-07
( O 0 5.558518978432403e-08
1 O 0 3.182642558385851e-07
/ O 0 3.202093807885831e-07
2 O 0 1.5034574118999444e-07
) O 0 8.243914884076275e-09
and O 0 5.594531060637564e-09
15 O 0 3.65770738142146e-08
years O 0 2.2362186768987158e-08
, O 0 1.1891019724430407e-08
respectively O 0 5.9515578243463096e-08
, O 0 1.4247278024015486e-08
and O 0 6.309421873851306e-09
their O 0 9.88662307577215e-09
father O 0 1.0386899162995178e-07
, O 0 3.6558869709324426e-08
apparently O 0 3.126402248199156e-07
healthy O 0 2.8844760890933685e-07
as O 0 1.0397047134347304e-07
well O 0 2.1572023456428724e-07
, O 0 3.7513856909754395e-07
presented O 0 6.172570465423632e-06
ARSA O 0 0.003581130877137184
and O 0 2.003478357437416e-06
GS O 1 0.9999874830245972
values O 0 2.347279917103151e-07
within O 0 9.597702899100113e-08
the O 0 5.3467992700007017e-08
range O 0 1.330463760496059e-06
of O 0 6.512142590509029e-06
MLD B-Disease 1 1.0
patients O 0 3.126458250335418e-05
. O 0 1.8464888853486627e-05

Mutation O 0 1.3599857084045652e-05
screening O 0 2.334836153750075e-06
and O 0 2.2511612485232035e-07
sequence O 0 2.599344384179858e-07
analysis O 0 1.784130176929466e-07
disclosed O 0 5.994336333969841e-07
the O 0 9.581716398088247e-08
involvement O 0 6.248299087019404e-07
of O 0 3.5085045624327904e-07
three O 0 3.2276574302159133e-07
different O 0 3.193012503288628e-07
ARSA O 0 0.0005151389632374048
mutations O 0 7.112050184332475e-07
being O 0 1.0990333976224065e-07
the O 0 4.335986503178901e-08
molecular O 0 7.931643040137715e-07
basis O 0 4.1920387161553663e-07
of O 0 1.5324994819820859e-06
intrafamilial O 0 0.00020228156063240021
phenotypic O 0 0.00035464673419483006
heterogeneity O 0 0.0006209266139194369
. O 0 0.00014156785618979484

The O 0 1.4096929589868523e-05
late O 0 0.00045638068695552647
infantile O 0 0.10154310613870621
patient O 0 3.0657381557830377e-06
inherited O 0 1.188343685498694e-05
from O 0 3.8840042293486476e-07
his O 0 4.82608413676644e-07
mother O 0 1.6979764438929124e-07
the O 0 1.5393825947285222e-07
frequent O 0 2.6198563318757806e-07
0 O 0 5.451617653307039e-06
- O 0 2.1551554709731136e-06
type O 0 1.5126850030355854e-06
mutation O 0 9.026305178849725e-07
459 O 0 2.766059196801507e-06
+ O 0 2.5625968191889115e-06
1G O 0 5.770159623352811e-05
> O 0 1.143892632171628e-06
A O 0 3.05182197735121e-07
, O 0 2.9003363266610904e-08
and O 0 1.7336313717919438e-08
from O 0 2.071282878546299e-08
his O 0 4.066249914558284e-08
father O 0 1.001171838765913e-07
a O 0 4.23564863183401e-08
novel O 0 1.1064517480008362e-07
, O 0 6.003683949984406e-08
single O 0 2.2837221536065044e-07
basepair O 0 9.434347703063395e-06
microdeletion O 0 5.570752364292275e-06
of O 0 6.257631639527972e-07
guanine O 0 1.8061368791677523e-06
at O 0 1.044978603204072e-06
nucleotide O 0 3.895303279932705e-07
7 O 0 4.853537234339456e-07
in O 0 5.925720714117233e-08
exon O 0 9.815057637752034e-07
1 O 0 7.296793000932666e-07
( O 0 4.092896972451854e-07
7delG O 0 3.095440479228273e-05
) O 0 1.947611735886312e-06
. O 0 1.3569735529017635e-05

The O 0 1.0235069566988386e-05
two O 0 4.668666406359989e-06
clinically O 0 0.003501183819025755
unaffected O 0 1.388286727888044e-05
siblings O 0 2.9622822239616653e-06
carried O 0 8.339621331288072e-07
the O 0 4.632775585378113e-07
maternal O 0 2.3280167624761816e-06
mutation O 0 2.3646280169487e-06
459 O 0 8.119829544739332e-06
+ O 0 1.0898005712078884e-05
1G O 0 0.0004558242217171937
> O 0 1.0040783308795653e-05
A O 0 9.112911243391864e-07
and O 0 8.287288721930963e-08
, O 0 3.322126573834794e-08
on O 0 2.645575669646405e-08
their O 0 6.800377150284476e-09
paternal O 0 1.0482389711796714e-07
allele O 0 3.895281110999349e-07
, O 0 5.506832323476374e-08
a O 0 6.945452213358294e-08
novel O 0 1.5770515915392025e-07
cytosine O 0 8.0978441019397e-07
to O 0 6.366676785773961e-08
thymidine O 0 3.15158308694663e-06
transition O 0 2.3672230327065336e-06
at O 0 1.415066890331218e-06
nucleotide O 0 1.254833136954403e-06
2435 O 0 2.141126969945617e-05
in O 0 1.3333837500795198e-07
exon O 0 9.673095746620675e-07
8 O 0 6.609842557736556e-07
, O 0 7.525540013375576e-08
resulting O 0 2.267093464070058e-07
in O 0 4.8804210450725805e-08
substitution O 0 6.145354518594104e-07
of O 0 5.878636102352175e-07
alanine O 0 5.775752470071893e-06
464 O 0 5.968694040348055e-06
by O 0 8.625998475508823e-07
valine O 0 0.00033382445690222085
( O 0 5.353163942345418e-06
A464V O 0 0.00015459094720426947
) O 0 6.096865945437457e-06
. O 0 3.193170778104104e-05

The O 0 1.858565883594565e-05
fathers O 0 3.124586146441288e-05
genotype O 0 2.3094258722267114e-05
thus O 0 7.330611424549716e-06
was O 0 2.4067398044280708e-05
7delG O 0 0.0002294439182151109
/ O 0 0.00048473908100277185
A464V O 0 0.0011152629740536213
. O 0 9.695423068478703e-05

Mutation O 0 4.8105026507982984e-05
A464V O 0 6.419441342586651e-05
was O 0 1.6003962173272157e-06
not O 0 4.607119663546655e-08
found O 0 7.026438453294759e-08
in O 0 8.294056641489078e-08
18 O 0 1.7931870388565585e-05
unrelated O 0 0.0006319044041447341
MLD B-Disease 1 1.0
patients O 0 1.9894253000529716e-06
and O 0 8.154191277753853e-07
50 O 0 3.0699980015924666e-06
controls O 0 4.292971425456926e-05
. O 0 2.6408515623188578e-05

A464V O 0 0.00023086127475835383
, O 0 1.4814238511462463e-06
although O 0 1.0163394108531065e-06
clearly O 0 3.045595803996548e-06
modifying O 0 2.641148785187397e-05
ARSA O 1 0.5577439069747925
and O 0 6.848737939435523e-06
GS O 1 1.0
levels O 0 2.500137497918331e-06
, O 0 7.272706881167323e-08
apparently O 0 2.0632990072044777e-07
bears O 0 3.0521130156557774e-07
little O 0 8.735909062806968e-08
significance O 0 1.617162439515596e-07
for O 0 3.131623671492889e-08
clinical O 0 7.337636134252534e-07
manifestation O 0 3.1215181479637977e-06
of O 0 3.149227495669038e-06
MLD B-Disease 1 1.0
, O 0 1.6025542208808474e-06
mimicking O 0 9.47495846048696e-06
the O 0 1.3282249256008072e-06
frequent O 0 1.0285363714501727e-05
ARSA O 0 0.08775368332862854
pseudodeficiency O 0 0.0018063560128211975
allele O 0 0.0005172729725018144
. O 0 8.680687460582703e-05

Our O 0 2.295627837156644e-06
results O 0 1.1104863233413198e-06
demonstrate O 0 1.7158534149075422e-07
that O 0 8.577565324685565e-09
in O 0 4.467168857047454e-09
certain O 0 2.8789845174514994e-08
genetic O 0 3.0140415674395626e-07
conditions O 0 9.946594218490645e-06
MLD B-Disease 1 1.0
- O 0 0.15413101017475128
like O 0 3.7332804367906647e-06
ARSA O 1 0.9983012676239014
and O 0 2.0076747659913963e-06
GS O 1 0.9999998807907104
values O 0 5.951489612243677e-08
need O 0 1.6726859897175927e-08
not O 0 2.2759083506684874e-09
be O 0 1.0577968723168851e-08
paralleled O 0 1.0036880837560602e-07
by O 0 4.201267955750154e-08
clinical O 0 3.3326319680782035e-05
disease O 0 1.8637929315445945e-05
, O 0 5.834262495341136e-08
a O 0 6.742608604781708e-08
finding O 0 3.2685954920452787e-07
with O 0 1.1786971754190745e-07
serious O 0 2.7203224817640148e-05
diagnostic O 0 2.129339009115938e-05
and O 0 1.8907203411799856e-06
prognostic O 0 0.34452441334724426
implications O 0 0.00022994214668869972
. O 0 3.407550684642047e-05

Moreover O 0 1.85275621333858e-05
, O 0 1.8667548147277557e-06
further O 0 5.00822534377221e-06
ARSA O 0 0.0024701403453946114
alleles O 0 6.10584447713336e-06
functionally O 0 2.466096930220374e-06
similar O 0 1.047457587333156e-07
to O 0 5.106342371163919e-08
A464V O 0 1.6792444057500688e-06
might O 0 1.1173247571605316e-07
exist O 0 6.078278147469973e-08
which O 0 1.3895118833318065e-08
, O 0 1.3987815350446908e-08
together O 0 7.652317890460836e-09
with O 0 8.799283968130567e-09
0 O 0 3.474845584605646e-07
- O 0 7.049997918784356e-08
type O 0 5.3812371447747864e-08
mutations O 0 4.8546208830657633e-08
, O 0 1.5066962788523597e-08
may O 0 1.4315845930923388e-07
cause O 0 4.928644102619728e-06
pathological O 0 0.0003173259901814163
ARSA O 1 0.9390758872032166
and O 0 2.417137238808209e-06
GS O 1 1.0
levels O 0 3.001406128078088e-07
, O 0 6.4112257724957544e-09
but O 0 2.6543387487976133e-09
not O 0 4.8751993553253214e-09
clinical O 0 2.1760547497251537e-07
outbreak O 0 1.2180143471596239e-07
of O 0 4.458735247681034e-07
the O 0 3.1044626211951254e-06
disease O 0 6.013876190991141e-05
. O 0 1.2549886605484062e-06
. O 0 1.599856659595389e-05

Human O 1 0.8967389464378357
MLH1 O 1 1.0
deficiency O 1 0.9999997615814209
predisposes O 0 0.0009362283744849265
to O 0 6.393378043867415e-06
hematological B-Disease 1 0.9999971389770508
malignancy I-Disease 1 0.9999959468841553
and O 0 0.00010915473831119016
neurofibromatosis B-Disease 1 0.9999985694885254
type I-Disease 1 0.8260019421577454
1 I-Disease 0 0.00669229356572032
. O 0 1.777000943548046e-05

Heterozygous O 0 0.000518077053129673
germ O 0 0.002569916658103466
- O 0 8.958112448453903e-05
line O 0 8.703453204361722e-06
mutations O 0 1.389460976497503e-06
in O 0 1.321899958384165e-07
the O 0 5.962510840618052e-07
DNA O 0 1.0440240657771938e-05
mismatch O 0 0.001337749301455915
repair O 0 1.257630174222868e-05
genes O 0 6.064972239983035e-07
lead O 0 2.2482226995634846e-06
to O 0 4.4005332711094525e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9967432618141174

The O 0 1.3397303519013803e-05
disease O 0 3.8711608794983476e-05
susceptibility O 0 3.9635369830648415e-06
of O 0 1.082524363482662e-06
individuals O 0 9.573678738661329e-08
who O 0 1.9471217171940225e-07
constitutionally O 0 6.398108780558687e-07
lack O 0 7.904345693532377e-07
both O 0 6.064555577722786e-07
wild O 0 1.6250822909569251e-06
- O 0 2.1967148313706275e-06
type O 0 1.7441008139940095e-06
alleles O 0 1.4446729892370058e-06
is O 0 1.3866714709820371e-07
unknown O 0 2.504060375940753e-06
. O 0 9.05507658899296e-06

We O 0 1.4470584801529185e-06
have O 0 5.2563603247790525e-08
identified O 0 1.2543134175757586e-07
three O 0 2.4349230187681314e-08
offspring O 0 9.416125124062091e-08
in O 0 3.605831722097719e-08
a O 0 3.0713158594153356e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.0509340983117e-05
who O 0 7.259295216499595e-06
developed O 0 0.25953495502471924
hematological B-Disease 1 0.9999994039535522
malignancy I-Disease 1 0.9999861717224121
at O 0 1.6264350051642396e-05
a O 0 9.68427613656786e-08
very O 0 3.1387159538098786e-08
early O 0 1.5167093181389646e-07
age O 0 1.7265571727875795e-07
, O 0 3.313981622454776e-08
and O 0 1.9757271374487573e-08
at O 0 9.48849177007105e-08
least O 0 1.3238649287927728e-08
two O 0 5.72773695139972e-09
of O 0 1.1746390526923278e-08
them O 0 6.496135629419086e-09
displayed O 0 1.4298680639512895e-07
signs O 0 6.021948024681478e-07
of O 0 8.733373988434323e-07
neurofibromatosis B-Disease 0 0.11792228370904922
type I-Disease 0 2.514486368454527e-05
1 I-Disease 0 3.769942122744396e-05
( O 0 1.022771243697207e-06
NF1 B-Disease 0 0.0003088008379563689
) O 0 2.032691554632038e-06
. O 0 7.53954964238801e-06

DNA O 0 9.458058229938615e-06
sequence O 0 8.286938850687875e-07
analysis O 0 2.6796655561156513e-07
and O 0 1.66572547755095e-07
allele O 0 1.3476266076395405e-06
- O 0 4.055461033658503e-07
specific O 0 4.241250906034111e-08
amplification O 0 1.8592606920719845e-06
in O 0 4.665749742116532e-08
two O 0 1.6002374536583375e-07
siblings O 0 1.0493757827134687e-06
revealed O 0 1.8203928675575298e-06
a O 0 8.366171755369578e-07
homozygous O 0 1.4069140888750553e-05
MLH1 O 0 0.005826869513839483
mutation O 0 8.209911356971134e-06
( O 0 2.5340582396893296e-06
C676T O 0 7.188940071500838e-05
- O 0 4.2621239117579535e-05
- O 0 3.2276715501211584e-05
> O 0 5.524699736270122e-05
Arg226Stop O 0 0.0013459898764267564
) O 0 3.0569417504011653e-06
. O 0 1.1739260116883088e-05

Thus O 0 1.2542871445475612e-05
, O 0 1.4715825500388746e-06
a O 0 1.3360864841160947e-06
homozygous O 0 1.270301072509028e-05
germ O 0 0.0008034494239836931
- O 0 0.00016325876640621573
line O 0 0.00019272817007731646
MLH1 O 1 0.9999605417251587
mutation O 0 1.2265729310456663e-05
and O 0 1.0731162092270097e-06
consequent O 1 0.9856524467468262
mismatch O 1 1.0
repair O 1 0.9999986886978149
deficiency O 1 0.9999996423721313
results O 0 0.0005653727566823363
in O 0 6.029953283359646e-07
a O 0 2.9154391540942015e-06
mutator O 1 0.9595728516578674
phenotype O 0 4.585332499118522e-05
characterized O 0 3.974488436142565e-07
by O 0 7.805706303543047e-08
leukemia B-Disease 1 0.9995724558830261
and O 0 0.0028706451412290335
/ O 1 1.0
or O 1 0.9998669624328613
lymphoma B-Disease 1 1.0
associated O 0 0.0004834582796320319
with O 0 2.7409917038312415e-06
neurofibromatosis B-Disease 1 0.9999651908874512
type I-Disease 0 0.00048258263268508017
1 I-Disease 0 3.647885023383424e-05
. O 0 5.962100999568065e-07
. O 0 3.7365823573054513e-06

Missense O 0 0.00039934823871590197
mutations O 0 9.755214705364779e-06
in O 0 3.228442437830381e-07
the O 0 2.6583279577607755e-07
most O 0 7.228687337601514e-08
ancient O 0 2.80396506013858e-07
residues O 0 3.505741688059061e-07
of O 0 2.5720814278429316e-07
the O 0 8.735573260310048e-07
PAX6 O 0 0.48174506425857544
paired O 0 5.148859600012656e-06
domain O 0 9.731109003041638e-07
underlie O 0 6.149085947981803e-06
a O 0 4.723121662664198e-07
spectrum O 0 6.663012027274817e-05
of O 0 0.013639054261147976
human O 1 0.9999991655349731
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9919312596321106

Mutations O 0 1.6778976714704186e-05
of O 0 2.3589925604028394e-06
the O 0 1.155161157839757e-06
human O 0 2.9859772894269554e-06
PAX6 O 0 0.24388530850410461
gene O 0 5.5907734349602833e-05
underlie O 1 0.9999880790710449
aniridia B-Disease 1 1.0
( O 1 0.9999469518661499
congenital B-Disease 1 1.0
absence I-Disease 0 0.08770503848791122
of I-Disease 0 0.0005201430176384747
the I-Disease 0 0.00010935060709016398
iris I-Disease 1 0.8309595584869385
) O 0 2.6937297548101924e-07
, O 0 1.0576378173254852e-07
a O 0 2.479791589848901e-07
rare O 0 1.5602352505084127e-05
dominant O 1 0.9999994039535522
malformation B-Disease 1 0.9999998807907104
of I-Disease 0 0.03402574360370636
the I-Disease 0 0.004837623797357082
eye I-Disease 1 0.9976867437362671
. O 0 9.272355964640155e-05

The O 0 4.8409542614535894e-06
spectrum O 0 2.388546272413805e-05
of O 0 3.4159370443376247e-06
PAX6 O 1 0.880240261554718
mutations O 0 1.1102564712928142e-05
in O 0 1.385762288919068e-06
aniridia B-Disease 1 1.0
patients O 0 6.069230948924087e-07
is O 0 4.8300254462674275e-08
highly O 0 2.279703039675951e-07
biased O 0 3.284795013769326e-07
, O 0 1.813461381061643e-08
with O 0 7.726926654072486e-09
92 O 0 3.126151852939074e-07
% O 0 1.0863883126432938e-08
of O 0 3.4750176070019734e-08
all O 0 2.2514203834589352e-08
reported O 0 3.607365428592857e-08
mutations O 0 7.048760863881398e-08
leading O 0 8.07010778203221e-08
to O 0 1.7068419566612647e-08
premature O 0 4.816841965293861e-07
truncation O 0 3.61190723197069e-06
of O 0 4.1830375607787573e-07
the O 0 2.2815561351308133e-07
protein O 0 2.8861435907856503e-07
( O 0 3.924282054867945e-08
nonsense O 0 4.348970037426625e-07
, O 0 3.68587507182383e-08
splicing O 0 2.73583680154843e-07
, O 0 2.755894890071886e-08
insertions O 0 2.530795200073044e-07
and O 0 6.351976367113821e-08
deletions O 0 7.640477974746318e-07
) O 0 6.184462364444698e-08
and O 0 5.976652062145149e-08
just O 0 8.282358265887524e-08
2 O 0 1.7464962809299323e-07
% O 0 1.232865098899083e-08
leading O 0 3.649735091926232e-08
to O 0 4.867431790955834e-09
substitution O 0 1.3193407255585043e-07
of O 0 1.0332342981200782e-07
one O 0 1.214367699731156e-07
amino O 0 2.27605355007654e-07
acid O 0 8.475244328565168e-08
by O 0 2.1384311210681517e-08
another O 0 1.4545227600137878e-07
( O 0 3.94117876112432e-07
missense O 0 2.8247892259969376e-05
) O 0 1.892271598080697e-06
. O 0 1.3838809536537156e-05

The O 0 4.913644261250738e-06
extraordinary O 0 6.203694738360355e-06
conservation O 0 6.724204695274238e-07
of O 0 5.575581667471852e-07
the O 0 6.698186894027458e-07
PAX6 O 0 0.0004560858360491693
protein O 0 1.7594787777852616e-06
at O 0 9.060457273335487e-07
the O 0 2.4596678827037977e-07
amino O 0 8.634113441985392e-07
acid O 0 7.989697792254447e-07
level O 0 8.9226941781817e-06
amongst O 0 4.926040674035903e-06
vertebrates O 0 2.8093070341128623e-06
predicts O 0 2.765402484783408e-07
that O 0 1.2756326661644835e-08
pathological O 0 1.026561790240521e-06
missense O 0 3.0964999950811034e-06
mutations O 0 2.5044539597729454e-07
should O 0 3.0684766727517854e-08
in O 0 1.440631525184699e-08
fact O 0 2.0416029755665477e-08
be O 0 1.2027264517655567e-08
common O 0 1.3913072471893884e-08
even O 0 7.457322759307772e-09
though O 0 6.0329758966304325e-09
they O 0 4.697034761136365e-09
are O 0 1.1916085895791184e-08
hardly O 0 4.0709997506382933e-07
ever O 0 7.312801244552247e-07
seen O 0 1.1712137393260491e-06
in O 0 1.0539019967836794e-06
aniridia B-Disease 1 0.999998927116394
patients O 0 1.156855341832852e-05
. O 0 2.0861863958998583e-05

This O 0 2.1297981334100768e-07
indicates O 0 3.2878287470339274e-07
that O 0 2.0233326125662643e-08
there O 0 2.4824219124752744e-08
is O 0 1.7053904954877908e-08
a O 0 4.935897024438418e-08
heavy O 0 1.1635992450464983e-05
ascertainment O 0 0.11472535133361816
bias O 0 4.170500687905587e-06
in O 0 4.040605006139231e-08
the O 0 2.3694079587244232e-08
selection O 0 1.833127925010558e-07
of O 0 8.915688454180781e-08
patients O 0 4.277076470771135e-08
for O 0 6.609899827481058e-08
PAX6 O 0 3.83880251320079e-05
mutation O 0 1.3947804688996257e-07
analysis O 0 5.64566526861654e-08
and O 0 2.2597623328124428e-08
that O 0 9.882381135639662e-09
the O 0 1.1078708439526963e-07
missing O 0 4.058918875671225e-06
PAX6 O 0 0.10569800436496735
missense O 0 5.8867088227998465e-05
mutations O 0 2.556884510340751e-06
frequently O 0 4.4383037334227993e-07
may O 0 3.0859607704769587e-06
underlie O 0 0.00022022236953489482
phenotypes O 0 8.782400254858658e-05
distinct O 0 2.6339835130784195e-06
from O 0 2.1718369680456817e-06
textbook O 0 0.0007184322457760572
aniridia B-Disease 1 0.9999984502792358
. O 0 0.00016204873099923134

Here O 0 4.491495928959921e-06
we O 0 4.603715808570996e-07
present O 0 4.217453977162222e-07
four O 0 6.503626082121627e-07
novel O 0 1.6202326378333964e-06
PAX6 O 0 0.00041517463978379965
missense O 0 1.5435238310601562e-05
mutations O 0 1.6983293562589097e-06
, O 0 2.3361494072560163e-07
two O 0 1.638521922586733e-07
in O 0 2.2295414225936838e-07
association O 0 1.2602141623574425e-06
with O 0 5.831458906868647e-07
atypical O 0 0.007266663946211338
phenotypes O 0 0.2519589960575104
ectopia B-Disease 1 0.9762475490570068
pupillae I-Disease 0 0.035792019218206406
( O 0 5.602536816695647e-07
displaced B-Disease 0 5.554163067245099e-07
pupils I-Disease 0 4.30174532084493e-06
) O 0 5.962328373243508e-07
and O 0 5.6915781897259876e-05
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999997615814209
( O 0 6.075779310776852e-06
searching B-Disease 0 4.322446784499334e-06
gaze I-Disease 0 2.2740819986211136e-05
) O 0 9.812027457201111e-08
, O 0 5.165282956909323e-08
and O 0 4.690501853588103e-08
two O 0 1.1049248627159614e-07
in O 0 8.037970644636516e-08
association O 0 8.934192408105446e-08
with O 0 6.785971606859675e-08
more O 0 2.7067702035310504e-07
recognizable O 0 9.125002543441951e-05
aniridia B-Disease 1 0.9999936819076538
phenotypes O 0 0.0002442500554025173
. O 0 1.728236020426266e-05

Strikingly O 0 0.00010047265095636249
, O 0 6.567248078681587e-07
all O 0 2.3399110204991302e-07
four O 0 1.466234067493133e-07
mutations O 0 7.255651013338138e-08
are O 0 1.2490714240698253e-08
located O 0 6.997202461889174e-08
within O 0 9.50657081943973e-08
the O 0 4.157560908879532e-07
PAX6 O 0 0.010485819540917873
paired O 0 1.713789288260159e-06
domain O 0 3.806825645824574e-07
and O 0 1.077153441997325e-07
affect O 0 3.356271065513283e-07
amino O 0 2.939760861409013e-07
acids O 0 4.6588933599878146e-08
which O 0 6.407521624396395e-09
are O 0 3.6671219394435184e-09
highly O 0 3.062092090999613e-08
conserved O 0 5.945816639041368e-08
in O 0 7.594896267448803e-09
all O 0 2.302820689692453e-08
known O 0 1.0929856131269844e-07
paired O 0 7.431950734826387e-07
domain O 0 6.275039936554094e-07
proteins O 0 5.107028755446663e-07
. O 0 3.947534878534498e-06

Our O 0 4.008357336715562e-06
results O 0 1.327371478510031e-06
support O 0 1.4771210032904492e-07
the O 0 6.61914683064424e-08
hypothesis O 0 7.034216054080389e-08
that O 0 1.8441699278781698e-09
the O 0 1.0051628862584039e-08
under O 0 4.9226031251237146e-08
- O 0 8.443812760106084e-08
representation O 0 6.195183033241847e-08
of O 0 1.368100583931664e-07
missense O 0 4.190147137705935e-06
mutations O 0 3.56129220335788e-07
is O 0 2.6251528950638203e-08
caused O 0 2.190091095144453e-07
by O 0 1.2009641636723245e-07
ascertainment O 0 0.0054093305952847
bias O 0 5.079850325273583e-06
and O 0 7.62770895335052e-08
suggest O 0 6.640151184456045e-08
that O 0 5.609950282092768e-09
a O 0 2.7690830961546453e-08
substantial O 0 1.91759269796421e-07
burden O 0 9.262590765501955e-07
of O 0 1.602081101736985e-05
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9933938384056091
related I-Disease 0 2.7085543479188345e-05
disease I-Disease 0 6.9244201768015046e-06
remains O 0 1.1520121745434153e-07
to O 0 2.1988553200458227e-08
be O 0 1.0814105166900845e-07
uncovered O 0 3.5040075090364553e-06
. O 0 1.1832331665573292e-06
. O 0 9.301706995756831e-06

The O 0 3.873432433465496e-06
chromosomal O 0 6.82275867802673e-06
order O 0 5.289509203976195e-07
of O 0 7.597890316901612e-07
genes O 0 4.552620112008299e-07
controlling O 0 5.0571079555084e-06
the O 0 1.0817462907652953e-06
major O 0 0.00023524659627582878
histocompatibility O 1 0.999997615814209
complex O 0 8.681473991600797e-05
, O 0 2.0401866152042203e-07
properdin O 0 4.578820153255947e-06
factor O 0 2.818724453845789e-07
B O 0 8.566190444980748e-06
, O 0 1.1359379215036824e-07
and O 0 3.4833760764740873e-07
deficiency B-Disease 0 2.308926013938617e-05
of I-Disease 0 3.396180545678362e-07
the I-Disease 0 1.0373811676345213e-07
second I-Disease 0 2.5143833681795513e-07
component I-Disease 0 4.7148500925686676e-07
of I-Disease 0 8.442788157481118e-07
complement I-Disease 0 1.1834953511424828e-05
. O 0 1.4121378626441583e-05

The O 0 1.647245653657592e-06
relationship O 0 3.573403546397458e-07
of O 0 2.392003750628646e-07
the O 0 1.7008467523282889e-07
genes O 0 6.51366889314886e-08
coding O 0 2.250281170290691e-07
for O 0 3.8236930066659625e-08
HLA O 0 7.664970098630874e-07
to O 0 8.318990829536688e-09
those O 0 1.3221717054534565e-08
coding O 0 2.767750686416548e-07
for O 0 2.7084894327344955e-08
properdin O 0 1.1335143881296972e-06
Factor O 0 1.9244278348651278e-07
B O 0 1.6998086493913434e-06
allotypes O 0 3.3349431305396138e-06
and O 0 4.441140433186774e-08
for O 0 8.737242040979254e-08
deficiency B-Disease 0 2.540535888329032e-06
of I-Disease 0 5.928117374764952e-08
the I-Disease 0 2.0470970696351287e-08
second I-Disease 0 4.7225498178704584e-08
component I-Disease 0 5.147481374478957e-08
of I-Disease 0 3.008220161859754e-08
complement I-Disease 0 4.165283655765961e-07
( O 0 1.8459397210790485e-07
C2 O 0 0.17060202360153198
) O 0 4.9036923854828274e-08
was O 0 8.813867680146359e-08
studied O 0 1.9124152572658204e-07
in O 0 1.2524135506453149e-08
families O 0 1.0427368302146078e-08
of O 0 3.1964614777280076e-07
patients O 0 3.492887344691553e-06
with O 0 0.004401813726872206
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.923279881477356

Patients O 0 6.224631761142518e-06
were O 0 6.777860335205332e-07
selected O 0 3.547434914707992e-07
because O 0 7.007941604797452e-08
they O 0 3.937552861543736e-08
were O 0 2.8475017188611673e-07
heterozygous O 0 1.3736780601902865e-06
or O 0 1.4192199842000264e-06
homozygous O 0 0.000184280623216182
for O 0 0.002814226085320115
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.15899468958377838

12 O 0 1.8773595002130605e-05
families O 0 5.850676529917109e-07
with O 0 3.682924045733671e-07
15 O 0 3.9900241972645745e-06
matings O 0 4.513716703513637e-05
informative O 0 7.224910950753838e-05
for O 0 0.0001320914743700996
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.5713145078043453e-05
found O 0 3.3031355997081846e-06
. O 0 1.522857928648591e-05

Of O 0 2.053837670246139e-05
57 O 0 2.963289625768084e-05
informative O 0 1.8279575670021586e-05
meioses O 0 3.105117866653018e-05
, O 0 1.535932057095124e-07
two O 0 5.3110625231056474e-08
crossovers O 0 2.6777726702675864e-07
were O 0 7.829638093426183e-08
noted O 0 1.724822737969589e-07
between O 0 1.0399797929494525e-06
the O 0 6.89410007908009e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 1.649603831310742e-07
and O 0 4.491717575660914e-08
the O 0 1.5012567189387482e-07
HLA O 0 6.7005589698965196e-06
- O 0 3.790060816299956e-07
B O 0 3.915878608040657e-07
gene O 0 1.2911052671427115e-08
, O 0 3.7213059300711393e-09
with O 0 5.850908646465314e-09
a O 0 3.7860864665617555e-08
recombinant O 0 1.1642796238220399e-07
fraction O 0 4.877573189787654e-08
of O 0 1.8990026262599713e-07
0 O 0 5.608247647614917e-06
. O 0 4.96140455652494e-06

035 O 0 0.16999395191669464
. O 0 0.0018779695965349674

A O 0 2.21092595893424e-05
lod O 0 7.318027201108634e-05
score O 0 2.1357038804126205e-06
of O 0 5.558391649174155e-07
13 O 0 1.490517433921923e-06
was O 0 4.387395051708154e-07
calculated O 0 2.713254616537597e-07
for O 0 1.4714071028265607e-07
linkage O 0 7.057934271870181e-05
between O 0 0.4575309157371521
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 8.350481039087754e-06
HLA O 0 0.0001065825272235088
- O 0 6.050748879715684e-07
B O 0 5.109966991767578e-07
at O 0 4.271842257708158e-08
a O 0 8.341043411519422e-09
maximum O 0 4.742172521332577e-08
likelihood O 0 2.9100888809807657e-08
value O 0 1.5863550473227406e-08
of O 0 3.079693300378494e-08
the O 0 2.4307700741132976e-08
recombinant O 0 1.1346624972929931e-07
fraction O 0 7.91974059666245e-08
of O 0 3.132263657334988e-07
0 O 0 6.169981134007685e-06
. O 0 1.0803712939377874e-05

04 O 0 0.03732249140739441
. O 0 0.0014654133701696992

18 O 0 1.4278134585765656e-05
families O 0 1.9936727824187983e-07
with O 0 2.3193734932647203e-07
21 O 0 2.276062787132105e-06
informative O 0 1.5173749261521152e-06
matings O 0 1.0176632940783747e-06
for O 0 4.892723737270899e-08
both O 0 7.74661543800903e-08
properdin O 0 4.835122581425821e-06
Factor O 0 6.623276931350119e-07
B O 0 3.650477310657152e-06
allotype O 0 6.188549832586432e-06
and O 0 4.36768203826432e-07
HLA O 0 1.3798523468722124e-05
- O 0 1.044656755766482e-06
B O 0 3.129172228000243e-06
were O 0 2.9840930437785573e-07
found O 0 5.006402261642506e-07
. O 0 5.1905881264247e-06

Of O 0 2.2401080059353262e-05
72 O 0 2.3570344637846574e-05
informative O 0 1.0390280294814147e-05
meioses O 0 3.493175972835161e-05
, O 0 2.588865015695774e-07
three O 0 1.4690823491037008e-07
recombinants O 0 6.930815743544372e-06
were O 0 1.0072167100361185e-07
found O 0 3.523350500245215e-08
, O 0 3.7433832034139414e-08
giving O 0 8.199899070859828e-08
a O 0 8.324517608571114e-08
recombinant O 0 2.50009662750017e-07
fraction O 0 1.1922752207738085e-07
of O 0 3.625099225246231e-07
0 O 0 9.879491699393839e-06
. O 0 8.575262654630933e-06

042 O 0 0.02143930085003376
. O 0 0.001553877955302596

A O 0 1.7749753169482574e-05
lod O 0 5.036220318288542e-05
score O 0 2.2395709038391942e-06
of O 0 9.926266102411319e-07
16 O 0 4.080809503648197e-06
between O 0 1.3237510074759484e-06
HLA O 0 2.0262858015485108e-05
- O 0 4.852093411500391e-07
B O 0 5.90726983773493e-07
and O 0 1.654283643404142e-08
Factor O 0 1.6352905163330433e-07
B O 0 1.5537615354332956e-06
allotypes O 0 2.0405284431035398e-06
was O 0 1.1771873431598578e-07
calculated O 0 4.058749070168233e-08
at O 0 4.0597246453444313e-08
a O 0 9.412889134807756e-09
maximum O 0 5.961486948535821e-08
likelihood O 0 4.13553351563678e-08
value O 0 1.686120043586925e-08
of O 0 2.227033313317861e-08
the O 0 2.0815880574787116e-08
recombinant O 0 5.513096112963467e-08
fraction O 0 4.1447883347700554e-08
of O 0 1.7306933841609862e-07
0 O 0 5.248433353699511e-06
. O 0 7.839065801817924e-06

04 O 0 0.028943028301000595
. O 0 0.0008834636537358165

A O 0 6.639664661634015e-06
crossover O 0 2.649959924383438e-06
was O 0 5.847285251547873e-07
shown O 0 3.5675153498004875e-08
to O 0 1.7272251184863308e-08
have O 0 1.3763024497848164e-08
occurred O 0 2.733849271407962e-07
between O 0 2.906738316710289e-08
genes O 0 4.430325883930664e-09
for O 0 5.6895190780892335e-09
Factor O 0 6.39376551703208e-08
B O 0 6.750663601451379e-07
and O 0 1.0827066176943845e-07
HLA O 0 3.658597961475607e-06
- O 0 3.39284298433995e-07
D O 0 1.7475587128501502e-06
, O 0 4.9482736130812555e-08
in O 0 2.8346958558245205e-08
which O 0 1.1765992979917428e-07
HLA O 0 5.807904017274268e-06
- O 0 8.503773756274313e-07
D O 0 5.355799203243805e-06
segregared O 0 1.107783737097634e-05
with O 0 2.0302607595112931e-07
HLA O 0 3.7484500353457406e-05
- O 0 1.0476937859493773e-06
A O 0 6.413271194105619e-07
and O 0 5.973336101305904e-07
B O 0 0.00011349056876497343
. O 0 1.4211908819561359e-05

These O 0 4.0072958995551744e-07
studies O 0 1.5469586855942907e-07
suggest O 0 6.543292130345435e-08
that O 0 7.73019959154908e-09
the O 0 1.556945505853946e-08
genes O 0 9.434169889743771e-09
for O 0 1.3120501130003959e-08
Factor O 0 5.744215627601079e-07
B O 0 0.012425634078681469
and O 0 0.004707494284957647
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.782933622962446e-08
located O 0 1.8473816254527264e-08
outside O 0 9.226268637974044e-09
those O 0 3.4873857135409025e-09
for O 0 1.2877137578470865e-08
HLA O 0 5.769046538262046e-07
, O 0 4.091250893623055e-09
that O 0 9.928172728379536e-10
the O 0 4.574631340403812e-09
order O 0 2.076821203900181e-08
of O 0 8.667942097417836e-08
genese O 0 6.630268217122648e-06
is O 0 2.5495646127637883e-07
HLA O 0 5.962299383099889e-06
- O 0 3.357475009124755e-07
A O 0 3.06431843455357e-07
, O 0 1.179680140239725e-07
- O 0 2.818703137563716e-07
B O 0 8.801744684205914e-07
, O 0 4.084500915269018e-08
- O 0 1.4103848400282004e-07
D O 0 5.112520966576994e-07
, O 0 2.8246194716530226e-08
Factor O 0 2.793451301386085e-07
B O 0 1.084064115275396e-05
allotype O 0 0.0005708446260541677
, O 0 2.0362562281661667e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
, O 0 2.5071180687064043e-08
that O 0 4.120878305258202e-09
the O 0 2.3501620205479412e-08
genes O 0 5.749291176471161e-08
coding O 0 1.2777751408066251e-06
for O 0 2.6191021333943354e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999978542327881
and O 0 1.8504573517930112e-07
Factor O 0 4.425113218076149e-07
B O 0 1.015820998873096e-06
allotypes O 0 5.854477649336332e-07
are O 0 3.3088640716272266e-09
approximately O 0 1.8873747009706676e-08
3 O 0 4.530989272666375e-08
- O 0 4.1633764880089075e-08
- O 0 2.6233957228782856e-08
5 O 0 5.617480169917144e-08
centimorgans O 0 6.293138881119376e-07
from O 0 1.362033508200966e-08
the O 0 1.0483949353101707e-07
HLA O 0 4.582004748954205e-06
- O 0 3.2272882322104124e-07
A O 0 3.6225523558641726e-07
and O 0 2.3200460930183908e-07
HLA O 0 2.8273874704609625e-05
- O 0 7.345890935539501e-07
B O 0 7.081965236466203e-07
loci O 0 1.8402131729544635e-07
, O 0 7.4416792728015935e-09
and O 0 5.654132717580751e-09
that O 0 1.3549228405906888e-09
the O 0 7.975643256941112e-09
apparent O 0 1.0538079209254647e-07
lack O 0 2.5359437927363615e-07
of O 0 3.885056401031761e-07
recombinants O 0 5.588407930190442e-06
between O 0 7.736560547755289e-08
the O 0 3.306499607447222e-08
Factor O 0 2.2716274372669432e-07
B O 0 4.262870788807049e-06
gene O 0 2.2377903405867983e-06
and O 0 3.3715063182171434e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.5085763038769073e-07
suggests O 0 3.728732522745304e-08
that O 0 3.6525047431013036e-09
these O 0 3.819711213992605e-09
two O 0 7.640767130112636e-09
genes O 0 1.1413778366886618e-08
lie O 0 5.9155571108249205e-08
in O 0 9.845336990110809e-09
close O 0 1.0488149371212785e-07
proximity O 0 1.861643994516271e-07
to O 0 6.558123288868956e-08
one O 0 3.521087705848913e-07
another O 0 2.8343122266960563e-06
. O 0 1.8648670447873883e-05

Distribution O 0 3.171693833792233e-06
of O 0 3.308535951873637e-06
emerin O 0 0.00016556891205254942
and O 0 7.391174108306586e-07
lamins O 0 0.0001593609049450606
in O 0 1.1300934232849613e-07
the O 0 1.1147384526566384e-07
heart O 0 8.906949915399309e-07
and O 0 1.9542356710644526e-07
implications O 0 7.910878593975212e-06
for O 0 1.946909833350219e-06
Emery B-Disease 1 0.9991208910942078
- I-Disease 1 0.9999991655349731
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.47211045026779175

Emerin O 0 0.0029240918811410666
is O 0 1.4945200064175879e-06
a O 0 7.046206178529246e-07
nuclear O 0 3.996173745690612e-06
membrane O 0 1.5574702274534502e-06
protein O 0 2.015990929749023e-07
which O 0 1.5447643164634428e-08
is O 0 2.4289578348657415e-08
missing O 0 3.9380114458253956e-07
or O 0 1.2169589069799258e-07
defective O 0 7.349966381298145e-06
in O 0 8.014102377273957e-07
Emery B-Disease 1 0.9996291399002075
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9998701810836792
EDMD B-Disease 1 1.0
) O 0 6.726258288836107e-05
. O 0 3.281025783508085e-05

It O 0 5.253479002931272e-07
is O 0 1.131621516492487e-07
one O 0 8.056588995941638e-08
member O 0 1.1122069309976723e-07
of O 0 1.8678629487567378e-07
a O 0 2.247619619311081e-07
family O 0 8.605525181337725e-08
of O 0 5.614523388430825e-07
lamina O 1 0.9225139021873474
- O 0 0.0006656572222709656
associated O 0 3.9012070374155883e-07
proteins O 0 6.678357067357865e-08
which O 0 4.584416757325016e-08
includes O 0 2.0207569662034075e-07
LAP1 O 0 0.00024071238294709474
, O 0 4.2861088900281175e-07
LAP2 O 0 0.00012605785741470754
and O 0 1.1969819979640306e-06
lamin O 0 2.5334820747957565e-05
B O 0 9.73410078586312e-06
receptor O 0 3.5288096569274785e-06
( O 0 5.57449197913229e-07
LBR O 0 8.992639777716249e-05
) O 0 5.0105713853554334e-06
. O 0 2.9956127036712132e-05

A O 0 5.579327989835292e-05
panel O 0 2.267064519401174e-05
of O 0 2.425306547593209e-06
16 O 0 4.912018539471319e-06
monoclonal O 0 1.5662136547689443e-06
antibodies O 0 3.3867652859953523e-07
( O 0 4.7058074414962903e-07
mAbs O 0 1.0507284059713129e-05
) O 0 1.0741457145968525e-07
has O 0 2.4621268579494426e-08
been O 0 2.875165172611105e-08
mapped O 0 3.144366544916011e-08
to O 0 7.582506178493986e-09
six O 0 3.9055990441738686e-08
specific O 0 7.876818308716338e-09
sites O 0 1.8252949374186755e-08
throughout O 0 2.6598234725838665e-08
the O 0 4.234364325839124e-08
emerin O 0 1.5840561218283256e-06
molecule O 0 7.738021423620012e-08
using O 0 4.6578808365893565e-08
phage O 0 7.656503271391557e-07
- O 0 1.1124232912607113e-07
displayed O 0 4.724414637280461e-08
peptide O 0 7.662471546154848e-08
libraries O 0 1.827228146566995e-08
and O 0 9.266654110717809e-09
has O 0 6.836648580588189e-09
been O 0 5.590541807265481e-09
used O 0 9.327620453802865e-09
to O 0 3.648099422548512e-08
localize O 0 7.4715148912218865e-06
emerin O 0 0.0007450967677868903
in O 0 6.395802643055504e-07
human O 0 2.6997859094990417e-06
and O 0 7.092684427334461e-06
rabbit O 0 1.8730550436885096e-05
heart O 0 0.0001058351990650408
. O 0 6.626753747696057e-05

Several O 0 1.6545776816201396e-05
mAbs O 0 9.141297778114676e-05
against O 0 6.469006166298641e-06
different O 0 1.8749603896139888e-06
emerin O 0 5.046080332249403e-05
epitopes O 0 6.80200810165843e-06
did O 0 1.2856307307629322e-07
not O 0 5.792328039433414e-08
recognize O 0 5.64640799893823e-07
intercalated O 0 1.7093794667744078e-05
discs O 0 3.595129783207085e-06
in O 0 6.781921513265843e-08
the O 0 7.478320895870638e-08
heart O 0 4.3758331003118656e-07
, O 0 2.1387778659232026e-08
though O 0 1.377823188875027e-08
they O 0 1.3421145972358772e-08
recognized O 0 5.973061689701353e-08
cardiomyocyte O 0 2.0569541447912343e-06
nuclei O 0 9.899870292429114e-07
strongly O 0 1.9317094768211973e-07
, O 0 9.65462021440544e-08
both O 0 7.072786445405654e-08
at O 0 1.0479645879968302e-06
the O 0 1.644762477326367e-07
rim O 0 1.5021819308458362e-06
and O 0 5.2574026909724125e-08
in O 0 5.741565445305241e-08
intranuclear O 0 6.003019279887667e-06
spots O 0 6.755854542461748e-07
or O 0 3.307048928036238e-07
channels O 0 3.4685226637520827e-06
. O 0 3.6478704714681953e-06

A O 0 0.00027516132104210556
polyclonal O 0 0.0006018524873070419
rabbit O 0 2.3114111172617413e-05
antiserum O 0 6.43165985820815e-05
against O 0 9.398499059898313e-06
emerin O 0 7.659266702830791e-05
did O 0 2.5372816025992506e-07
recognize O 0 3.813497073679173e-07
both O 0 1.6434280780686095e-07
nuclear O 0 4.616105343302479e-06
membrane O 0 1.983870333788218e-06
and O 0 1.8245104627112596e-07
intercalated O 0 4.385543434182182e-06
discs O 0 7.225723379633564e-07
but O 0 2.9193842010499793e-08
, O 0 2.2109334807396408e-08
after O 0 2.5819655746772696e-08
affinity O 0 2.9368649734351493e-08
purification O 0 1.0398990468729608e-07
against O 0 3.862911057694873e-08
a O 0 4.356163074703545e-08
pure O 0 8.364847303710121e-07
- O 0 5.437020718090935e-07
emerin O 0 2.1213138552411692e-06
band O 0 1.322449634244549e-07
on O 0 4.682528498278771e-08
a O 0 2.5359890187814926e-08
western O 0 1.329579362163713e-07
blot O 0 1.8049125856123283e-06
, O 0 1.2366265877972182e-07
it O 0 2.630535966829939e-08
stained O 0 2.711040451686131e-06
only O 0 9.00235690437512e-08
the O 0 2.3871177745604655e-07
nuclear O 0 1.3692462744074874e-05
membrane O 0 2.5832154278759845e-05
. O 0 1.2126866749895271e-05

These O 0 7.690817369621072e-07
results O 0 8.609084716226789e-07
would O 0 4.813617948684623e-08
not O 0 1.7814754116329823e-08
be O 0 1.592487741675086e-08
expected O 0 1.352598815174133e-07
if O 0 1.1289375834167004e-07
immunostaining O 0 1.3400434909272008e-05
at O 0 1.596821107341384e-06
intercalated O 0 7.28201803212869e-06
discs O 0 1.6165346323759877e-06
were O 0 5.217564336135183e-08
due O 0 1.0369162595225134e-07
to O 0 8.286842323457222e-09
a O 0 1.2699035600860498e-08
product O 0 8.554233765778463e-09
of O 0 5.4710483254893916e-08
the O 0 5.715146400575577e-08
emerin O 0 2.2328574686980573e-06
gene O 0 3.278109872439927e-08
and O 0 2.0221481378257522e-08
, O 0 2.4625446570780696e-08
therefore O 0 4.32993694232664e-08
, O 0 1.0791930016296192e-08
cast O 0 3.470718468179257e-08
some O 0 1.1022301293905912e-08
doubt O 0 1.434410705769551e-07
upon O 0 1.1130281762916638e-07
the O 0 6.03751360017668e-08
hypothesis O 0 7.533193979725183e-07
that O 0 7.798250578616717e-08
cardiac B-Disease 1 0.8205559253692627
defects I-Disease 0 0.0056692766956985
in O 0 2.9362743134697666e-06
EDMD B-Disease 1 1.0
are O 0 2.652321597906848e-07
caused O 0 9.85745714388031e-07
by O 0 3.480051802284834e-08
absence O 0 9.28902295527223e-07
of O 0 1.594690616002481e-06
emerin O 0 0.00010775497503345832
from O 0 8.881596045284823e-07
intercalated O 0 7.46576115489006e-05
discs O 0 0.00010854587162612006
. O 0 1.5771429389133118e-05

Although O 0 1.8888509657699615e-05
emerin O 0 0.00028927059611305594
was O 0 2.674347797437804e-06
abundant O 0 5.348370564206562e-07
in O 0 2.9513360644273234e-08
the O 0 5.341967934668901e-08
membranes O 0 2.548494819620828e-07
of O 0 1.716478550406464e-07
cardiomyocyte O 0 4.664567313739099e-06
nuclei O 0 2.4575815587013494e-06
, O 0 7.71506094565666e-08
it O 0 1.563408957849788e-08
was O 0 1.5203951875264465e-07
absent O 0 1.2917547564939014e-07
from O 0 1.351498379875693e-08
many O 0 2.6052752843952476e-08
non O 0 2.1562634628935484e-06
- O 0 4.338545295468066e-06
myocyte O 0 6.410008791135624e-05
cells O 0 4.266736652880354e-07
in O 0 7.155025372185264e-08
the O 0 8.199630769922805e-07
heart O 0 5.050513573223725e-05
. O 0 3.520676546031609e-05

This O 0 2.887539665152872e-07
distribution O 0 4.198644774078275e-07
of O 0 4.3877759026145213e-07
emerin O 0 2.125162245647516e-05
was O 0 2.3744009070014727e-07
similar O 0 1.4030407058385208e-08
to O 0 5.3268456312594026e-09
that O 0 5.6635229839230306e-09
of O 0 2.1195533861373406e-07
lamin O 0 3.231530718039721e-05
A O 0 7.997657007763337e-07
, O 0 3.9004252272434314e-08
a O 0 3.022771721816753e-08
candidate O 0 1.1784543829662653e-07
gene O 0 1.0910027725685723e-07
for O 0 5.688078630328164e-08
an O 0 7.494342213476557e-08
autosomal O 0 2.576070755822002e-06
form O 0 7.5468947215995286e-06
of O 0 0.32410284876823425
EDMD B-Disease 1 1.0
. O 0 0.0019150404259562492

In O 0 4.309201813157415e-06
contrast O 0 5.849700755788945e-06
, O 0 3.1789161312190117e-06
lamin O 0 0.0006738850497640669
B1 O 0 0.06456303596496582
was O 0 4.212881776766153e-06
absent O 0 1.6192996099562151e-06
from O 0 8.834721398898182e-08
cardiomyocyte O 0 6.766778369637905e-06
nuclei O 0 6.011085588397691e-06
, O 0 2.1585029230664077e-07
showing O 0 3.162585642257909e-07
that O 0 1.1905685681767864e-07
lamin O 0 5.8198784245178103e-05
B1 O 0 0.00012500975572038442
is O 0 1.946725802781657e-08
not O 0 8.755989711062284e-09
essential O 0 7.507261301498147e-08
for O 0 4.531213804170875e-08
localization O 0 3.1527135888609337e-06
of O 0 3.784018360875052e-07
emerin O 0 9.244206012226641e-06
to O 0 1.4290174021880375e-07
the O 0 7.84602775638632e-07
nuclear O 0 9.39624005695805e-05
lamina O 1 0.9140543937683105
. O 0 0.0001288850326091051

Lamin O 1 0.9106785655021667
B1 O 1 0.9986078143119812
is O 0 1.2511515024016262e-06
also O 0 3.691285712648096e-07
almost O 0 5.386237376114877e-07
completely O 0 1.8574972955320845e-06
absent O 0 6.7455866883392446e-06
from O 0 2.48195919994032e-06
skeletal O 1 0.7105808258056641
muscle O 0 0.02054787054657936
nuclei O 1 0.9932169318199158
. O 0 0.0005531802889890969

In O 0 1.514219638920622e-05
EDMD B-Disease 1 0.9999992847442627
, O 0 6.375146881509863e-07
the O 0 1.5751382420603477e-07
additional O 0 2.0711334514089685e-07
absence O 0 1.1411403875172255e-06
of O 0 1.543840198792168e-06
lamin O 0 0.0009041443699970841
B1 O 1 0.8789753913879395
from O 0 8.783983957982855e-07
heart O 0 0.0008176862029358745
and O 0 4.716158946393989e-05
skeletal O 1 0.99998939037323
muscle O 0 0.06830175966024399
nuclei O 0 0.17571397125720978
which O 0 4.0850002847037103e-07
already O 0 1.3014430066959903e-07
lack O 0 8.777142852522957e-07
emerin O 0 9.782296729099471e-06
may O 0 4.3689773576716107e-08
offer O 0 2.2303106916865545e-08
an O 0 2.043713642763123e-09
alternative O 0 3.296915096484554e-08
explanation O 0 4.523027996583551e-08
of O 0 3.0247210958123105e-08
why O 0 4.04227762373921e-08
these O 0 1.702647445256389e-08
tissues O 0 1.811294509934669e-07
are O 0 2.302583546054393e-08
particularly O 0 3.290620611551276e-07
affected O 0 4.2363438979009516e-07
. O 0 5.955355959486042e-07
. O 0 5.18777687830152e-06

Genetic O 0 1.5461724615306593e-05
mapping O 0 6.479768671852071e-06
of O 0 2.4398127607128117e-06
the O 0 4.495798748394009e-06
copper B-Disease 1 0.8644605278968811
toxicosis I-Disease 1 0.9999507665634155
locus O 0 5.541446807910688e-05
in O 0 1.6361561847588746e-06
Bedlington O 0 0.0021537072025239468
terriers O 0 2.2654672648059204e-05
to O 0 2.0619692975287762e-07
dog O 0 7.179262979661871e-07
chromosome O 0 1.123168090089166e-06
10 O 0 2.5961833216570085e-07
, O 0 7.633850884758431e-08
in O 0 2.7792475876253775e-08
a O 0 8.391135963847773e-08
region O 0 3.02585505096431e-07
syntenic O 0 1.717402301437687e-05
to O 0 2.356918571422284e-07
human O 0 1.08792892206111e-06
chromosome O 0 3.246784444854711e-06
region O 0 1.7466722965764347e-06
2p13 O 0 0.0001559535157866776
- O 0 8.164768951246515e-05
p16 O 0 9.665927791502327e-05
. O 0 3.017264862137381e-05

Abnormal O 1 0.999645471572876
hepatic B-Disease 1 0.9999992847442627
copper I-Disease 0 0.04896608367562294
accumulation I-Disease 0 0.00012520886957645416
is O 0 1.58720297349646e-07
recognized O 0 7.514324096291602e-08
as O 0 6.000524876981217e-08
an O 0 1.6479481246278738e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.0006592730642296374
man O 1 0.9996930360794067
, O 0 5.463229172164574e-05
mouse O 0 0.000100591620139312
, O 0 5.185927420825465e-06
rat O 0 3.0601258913520724e-05
and O 0 3.025144906132482e-06
dog O 0 4.961044032825157e-05
. O 0 4.025371526950039e-05

The O 0 3.632623702287674e-06
major O 0 2.5934762106771814e-06
cause O 0 7.682896466576494e-06
of O 0 0.00012228181003592908
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9988387227058411
accumulation I-Disease 0 0.037512656301259995
in O 0 1.2333564427535748e-06
man O 0 2.3312706616707146e-05
is O 0 6.471922375794747e-08
a O 0 2.113215771260002e-07
dysfunctional O 0 1.6545351400054642e-06
ATP7B O 0 0.034361086785793304
gene O 0 1.0869136986002559e-06
, O 0 4.5004730964137707e-07
causing O 0 9.437995322514325e-05
Wilson B-Disease 0 0.004564689937978983
disease I-Disease 1 0.9023476243019104
( O 0 2.3035137928673066e-05
WD B-Disease 1 0.999850869178772
) O 0 1.2598004104802385e-05
. O 0 3.262790778535418e-05

Mutations O 0 1.8875869500334375e-05
in O 0 4.660911372411647e-07
the O 0 4.846007755077153e-07
ATP7B O 0 0.00041687284829095006
genes O 0 1.0046150578091328e-07
have O 0 1.8687122960159286e-08
also O 0 5.88742814500165e-08
been O 0 1.1860785065209711e-07
demonstrated O 0 2.162921873605228e-06
in O 0 8.126801844809961e-07
mouse O 0 2.044042594206985e-05
and O 0 9.491914170212112e-06
rat O 0 8.495730435242876e-05
. O 0 1.3714691704080906e-05

The O 0 1.8141354303224944e-05
ATP7B O 0 0.0037784907035529613
gene O 0 1.9582389541028533e-06
has O 0 1.385569134981779e-07
been O 0 8.310112775689049e-08
excluded O 0 2.4805342491163174e-07
in O 0 2.6364881833274012e-08
the O 0 6.927947993062844e-08
much O 0 3.3517036968078173e-07
rarer O 0 0.003504878841340542
human O 0 6.679476064164191e-05
copper B-Disease 1 0.9992363452911377
overload I-Disease 1 0.9999815225601196
disease O 1 0.9389051795005798
non B-Disease 0 0.00046833493979647756
- I-Disease 0 1.7743524949764833e-05
Indian I-Disease 0 2.3680350125232508e-07
childhood I-Disease 0 1.223557660523511e-06
cirrhosis I-Disease 0 0.1495380699634552
, O 0 3.1277619427783065e-07
indicating O 0 2.292320004926296e-06
genetic O 0 8.726698979444336e-06
heterogeneity O 0 0.00017017019854392856
. O 0 4.678179175243713e-05

By O 0 5.216974841459887e-06
investigating O 0 2.1245785319479182e-05
the O 0 2.260556811961578e-06
common O 0 0.000302850385196507
autosomal O 1 0.9999935626983643
recessive O 1 0.9999990463256836
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 0.01561285462230444
CT B-Disease 1 0.9999990463256836
) O 0 6.61861690787191e-07
in O 0 2.916791572715738e-07
Bedlington O 0 0.0005121895810589194
terriers O 0 7.675089364056475e-06
, O 0 6.418373743599659e-08
we O 0 2.7224633214473215e-08
have O 0 1.0225373436867358e-08
identified O 0 4.2200124283908735e-08
a O 0 2.5662394875780592e-08
new O 0 1.0471079292528884e-07
locus O 0 1.614745769984438e-06
involved O 0 9.9893031801912e-07
in O 0 7.028474101389293e-06
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.12567730247974396

We O 0 5.754683570557972e-06
examined O 0 3.916564764949726e-06
whether O 0 2.2959095247188088e-07
the O 0 4.2150173840127536e-07
WD B-Disease 0 0.00021634426957461983
gene O 0 4.425705810717773e-06
ATP7B O 0 0.1902257651090622
was O 0 4.590883690980263e-06
also O 0 2.588731717878545e-07
causative O 0 1.8442661939843674e-06
for O 0 3.7832859334230307e-07
CT B-Disease 0 0.0028294012881815434
by O 0 3.0935228778616874e-07
investigating O 0 1.8114809563485323e-06
the O 0 5.865140337846242e-07
chromosomal O 0 2.2453032215707935e-05
co O 0 3.313390334369615e-05
- O 0 1.6002319171093404e-05
localization O 0 5.492953641805798e-05
of O 0 5.578940090344986e-06
ATP7B O 1 0.62456214427948
and O 0 8.237369684138685e-07
C04107 O 0 5.88380726185278e-06
, O 0 7.227115617070012e-08
using O 0 1.1290860868484742e-07
fluorescence O 0 7.439601859005052e-07
in O 0 4.206495773928509e-08
situ O 0 1.5957737105054548e-06
hybridization O 0 8.542104978914722e-07
( O 0 2.940206513812882e-07
FISH O 0 4.583481768349884e-06
) O 0 1.0323039987270022e-06
. O 0 6.633380053244764e-06

C04107 O 0 0.00039107855991460383
is O 0 1.2618461369129363e-06
an O 0 3.003576694027288e-07
anonymous O 0 1.7427008742743055e-06
microsatellite O 0 3.982428461313248e-05
marker O 0 1.1543612345121801e-05
closely O 0 3.1162387585936813e-06
linked O 0 2.2187790818861686e-05
to O 0 8.12929829407949e-06
CT B-Disease 1 0.999996542930603
. O 0 0.0005959012778475881

However O 0 2.4195096557377838e-05
, O 0 1.2380901353026275e-05
BAC O 0 0.010441213846206665
clones O 0 1.2338773558440153e-05
containing O 0 3.3023200103343697e-06
ATP7B O 0 0.003387684701010585
and O 0 9.524771940050414e-07
C04107 O 0 1.1671533684420865e-05
mapped O 0 4.3385099957049533e-07
to O 0 4.634405925685314e-08
the O 0 2.8062979140486277e-07
canine O 0 6.830186976003461e-06
chromosome O 0 3.2740663300501183e-06
regions O 0 7.041376193228643e-07
CFA22q11 O 0 0.00022370368242263794
and O 0 1.352826302536414e-06
CFA10q26 O 0 0.0032362337224185467
, O 0 2.582801243988797e-07
respectively O 0 4.738985239782778e-07
, O 0 6.258581208840042e-08
demonstrating O 0 2.2815973466094874e-07
that O 0 2.2337632188396128e-08
WD B-Disease 0 1.0694744560169056e-05
cannot O 0 3.60912792984891e-07
be O 0 2.3501625889821298e-07
homologous O 0 1.7832571757026017e-06
to O 0 9.673731256043538e-07
CT B-Disease 1 0.5444250106811523
. O 0 5.520165359484963e-05

The O 0 2.747122198343277e-05
copper O 0 6.983020284678787e-05
transport O 0 8.981235623650718e-06
genes O 0 9.220024139722227e-07
CTR1 O 0 0.0003396221436560154
and O 0 4.0370505871578644e-07
CTR2 O 0 0.298453688621521
were O 0 3.0096583714112057e-07
also O 0 4.956236310249551e-08
excluded O 0 1.6507038935742457e-07
as O 0 2.5930155800324428e-08
candidate O 0 4.849373880233543e-08
genes O 0 2.34512462782277e-08
for O 0 3.3825877210347244e-08
CT B-Disease 0 0.0003327907470520586
since O 0 1.1922296039301727e-07
they O 0 2.8903848203754023e-08
both O 0 8.09466556006555e-08
mapped O 0 3.4139335980398755e-07
to O 0 2.1534265215450432e-07
canine O 0 2.539781416999176e-05
chromosome O 0 1.3831408068654127e-05
region O 0 1.0951054719043896e-05
CFA11q22 O 0 0.006405838765203953
. O 0 8.668452937854454e-05

2 O 0 0.0001783238403731957
- O 0 0.0001815759314922616
22 O 0 7.942616502987221e-05
. O 0 6.092245894251391e-05

5 O 0 0.0008346812683157623
. O 0 0.0002746748214121908

A O 0 3.432239100220613e-05
transcribed O 0 4.2940519051626325e-06
sequence O 0 5.525548658624757e-07
identified O 0 3.537624024829711e-07
from O 0 5.4428937801276334e-08
the O 0 3.6193580399412895e-07
C04107 O 0 4.555555642582476e-05
- O 0 4.518390596786048e-06
containing O 0 1.6839785530464724e-06
BAC O 1 0.9915932416915894
was O 0 9.367986990582722e-07
found O 0 1.8956329839170394e-08
to O 0 8.87957085637936e-09
be O 0 2.9258673706067384e-08
homologous O 0 1.1380892317447433e-07
to O 0 1.1854718984238843e-08
a O 0 3.9769822990365356e-08
gene O 0 6.50217444331247e-08
expressed O 0 9.051012028749028e-08
from O 0 7.432206672319808e-08
human O 0 3.2863115961845324e-07
chromosome O 0 1.461256488255458e-06
2p13 O 0 6.755765298294136e-06
- O 0 2.5294514216511743e-06
p16 O 0 1.26683426060481e-06
, O 0 4.486477322984683e-08
a O 0 5.038080175268078e-08
region O 0 1.583559310347482e-07
devoid O 0 2.4026696792134317e-06
of O 0 9.106597786967541e-08
any O 0 8.959054298429692e-08
positional O 0 1.0009625839302316e-05
candidate O 0 5.332777163857827e-06
genes O 0 5.754936410085065e-06
. O 0 1.710583092062734e-05

Molecular O 0 1.569143387314398e-05
analysis O 0 6.452017373703711e-07
of O 0 6.293763590292656e-07
the O 0 6.09426365372201e-07
APC B-Disease 0 3.731927790795453e-06
gene O 0 3.059634821056534e-07
in O 0 1.0676584594193628e-07
205 O 0 5.052361302659847e-07
families O 0 2.571085211400259e-08
: O 0 9.525447808300669e-08
extended O 0 7.949128075779299e-07
genotype O 0 9.54506413108902e-06
- O 0 3.915358320227824e-06
phenotype O 0 1.9158978830091655e-06
correlations O 0 6.700033736706246e-07
in O 0 4.9024951209730716e-08
FAP B-Disease 0 2.144670133930049e-06
and O 0 2.0759022945071592e-08
evidence O 0 4.519905871802621e-08
for O 0 8.174738219679512e-09
the O 0 1.6922674817010375e-08
role O 0 8.702945564209585e-08
of O 0 6.399451422112179e-07
APC B-Disease 0 8.65923266246682e-06
amino O 0 1.4822406910752761e-06
acid O 0 1.418382566953369e-06
changes O 0 1.0562469469732605e-05
in O 0 0.06178673729300499
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9943588376045227
. O 0 0.0002153563837055117

BACKGROUND O 0 0.00024119805311784148
/ O 0 0.0003271348832640797
AIMS O 0 5.8390796766616404e-05
The O 0 1.5931158259263611e-06
development O 0 7.333449502766598e-06
of O 1 0.604363203048706
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.161376807587658e-07
a O 0 7.059605877657305e-08
variable O 0 1.8023206393991131e-07
range O 0 1.7369254123877909e-07
of O 0 1.5695032118401286e-07
extracolonic O 0 1.0651171578501817e-05
manifestations O 0 1.8164362700190395e-05
in O 0 7.711528837717196e-07
familial B-Disease 1 0.999990701675415
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 0.0026894097682088614
FAP B-Disease 0 0.04641387239098549
) O 0 1.9172287579749536e-07
is O 0 1.4563876327144953e-08
the O 0 1.5017445065268475e-08
result O 0 5.1464997596895046e-08
of O 0 1.1616423023497191e-07
the O 0 1.202190276217152e-07
dominant O 0 4.433705544215627e-05
inheritance O 0 3.2992506930895615e-06
of O 0 7.207356247818097e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999955892562866
( O 0 0.00012085401976946741
APC B-Disease 0 0.0001844467333285138
) O 0 2.292046701768413e-06
gene O 0 5.627385235129623e-06
mutations O 0 2.2826212443760596e-05
. O 0 4.2334970203228295e-05

In O 0 7.297328465938335e-07
this O 0 8.696491704540676e-08
study O 0 5.198085517577056e-08
, O 0 8.895131742292506e-09
direct O 0 1.818976436140929e-08
mutation O 0 1.7604451230113227e-08
analysis O 0 2.5144977655600087e-08
of O 0 4.8413422604198786e-08
the O 0 1.1044065217902244e-07
APC B-Disease 0 1.0714054496929748e-06
gene O 0 9.016654445304084e-08
was O 0 1.9419699981426675e-07
performed O 0 3.9947419594454914e-08
to O 0 2.496948425800838e-08
determine O 0 3.530441858856648e-07
genotype O 0 7.608370196976466e-06
- O 0 5.684651569026755e-06
phenotype O 0 2.2688202534482116e-06
correlations O 0 9.312892075286072e-07
for O 0 1.3097228190872556e-07
nine O 0 1.2167063232482178e-06
extracolonic O 0 1.541079291200731e-05
manifestations O 0 4.4239204726181924e-06
and O 0 3.357346045618215e-08
to O 0 1.2238542623776993e-08
investigate O 0 7.24909483551528e-08
the O 0 2.798722675834142e-08
incidence O 0 6.525613116536988e-07
of O 0 4.697046449564368e-07
APC B-Disease 0 4.571830231725471e-06
mutations O 0 9.115371426560159e-07
in O 0 8.483798410452437e-07
non O 1 0.998809814453125
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.004721402190625668

METHODS O 0 6.343181303236634e-05
The O 0 9.612680514692329e-06
APC B-Disease 0 1.808978595363442e-05
gene O 0 1.0298281267751008e-06
was O 0 9.453444249629683e-07
analysed O 0 1.455737219657749e-06
in O 0 1.3534311449348024e-07
190 O 0 1.833643523241335e-06
unrelated O 0 1.6536406519662705e-06
FAP B-Disease 0 8.8894012151286e-06
and O 0 4.895730398857268e-07
15 O 0 2.2020669348421507e-05
non O 1 0.9982650876045227
- O 1 0.9999994039535522
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.3820400656404672e-06
using O 0 1.6667423778926604e-06
denaturing O 0 9.49205132201314e-05
gradient O 0 5.645134297083132e-05
gel O 0 1.8017235561273992e-05
electrophoresis O 0 1.3493163351085968e-06
, O 0 5.862216312380042e-08
the O 0 6.725320389477929e-08
protein O 0 1.439597809849147e-07
truncation O 0 1.0578663705018698e-06
test O 0 3.050250541036803e-07
, O 0 5.161009042353726e-08
and O 0 7.916055722034798e-08
direct O 0 5.696438165614381e-07
sequencing O 0 5.5603813962079585e-06
. O 0 4.59089233117993e-06

RESULTS O 0 0.0001650437043281272
Chain O 0 1.2601271919265855e-05
terminating O 0 6.104685780883301e-06
signals O 0 1.6915531659833505e-06
were O 0 1.4896804145791975e-07
only O 0 3.090207911782272e-08
identified O 0 9.104687848093818e-08
in O 0 1.8267995116616476e-08
patients O 0 1.751369005376091e-08
belonging O 0 4.215153737163746e-08
to O 0 2.497253070998795e-08
the O 0 2.7241884481554735e-07
FAP B-Disease 0 5.9273570514051244e-05
group O 0 7.298532409549807e-07
( O 0 4.354136819983978e-07
105 O 0 4.008934411103837e-06
patients O 0 8.454076123598497e-07
) O 0 9.566227845425601e-07
. O 0 9.511333701084368e-06

Amino O 0 3.919114897144027e-05
acid O 0 3.136010718662874e-06
changes O 0 4.1201266753887467e-07
were O 0 2.4536325327062514e-07
identified O 0 1.9435042020177207e-07
in O 0 2.6231708361024175e-08
four O 0 1.0963094609905966e-07
patients O 0 2.9447626559431228e-08
, O 0 1.7115983297344428e-08
three O 0 1.754097134210042e-08
of O 0 6.402906649327633e-08
whom O 0 1.069737649572744e-07
belonged O 0 2.053013758995803e-07
to O 0 1.7099635485351428e-08
the O 0 9.802506895084662e-08
non O 0 3.271040986874141e-05
- O 0 0.00012882554437965155
FAP O 0 0.0004472874279599637
group O 0 2.4585715436842293e-05
of O 1 0.9999985694885254
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0239198487251997
. O 0 0.0001088147982954979

Genotype O 0 0.006123683415353298
- O 0 0.0005909193423576653
phenotype O 0 4.766636993736029e-05
correlations O 0 7.97483153291978e-06
identified O 0 8.460640970042732e-07
significant O 0 4.746298998270504e-07
differences O 0 1.0139394817088032e-06
in O 0 8.066952972285435e-08
the O 0 8.009688912125057e-08
nature O 0 9.256218191922017e-08
of O 0 8.150282582164436e-08
certain O 0 1.5951270881942037e-07
extracolonic O 0 7.007983367657289e-05
manifestations O 0 5.913197674090043e-05
in O 0 3.6246601098355313e-07
FAP B-Disease 0 1.115794111683499e-05
patients O 0 1.24587160144074e-07
belonging O 0 2.502085862943204e-07
to O 0 1.1424444323893113e-07
three O 0 9.702706620373647e-07
mutation O 0 9.993877029046416e-06
subgroups O 0 4.8218007577816024e-05
. O 0 3.584997830330394e-05

CONCLUSIONS O 0 9.592478454578668e-05
Extended O 0 3.6538658605422825e-05
genotype O 0 0.0001843808131525293
- O 0 3.2460509828524664e-05
phenotype O 0 9.679301001597196e-06
correlations O 0 3.585522563298582e-06
made O 0 1.1043285752521115e-07
in O 0 2.234257578948018e-08
this O 0 7.29288718304133e-09
study O 0 1.7562195253617574e-08
may O 0 1.118085446449868e-08
have O 0 5.080352583064496e-09
the O 0 1.2408387206619409e-08
potential O 0 2.6075124281987883e-08
to O 0 3.0615066037853467e-09
determine O 0 1.920353653872553e-08
the O 0 1.4452662178143783e-08
most O 0 8.876420487524683e-09
appropriate O 0 6.028457733009418e-08
surveillance O 0 1.6146381653925346e-07
and O 0 5.133617619890174e-08
prophylactic O 0 4.322783570387401e-05
treatment O 0 1.8276762148161652e-06
regimens O 0 1.8988156398336287e-06
for O 0 3.2447175613015133e-08
those O 0 1.3856848113391607e-08
patients O 0 9.11790909441379e-09
with O 0 5.1245852006331916e-09
mutations O 0 1.5863314217767766e-07
associated O 0 6.757440473847964e-08
with O 0 9.17756679541526e-08
life O 0 1.2168258081146632e-06
threatening O 0 4.205009827273898e-05
conditions O 0 0.0002298513863934204
. O 0 4.263559094397351e-05

This O 0 8.788769036982558e-07
study O 0 3.313950287520129e-07
also O 0 5.277506787138009e-08
provided O 0 6.136241381682339e-08
evidence O 0 1.6603283370386634e-07
for O 0 6.273472052953366e-08
the O 0 9.657622257464027e-08
pathological O 0 3.635545226643444e-06
nature O 0 3.4511629110056674e-07
of O 0 8.065296697168378e-07
amino O 0 8.570746672376117e-07
acid O 0 1.9611321988577401e-07
changes O 0 2.3584904340623325e-07
in O 0 7.131400536763977e-08
APC O 0 1.1465795068943407e-06
associated O 0 4.777187712079467e-08
with O 0 3.2401292315853425e-08
both O 0 2.521308317682269e-07
FAP B-Disease 0 1.8541240933700465e-05
and O 0 1.1478879287096788e-06
non O 1 0.9985446929931641
- O 1 0.9999996423721313
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.9116590920020826e-05
. O 0 5.27058364241384e-06
. O 0 1.8125012502423488e-05

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.9682682156562805
cancer B-Disease 1 0.9929149150848389
risk O 0 1.019881347019691e-05
of O 0 1.6879670511116274e-05
the O 0 2.323825901839882e-05
APC O 0 0.000446411722805351
I1307K O 0 0.00046778708929196
polymorphism O 0 0.00011126855679322034
. O 0 4.753210305352695e-05

Germ O 1 0.8023065328598022
- O 0 0.0005064510041847825
line O 0 2.416516508674249e-05
and O 0 1.0097314770973753e-06
somatic O 0 1.4907798686181195e-05
truncating O 0 3.1570882583764615e-06
mutations O 0 8.907869641916477e-08
of O 0 6.2197152317367e-08
the O 0 1.2589968889642478e-07
APC B-Disease 0 8.628153977952024e-07
gene O 0 6.757839088322726e-08
are O 0 1.7862012313685227e-08
thought O 0 1.9703914233559772e-07
to O 0 1.329073455735852e-07
initiate O 0 2.318405131518375e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.00041295355185866356
formation O 0 0.0009890783112496138
in O 0 3.490039307507686e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9999783039093018
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 0.006697531323879957
respectively O 0 0.0018107193754985929
. O 0 0.0001349894009763375

Recently O 0 2.879262865462806e-05
, O 0 2.336384341106168e-06
an O 0 1.7400352589902468e-06
isoleucine O 0 0.006252430845052004
- O 0 0.00404277304187417
- O 0 0.004337036982178688
> O 0 0.0005609812797047198
lysine O 0 6.678119098069146e-05
polymorphism O 0 3.0171784146659775e-06
at O 0 7.923160296741116e-07
codon O 0 3.349627604620764e-06
1307 O 0 6.607091927435249e-05
( O 0 2.0961928726137558e-07
I1307K O 0 2.4446312636428047e-06
) O 0 3.373418877572476e-08
of O 0 3.272393556130737e-08
the O 0 4.489575999855333e-08
APC B-Disease 0 5.779195362265455e-07
gene O 0 4.637093908854695e-08
has O 0 1.6361431320888187e-08
been O 0 1.7717601608069344e-08
identified O 0 2.9055188477400407e-08
in O 0 1.0632867919468936e-08
6 O 0 3.345048753544688e-07
% O 0 2.4741074966527776e-08
- O 0 1.3793831499242515e-07
7 O 0 1.5121224805625388e-07
% O 0 8.974716969589736e-09
of O 0 6.64118928739299e-08
the O 0 2.0066228501036676e-07
Ashkenazi O 0 3.132812253170414e-06
Jewish O 0 7.852398198338051e-07
population O 0 6.082134973439679e-07
. O 0 1.0153261428058613e-05

To O 0 1.830084897846973e-06
assess O 0 4.100271326024085e-06
the O 0 3.025463115591265e-07
risk O 0 4.551079086922982e-07
of O 0 2.748722067735798e-07
this O 0 8.446261290373513e-08
common O 0 9.508780181022303e-07
APC B-Disease 0 2.8630402084672824e-05
allelic O 0 0.00033246667589992285
variant O 0 0.00561381783336401
in O 0 4.595605787471868e-06
colorectal O 1 1.0
carcinogenesis O 1 0.9999778270721436
, O 0 1.9598758171923691e-07
we O 0 4.252526863979256e-08
have O 0 1.0459198840351291e-08
analyzed O 0 3.357006761461889e-08
a O 0 1.9438539666793986e-08
large O 0 5.8720864615224855e-08
cohort O 0 1.0642098686730606e-06
of O 0 6.82344079905306e-07
unselected O 0 9.108102676691487e-05
Ashkenazi O 0 2.1155372451175936e-05
Jewish O 0 2.055950062640477e-06
subjects O 0 7.86727832746692e-06
with O 0 8.579054906476813e-07
adenomatous B-Disease 0 0.0029858124908059835
polyps I-Disease 0 0.00016072702419478446
and O 0 1.6564201814617263e-06
. O 0 1.639354923099745e-05
or O 1 0.9999974966049194
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.8602113414090127e-06
for O 0 3.412804119307111e-07
the O 0 8.186129321074986e-07
APC O 0 2.0808292902074754e-05
I1307K O 0 5.471800977829844e-05
polymorphism O 0 4.932489537168294e-05
. O 0 2.3068549126037396e-05

The O 0 2.4990575184347108e-05
APC O 0 7.871138950577006e-05
I1307K O 0 5.471665281220339e-05
allele O 0 9.806302841752768e-06
was O 0 1.2295537317186245e-06
identified O 0 1.9270100892754272e-07
in O 0 4.988748258938358e-08
48 O 0 4.6926317054385436e-07
( O 0 8.859273492589637e-08
10 O 0 1.0846495257510469e-07
. O 0 1.712708730394752e-08
1 O 0 2.045216547230666e-07
% O 0 2.7362689891674563e-08
) O 0 5.994747453996752e-08
of O 0 5.932002409281267e-07
476 O 0 1.6992113160085864e-05
patients O 0 2.351772991460166e-06
. O 0 1.5908437489997596e-05

Compared O 0 3.6372650811244966e-06
with O 0 7.52889945943025e-08
the O 0 8.132300877150556e-08
frequency O 0 4.5291056949281483e-07
in O 0 9.582755033932244e-09
two O 0 6.5936034410185584e-09
separate O 0 7.143786451280221e-09
population O 0 1.0252885207506779e-09
control O 0 2.8547825436930907e-08
groups O 0 7.964804815685511e-09
, O 0 3.2327275079069295e-08
the O 0 1.5531466601714783e-07
APC O 0 3.3341641483275453e-06
I1307K O 0 6.9476113822020125e-06
allele O 0 8.56899760037777e-07
is O 0 1.697511109455263e-08
associated O 0 2.013423561209038e-08
with O 0 5.964464033780814e-09
an O 0 6.998294388438353e-09
estimated O 0 2.0382142196240238e-08
relative O 0 1.948637589066493e-07
risk O 0 2.8357729320305225e-07
of O 0 1.4831230146228336e-06
1 O 0 5.718797183362767e-05
. O 0 1.3633530215884093e-05

5 O 0 0.00015179472393356264
- O 0 0.0001078533532563597
1 O 0 8.205090853152797e-05
. O 0 4.7363602789118886e-05

7 O 0 0.0001990713062696159
for O 0 4.5337081246543676e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999934434890747
( O 0 4.025035650556674e-06
both O 0 1.129308543568186e-06
P O 0 0.0003791166818700731
= O 0 8.848540346662048e-06
. O 0 5.540873075915442e-07
01 O 0 3.003796882694587e-05
) O 0 1.934630972755258e-06
. O 0 1.3636794392368756e-05

Furthermore O 0 1.6590887753409334e-05
, O 0 9.156207170235575e-07
compared O 0 6.278165187723062e-07
with O 0 2.3353720735030947e-07
noncarriers O 0 0.00014036240463610739
, O 0 8.092587222563452e-07
APC O 0 6.320099146250868e-06
I1307K O 0 4.624834673450096e-06
carriers O 0 1.6109530065477884e-07
had O 0 4.190783542412646e-08
increased O 0 4.277810816688543e-08
numbers O 0 7.543014390876124e-08
of O 0 8.290005553135416e-07
adenomas B-Disease 1 0.9991505146026611
and O 0 0.03013278730213642
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9959424138069153
per O 0 6.9698495508419e-07
patient O 0 2.3173062402293e-07
( O 0 1.0643524461784182e-07
P O 0 2.3066439098329283e-05
= O 0 8.045929575928312e-07
. O 0 1.7451634803933302e-08
03 O 0 6.543729114127927e-07
) O 0 7.442771732257825e-09
, O 0 7.46523554084888e-09
as O 0 9.735611428141056e-09
well O 0 2.2674042199355426e-08
as O 0 3.303795281794919e-08
a O 0 1.497246131521024e-07
younger O 0 3.584325668271049e-06
age O 0 1.3711187420994975e-05
at O 0 6.265340925892815e-05
diagnosis O 0 0.0004741563752759248
. O 0 2.8443842893466353e-05

We O 0 3.390945266801282e-06
conclude O 0 4.2159363147220574e-06
that O 0 7.890399444931973e-08
the O 0 2.929347147073713e-07
APC O 0 1.1315937626932282e-05
I1307K O 0 1.384653205604991e-05
variant O 0 8.575246283726301e-06
leads O 0 6.223915534064872e-07
to O 0 7.210070407381863e-08
increased O 0 6.8115828071313445e-06
adenoma B-Disease 1 1.0
formation O 0 1.7530053810332902e-05
and O 0 1.1289935031300047e-07
directly O 0 2.6091591109889123e-08
contributes O 0 4.24617008221162e-09
to O 0 1.7005920005530584e-09
3 O 0 2.6152624954534076e-08
% O 0 2.5178654716739857e-09
- O 0 1.252057746370383e-08
4 O 0 1.7447341349452472e-08
% O 0 2.8166933230266977e-09
of O 0 2.9587702954358974e-08
all O 0 1.2280004568765435e-07
Ashkenazi O 0 6.328909512376413e-05
Jewish O 0 0.006140111479908228
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00022354121028911322

The O 0 2.570431433923659e-06
estimated O 0 6.737889748364978e-07
relative O 0 1.7538615111334366e-06
risk O 0 5.838197694174596e-07
for O 0 1.8426700876261748e-07
carriers O 0 3.674251729535172e-07
may O 0 3.5170000955986325e-07
justify O 0 7.181166097325331e-07
specific O 0 4.7200821029491635e-08
clinical O 0 2.942832395547157e-07
screening O 0 5.7017540910919706e-08
for O 0 1.4170661977175314e-08
the O 0 3.044516461159219e-08
360 O 0 4.590462765463599e-07
, O 0 3.346739418930156e-08
000 O 0 1.4408585968794796e-07
Americans O 0 1.810371941246558e-08
expected O 0 3.549556026882783e-08
to O 0 1.4278835003267432e-08
harbor O 0 2.8865511580988823e-07
this O 0 1.4494180966551085e-08
allele O 0 4.709443715000816e-07
, O 0 3.36347376617141e-08
and O 0 1.576260011404429e-08
genetic O 0 1.8597908990614087e-08
testing O 0 2.5754729904292617e-08
in O 0 5.238022460218872e-09
the O 0 1.7476750713285583e-08
setting O 0 9.388793387188343e-08
of O 0 5.041838946340249e-08
long O 0 6.954784481649767e-08
- O 0 1.1559641421854394e-07
term O 0 1.4615196164413646e-07
- O 0 9.73329292719427e-08
outcome O 0 8.425665498634771e-08
studies O 0 1.925720027884381e-08
may O 0 2.6401718145052655e-08
impact O 0 5.186943781154696e-07
significantly O 0 4.3942891352344304e-06
on O 1 0.8423617482185364
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.081115442502778e-05
in O 0 1.6605904207267486e-08
this O 0 1.559525131256123e-08
population O 0 7.962650983017738e-08
. O 0 2.80405538433115e-06

Localization O 0 0.0008418710203841329
of O 0 1.6493411749252118e-05
human O 0 1.9802996575890575e-06
BRCA1 O 0 7.027871106402017e-06
and O 0 1.788625638710073e-07
its O 0 1.029323897228096e-07
loss O 0 3.3188191537192324e-06
in O 0 1.3619806793485623e-07
high O 0 5.3765441407449543e-05
- O 0 4.178351446171291e-05
grade O 0 0.009030771441757679
, O 0 5.67302458875929e-06
non B-Disease 1 0.9975576400756836
- I-Disease 1 0.9998900890350342
inherited I-Disease 1 0.9999964237213135
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.011071210727095604

Although O 0 2.917305209848564e-06
the O 0 7.535119834756188e-07
link O 0 8.955737484939164e-07
between O 0 4.792744334736199e-07
the O 0 1.065379706233216e-06
BRCA1 O 0 9.510579548077658e-05
tumour B-Disease 1 1.0
- O 0 0.00015093972615431994
suppressor O 0 7.464066584361717e-05
gene O 0 1.5626776530552888e-06
and O 0 7.118488156265812e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 7.566078693344025e-06
established O 0 2.7796355084319657e-07
, O 0 1.1348179285164406e-08
the O 0 9.157647085089593e-09
role O 0 3.0811385443030304e-08
, O 0 7.237928034697916e-09
if O 0 3.775527002147783e-09
any O 0 1.0029758357177343e-08
, O 0 2.008927602048516e-08
of O 0 1.1732489468840868e-07
BRCA1 O 0 2.1304431356838904e-06
in O 0 1.487987901782617e-07
non B-Disease 0 0.0006007796037010849
- I-Disease 0 0.0725155770778656
familial I-Disease 0 0.003098890883848071
cancers I-Disease 1 0.9966532588005066
is O 0 1.981072045964538e-06
unclear O 0 2.5331752112833783e-05
. O 0 4.5899087126599625e-05

BRCA1 O 0 0.00014914621715433896
mutations O 0 5.606333161267685e-06
are O 0 1.5070735059907747e-07
rare O 0 5.812159997731214e-07
in O 0 1.1706593738836091e-07
sporadic B-Disease 0 0.0002214626147178933
cancers I-Disease 1 0.9993721842765808
, O 0 7.118748044376844e-07
but O 0 2.1896525481679419e-07
loss O 0 1.3269183909869753e-05
of O 0 3.072221034017275e-06
BRCA1 O 0 5.271528607408982e-06
resulting O 0 2.4810074705783336e-07
from O 0 2.2440506342036315e-08
reduced O 0 3.867268674184743e-07
expression O 0 1.1535105670645862e-07
or O 0 2.4210349280906485e-08
incorrect O 0 2.2320348591620132e-07
subcellular O 0 2.6026038995041745e-06
localization O 0 2.945324240499758e-06
is O 0 1.78322956401189e-08
postulated O 0 1.69140349726149e-07
to O 0 6.2044276383232955e-09
be O 0 2.5672138193044702e-08
important O 0 6.760559756457951e-08
in O 0 6.551084652528516e-08
non B-Disease 0 0.00010585226118564606
- I-Disease 0 0.3540206849575043
familial I-Disease 1 0.9994394183158875
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9999960660934448

Epigenetic O 0 0.00031131727155297995
loss O 0 5.976988541078754e-05
, O 0 4.630695116247807e-07
however O 0 2.336223019483441e-07
, O 0 3.7375691874785844e-08
has O 0 4.041073253802097e-09
not O 0 4.690302368715038e-09
received O 0 1.120164494494702e-08
general O 0 2.156144596199283e-08
acceptance O 0 7.189993311840226e-08
due O 0 1.2076404232175264e-07
to O 0 2.4440895529664886e-08
controversy O 0 3.5607993709163566e-07
regarding O 0 2.8953323294445e-07
the O 0 2.0945901724189753e-07
subcellular O 0 1.433277520845877e-05
localization O 0 1.2962548680661712e-05
of O 0 7.264679311447253e-07
BRCA1 O 0 1.3636134781336295e-06
proteins O 0 2.804584653404163e-08
, O 0 2.7356845677672936e-08
reports O 0 2.9845139692952216e-08
of O 0 4.034398060070998e-08
which O 0 1.1946443834176534e-08
have O 0 1.1867274274379724e-08
ranged O 0 5.585587246059731e-07
from O 0 2.0933814681711738e-08
exclusively O 0 5.562995042396324e-08
nuclear O 0 2.7032155003325897e-07
, O 0 2.0636484521219245e-08
to O 0 1.4477575582816371e-08
conditionally O 0 8.214117883653671e-07
nuclear O 0 2.976272241994593e-07
, O 0 1.6098217869853215e-08
to O 0 5.813088232997643e-09
the O 0 1.8210216978786775e-07
ER O 0 6.108139496063814e-05
/ O 0 1.4471093891188502e-05
golgi O 0 1.2111206160625443e-05
, O 0 9.467647998917528e-08
to O 0 5.440755757035731e-08
cytoplasmic O 0 3.2981779440888204e-06
invaginations O 0 1.568371408211533e-05
into O 0 5.695731601917942e-07
the O 0 1.7969863392863772e-06
nucleus O 0 0.00010400087194284424
. O 0 2.9562843337771483e-05

In O 0 2.124861111951759e-06
an O 0 3.294375972018315e-07
attempt O 0 8.085042395578057e-07
to O 0 1.3520171648906398e-07
resolve O 0 1.4725203527632402e-06
this O 0 6.888563319762397e-08
issue O 0 2.7622263587545604e-07
, O 0 5.804083968996565e-08
we O 0 8.283843300205262e-08
have O 0 1.0372129821689668e-07
comprehensively O 0 7.695829481235705e-06
characterized O 0 5.586807105828484e-07
19 O 0 5.665092885465128e-06
anti O 0 0.00011713404819602147
- O 0 0.0002530989295337349
BRCA1 O 0 3.4939155739266425e-05
antibodies O 0 4.315148089517606e-06
. O 0 1.9577571947593242e-05

These O 0 2.9302682378329337e-06
reagents O 0 2.0868908904958516e-05
detect O 0 7.124084277165821e-06
a O 0 1.9862102362822043e-06
220 O 0 6.109660262154648e-06
- O 0 1.470950974180596e-05
kD O 0 5.907493323320523e-05
protein O 0 5.065300001660944e-07
localized O 0 4.290640163162607e-07
in O 0 2.570869384044272e-08
discrete O 0 1.5075436010647536e-07
nuclear O 0 4.129374815420306e-07
foci O 0 1.3498544149115332e-06
in O 0 1.2140823457684746e-08
all O 0 1.9640234327766848e-08
epithelial O 0 4.975084380021144e-07
cell O 0 5.336504500519368e-07
lines O 0 1.2692707684891502e-07
, O 0 1.9791329464169394e-08
including O 0 1.6346239917197636e-08
those O 0 1.5166842004532555e-08
derived O 0 2.208493725674998e-07
from O 0 6.644647783105029e-07
breast B-Disease 0 0.00024576610303483903
malignancies I-Disease 0 0.003216404700651765
. O 0 4.071841249242425e-05

Immunohistochemical O 0 0.00899647455662489
staining O 0 0.0041060359217226505
of O 0 0.00022425422503147274
human O 0 5.39352695341222e-05
breast O 0 9.116695582633838e-05
specimens O 0 2.2091769551479956e-06
also O 0 7.311818421840144e-07
revealed O 0 7.202550477813929e-06
BRCA1 O 0 1.4716987607243937e-05
nuclear O 0 4.428541797096841e-05
foci O 0 0.01804068498313427
in O 0 2.8770111839548917e-06
benign O 1 0.999984860420227
breast O 1 0.9999949932098389
, O 0 0.0646466538310051
invasive B-Disease 1 0.9999982118606567
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999877214431763
and O 0 4.6421377192018554e-05
low B-Disease 1 0.9999310970306396
- I-Disease 1 0.9999808073043823
grade I-Disease 1 0.9999924898147583
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0002945945889223367

Conversely O 0 8.713902934687212e-05
, O 0 2.6678187623474514e-06
BRCA1 O 0 5.645709279633593e-06
expression O 0 4.3951467887382023e-07
was O 0 2.293130592079251e-07
reduced O 0 1.0724547649942906e-07
or O 0 1.633339863360561e-08
undetectable O 0 1.8561412673534505e-07
in O 0 2.6332804825557332e-09
the O 0 4.8123491858120815e-09
majority O 0 5.625669263764621e-09
of O 0 6.434492405560377e-08
high O 0 1.0414803909952752e-05
- O 0 5.909511855861638e-06
grade O 0 5.7697634474607185e-05
, O 0 4.147049367020372e-06
ductal B-Disease 1 0.9999909400939941
carcinomas I-Disease 1 1.0
, O 0 8.414904328901684e-08
suggesting O 0 5.686950643735145e-08
that O 0 7.298592397120274e-09
absence O 0 2.9186111305534723e-07
of O 0 4.830725401916425e-07
BRCA1 O 0 1.4980918194851256e-06
may O 0 6.128545493311321e-08
contribute O 0 2.044623137464896e-08
to O 0 9.956679924982836e-09
the O 0 5.0824972674945457e-08
pathogenesis O 0 1.3819726518704556e-05
of O 0 3.0428441988306076e-08
a O 0 1.784352221534391e-08
significant O 0 4.063985414859417e-08
percentage O 0 1.1985636660938326e-07
of O 0 5.001081717637135e-07
sporadic B-Disease 0 0.17117592692375183
breast I-Disease 1 0.9811382293701172
cancers I-Disease 1 0.7473479509353638
. O 0 6.0318552641547285e-06
. O 0 2.9173301300033927e-05

